FN Thomson Reuters Web of Science™
VR 1.0
PT J
AU Brugge, WR
DeWitt, J
Klapman, JB
Ashfaq, R
Shidham, V
Chhieng, D
Kwon, R
Baloch, Z
Zarka, M
Staerkel, G
AF Brugge, William R.
DeWitt, John
Klapman, Jason B.
Ashfaq, Raheela
Shidham, Vinod
Chhieng, David
Kwon, Richard
Baloch, Zubair
Zarka, Matthew
Staerkel, Gregg
TI Techniques for cytologic sampling of pancreatic and bile duct lesions:
The Papanicolaou Society of Cytopathology Guidelines
SO CYTOJOURNAL
LA English
DT Article
DE Bile duct; cytology; fine-needle aspiration; pancreas; techniques
ID FINE-NEEDLE-ASPIRATION; MALIGNANT BILIARY OBSTRUCTION; BRUSH CYTOLOGY;
STRICTURE DILATION; DIAGNOSTIC-ACCURACY; 25-GAUGE NEEDLES;
CANCER-DETECTION; ERCP; BIOPSY; 22-GAUGE
AB The Papanicolaou Society of Cytopathology has developed a set of guidelines for pancreatobiliary cytology, including indications for endoscopic ultrasound guided fine-needle aspiration biopsy, techniques of the endoscopic retrograde cholangiopancreatography, terminology and nomenclature of pancreatobiliary disease, ancillary testing, and postbiopsy management. All documents are based on the expertise of the authors, a review of literature, discussions of the draft document at several national and international meetings over an 18 month period and synthesis of online comments of the draft document on the Papanicolaou Society of Cytopathology website [www.papsociety.org]. This document presents the results of these discussions regarding the use of sampling techniques in the cytological diagnosis of biliary and pancreatic lesions. This document summarizes the current state of the art for techniques in acquiring cytology specimens from the biliary tree as well as solid and cystic lesions of the pancreas.
C1 [Brugge, William R.] Massachusetts Gen Hosp, Dept Med, Gastroenterol Unit, Boston, MA 02114 USA.
[DeWitt, John] Indiana Univ, Med Ctr, Dept Med, Indianapolis, IN USA.
[Klapman, Jason B.] Univ S Florida, H Lee Moffitt Canc Ctr, Gastrointestinal Oncol Dept, Tampa, FL 33682 USA.
[Kwon, Richard] Univ Michigan, Med Ctr, Dept Internal Med, Ann Arbor, MI 48109 USA.
[Shidham, Vinod] Wayne State Univ, Dept Pathol, Detroit, MI 48202 USA.
[Chhieng, David] Yale Univ, Med Ctr, Dept Pathol, New Haven, CT USA.
[Baloch, Zubair] Univ Penn, Dept Pathol, Philadelphia, PA 19104 USA.
[Zarka, Matthew] Mayo Clin, Dept Pathol, Scottsdale, AZ USA.
[Staerkel, Gregg] Univ Texas Houston, MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Ashfaq, Raheela] Caris Diagnost, Dallas, TX USA.
RP Brugge, WR (reprint author), Massachusetts Gen Hosp, Dept Med, Gastroenterol Unit, Boston, MA 02114 USA.
EM wbrugge@partners.org; jodewitt@iupui.edu; jason.klapman@moffitt.org;
raheela@sbcglobal.net; vshidham@med.wayne.edu; david.chhieng@yale.edu;
rskwon@umich.edu; baloch@mail.med.upenn.edu; Zarka.Matthew@mayo.edu;
gstaerke@mdanderson.org
NR 36
TC 4
Z9 4
U1 0
U2 0
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
INDIA
SN 0974-5963
EI 1742-6413
J9 CYTOJOURNAL
JI CytoJournal
PD JUN 2
PY 2014
VL 11
AR 2
DI 10.4103/1742-6413.133311
PG 6
WC Pathology
SC Pathology
GA AO3QV
UT WOS:000341249800002
PM 25191516
ER
PT J
AU Kurtycz, DFI
Field, A
Tabatabai, L
Michaels, C
Young, N
Schmidt, CM
Farrell, J
Gopal, D
Simeone, D
Merchant, NB
Pitman, MB
AF Kurtycz, Daniel F. I.
Field, Andrew
Tabatabai, Laura
Michaels, Claire
Young, Nancy
Schmidt, C. Max
Farrell, James
Gopal, Deepak
Simeone, Diane
Merchant, Nipun B.
Pitman, Martha Bishop
TI Post-brushing and fine-needle aspiration biopsy follow-up and treatment
options for patients with pancreatobiliary lesions: The Papanicolaou
Society of Cytopathology Guidelines
SO CYTOJOURNAL
LA English
DT Article
DE Cytology; guidelines; management; pancreas; Papanicolaou Society of
Cytopathology; treatment
ID INTERNATIONAL CONSENSUS GUIDELINES; EUS-GUIDED FNA; ENDOSCOPIC
ULTRASOUND; NEUROENDOCRINE TUMORS; PATHOLOGICAL CLASSIFICATION;
LYMPHOEPITHELIAL CYSTS; MUCINOUS CYSTS; PANCREAS; DIAGNOSIS; MANAGEMENT
AB The Papanicolaou Society of Cytopathology (PSC) has developed a set of guidelines for pancreatobiliary cytology including indications for endoscopic ultrasound (EUS) guided fine-needle aspiration (FNA) biopsy, techniques of EUS-FNA, terminology and nomenclature for pancreatobiliary cytology, ancillary testing and post-procedure management. All documents are based on the expertise of the authors, a review of the literature and discussions of the draft document at several national and international meetings over an 18 month period and synthesis of online comments of the draft document on the PSC web site (www.papsociety.org). This document selectively presents the results of these discussions and focuses on the follow-up and treatment options for patients after procedures performed for obtaining cytology samples for the evaluation of biliary strictures and solid and cystic masses in the pancreas. These recommendations follow the six-tiered terminology and nomenclature scheme proposed by committee III.
C1 [Kurtycz, Daniel F. I.] Univ Wisconsin, Dept Pathol, Madison, WI 53706 USA.
[Field, Andrew] St Vincents Hosp, Dept Surg, Sydney, NSW 2010, Australia.
[Tabatabai, Laura] UCSF, San Francisco, CA 94143 USA.
[Michaels, Claire] Case Western Reserve Univ, Cleveland, OH 44106 USA.
[Young, Nancy] Albert Einstein Coll Med, Philadelphia, PA USA.
[Schmidt, C. Max] Indiana Univ, Bloomington, IN 47405 USA.
[Farrell, James] Univ Calif Los Angeles, Los Angeles, CA 90024 USA.
[Gopal, Deepak] Univ Wisconsin, Div Gastroenterol, Madison, WI 53706 USA.
[Simeone, Diane] Univ Michigan, Dept Med, Ann Arbor, MI 48109 USA.
[Merchant, Nipun B.] Vanderbilt Univ, Div Surg Oncol, Nashville, TN USA.
[Pitman, Martha Bishop] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cambridge, MA 02138 USA.
RP Kurtycz, DFI (reprint author), Univ Wisconsin, Dept Pathol, Madison, WI 53706 USA.
EM dkurtycz@wisc.edu; afield@stvincents.com.au; laura.tabatabai@ucsf.edu;
Claire.michael@case.edu; YoungNan@einstein.edu; maxschmi@iupui.edu;
jfarrell@mednet.ucla.edu; dvg@medicine.wisc.edu; simeone@umich.edu;
nipun.merchant@vanderbilt.edu; mpitman@mgh.harvard.edu
NR 57
TC 1
Z9 1
U1 0
U2 2
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
INDIA
SN 0974-5963
EI 1742-6413
J9 CYTOJOURNAL
JI CytoJournal
PD JUN 2
PY 2014
VL 11
AR 5
DI 10.4103/1742-6413.133356
PG 9
WC Pathology
SC Pathology
GA AO3QV
UT WOS:000341249800005
PM 25191519
ER
PT J
AU Layfield, LJ
Ehya, H
Filie, AC
Hruban, RH
Jhala, N
Joseph, L
Vielh, P
Pitman, MB
AF Layfield, Lester J.
Ehya, Hormoz
Filie, Armando C.
Hruban, Ralph H.
Jhala, Nirag
Joseph, Loren
Vielh, Philippe
Pitman, Martha B.
TI Utilization of ancillary studies in the cytologic diagnosis of biliary
and pancreatic lesions: The Papanicolaou Society of Cytopathology
Guidelines
SO CYTOJOURNAL
LA English
DT Article
DE Ancillary studies; biliary tract; endoscopic ultrasound; fine-needle
aspiration; molecular diagnosis; pancreas
ID FINE-NEEDLE-ASPIRATION; IN-SITU HYBRIDIZATION; CYST FLUID ANALYSIS;
DIGITAL IMAGE-ANALYSIS; ACINAR CELL-CARCINOMA; TUMOR-SUPPRESSOR GENE;
K-RAS MUTATIONS; PAPILLARY MUCINOUS NEOPLASMS; ENDOBILIARY BRUSH
CYTOLOGY; BILE-DUCT STRICTURES
AB The Papanicolaou Society of Cytopathology has developed a set of guidelines for pancreatobiliary cytology including indications for endoscopic ultrasound guided fine needle aspiration, terminology and nomenclature of pancreatobiliary disease, ancillary testing and post-biopsy management. All documents are based on the expertise of the authors, a review of the literature, discussion of the draft document at several national and international meetings and synthesis of selected online comments of the draft document. This document presents the results of these discussions regarding the use of ancillary testing in the cytologic diagnosis of biliary and pancreatic lesions. Currently, fluorescence in-situ hybridization (FISH) appears to be the most clinically relevant ancillary technique for cytology of bile duct strictures. The addition of FISH analysis to routine cytologic evaluation appears to yield the highest sensitivity without loss in specificity. Loss of immunohistochemical staining for the protein product of the SMAD4 gene and positive staining for mesothelin support a diagnosis of ductal adenocarcinoma. Immunohistochemical markers for endocrine and exocrine differentiation are sufficient for a diagnosis of endocrine and acinar tumors. Nuclear staining for beta-catenin supports a diagnosis of solid-pseudopapillary neoplasm. Cyst fluid analysis for amylase and carcinoembryonic antigen aids in the pre-operative classification of pancreatic cysts. A number of gene mutations (KRAS, GNAS, von Hippel-Lindau, RNF43 and CTNNB1) may be of aid in the diagnosis of cystic neoplasms. Other ancillary techniques do not appear to improve diagnostic sensitivity sufficiently to justify their increased costs.
C1 [Layfield, Lester J.] Univ Missouri, Dept Pathol, Dept Pathol & Anat Sci, Columbia, MO 65201 USA.
[Ehya, Hormoz] Fox Chase Canc Ctr, Dept Pathol, Philadelphia, PA 19111 USA.
[Joseph, Loren] Univ Chicago, Dept Pathol, Chicago, IL 60637 USA.
[Pitman, Martha B.] Harvard Univ, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02115 USA.
[Filie, Armando C.] NCI, Pathol Lab, Bethesda, MD 20892 USA.
[Hruban, Ralph H.] Johns Hopkins Univ, Sch Med, Sol Goldman Pancreat Canc Res Ctr, Baltimore, MD USA.
[Jhala, Nirag] Hosp Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA 19104 USA.
[Vielh, Philippe] Inst Gustave Roussy, Dept Pathol, Villejuif, France.
RP Layfield, LJ (reprint author), Univ Missouri, Dept Pathol, Dept Pathol & Anat Sci, Columbia, MO 65201 USA.
EM layfieldl@health.missouri.edu; hormoz.eya@fccc.edu; afilie@mail.nih.gov;
rhruban@jhmi.edu; Nirag.Jhala@uphs.upenn.edu; ljlj@midway.uchicago.edu;
vielh@igr.fr; mpitman@mgh.harvard.edu
NR 117
TC 8
Z9 8
U1 0
U2 6
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
INDIA
SN 0974-5963
EI 1742-6413
J9 CYTOJOURNAL
JI CytoJournal
PD JUN 2
PY 2014
VL 11
AR 4
DI 10.4103/1742-6413.133352
PG 12
WC Pathology
SC Pathology
GA AO3QV
UT WOS:000341249800004
PM 25191518
ER
PT J
AU Pitman, MB
Centeno, BA
Ali, SZ
Genevay, M
Stelow, E
Mino-Kenudson, M
Fernandez-del Castillo, C
Schmidt, CM
Brugge, WR
Layfield, LJ
AF Pitman, Martha B.
Centeno, Barbara A.
Ali, Syed Z.
Genevay, Muriel
Stelow, Ed
Mino-Kenudson, Mari
Fernandez-del Castillo, Carlos
Schmidt, C. Max
Brugge, William R.
Layfield, Lester J.
TI Standardized terminology and nomenclature for pancreatobiliary cytology:
The Papanicolaou Society of Cytopathology Guidelines
SO CYTOJOURNAL
LA English
DT Article
DE Guidelines; nomenclature; pancreas; Papanicolaou Society of
Cytopathology; terminology
ID FINE-NEEDLE-ASPIRATION; PAPILLARY MUCINOUS NEOPLASMS; ACINAR-CELL
CARCINOMA; CYST FLUID ANALYSIS; DUCT BRUSHING CYTOLOGY; INTERNATIONAL
CONSENSUS GUIDELINES; ATYPICAL EPITHELIAL-CELLS; INTRAEPITHELIAL
NEOPLASIA; DIFFERENTIAL-DIAGNOSIS; NEUROENDOCRINE TUMORS
AB The Papanicolaou Society of Cytopathology has developed a set of guidelines for pancreatobiliary cytology including indications for endoscopic ultrasound (EUS) guided fine-needle aspiration (FNA) biopsy, techniques of EUS-FNA, terminology and nomenclature of pancreatobiliary disease, ancillary testing and post-biopsy treatment and management. All documents are based on the expertise of the authors, a review of the literature, discussion of the draft document at several national and international meetings over an 18 month period and synthesis of online comments of the draft document on the Papanicolaou Society of Cytopathology web site [www.papsociety.org]. This document selectively presents the results of these discussions and focuses on a proposed standardized terminology scheme for pancreatobiliary specimens that correlate cytological diagnosis with biological behavior and increasingly conservative patient management of surveillance only. The proposed terminology scheme recommends a six-tiered system: Non-diagnostic, negative, atypical, neoplastic [benign or other], suspicious and positive. Unique to this scheme is the "neoplastic" category separated into "benign" (serous cystadenoma) or "other" (premalignant mucinous cysts, neuroendocrine tumors and solid-pseudopapillary neoplasms (SPNs)). The positive or malignant category is reserved for high-grade, aggressive malignancies including ductal adenocarcinoma, acinar cell carcinoma, poorly differentiated neuroendocrine carcinomas, pancreatoblastoma, lymphoma and metastases. Interpretation categories do not have to be used. Some pathology laboratory information systems require an interpretation category, which places the cytological diagnosis into a general category. This proposed scheme provides terminology that standardizes the category of the various diseases of the pancreas, some of which are difficult to diagnose specifically by cytology. In addition, this terminology scheme attempts to provide maximum flexibility for patient management, which has become increasingly conservative for some neoplasms.
C1 [Pitman, Martha B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02138 USA.
[Centeno, Barbara A.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Ali, Syed Z.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Genevay, Muriel] Hosp Pathol Clin, Geneva, Switzerland.
[Stelow, Ed] Univ Virginia, Med Ctr, Charlottesville, VA USA.
[Fernandez-del Castillo, Carlos] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg, Boston, MA USA.
[Schmidt, C. Max] Indiana Univ, Med Ctr, Dept Surg, Indianapolis, IN 46202 USA.
[Brugge, William R.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Med,Div Gastroenterol, Boston, MA USA.
[Layfield, Lester J.] Univ Missouri, Dept Pathol & Anat Sci, Columbia, MO USA.
RP Pitman, MB (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02138 USA.
EM mpitman@partners.org; barbara.centeno@moffitt.org; sali@jhmi.edu;
Muriel.Genevay@dianapath.ch; es7yj@cms.mail.virginia.edu;
mminokenudson@partners.org; cfernandez@partners.org; maxschmi@iupui.edu;
wbrugge@partners.org; layfieldl@health.missouri.edu
NR 86
TC 4
Z9 4
U1 0
U2 1
PU MEDKNOW PUBLICATIONS & MEDIA PVT LTD
PI MUMBAI
PA B-9, KANARA BUSINESS CENTRE, OFF LINK RD, GHAKTOPAR-E, MUMBAI, 400075,
INDIA
SN 0974-5963
EI 1742-6413
J9 CYTOJOURNAL
JI CytoJournal
PD JUN 2
PY 2014
VL 11
AR 3
DI 10.4103/1742-6413.133343
PG 13
WC Pathology
SC Pathology
GA AO3QV
UT WOS:000341249800003
PM 25191517
ER
PT J
AU Kana, RK
Uddin, LQ
Kenet, T
Chugani, D
Muller, RA
AF Kana, Rajesh K.
Uddin, Lucina Q.
Kenet, Tal
Chugani, Diane
Mueller, Ralph-Axel
TI Brain connectivity in autism
SO FRONTIERS IN HUMAN NEUROSCIENCE
LA English
DT Editorial Material
DE brain connectivity; multimodal imaging methods; diffusion tensor
imaging; functional connectivity; autism spectrum disorders; white
matter
ID HIGH-FUNCTIONING AUTISM; UNDERCONNECTIVITY; DISORDER; MOTION; MRI
C1 [Kana, Rajesh K.] Univ Alabama Birmingham, Birmingham, AL 35294 USA.
[Uddin, Lucina Q.] Univ Miami, Coral Gables, FL 33124 USA.
[Kenet, Tal] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Chugani, Diane] Wayne State Univ, Dept Pediat, Detroit, MI 48202 USA.
[Chugani, Diane] Wayne State Univ, Dept Neurol, Detroit, MI USA.
[Mueller, Ralph-Axel] San Diego State Univ, Dept Psychol, San Diego, CA 92182 USA.
RP Kana, RK (reprint author), Univ Alabama Birmingham, Birmingham, AL 35294 USA.
OI Uddin, Lucina/0000-0003-2278-8962
NR 28
TC 18
Z9 19
U1 5
U2 24
PU FRONTIERS RESEARCH FOUNDATION
PI LAUSANNE
PA PO BOX 110, LAUSANNE, 1015, SWITZERLAND
SN 1662-5161
J9 FRONT HUM NEUROSCI
JI Front. Hum. Neurosci.
PD JUN 2
PY 2014
VL 8
AR 349
DI 10.3389/fnhum.2014.00349
PG 4
WC Neurosciences; Psychology
SC Neurosciences & Neurology; Psychology
GA AM0XE
UT WOS:000339570200001
PM 24917800
ER
PT J
AU Colen, RR
Vangel, M
Wang, JX
Gutman, DA
Hwang, SN
Wintermark, M
Jain, R
Jilwan-Nicolas, M
Chen, JY
Raghavan, P
Holder, CA
Rubin, D
Huang, E
Kirby, J
Freymann, J
Jaffe, CC
Flanders, A
Zinn, PO
AF Colen, Rivka R.
Vangel, Mark
Wang, Jixin
Gutman, David A.
Hwang, Scott N.
Wintermark, Max
Jain, Rajan
Jilwan-Nicolas, Manal
Chen, James Y.
Raghavan, Prashant
Holder, Chad A.
Rubin, Daniel
Huang, Eric
Kirby, Justin
Freymann, John
Jaffe, Carl C.
Flanders, Adam
Zinn, Pascal O.
CA TCGA Glioma Phenotype Res Grp
TI Imaging genomic mapping of an invasive MRI phenotype predicts patient
outcome and metabolic dysfunction: a TCGA glioma phenotype research
group project
SO BMC MEDICAL GENOMICS
LA English
DT Article
DE Radiogenomics; MRI segmentation; Glioblastoma; Imaging genomics;
Invasion; Biomarker
ID FACTOR-KAPPA-B; CANCER-CELL METABOLISM; GLIOBLASTOMA-MULTIFORME;
GENE-EXPRESSION; MICROARRAY ANALYSIS; IDENTIFICATION; HETEROGENEITY;
MITOCHONDRIA; GENERATION; PROFILE
AB Background: Invasion of tumor cells into adjacent brain parenchyma is a major cause of treatment failure in glioblastoma. Furthermore, invasive tumors are shown to have a different genomic composition and metabolic abnormalities that allow for a more aggressive GBM phenotype and resistance to therapy. We thus seek to identify those genomic abnormalities associated with a highly aggressive and invasive GBM imaging-phenotype.
Methods: We retrospectively identified 104 treatment-naive glioblastoma patients from The Cancer Genome Atlas (TCGA) whom had gene expression profiles and corresponding MR imaging available in The Cancer Imaging Archive (TCIA). The standardized VASARI feature-set criteria were used for the qualitative visual assessments of invasion. Patients were assigned to classes based on the presence (Class A) or absence (Class B) of statistically significant invasion parameters to create an invasive imaging signature; imaging genomic analysis was subsequently performed using GenePattern Comparative Marker Selection module (Broad Institute).
Results: Our results show that patients with a combination of deep white matter tracts and ependymal invasion (Class A) on imaging had a significant decrease in overall survival as compared to patients with absence of such invasive imaging features (Class B) (8.7 versus 18.6 months, p < 0.001). Mitochondrial dysfunction was the top canonical pathway associated with Class A gene expression signature. The MYC oncogene was predicted to be the top activation regulator in Class A.
Conclusion: We demonstrate that MRI biomarker signatures can identify distinct GBM phenotypes associated with highly significant survival differences and specific molecular pathways. This study identifies mitochondrial dysfunction as the top canonical pathway in a very aggressive GBM phenotype. Thus, imaging-genomic analyses may prove invaluable in detecting novel targetable genomic pathways.
C1 [Colen, Rivka R.; Wang, Jixin] Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, Houston, TX 77030 USA.
[Vangel, Mark] Massachussets Gen Hosp, Boston, MA USA.
[Gutman, David A.; Hwang, Scott N.; Holder, Chad A.] Emory Univ, Dept Radiol, Atlanta, GA 30322 USA.
[Wintermark, Max; Jilwan-Nicolas, Manal; Raghavan, Prashant] Univ Virginia, Charlottesville, VA USA.
[Jain, Rajan] NYU, Dept Radiol, Med Ctr, New York, NY 10016 USA.
[Chen, James Y.] Univ Calif San Diego, San Diego, CA 92103 USA.
[Chen, James Y.] Univ Calif San Diego, San Diego Med Ctr, Dept Radiol, San Diego, CA 92103 USA.
[Rubin, Daniel] Stanford Univ, Stanford, CA 94305 USA.
[Huang, Eric; Kirby, Justin; Freymann, John] Leidos Biomed Res Inc, Clin Monitoring Res Program, Frederick Natl Lab Canc Res, Frederick, MD 21702 USA.
[Jaffe, Carl C.] NCI, NIH, Rockville, MD USA.
[Flanders, Adam] Thomas Jefferson Univ Hosp, Dept Radiol, Philadelphia, PA 19107 USA.
[Zinn, Pascal O.] Baylor Coll Med, Dept Neurosurg, Houston, TX 77030 USA.
RP Colen, RR (reprint author), Univ Texas MD Anderson Canc Ctr, Dept Diagnost Radiol, 1400 Pressler St,Unit 1482,Rm FCT 16-5037, Houston, TX 77030 USA.
EM rcolen@mdanderson.org; zinn@bcm.edu
OI Hwang, Scott/0000-0002-6496-2087; Wintermark, Max/0000-0002-6726-3951
FU John S. Dunn Research Foundation Center for Radiological Sciences;
MDACC; National Cancer Institute, National Institutes of Health
[HHSN261200800001E]
FX This work was supported in part by the John S. Dunn Research Foundation
Center for Radiological Sciences (RRC). This work was supported in part
by MDACC startup funding (RRC). This project has been funded in whole or
in part with federal funds from the National Cancer Institute, National
Institutes of Health, under Contract No. HHSN261200800001E. The content
of this publication does not necessarily reflect the views or policies
of the Department of Health and Human Services, nor does mention of
trade names, commercial products, or organizations imply endorsement by
the U.S. Government (JK and JF).
NR 45
TC 16
Z9 16
U1 1
U2 12
PU BIOMED CENTRAL LTD
PI LONDON
PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND
SN 1755-8794
J9 BMC MED GENOMICS
JI BMC Med. Genomics
PD JUN 2
PY 2014
VL 7
AR 30
DI 10.1186/1755-8794-7-30
PG 9
WC Genetics & Heredity
SC Genetics & Heredity
GA AK5KX
UT WOS:000338464600001
PM 24889866
ER
PT J
AU Weber, GF
Chousterman, BG
Hilgendorf, I
Robbins, CS
Theurl, I
Gerhardt, LMS
Iwamoto, Y
Quach, TD
Ali, M
Chen, JW
Rothstein, TL
Nahrendorf, M
Weissleder, R
Swirski, FK
AF Weber, Georg F.
Chousterman, Benjamin G.
Hilgendorf, Ingo
Robbins, Clinton S.
Theurl, Igor
Gerhardt, Louisa M. S.
Iwamoto, Yoshiko
Quach, Tam D.
Ali, Muhammad
Chen, John W.
Rothstein, Thomas L.
Nahrendorf, Matthias
Weissleder, Ralph
Swirski, Filip K.
TI Pleural innate response activator B cells protect against pneumonia via
a GM-CSF-IgM axis
SO JOURNAL OF EXPERIMENTAL MEDICINE
LA English
DT Article
ID COLONY-STIMULATING FACTOR; INFLUENZA-VIRUS INFECTION; ANTIBODY-PRODUCING
CELLS; IMMUNOGLOBULIN-M; DEFICIENT MICE; BONE-MARROW; T-CELLS;
DIFFERENTIATION; EXPRESSION; BLIMP-1
AB Pneumonia is a major cause of mortality worldwide and a serious problem in critical care medicine, but the immunophysiological processes that confer either protection or morbidity are not completely understood. We show that in response to lung infection, B1a B cells migrate from the pleural space to the lung parenchyma to secrete polyreactive emergency immunoglobulin M ( IgM). The process requires innate response activator (IRA) B cells, a transitional B1a-derived inflammatory subset which controls IgM production via autocrine granulocyte/macrophage colony-stimulating factor (GM-CSF) signaling. The strategic location of these cells, coupled with the capacity to produce GM-CSF-dependent IgM, ensures effective early frontline defense against bacteria invading the lungs. The study describes a previously unrecognized GM-CSF-IgM axis and positions IRA B cells as orchestrators of protective IgM immunity.
C1 [Weber, Georg F.; Chousterman, Benjamin G.; Hilgendorf, Ingo; Robbins, Clinton S.; Theurl, Igor; Gerhardt, Louisa M. S.; Iwamoto, Yoshiko; Ali, Muhammad; Chen, John W.; Nahrendorf, Matthias; Weissleder, Ralph; Swirski, Filip K.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Weber, Georg F.] Tech Univ Dresden, Med Fak Carl Gustav Carus, Dept Visceral Thorac & Vasc Surg, D-01307 Dresden, Germany.
[Quach, Tam D.; Rothstein, Thomas L.] Feinstein Inst Med Res, Ctr Oncol & Cell Biol, Manhasset, NY 11030 USA.
[Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
RP Swirski, FK (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
EM georg.weber@uniklinikum-dresden.de; fswirski@mgh.harvard.edu
FU National Institutes of Health [R01HL095612, R56AI104695, AI029690];
German Research Foundation; Societe Francaise d'Anesthesie-Reanimation;
Institut Servier; Fondation Groupe Pasteur Mutualite; Fulbright
Scholarship (Monahan Foundation); MGH Executive Committee on Research
(ECOR) Postdoctoral Award; Max Kade Foundation; Boehringer Ingelheim
Fonds; Fulbright Scholarship (Fulbright Scholarship)
FX This work was supported by National Institutes of Health grant
R01HL095612 and R56AI104695 (to F.K. Swirski) and AI029690 (to T.L.
Rothstein). G.F. Weber and I. Hilgendorf were supported by the German
Research Foundation. B.G. Chousterman was supported by Societe Francaise
d'Anesthesie-Reanimation, Institut Servier, Fondation Groupe Pasteur
Mutualite, and a Fulbright Scholarship (Monahan Foundation and Harvard
French Scholarship Fund). C.S. Robbins was supported by the MGH
Executive Committee on Research (ECOR) Postdoctoral Award. I. Theurl was
supported by the Max Kade Foundation. L.M.S. Gerhardt was supported by
the Boehringer Ingelheim Fonds.
NR 55
TC 33
Z9 33
U1 2
U2 5
PU ROCKEFELLER UNIV PRESS
PI NEW YORK
PA 1114 FIRST AVE, 4TH FL, NEW YORK, NY 10021 USA
SN 0022-1007
EI 1540-9538
J9 J EXP MED
JI J. Exp. Med.
PD JUN 2
PY 2014
VL 211
IS 6
BP 1243
EP 1256
DI 10.1084/jem.20131471
PG 14
WC Immunology; Medicine, Research & Experimental
SC Immunology; Research & Experimental Medicine
GA AJ0RV
UT WOS:000337364500018
PM 24821911
ER
PT J
AU Tompkins, RG
AF Tompkins, R. G.
TI GENOMIC RESPONSES IN MOUSE MODELS POORLY MIMIC HUMAN INFLAMMATORY
DISEASES
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
CT 15th Annual European Congress of Rheumatology (EULAR)
CY JUN 11-14, 2014
CL Paris, FRANCE
C1 [Tompkins, R. G.] Harvard Univ, Sch Med, Mass Gen Hosp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 5
U2 7
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2014
VL 73
SU 2
MA SP0136
BP 37
EP 37
DI 10.1136/annrheumdis-2014-eular.1698
PG 1
WC Rheumatology
SC Rheumatology
GA AX4RT
UT WOS:000346919800137
ER
PT J
AU Stone, JH
AF Stone, J. H.
TI IGG4-RELATED DISEASE
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
CT 15th Annual European Congress of Rheumatology (EULAR)
CY JUN 11-14, 2014
CL Paris, FRANCE
C1 [Stone, J. H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2014
VL 73
SU 2
MA SP0205
BP 53
EP 53
DI 10.1136/annrheumdis-2014-eular.6350
PG 1
WC Rheumatology
SC Rheumatology
GA AX4RT
UT WOS:000346919800205
ER
PT J
AU Owczarczyk, K
Holweg, C
Ortmann, W
Behrens, T
Brunetta, P
Specks, U
Phippard, D
Ding, L
Lim, N
Tchao, N
Ikle, D
Stone, J
AF Owczarczyk, K.
Holweg, C.
Ortmann, W.
Behrens, T.
Brunetta, P.
Specks, U.
Phippard, D.
Ding, L.
Lim, N.
Tchao, N.
Ikle, D.
Stone, J.
CA Rave-Itn Res Grp
TI THE ROLE OF BASELINE FCRL5 MRNA EXPRESSION IN PREDICTING RESPONSE TO
RITUXIMAB (RTX) THERAPY IN PATIENTS WITH GRANULOMATOUS POLYANGIITIS
(GPA) OR MICROSCOPIC POLYANGIITIS (MPA)
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
CT 15th Annual European Congress of Rheumatology (EULAR)
CY JUN 11-14, 2014
CL Paris, FRANCE
C1 [Owczarczyk, K.] Royal Free Hosp, London NW3 2QG, England.
[Holweg, C.; Ortmann, W.; Behrens, T.; Brunetta, P.] Genentech Inc, San Francisco, CA USA.
[Specks, U.] Mayo Clin Fdn, Rochester, MN USA.
[Ding, L.] NIAID, Bethesda, MD 20892 USA.
[Ikle, D.] Rho, Chapel Hill, NC USA.
[Stone, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2014
VL 73
SU 2
MA OP0232
BP 150
EP 150
DI 10.1136/annrheumdis-2014-eular.4265
PG 1
WC Rheumatology
SC Rheumatology
GA AX4RT
UT WOS:000346919800452
ER
PT J
AU Castelino, FV
George, LM
Bain, G
Goulet, L
Lafyatis, R
Tager, AM
AF Castelino, F. V.
George, L. M.
Bain, G.
Goulet, L.
Lafyatis, R.
Tager, A. M.
TI AUTOTAXIN IS OVER-EXPRESSED IN SYSTEMIC SCLEROSIS (SSC) SKIN, MEDIATES
BLEOMYCIN-INDUCED DERMAL FIBROSIS VIA IL-6, AND IS A TARGET FOR SSC
THERAPY
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
CT 15th Annual European Congress of Rheumatology (EULAR)
CY JUN 11-14, 2014
CL Paris, FRANCE
C1 [Castelino, F. V.] Massachusetts Gen Hosp, Rheumatol, Boston, MA 02114 USA.
[George, L. M.; Tager, A. M.] Massachusetts Gen Hosp, Pulmonary & Crit Care, Boston, MA 02114 USA.
[Bain, G.; Goulet, L.] PharmAkea Therapeut, San Diego, CA USA.
[Lafyatis, R.] Boston Univ, Rheumatol, Boston, MA 02215 USA.
NR 1
TC 1
Z9 1
U1 3
U2 4
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2014
VL 73
SU 2
MA OP0241
BP 153
EP 153
DI 10.1136/annrheumdis-2014-eular.2979
PG 1
WC Rheumatology
SC Rheumatology
GA AX4RT
UT WOS:000346919800461
ER
PT J
AU Ng, B
AF Ng, B.
TI FACTORS ASSOCIATED WITH METHOTREXATE TREATMENT DURATION, INCLUDING
SUBCUTANEOUS USE, IN PATIENTS WITH RHEUMATOID ARTHRITIS: OBSERVATIONS
FROM THE VETERANS AFFAIRS DATABASE
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
CT 15th Annual European Congress of Rheumatology (EULAR)
CY JUN 11-14, 2014
CL Paris, FRANCE
C1 [Ng, B.] VA Puget Sound Healthcare Syst, Div Rheumatol, Seattle, WA USA.
[Ng, B.] Univ Washington, Seattle, WA 98195 USA.
NR 2
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2014
VL 73
SU 2
MA THU0115
BP 217
EP 218
DI 10.1136/annrheumdis-2014-eular.3021
PG 2
WC Rheumatology
SC Rheumatology
GA AX4RT
UT WOS:000346919801132
ER
PT J
AU Zeron, PB
Retamozo, S
Gheitasi, H
Bove, A
Kostov, B
Siso-Almirall, A
Ramos-Casals, M
Stone, JH
AF Brito Zeron, P.
Retamozo, S.
Gheitasi, H.
Bove, A.
Kostov, B.
Siso-Almirall, A.
Ramos-Casals, M.
Stone, J. H.
CA GEAS-SEMI Study Grp
TI IGG4-RELATED DISEASE OR PRIMARY SJOGREN SYNDROME? ORGAN-SPECIFIC
INVOLVEMENT AND IMMUNOLOGICAL PROFILE ARE CLUES IN DIFFERENTIATING TWO
DISEASES WITH A COMMON CLINICAL PRESENTATION
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
CT 15th Annual European Congress of Rheumatology (EULAR)
CY JUN 11-14, 2014
CL Paris, FRANCE
C1 [Brito Zeron, P.; Retamozo, S.; Gheitasi, H.; Bove, A.; Ramos-Casals, M.] Hosp Clin Barcelona, IDIBAPS, Lab Autoimmune Dis Josep Font, Dept Autoimmune Dis,ICMiD, Barcelona, Spain.
[Kostov, B.; Siso-Almirall, A.] CAPSE, Primary Care Res Grp, IDIBAPS, Ctr Assistencia Primaria ABS Les Corts, Barcelona, Spain.
[Stone, J. H.] Harvard Univ, Sch Med, Boston, MA USA.
[Stone, J. H.] Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2014
VL 73
SU 2
MA THU0396
BP 318
EP 319
DI 10.1136/annrheumdis-2014-eular.5099
PG 2
WC Rheumatology
SC Rheumatology
GA AX4RT
UT WOS:000346919801412
ER
PT J
AU Nagaraja, V
Spiegel, BM
Hays, RD
Khanna, P
Chang, L
Melmed, GY
Bolus, R
Khanna, D
AF Nagaraja, V.
Spiegel, B. M.
Hays, R. D.
Khanna, P.
Chang, L.
Melmed, G. Y.
Bolus, R.
Khanna, D.
TI DEVELOPMENT AND VALIDATION OF PATIENT-REPORTED OUTCOMES MEASUREMENT
INFORMATION SYSTEM (PROMIS (R)) GASTROINTESTINAL (GI) SYMPTOM SCALES IN
SYSTEMIC SCLEROSIS
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
CT 15th Annual European Congress of Rheumatology (EULAR)
CY JUN 11-14, 2014
CL Paris, FRANCE
C1 [Nagaraja, V.; Khanna, P.; Khanna, D.] Univ Michigan, Div Rheumatol, Ann Arbor, MI 48109 USA.
[Spiegel, B. M.] Vet Affairs Greater Los Angeles Healthcare Syst, Div Gastroenterol, Los Angeles, CA USA.
[Hays, R. D.] Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA USA.
[Chang, L.; Bolus, R.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Los Angeles, CA 90095 USA.
[Melmed, G. Y.] Cedars Sinai Med Ctr, Div Gastroenterol, Los Angeles, CA 90048 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2014
VL 73
SU 2
MA FRI0223
BP 463
EP 463
DI 10.1136/annrheumdis-2014-eular.2423
PG 1
WC Rheumatology
SC Rheumatology
GA AX4RT
UT WOS:000346919802328
ER
PT J
AU Singh, JA
AF Singh, J. A.
TI THE IMPACT OF GOUT ON PATIENT'S LIVES AND DIFFERENCES BY RACE AND
GENDER: A PATIENT PERSPECTIVE
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
CT 15th Annual European Congress of Rheumatology (EULAR)
CY JUN 11-14, 2014
CL Paris, FRANCE
C1 [Singh, J. A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Singh, J. A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2014
VL 73
SU 2
MA SAT0520
BP 779
EP 780
DI 10.1136/annrheumdis-2014-eular.1147
PG 2
WC Rheumatology
SC Rheumatology
GA AX4RT
UT WOS:000346919804247
ER
PT J
AU Singh, JA
AF Singh, J. A.
TI FACILITATORS AND BARRIERS TO ADHERENCE TO URATE-LOWERING THERAPY IN
AFRICAN-AMERICANS WITH GOUT: A QUALITATIVE STUDY
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
CT 15th Annual European Congress of Rheumatology (EULAR)
CY JUN 11-14, 2014
CL Paris, FRANCE
C1 [Singh, J. A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Singh, J. A.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2014
VL 73
SU 2
MA SAT0519
BP 779
EP 779
DI 10.1136/annrheumdis-2014-eular.1148
PG 1
WC Rheumatology
SC Rheumatology
GA AX4RT
UT WOS:000346919804246
ER
PT J
AU Singh, JA
Bharat, A
Edwards, L
AF Singh, J. A.
Bharat, A.
Edwards, L.
TI AN INTERNET SURVEY OF COMMON TREATMENTS USED BY PATIENTS WITH GOUT
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
CT 15th Annual European Congress of Rheumatology (EULAR)
CY JUN 11-14, 2014
CL Paris, FRANCE
C1 [Singh, J. A.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Singh, J. A.; Bharat, A.] Univ Alabama Birmingham, Birmingham, AL USA.
[Edwards, L.] Univ Florida, Gainesville, FL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2014
VL 73
SU 2
MA AB0833
BP 1078
EP 1078
DI 10.1136/annrheumdis-2014-eular.4846
PG 1
WC Rheumatology
SC Rheumatology
GA AX4RT
UT WOS:000346919806113
ER
PT J
AU Bessette, L
Liote, F
Moragues, C
Moericke, R
Zhang, Z
Ferreira, A
Lecomte, P
Kessabi, S
Tian, H
Li, L
Singh, J
AF Bessette, L.
Liote, F.
Moragues, C.
Moericke, R.
Zhang, Z.
Ferreira, A.
Lecomte, P.
Kessabi, S.
Tian, H.
Li, L.
Singh, J.
TI BURDEN OF REFRACTORY GOUTY ARTHRITIS AMONG DIFFICULT-TO-TREAT PATIENTS
OVER ONE YEAR: POST- HOC ANALYSIS FROM MOTION OBSERVATIONAL STUDY
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
CT 15th Annual European Congress of Rheumatology (EULAR)
CY JUN 11-14, 2014
CL Paris, FRANCE
C1 [Bessette, L.] CHUL, Quebec City, PQ, Canada.
[Liote, F.] Hosp Lariboisiere, Paris, France.
[Moragues, C.] Hosp Platon, Barcelona, Spain.
[Moericke, R.] Inst Pravent Med, Magdeburg, Germany.
[Moericke, R.] Klin Forsch GbR, Magdeburg, Germany.
[Zhang, Z.] Haerbin Med Univ, Affiliated Hosp 1, Haerbin City, Peoples R China.
[Ferreira, A.; Lecomte, P.; Kessabi, S.] Novartis Pharmaceut AG, Basel, Switzerland.
[Tian, H.] Novartis Pharmaceut, E Hanover, NJ USA.
[Li, L.] Novartis Pharmaceut, Shanghai, Peoples R China.
[Singh, J.] Univ Alabama Birmingham, Birmingham, AL USA.
[Singh, J.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2014
VL 73
SU 2
MA AB1069
BP 1154
EP 1155
DI 10.1136/annrheumdis-2014-eular.4348
PG 2
WC Rheumatology
SC Rheumatology
GA AX4RT
UT WOS:000346919806349
ER
PT J
AU Bessette, L
Liote, F
Moragues, C
Moericke, R
Zhang, Z
Lecomte, P
Ferreira, A
Kessabi, S
Tian, H
Li, L
Singh, J
AF Bessette, L.
Liote, F.
Moragues, C.
Moericke, R.
Zhang, Z.
Lecomte, P.
Ferreira, A.
Kessabi, S.
Tian, H.
Li, L.
Singh, J.
TI DISEASE BURDEN OF REFRACTORY GOUTY ARTHRITIS: A ONE YEAR MULTINATIONAL
PROSPECTIVE OBSERVATIONAL STUDY
SO ANNALS OF THE RHEUMATIC DISEASES
LA English
DT Meeting Abstract
CT 15th Annual European Congress of Rheumatology (EULAR)
CY JUN 11-14, 2014
CL Paris, FRANCE
C1 [Bessette, L.] CHUL, Quebec City, PQ, Canada.
[Liote, F.] Hop Lariboisiere, F-75475 Paris, France.
[Moragues, C.] Hosp Platon, Barcelona, Spain.
[Moericke, R.] Inst Pravent Med, Magdeburg, Germany.
[Moericke, R.] Klin Forsch GbR, Magdeburg, Germany.
[Zhang, Z.] Haerbin Med Univ, Affiliated Hosp 1, Haerbin City, Peoples R China.
[Lecomte, P.; Ferreira, A.; Kessabi, S.] Novartis Pharmaceut AG, Basel, Switzerland.
[Tian, H.] Novartis Pharmaceut, E Hanover, NJ USA.
[Li, L.] Novartis Pharmaceut, Shanghai, Peoples R China.
[Singh, J.] Univ Alabama Birmingham, Birmingham, AL USA.
[Singh, J.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 0003-4967
EI 1468-2060
J9 ANN RHEUM DIS
JI Ann. Rheum. Dis.
PD JUN
PY 2014
VL 73
SU 2
MA AB1068
BP 1154
EP 1154
DI 10.1136/annrheumdis-2014-eular.4215
PG 1
WC Rheumatology
SC Rheumatology
GA AX4RT
UT WOS:000346919806348
ER
PT J
AU Guanci, MM
AF Guanci, Mary McKenna
TI We recently had a 50-year-old patient with a large middle cerebral
artery (MCA) ischemic stroke who deteriorated within hours of admission.
When his right pupil became large and nonreactive, the neurosurgeon was
called who did a craniectomy. He ordered mild hypothermia (34 degrees C
target) for 72 hours. What are the challenges and nursing interventions
related to instituting mild hypothermia in this patient population?
SO THERAPEUTIC HYPOTHERMIA AND TEMPERATURE MANAGEMENT
LA English
DT Letter
ID THERAPEUTIC HYPOTHERMIA
C1 Massachusetts Gen Hosp, Neurosci ICU, Boston, MA 02114 USA.
RP Guanci, MM (reprint author), Massachusetts Gen Hosp, Neurosci ICU, Boston, MA 02114 USA.
NR 4
TC 0
Z9 0
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2153-7658
EI 2153-7933
J9 THER HYPOTHERMIA TEM
JI Ther. Hypothermia Temp. Manag.
PD JUN 1
PY 2014
VL 4
IS 2
BP 102
EP 102
PG 1
WC Critical Care Medicine
SC General & Internal Medicine
GA CF3UL
UT WOS:000352474100013
ER
PT J
AU Cole, C
AF Cole, Clare
TI Successful Pregnancy and Delivery with Maple Syrup Urine Disease
SO JOGNN-JOURNAL OF OBSTETRIC GYNECOLOGIC AND NEONATAL NURSING
LA English
DT Meeting Abstract
DE maple syrup urine disease; pregnancy; postpartum
C1 [Cole, Clare] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0884-2175
EI 1552-6909
J9 JOGNN-J OBST GYN NEO
JI JOGNN
PD JUN
PY 2014
VL 43
SU 1
SI SI
BP S95
EP S96
DI 10.1111/1552-6909.12336
PG 2
WC Nursing; Obstetrics & Gynecology
SC Nursing; Obstetrics & Gynecology
GA CB9NR
UT WOS:000349959000133
ER
PT J
AU Mifflin, J
AF Mifflin, Jeffrey
TI CARLETON WATKINS: The Stanford Albums
SO JOURNAL OF THE WEST
LA English
DT Book Review
C1 [Mifflin, Jeffrey] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Mifflin, J (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 1
TC 0
Z9 0
U1 0
U2 2
PU ABC-CLIO
PI SANTA BARBARA
PA 130 CREMONA DR, SANTA BARBARA, CA 93117 USA
SN 0022-5169
EI 1930-0115
J9 J WEST
JI J. West
PD SUM
PY 2014
VL 53
IS 3
BP 89
EP 89
PG 1
WC History
SC History
GA CC1DQ
UT WOS:000350081800014
ER
PT J
AU Mifflin, J
AF Mifflin, Jeffrey
TI IRON MUSE: Photographing the Transcontinental Railroad
SO JOURNAL OF THE WEST
LA English
DT Book Review
C1 [Mifflin, Jeffrey] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Mifflin, J (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ABC-CLIO
PI SANTA BARBARA
PA 130 CREMONA DR, SANTA BARBARA, CA 93117 USA
SN 0022-5169
EI 1930-0115
J9 J WEST
JI J. West
PD SUM
PY 2014
VL 53
IS 3
BP 95
EP 95
PG 1
WC History
SC History
GA CC1DQ
UT WOS:000350081800029
ER
PT J
AU Baker, JM
Boyce, FM
AF Baker, Jessica M.
Boyce, Frederick M.
TI High-throughput Functional Screening using a Homemade Dual-glow
Luciferase Assay
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Cellular Biology; Issue 88; Luciferases; Gene Transfer Techniques;
Transfection; High-Throughput Screening Assays; Transfections; Robotics
ID ALPHA-SYNUCLEIN GENE; FAMILIAL PARKINSONS-DISEASE; MAMMALIAN-CELLS;
ALLELIC VARIATION; DUPLICATION; LOCUS; TRANSCRIPTION; NACP-REP1; SYSTEM;
GENOME
AB We present a rapid and inexpensive high-throughput screening protocol to identify transcriptional regulators of alpha-synuclein, a gene associated with Parkinson's disease. 293T cells are transiently transfected with plasmids from an arrayed ORF expression library, together with luciferase reporter plasmids, in a one-gene-per-well microplate format. Firefly luciferase activity is assayed after 48 hr to determine the effects of each library gene upon alpha-synuclein transcription, normalized to expression from an internal control construct (a hCMV promoter directing Renilla luciferase). This protocol is facilitated by a bench-top robot enclosed in a biosafety cabinet, which performs aseptic liquid handling in 96-well format. Our automated transfection protocol is readily adaptable to high-throughput lentiviral library production or other functional screening protocols requiring triple-transfections of large numbers of unique library plasmids in conjunction with a common set of helper plasmids. We also present an inexpensive and validated alternative to commercially-available, dual luciferase reagents which employs PTC124, EDTA, and pyrophosphate to suppress firefly luciferase activity prior to measurement of Renilla luciferase. Using these methods, we screened 7,670 human genes and identified 68 regulators of alpha-synuclein. This protocol is easily modifiable to target other genes of interest.
C1 [Baker, Jessica M.; Boyce, Frederick M.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RP Boyce, FM (reprint author), Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
EM fmboyce@rics.bwh.harvard.edu
NR 23
TC 1
Z9 1
U1 2
U2 7
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD JUN
PY 2014
IS 88
AR e50282
DI 10.3791/50282
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CB0BQ
UT WOS:000349290100003
ER
PT J
AU Jones, CN
Hoang, AN
Dimisko, L
Hamza, B
Martel, J
Irimia, D
AF Jones, Caroline N.
Hoang, Anh N.
Dimisko, Laurie
Hamza, Bashar
Martel, Joseph
Irimia, Daniel
TI Microfluidic Platform for Measuring Neutrophil Chemotaxis from
Unprocessed Whole Blood
SO JOVE-JOURNAL OF VISUALIZED EXPERIMENTS
LA English
DT Article
DE Bioengineering; Issue 88; chemotaxis; neutrophil; whole blood assay;
microfluidic device; chemoattractant; migration; inflammation
ID INFLAMMATION
AB Neutrophils play an essential role in protection against infections and their numbers in the blood are frequently measured in the clinic. Higher neutrophil counts in the blood are usually an indicator of ongoing infections, while low neutrophil counts are a warning sign for higher risks for infections. To accomplish their functions, neutrophils also have to be able to move effectively from the blood where they spend most of their life, into tissues, where infections occur. Consequently, any defects in the ability of neutrophils to migrate can increase the risks for infections, even when neutrophils are present in appropriate numbers in the blood. However, measuring neutrophil migration ability in the clinic is a challenging task, which is time consuming, requires large volume of blood, and expert knowledge. To address these limitations, we designed a robust microfluidic assays for neutrophil migration, which requires a single droplet of unprocessed blood, circumvents the need for neutrophil separation, and is easy to quantify on a simple microscope. In this assay, neutrophils migrate directly from the blood droplet, through small channels, towards the source of chemoattractant. To prevent the granular flow of red blood cells through the same channels, we implemented mechanical filters with right angle turns that selectively block the advance of red blood cells. We validated the assay by comparing neutrophil migration from blood droplets collected from finger prick and venous blood. We also compared these whole blood (WB) sources with neutrophil migration from samples of purified neutrophils and found consistent speed and directionality between the three sources. This microfluidic platform will enable the study of human neutrophil migration in the clinic and the research setting to help advance our understanding of neutrophil functions in health and disease.
C1 [Jones, Caroline N.; Hoang, Anh N.; Dimisko, Laurie; Hamza, Bashar; Martel, Joseph; Irimia, Daniel] Massachusetts Gen Hosp, Dept Surg, BioMEMS Resource Ctr, Boston, MA 02114 USA.
[Jones, Caroline N.; Hoang, Anh N.; Irimia, Daniel] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Jones, Caroline N.; Hoang, Anh N.; Irimia, Daniel] Shriners Burns Hosp, Boston, MA USA.
[Martel, Joseph] Harvard Univ, Sch Engn & Appl Sci, Cambridge, MA 02138 USA.
RP Irimia, D (reprint author), Massachusetts Gen Hosp, Dept Surg, BioMEMS Resource Ctr, Boston, MA 02114 USA.
EM DIRIMIA@partners.org
FU National Institutes of Health [GM092804, DE019938]; Shriners Burns
Hospital
FX Support from the National Institutes of Health (grants GM092804,
DE019938) and Shriners Burns Hospital.
NR 17
TC 1
Z9 1
U1 1
U2 3
PU JOURNAL OF VISUALIZED EXPERIMENTS
PI CAMBRIDGE
PA 1 ALEWIFE CENTER, STE 200, CAMBRIDGE, MA 02140 USA
SN 1940-087X
J9 JOVE-J VIS EXP
JI J. Vis. Exp.
PD JUN
PY 2014
IS 88
AR e51215
DI 10.3791/51215
PG 6
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA CB0BQ
UT WOS:000349290100015
ER
PT J
AU Parsania, S
Shabani, M
Moazzami, K
Razavinasab, M
Larizadeh, MH
Nazeri, M
Asadi-Shekaari, M
Kermani, M
AF Parsania, Shahrnaz
Shabani, Mohammad
Moazzami, Kasra
Razavinasab, Moazamehosdadat
Larizadeh, Mohammad Hassan
Nazeri, Masoud
Asadi-Shekaari, Majid
Kermani, Moein
TI Gender difference in motor impairments induced by chronic administration
of vinblastine
SO IRANIAN JOURNAL OF BASIC MEDICAL SCIENCES
LA English
DT Article
DE Anticancer; Learning and memory; Motor function; Vinblastine
ID SEXUAL-DIMORPHISM; FEMALE RATS; PERIPHERAL NEUROPATHY; CISPLATIN;
EXPOSURE; MEMORY; PERFORMANCE; VINFLUNINE; COLCHICINE; LEUKEMIA
AB Objective(s): Neurotoxicity of anticancer drugs complicates treatment of cancer patients. Vinblastine (VBL) is reported to induce motor and cognitive impairments in patients receiving chronic low-dose regimen.
Materials and Methods: The effects of VBL treatment on motor, learning and memory functions of male and female Wistar rats were studied by behavioral related tests. Animals were given chronic intraperitoneal injections of VBL (0.2 mg/kg/week for 5 weeks) from postnatal day 23 to 52. Motor function was evaluated using grasping test and balancing was evaluated by the rotarod. Spatial learning and memory and anxiety-like behavior were determined using Morris water maze (MWM) task and open field test, respectively.
Results: Administration of VBL caused severe damage to motor and balance function of male rats in comparison to female rats treated with VBL and rats treated with saline. Memory and locomotion were affected in both male and female rats compared with saline treated rats, while a sex difference was also observed in these parameters; male rats showed more impairment compared with female ones. Both male and female rats showed cognitive impairments in MWM task and no sex differences were observed in these functions.
Conclusion: Results revealed that VBL is a potent neurotoxic agent and despite the profound effect of VBL on motor and cognitive functions, it seems that male rats are more susceptible to motor deficits induced by VBL.
C1 [Parsania, Shahrnaz; Razavinasab, Moazamehosdadat] Kerman Univ Med Sci, Neuropharmacol Inst, Physiol Res Ctr, Kerman, Iran.
[Shabani, Mohammad; Asadi-Shekaari, Majid] Kerman Univ Med Sci, Neuropharmacol Inst, Kerman Neurosci Res Ctr, Kerman, Iran.
[Moazzami, Kasra] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Cardiovasc Res Ctr, Boston, MA 02129 USA.
[Larizadeh, Mohammad Hassan] Kerman Univ Med Sci, Dept Radiat Oncol, Kerman, Iran.
[Nazeri, Masoud; Kermani, Moein] Kerman Univ Med Sci, Student Res Committee, Kerman, Iran.
RP Shabani, M (reprint author), Kerman Univ Med Sci, Neuropharmacol Inst, Kerman Neurosci Res Ctr, Kerman, Iran.
EM shabanimoh@yahoo.com
RI Asadi-Shekaari, Majid/H-1791-2015
OI Asadi-Shekaari, Majid/0000-0003-4367-2280
NR 40
TC 2
Z9 2
U1 0
U2 1
PU MASHHAD UNIV MED SCIENCES
PI MASHHAD
PA VICE-CHANCELLOR FOR RES CTR OFF IJBMS, DANESHGAH ST, PO BOX 9138813944 -
445, MASHHAD, 00000, IRAN
SN 2008-3866
EI 2008-3874
J9 IRAN J BASIC MED SCI
JI Iran. J. Basic Med. Sci.
PD JUN
PY 2014
VL 17
IS 6
BP 433
EP 440
PG 8
WC Medicine, Research & Experimental; Pharmacology & Pharmacy
SC Research & Experimental Medicine; Pharmacology & Pharmacy
GA AU1BJ
UT WOS:000345355700007
PM 25140205
ER
PT J
AU Hess, DR
Altobelli, NP
AF Hess, Dean R.
Altobelli, Neila P.
TI Tracheostomy Tubes
SO RESPIRATORY CARE
LA English
DT Article
DE airway management; decannulation; fenestrated tracheostomy tube; inner
cannula; speaking valve; tracheostomy button; tracheostomy team;
tracheostomy tube
ID VENTILATOR-DEPENDENT PATIENTS; MECHANICAL VENTILATION; SPEAKING VALVE;
NEUROMUSCULAR DISEASE; SPEECH PRODUCTION; WARD MORTALITY; MATERIAL WEAR;
DECANNULATION; CARE; TEAM
AB Tracheostomy tubes are used to administer positive-pressure ventilation, to provide a patent airway, and to provide access to the lower respiratory tract for airway clearance. They are available in a variety of sizes and styles from several manufacturers. The dimensions of tracheostomy tubes are given by their inner diameter, outer diameter, length, and curvature. Differences in dimensions between tubes with the same inner diameter from different manufacturers are not commonly appreciated but may have important clinical implications. Tracheostomy tubes can be cuffed or uncuffed and may be fenestrated. Some tracheostomy tubes are designed with an inner cannula. It is important for clinicians caring for patients with a tracheostomy tube to appreciate the nuances of various tracheostomy tube designs and to select a tube that appropriately fits the patient. The optimal frequency of changing a chronic tracheostomy tube is controversial. Specialized teams may be useful in managing patients with a tracheostomy. Speech can be facilitated with a speaking valve in patients with a tracheostomy tube who are breathing spontaneously. In mechanically ventilated patients with a tracheostomy, a talking tracheostomy tube, a deflated cuff technique with a speaking valve, or a deflated cuff technique without a speaking valve can be used to facilitate speech.
C1 [Hess, Dean R.; Altobelli, Neila P.] Massachusetts Gen Hosp, Resp Care Dept, Boston, MA 02114 USA.
[Hess, Dean R.] Harvard Univ, Sch Med, Dept Anesthesia, Boston, MA 02115 USA.
RP Hess, DR (reprint author), Massachusetts Gen Hosp, Ellison 401, Boston, MA 02114 USA.
EM dhess@partners.org
NR 54
TC 3
Z9 5
U1 1
U2 8
PU DAEDALUS ENTERPRISES INC
PI IRVING
PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA
SN 0020-1324
EI 1943-3654
J9 RESP CARE
JI Respir. Care
PD JUN
PY 2014
VL 59
IS 6
BP 956
EP 971
DI 10.4187/respcare.02920
PG 16
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA CA8VT
UT WOS:000349199700018
PM 24891201
ER
PT J
AU Pardee, AB
AF Pardee, Arthur B.
TI Francois Jacob memorial
SO RESEARCH IN MICROBIOLOGY
LA English
DT Biographical-Item
C1 Dana Farber Inst, Dept Adult Oncol, Boston, MA 02115 USA.
RP Pardee, AB (reprint author), Dana Farber Inst, Dept Adult Oncol, Boston, MA 02115 USA.
EM arthur_pardee@dfci.harvard.edu
NR 1
TC 0
Z9 0
U1 1
U2 1
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 0923-2508
EI 1769-7123
J9 RES MICROBIOL
JI Res. Microbiol.
PD JUN
PY 2014
VL 165
IS 5
BP 394
EP 395
DI 10.1016/j.resmic.2014.05.037
PG 2
WC Microbiology
SC Microbiology
GA AY5PS
UT WOS:000347625000030
ER
PT J
AU Kong, CY
Kroep, S
Curtius, K
Hazelton, WD
Jeon, J
Meza, R
Heberle, CR
Miller, MC
Choi, SE
Lansdorp-Vogelaar, I
van Ballegooijen, M
Feuer, EJ
Inadomi, JM
Hur, C
Luebeck, EG
AF Kong, Chung Yin
Kroep, Sonja
Curtius, Kit
Hazelton, William D.
Jeon, Jihyoun
Meza, Rafael
Heberle, Curtis R.
Miller, Melecia C.
Choi, Sung Eun
Lansdorp-Vogelaar, Iris
van Ballegooijen, Marjolein
Feuer, Eric J.
Inadomi, John M.
Hur, Chin
Luebeck, E. Georg
TI Exploring the Recent Trend in Esophageal Adenocarcinoma Incidence and
Mortality Using Comparative Simulation Modeling
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID GASTROESOPHAGEAL-REFLUX DISEASE; HELICOBACTER-PYLORI INFECTION; SERVICES
TASK-FORCE; BARRETTS-ESOPHAGUS; COLORECTAL-CANCER; COST-EFFECTIVENESS;
GASTRIC CARDIA; MEDICARE POPULATION; NATURAL-HISTORY; BREAST-CANCER
AB Background: The incidence of esophageal adenocarcinoma (EAC) has increased five-fold in the United States since 1975. The aim of our study was to estimate future U. S. EAC incidence and mortality and to shed light on the potential drivers in the disease process that are conduits for the dramatic increase in EAC incidence.
Methods: A consortium of three research groups calibrated independent mathematical models to clinical and epidemiologic data including EAC incidence from the Surveillance, Epidemiology, and End Results (SEER 9) registry from 1975 to 2010. We then used a comparative modeling approach to project EAC incidence and mortality to year 2030.
Results: Importantly, all three models identified birth cohort trends affecting cancer progression as a major driver of the observed increases in EAC incidence and mortality. All models predict that incidence and mortality rates will continue to increase until 2030 but with a plateauing trend for recent male cohorts. The predicted ranges of incidence and mortality rates (cases per 100,000 person years) in 2030 are 8.4 to 10.1 and 5.4 to 7.4, respectively, for males, and 1.3 to 1.8 and 0.9 to 1.2 for females. Estimates of cumulative cause-specific EAC deaths between both sexes for years 2011 to 2030 range between 142,300 and 186,298, almost double the number of deaths in the past 20 years.
Conclusions: Through comparative modeling, the projected increases in EAC cases and deaths represent a critical public health concern that warrants attention from cancer control planners to prepare potential interventions.
Impact: Quantifying this burden of disease will aid health policy makers to plan appropriate cancer control measures. (C) 2014 AACR.
C1 [Kong, Chung Yin; Heberle, Curtis R.; Miller, Melecia C.; Choi, Sung Eun; Hur, Chin] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA.
[Heberle, Curtis R.; Miller, Melecia C.; Choi, Sung Eun; Hur, Chin] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Kong, Chung Yin; Hur, Chin] Harvard Univ, Sch Med, Boston, MA USA.
[Curtius, Kit] Univ Washington, Sch Med, Dept Appl Math, Seattle, WA USA.
[Inadomi, John M.] Univ Washington, Sch Med, Div Gastroenterol, Seattle, WA USA.
[Jeon, Jihyoun] Fred Hutchinson Canc Res Ctr, Program Biostat & Biomath, Seattle, WA 98104 USA.
[Hazelton, William D.; Luebeck, E. Georg] Fred Hutchinson Canc Res Ctr, Program Computat Biol, Seattle, WA 98104 USA.
[Meza, Rafael] Univ Michigan, Dept Epidemiol, Ann Arbor, MI 48109 USA.
[Feuer, Eric J.] NCI, Surveillance Res Program, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
[Kroep, Sonja; Lansdorp-Vogelaar, Iris; van Ballegooijen, Marjolein] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands.
RP Kong, CY (reprint author), Massachusetts Gen Hosp, Dept Radiol, Inst Technol Assessment, 101 Merrimac St,10th Floor, Boston, MA 02114 USA.
EM joey@mgh-ita.org
OI Heberle, Curtis/0000-0003-1445-5420; Hur, Chin/0000-0002-2819-7576
FU NIH [U01CA152926, K25CA133141]
FX This work was supported by the NIH (grant No. U01CA152926 to the CISNET
Esophagus group and grant No. K25CA133141 to Dr. C.Y. Kong).
NR 37
TC 13
Z9 15
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD JUN
PY 2014
VL 23
IS 6
BP 997
EP 1006
DI 10.1158/1055-9965.EPI-13-1233
PG 10
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA AT9UD
UT WOS:000345270800011
PM 24692500
ER
PT J
AU Wu, L
Goldstein, AM
Yu, K
Yang, XR
Rabe, KG
Arslan, AA
Canzian, F
Wolpin, BM
Stolzenberg-Solomon, R
Amundadottir, LT
Petersen, GM
AF Wu, Lang
Goldstein, Alisa M.
Yu, Kai
Yang, Xiaohong Rose
Rabe, Kari G.
Arslan, Alan A.
Canzian, Federico
Wolpin, Brian M.
Stolzenberg-Solomon, Rachael
Amundadottir, Laufey T.
Petersen, Gloria M.
TI Variants Associated with Susceptibility to Pancreatic Cancer and
Melanoma Do Not Reciprocally Affect Risk
SO CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; LOCI
AB Background: Melanoma cases may exist in pancreatic cancer kindreds, whereas there is increased risk of pancreatic cancer in familial melanoma. The two cancers may share genetic susceptibility variants in common.
Methods: Three dbGaP (datasets in Genotypes and Phenotypes)-deposited GWAS (genome-wide association study) datasets (MD Anderson melanoma, PanScan 1, and PanScan 2 for pancreatic cancer) were used. Thirty-seven melanoma susceptibility variants in 22 genomic regions from published GWAS, plus melanoma-related genes and pathways were examined for pancreatic cancer risk in the PanScan datasets. Conversely, nine known pancreatic cancer susceptibility variants were examined for melanoma risk in the MD Anderson dataset.
Results: In the PanScan data, initial associations were found with melanoma susceptibility variants in NCOA6 [rs4911442; OR, 1.32; 95% confidence interval (CI), 1.03-1.70; P = 0.03], YWHAZP5 (rs17119461; OR, 2.62; 95% CI, 1.08-6.35; P = 0.03), and YWHAZP5(rs17119490; OR, 2.62; 95% CI, 1.08-6.34; P = 0.03), TYRP1 (P = 0.04), and IFNA13 (P = 0.04). In the melanoma dataset, two pancreatic cancer susceptibility variants were associated: NR5A2 (rs12029406; OR, 1.39; 95% CI, 1.01-1.92; P = 0.04) and CLPTM1L-TERT (rs401681; OR, 1.16; 95% CI, 1.01-1.34; P = 0.04). None of these associations remained significant after correcting for multiple comparisons.
Conclusion: Reported variants of melanoma genes and pathways do not play a role in pancreatic cancer predisposition. Reciprocally, pancreatic cancer susceptibility variants are not associated with melanoma risk.
Impact: Known melanoma-related genes and pathways, as well as GWAS-derived susceptibility variants of melanoma and pancreatic cancer, do not explain the shared genetic etiology of these two cancers. (C) 2014 AACR.
C1 [Wu, Lang; Rabe, Kari G.; Petersen, Gloria M.] Mayo Clin, Dept Hlth Sci Res, Rochester, MN 55905 USA.
[Goldstein, Alisa M.; Yu, Kai; Yang, Xiaohong Rose; Stolzenberg-Solomon, Rachael; Amundadottir, Laufey T.] NCI, Div Canc Epidemiol & Genet, NIH, Bethesda, MD 20892 USA.
[Arslan, Alan A.] NYU, Sch Med, Dept Obstet & Gynecol, New York, NY USA.
[Arslan, Alan A.] NYU, Sch Med, Dept Environm Med, New York, NY USA.
[Wolpin, Brian M.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Canzian, Federico] German Canc Res Ctr, Genom Epidemiol Grp, Heidelberg, Germany.
RP Petersen, GM (reprint author), Mayo Clin, Coll Med, Dept Hlth Sci Res, 200 First St Southwest, Rochester, MN 55905 USA.
EM Petersen.Gloria@mayo.edu
RI Amundadottir, Laufey/L-7656-2016
OI Amundadottir, Laufey/0000-0003-1859-8971
FU Mayo Clinic SPORE in Pancreatic Cancer [P50CA102701]; Intramural
Research Program of the NIH, National Cancer Institute (NCI), Division
of Cancer Epidemiology and Genetics (DCEG); NIH/NCRR CTSA [TL1
RR024152]; [R01CA97075]
FX This study was supported in part by Mayo Clinic SPORE in Pancreatic
Cancer (P50CA102701), R01CA97075, and the Intramural Research Program of
the NIH, National Cancer Institute (NCI), Division of Cancer
Epidemiology and Genetics (DCEG). L. Wu is a trainee in the program
funded by NIH/NCRR CTSA grant number TL1 RR024152.
NR 8
TC 10
Z9 11
U1 0
U2 1
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1055-9965
EI 1538-7755
J9 CANCER EPIDEM BIOMAR
JI Cancer Epidemiol. Biomarkers Prev.
PD JUN
PY 2014
VL 23
IS 6
BP 1121
EP 1124
DI 10.1158/1055-9965.EPI-13-0627
PG 4
WC Oncology; Public, Environmental & Occupational Health
SC Oncology; Public, Environmental & Occupational Health
GA AT9UD
UT WOS:000345270800025
PM 24642353
ER
PT J
AU Choi, JE
Mostoslavsky, R
AF Choi, Jee-Eun
Mostoslavsky, Raul
TI Sirtuins, metabolism, and DNA repair
SO CURRENT OPINION IN GENETICS & DEVELOPMENT
LA English
DT Article
ID FATTY-ACID OXIDATION; HISTONE DEACETYLASE SIRT6; TUMOR-SUPPRESSOR;
CELL-CYCLE; GLUTAMINE-METABOLISM; CALORIE RESTRICTION; GENOMIC
INSTABILITY; MAMMALIAN SIRTUINS; LIPID-METABOLISM; SKELETAL-MUSCLE
AB Cells evolve to actively coordinate nutrient availability with cellular activity in order to maintain metabolic homeostasis. In addition, active pathways to repair DNA damage are crucial to avoid deleterious genomic instability. In recent years, it has become increasingly clear that availability of intermediate metabolites may play an important role in DNA repair, suggesting that these two seemingly distant cellular activities may be highly coordinated. The sirtuin family of proteins now described as deacylases (they can also remove acyl groups other than acetyl moieties), it appears to have evolved to control both metabolism and DNA repair. In this review, we discuss recent advances that lay the foundation to understanding the role of sirtuins in these two biological processes, and the potential crosstalk to coordinate them.
C1 [Choi, Jee-Eun] Harvard Univ, Biol & Biomed Sci Grad Program, Sch Med, Boston, MA 02115 USA.
[Choi, Jee-Eun; Mostoslavsky, Raul] Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
RP Mostoslavsky, R (reprint author), Harvard Univ, Massachusetts Gen Hosp, Ctr Canc, Sch Med, Boston, MA 02114 USA.
EM rmostoslavsky@mgh.harvard.edu
FU NIH [GM093072-01, DK088190-01A1, CA175727-01A1]; National Pancreatic
Foundation
FX Work in the Mostoslavsky lab is supported in part by NIH grants
GM093072-01, DK088190-01A1, CA175727-01A1 and the National Pancreatic
Foundation. RM is the Kristine and Bob Higgins MGH Research Scholar, a
Howard Goodman Awardee and the Andrew Warshaw Institute for Pancreatic
Cancer Research Fellow.
NR 86
TC 31
Z9 32
U1 0
U2 10
PU CURRENT BIOLOGY LTD
PI LONDON
PA 84 THEOBALDS RD, LONDON WC1X 8RR, ENGLAND
SN 0959-437X
EI 1879-0380
J9 CURR OPIN GENET DEV
JI Curr. Opin. Genet. Dev.
PD JUN
PY 2014
VL 26
BP 24
EP 32
DI 10.1016/j.gde.2014.05.005
PG 9
WC Cell Biology; Genetics & Heredity
SC Cell Biology; Genetics & Heredity
GA AT6PH
UT WOS:000345060800005
PM 25005742
ER
PT J
AU Drapeau, E
Dorr, NP
Elder, GA
Buxbaum, JD
AF Drapeau, Elodie
Dorr, Nate P.
Elder, Gregory A.
Buxbaum, Joseph D.
TI Absence of strong strain effects in behavioral analyses of
Shank3-deficient mice
SO DISEASE MODELS & MECHANISMS
LA English
DT Article
DE Shank3; Phelan-McDermid syndrome; Autism spectrum disorders; 22q13;
Mouse strain; Genetic modifier; Behavior
ID AUTISM SPECTRUM DISORDERS; 22Q13 DELETION SYNDROME; COPY NUMBER
VARIATION; INBRED MOUSE STRAINS; POSTSYNAPTIC DENSITY PROTEINS; KNOCKOUT
MICE; MUTANT MICE; SYNAPTIC FUNCTION; LABORATORY MICE; SHANK FAMILY
AB Haploinsufficiency of SHANK3, caused by chromosomal abnormalities or mutations that disrupt one copy of the gene, leads to a neurodevelopmental syndrome called Phelan-McDermid syndrome, symptoms of which can include absent or delayed speech, intellectual disability, neurological changes and autism spectrum disorders. The SHANK3 protein forms a key structural part of the post-synaptic density. We previously generated and characterized mice with a targeted disruption of Shank3 in which exons coding for the ankyrin-repeat domain were deleted and expression of full-length Shank3 was disrupted. We documented specific deficits in synaptic function and plasticity, along with reduced reciprocal social interactions, in Shank3 heterozygous mice. Changes in phenotype owing to a mutation at a single locus are quite frequently modulated by other loci, most dramatically when the entire genetic background is changed. In mice, each strain of laboratory mouse represents a distinct genetic background and alterations in phenotype owing to gene knockout or transgenesis are frequently different across strains, which can lead to the identification of important modifier loci. We have investigated the effect of genetic background on phenotypes of Shank3 heterozygous, knockout and wild-type mice, using C57BL/6, 129SVE and FVB/Ntac strain backgrounds. We focused on observable behaviors with the goal of carrying out subsequent analyses to identify modifier loci. Surprisingly, there were very modest strain effects over a large battery of analyses. These results indicate that behavioral phenotypes associated with Shank3 haploinsufficiency are largely strain-independent.
C1 [Drapeau, Elodie; Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Seaver Autism Ctr Res & Treatment, New York, NY 10029 USA.
[Drapeau, Elodie; Dorr, Nate P.; Elder, Gregory A.; Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
[Elder, Gregory A.; Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, New York, NY 10029 USA.
[Elder, Gregory A.] Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA.
[Elder, Gregory A.] James J Peters VA Med Ctr, Neurol Serv, Bronx, NY 10468 USA.
[Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA.
[Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Syst Biol Ctr New York, New York, NY 10029 USA.
[Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA.
[Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA.
[Buxbaum, Joseph D.] Icahn Sch Med Mt Sinai, Mindich Child Hlth & Dev Inst, New York, NY 10029 USA.
RP Buxbaum, JD (reprint author), Icahn Sch Med Mt Sinai, Seaver Autism Ctr Res & Treatment, New York, NY 10029 USA.
EM joseph.buxbaum@mssm.edu
OI Buxbaum, Joseph/0000-0001-8898-8313
FU National Institutes of Health [R01MH093725]; Beatrice and Samuel A.
Seaver Foundation; Simons Foundation Autism Research Initiative
FX This work was supported by the National Institutes of Health [grant
number: R01MH093725], the Beatrice and Samuel A. Seaver Foundation, and
the Simons Foundation Autism Research Initiative.
NR 75
TC 8
Z9 8
U1 1
U2 7
PU COMPANY OF BIOLOGISTS LTD
PI CAMBRIDGE
PA BIDDER BUILDING CAMBRIDGE COMMERCIAL PARK COWLEY RD, CAMBRIDGE CB4 4DL,
CAMBS, ENGLAND
SN 1754-8403
EI 1754-8411
J9 DIS MODEL MECH
JI Dis. Model. Mech.
PD JUN
PY 2014
VL 7
IS 6
BP 667
EP 681
DI 10.1242/dmm.013821
PG 15
WC Cell Biology; Pathology
SC Cell Biology; Pathology
GA AT5SQ
UT WOS:000345002600008
PM 24652766
ER
PT J
AU Gonzalez-Quesada, CJ
Giugliano, RP
AF Gonzalez-Quesada, Carlos J.
Giugliano, Robert P.
TI Comparison of the Phase III Clinical Trial Designs of Novel Oral
Anticoagulants Versus Warfarin for the Treatment of Nonvalvular Atrial
Fibrillation: Implications for Clinical Practice (vol 14, pg 111, 2014)
SO AMERICAN JOURNAL OF CARDIOVASCULAR DRUGS
LA English
DT Correction
C1 [Gonzalez-Quesada, Carlos J.] Brigham & Womens Hosp, Dept Med, Phyllis Jen Ctr Primary Care, Boston, MA 02115 USA.
[Giugliano, Robert P.] Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc, Boston, MA 02115 USA.
RP Giugliano, RP (reprint author), Brigham & Womens Hosp, TIMI Study Grp, Div Cardiovasc, 350 Longwood Ave,1st Floor Off, Boston, MA 02115 USA.
EM rgiugliano@partners.org
NR 1
TC 0
Z9 0
U1 0
U2 0
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1175-3277
EI 1179-187X
J9 AM J CARDIOVASC DRUG
JI Am. J. Cardiovasc. Drugs
PD JUN
PY 2014
VL 14
IS 3
BP 237
EP 237
DI 10.1007/s40256-014-0075-2
PG 1
WC Cardiac & Cardiovascular Systems; Pharmacology & Pharmacy
SC Cardiovascular System & Cardiology; Pharmacology & Pharmacy
GA AT0BA
UT WOS:000344600600008
ER
PT J
AU Wu, Y
Johnson, KB
Roccaro, G
Lopez, J
Zheng, H
Muiru, A
Ufere, N
Rajbhandari, R
Kattan, O
Chung, RT
AF Wu, Ying
Johnson, Kara B.
Roccaro, Giorgio
Lopez, Joanna
Zheng, Hui
Muiru, Anthony
Ufere, Nneka
Rajbhandari, Ruma
Kattan, Omar
Chung, Raymond T.
TI Poor Adherence to AASLD Guidelines for Chronic Hepatitis B Management
and Treatment in a Large Academic Medical Center
SO AMERICAN JOURNAL OF GASTROENTEROLOGY
LA English
DT Article
ID PERSISTENTLY NORMAL ALT; VIRUS INFECTION; POPULATION; CIRRHOSIS; UPDATE;
LEVEL; HBV
AB OBJECTIVES: Adherence to the American Association for the Study of Liver Disease (AASLD) guidelines for the management of chronic hepatitis B (CHB) has not been systematically assessed. We sought to comprehensively evaluate adherence to five key areas of these guidelines. We also evaluated physician and patient factors underlying nonadherence, and predictors of nonadherence such as physician type, patient demographic factors, and phase of CHB infection.
METHODS: Nine hundred and sixty-two adult patients were retrospectively identified. Each patient chart was reviewed in detail. The primary outcome was adherence to five areas of the AASLD guidelines: (i) timely alanine aminotransferase (ALT)/hepatitis B virus DNA level checks needed to monitor inactive carrier and immune-tolerant phases; (ii) liver biopsy to guide decisions on initiating treatment; (iii) treatment initiation when indicated; (iv) hepatocellular carcinoma (HCC) screening; (v) testing for hepatitis A virus (HAV) immunity, HIV, and hepatitis C virus (HCV) co-infections.
RESULTS: Sixty percent did not undergo clinically indicated liver biopsies, largely owing to physician nonadherence. Eighty-nine percent of these missed biopsies were needed to further assess possible e-antigen-negative CHB. A high treatment initiation rate was found for the treatment eligible, but 121 patients had unclear treatment eligibility as they warranted, but did not undergo, liver biopsy. Forty-five percent did not have timely HCC screening, although gastroenterology physicians had the highest odds of adherence, and 29 % did not have timely CHB lab assessment; patients seen by gastroenterologists had twice the odds compared with primary care physicians of undergoing timely lab monitoring. Thirty-five, 24, and 54 % were not tested for HAV, HCV, and HIV co-infections.
CONCLUSIONS: Our findings show remarkably poor adherence to AASLD guidelines, particularly in the areas of liver biopsy, timely HCC and ALT monitoring, and testing for co-infection. These findings call for greater efforts to meet physician knowledge gaps, incorporation of decision support tools, and improved communication among providers.
C1 [Wu, Ying; Johnson, Kara B.; Rajbhandari, Ruma; Chung, Raymond T.] Massachusetts Gen Hosp, Ctr Liver, Boston, MA 02114 USA.
[Wu, Ying; Johnson, Kara B.; Rajbhandari, Ruma; Chung, Raymond T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
[Wu, Ying; Johnson, Kara B.; Roccaro, Giorgio; Lopez, Joanna; Zheng, Hui; Muiru, Anthony; Ufere, Nneka; Rajbhandari, Ruma; Kattan, Omar; Chung, Raymond T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Wu, Ying; Johnson, Kara B.; Roccaro, Giorgio; Lopez, Joanna; Muiru, Anthony; Ufere, Nneka; Rajbhandari, Ruma; Kattan, Omar; Chung, Raymond T.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Zheng, Hui] Massachusetts Gen Hosp, Ctr Biostat, Boston, MA 02114 USA.
RP Chung, RT (reprint author), Massachusetts Gen Hosp, Ctr Liver, 55 Fruit St, Boston, MA 02114 USA.
EM RTChung@partners.org
OI Rajbhandari, Ruma/0000-0001-8281-550X
FU Bristol Myers Squibb Virology Fellowship; NIH [DK007191, DK078772]
FX Financial assistance was provided by Bristol Myers Squibb Virology
Fellowship; and NIH DK007191 (Ying Wu, Kara B. Johnson) DK078772
(Raymond T. Chung).
NR 25
TC 17
Z9 18
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 0002-9270
EI 1572-0241
J9 AM J GASTROENTEROL
JI Am. J. Gastroenterol.
PD JUN
PY 2014
VL 109
IS 6
BP 867
EP 875
DI 10.1038/ajg.2014.72
PG 9
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AS7UA
UT WOS:000344458900012
PM 24732869
ER
PT J
AU Huang, SA
AF Huang, Stephen A.
TI A Baby Boy with Hypothyroidism and Hemangioendothelioma Comment
SO CLINICAL CHEMISTRY
LA English
DT Editorial Material
C1 [Huang, Stephen A.] Boston Childrens Hosp, Div Endocrinol, Thyroid Program, Boston, MA 02115 USA.
[Huang, Stephen A.] Brigham & Womens Hosp, Div Endocrinol Diabet & Hypertens, Thyroid Sect, Boston, MA 02115 USA.
[Huang, Stephen A.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Huang, SA (reprint author), Boston Childrens Hosp, 300 Long Wood Ave, Boston, MA 02115 USA.
EM stephen.huang@childrens.harvard.edu
NR 0
TC 0
Z9 0
U1 0
U2 0
PU AMER ASSOC CLINICAL CHEMISTRY
PI WASHINGTON
PA 2101 L STREET NW, SUITE 202, WASHINGTON, DC 20037-1526 USA
SN 0009-9147
EI 1530-8561
J9 CLIN CHEM
JI Clin. Chem.
PD JUN
PY 2014
VL 60
IS 6
BP 821
EP 821
DI 10.1373/clinchem.2013.214304
PG 1
WC Medical Laboratory Technology
SC Medical Laboratory Technology
GA AT2QG
UT WOS:000344778600006
PM 24872367
ER
PT J
AU Hershenberg, R
Gros, DF
Brawman-Mintzer, O
AF Hershenberg, Rachel
Gros, Daniel F.
Brawman-Mintzer, Olga
TI Role of Atypical Antipsychotics in the Treatment of Generalized Anxiety
Disorder
SO CNS DRUGS
LA English
DT Review
ID FUMARATE QUETIAPINE XR; SEROTONIN REUPTAKE INHIBITORS;
OBSESSIVE-COMPULSIVE DISORDER; PLACEBO-CONTROLLED TRIAL;
POSTTRAUMATIC-STRESS-DISORDER; MAJOR DEPRESSIVE DISORDER; OPEN-LABEL
TRIAL; DOUBLE-BLIND; PANIC DISORDER; PRIMARY-CARE
AB Evidence-based treatment approaches for generalized anxiety disorder (GAD) comprise psychotherapy, pharmacotherapy, or a combination of the two. First-line pharmacotherapy agents include selective serotonin reuptake inhibitors, selective serotonin-norepinephrine reuptake inhibitors, and, in certain European guidelines, pregabalin, which gained European Commission approval. Although short- and long-term efficacy have been established for these agents in controlled trials, response rates of 60-70 % are insufficient, remission rates are relatively modest, and relapse rates considerable. Moreover, questions increasingly arise regarding tolerability and side-effect profiles. As an alternative, antipsychotics have long been of interest for the treatment of anxiety disorders, but investigation had been tempered by their potential for irreversible side effects. With the improved side-effect profiles of atypical antipsychotics, these agents are increasingly being investigated across Axis I disorders. Atypical antipsychotics such as quetiapine, aripiprazole, olanzapine, and risperidone have been shown to be helpful in addressing a range of anxiety and depressive symptoms in individuals with schizophrenia and schizoaffective disorders, and have since been used in the treatment of a range of mood and anxiety disorders. In this article, we review the efficacy and tolerability of atypical antipsychotics as adjunctive therapy and/or monotherapy for individuals with GAD, a currently off-label indication. The most evidence has accumulated for quetiapine. Findings suggest that approximately 50 % of participants tolerate the side effects, most commonly sedation and fatigue. Among this subset, those who continue treatment demonstrate significant reductions in anxiety when used as adjunctive therapy or monotherapy. The appropriateness of the use of antipsychotics in the treatment of GAD is discussed.
C1 [Hershenberg, Rachel] Philadelphia VA Med Ctr, Educ & Clin Ctr, VISN Mental Illness Res 4, Philadelphia, PA 19104 USA.
[Hershenberg, Rachel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Gros, Daniel F.; Brawman-Mintzer, Olga] Ralph H Johnson VA Med Ctr, Mental Hlth Serv, Charleston, SC USA.
[Gros, Daniel F.; Brawman-Mintzer, Olga] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC 29425 USA.
RP Brawman-Mintzer, O (reprint author), Med Univ S Carolina, Dept Psychiat & Behav Sci, 171 Ashley Ave, Charleston, SC 29425 USA.
EM rhersh@mail.med.upenn.edu; mintzero@musc.edu
FU Forest Laboratories
FX This material is the result of work supported with resources and the use
of facilities of the VISN 4 Mental Illness Research, Education, and
Clinical Center, Philadelphia Veterans Affairs Medical Center,
Philadelphia, PA, USA, and the Ralph H. Johnson Veterans Affairs Medical
Center. The views expressed in this article are those of the authors and
do not necessarily reflect the position or policy of the Department of
Veterans Affairs or the US government. There were no conflicts of
interest in the preparation of this manuscript for Drs. Rachel
Hershenberg or Daniel F. Gros. Dr. Olga Brawman-Mintzer received grant
support from Forest Laboratories.
NR 97
TC 8
Z9 8
U1 6
U2 16
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1172-7047
EI 1179-1934
J9 CNS DRUGS
JI CNS Drugs
PD JUN
PY 2014
VL 28
IS 6
BP 519
EP 533
DI 10.1007/s40263-014-0162-6
PG 15
WC Clinical Neurology; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA AT0FT
UT WOS:000344613300004
PM 24794100
ER
PT J
AU Fisher, LB
Overholser, JC
AF Fisher, Lauren B.
Overholser, James C.
TI The Measurement of Positive Attitudes: The Glass is Half Full
SO JOURNAL OF RATIONAL-EMOTIVE AND COGNITIVE-BEHAVIOR THERAPY
LA English
DT Article
DE Positive cognitions; Positive thoughts; Depression; Assessment; Coping
ID BECK DEPRESSION INVENTORY; SUICIDE IDEATION; PSYCHIATRIC OUTPATIENTS;
COGNITIVE VULNERABILITY; HOPELESSNESS SCALE; PSYCHOMETRIC PROPERTIES;
EVENTUAL SUICIDE; FUTURE THINKING; LIFE; DISORDERS
AB Positive thoughts play a significant role in the experience and recovery from depression. The Coping Attitudes Scale (CAS) is a rationally derived measure of positive cognitions. The CAS contains statements reflective of coping attitudes along five domains: life perspective, personal accomplishment, positive future, self-worth, and coping with problems. The current study examined the CAS in psychiatric outpatients and college students. Measures of depression, hopelessness, suicidal ideation and positive attitudes were administered to 82 adult psychiatric outpatients and 156 college students. Depression and hopelessness were strongly, negatively, partially correlated with each of the CAS factors, after controlling for age. Relationships among individual CAS factors and suicidal ideation demonstrated weak to moderate partial associations, after controlling for age. Depression was significantly associated with the coping with problems subscale (R-2 = .530). Hopelessness was significantly related to the positive future subscale (R-2 = .696). Further, the CAS demonstrated a significant relationship with depression and hopelessness, even after accounting for the Automatic Thoughts Questionnaire-Revised, Positive subscale. The CAS may be an improved measure of positive attitudes that could be useful in establishing a patient's baseline of positive thinking, determining targets for therapy, and in monitoring progress in treatment.
C1 [Fisher, Lauren B.] Harvard Univ, Dept Psychiat, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
[Overholser, James C.] Case Western Reserve Univ, Dept Psychol Sci, Cleveland, OH 44106 USA.
RP Fisher, LB (reprint author), Harvard Univ, Dept Psychiat, Massachusetts Gen Hosp, Sch Med, One Bowdoin Sq,6th Floor, Boston, MA 02114 USA.
EM lbfisher@partners.org
NR 60
TC 1
Z9 1
U1 3
U2 8
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0894-9085
EI 1573-6563
J9 J RATION-EMOT COGN-B
JI J. Ration.-Emot. Cogn.-Behav. Ther.
PD JUN
PY 2014
VL 32
IS 2
BP 121
EP 138
DI 10.1007/s10942-013-0173-0
PG 18
WC Psychology, Clinical
SC Psychology
GA AT0IP
UT WOS:000344620400001
ER
PT J
AU Aslakson, RA
Schuster, ALR
Miller, J
Weiss, M
Volandes, AE
Bridges, JFP
AF Aslakson, Rebecca A.
Schuster, Anne L. R.
Miller, Judith
Weiss, Matthew
Volandes, Angelo E.
Bridges, John F. P.
TI An Environmental Scan of Advance Care Planning Decision Aids for
Patients Undergoing Major Surgery: A Study Protocol
SO PATIENT-PATIENT CENTERED OUTCOMES RESEARCH
LA English
DT Article
ID CONJOINT-ANALYSIS; CONTROLLED-TRIAL; PALLIATIVE CARE; VIDEO IMAGES;
LIFE; END; INTERVENTIONS; DIRECTIVES; HEALTH; OUTCOMES
AB Background Patients who undergo major surgery are at risk for perioperative morbidity and mortality. It would be appropriate to initiate advance care planning with patients prior to surgery, but surgeons may experience difficulty initiating such conversations. Rather than focus on changing clinician behavior, advance care planning decision aids can be an innovative vehicle to motivate advance care planning among surgical patients and their families.
Objective The purpose of this paper is to describe a study protocol for conducting an environmental scan concerning advance care planning decision aids that may be relevant to patients undergoing high-risk surgery.
Methods/design This study will gather information from written or verbal data sources that incorporate professional and lay perspectives: a systematic review, a grey literature review, key informant interviews, and patient and family engagement. It is envisioned that this study will generate three outcomes: a synthesis of current evidence, a summary of gaps in knowledge, and a taxonomy of existing advance care planning decision aids.
Discussion This environmental scan will demonstrate principles of patient-centered outcomes research, and it will exemplify a pioneering approach for reviewing complex interventions. Anticipated limitations are that information will be gathered from a small sample of patients and families, and that potentially relevant information could also be missing from the environmental scan due to the inclusion/exclusion criteria. Outcomes from the environmental scan will inform future patient-centered research to develop and evaluate a new decision aid.
C1 [Aslakson, Rebecca A.] Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care Med, Baltimore, MD 21287 USA.
[Schuster, Anne L. R.; Bridges, John F. P.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA.
[Weiss, Matthew] Johns Hopkins Sch Med, Dept Surg, Baltimore, MD USA.
[Volandes, Angelo E.] Massachusetts Gen Hosp, Gen Med Unit, Boston, MA 02114 USA.
RP Aslakson, RA (reprint author), Johns Hopkins Sch Med, Dept Anesthesiol & Crit Care Med, 600 North Wolfe St,Meyer 297A, Baltimore, MD 21287 USA.
EM raslaks1@jhmi.edu
FU Patient-Centered Outcomes Research Institute (PCORI) Communication and
Dissemination Research Award [CD-12-11-4362]
FX This work was (partially) supported through a Patient-Centered Outcomes
Research Institute (PCORI) Communication and Dissemination Research
Award (CD-12-11-4362).
NR 47
TC 4
Z9 4
U1 4
U2 12
PU ADIS INT LTD
PI NORTHCOTE
PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND
SN 1178-1653
EI 1178-1661
J9 PATIENT
JI Patient
PD JUN
PY 2014
VL 7
IS 2
BP 207
EP 217
DI 10.1007/s40271-014-0046-3
PG 11
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA AS6IH
UT WOS:000344366900009
PM 24469597
ER
PT J
AU Garrett-Bakelman, FE
Li, S
Chung, S
Hricik, T
Rapaport, F
Mayden, C
Bar, H
Liu, L
Patel, J
Sheridan, C
Ishii, J
Zumbo, P
Gandara, J
Becker, M
Brown, A
Lewis, ID
To, LB
D'Andrea, RJ
Dohner, K
Bullinger, L
Dohner, H
Sanders, M
Valk, PJ
Delwel, R
Lowenberg, B
Michor, F
Guzman, M
Park, C
Carroll, M
Levine, R
Mason, CE
Melnick, A
AF Garrett-Bakelman, F. E.
Li, S.
Chung, S.
Hricik, T.
Rapaport, F.
Mayden, C.
Bar, H.
Liu, L.
Patel, J.
Sheridan, C.
Ishii, J.
Zumbo, P.
Gandara, J.
Becker, M.
Brown, A.
Lewis, I. D.
To, L. Bik
D'Andrea, R. J.
Doehner, K.
Bullinger, L.
Doehner, H.
Sanders, M.
Valk, P. J.
Delwel, R.
Lowenberg, B.
Michor, F.
Guzman, M.
Park, C.
Carroll, M.
Levine, R.
Mason, C. E.
Melnick, A.
TI DNA METHYLATION PATTERNS AT DISEASE RELAPSE IN ACUTE MYELOID LEUKEMIA
TARGET CONVERGENT ELEMENTS AND PATHWAYS DESPITE INTER-PATIENT
HETEROGENEITY
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Garrett-Bakelman, F. E.; Melnick, A.] Weill Cornell Med Coll, Dept Med, New York, NY USA.
[Li, S.; Mayden, C.; Zumbo, P.; Gandara, J.; Mason, C. E.] Weill Cornell Med Coll, Dept Physiol & Biophys, New York, NY USA.
[Li, S.; Mason, C. E.] Weill Med Coll, HRH Prince Alwaleed Bin Talal Bin Abdulaziz Alsau, New York, NY USA.
[Chung, S.; Hricik, T.; Rapaport, F.; Patel, J.; Park, C.; Levine, R.] Mem Sloan Kettering Canc Ctr, Human Oncol & Pathogenesis Program, New York, NY 10021 USA.
[Bar, H.] Cornell Univ, Dept Stat Sci, Ithaca, NY USA.
[Liu, L.] Harvard Univ, Sch Med, Boston, MA USA.
[Sheridan, C.; Ishii, J.] Weill Cornell Med Coll, Epigen Core, New York, NY USA.
[Zumbo, P.] Weill Cornell Med Coll, Inst Computat Biomed, New York, NY USA.
[Becker, M.] Univ Rochester, Med Ctr, Sch Med & Dent, Rochester, NY 14627 USA.
[Brown, A.; D'Andrea, R. J.] SA Pathol, Ctr Canc Biol, Adelaide, SA, Australia.
[Brown, A.; D'Andrea, R. J.] Univ S Australia, Sch Pharm & Med Sci, Adelaide, SA 5001, Australia.
[Brown, A.; Lewis, I. D.; To, L. Bik; D'Andrea, R. J.] SA Pathol, Directorate Haematol, Adelaide, SA, Australia.
[Brown, A.; Lewis, I. D.; To, L. Bik; D'Andrea, R. J.] Univ Adelaide, Adelaide, SA, Australia.
[Doehner, K.; Bullinger, L.; Doehner, H.] Univ Hosp Ulm, Dept Internal Med 3, Ulm, Germany.
[Sanders, M.; Valk, P. J.; Delwel, R.; Lowenberg, B.] Erasmus MC, Dept Hematol, Rotterdam, Netherlands.
[Michor, F.] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Guzman, M.] Weill Cornell Med Coll, New York, NY USA.
[Carroll, M.] Univ Penn, Div Hematol & Oncol, Philadelphia, PA 19104 USA.
[Levine, R.] Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY 10021 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA P137
BP 16
EP 16
PG 1
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830900039
ER
PT J
AU Brown, JR
Harb, WA
Hill, BT
Gabrilove, J
Sharman, JP
Schreeder, MT
Barr, PM
Foran, JM
Miller, TP
Burger, JA
Kelly, KR
Mahadevan, D
Ma, S
Barnett, E
Marine, J
Nava-Parada, P
Azaryan, A
Mei, J
Kipps, TJ
AF Brown, J. R.
Harb, W. A.
Hill, B. T.
Gabrilove, J.
Sharman, J. P.
Schreeder, M. T.
Barr, P. M.
Foran, J. M.
Miller, T. P.
Burger, J. A.
Kelly, K. R.
Mahadevan, D.
Ma, S.
Barnett, E.
Marine, J.
Nava-Parada, P.
Azaryan, A.
Mei, J.
Kipps, T. J.
TI PHASE 1 STUDY OF SINGLE AGENT CC-292, A HIGHLY SELECTIVE BRUTON'S
TYROSINE KINASE (BTK) INHIBITOR, IN RELAPSED/REFRACTORY CHRONIC
LYMPHOCYTIC LEUKEMIA (CLL)
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Brown, J. R.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Harb, W. A.] Horizon Oncol Ctr, Lafayette, IN 47905 USA.
[Hill, B. T.] Cleveland Clin, Taussig Canc Inst, Dept Hematol Oncol & Blood Disorders, Cleveland, OH 44106 USA.
[Gabrilove, J.] Mt Sinai Sch Med, New York, NY USA.
[Sharman, J. P.] Willamette Valley Canc Inst, Eugene, OR USA.
[Sharman, J. P.] Res Ctr US Oncol Res, Eugene, OR USA.
[Schreeder, M. T.] Clearview Canc Inst, Huntsville, AL 35805 USA.
[Barr, P. M.] Univ Rochester, Med Ctr, Rochester, NY 14627 USA.
[Foran, J. M.] Mayo Clin, Jacksonville, FL USA.
[Miller, T. P.] Univ Arizona, Ctr Canc, Tucson, AZ USA.
[Burger, J. A.] Univ Texas MD Anderson Canc Ctr, Dept Leukemia, Houston, TX 77030 USA.
[Kelly, K. R.] Univ Texas Hlth Sci Ctr San Antonio, CTRC Inst Drug Dev, San Antonio, TX 78229 USA.
[Mahadevan, D.] Univ Tennessee, Ctr Hlth Sci, ACORN Res LLC, West Clin, Memphis, TN 38163 USA.
[Ma, S.] Northwestern Univ, Feinberg Sch Med, Robert H Lurie Comprehens Canc Ctr, Chicago, IL 60611 USA.
[Barnett, E.; Marine, J.; Nava-Parada, P.; Mei, J.] Celgene Corp, Summit, NJ USA.
[Azaryan, A.] Celgene Corp, Berkeley Hts, NJ USA.
[Kipps, T. J.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA P235
BP 54
EP 55
PG 2
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830900136
ER
PT J
AU Michele, C
Cagnetta, A
Tai, YT
Chauhan, D
Nencioni, A
Patrone, F
Gobbi, M
Munshi, N
Anderson, KC
AF Michele, C.
Cagnetta, A.
Tai, Y. T.
Chauhan, D.
Nencioni, A.
Patrone, F.
Gobbi, M.
Munshi, N.
Anderson, K. C.
TI IDENTIFICATION OF NOVEL ALTERNATIVE SPLICE VARIANTS OF SIRTUINS IN
MULTIPLE MYELOMA: A BIOLOGICALLY RELEVANT INDICATOR OF POOR OUTCOME
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Michele, C.; Cagnetta, A.; Nencioni, A.; Patrone, F.; Gobbi, M.] IRCCS AOU San Martino IST, Genoa, Italy.
[Michele, C.; Cagnetta, A.; Tai, Y. T.; Chauhan, D.; Munshi, N.; Anderson, K. C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA P327
BP 94
EP 94
PG 1
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830900228
ER
PT J
AU Fulciniti, M
Samur, MK
Bandi, R
Bashin, M
Shah, P
Gkotzamanidou, M
Cagnetta, A
Magrangeas, F
Minvielle, S
Li, C
Anderson, K
Avet-Ioiseau, H
Munshi, N
AF Fulciniti, M.
Samur, M. Kemal
Bandi, R.
Bashin, M.
Shah, P.
Gkotzamanidou, M.
Cagnetta, A.
Magrangeas, F.
Minvielle, S.
Li, C.
Anderson, K.
Avet-Ioiseau, H.
Munshi, N.
TI TRANSCRIPTIONAL REGULATION OF ALTERNATE SPLICING BY DP1 AND THEIR
FUNCTIONAL IMPACT IN MULTIPLE MYELOMA
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Fulciniti, M.; Samur, M. Kemal; Bandi, R.; Bashin, M.; Shah, P.; Gkotzamanidou, M.; Cagnetta, A.; Li, C.; Anderson, K.; Munshi, N.] Dana Farber Canc Inst, Boston, MA USA.
[Magrangeas, F.; Minvielle, S.] Ctr Canc Res, Nantes, France.
[Avet-Ioiseau, H.] Unite Genom Myelome, Toulouse, France.
RI Magrangeas, Florence/L-3080-2015; Minvielle, Stephane/K-8251-2015
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA P339
BP 99
EP 100
PG 2
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830900240
ER
PT J
AU Gkotzamanidou, M
Shammas, M
Dimopoulos, AM
Anderson, KC
Munshi, NC
Souliotis, VL
AF Gkotzamanidou, M.
Shammas, M.
Dimopoulos, A. M.
Anderson, K. C.
Munshi, N. C.
Souliotis, V. L.
TI MODIFYING DNA REPAIR PATHWAYS IN CHEMOTHERAPY BY GENOTOXIC DRUGS -
TOWARDS PERSONALIZED MYELOMA THERAPY
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Gkotzamanidou, M.; Shammas, M.; Anderson, K. C.; Munshi, N. C.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Dimopoulos, A. M.] Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece.
[Souliotis, V. L.] Natl Hellen Res Fdn, Athens, Greece.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA P344
BP 101
EP 101
PG 1
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830900245
ER
PT J
AU Plesner, T
Arkenau, HT
Lokhorst, HM
Gimsing, P
Krejcik, J
Lemech, C
Minnema, MC
Lassen, U
Ahmadi, T
Yeh, H
Guckert, M
Brun, NC
Lisby, S
Basse, L
Palumbo, A
Richardson, PG
AF Plesner, T.
Arkenau, H. T.
Lokhorst, H. M.
Gimsing, P.
Krejcik, J.
Lemech, C.
Minnema, M. C.
Lassen, U.
Ahmadi, T.
Yeh, H.
Guckert, M.
Brun, N. C.
Lisby, S.
Basse, L.
Palumbo, A.
Richardson, P. G.
TI SAFETY AND EFFICACY OF DARATUMUMAB WITH LENALIDOMIDE AND DEXAMETHASONE
IN RELAPSED OR RELAPSED, REFRACTORY MULTIPLE MYELOMA
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Plesner, T.; Krejcik, J.] Vejle Hosp, Vejle, Denmark.
[Arkenau, H. T.; Lemech, C.] Sarah Cannon Res Ctr, London, England.
[Lokhorst, H. M.; Minnema, M. C.] UMC Utrecht, Utrecht, Netherlands.
[Gimsing, P.; Lassen, U.] Univ Copenhagen, Copenhagen, Denmark.
[Ahmadi, T.; Yeh, H.; Guckert, M.] Janssen Res & Dev, Raritan, NJ USA.
[Brun, N. C.; Lisby, S.; Basse, L.] Genmab AS, Copenhagen, Denmark.
[Palumbo, A.] Univ Turin, Turin, Italy.
[Richardson, P. G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA P350
BP 104
EP 104
PG 1
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830900251
ER
PT J
AU Richardson, P
Hofmeister, C
Raje, N
Siegel, D
Lonial, S
Laubach, J
Efebera, Y
Vesole, DH
Nooka, AK
Rosenblatt, J
Zaki, MH
Hua, Y
Li, Y
Shah, S
Wang, J
Anderson, KC
AF Richardson, P.
Hofmeister, C.
Raje, N.
Siegel, D.
Lonial, S.
Laubach, J.
Efebera, Y.
Vesole, D. H.
Nooka, A. K.
Rosenblatt, J.
Zaki, M. H.
Hua, Y.
Li, Y.
Shah, S.
Wang, J.
Anderson, K. C.
TI POMALIDOMIDE, BORTEZOMIB, AND LOW-DOSE DEXAMETHASONE (PVD) IN
LENALIDOMIDE-REFRACTORY AND PROTEASOME INHIBITOR-EXPOSED MYELOMA: THE
MM-005 TRIAL
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Richardson, P.; Laubach, J.; Anderson, K. C.] Dana Farber Canc Inst, Jerome Lipper Multiple Myeloma Ctr, Boston, MA 02115 USA.
[Hofmeister, C.] Ohio State Univ, Div Hematol, Columbus, OH 43210 USA.
[Raje, N.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Siegel, D.; Vesole, D. H.] Hackensack UMC, John Theurer Canc Ctr, Hackensack, NJ USA.
[Lonial, S.; Nooka, A. K.] Winship Canc Inst, Atlanta, GA USA.
[Efebera, Y.] Ohio State Univ, Columbus, OH 43210 USA.
[Rosenblatt, J.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Zaki, M. H.; Hua, Y.; Li, Y.; Shah, S.; Wang, J.] Celgene Corp, Summit, NJ USA.
RI Efebera, Yvonne/E-3012-2011
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA P351
BP 104
EP 104
PG 1
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830900252
ER
PT J
AU Lokhorst, H
Laubach, J
Nahi, H
Plesner, T
Gimsing, P
Hansson, M
Minnema, M
Lassen, U
Krejcik, J
Ahmadi, T
Khan, I
Uhlar, C
Lisby, S
Basse, L
Brun, N
Richardson, P
AF Lokhorst, H.
Laubach, J.
Nahi, H.
Plesner, T.
Gimsing, P.
Hansson, M.
Minnema, M.
Lassen, U.
Krejcik, J.
Ahmadi, T.
Khan, I.
Uhlar, C.
Lisby, S.
Basse, L.
Brun, N.
Richardson, P.
TI DOSE-DEPENDENT EFFICACY OF DARATUMUMAB (DARA) AS MONOTHERAPY IN PATIENTS
WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA (RR MM)
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Lokhorst, H.; Minnema, M.] UMC Utrecht, Utrecht, Netherlands.
[Laubach, J.; Richardson, P.] Harvard Univ, Sch Med, Boston, MA USA.
[Laubach, J.; Richardson, P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Nahi, H.] Karolinska Inst Internal Med, Stockholm, Sweden.
[Plesner, T.; Krejcik, J.] Vejle Hosp, Vejle, Denmark.
[Gimsing, P.; Lassen, U.] Univ Copenhagen Hosp, DK-2100 Copenhagen, Denmark.
[Hansson, M.] Lund Univ, Stockholm, Sweden.
[Ahmadi, T.; Khan, I.; Uhlar, C.] Janssen R&D, Raritan, NJ USA.
[Lisby, S.; Basse, L.; Brun, N.] Genmab AS, Copenhagen, Denmark.
NR 1
TC 0
Z9 0
U1 0
U2 1
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA P356
BP 106
EP 107
PG 2
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830900257
ER
PT J
AU Richardson, PG
Rosenbaum, CA
Hofmeister, CC
Htut, M
Vesole, DH
Berdeja, JG
Liedtke, M
Chari, A
Smith, SD
Lebovic, D
Berg, D
Liao, E
Tejura, B
Hui, AM
Baz, R
AF Richardson, P. G.
Rosenbaum, C. A.
Hofmeister, C. C.
Htut, M.
Vesole, D. H.
Berdeja, J. G.
Liedtke, M.
Chari, A.
Smith, S. D.
Lebovic, D.
Berg, D.
Liao, E.
Tejura, B.
Hui, A. M.
Baz, R.
TI ORAL INVESTIGATIONAL PROTEASOME INHIBITOR IXAZOMIB CITRATE (MLN9708)
PLUS LENALIDOMIDE-DEXAMETHASONE IN ELDERLY PATIENTS (PTS) WITH
PREVIOUSLY UNTREATED MULTIPLE MYELOMA
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Richardson, P. G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Rosenbaum, C. A.] Univ Chicago, Chicago, IL 60637 USA.
[Hofmeister, C. C.] Ohio State Univ, Columbus, OH 43210 USA.
[Htut, M.] City Hope Natl Med, Hematol & Stem Cell Transplant, Duarte, CA USA.
[Vesole, D. H.] Hackensack Univ, John Theurer Canc Ctr, Med Ctr, Hackensack, NJ USA.
[Berdeja, J. G.] Sarah Cannon Res Inst, Nashville, TN USA.
[Liedtke, M.] Stanford Canc Inst, Stanford, CA USA.
[Chari, A.] Mt Sinai Sch Med, New York, NY USA.
[Smith, S. D.] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA.
[Lebovic, D.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Berg, D.; Liao, E.; Tejura, B.; Hui, A. M.] Takeda Pharmaceut Int Co, Cambridge, MA USA.
[Baz, R.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA P355
BP 106
EP 106
PG 1
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830900256
ER
PT J
AU Raje, N
Vogl, D
Bensinger, W
Voorhees, P
Hari, P
Berdeja, J
Jagannath, S
Jones, S
Wheeler, C
Supko, J
Orlowski, R
Richardson, P
Lonial, S
AF Raje, N.
Vogl, D.
Bensinger, W.
Voorhees, P.
Hari, P.
Berdeja, J.
Jagannath, S.
Jones, S.
Wheeler, C.
Supko, J.
Orlowski, R.
Richardson, P.
Lonial, S.
TI RICOLINOSTAT (ACY-1215), THE FIRST SELECTIVE HISTONE DEACETYLASE 6
INHIBITOR, IS ACTIVE AND WELL TOLDERATED IN COMBINATION WITH
LENALIDOMIDE OR BORTEZOMIB IN PATIENTS WITH REFRACTORY MYELOMA
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Raje, N.; Supko, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Vogl, D.] Univ Penn, Philadelphia, PA 19104 USA.
[Bensinger, W.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Voorhees, P.] Univ N Carolina, Chapel Hill, NC USA.
[Hari, P.] Med Coll Wisconsin, Milwaukee, WI 53226 USA.
[Berdeja, J.] Sarah Cannon Res Inst, Nashville, TN USA.
[Jagannath, S.] Mt Sinai Hosp, New York, NY 10029 USA.
[Jones, S.; Wheeler, C.] Acetylon Pharmaceut Inc, Boston, MA USA.
[Orlowski, R.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Richardson, P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Lonial, S.] Emory Univ, Sch Med, Winship Canc Inst, Atlanta, GA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA P358
BP 107
EP 108
PG 2
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830900259
ER
PT J
AU Laubach, JP
Raje, N
Armand, P
Schlossman, RL
Rosenblatt, J
Matous, JV
Hedlund, J
Martin, M
Reynolds, C
Shain, KH
Zackon, I
Stampleman, L
Boswell, EN
Chuma, S
Liguori, R
Handisides, DR
Kroll, S
Anderson, KC
Richardson, PG
Ghobrial, IM
AF Laubach, J. P.
Raje, N.
Armand, P.
Schlossman, R. L.
Rosenblatt, J.
Matous, J. V.
Hedlund, J.
Martin, M.
Reynolds, C.
Shain, K. H.
Zackon, I.
Stampleman, L.
Boswell, E. N.
Chuma, S.
Liguori, R.
Handisides, D. R.
Kroll, S.
Anderson, K. C.
Richardson, P. G.
Ghobrial, I. M.
TI PRELIMINARY SAFETY AND EFFICACY OF TH-302, AN INVESTIGATIONAL
HYPOXIA-TARGETED DRUG, AND DEXAMETHASONE (DEX) IN PATIENTS (PTS) WITH
RELAPSED/REFRACTORY MULTIPLE MYELOMA (RR MM)
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Laubach, J. P.; Armand, P.; Schlossman, R. L.; Boswell, E. N.; Chuma, S.; Liguori, R.; Anderson, K. C.; Richardson, P. G.; Ghobrial, I. M.] Harvard Univ, Dana Farber Canc Inst, Sch Med, Jerome Lipper Multiple Myeloma Ctr,Dept Med Oncol, Cambridge, MA 02138 USA.
[Raje, N.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Rosenblatt, J.] Beth Israel Deaconess, Boston, MA USA.
[Matous, J. V.] Colorado Blood Canc Inst, Denver, CO USA.
[Hedlund, J.] Maine Ctr Canc Med, Scarborough, ME USA.
[Hedlund, J.; Martin, M.; Reynolds, C.; Zackon, I.; Stampleman, L.; Liguori, R.; Ghobrial, I. M.] Blood Canc Res Partnership, Boston, MA USA.
[Martin, M.] West Clin, Memphis, TN USA.
[Reynolds, C.] Ocala Oncol Ctr, Ocala, FL USA.
[Shain, K. H.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[Zackon, I.] New York Oncol, Hematol, Albany, NY USA.
[Stampleman, L.] Pacific Canc Care, Salina, CA USA.
[Handisides, D. R.; Kroll, S.] Threshold Pharmaceut Inc, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA P360
BP 108
EP 109
PG 2
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830900261
ER
PT J
AU Rampal, R
Al-Shahrour, F
Abdel-Wahab, O
Patel, J
Brunel, JP
Mermel, C
Bass, A
Pretz, J
Ahn, J
Hricik, T
Kilpivaara, O
Wadleigh, M
Busque, L
Gililand, DG
Golub, T
Ebert, B
Levine, R
AF Rampal, R.
Al-Shahrour, F.
Abdel-Wahab, O.
Patel, J.
Brunel, J. P.
Mermel, C.
Bass, A.
Pretz, J.
Ahn, J.
Hricik, T.
Kilpivaara, O.
Wadleigh, M.
Busque, L.
Gililand, D. G.
Golub, T.
Ebert, B.
Levine, R.
TI INTEGRATED GENOMIC ANALYSIS ILLUSTRATES THE CENTRAL ROLE OF JAK-STAT
PATHWAY ACTIVATION IN MYELOPROLIFERATIVE NEOPLASM PATHOGENESIS
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Rampal, R.; Abdel-Wahab, O.; Patel, J.; Ahn, J.; Hricik, T.; Levine, R.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Al-Shahrour, F.; Brunel, J. P.; Bass, A.; Pretz, J.; Wadleigh, M.; Ebert, B.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mermel, C.; Golub, T.] Broad Inst Harvard Univ & MIT, Boston, MA USA.
[Kilpivaara, O.] Univ Helsinki, Helsinki, Finland.
[Busque, L.] Hop Maison Neuve Rosemont, Montreal, PQ H1T 2M4, Canada.
[Gililand, D. G.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA P390
BP 121
EP 121
PG 1
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830900291
ER
PT J
AU Kuruvilla, J
Cerchietti, L
Wagner-Johnston, N
Stone, R
Jacobsen, E
Mau-Sorensen, M
Brown, P
Baz, R
Shal, B
Flynn, J
Flinn, I
Kukreti, V
Tiedemann, R
Goy, A
Landesman, Y
Klebanov, B
Shacham, E
Saint-Martin, JR
Marshall, T
McCartney, J
McCauley, D
Carlson, R
Rebello, S
Rashal, T
Mirza, MR
Shacham, S
Kauffman, M
Gutierrez, M
AF Kuruvilla, J.
Cerchietti, L.
Wagner-Johnston, N.
Stone, R.
Jacobsen, E.
Mau-Sorensen, M.
Brown, P.
Baz, R.
Shal, B.
Flynn, J.
Flinn, I.
Kukreti, V.
Tiedemann, R.
Goy, A.
Landesman, Y.
Klebanov, B.
Shacham, E.
Saint-Martin, J. R.
Marshall, T.
McCartney, J.
McCauley, D.
Carlson, R.
Rebello, S.
Rashal, T.
Mirza, M. R.
Shacham, S.
Kauffman, M.
Gutierrez, M.
TI THE ORAL SELECTIVE INHIBITOR OF NUCLEAR EXPORT (SINE) SELINEXOR
(KPT-330) ACTIVITY IN DOUBLE HIT DIFFUSE LARGE B CELL LYMPHOMAS (DLBCL)
IN PRECLINICAL MODELS & CLINICAL ACTIVITY IN PATIENTS WITH DLBCL
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Kuruvilla, J.; Kukreti, V.; Tiedemann, R.] Princess Margaret Canc Ctr, Toronto, ON, Canada.
[Cerchietti, L.] Cornell Univ, Wiel Cornell Med Coll, New York, NY 10021 USA.
[Wagner-Johnston, N.] Washington Univ, Sch Med, St Louis, MO USA.
[Stone, R.; Jacobsen, E.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Mau-Sorensen, M.] Rigshosp, Dept Oncol, DK-2100 Copenhagen, Denmark.
[Brown, P.] Rigshosp, Dept Hematol, DK-2100 Copenhagen, Denmark.
[Baz, R.; Shal, B.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Flynn, J.] Ohio State Univ, James Canc Hosp, Columbus, OH 43210 USA.
[Flinn, I.] Tennessee Oncol, Sarah Cannon Res Inst, Nashville, TN USA.
[Goy, A.; Gutierrez, M.] Hackensack Univ, Med Ctr, Hackensack, NJ USA.
[Landesman, Y.; Klebanov, B.; Shacham, E.; Saint-Martin, J. R.; Marshall, T.; McCartney, J.; McCauley, D.; Carlson, R.; Rashal, T.; Mirza, M. R.; Shacham, S.; Kauffman, M.] Karyopharm Therapeut, Natick, MA USA.
[Rebello, S.] Ozmosis Res, Toronto, ON, Canada.
NR 0
TC 0
Z9 0
U1 5
U2 5
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA P466
BP 152
EP 152
PG 1
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830900366
ER
PT J
AU Staber, P
Zhang, P
Ye, M
Welner, R
Levantini, E
Di Ruscio, A
Ebralidze, A
Bach, C
Zhang, H
Zhang, J
Huang, G
Tenen, D
AF Staber, P.
Zhang, P.
Ye, M.
Welner, R.
Levantini, E.
Di Ruscio, A.
Ebralidze, A.
Bach, C.
Zhang, H.
Zhang, J.
Huang, G.
Tenen, D.
TI THE RUNX-PU.1 PATHWAY PRESERVES NORMAL AND AML/ETO9A LEUKEMIC STEM CELLS
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Staber, P.] Med Univ Vienna, Div Hematol, Vienna, Austria.
[Zhang, P.; Ye, M.; Welner, R.; Levantini, E.; Di Ruscio, A.; Ebralidze, A.; Bach, C.; Zhang, H.; Zhang, J.] BIDMC, Boston, MA USA.
[Huang, G.] Cincinnati Childrens Hosp Med Ctr, Cincinnati, OH 45229 USA.
[Tenen, D.] Natl Univ Singapore, Canc Sci Inst, Singapore 117548, Singapore.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA P516
BP 172
EP 172
PG 1
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830900415
ER
PT J
AU San-Miguel, J
Hungria, VT
Yoon, SS
Beksac, M
Dimopoulos, MA
Elghandour, A
Jedrzejczak, WW
Guenther, A
Nakorn, TN
Siritanaratkul, N
Schlossman, RL
Hou, J
Moreau, P
Lonial, S
Lee, JH
Einsele, H
Salwender, H
Sopala, M
Bengoudifa, BR
Corrado, C
Binlich, F
Richardson, P
AF San-Miguel, J.
Hungria, V. T.
Yoon, S. S.
Beksac, M.
Dimopoulos, M. A.
Elghandour, A.
Jedrzejczak, W. W.
Guenther, A.
Nakorn, T. Na
Siritanaratkul, N.
Schlossman, R. L.
Hou, J.
Moreau, P.
Lonial, S.
Lee, J. H.
Einsele, H.
Salwender, H.
Sopala, M.
Bengoudifa, B. R.
Corrado, C.
Binlich, F.
Richardson, P.
TI RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 3 STUDY OF
PANOBINOSTAT OR PLACEBO PLUS BORTEZOMIB AND DEXAMETHASONE IN RELAPSED OR
RELAPSED AND REFRACTORY MULTIPLE MYELOMA (PANORAMA 1)
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [San-Miguel, J.] Univ Navarra, E-31080 Pamplona, Spain.
[Hungria, V. T.] Irmandade da Santa Casa de Misericordia Sao Paulo, Sao Paulo, Brazil.
[Yoon, S. S.] Seoul Natl Univ, Coll Med, Dept Internal Med, Seoul 151, South Korea.
[Beksac, M.] Ankara Univ, Sch Med, TR-06100 Ankara, Turkey.
[Dimopoulos, M. A.] Univ Athens, Sch Med, Dept Clin Therapeut, GR-11527 Athens, Greece.
[Elghandour, A.] Univ Alexandria, Alexandria, Egypt.
[Jedrzejczak, W. W.] Med Univ Warsaw, Warsaw, Poland.
[Guenther, A.] Univ Hosp Schleswig Holstein, Div Stem Cell Transplantat & Immunotherapy, Dept Med 2, Kiel, Germany.
[Guenther, A.] Univ Kiel, Kiel, Germany.
[Nakorn, T. Na] Chulalongkorn Univ, Bangkok, Thailand.
[Nakorn, T. Na] King Chulalongkorn Mem Hosp, Bangkok, Thailand.
[Siritanaratkul, N.] Siriraj Hosp, Bangkok, Thailand.
[Schlossman, R. L.; Richardson, P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Hou, J.] Chang Zheng Hosp, Shanghai, Peoples R China.
[Moreau, P.] Univ Hosp Nantes, Nantes, France.
[Lonial, S.] Winship Canc Inst, Atlanta, GA USA.
[Lee, J. H.] Gachon Univ, Dept Internal Med, Gil Hosp, Inchon, South Korea.
[Einsele, H.] Univ Wurzburg, Med Klin & Poliklin 2, D-97070 Wurzburg, Germany.
[Salwender, H.] Asklepios Klin Altona, Hamburg, Germany.
[Sopala, M.; Bengoudifa, B. R.; Corrado, C.] Novartis Pharma AG, Basel, Switzerland.
[Binlich, F.] Novartis Pharma SAS, Rueil Malmaison, France.
RI richard, chrystelle/K-8595-2015;
OI Elghandour, ASHRAF/0000-0002-8841-048X
NR 0
TC 0
Z9 0
U1 1
U2 10
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA S641
BP 219
EP 220
PG 2
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830901090
ER
PT J
AU Facon, T
Dimopoulos, MA
Dispenzieri, A
Catalano, JV
Belch, A
Hulin, C
Cavo, M
Pinto, A
Weisel, KC
Ludwig, H
Bahlis, N
Banos, A
Tiab, M
Delforge, M
Cavenagh, J
Geraldes, C
Lee, JJ
Chen, C
Oriol, A
De La Rubia, J
Qiu, L
White, D
Binder, D
Anderson, KC
Moreau, P
Attal, M
Knight, R
Chen, G
Van Oostendorp, J
Jacques, CJ
Ervin-Haynes, A
Benboubker, L
AF Facon, T.
Dimopoulos, M. A.
Dispenzieri, A.
Catalano, J. V.
Belch, A.
Hulin, C.
Cavo, M.
Pinto, A.
Weisel, K. C.
Ludwig, H.
Bahlis, N.
Banos, A.
Tiab, M.
Delforge, M.
Cavenagh, J.
Geraldes, C.
Lee, J. J.
Chen, C.
Oriol, A.
De La Rubia, J.
Qiu, L.
White, D.
Binder, D.
Anderson, K. C.
Moreau, P.
Attal, M.
Knight, R.
Chen, G.
Van Oostendorp, J.
Jacques, C. J.
Ervin-Haynes, A.
Benboubker, L.
TI LENALIDOMIDE plus LOW-DOSE DEXAMETHASONE (RD) VS.
MELPHALAN-PREDNISONE-THALIDOMIDE (MPT) IN NEWLY DIAGNOSED MULTIPLE
MYELOMA (NDMM) PATIENTS (PTS): THE FIRST TRIAL
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Facon, T.] CHRU Lille, Serv Malad Sang, Hop Claude Huriez, F-59037 Lille, France.
[Dimopoulos, M. A.] Univ Athens, Sch Med, GR-11527 Athens, Greece.
[Dispenzieri, A.] Mayo Clin, Ctr Canc, Rochester, MN USA.
[Catalano, J. V.] Monash Univ, Frankston Hosp, Frankston, Australia.
[Belch, A.] Univ Alberta, Edmonton, AB, Canada.
[Belch, A.] Cross Canc Inst, Edmonton, AB T6G 1Z2, Canada.
[Hulin, C.] Univ Hosp, Nancy, France.
[Cavo, M.] Univ Bologna, Sch Med, Seragnoli Inst Hematol, Bologna, Italy.
[Pinto, A.] IRCCS, Hematol Oncol Unit, Ist G Pascale, Naples, Italy.
[Weisel, K. C.] Univ Tubingen, Tubingen, Germany.
[Ludwig, H.] Wilhelminen Hosp, Dept Internal Med 1, Ctr Oncol & Hematol, Vienna, Austria.
[Bahlis, N.] Univ Calgary, Calgary, AB, Canada.
[Banos, A.] Ctr Hosp Cote Basque, Bayonne, France.
[Tiab, M.] Ctr Hosp, Dept Med Interne Oudairies, La Roche Sur Yon, France.
[Delforge, M.] Univ Hosp Leuven, Leuven, Belgium.
[Cavenagh, J.] St Bartholomews Hosp, Dept Haematol, London, England.
[Geraldes, C.] Coimbra Univ Hosp, Clin Hematol Dept, Coimbra, Portugal.
[Lee, J. J.] Chonnam Natl Univ, Dept Hematol Oncol, Hwasun Hosp, Jeollanamdo, South Korea.
[Chen, C.] Princess Margaret Canc Ctr, Toronto, ON, Canada.
[Oriol, A.] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain.
[De La Rubia, J.] Hosp Univ La Fe, Valencia, Spain.
[Qiu, L.] CAMS, State Key Lab Expt Hematol, Inst Hematol, Tianjin, Peoples R China.
[Qiu, L.] CAMS, Blood Dis Hosp, Tianjin, Peoples R China.
[Qiu, L.] PUMC, Tianjin, Peoples R China.
[White, D.] Queen Elizabeth 2 Hlth Sci Ctr, Halifax, NS, Canada.
[Binder, D.] Kantonsspital Winterthur, Winterthur, Switzerland.
[Anderson, K. C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Moreau, P.] CHU Nantes, Serv Hematol, F-44035 Nantes 01, France.
[Attal, M.] Univ Hop Purpan, Ctr Hosp Reg, Toulouse, France.
[Knight, R.; Chen, G.; Van Oostendorp, J.; Jacques, C. J.; Ervin-Haynes, A.] Celgene Corp, Summit, NJ USA.
[Benboubker, L.] Univ Hosp Tours, Tours, France.
RI FACON, THIERRY/M-9736-2014; richard, chrystelle/K-8595-2015
OI FACON, THIERRY/0000-0001-7705-8460;
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA S643
BP 220
EP 221
PG 2
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830901092
ER
PT J
AU Stewart, AK
Jacobus, S
Fonseca, R
Weiss, M
Callander, NS
Chanan-Khan, AA
Rajkumar, SV
AF Stewart, A. K.
Jacobus, S.
Fonseca, R.
Weiss, M.
Callander, N. S.
Chanan-Khan, A. A.
Rajkumar, S. V.
TI E1A06: A PHASE III TRIAL COMPARING MELPHALAN, PREDNISONE, AND
THALIDOMIDE (MPT) VERSUS MELPHALAN, PREDNISONE, AND LENALIDOMIDE (MPR)
IN NEWLY DIAGNOSED MULTIPLE MYELOMA MM)
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Stewart, A. K.; Fonseca, R.] Mayo Clin, Scottsdale, AZ USA.
[Jacobus, S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Weiss, M.] Marshfield Clin Fdn Med Res & Educ, Marshfield, WI USA.
[Callander, N. S.] Univ Wisconsin, Madison, WI 53706 USA.
[Chanan-Khan, A. A.] Mayo Clin, Jacksonville, FL 32224 USA.
[Rajkumar, S. V.] Mayo Clin, Rochester, MN USA.
NR 0
TC 2
Z9 2
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA S642
BP 220
EP 220
PG 1
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830901091
ER
PT J
AU Groschel, S
Sanders, MA
Hoogenboezem, R
de Wit, E
Britta, BA
Erpelinck, C
van der Velden, VH
Havermans, M
Avellino, R
van Lom, K
Rombouts, EJ
van Duin, M
Dohner, K
Beverloo, HB
Bradner, JE
Dohner, H
Lowenberg, B
Valk, PJ
Bindels, EM
de Laat, W
Delwel, R
AF Groschel, S.
Sanders, M. A.
Hoogenboezem, R.
de Wit, E.
Britta, B. A.
Erpelinck, C.
van der Velden, V. H.
Havermans, M.
Avellino, R.
van Lom, K.
Rombouts, E. J.
van Duin, M.
Doehner, K.
Beverloo, H. B.
Bradner, J. E.
Doehner, H.
Lowenberg, B.
Valk, P. J.
Bindels, E. M.
de laat, W.
Delwel, R.
TI A SINGLE ONCOGENIC ENHANCER-REARRANGEMENT CAUSES CONCOMITANT EVI1 AND
GATA2 DEREGULATION IN LEUKEMIA
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Groschel, S.; Sanders, M. A.; Hoogenboezem, R.; Erpelinck, C.; Havermans, M.; Avellino, R.; van Lom, K.; Rombouts, E. J.; van Duin, M.; Lowenberg, B.; Valk, P. J.; Bindels, E. M.; Delwel, R.] Erasmus MC, Dept Hematol, Rotterdam, Netherlands.
[de Wit, E.; Britta, B. A.; de laat, W.] Hubrecht Inst KNAW, Utrecht, Netherlands.
[de Wit, E.; Britta, B. A.; de laat, W.] Univ Med Ctr Utrecht, Utrecht, Netherlands.
[van der Velden, V. H.] Erasmus MC, Dept Immunol, Rotterdam, Netherlands.
[Doehner, K.; Doehner, H.] Uniklin Ulm, Ulm, Germany.
[Beverloo, H. B.] Erasmus MC, Dept Clin Genet, Rotterdam, Netherlands.
[Bradner, J. E.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA S691
BP 243
EP 243
PG 1
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830901140
ER
PT J
AU Hillmen, P
Brown, JR
O'Brien, S
Barrientos, J
Kay, NE
Reddy, NM
Coutre, S
Tam, C
Mulligan, S
Jaeger, U
Devereux, S
Barr, PM
Furman, R
Kipps, T
Cymbalista, F
Pocock, C
Thornton, P
Caligaris-Cappio, F
Robak, T
Delgado, J
Schuster, SJ
Montillo, M
Schuh, A
DeVos, S
Gill, D
Bloor, A
Dearden, C
Moreno, C
Jones, JJ
Chu, AD
Fardis, M
McGreivy, J
Clow, F
James, D
Byrd, JC
AF Hillmen, P.
Brown, J. R.
O'Brien, S.
Barrientos, J.
Kay, N. E.
Reddy, N. M.
Coutre, S.
Tam, C.
Mulligan, S.
Jaeger, U.
Devereux, S.
Barr, P. M.
Furman, R.
Kipps, T.
Cymbalista, F.
Pocock, C.
Thornton, P.
Caligaris-Cappio, F.
Robak, T.
Delgado, J.
Schuster, S. J.
Montillo, M.
Schuh, A.
DeVos, S.
Gill, D.
Bloor, A.
Dearden, C.
Moreno, C.
Jones, J. J.
Chu, A. D.
Fardis, M.
McGreivy, J.
Clow, F.
James, D.
Byrd, J. C.
TI RANDOMIZED COMPARISON OF IBRUTINIB VERSUS OFATUMUMAB IN PREVIOUSLY
TREATED CHRONIC LYMPHOCYTIC LEUKEMIA / SMALL LYMPHOCYTIC LYMPHOMA:
RESULTS FROM THE PHASE III PCYC-1112 RESONATE((TM)) TRIAL
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Hillmen, P.] Leeds Teaching Hosp, St James Inst Oncol, Leeds, W Yorkshire, England.
[Brown, J. R.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[O'Brien, S.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Barrientos, J.] Hofstra North Shore LIJ Sch Med, Hempstead, NY USA.
[Kay, N. E.] Mayo Clin, Rochester, MN USA.
[Reddy, N. M.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Coutre, S.] Stanford Univ, Sch Med, Palo Alto, CA 94304 USA.
[Tam, C.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
[Tam, C.] St Vincents Hosp, Melbourne, Vic, Australia.
[Mulligan, S.] Royal N Shore Hosp, Sydney, NSW, Australia.
[Jaeger, U.] Med Univ Vienna, Vienna, Austria.
[Devereux, S.] NHS Fdn Trust Denmark Hill, Kings Coll Hosp, London, England.
[Barr, P. M.] Univ Rochester, Ctr Canc, Rochester, NY 14627 USA.
[Furman, R.] New York Presbyterian Hosp, Cornell Med Ctr, New York, NY USA.
[Kipps, T.] Moores UCSD Canc Ctr, San Diego, CA USA.
[Cymbalista, F.] Hop Avicenne, Paris, France.
[Pocock, C.] East Kent Hosp Univ NHS Fdn Trust, Kent & Canterbury Hosp, Canterbury, Kent, England.
[Thornton, P.] Beaumont Hosp, Dublin 9, Ireland.
[Caligaris-Cappio, F.] Univ Vita Salute San Raffaele, Milan, Italy.
[Robak, T.] Med Univ Lodz, Lodz, Poland.
[Robak, T.] Copernicus Mem Hosp, Lodz, Poland.
[Delgado, J.] Hosp Clin Barcelona, Barcelona, Spain.
[Schuster, S. J.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA.
[Montillo, M.] Osped Niguarda Ca Granda, Milan, Italy.
[Schuh, A.] Oxford Biomed Res Ctr, Oxford, England.
[DeVos, S.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Gill, D.] Princess Alexandra Hosp, Brisbane, Qld 4102, Australia.
[Bloor, A.] Christie NHS Fdn Trust Hematol & Transplant Unit, Manchester, Lancs, England.
[Dearden, C.] Royal Marsden Hosp, Sutton, Surrey, England.
[Dearden, C.] Inst Canc Res, Sutton, Surrey, England.
[Moreno, C.] Hosp Santa Creu St Pau, Barcelona, Spain.
[Jones, J. J.; Byrd, J. C.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
[Chu, A. D.; Fardis, M.; McGreivy, J.; Clow, F.; James, D.] Pharmacyclics Inc, Sunnyvale, CA USA.
RI Delgado, Julio/D-4891-2013
OI Delgado, Julio/0000-0002-5157-4376
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA S693
BP 244
EP 244
PG 1
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830901142
ER
PT J
AU Gkotzamanidou, M
Shammas, M
Samur, MK
Souliotis, VL
Fulciniti, M
Minvielle, S
Magrangeas, F
Avet-Loiseau, H
Anderson, KC
Munshi, NC
AF Gkotzamanidou, M.
Shammas, M.
Samur, M. Kemal
Souliotis, V. L.
Fulciniti, M.
Minvielle, S.
Magrangeas, F.
Avet-Loiseau, H.
Anderson, K. C.
Munshi, N. C.
TI HDAC8 INHIBITS MYELOMA CELLULAR GROWTH THROUGH REGULATION OF HOMOLOGOUS
RECOMBINATION AND CYTOSKELETON INTEGRITY
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Gkotzamanidou, M.; Shammas, M.; Fulciniti, M.; Anderson, K. C.; Munshi, N. C.] Harvard Univ, Sch Med, Boston, MA USA.
[Samur, M. Kemal] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Souliotis, V. L.] Natl Hellen Res Fdn, Inst Biol Med Chem & Biotechnol, Athens, Greece.
[Minvielle, S.; Magrangeas, F.; Avet-Loiseau, H.] Univ Nantes, Ctr Canc Res Nantes Angers, Nantes, France.
RI Magrangeas, Florence/L-3080-2015; Minvielle, Stephane/K-8251-2015
NR 0
TC 0
Z9 0
U1 0
U2 3
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA S697
BP 246
EP 246
PG 1
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830901146
ER
PT J
AU Cottini, F
Hideshima, T
Xu, C
Ponzoni, M
Richardson, P
Cappio, FC
Anderson, K
Tonon, G
AF Cottini, F.
Hideshima, T.
Xu, C.
Ponzoni, M.
Richardson, P.
Cappio, F. Caligaris
Anderson, K.
Tonon, G.
TI INHIBITION OF THE STK4 KINASE RESTORES THE HIPPO CO-FACTOR YAP1 AND
INDUCES DNA-DAMAGE MEDIATED APOPTOSIS IN MULTIPLE MYELOMA CELLS
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Cottini, F.; Hideshima, T.; Xu, C.; Richardson, P.; Anderson, K.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ponzoni, M.] Ist Sci San Raffaele, Pathol Unit, I-20132 Milan, Italy.
[Cappio, F. Caligaris; Tonon, G.] Ist Sci San Raffaele, Div Mol Oncol, I-20132 Milan, Italy.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA S699
BP 247
EP 247
PG 1
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830901148
ER
PT J
AU Roccaro, A
Sacco, A
Moschetta, M
Mishima, Y
Maiso, P
Lonardi, S
Zboralski, D
Krushinski, A
Rossi, G
Ghobrial, I
AF Roccaro, A.
Sacco, A.
Moschetta, M.
Mishima, Y.
Maiso, P.
Lonardi, S.
Zboralski, D.
Krushinski, A.
Rossi, G.
Ghobrial, I.
TI IN VIVO TARGETING OF STROMAL-DERIVED FACTOR-1 AS A STRATEGY TO PREVENT
MYELOMA CELL BONE TO BONE DISSEMINATION
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Roccaro, A.; Sacco, A.; Moschetta, M.; Mishima, Y.; Maiso, P.; Ghobrial, I.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Lonardi, S.; Rossi, G.] Spedali Civili Brescia, Brescia, Italy.
[Zboralski, D.; Krushinski, A.] NOXXON Pharma AG, Berlin, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA S700
BP 247
EP 248
PG 2
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830901149
ER
PT J
AU Roberts, AW
Ma, S
Kipps, T
Barrientos, JC
Davids, MS
Anderson, MA
Tam, C
Mason-Bright, T
Rudersdorf, NK
Yang, J
Munasinghe, W
Zhu, M
Cerri, E
Enschede, SH
Humerickhouse, RA
Seymour, JF
AF Roberts, A. W.
Ma, S.
Kipps, T.
Barrientos, J. C.
Davids, M. S.
Anderson, M. A.
Tam, C.
Mason-Bright, T.
Rudersdorf, N. K.
Yang, J.
Munasinghe, W.
Zhu, M.
Cerri, E.
Enschede, S. H.
Humerickhouse, R. A.
Seymour, J. F.
TI ABT-199 (GDC-0199) COMBINED WITH RITUXIMAB (R) IN PATIENTS (PTS) WITH
RELAPSED / REFRACTORY (R/R) CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): INTERIM
RESULTS OF A PHASE 1B STUDY
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Roberts, A. W.; Anderson, M. A.] Royal Melbourne Hosp, Melbourne, Vic, Australia.
[Roberts, A. W.; Anderson, M. A.] Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.
[Ma, S.] Northwestern Univ, Chicago, IL 60611 USA.
[Kipps, T.] Univ Calif San Diego, San Diego, CA 92103 USA.
[Barrientos, J. C.] Hofstra North Shore LIJ Sch Med, New Hide Pk, NY USA.
[Davids, M. S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Tam, C.; Seymour, J. F.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
[Mason-Bright, T.; Rudersdorf, N. K.; Yang, J.; Munasinghe, W.; Zhu, M.; Cerri, E.; Enschede, S. H.; Humerickhouse, R. A.] AbbVie, N Chicago, IL USA.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA S703
BP 249
EP 249
PG 1
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830901152
ER
PT J
AU Seymour, JF
Davids, MS
Pagel, JM
Kahl, BS
Wierda, WG
Puvvada, S
Gerecitano, JF
Kipps, TJ
Anderson, MA
Huang, DC
Rudersdorf, NK
Gressick, LA
Montalvo, NP
Yang, J
Zhu, M
Dunbar, M
Cerri, E
Enschede, SH
Humerickhouse, RA
Roberts, AW
AF Seymour, J. F.
Davids, M. S.
Pagel, J. M.
Kahl, B. S.
Wierda, W. G.
Puvvada, S.
Gerecitano, J. F.
Kipps, T. J.
Anderson, M. A.
Huang, D. C.
Rudersdorf, N. K.
Gressick, L. A.
Montalvo, N. P.
Yang, J.
Zhu, M.
Dunbar, M.
Cerri, E.
Enschede, S. H.
Humerickhouse, R. A.
Roberts, A. W.
TI ABT-199 (GDC-0199) IN RELAPSED/REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA
AND SMALL LYMPHOCYTIC LYMPHOMA: HIGH RESPONSE RATES AMONG PATIENTS WITH
HIGH RISK DISEASE FEATURES INCLUDING UNMUTATED IGHV
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Seymour, J. F.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
[Davids, M. S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Pagel, J. M.] Univ Washington, Seattle, WA 98195 USA.
[Kahl, B. S.] Univ Wisconsin, Madison, WI 53706 USA.
[Wierda, W. G.] Univ Texas Houston, Houston, TX USA.
[Puvvada, S.] Univ Arizona, Tucson, AZ USA.
[Gerecitano, J. F.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Kipps, T. J.] Univ Calif San Diego, San Diego, CA 92103 USA.
[Anderson, M. A.; Roberts, A. W.] Royal Melbourne Hosp, Melbourne, Vic, Australia.
[Anderson, M. A.; Huang, D. C.; Roberts, A. W.] Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.
[Rudersdorf, N. K.; Gressick, L. A.; Montalvo, N. P.; Yang, J.; Zhu, M.; Dunbar, M.; Cerri, E.; Enschede, S. H.; Humerickhouse, R. A.] AbbVie, N Chicago, IL USA.
NR 0
TC 2
Z9 2
U1 1
U2 6
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA S702
BP 249
EP 249
PG 1
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830901151
ER
PT J
AU DeBoer, R
Mulkey, F
Koval, G
Wetzler, M
Marcucci, G
Stone, RM
Larson, RA
Geyer, S
Mullighan, C
Stock, W
AF DeBoer, R.
Mulkey, F.
Koval, G.
Wetzler, M.
Marcucci, G.
Stone, R. M.
Larson, R. A.
Geyer, S.
Mullighan, C.
Stock, W.
TI CLINICAL IMPACT OF ABL1 KINASE AND IKZF1 MUTATIONS IN ADULTS WITH
PHILADELPHIA CHROMOSOME-POSITIVE (PH plus ) ACUTE LYMPHOBLASTIC LEUKEMIA
(ALL): MOLECULAR ANALYSIS OF CALGB 10001 AND 9665 (ALLIANCE)
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [DeBoer, R.; Larson, R. A.; Stock, W.] Univ Chicago, Chicago, IL 60637 USA.
[Mulkey, F.] Duke Univ, Alliance Stat & Data Ctr, Durham, NC 27706 USA.
[Koval, G.] Indiana Univ, Gary, IN USA.
[Wetzler, M.] Roswell Pk Canc Inst, Buffalo, NY 14263 USA.
[Marcucci, G.] Ohio State Univ, Med Ctr, Columbus, OH 43210 USA.
[Stone, R. M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Geyer, S.] Ohio State Univ, Med Ctr, Alliance Stat & Data Ctr, Columbus, OH 43210 USA.
[Mullighan, C.] St Jude Childrens Res Hosp, Memphis, TN USA.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA S723
BP 258
EP 258
PG 1
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830901172
ER
PT J
AU Walter, D
Lier, A
Geiselhart, A
Huntscha, S
Brocks, D
Bayindir, I
Kaschutnig, P
Mudder, K
Holland-Letz, T
Schmezer, P
Lane, S
Essers, MAG
Williams, DA
Williams, DA
Trumpp, A
Milsom, MD
AF Walter, D.
Lier, A.
Geiselhart, A.
Huntscha, S.
Brocks, D.
Bayindir, I.
Kaschutnig, P.
Muedder, K.
Holland-Letz, T.
Schmezer, P.
Lane, S.
Essers, M. A. G.
Williams, D. A.
Williams, D. A.
Trumpp, A.
Milsom, M. D.
TI STRESS-INDUCED EXIT FROM QUIESCENCE INDUCES DE NOVO DNA DAMAGE IN
HEMATOPOIETIC STEM CELLS AND RESULTS IN BONE MARROW FAILURE IN THE
ABSENCE OF A FUNCTIONAL FANCONI ANEMIA SIGNALLING PATHWAY
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Walter, D.; Lier, A.; Huntscha, S.; Muedder, K.; Essers, M. A. G.; Trumpp, A.; Milsom, M. D.] Heidelberg Inst Stem Cell Technol & Expt Med HIST, Heidelberg, Germany.
[Geiselhart, A.; Brocks, D.; Bayindir, I.; Kaschutnig, P.; Holland-Letz, T.; Schmezer, P.; Essers, M. A. G.; Trumpp, A.; Milsom, M. D.] German Canc Res Ctr, Heidelberg, Germany.
[Lane, S.] Queensland Inst Med Res, Brisbane, Qld 4006, Australia.
[Williams, D. A.; Williams, D. A.] Boston Childrens Hosp, Boston, MA USA.
[Williams, D. A.] Harvard Univ, Sch Med, Boston, MA USA.
[Williams, D. A.] Dana Faber Canc Inst, Boston, MA USA.
[Williams, D. A.] Harvard Stem Cell Inst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA S729
BP 261
EP 261
PG 1
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830901178
ER
PT J
AU le Coutre, PD
Kim, DW
Pinilla-Ibarz, J
Paquette, R
Chuah, C
Nicolini, FE
Apperley, JF
Khoury, HJ
Talpaz, M
DiPersio, JF
DeAngelo, D
Abruzzese, E
Rea, D
Baccarani, M
Muller, M
Gambacorti-Passerini, C
Lustgarten, S
Haluska, FG
Guilhot, F
Deininger, MW
Hochhaus, A
Hughes, TP
Shah, NP
Kantarjian, HM
Cortes, JE
AF le Coutre, P. D.
Kim, D. W.
Pinilla-Ibarz, J.
Paquette, R.
Chuah, C.
Nicolini, F. E.
Apperley, J. F.
Khoury, H. J.
Talpaz, M.
DiPersio, J. F.
DeAngelo, D.
Abruzzese, E.
Rea, D.
Baccarani, M.
Muller, M.
Gambacorti-Passerini, C.
Lustgarten, S.
Haluska, F. G.
Guilhot, F.
Deininger, M. W.
Hochhaus, A.
Hughes, T. P.
Shah, N. P.
Kantarjian, H. M.
Cortes, J. E.
TI PONATINIB IN PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME- POSITIVE (PH
plus ) LEUKEMIAS RESISTANT OR INTOLERANT TO DASATINIB OR NILOTINIB, OR
WITH THE T315I MUTATION: LONGER-TERM FOLLOW-UP OF THE PACE TRIAL
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [le Coutre, P. D.] Charite, D-13353 Berlin, Germany.
[Kim, D. W.] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea.
[Pinilla-Ibarz, J.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Paquette, R.] Univ Calif Los Angeles, Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA.
[Chuah, C.] Singapore Gen Hosp, Duke NUS Grad Med Sch, Singapore, Singapore.
[Nicolini, F. E.] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France.
[Apperley, J. F.] Univ London Imperial Coll Sci Technol & Med, London, England.
[Khoury, H. J.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
[Talpaz, M.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[DiPersio, J. F.] Washington Univ, Sch Med, St Louis, MO USA.
[DeAngelo, D.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Abruzzese, E.] Univ Roma Tor Vergata, S Eugenio Hosp, Rome, Italy.
[Rea, D.] Hop St Louis, Paris, France.
[Baccarani, M.] Orsola Malpighi Univ Hosp, Bologna, Italy.
[Muller, M.] Univ Med Mannheim, Med Klin 3, Mannheim, Germany.
[Gambacorti-Passerini, C.] Azienda Osped San Gerardo Univ Milano Bicocca, Unita Ric Clin Ematol, Monza, Italy.
[Lustgarten, S.; Haluska, F. G.] ARIAD Pharmaceut Inc, Cambridge, MA 02139 USA.
[Guilhot, F.] CHU Poitiers Univ Hosp, Poitiers, France.
[Deininger, M. W.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
[Hochhaus, A.] Univ Klinikum Jena, Jena, Germany.
[Hughes, T. P.] SA Pathol, Adelaide, SA, Australia.
[Shah, N. P.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Kantarjian, H. M.; Cortes, J. E.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA P893
BP 334
EP 334
PG 1
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830901340
ER
PT J
AU Nicolini, FE
Cortes, JE
Kim, DW
Pinilla-Ibarz, J
le Coutre, PD
Paquette, R
Chuah, C
Apperley, JF
Khoury, HJ
Talpaz, M
DiPersio, JF
DeAngelo, DJ
Abruzzese, E
Rea, D
Baccarani, M
Muller, MC
Gambacorti-Passerini, C
Lustgarten, S
Rivera, VM
Haluska, FG
Guilhot, F
Deininger, MW
Hughes, TP
Shah, NP
Kantarjian, HM
Hochhaus, A
AF Nicolini, F. E.
Cortes, J. E.
Kim, D. W.
Pinilla-Ibarz, J.
le Coutre, P. D.
Paquette, R.
Chuah, C.
Apperley, J. F.
Khoury, H. J.
Talpaz, M.
DiPersio, J. F.
DeAngelo, D. J.
Abruzzese, E.
Rea, D.
Baccarani, M.
Muller, M. C.
Gambacorti-Passerini, C.
Lustgarten, S.
Rivera, V. M.
Haluska, F. G.
Guilhot, F.
Deininger, M. W.
Hughes, T. P.
Shah, N. P.
Kantarjian, H. M.
Hochhaus, A.
TI CLINICAL IMPACT OF DOSE MODIFICATION AND DOSE INTENSITY ON RESPONSE TO
PONATINIB IN PATIENTS (PTS) WITH PHILADELPHIA CHROMOSOME-POSITIVE (PH
plus ) LEUKEMIAS
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Nicolini, F. E.] Ctr Hosp Lyon Sud, F-69310 Pierre Benite, France.
[Cortes, J. E.; Kantarjian, H. M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Kim, D. W.] Catholic Univ Korea, Seoul St Marys Hosp, Seoul, South Korea.
[Pinilla-Ibarz, J.] Univ S Florida, H Lee Moffitt Canc Ctr, Tampa, FL 33682 USA.
[le Coutre, P. D.] Charite, D-13353 Berlin, Germany.
[Paquette, R.] Univ Calif Los Angeles, Ronald Reagan UCLA Med Ctr, Los Angeles, CA USA.
[Chuah, C.] Singapore Gen Hosp, Duke NUS Grad Med Sch, Singapore, Singapore.
[Apperley, J. F.] Univ London Imperial Coll Sci Technol & Med, London, England.
[Khoury, H. J.] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA.
[Talpaz, M.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[DiPersio, J. F.] Washington Univ, Sch Med, St Louis, MO USA.
[DeAngelo, D. J.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Abruzzese, E.] Univ Roma Tor Vergata, S Eugenio Hosp, Rome, Italy.
[Rea, D.] Hop St Louis, Serv Malad Sang, Paris, France.
[Rea, D.] Hop St Louis, CIC Clin Invest Ctr, Paris, France.
[Baccarani, M.] S Orsola Malpighi Univ Hosp, Bologna, Italy.
[Muller, M. C.] Univ Med, Med Klin 3, Mannheim, Germany.
[Gambacorti-Passerini, C.] Azienda Osped San Gerardo Univ Milano Bicocca, Unita Ric Clin Ematol, Monza, Italy.
[Lustgarten, S.; Rivera, V. M.; Haluska, F. G.] ARIAD Pharmaceut Inc, Cambridge, MA USA.
[Guilhot, F.] Univ Hosp, CHU Poitiers, Poitiers, France.
[Deininger, M. W.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT USA.
[Hughes, T. P.] Inst Med & Vet Sci, Adelaide, SA 5000, Australia.
[Shah, N. P.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Hochhaus, A.] Univ Klinikum Jena, Jena, Germany.
NR 0
TC 0
Z9 0
U1 0
U2 3
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA P894
BP 334
EP 334
PG 1
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830901341
ER
PT J
AU Cagnetta, A
Cea, M
Fulciniti, M
Yu-Tzu, T
Chauhan, D
Gobbi, M
Treon, S
Anderson, KC
AF Cagnetta, A.
Cea, M.
Fulciniti, M.
Yu-Tzu, T.
Chauhan, D.
Gobbi, M.
Treon, S.
Anderson, K. C.
TI INHIBITION OF NAMPT AUGMENTS IBRUTINIB INDUCED KILLING IN MYD88 L265P
EXPRESSING WALDENSTROM'S MACROGLOBULINEMIA CELLS
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Cagnetta, A.; Cea, M.; Fulciniti, M.; Yu-Tzu, T.; Chauhan, D.; Treon, S.; Anderson, K. C.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Cea, M.; Gobbi, M.] IRCCS AOU San Martino IST, Genoa, Italy.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA P951
BP 358
EP 358
PG 1
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830901398
ER
PT J
AU Mellqvist, UH
Paba-Prada, C
Palumbo, A
Plesner, T
Sonneveld, P
Voorhees, P
Byrne, C
Harmenberg, J
Nordstrom, E
Richardson, PG
AF Mellqvist, U. H.
Paba-Prada, C.
Palumbo, A.
Plesner, T.
Sonneveld, P.
Voorhees, P.
Byrne, C.
Harmenberg, J.
Nordstrom, E.
Richardson, P. G.
TI AN ONGOING OPEN-LABEL PHASE 1/2A STUDY OF THE SAFETY AND EFFICACY OF
MELFLUFEN AND DEXAMETHASONE COMBINATION FOR PATIENTS WITH RELAPSED AND
RELAPSED-REFRACTORY MULTIPLE MYELOMA (RRMM)
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Mellqvist, U. H.] Boras Hosp, Boras, Sweden.
[Paba-Prada, C.; Richardson, P. G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Palumbo, A.] Turin Hosp, Turin, Italy.
[Plesner, T.] Vejle Hosp, Vejle, Denmark.
[Sonneveld, P.] Erasmus, Rotterdam, Netherlands.
[Voorhees, P.] Univ N Carolina, Chapel Hill, NC USA.
[Byrne, C.] Oncopeptides AB, Miami, FL USA.
[Harmenberg, J.; Nordstrom, E.] Oncopeptides AB, Stockholm, Sweden.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA P988
BP 375
EP 376
PG 2
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830901435
ER
PT J
AU Casper, C
Chaturvedi, S
Munshi, N
Wong, R
Qi, M
Schaffer, M
Bandekar, R
Huang, Y
Hall, B
Vermeulen, J
Reddy, M
Van Rhee, F
AF Casper, C.
Chaturvedi, S.
Munshi, N.
Wong, R.
Qi, M.
Schaffer, M.
Bandekar, R.
Huang, Y.
Hall, B.
Vermeulen, J.
Reddy, M.
Van Rhee, F.
TI INFLAMMATORY AND ANEMIA-RELATED MARKERS IN A PHASE 2, RANDOMIZED,
DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY OF SILTUXIMAB (ANTI-IL-6
MONOCLONAL ANTIBODY) IN MULTICENTRIC CASTLEMAN'S DISEASE PATIENTS
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Casper, C.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Chaturvedi, S.; Qi, M.; Schaffer, M.; Bandekar, R.; Huang, Y.; Hall, B.; Reddy, M.] Janssen Res & Dev, Spring House, PA USA.
[Munshi, N.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Wong, R.] Chinese Univ Hong Kong, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China.
[Vermeulen, J.] Janssen Res & Dev, Leiden, Netherlands.
[Van Rhee, F.] Univ Arkansas Med Sci, Myeloma Inst Res & Therapy, Little Rock, AR 72205 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA P1211
BP 465
EP 465
PG 1
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830902196
ER
PT J
AU Roccaro, A
Sacco, A
Jimenez, C
Maiso, P
Moschetta, M
Mishima, Y
Alajawai, Y
Kuhne, M
Cardarelli, P
Cohen, L
San Miguel, J
Garcia-Sanz, R
Ghobrial, I
AF Roccaro, A.
Sacco, A.
Jimenez, C.
Maiso, P.
Moschetta, M.
Mishima, Y.
Alajawai, Y.
Kuhne, M.
Cardarelli, P.
Cohen, L.
San Miguel, J.
Garcia-Sanz, R.
Ghobrial, I.
TI A NOVEL ACTIVATING SOMATIC MUTATION OF CXCR4 PLAYS A CRUCIAL ROLE IN
MODULATING WALDENSTROM MACROGLOBULINEMIA BIOLOGY
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Roccaro, A.; Sacco, A.; Maiso, P.; Moschetta, M.; Mishima, Y.; Alajawai, Y.; Ghobrial, I.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Jimenez, C.; Garcia-Sanz, R.] Univ Salamanca, E-37008 Salamanca, Spain.
[Kuhne, M.; Cardarelli, P.] Bristol Myers Squibb, Redwood City, CA USA.
[Cohen, L.] Bristol Myers Squibb, Lawrenceville, NJ USA.
[San Miguel, J.] Univ Navarra, E-31080 Pamplona, Spain.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA S1301
BP 502
EP 503
PG 2
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830902286
ER
PT J
AU Placke, T
Faber, K
Nonami, A
Putwain, S
Salih, H
Heidel, F
Kramer, A
Root, D
Barbie, D
Armstrong, S
Hahn, W
Huntly, B
Sykes, S
Milsom, M
Scholl, C
Frohling, S
AF Placke, T.
Faber, K.
Nonami, A.
Putwain, S.
Salih, H.
Heidel, F.
Kraemer, A.
Root, D.
Barbie, D.
Armstrong, S.
Hahn, W.
Huntly, B.
Sykes, S.
Milsom, M.
Scholl, C.
Froehling, S.
TI REQUIREMENT FOR CDK6 IN MLL-REARRANGED ACUTE MYELOID LEUKEMIA
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Placke, T.; Froehling, S.] Natl Ctr Tumor Dis, Heidelberg, Germany.
[Faber, K.; Scholl, C.] Univ Ulm, D-89069 Ulm, Germany.
[Nonami, A.; Barbie, D.; Hahn, W.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Putwain, S.; Huntly, B.] Cambridge Inst Med Res, Cambridge, England.
[Salih, H.] Univ Tubingen, Tubingen, Germany.
[Heidel, F.] Univ Magdeburg, D-39106 Magdeburg, Germany.
[Kraemer, A.; Milsom, M.] German Canc Res Ctr, Heidelberg, Germany.
[Root, D.] Broad Inst Harvard & MIT, Cambridge, MA USA.
[Armstrong, S.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Sykes, S.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA S1323
BP 513
EP 513
PG 1
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830902308
ER
PT J
AU Wedeh, G
Cerny-Reiterer, S
Hadzijusufovic, E
Herrmann, H
Blatt, K
Eisenwort, G
Hoermann, G
Sperr, WR
Muellauer, L
Vakoc, CR
Bradner, JE
Horny, H
Zuber, J
Arock, M
Valent, P
AF Wedeh, G.
Cerny-Reiterer, S.
Hadzijusufovic, E.
Herrmann, H.
Blatt, K.
Eisenwort, G.
Hoermann, G.
Sperr, W. R.
Muellauer, L.
Vakoc, C. R.
Bradner, J. E.
Horny, H. P.
Zuber, J.
Arock, M.
Valent, P.
TI THE EPIGENETIC READER BRD4 SERVES AS A NOVEL MARKER AND TARGET IN
AGGRESSIVE SYSTEMIC MASTOCYTOSIS AND MAST CELL LEUKEMIA
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Wedeh, G.; Arock, M.] Ecole Normale Super, LBPA, Cachan, France.
[Wedeh, G.; Cerny-Reiterer, S.; Hadzijusufovic, E.; Blatt, K.; Sperr, W. R.; Valent, P.] Med Univ Vienna, Div Hematol & Hemostaseol, Dept Med 1, Vienna, Austria.
[Cerny-Reiterer, S.; Hadzijusufovic, E.; Herrmann, H.; Eisenwort, G.; Sperr, W. R.; Valent, P.] Med Univ Vienna, Ludwig Boltzmann Cluster Oncol LB CO, Vienna, Austria.
[Hadzijusufovic, E.] Univ Vet Med, Clin Unit Internal Med, Clin Small Anim, Dept Clin Compan Anim & Horses, Vienna, Austria.
[Hoermann, G.] Med Univ Vienna, Dept Lab Med, Vienna, Austria.
[Muellauer, L.] Med Univ Vienna, Dept Clin Pathol, Vienna, Austria.
[Vakoc, C. R.] Cold Spring Harbor Lab, Cold Spring Harbor, NY 11724 USA.
[Bradner, J. E.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Horny, H. P.] Univ Munich, Inst Pathol, D-80539 Munich, Germany.
[Zuber, J.] Res Inst Mol Pathol IMP, Vienna, Austria.
RI Hadzijusufovic, Emir/B-8109-2016; Hoermann, Gregor/B-8832-2016
OI Hadzijusufovic, Emir/0000-0001-7409-4204; Hoermann,
Gregor/0000-0002-7374-4380
NR 0
TC 0
Z9 0
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA S1327
BP 514
EP 515
PG 2
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830902312
ER
PT J
AU Davids, MS
Seymour, JF
Gerecitano, JF
Kahl, BS
Pagel, JM
Wierda, WG
Anderson, M
Rudersdorf, NK
Gressick, LA
Montalvo, NP
Yang, J
Zhu, M
Dunbar, M
Cerri, E
Enschede, SH
Humerickhouse, RA
Roberts, AW
AF Davids, M. S.
Seymour, J. F.
Gerecitano, J. F.
Kahl, B. S.
Pagel, J. M.
Wierda, W. G.
Anderson, M. A.
Rudersdorf, N. K.
Gressick, L. A.
Montalvo, N. P.
Yang, J.
Zhu, M.
Dunbar, M.
Cerri, E.
Enschede, S. H.
Humerickhouse, R. A.
Roberts, A. W.
TI PHASE I STUDY OF ABT-199 (GDC-0199) IN PATIENTS WITH RELAPSED/REFRACTORY
NON-HODGKIN LYMPHOMA: RESPONSES OBSERVED IN DIFFUSE LARGE B-CELL (DLBCL)
AND FOLLICULAR LYMPHOMA (FL) AT HIGHER COHORT DOSES
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Davids, M. S.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Seymour, J. F.] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia.
[Gerecitano, J. F.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Kahl, B. S.] Univ Wisconsin, Madison, WI 53706 USA.
[Pagel, J. M.] Univ Washington, Seattle, WA 98195 USA.
[Wierda, W. G.] Univ Texas Houston, Houston, TX USA.
[Anderson, M. A.; Roberts, A. W.] Royal Melbourne Hosp, Melbourne, Vic, Australia.
[Anderson, M. A.; Roberts, A. W.] Walter & Eliza Hall Inst Med Res, Melbourne, Vic 3050, Australia.
[Rudersdorf, N. K.; Gressick, L. A.; Montalvo, N. P.; Yang, J.; Zhu, M.; Dunbar, M.; Cerri, E.; Enschede, S. H.; Humerickhouse, R. A.] AbbVie, N Chicago, IL USA.
NR 0
TC 4
Z9 5
U1 0
U2 1
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA S1348
BP 525
EP 525
PG 1
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830902332
ER
PT J
AU Garzon, R
Flinn, I
Berdeja, J
DeAngelo, D
Wadleigh, M
Yee, K
Schuh, A
Mau-Sorensen, M
Brown, P
Lancet, J
Shah, B
Gutierrez, M
Gabrail, N
Wagner-Johnston, N
Blum, W
Carlson, R
Klebanov, B
McCauley, D
Shacham, E
McCartney, J
Marshall, T
Saint-Martin, JR
Rebello, S
Rashal, T
Kauffman, M
Shacham, S
Mirza, M
Stone, R
AF Garzon, R.
Flinn, I.
Berdeja, J.
DeAngelo, D.
Wadleigh, M.
Yee, K.
Schuh, A.
Mau-Sorensen, M.
Brown, P.
Lancet, J.
Shah, B.
Gutierrez, M.
Gabrail, N.
Wagner-Johnston, N.
Blum, W.
Carlson, R.
Klebanov, B.
McCauley, D.
Shacham, E.
McCartney, J.
Marshall, T.
Saint-Martin, J. R.
Rebello, S.
Rashal, T.
Kauffman, M.
Shacham, S.
Mirza, M.
Stone, R.
TI A PHASE 1 DOSE ESCALATION STUDY OF THE ORAL SELECTIVE INHIBITOR OF
NUCLEAR EXPORT (SINE) SELINEXOR (KPT-330) IN PATIENTS (PTS) WITH
RELAPSED / REFRACTORY ACUTE MYELOID LEUKEMIA (AML)
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Garzon, R.; Blum, W.] Ohio State Univ, Columbus, OH 43210 USA.
[Flinn, I.; Berdeja, J.] Sarah Cannon Res Inst, Nashville, TN USA.
[DeAngelo, D.; Wadleigh, M.; Stone, R.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Yee, K.; Schuh, A.] Princess Margaret Canc Ctr, Toronto, ON, Canada.
[Mau-Sorensen, M.] Rigshosp Univ Hosp, Dept Oncol, Copenhagen, Denmark.
[Brown, P.] Rigshosp Univ Hosp, Dept Hematol, Copenhagen, Denmark.
[Lancet, J.; Shah, B.] Univ S Florida, Coll Med, H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Gutierrez, M.] Hackensack Univ Med Ctr, Hackensack, NJ USA.
[Gabrail, N.] Gabrail Canc Ctr, Canton, OH USA.
[Wagner-Johnston, N.] Washington Univ, Sch Med, St Louis, MO USA.
[Carlson, R.; Klebanov, B.; McCauley, D.; Shacham, E.; McCartney, J.; Marshall, T.; Saint-Martin, J. R.; Rashal, T.; Kauffman, M.; Shacham, S.; Mirza, M.] Karyopharm Therapeut, Natick, MA USA.
[Rebello, S.] Ozmosis Res, Toronto, ON, Canada.
RI Garzon, Ramiro/E-3104-2011
NR 0
TC 1
Z9 1
U1 1
U2 7
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA S1353
BP 527
EP 528
PG 2
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830902337
ER
PT J
AU Dombret, H
Seymour, JF
Butrym, A
Wierzbowska, A
Selleslag, D
Jang, JH
Kumar, R
Cavenagh, J
Schuh, A
Candoni, A
Recher, C
Sandhu, I
Bernal, T
Al-Ali, HK
Martinelli, G
Stone, RM
Minden, MD
McIntyre, H
Songer, S
Lucy, L
Beach, C
Dohner, H
AF Dombret, H.
Seymour, J. F.
Butrym, A.
Wierzbowska, A.
Selleslag, D.
Jang, J. H.
Kumar, R.
Cavenagh, J.
Schuh, A.
Candoni, A.
Recher, C.
Sandhu, I.
Bernal, T.
Al-Ali, H. K.
Martinelli, G.
Stone, R. M.
Minden, M. D.
McIntyre, H.
Songer, S.
Lucy, L.
Beach, C.
Doehner, H.
TI RESULTS OF A PHASE 3, MULTICENTER, RANDOMIZED, OPEN-LABEL STUDY OF
AZACITIDINE (AZA) VS CONVENTIONAL CARE REGIMENS (CCR) IN OLDER PATIENTS
WITH NEWLY DIAGNOSED ACUTE MYELOID LEUKEMIA (AML)
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Dombret, H.] Hop St Louis, Paris 10, France.
[Seymour, J. F.] Peter MacCallum Canc Ctr, East Melbourne, Australia.
[Butrym, A.] Wroclaw Med Univ, Wroclaw, Poland.
[Wierzbowska, A.] Med Univ Lodz, Lodz, Poland.
[Selleslag, D.] Algemeen Ziekenhuis St Jan, Brugge, Belgium.
[Jang, J. H.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Seoul, South Korea.
[Kumar, R.] Canc Care Manitoba, Winnipeg, MB, Canada.
[Cavenagh, J.] Barts Hlth NHS Trust, London, England.
[Schuh, A.; Minden, M. D.] Princess Margaret Canc Ctr, Toronto, ON, Canada.
[Candoni, A.] Azienda Osped Univ S Maria della Misericordia Udi, Udine, Italy.
[Recher, C.] Ctr Hosp Univ Toulouse, Toulouse 09, France.
[Sandhu, I.] Univ Alberta Hosp, Edmonton, AB T6G 2B7, Canada.
[Bernal, T.] Univ Oviedo, Hosp Cent Asturias, E-33080 Oviedo, Spain.
[Al-Ali, H. K.] Univ Klinikum Leipzig, Leipzig, Germany.
[Martinelli, G.] Azienda Osped Univ Bologna, Policlin S Orsola Malpighi, Bologna, Italy.
[Stone, R. M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[McIntyre, H.; Songer, S.; Lucy, L.; Beach, C.] Celgene Corp, Summit, NJ USA.
[Doehner, H.] Univ Ulm Klinikum, Ulm, Germany.
RI Wierzbowska, Agnieszka/S-9449-2016
NR 0
TC 4
Z9 4
U1 0
U2 1
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA LB2433
BP 788
EP 789
PG 2
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830904042
ER
PT J
AU Agresta, S
Stein, EM
Tallman, MS
Levine, RL
Yua, H
Yen, K
Fan, B
Flinn, IW
Fathi, AT
Stone, RM
DeAngelo, DJ
DeBotton, S
Pollyea, DA
AF Agresta, S.
Stein, E. M.
Tallman, M. S.
Levine, R. L.
Yua, H.
Yen, K.
Fan, B.
Flinn, I. W.
Fathi, A. T.
Stone, R. M.
DeAngelo, D. J.
DeBotton, S.
Pollyea, D. A.
TI A PHASE I STUDY OF AG-221, A FIRST IN CLASS, POTENT INHIBITOR OF THE
IDH2-MUTANT PROTEIN, IN PATIENTS WITH IDH2 MUTANT POSITIVE ADVANCED
HEMATOLOGIC MALIGNANCIES
SO HAEMATOLOGICA
LA English
DT Meeting Abstract
CT 19th Congress of the European-Hematology-Association
CY JUN 12-15, 2014
CL Milan, ITALY
SP European Hematol Assoc
C1 [Agresta, S.; Yua, H.; Yen, K.; Fan, B.] Agios, Clin Dev, Cambridge, MA USA.
[Stein, E. M.] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Tallman, M. S.; Levine, R. L.] Weill Cornell Med Coll, Mem Sloan Kettering Canc Ctr, Leukemia Serv, New York, NY USA.
[Flinn, I. W.] Sarah Cannon, Sarah Cannon Res Inst, Nashville, TN USA.
[Fathi, A. T.] Massachusetts Gen, Massachusetts Gen Hosp, Ctr Canc, Boston, MA USA.
[Stone, R. M.; DeAngelo, D. J.] Harvard, Sch Med, Harvard Univ, Boston, MA USA.
[DeBotton, S.] Inst Gustave Roussy, Villejuif, France.
[Pollyea, D. A.] Univ Colorado, Ctr Canc, Aurora, CO USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
SU 1
MA LB2434
BP 789
EP 789
PG 1
WC Hematology
SC Hematology
GA AQ5FD
UT WOS:000342830904043
ER
PT J
AU Basu, PP
Shah, NJ
Siriki, R
Rahaman, M
AF Basu, P. Patrick
Shah, Niraj J.
Siriki, Ravi
Rahaman, Md
TI Telaprevir with Adjusted Dose of Ribavirin in Naive CHC-G1: Efficacy and
Treatment in CHC in Hemodialysis Population. TARGET C Trial- A Placebo
Randomized Control Clinical Trial.
SO LIVER TRANSPLANTATION
LA English
DT Meeting Abstract
CT Joint International Congress of ILTS, ELITA and LICAGE
CY JUN 04-07, 2014
CL London, ENGLAND
SP ILTS, ELITA, LICAGE
C1 [Basu, P. Patrick] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA.
[Siriki, Ravi; Rahaman, Md] NSLIJHS Hofstra North Shore LIJ Sch Med, New York, NY USA.
[Shah, Niraj J.] Icahn Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY 10029 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUN
PY 2014
VL 20
SU 1
MA P-298
BP S244
EP S244
PG 1
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA AM6FU
UT WOS:000339959602150
ER
PT J
AU Basu, PP
Shah, NJ
Aloysius, M
AF Basu, P. Patrick
Shah, Niraj J.
Aloysius, Mark
TI Role of Intravenous N-Acetyl Cysteine (NAC) With Steroid in Acute
Alcoholic Hepatitis (AAH) With High Morbidity Score: A Randomized Open
Label Prospective Clinical Pilot Trial
SO LIVER TRANSPLANTATION
LA English
DT Meeting Abstract
CT Joint International Congress of ILTS, ELITA and LICAGE
CY JUN 04-07, 2014
CL London, ENGLAND
SP ILTS, ELITA, LICAGE
C1 [Basu, P. Patrick] Columbia Sch Phys & Surg, New York, NY USA.
[Basu, P. Patrick; Aloysius, Mark] Kings Cty Hosp Med Ctr, New York, NY USA.
[Shah, Niraj J.] Mt Sinai Sch Med, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUN
PY 2014
VL 20
SU 1
MA P-54
BP S168
EP S168
PG 1
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA AM6FU
UT WOS:000339959601203
ER
PT J
AU Basu, PP
Shah, NJ
Aloysius, M
AF Basu, P. Patrick
Shah, Niraj J.
Aloysius, Mark
TI Role of Mycophenolate Mofetil (MMF) in Steroid Non Responsive Severe
Acute Alcoholic Hepatitis: A Randomized Open Label Placebo Control
Prospective Clinical Pilot Trial
SO LIVER TRANSPLANTATION
LA English
DT Meeting Abstract
CT Joint International Congress of ILTS, ELITA and LICAGE
CY JUN 04-07, 2014
CL London, ENGLAND
SP ILTS, ELITA, LICAGE
C1 [Basu, P. Patrick] Columbia Sch Phys & Surg, New York, NY USA.
[Aloysius, Mark] Kings Cty Hosp, Med Ctr, New York, NY USA.
[Shah, Niraj J.] Mt Sinai Sch Med, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUN
PY 2014
VL 20
SU 1
MA O-122
BP S142
EP S142
PG 1
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA AM6FU
UT WOS:000339959601122
ER
PT J
AU Basu, PP
Shah, NJ
Aloysius, M
Siriki, R
Rahaman, M
AF Basu, P. Patrick
Shah, Niraj J.
Aloysius, Mark
Siriki, Ravi
Rahaman, Md
TI Romiplostim's Effect to Optimize SVR with Telaprevir, Ribavirin, And Peg
Interferon-alfa 2a in Thrombocytopenic Cirrhotics with Chronic Hepatitis
C. A Placebo Controlled Prospective Clinical Trial: RESTRAINT C Trial.
SO LIVER TRANSPLANTATION
LA English
DT Meeting Abstract
CT Joint International Congress of ILTS, ELITA and LICAGE
CY JUN 04-07, 2014
CL London, ENGLAND
SP ILTS, ELITA, LICAGE
C1 [Basu, P. Patrick] Columbia Univ Coll Phys & Surg, New York, NY USA.
[Basu, P. Patrick; Aloysius, Mark; Siriki, Ravi; Rahaman, Md] NSLIJHS, Hofstra North Shore LIJ Sch Med, New York, NY USA.
[Shah, Niraj J.] Mt Sinai Sch Med Mt Sinai, James J Peters VA Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUN
PY 2014
VL 20
SU 1
MA O-69
BP S124
EP S124
PG 1
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA AM6FU
UT WOS:000339959601069
ER
PT J
AU Curry, MP
Terrault, N
O'Leary, J
Forns, X
Brown, R
Chung, RT
Gane, E
Fenkel, JM
Gordon, F
Kuo, A
Schiano, T
Schiff, E
Befeler, A
McHutchison, JG
Symonds, WT
Denning, J
McNair, L
Arterburn, S
Moonka, D
Everson, G
Afdhal, N
AF Curry, Michael P.
Terrault, Norah
O'Leary, Jacqueline
Forns, Xavier
Brown, Robert, Jr.
Chung, Raymond T.
Gane, Edward
Fenkel, Jonathan M.
Gordon, Fredric
Kuo, Alexander
Schiano, Thomas
Schiff, Eugene
Befeler, Alex
McHutchison, John G.
Symonds, William T.
Denning, Jill
McNair, Lindsay
Arterburn, Sarah
Moonka, Dilip
Everson, Gregory
Afdhal, Nezam
TI Sofosbuvir Plus Ribavirin before Transplantation Prevented HCV Infection
Post-Transplant in Patients with HCV Cirrhosis and HCC: Results of an
Open-Label Trial
SO LIVER TRANSPLANTATION
LA English
DT Meeting Abstract
CT Joint International Congress of ILTS, ELITA and LICAGE
CY JUN 04-07, 2014
CL London, ENGLAND
SP ILTS, ELITA, LICAGE
C1 [Curry, Michael P.; Afdhal, Nezam] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Terrault, Norah] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[O'Leary, Jacqueline] Baylor Univ, Med Ctr, Dallas, TX USA.
[Forns, Xavier] Hosp Clin Barcelona, Liver Unit, IDIBAPS, CIBEREHD, Barcelona, Spain.
[Brown, Robert, Jr.] Columbia Univ, New York, NY 10027 USA.
[Chung, Raymond T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Gane, Edward] Auckland City Hosp, Auckland, New Zealand.
[Fenkel, Jonathan M.] Thomas Jefferson Univ Hosp, Philadelphia, PA 19107 USA.
[Gordon, Fredric] Lahey Clin Fdn, Burlington, MA USA.
[Kuo, Alexander] Univ Calif San Diego, San Diego, CA 92103 USA.
[Schiano, Thomas] Mt Sinai Sch Med, New York, NY USA.
[Schiff, Eugene] Univ Miami, Miami, FL USA.
[Befeler, Alex] St Louis Univ, St Louis, MO 63103 USA.
[McHutchison, John G.; Symonds, William T.; Denning, Jill; McNair, Lindsay; Arterburn, Sarah] Gilead Sci Inc, Foster City, CA 94404 USA.
[Moonka, Dilip] Henry Ford Hlth Syst, Detroit, MI USA.
[Everson, Gregory] Univ Colorado, Denver, CO 80202 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUN
PY 2014
VL 20
SU 1
MA O-137
BP S150
EP S150
PG 1
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA AM6FU
UT WOS:000339959601146
ER
PT J
AU Liu, QL
Rehman, H
Krishnasamy, Y
Schnellmann, R
Lemasters, J
Zhong, Z
AF Liu, Qinlong
Rehman, Hasibur
Krishnasamy, Yasodha
Schnellmann, Rick
Lemasters, John
Zhong, Zhi
TI AMP-Activated Protein Kinase (AMPK) Deficiency Increases Mitochondrial
Dysfunction after Liver Transplantation in Mice
SO LIVER TRANSPLANTATION
LA English
DT Meeting Abstract
CT Joint International Congress of ILTS, ELITA and LICAGE
CY JUN 04-07, 2014
CL London, ENGLAND
SP ILTS, ELITA, LICAGE
C1 [Liu, Qinlong; Rehman, Hasibur; Krishnasamy, Yasodha; Schnellmann, Rick; Lemasters, John; Zhong, Zhi] Med Univ S Carolina, Charleston, SC USA.
[Schnellmann, Rick] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUN
PY 2014
VL 20
SU 1
MA P-518
BP S312
EP S312
PG 1
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA AM6FU
UT WOS:000339959602387
ER
PT J
AU Op den Dries, S
Westerkamp, AC
Karimian, N
Gouw, ASH
Markmann, JF
Lisman, T
Yeh, H
Uygun, K
Martins, P
Porte, RJ
AF Op den Dries, Sanna
Westerkamp, Andrie C.
Karimian, Negin
Gouw, Annette S. H.
Markmann, James F.
Lisman, Ton
Yeh, Heidi
Uygun, Korkut
Martins, Paulo
Porte, Robert J.
TI Injury of Peribiliary Glands and Vascular Plexus before Liver
Transplantation Predicts Formation of Non-Anastomotic Biliary Strictures
SO LIVER TRANSPLANTATION
LA English
DT Meeting Abstract
CT Joint International Congress of ILTS, ELITA and LICAGE
CY JUN 04-07, 2014
CL London, ENGLAND
SP ILTS, ELITA, LICAGE
C1 [Op den Dries, Sanna; Westerkamp, Andrie C.; Karimian, Negin; Lisman, Ton; Porte, Robert J.] Univ Med Ctr Groningen UMCG, Dept Surg, Sect Hepatopancreatobiliary Surg & Liver Transpla, Groningen, Netherlands.
[Gouw, Annette S. H.] Univ Med Ctr Groningen UMCG, Dept Pathol, Groningen, Netherlands.
[Op den Dries, Sanna; Markmann, James F.; Yeh, Heidi; Uygun, Korkut; Martins, Paulo] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1527-6465
EI 1527-6473
J9 LIVER TRANSPLANT
JI Liver Transplant.
PD JUN
PY 2014
VL 20
SU 1
MA O-112
BP S138
EP S139
PG 2
WC Gastroenterology & Hepatology; Surgery; Transplantation
SC Gastroenterology & Hepatology; Surgery; Transplantation
GA AM6FU
UT WOS:000339959601112
ER
PT J
AU Mateos, MV
Bringhen, S
Richardson, PG
Lahuerta, JJ
Larocca, A
Oriol, A
Boccadoro, M
Garcia-Sanz, R
Di Raimondo, F
Esseltine, DL
van de Velde, H
Desai, A
Londhe, A
San Miguel, JF
Palumbo, A
AF Mateos, Maria-Victoria
Bringhen, Sara
Richardson, Paul G.
Jose Lahuerta, Juan
Larocca, Alessandra
Oriol, Albert
Boccadoro, Mario
Garcia-Sanz, Ramon
Di Raimondo, Francesco
Esseltine, Dixie-Lee
van de Velde, Helgi
Desai, Avinash
Londhe, Anil
San Miguel, Jesus F.
Palumbo, Antonio
TI Bortezomib cumulative dose, efficacy, and tolerability with three
different bortezomib-melphalan-prednisone regimens in previously
untreated myeloma patients ineligible for high-dose therapy
SO HAEMATOLOGICA
LA English
DT Article
ID DIAGNOSED MULTIPLE-MYELOMA; PERIPHERAL NEUROPATHY; INITIAL TREATMENT;
TRIAL; MAINTENANCE; INDUCTION; PHASE-3; REVERSIBILITY; THALIDOMIDE; RISK
AB Substantial efficacy has been demonstrated with bortezomib-melphalan-prednisone in phase III studies in transplant-ineligible myeloma patients using various twice-weekly and once-weekly bortezomib dosing schedules. In VISTA, the regimen comprised four 6-week twice-weekly cycles, plus five 6-week once-weekly cycles. In the GIMEMA MM-03-05 study, the bortezomib-melphalan-prednisone regimen was either per VISTA ('GIMEMA twice-weekly'), or comprised nine 5-week once-weekly cycles ('GIMEMA once-weekly'). In the GEM2005MAS65 study, the regimen comprised one 6-week twice-weekly cycle, plus five 5-week once-weekly cycles. We evaluated the cumulative bortezomib dose administered during bortezomib-melphalan-prednisone, as well as efficacy and tolerability, using patient-level study data. Over all bortezomib-melphalan-prednisone cycles (nine in VISTA/GIMEMA; six in GEM2005MAS65), the median cumulative bortezomib dose administered was 38.5, 42.1, 40.3, and 32.9 mg/m(2) in VISTA, GIMEMA twice-weekly, GIMEMA once-weekly, and GEM2005MAS65, respectively, and the respective proportions of planned bortezomib dose actually delivered were 57.0%, 62.3%, 86.1%, and 90.4%. Response rates following bortezomib-melphalan-prednisone were 74-87% and appeared generally similar between studies. Three-year survival rates were 67.9-75.7% across studies. Grade 3/4 peripheral neuropathy rates were 13% in VISTA and 14% in GIMEMA twice-weekly, but were lower at 2% in GIMEMA once-weekly and 7% in GEM2005MAS65. Discontinuations and bortezomib dose reductions due to peripheral neuropathy were reduced in GIMEMA once-weekly versus VISTA and GIMEMA twice-weekly. Exclusive or predominant use of once-weekly bortezomib dosing in GIMEMA once-weekly and GEM2005MAS65 resulted in high efficacy, comparable with that demonstrated in VISTA, and similar cumulative bortezomib dose with reduced toxicity. Trials are registered with ClinicalTrials.gov: VISTA (Identifier: 00111319), GIMEMA MM-03-05 (Identifier: 01063179), and GEM2005MAS65 (Identifier: 00443235).
C1 [Mateos, Maria-Victoria; Garcia-Sanz, Ramon] IBMCC USAL CSIC, CIC, Hosp Univ Salamanca, Serv Hematol, Salamanca, Spain.
[Bringhen, Sara; Larocca, Alessandra; Boccadoro, Mario; Palumbo, Antonio] Univ Turin, Myeloma Unit, Div Hematol, Azienda Osped Univ AOU S Giovanni Battista, Turin, Italy.
[Richardson, Paul G.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Jose Lahuerta, Juan] Hosp Univ 12 Octubre, Madrid, Spain.
[Oriol, Albert] Hosp Badalona Germans Trias & Pujol, Badalona, Spain.
[Di Raimondo, Francesco] Univ Catania, Osped Ferrarotto, Catania, Italy.
[Esseltine, Dixie-Lee] Takeda Pharmaceut Int Co, Cambridge, MA USA.
[van de Velde, Helgi] Janssen Res & Dev, Beerse, Belgium.
[Desai, Avinash] Janssen Global Serv, Raritan, NJ USA.
[Londhe, Anil] Janssen Res & Dev, Horsham, PA USA.
[San Miguel, Jesus F.] Univ Navarra Clin, Ctr Invest Med Aplicada, Pamplona, Spain.
RP Mateos, MV (reprint author), IBMCC USAL CSIC, CIC, Hosp Univ Salamanca, Serv Hematol, Salamanca, Spain.
EM mvmateos@usal.es
RI Garcia-Sanz, Ramon/B-7986-2017;
OI Garcia-Sanz, Ramon/0000-0003-4120-2787; SAN MIGUEL,
JESUS/0000-0002-9183-4857
FU Millennium: The Takeda Oncology Company; Janssen Global Services
FX The authors would like to acknowledge the writing assistance of Steve
Hill of FireKite during the development of this publication, which was
funded by Millennium: The Takeda Oncology Company, and Janssen Global
Services.
NR 23
TC 9
Z9 9
U1 0
U2 0
PU FERRATA STORTI FOUNDATION
PI PAVIA
PA VIA GIUSEPPE BELLI 4, 27100 PAVIA, ITALY
SN 0390-6078
J9 HAEMATOLOGICA
JI Haematologica
PD JUN 1
PY 2014
VL 99
IS 6
BP 1114
EP 1122
DI 10.3324/haematol.2013.099341
PG 9
WC Hematology
SC Hematology
GA AQ5FN
UT WOS:000342832100029
PM 24763402
ER
PT J
AU Halban, PA
Polonsky, KS
Bowden, DW
Hawkins, MA
Ling, C
Mather, KJ
Powers, AC
Rhodes, CJ
Sussel, L
Weir, GC
AF Halban, Philippe A.
Polonsky, Kenneth S.
Bowden, Donald W.
Hawkins, Meredith A.
Ling, Charlotte
Mather, Kieren J.
Powers, Alvin C.
Rhodes, Christopher J.
Sussel, Lori
Weir, Gordon C.
TI beta-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and
Prospects for Prevention and Treatment
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID STIMULATED INSULIN-SECRETION; HUMAN PANCREATIC-ISLETS;
GASTRIC-BYPASS-SURGERY; DNA METHYLATION; EPIGENETIC REGULATION; HISTONE
MODIFICATIONS; ACTIVATING MUTATIONS; SUSCEPTIBILITY LOCI; GLYCEMIC
CONTROL; CONTROLLED-TRIAL
AB OBJECTIVE: This article examines the foundation of beta-cell failure in type 2 diabetes (T2D) and suggests areas for future research on the underlying mechanisms that may lead to improved prevention and treatment.
RESEARCH DESIGN AND METHODS: A group of experts participated in a conference on 14-16 October 2013 cosponsored by the Endocrine Society and the American Diabetes Association. A writing group prepared this summary and recommendations.
RESULTS: The writing group based this article on conference presentations, discussion, and debate. Topics covered include genetic predisposition, foundations of beta-cell failure, natural history of beta-cell failure, and impact of therapeutic interventions.
CONCLUSIONS: beta-Cell failure is central to the development and progression of T2D. It antedates and predicts diabetes onset and progression, is in part genetically determined, and often can be identified with accuracy even though current tests are cumbersome and not well standardized. Multiple pathways underlie decreased beta-cell function and mass, some of which may be shared and may also be a consequence of processes that initially caused dysfunction. Goals for future research include to 1) impact the natural history of beta-cell failure; 2) identify and characterize genetic loci for T2D; 3) target beta-cell signaling, metabolic, and genetic pathways to improve function/mass; 4) develop alternative sources of beta-cells for cell-based therapy; 5) focus on metabolic environment to provide indirect benefit to beta-cells; 6) improve understanding of the physiology of responses to bypass surgery; and 7) identify circulating factors and neuronal circuits underlying the axis of communication between the brain and beta-cells.
C1 [Halban, Philippe A.] Univ Geneva, Dept Genet Med & Dev, Geneva, Switzerland.
[Polonsky, Kenneth S.] Univ Chicago, Endocrinol Sect, Dept Med, Chicago, IL 60637 USA.
[Bowden, Donald W.] Wake Forest Univ, Ctr Genom & Personalized Med Res, Winston Salem, NC 27106 USA.
[Bowden, Donald W.] Wake Forest Univ, Ctr Diabet Res, Winston Salem, NC 27106 USA.
[Hawkins, Meredith A.] Albert Einstein Coll Med, Dept Med Endocrinol, Bronx, NY 10461 USA.
[Hawkins, Meredith A.] Albert Einstein Coll Med, Global Diabet Inst, Bronx, NY 10461 USA.
[Ling, Charlotte] Lund Univ, Dept Clin Sci, Lund, Sweden.
[Mather, Kieren J.] Indiana Univ, Dept Endocrinol, Indianapolis, IN 46202 USA.
[Powers, Alvin C.] Vanderbilt Univ, Sch Med, Div Diabet, Nashville, TN 37232 USA.
Vanderbilt Univ, Sch Med, Div Diabet Endocrinol & Metab, Nashville, TN 37232 USA.
[Rhodes, Christopher J.] Univ Chicago, Dept Med, Kovler Diabet Ctr, Chicago, IL 60637 USA.
[Sussel, Lori] Columbia Univ, Naomi Berrie Diabet Ctr, New York, NY 10027 USA.
[Weir, Gordon C.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02215 USA.
RP Halban, PA (reprint author), Univ Geneva, Dept Genet Med & Dev, Geneva, Switzerland.
EM philippe.halban@unige.ch
FU Novo Nordisk; Sanofi; Merck Co.; Eli Lilly Co.
FX Duality of Interest. K.J.M. received study support from Novo Nordisk,
Sanofi, and Merck & Co. C.J.R. received compensation for consulting work
at Sanofi, Merck & Co., and enGene and also received compensation from
Merck & Co. for a speaker role. G.C.W. received a consulting fee from
Merck & Co., Novo Nordisk, and Eli Lilly & Co. No other potential
conflicts of interest relevant to this article were reported.; This
article is based on a conference jointly sponsored by the Endocrine
Society and the American Diabetes Association and supported by an
educational grant from Novo Nordisk, Sanofi, and Lilly USA.
NR 86
TC 19
Z9 19
U1 2
U2 11
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JUN
PY 2014
VL 99
IS 6
BP 1983
EP 1992
DI 10.1210/jc.2014-1425
PG 10
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AP8PI
UT WOS:000342340500037
PM 24712577
ER
PT J
AU Tritos, NA
Johannsson, G
Korbonits, M
Miller, KK
Feldt-Rasmussen, U
Yuen, KCJ
King, D
Mattsson, AF
Jonsson, PJ
Koltowska-Haggstrom, M
Klibanski, A
Biller, BMK
AF Tritos, Nicholas A.
Johannsson, Gudmundur
Korbonits, Marta
Miller, Karen K.
Feldt-Rasmussen, Ulla
Yuen, Kevin C. J.
King, Donna
Mattsson, Anders F.
Jonsson, Peter J.
Koltowska-Haggstrom, Maria
Klibanski, Anne
Biller, Beverly M. K.
TI Effects of Long-term Growth Hormone Replacement in Adults With Growth
Hormone Deficiency Following Cure of Acromegaly: A KIMS Analysis
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID QUALITY-OF-LIFE; CARDIOVASCULAR RISK-FACTORS; ONSET GH DEFICIENCY;
HYPOPITUITARY PATIENTS; DIABETES-MELLITUS; ENDOCRINE-SOCIETY; PITUITARY
DISEASE; TREATED PATIENTS; QOL-AGHDA; THERAPY
AB Context: GH deficiency (GHD) may occur in adults with cured acromegaly (acroGHD).
Objective: Our objective was to examine the effectiveness and safety of GH replacement in acroGHD.
Design: This study was a retrospective analysis of data from KIMS (Pfizer International Metabolic Database).
Setting: Data were extracted from a pharmaco-epidemiological survey of >16 000 GHD adults from 31 countries.
Patients: The effectiveness population included 115 adults with acroGHD and 142 age-, gender-, and body mass index-matched GHD adults with nonfunctioning pituitary adenoma (NFPA) followed up to 5 years on GH. The safety population included 164 adults with acroGHD and 2469 with NFPA, all GH-replaced. Both acroGHD and NFPA were compared with several cohorts from the general population (including the World Health Organization Global Burden of Disease).
Outcome Measures: Outcome measures included quality of life (QoL-AGHDA), lipids, serious adverse events, and additional safety endpoints.
Results: Median GH dose was 0.3 mg/d in acroGHD and NFPA at 5 years. There were comparable improvements in QoL-AGHDA and total and low-density lipoprotein cholesterol in acroGHD and NFPA. High-density lipoprotein cholesterol increased only in acroGHD. Cardiovascular mortality was increased in acroGHD vs NFPA(standardized mortality ratio = 3.03, P = .02). All-cause mortality was similar in acroGHD (ratio between observed/expected cases [95% confidence interval] = 1.32 [0.70-2.25]) and lower in NFPA [observed/expected = 0.58 [0.48-0.70]) in comparison with the general population. There was no difference in incidence of all cancers, benign or malignant brain tumors, or diabetes mellitus between acroGHD and NFPA.
Conclusions: GH replacement has comparable effects on quality of life and lipids in acroGHD and NFPA. Further investigation is needed to examine whether the increased cardiovascular mortality may be attributed to the history of previous GH excess in acroGHD.
C1 [Tritos, Nicholas A.; Miller, Karen K.; Klibanski, Anne; Biller, Beverly M. K.] Massachusetts Gen Hosp, Neuroendocrine Unit, Boston, MA 02114 USA.
[Tritos, Nicholas A.; Miller, Karen K.; Klibanski, Anne; Biller, Beverly M. K.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
[Johannsson, Gudmundur] Sahlgrens Univ Hosp, Dept Endocrinol, SE-41345 Gothenburg, Sweden.
[Korbonits, Marta] Queen Mary Univ London, Dept Endocrinol Barts, London EC1M 6BQ, England.
[Korbonits, Marta] Queen Mary Univ London, London Sch Med, London EC1M 6BQ, England.
[Feldt-Rasmussen, Ulla] Univ Copenhagen, Natl Univ Hosp, Rigshosp, Dept Med Endocrinol, DK-2100 Copenhagen, Denmark.
[Yuen, Kevin C. J.] Oregon Hlth & Sci Univ, Div Endocrinol Diabet & Clin Nutr, Portland, OR 97239 USA.
[King, Donna] Pfizer Inc, New York, NY 10017 USA.
[Jonsson, Peter J.; Koltowska-Haggstrom, Maria] Pfizer Endocrine Care, SE-19091 Soilentuna, Sweden.
RP Tritos, NA (reprint author), Massachusetts Gen Hosp, Neuroendocrine Unit, Zero Emerson Pl,Suite 112, Boston, MA 02114 USA.
EM ntritos@partners.org
OI Johannsson, Gudmundur/0000-0003-3484-8440; Korbonits,
Marta/0000-0002-4101-9432
FU Pfizer; Ipsen; Novo-Nordisk; Novartis; Syntaxin; Eli Lilly; Versartis;
Rhythm Pharmaceuticals
FX N.A.T. has received research support from Pfizer and Ipsen and
consulting honoraria from Pfizer and Corcept; G.J. has received research
grants from Novo-Nordisk and Pfizer, occasional speaker honoraria from
Pfizer, Novo-Nordisk, Merck Serono, and Otsuka and has served on the
advisory board for Pfizer and acted as consultant for Viropharma and
Astra Zeneca; M.K. has received research support from Pfizer, Novartis,
and Syntaxin and occasional consulting and speaker honoraria from
Pfizer, Chiasma, Sanofi, and Syntaxin; U.F.-R. has received research
grants from Novo-Nordisk and Novartis, occasional consulting and speaker
honoraria from Pfizer, Novo-Nordisk, IPSEN, and Novartis and serves on
the advisory board for Pfizer; K.C.J.Y. has received research grants
from Pfizer, Novo Nordisk, Eli Lilly, and Versartis and served on the
advisory boards for Pfizer, Novo Nordisk, and Corcept Therapeutics;
D.K., A.F.M., and P.J.J. are full-time employees of Pfizer; M.K.-H. was
employed by Pfizer Health AB during the study; K.K.M. has received
research grants for investigator-initiated studies from Pfizer and
Ipsen; A.K. has received research grant support from Ipsen, Novartis,
and Rhythm Pharmaceuticals; and B.M.K.B. has served as a consultant to
Pfizer, Novartis, and Novo Nordisk and as the principal investigator of
research grants from Novo Nordisk and Novartis to Massachusetts General
Hospital.
NR 54
TC 9
Z9 9
U1 0
U2 2
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JUN
PY 2014
VL 99
IS 6
BP 2018
EP 2029
DI 10.1210/jc.2014-1013
PG 12
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AP8PI
UT WOS:000342340500042
PM 24694339
ER
PT J
AU Shores, MM
Biggs, ML
Arnold, AM
Smith, NL
Longstreth, WT
Kizer, JR
Hirsch, CH
Cappola, AR
Matsumoto, AM
AF Shores, Molly M.
Biggs, Mary L.
Arnold, Alice M.
Smith, Nicholas L.
Longstreth, W. T., Jr.
Kizer, Jorge R.
Hirsch, Calvin H.
Cappola, Anne R.
Matsumoto, Alvin M.
TI Testosterone, Dihydrotestosterone, and Incident Cardiovascular Disease
and Mortality in the Cardiovascular Health Study
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID LOW SERUM TESTOSTERONE; CORONARY-ARTERY DISEASE; ENDOGENOUS
SEX-HORMONES; POPULATION-BASED COHORT; OLDER MEN; PLASMA TESTOSTERONE;
ELDERLY-MEN; ANDROGEN DEFICIENCY; PREDICT MORTALITY; MASS-SPECTROMETRY
AB Context: Low testosterone (T) is associated with prevalent cardiovascular disease (CVD) and mortality. DHT, a more potent androgen, may also be associated with CVD and mortality, but few studies have examined this.
Objective: The study objective was to examine whether T and DHT are risk factors for incident CVD and mortality.
Design: In a longitudinal cohort study, we evaluated whether total T, calculated free T (cFT), DHT, and calculated free DHT were associated with incident CVD and mortality in men in the Cardiovascular Health Study (mean age 76, range 66-97 years) who were free of CVD at the time of blood collection.
Main Outcome: The main outcomes were incident CVD and all-cause mortality.
Results: Among 1032 men followed for a median of 9 years, 436 incident CVD events and 777 deaths occurred. In models adjusted for cardiovascular risk factors, total T and cFT were not associated with incident CVD or all-cause mortality, whereas DHT and calculated free DHT had curvilinear associations with incident CVD (P < .002 and P = .04, respectively) and all-cause mortality (P < .001 for both).
Conclusions: In a cohort of elderly men, DHT and calculated free DHT were associated with incident CVD and all-cause mortality. Further studies are needed to confirm these results and to clarify the underlying physiologic mechanisms.
C1 [Shores, Molly M.; Smith, Nicholas L.; Matsumoto, Alvin M.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Smith, Nicholas L.] VA Epidemiol Res & Informat Ctr, Seattle, WA 98108 USA.
[Shores, Molly M.] Univ Washington, Dept Psychiat & Behav Sci, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.
[Biggs, Mary L.; Arnold, Alice M.] Univ Washington, Dept Biostat, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.
[Smith, Nicholas L.; Longstreth, W. T., Jr.] Univ Washington, Dept Epidemiol, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.
[Longstreth, W. T., Jr.] Univ Washington, Dept Neurol, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.
[Matsumoto, Alvin M.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98195 USA.
[Kizer, Jorge R.] Albert Einstein Coll Med, Dept Med, Bronx, NY 10461 USA.
[Kizer, Jorge R.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10461 USA.
[Hirsch, Calvin H.] Univ Calif Davis, Dept Internal Med, Davis, CA 95616 USA.
[Cappola, Anne R.] Univ Penn, Dept Internal Med, Div Endocrinol, Philadelphia, PA 19104 USA.
RP Shores, MM (reprint author), VA Puget Sound Hlth Care Syst, 1660 South Columbian Way,S-116A, Seattle, WA 98108 USA.
EM molly.shores@va.gov
FU VA Research Service; VA Epidemiology Research and Information Center; VA
Geriatric Research, Education and Clinical Center; NIH [1R01HL091952];
National Heart, Lung, and Blood Institute [HHSN268201200036C,
N01-HC-85239, N01 HC-55222, N01-HC-85079, N01-HC-85080, N01-HC-85081,
N01-HC-85082, N01-HC-85083, N01-HC85086, HL080295]; National Institute
on Aging [AG-023629]
FX This work was supported by the VA Research Service, the VA Epidemiology
Research and Information Center, and the VA Geriatric Research,
Education and Clinical Center; by NIH 1R01HL091952 and contracts
HHSN268201200036C, N01-HC-85239, N01 HC-55222, N01-HC-85079,
N01-HC-85080, N01-HC-85081, N01-HC-85082, N01-HC-85083, N01-HC85086, and
Grant HL080295 from the National Heart, Lung, and Blood Institute, with
additional contribution from the National Institute of Neurological
Disorders and Stroke. Additional support was provided by AG-023629 from
the National Institute on Aging. A full list of principal CHS
investigators and institutions can be found at http://www.chs-nhlbi.org.
NR 43
TC 22
Z9 22
U1 0
U2 4
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JUN
PY 2014
VL 99
IS 6
BP 2061
EP 2068
DI 10.1210/jc.2013-3576
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AP8PI
UT WOS:000342340500047
PM 24628549
ER
PT J
AU Ghosh, P
Vaidya, A
Sahoo, R
Goldfine, A
Herring, N
Bry, L
Chorev, M
Halperin, JA
AF Ghosh, Pamela
Vaidya, Anand
Sahoo, Rupam
Goldfine, Allison
Herring, Neil
Bry, Lynn
Chorev, Michael
Halperin, Jose A.
TI Glycation of the Complement Regulatory Protein CD59 Is a Novel Biomarker
for Glucose Handling in Humans
SO JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
LA English
DT Article
ID MANNOSE-BINDING LECTIN; VASCULAR COMPLICATIONS; CARDIOVASCULAR-DISEASE;
DIABETIC-NEPHROPATHY; ENDOTHELIAL-CELLS; TOLERANCE; ACTIVATION;
NEUROPATHY; ASSOCIATION; PREVALENCE
AB Context: Human CD59, an inhibitor of the membrane attack complex of complement, is inactivated by glycation. Glycation inactivation of CD59 enhances complement-mediated injury in target organs of diabetes complications.
Objective: We hypothesized that circulating soluble glycated CD59 (GCD59) represents a novel biomarker of blood glucose handling and aimed to conduct human study protocols to test this hypothesis.
Design, Setting, Participants, and Outcome Measures: Using a newly developed ELISA, we measured circulating soluble GCD59 in samples from 3 separate human studies evaluating acute and chronic glucose handling and glucose responses to insulin therapy. Study 1 (normal vs diabetic subjects) evaluated the cross-sectional association between GCD59 and glycated hemoglobin (HbA1c) in 400 subjects with and without type 2 diabetes. Study 2 (oral glucose tolerance test [OGTT] in nondiabetics) evaluated whether fasting GCD59 independently predicted the 2-hour glucose response to an OGTT in 109 subjects without a diagnosis of diabetes. Study 3 (intensified insulin treatment) evaluated the effect of intensification of glycemic control with insulin on GCD59 in 21 poorly controlled individuals with diabetes.
Results: In study 1 (normal vs diabetic subjects), GCD59 was independently and positively associated with HbA1c in individuals with and without diabetes (beta = 1.1, P < .0001 and beta = 1.1, P < .001, respectively). In study 2 (OGTT in nondiabetics), a single GCD59 measurement independently predicted the results of the 2-hour OGTT (beta = 19.8, P < .05) after multivariate modeling. In study 3 (intensified insulin treatment), intensification of glucose control with insulin resulted in a concomitant and parallel reduction of average weekly glucose and GCD59 within 2 weeks.
Conclusions: We observed robust relationships between a single measurement of blood levels of GCD59 and both acute (2-hour OGTT) and chronic (HbA1c) measures of glucose handling. Lowering of GCD59 levels closely reflected lowering of average weekly glucose within 2 weeks. The role of GCD59 in the diagnosis, management, and vascular risk stratification in diabetes warrants further investigation.
C1 [Ghosh, Pamela; Sahoo, Rupam; Chorev, Michael; Halperin, Jose A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Hematol, Boston, MA 02115 USA.
[Vaidya, Anand] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
[Vaidya, Anand] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Endocrinol Diabet & Hypertens, Boston, MA 02115 USA.
[Herring, Neil; Bry, Lynn] Partners Hlthcare Syst, Crimson Biospecimen Core, Boston, MA 02115 USA.
[Goldfine, Allison] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.
RP Halperin, JA (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
EM jose_halperin@hms.harvard.edu
RI SAHOO, RUPAM/B-3935-2016
FU National Institutes of Health [DK62294, DK089206]; National Heart, Lung,
and Blood Institute of the National Institutes of Health [K23HL111771]
FX This work was supported by National Institutes of Health Grants DK62294
(to J.A.H.), DK089206 (to J.A.H.), and by the National Heart, Lung, and
Blood Institute of the National Institutes of Health under Award Number
K23HL111771 (to A.V.). The content is solely the responsibility of the
authors and does not necessarily represent the official views of the
National Institutes of Health.
NR 37
TC 3
Z9 3
U1 1
U2 3
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0021-972X
EI 1945-7197
J9 J CLIN ENDOCR METAB
JI J. Clin. Endocrinol. Metab.
PD JUN
PY 2014
VL 99
IS 6
BP E999
EP E1006
DI 10.1210/jc.2013-4232
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AP8PI
UT WOS:000342340500008
PM 24628556
ER
PT J
AU Boyer, N
Gupta, R
Schevchuck, A
Hindnavis, V
Maliske, S
Sheldon, M
Drachman, D
Yeghiazarians, Y
AF Boyer, Nathan
Gupta, Rajesh
Schevchuck, Alex
Hindnavis, Vindhya
Maliske, Seth
Sheldon, Mark
Drachman, Douglas
Yeghiazarians, Yerem
TI Coronary Artery Aneurysms in Acute Coronary Syndrome: Case Series,
Review, and Proposed Management Strategy
SO JOURNAL OF INVASIVE CARDIOLOGY
LA English
DT Review
DE aneurysm; coronary disease; catheterization; revascularization;
infarction
ID POLYTETRAFLUOROETHYLENE-COVERED STENT; ACUTE MYOCARDIAL-INFARCTION;
PACLITAXEL-ELUTING STENT; ST-SEGMENT ELEVATION; HEART-ASSOCIATION;
KAWASAKI-DISEASE; IMPLANTATION; ECTASIA; COMMITTEE; GRAFT
AB Coronary artery aneurysm (CAA) is an uncommon clinical finding, with an incidence varying from 1.5%-4.9% in adults, and is usually considered a variant of coronary artery disease (CAD). CAA identified in the context of acute coronary syndrome (ACS) represents a unique management challenge, particularly if the morphology of the CAA is suspected to have provoked the acute clinical syndrome. CAA is associated with thrombus formation due to abnormal laminar flow, as well as abnormal platelet and endothelial-derived pathophysiologic factors within the CAA. Once formed, mural thrombus may potentiate the deposition of additional thrombus within aneurysmal segments. Percutaneous revascularization of CAA has been associated with complications including distal embolization of thrombus, no-reflow phenomenon, stent malapposition, dissection, and rupture. Presently, there are no formal guidelines to direct the management of CAA in patients presenting with ACS; controversies exist whether conservative, surgical, or catheter-based management should be pursued. In this manuscript, we present an extensive review of the existing literature and associated clinical guidelines, and propose a management algorithm for patients with this complex clinical scenario. Armed with this perspective, therapeutic decisions may be tailored to synthesize patient factors and preferences, individualized clinical assessment, and existing American Heart Association/American College of Cardiology guidelines for management of ACS.
C1 [Boyer, Nathan; Hindnavis, Vindhya; Yeghiazarians, Yerem] Univ Calif San Francisco, Div Cardiol, San Francisco, CA USA.
[Gupta, Rajesh; Drachman, Douglas] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiovasc, Boston, MA USA.
[Maliske, Seth] Univ Iowa, Sch Med, Hosp & Clin, Iowa City, IA 52242 USA.
Univ New Mexico, Dept Internal Med, Div Cardiol, Albuquerque, NM 87131 USA.
RP Boyer, N (reprint author), 505 Parnassus Ave,Box 0103, San Francisco, CA 94143 USA.
EM nathan.boyer@ucsf.edu
NR 41
TC 6
Z9 7
U1 1
U2 8
PU H M P COMMUNICATIONS
PI MALVERN
PA 83 GENERAL WARREN BLVD, STE 100, MALVERN, PA 19355 USA
SN 1042-3931
EI 1557-2501
J9 J INVASIVE CARDIOL
JI J. Invasive Cardiol.
PD JUN
PY 2014
VL 26
IS 6
BP 283
EP 290
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AP8VP
UT WOS:000342357700019
PM 24907086
ER
PT J
AU Hawryluk, EB
Tsao, H
AF Hawryluk, Elena B.
Tsao, Hensin
TI Melanoma: Clinical Features and Genomic Insights
SO COLD SPRING HARBOR PERSPECTIVES IN BIOLOGY
LA English
DT Article
ID PRIMARY CUTANEOUS MELANOMA; BRAF INHIBITOR RESISTANCE; V600E MUTANT
MELANOMA; UVEAL MELANOMA; MALIGNANT-MELANOMA; METASTATIC MELANOMA;
MELANOCYTIC NEVI; MEK INHIBITION; MC1R VARIANTS; ULTRAVIOLET-RADIATION
AB Recent efforts in genomic research have enabled the characterization of molecular mechanisms underlying many types of cancers, ushering novel approaches for diagnosis and therapeutics. Melanoma is a molecularly heterogeneous disease, as many genetic alterations have been identified and the clinical features can vary. Although discoveries of frequent mutations including BRAF have already made clinically significant impact on patient care, there is a growing body of literature suggesting a role for additional mutations, driver and passenger types, in disease pathophysiology. Although some mutations have been strongly associated with clinical phenotypes of melanomas (such as physical distribution or morphologic subtype), the function or implications of many of the recently identified mutations remains less clear. The phenotypic and clinical impact of genomic mutations in melanoma remains a promising opportunity for progress in the care of melanoma patients.
C1 [Hawryluk, Elena B.] Harvard Univ, Boston Childrens Hosp, Sch Med, Dermatol Program, Boston, MA 02115 USA.
[Hawryluk, Elena B.; Tsao, Hensin] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol, Boston, MA 02114 USA.
RP Tsao, H (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Dermatol, Boston, MA 02114 USA.
EM htsao@partners.org
FU Dermatology Foundation; [K24 CA149202]
FX The authors gratefully acknowledge Dr. Matthew Hawryluk for his critical
review and comments on this work. Funding for this effort is supported
in part by K24 CA149202, the generous donors to the Massachusetts
General Hospital Millennium Melanoma fund (both to H.T.), and the
Dermatology Foundation Fellowship in Pediatric Dermatology (E.B.H.).
NR 113
TC 0
Z9 0
U1 0
U2 2
PU COLD SPRING HARBOR LAB PRESS, PUBLICATIONS DEPT
PI COLD SPRING HARBOR
PA 1 BUNGTOWN RD, COLD SPRING HARBOR, NY 11724 USA
SN 1943-0264
J9 CSH PERSPECT BIOL
JI Cold Spring Harbor Perspect. Biol.
PD JUN
PY 2014
VL 6
IS 6
AR a015388
DI 10.1101/cshperspect.a015388
PG 17
WC Cell Biology
SC Cell Biology
GA AO8AY
UT WOS:000341575800009
ER
PT J
AU Duebgen, M
Martinez-Quintanilla, J
Tamura, K
Hingtgen, S
Redjal, N
Wakimoto, H
Shah, K
AF Duebgen, Matthias
Martinez-Quintanilla, Jordi
Tamura, Kaoru
Hingtgen, Shawn
Redjal, Navid
Wakimoto, Hiroaki
Shah, Khalid
TI Stem Cells Loaded With Multimechanistic Oncolytic Herpes Simplex Virus
Variants for Brain Tumor Therapy
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID MESENCHYMAL PROGENITOR CELLS; HIGH-GRADE GLIOMA; MALIGNANT GLIOMA;
CLINICAL-EXPERIENCE; CELLULAR VEHICLES; CANCER-THERAPY; GLIOBLASTOMA;
VECTORS; VIROTHERAPY; EFFICACY
AB Background The current treatment regimen for malignant glioblastoma multiforme (GBM) is tumor resection followed by chemotherapy and radiation therapy. Despite the proven safety of oncolytic herpes simplex virus (oHSV) in clinical trials for GBMs, its efficacy is suboptimal mainly because of insufficient viral spread after tumor resection.
Methods Human mesenchymal stem cells (MSC) were loaded with oHSV (MSC-oHSV), and their fate was explored by real-time imaging in vitro and in vivo. Using novel diagnostic and armed oHSV mutants and real-time multimodality imaging, the efficacy of MSC-oHSV and its proapoptotic variant, oHSV-TRAIL encapsulated in biocompatible synthetic extracellular matrix (sECM), was tested in different mouse GBM models, which more accurately reflect the current clinical settings of malignant, resistant, and resected tumors. All statistical tests were two-sided.
Results MSC-oHSVs effectively produce oHSV progeny, which results in killing of GBMs in vitro and in vivo mediated by a dynamic process of oHSV infection and tumor destruction. sECM-encapsulated MSC-oHSVs result in statistically significant increased anti-GBM efficacy compared with direct injection of purified oHSV in a preclinical model of GBM resection, resulting in prolonged median survival in mice (P < .001 with Gehan-Breslow-Wilcoxin test). To supersede resistant tumors, MSC loaded with oHSV-TRAIL effectively induce apoptosis-mediated killing and prolonged median survival in mice bearing oHSV- and TRAIL-resistant GBM in vitro (P < .001 with chi(2) contingency test).
Conclusions Human MSC loaded with different oHSV variants provide a platform to translate oncolytic virus therapies to clinics in a broad spectrum of GBMs after resection and could also have direct implications in different cancer types.
C1 [Duebgen, Matthias; Martinez-Quintanilla, Jordi; Hingtgen, Shawn; Redjal, Navid; Wakimoto, Hiroaki; Shah, Khalid] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mol Neurotherapy & Imaging Lab, Boston, MA USA.
[Duebgen, Matthias; Martinez-Quintanilla, Jordi; Tamura, Kaoru; Hingtgen, Shawn; Redjal, Navid; Wakimoto, Hiroaki; Shah, Khalid] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA.
[Redjal, Navid; Wakimoto, Hiroaki] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA USA.
[Shah, Khalid] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurol, Boston, MA USA.
[Shah, Khalid] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
RP Shah, K (reprint author), Massachusetts Gen Hosp, Mol Neurotherapy & Imaging Lab, MGH East 149,13th St, Charlestown, MA 02129 USA.
EM kshah@mgh.harvard.edu
FU American Cancer Society; James McDonald Foundation
FX This work was supported by American Cancer Society (to KS) and James
McDonald Foundation (to KS).
NR 39
TC 11
Z9 11
U1 2
U2 13
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
EI 1460-2105
J9 JNCI-J NATL CANCER I
JI JNCI-J. Natl. Cancer Inst.
PD JUN
PY 2014
VL 106
IS 6
AR dju090
DI 10.1093/jnci/dju090
PG 9
WC Oncology
SC Oncology
GA AO8WT
UT WOS:000341636800005
PM 24838834
ER
PT J
AU Pilarski, R
Burt, R
Kohlman, W
Pho, L
Shannon, KM
Swisher, E
AF Pilarski, Robert
Burt, Randall
Kohlman, Wendy
Pho, Lana
Shannon, Kristen M.
Swisher, Elizabeth
TI RE: Cowden Syndrome and PTEN Hamartoma Tumor Syndrome: Systematic Review
and Revised Diagnostic Criteria Response
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Letter
C1 [Pilarski, Robert] Ohio State Univ, Div Human Genet, Dept Internal Med, Columbus, OH 43240 USA.
[Pilarski, Robert] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43240 USA.
[Burt, Randall; Kohlman, Wendy; Pho, Lana] Huntsman Canc Inst, Salt Lake City, UT USA.
[Burt, Randall; Kohlman, Wendy] Univ Utah, Sch Med, Salt Lake City, UT USA.
[Pho, Lana] Univ Utah, Dept Dermatol, Salt Lake City, UT USA.
[Shannon, Kristen M.] Massachusetts Gen Hosp, Ctr Canc, Ctr Canc Risk Assessment, Boston, MA USA.
[Swisher, Elizabeth] Univ Washington, Med Ctr, Seattle Canc Care Alliance, Seattle, WA 98195 USA.
RP Pilarski, R (reprint author), Ohio State Univ, James Comprehens Canc Ctr, 2001 Polaris Pkwy, Columbus, OH 43240 USA.
EM robert.pilarski@osumc.edu
RI Pilarski, Robert/E-3871-2011
NR 2
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
EI 1460-2105
J9 JNCI-J NATL CANCER I
JI JNCI-J. Natl. Cancer Inst.
PD JUN
PY 2014
VL 106
IS 6
AR dju131
DI 10.1093/jnci/dju131
PG 1
WC Oncology
SC Oncology
GA AO8WT
UT WOS:000341636800020
PM 24899680
ER
PT J
AU Stout, NK
Lee, SJ
Schechter, CB
Kerlikowske, K
Alagoz, O
Berry, D
Buist, DSM
Cevik, M
Chisholm, G
de Koning, HJ
Huang, H
Hubbard, RA
Miglioretti, DL
Munsell, MF
Trentham-Dietz, A
van Ravesteyn, NT
Tosteson, ANA
Mandelblatt, JS
AF Stout, Natasha K.
Lee, Sandra J.
Schechter, Clyde B.
Kerlikowske, Karla
Alagoz, Oguzhan
Berry, Donald
Buist, Diana S. M.
Cevik, Mucahit
Chisholm, Gary
de Koning, Harry J.
Huang, Hui
Hubbard, Rebecca A.
Miglioretti, Diana L.
Munsell, Mark F.
Trentham-Dietz, Amy
van Ravesteyn, Nicolien T.
Tosteson, Anna N. A.
Mandelblatt, Jeanne S.
TI Benefits, Harms, and Costs for Breast Cancer Screening After US
Implementation of Digital Mammography
SO JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE
LA English
DT Article
ID SERVICES TASK-FORCE; FILM MAMMOGRAPHY; UNITED-STATES; RISK-FACTORS;
DENSITY; WOMEN; AGE; CARE; RECOMMENDATION; POPULATION
AB Background Compared with film, digital mammography has superior sensitivity but lower specificity for women aged 40 to 49 years and women with dense breasts. Digital has replaced film in virtually all US facilities, but overall population health and cost from use of this technology are unclear.
Methods Using five independent models, we compared digital screening strategies starting at age 40 or 50 years applied annually, biennially, or based on density with biennial film screening from ages 50 to 74 years and with no screening. Common data elements included cancer incidence and test performance, both modified by breast density. Lifetime outcomes included mortality, quality-adjusted life-years, and screening and treatment costs.
Results For every 1000 women screened biennially from age 50 to 74 years, switching to digital from film yielded a median within-model improvement of 2 life-years, 0.27 additional deaths averted, 220 additional false-positive results, and $0.35 million more in costs. For an individual woman, this translates to a health gain of 0.73 days. Extending biennial digital screening to women ages 40 to 49 years was cost-effective, although results were sensitive to quality-of-life decrements related to screening and false positives. Targeting annual screening by density yielded similar outcomes to targeting by age. Annual screening approaches could increase costs to $5.26 million per 1000 women, in part because of higher numbers of screens and false positives, and were not efficient or cost-effective.
Conclusions The transition to digital breast cancer screening in the United States increased total costs for small added health benefits. The value of digital mammography screening among women aged 40 to 49 years depends on women's preferences regarding false positives.
C1 [Stout, Natasha K.] Harvard Univ, Sch Med, Dept Populat Med, Boston, MA 02215 USA.
[Stout, Natasha K.] Harvard Pilgrim Hlth Care Inst, Boston, MA 02215 USA.
[Lee, Sandra J.; Huang, Hui] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Schechter, Clyde B.] Albert Einstein Coll Med, Dept Family & Social Med, Bronx, NY 10467 USA.
[Schechter, Clyde B.] Albert Einstein Coll Med, Dept Epidemiol & Populat Hlth, Bronx, NY 10467 USA.
[Kerlikowske, Karla] Univ Calif San Francisco, Dept Epidemiol, San Francisco, CA 94143 USA.
[Kerlikowske, Karla] Univ Calif San Francisco, Dept Biostat, San Francisco, CA 94143 USA.
[Kerlikowske, Karla] Univ Calif San Francisco, Gen Internal Med Sect, Dept Vet Affairs, San Francisco, CA 94143 USA.
[Alagoz, Oguzhan; Cevik, Mucahit] Univ Wisconsin, Dept Ind & Syst Engn, Madison, WI USA.
[Alagoz, Oguzhan; Trentham-Dietz, Amy] Univ Wisconsin, Dept Populat Hlth Sci, Madison, WI USA.
[Alagoz, Oguzhan; Trentham-Dietz, Amy] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA.
[Berry, Donald; Chisholm, Gary; Munsell, Mark F.] Univ Texas MD Anderson Canc Ctr, Dept Biostat, Houston, TX 77030 USA.
[Buist, Diana S. M.; Hubbard, Rebecca A.] Grp Hlth Res Inst, Seattle, WA USA.
[de Koning, Harry J.; van Ravesteyn, Nicolien T.] Erasmus MC, Dept Publ Hlth, Rotterdam, Netherlands.
[Miglioretti, Diana L.] Univ Calif Davis, Sch Med, Dept Publ Hlth Sci, Davis, CA 95616 USA.
[Tosteson, Anna N. A.] Geisel Sch Med Dartmouth, Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH USA.
[Mandelblatt, Jeanne S.] Georgetown Univ, Med Ctr, Dept Oncol, Washington, DC 20007 USA.
[Mandelblatt, Jeanne S.] Lombardi Comprehens Canc Ctr, Canc Prevent & Control Program, Washington, DC USA.
RP Stout, NK (reprint author), Harvard Univ, Sch Med, Dept Populat Med, 133 Brookline Ave,6th Fl, Boston, MA 02215 USA.
EM natasha_stout@hms.harvard.edu
FU National Cancer Institute at the National Institutes of Health
[UC2CA148577]; National Cancer Institute as part of the Cancer
Intervention and Surveillance Modeling Network [U01CA152958]; National
Cancer Institute, National Cancer Institute at the National Institutes
of Health [U01CA63740, U01CA86076, U01CA86082, U01CA63736, U01CA70013,
U01CA69976, U01CA63731, U01CA70040, HHSN261201100031C, P01CA154292]
FX This work was supported by grant number UC2CA148577 from the National
Cancer Institute at the National Institutes of Health. The models used
in this analysis were also supported by grant number U01CA152958 from
the National Cancer Institute as part of the Cancer Intervention and
Surveillance Modeling Network. This work was also supported by the
National Cancer Institute-funded BCSC grant numbers U01CA63740,
U01CA86076, U01CA86082, U01CA63736, U01CA70013, U01CA69976, U01CA63731,
U01CA70040, HHSN261201100031C, and P01CA154292 from the National Cancer
Institute at the National Institutes of Health. The content is solely
the responsibility of the authors and does not necessarily represent the
official views of the National Cancer Institute or the National
Institutes of Health.
NR 40
TC 18
Z9 18
U1 1
U2 9
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0027-8874
EI 1460-2105
J9 JNCI-J NATL CANCER I
JI JNCI-J. Natl. Cancer Inst.
PD JUN
PY 2014
VL 106
IS 6
AR dju092
DI 10.1093/jnci/dju092
PG 8
WC Oncology
SC Oncology
GA AO8WT
UT WOS:000341636800007
PM 24872543
ER
PT J
AU Clark, CR
Baril, NC
Achille, E
Foster, S
Johnson, N
Taylor-Clark, K
Gagne, JJ
Olukoya, O
Huisingh, CE
Ommerborn, MJ
Viswanath, K
AF Clark, Cheryl R.
Baril, Nashira C.
Achille, Erline
Foster, Shauntell
Johnson, Natacha
Taylor-Clark, Kalahn
Gagne, Joshua J.
Olukoya, Oluwakemi
Huisingh, Carrie E.
Ommerborn, Mark J.
Viswanath, K.
TI Trust Yet Verify: Physicians as Trusted Sources of Health Information on
HPV for Black Women in Socioeconomically Marginalized Populations
SO PROGRESS IN COMMUNITY HEALTH PARTNERSHIPS-RESEARCH EDUCATION AND ACTION
LA English
DT Article
DE Human papilloma virus; human papilloma virus vaccines; African
Americans; health knowledge; attitudes; practice; health communication
ID HUMAN-PAPILLOMAVIRUS VACCINE; CERVICAL-CANCER; AFRICAN-AMERICAN;
UNITED-STATES; CARE-SYSTEM; DISPARITIES; DISTRUST; PARENTS; EXPERIENCES;
INFECTION
AB Background: Human papilloma virus (HPV) infection is highest among Black women and women of low socioeconomic position (SEP). These groups face inequities in access to health information on HPV.
Objectives: Our study sought to understand key information channels for delivering health information regarding HPV and the HPV vaccine to Black women of low SEP in Boston, Massachusetts. We anticipated that, owing to a legacy of experiences of discrimination, Black women of low SEP would prefer information from trusted and accessible sources, including friends, family, and community agencies, rather than clinical providers.
Methods: We conducted a qualitative analysis using focus groups. We conducted five focus groups among 25 women in Boston, Massachusetts.
Results: Contrary to what we anticipated, we found that women in all of the focus groups preferred to receive information from a physician or health center. Participants preferred to receive print materials they could triangulate with other sources. Notably, study participants had high access to care.
Conclusions: Our study suggests that physicians are trusted and preferred sources of information on HPV for Black women of low SEP in Boston. Our data underscore an important avenue for intervention: to improve dissemination of HPV-related information through physicians, including outreach in community settings.
C1 [Clark, Cheryl R.] Brigham & Womens Faulkner Hosp Program, Div Gen Med & Primary Care, Boston, MA 02130 USA.
[Clark, Cheryl R.; Johnson, Natacha; Huisingh, Carrie E.; Ommerborn, Mark J.] Brigham & Womens Hosp, Ctr Community Hlth & Hlth Equ, Boston, MA 02115 USA.
[Clark, Cheryl R.; Baril, Nashira C.; Achille, Erline; Foster, Shauntell] Boston REACH Coalit, Boston, MA USA.
[Baril, Nashira C.; Achille, Erline] Boston Publ Hlth Commiss, Ctr Hlth Equ & Social Justice, Boston, MA USA.
[Taylor-Clark, Kalahn] Natl Partnership Women & Families, Washington, DC USA.
[Taylor-Clark, Kalahn] Brookings Inst, Washington, DC 20036 USA.
[Gagne, Joshua J.] Dana Farber Canc Inst, Survey & Data Management Core, Boston, MA USA.
[Olukoya, Oluwakemi] Boston Publ Hlth Commiss, Boston, MA USA.
[Viswanath, K.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA USA.
[Viswanath, K.] Harvard Univ, Sch Publ Hlth, Dept Soc Human Dev & Hlth, Cambridge, MA 02138 USA.
RP Clark, CR (reprint author), Brigham & Womens Faulkner Hosp Program, Div Gen Med & Primary Care, Boston, MA 02130 USA.
FU NCI NIH HHS [3U01CA114644]
NR 26
TC 0
Z9 0
U1 2
U2 8
PU JOHNS HOPKINS UNIV PRESS
PI BALTIMORE
PA JOURNALS PUBLISHING DIVISION, 2715 NORTH CHARLES ST, BALTIMORE, MD
21218-4363 USA
SN 1557-0541
EI 1557-055X
J9 PROG COMM HLTH PARTN
JI Prog. Community Health Partnersh.
PD SUM
PY 2014
VL 8
IS 2
BP 169
EP 179
PG 11
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AO7UO
UT WOS:000341558300003
PM 25152098
ER
PT J
AU Donnelly, JP
Baddley, JW
Wang, HE
AF Donnelly, John P.
Baddley, John W.
Wang, Henry E.
TI Reply to "Acute Sinusitis and Pharyngitis as Inappropriate Indications
for Antibiotic Use"
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Letter
ID RESPIRATORY-TRACT INFECTIONS
C1 [Donnelly, John P.; Wang, Henry E.] Univ Alabama Birmingham, Dept Emergency Med, Birmingham, AL USA.
[Baddley, John W.] Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA.
[Baddley, John W.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Baddley, JW (reprint author), Univ Alabama Birmingham, Dept Med, Div Infect Dis, Birmingham, AL 35294 USA.
EM jbaddley@uab.edu
OI Donnelly, John/0000-0002-0646-9470
FU None [HS013852]
NR 4
TC 0
Z9 0
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JUN
PY 2014
VL 58
IS 6
BP 3573
EP 3573
DI 10.1128/AAC.02779-14
PG 1
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA AK9VP
UT WOS:000338776900082
PM 24829388
ER
PT J
AU Kadayifci, A
Parlar, S
Aydinli, M
Dag, MS
Demir, U
Savas, MC
AF Kadayifci, A.
Parlar, S.
Aydinli, M.
Dag, M. S.
Demir, U.
Savas, M. C.
TI Unsedated transnasal versus conventional oral endoscopy in endoscopy
naive patients
SO ACTA GASTRO-ENTEROLOGICA BELGICA
LA English
DT Article
DE transnasal endoscopy; ultrathin endoscope; unsedated oral endoscopy;
tolerability
ID UPPER GASTROINTESTINAL ENDOSCOPY; RANDOMIZED-TRIAL; TRANSORAL
ESOPHAGOGASTRODUODENOSCOPY; PERORAL ENDOSCOPY; EGD; SEDATION; DIAMETER;
SAFETY; PERFORMANCE; TOLERANCE
AB Background and study aims : Unsedated transnasal upper endoscopy (TNE) has been suggested as a more comfortable and safer method than unsedated transoral endoscopy (TOE). However, the numbers of comparative trials are limited. The current study aimed to assess the tolerability, safety, and efficacy of TNE in endoscopy naive patients.
Patients and methods : The current study was designed as a randomized, prospective, parallel arm trial including all eligible patients referred for upper endoscopy. Patients were randomized with a 1:1 ratio to undergo either unsedated TOE using a standard endoscope or unsedated TNE using an ultrathin endoscope. Post-procedure, all patients were asked to complete a questionnaire to assess pain, discomfort, distress and tolerability using a 10 cm visual analog scale (VAS). Patients' expectations and future preferences were also determined by multiple choice questions. Endoscope insertion rate, procedure duration, and side-effects were recorded for each patient.
Results : Each group included 200 patients. With the exception of nasal pain, mean VAS scores were significantly lower in TNE patients when compared to TOE patients (p = 0.0001). 85% and 54.5% of patients in TNE and TOE groups, respectively, found the procedure better than expected (p = 0001). A repeat procedure was significantly more acceptable for TNE than TOE (82.4% and 60.5%, respectively). Endoscope insertion failed in 3.5% of TNE patients. Mild epistaxis was observed in 4% of TNE patients.
Conclusion : Unsedated TNE was tolerated better in endoscopy naive patients than unsedated TOE in a large parallel arm trial.
C1 [Kadayifci, A.; Aydinli, M.; Dag, M. S.; Demir, U.; Savas, M. C.] Gaziantep Univ, Fac Med, Div Gastroenterol, Gaziantep, Turkey.
[Parlar, S.] Gaziantep Univ, Fac Hlth Sci, Dept Internal Med Nursing, Gaziantep, Turkey.
RP Kadayifci, A (reprint author), Massachusetts Gen Hosp, 3-H GI Associates,Zero Emerson Pl,Blossom St, Boston, MA 02114 USA.
EM akadayifci@mgh.harvard.edu
NR 23
TC 1
Z9 1
U1 0
U2 0
PU UNIV CATHOLIQUE LOUVAIN-UCL
PI BRUSSELS
PA CLIN UNIV SAINT LUC, AVE HIPPOCRATE 10, BRUSSELS, B-1200, BELGIUM
SN 0001-5644
EI 1477-4607
J9 ACTA GASTRO-ENT BELG
JI Acta Gastro-Enterol. Belg.
PD JUN
PY 2014
VL 77
IS 2
BP 224
EP 228
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AO3MP
UT WOS:000341234800003
PM 25090820
ER
PT J
AU Li, G
Millard, SP
Peskind, ER
Zhang, J
Yu, CE
Leverenz, JB
Mayer, C
Shofer, JS
Raskind, MA
Quinn, JF
Galasko, DR
Montine, TJ
AF Li, Ge
Millard, Steven P.
Peskind, Elaine R.
Zhang, Jing
Yu, Chang-En
Leverenz, James B.
Mayer, Cynthia
Shofer, Jane S.
Raskind, Murray A.
Quinn, Joseph F.
Galasko, Douglas R.
Montine, Thomas J.
TI Cross-Sectional and Longitudinal Relationships Between Cerebrospinal
Fluid Biomarkers and Cognitive Function in People Without Cognitive
Impairment From Across the Adult Life Span
SO JAMA NEUROLOGY
LA English
DT Article
ID ALZHEIMERS-DISEASE; OLDER-ADULTS; FOLLOW-UP; IN-VIVO; DECLINE; BRAIN;
DEMENTIA; MODELS; MATTER; RATIO
AB IMPORTANCE Age-related cognitive decline among older individuals with normal cognition is a complex trait that potentially derives from processes of aging, inherited vulnerabilities, environmental factors, and common latent diseases that can progress to cause dementia, such as Alzheimer disease and vascular brain injury.
OBJECTIVE To use cerebrospinal fluid (CSF) biomarkers to gain insight into this complex trait.
DESIGN, SETTING, AND PARTICIPANTS Secondary analyses of an academic multicenter cross-sectional (n = 315) and longitudinal (n = 158) study of 5 neuropsychological tests (Immediate Recall, Delayed Recall, Trail Making Test Parts A and B, and Category Fluency) in cognitively normal individuals aged 21 to 100 years.
MAIN OUTCOMES AND MEASURES To investigate the association of these cognitive function test results with age, sex, educational level, inheritance of the epsilon 4 allele of the apolipoprotein E gene, and CSF concentrations of beta-amyloid 42 (A beta 42) and tau (biomarkers of Alzheimer disease) as well as F-2-isoprostanes (measures of free radical injury).
RESULTS Age and educational level were broadly predictive of cross-sectional cognitive performance; of the genetic and CSF measures, only greater CSF F-2-isoprostane concentration was significantly associated with poorer executive function (adjusted R-2 <= 0.31). Longitudinal measures of cognitive abilities, except Category Fluency, also were associated broadly with age; of the genetic and CSF measures, only lower baseline CSF A beta 42 concentration was associated with longitudinal measures of immediate and delayed recall (marginal R-2 <= 0.31).
CONCLUSIONS AND RELEVANCE Our results suggest that age and educational level accounted for a substantial minority of variance in cross-sectional or longitudinal cognitive test performance in this large group of cognitively normal adults. Latent Alzheimer disease and other diseases that produce free radical injury, such as vascular brain injury, accounted for a small amount of variation in cognitive test performance across the adult human life span. Additional genetic and environmental factors likely contribute substantially to age-related cognitive decline.
C1 [Li, Ge; Peskind, Elaine R.; Leverenz, James B.; Shofer, Jane S.; Raskind, Murray A.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Millard, Steven P.; Peskind, Elaine R.; Mayer, Cynthia; Raskind, Murray A.] VA Puget Sound Hlth Care Syst, Vet Affairs VA Northwest Network Mental Illness R, Seattle, WA USA.
[Zhang, Jing; Montine, Thomas J.] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98195 USA.
[Yu, Chang-En] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Yu, Chang-En] VA Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Leverenz, James B.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA 98195 USA.
[Quinn, Joseph F.] Oregon Hlth & Sci Univ, Sch Med, Dept Neurol, Portland, OR 97201 USA.
[Quinn, Joseph F.] VA Parkinsons Dis Res Educ & Clin Ctr, Portland, OR USA.
[Galasko, Douglas R.] Univ Calif San Diego, Sch Med, Dept Neurosci, La Jolla, CA 92093 USA.
RP Montine, TJ (reprint author), Univ Washington, Sch Med, Dept Pathol, POB 357470, Seattle, WA 98195 USA.
EM tmontine@uw.edu
FU National Institutes of Health [AG023185, AG031892, AG05131, AG05136,
AG08017, AG033693, U01-NS082137]; Department of Veterans Affairs; Oregon
Clinical and Translational Research Institute [UL1TR000128]; Jane and
Lee Seidman Fund; Nancy and Buster Alvord Endowment
FX This work was supported by National Institutes of Health grants
AG023185, AG031892, AG05131, AG05136, AG08017, AG033693, and
U01-NS082137; the Department of Veterans Affairs; the Oregon Clinical
and Translational Research Institute grant UL1TR000128; the Jane and Lee
Seidman Fund; and the Nancy and Buster Alvord Endowment.
NR 46
TC 12
Z9 12
U1 1
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6149
EI 2168-6157
J9 JAMA NEUROL
JI JAMA Neurol.
PD JUN
PY 2014
VL 71
IS 6
BP 742
EP 751
DI 10.1001/jamaneurol.2014.445
PG 10
WC Clinical Neurology
SC Neurosciences & Neurology
GA AN3IF
UT WOS:000340479800012
PM 24756381
ER
PT J
AU Lu, LX
Della-Torre, E
Stone, JH
Clark, SW
AF Lu, Lucy X.
Della-Torre, Emanuel
Stone, John H.
Clark, Stephen W.
TI IgG4-Related Hypertrophic Pachymeningitis Clinical Features, Diagnostic
Criteria, and Treatment
SO JAMA NEUROLOGY
LA English
DT Review
ID CEREBROSPINAL-FLUID ANALYSIS; IGG4 PRODUCTION; DISEASE; IL-10; CELLS
AB IMPORTANCE IgG4-related hypertrophic pachymeningitis (IgG4-RHP) is an increasingly recognized manifestation of IgG4-related disease, a fibroinflammatory condition that can affect virtually any organ. It is estimated that IgG4-RHP may account for a high proportion of cases of hypertrophic pachymeningitis once considered idiopathic.
OBJECTIVE To summarize the current knowledge on IgG4-RHP including its pathological, clinical, and radiological presentations. Particular emphasis is placed on diagnostic and therapeutic implications.
EVIDENCE REVIEW This review is based on 21 reports published in the English medical literature since 2009. PubMed was searched with the following terms: IgG4, pachymeningitis, IgG4-related pachymeningitis, IgG4-related disease, IgG4-related, and IgG4 meningitis. Only cases with biopsy-proven IgG4-RHP were considered and included in this review.
FINDINGS Little is known with certainty regarding the pathogenesis of IgG4-RHP. The presence of oligoclonally restricted IgG4-positive plasma cells within inflammatory meningeal niches strongly suggests a specific response against a still unknown antigen. Clinical presentation of IgG4-RHP is not distinguishable from other forms of hypertrophic pachymeningitis and reflects mechanical compression of vascular or nerve structures, leading to functional deficits. Signs of systemic IgG4-related disease may concomitantly be present. Diagnostic process should rely primarily on magnetic resonance imaging, cerebrospinal fluid analysis, and meningeal biopsy. In particular, hallmark histopathological features of IgG4-RHP are a lymphoplasmacytic infiltration of IgG4-positive plasma cells, storiform fibrosis, and obliterative phlebitis. High-dose glucocorticoids are still the treatment of choice for IgG4-RHP because immunosuppressive agents have shown variable efficacy in reducing the meningeal hypertrophy. Rituximab is a promising therapeutic approach but experience with B-cell depletion strategies remains limited.
CONCLUSIONS AND RELEVANCE IgG4-related disease accounts for an increasing proportion of cases of idiopathic hypertrophic pachymeningitis. Clinicians should become familiar with this alternative differential diagnosis because a prompt, specific therapeutic approach may avoid long-term neurological complications.
C1 [Lu, Lucy X.; Clark, Stephen W.] Vanderbilt Univ, Sch Med, Nashville, TN 37232 USA.
[Della-Torre, Emanuel] Univ Vita Salute San Raffaele, San Raffaele Sci Inst, Unit Med & Clin Immunol, Milan, Italy.
[Stone, John H.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol Allergy & Immunol, Boston, MA USA.
[Clark, Stephen W.] Vanderbilt Univ, Dept Neurol, Sch Med, Nashville, TN 37232 USA.
RP Clark, SW (reprint author), Vanderbilt Univ, Dept Neurol, 1161 21st Ave, Nashville, TN 37232 USA.
EM stephen.w.clark@vanderbilt.edu
OI Della Torre, Emanuel/0000-0002-9192-4270
NR 17
TC 30
Z9 39
U1 0
U2 11
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6149
EI 2168-6157
J9 JAMA NEUROL
JI JAMA Neurol.
PD JUN
PY 2014
VL 71
IS 6
BP 785
EP 793
DI 10.1001/jamaneurol.2014.243
PG 9
WC Clinical Neurology
SC Neurosciences & Neurology
GA AN3IF
UT WOS:000340479800019
PM 24733677
ER
PT J
AU De Freitas, J
Falls, BA
Haque, OS
Bursztajn, HJ
AF De Freitas, Julian
Falls, Brian A.
Haque, Omar S.
Bursztajn, Harold J.
TI Recognizing Misleading Pharmaceutical Marketing Online
SO JOURNAL OF THE AMERICAN ACADEMY OF PSYCHIATRY AND THE LAW
LA English
DT Article
ID HEALTH INFORMATION; DRUG COMPANIES; INTERNET
AB In light of decision-making psychology, this article details how drug marketing operates across established and novel web domains and identifies some common misleading trends and influences on prescribing and patient-initiated medication requests. The Internet has allowed pharmaceutical marketing to become more salient than ever before. Although the Internet's growth has improved the dissemination of pharmaceutical information, it has also led to the increased influence of misleading pharmaceutical marketing. Such mismarketing is of concern, especially in psychiatry, since psychotropics generate considerable revenue for drug companies. In a climate of resource-limited drug regulation and time-strapped physicians, we recommend improving both independent monitoring and consumer awareness of Internet-enabled, potentially misleading, pharmaceutical marketing influences.
C1 [De Freitas, Julian] Univ Oxford, Dept Expt Psychol, Oxford OX1 3UD, England.
[Falls, Brian A.] Harvard Univ, Sch Med, Dept Psychiat, VA Boston Healthcare Syst, Boston, MA 02115 USA.
[Haque, Omar S.] Brown Univ, Dept Psychiat & Human Behav, Providence, RI 02912 USA.
[Bursztajn, Harold J.] Harvard Univ, Sch Med, Dept Psychiat, Program Psychiat & Law,Beth Israel Deaconess Med, Cambridge, MA 02138 USA.
[Bursztajn, Harold J.] Massachusetts Mental Hlth Ctr, Cambridge, MA USA.
RP Bursztajn, HJ (reprint author), 96 Larchwood Dr, Cambridge, MA 02138 USA.
EM harold_bursztajn@hms.harvard.edu
NR 31
TC 0
Z9 0
U1 2
U2 5
PU AMER ACAD PSYCHIATRY & LAW
PI BLOOMFIELD
PA ONE REGENCY DR, PO BOX 30, BLOOMFIELD, CT 06002 USA
SN 1093-6793
EI 1943-3662
J9 J AM ACAD PSYCHIATRY
JI J. Am. Acad. Psychiatry Law
PD JUN 1
PY 2014
VL 42
IS 2
BP 219
EP 225
PG 7
WC Law; Psychiatry
SC Government & Law; Psychiatry
GA AN8LW
UT WOS:000340856700012
ER
PT J
AU Possis, E
Bui, T
Gavian, M
Leskela, J
Linardatos, E
Loughlin, J
Strom, T
AF Possis, Elizabeth
Bui, Thao
Gavian, Margaret
Leskela, Jennie
Linardatos, Effie
Loughlin, Jennifer
Strom, Thad
TI Driving Difficulties Among Military Veterans: Clinical Needs and Current
Intervention Status
SO MILITARY MEDICINE
LA English
DT Review
ID POSTTRAUMATIC-STRESS-DISORDER; VEHICLE ACCIDENT SURVIVORS; MENTAL-HEALTH
PROBLEMS; RISK-TAKING BEHAVIORS; SENSATION-SEEKING;
RESIDENTIAL-TREATMENT; VIETNAM VETERANS; ERA VETERANS; US VETERANS;
GULF-WAR
AB Military personnel deployed to Iraq and Afghanistan often develop mental health difficulties, which may manifest as problematic driving behavior. Veterans may be more likely to engage in risky driving and to subsequently be involved in motor vehicle accidents and fatalities. This article reviews literature on driving difficulties among military veterans and evaluates available research on the potential pathways that underlie risky driving behavior. Current interventions for problematic driving behaviors are considered, and the necessity of modifying these interventions to address the unique difficulties encountered by military veterans is highlighted. The review concludes with a discussion of clinical implications of these findings and identification of possible avenues for future research and intervention.
C1 [Possis, Elizabeth; Leskela, Jennie; Strom, Thad] Minneapolis Vet Affairs Hlth Care Syst, Minneapolis, MN 55417 USA.
[Bui, Thao] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Gavian, Margaret] North Mem Med Ctr, Psychiat Partial Hosp Program, Robbinsdale, MN 55422 USA.
[Linardatos, Effie] Geisel Sch Med Dartmouth, Dept Psychiat, Lebanon, NH 03756 USA.
[Loughlin, Jennifer] Barrow Neurol Inst, Phoenix, AZ 85013 USA.
RP Possis, E (reprint author), Minneapolis Vet Affairs Hlth Care Syst, One Vet Dr 116A, Minneapolis, MN 55417 USA.
NR 58
TC 5
Z9 5
U1 1
U2 2
PU ASSOC MILITARY SURG US
PI BETHESDA
PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA
SN 0026-4075
EI 1930-613X
J9 MIL MED
JI Milit. Med.
PD JUN
PY 2014
VL 179
IS 6
BP 633
EP 639
DI 10.7205/MlLMED-D-13-00327
PG 7
WC Medicine, General & Internal
SC General & Internal Medicine
GA AN7UM
UT WOS:000340806500008
PM 24902130
ER
PT J
AU Chan, K
Hernandez, L
Yang, HD
Goetz, MB
AF Chan, Kee
Hernandez, Leilani
Yang, Heidi
Goetz, Matthew Bidwell
TI Comparative Cost Analysis of Clinical Reminder for HIV Testing at the
Veterans Affairs Healthcare System
SO VALUE IN HEALTH
LA English
DT Article
DE AIDS; cost analysis; Veterans Affairs Healthcare System
ID STRATEGIES; SETTINGS; STATEMENT; RECEIPT; TRIAL
AB Objective: To estimate the cost and health outcomes associated with a new HIV testing strategy that utilizes routine-based clinical reminders. Methods: We conducted an economic analysis of 1) traditional pretest/post-test counseling; 2) counseling and a new clinical reminders system; and 3) only clinical reminder in the veterans' health care system. A payer perspective decision model was conducted to calculate the 1-year budget impact of three HIV testing strategies. Parameter values were obtained from the literature, including patients' probability of accepting test, and costs associated with HIV testing procedures. Deidentified patient data, including total population screened and number of new HIV cases, were collected from one clinic in Los Angeles, California, from August 2004 to December 2011. Annual total costs and costs per new case were calculated on the basis of parameter values and patient data Sensitivity analyses were conducted to evaluate the robustness of the critical variable on costs. Results: The total cost of the clinical reminder system with pretest counseling was $81,726 over 1 year compared with $109,208 for traditional HIV testing. Under a clinical reminder system with no pretest counseling, the number of HIV tests performed and the number of new diagnoses increased for that year. In addition, cost per new diagnoses was the lowest. Conclusions: The clinical reminder system can reduce the cost per cases identified and promote better performance of HIV testing compared with traditional HIV testing. The fundamental decision model can be used for hospital facilities outside the Veteran Affairs adopting a similar program for improving the HIV testing rate.
C1 [Chan, Kee; Hernandez, Leilani; Yang, Heidi] Boston Univ, Sargent Coll, Coll Hlth & Rehabil Sci, Dept Hlth Sci, Boston, MA 02215 USA.
[Chan, Kee] Ctr Hlth Qual & Econ Res, Bedford, MA USA.
[Goetz, Matthew Bidwell] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Infect Dis Sect, Los Angeles, CA 90095 USA.
[Goetz, Matthew Bidwell] VA Greater Los Angeles Healthcare Syst, Dept Med, Infect Dis Sect, Los Angeles, CA USA.
RP Chan, K (reprint author), Boston Univ, Sargent Coll, Coll Hlth & Rehabil Sci, 635 Commonwealth Ave, Boston, MA 02215 USA.
EM keechan@bu.edu
OI Goetz, Matthew/0000-0003-4542-992X
NR 14
TC 1
Z9 1
U1 2
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1098-3015
EI 1524-4733
J9 VALUE HEALTH
JI Value Health
PD JUN
PY 2014
VL 17
IS 4
BP 334
EP 339
DI 10.1016/j.jval.2014.03.001
PG 6
WC Economics; Health Care Sciences & Services; Health Policy & Services
SC Business & Economics; Health Care Sciences & Services
GA AO1ON
UT WOS:000341082900005
PM 24968992
ER
PT J
AU Spring, BQ
Palanisami, A
Hasan, T
AF Spring, Bryan Q.
Palanisami, Akilan
Hasan, Tayyaba
TI Microscale receiver operating characteristic analysis of micrometastasis
recognition using activatable fluorescent probes indicates leukocyte
imaging as a critical factor to enhance accuracy
SO JOURNAL OF BIOMEDICAL OPTICS
LA English
DT Article
DE cancer micrometastases; molecular imaging; activatable probes;
leukocytes; immunoconjugates; image analysis
ID GROWTH-FACTOR RECEPTOR; EPITHELIAL OVARIAN-CANCER; VIVO; CELLS;
MICROENDOSCOPY; PHOTOIMMUNOTHERAPY; MICROENVIRONMENT; ENDOMICROSCOPY;
CARCINOMATOSIS; METASTASES
AB Molecular-targeted probes are emerging with applications for optical biopsy of cancer. An underexplored potential clinical use of these probes is to monitor residual cancer micrometastases that escape cytoreductive surgery and chemotherapy. Here, we show that leukocytes, or white blood cells, residing in nontumor tissues-as well as those infiltrating micrometastatic lesions-uptake cancer cell-targeted, activatable immunoconjugates nonspecifically, which limits the accuracy and resolution of micrometastasis recognition using these probes. Receiver operating characteristic analysis of freshly excised tissues from a mouse model of peritoneal carcinomatosis suggests that dual-color imaging, adding an immunostain for leukocytes, offers promise for enabling accurate recognition of single cancer cells. Our results indicate that leukocyte identification improves micrometastasis recognition sensitivity and specificity from 92 to 93%-for multicellular metastases >20 to 30 m in size-to 98 to 99.9% for resolving metastases as small as a single cell. (C) 2014 Society of Photo-Optical Instrumentation Engineers (SPIE)
C1 [Spring, Bryan Q.; Palanisami, Akilan; Hasan, Tayyaba] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Spring, Bryan Q.; Palanisami, Akilan; Hasan, Tayyaba] Harvard Univ, Sch Med, Wellman Ctr Photomed, Boston, MA 02214 USA.
[Hasan, Tayyaba] Massachusetts Gen Hosp, Dept Dermatol, Boston, MA 02114 USA.
[Hasan, Tayyaba] Harvard Univ, Cambridge, MA 02139 USA.
[Hasan, Tayyaba] MIT, Div Hlth Sci & Technol, Cambridge, MA 02139 USA.
RP Hasan, T (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM thasan@mgh.harvard.edu
FU U. S. National Institutes of Health [R01-AR40352, RC1-CA146337,
R01-CA160998, P01-CA084203, F32-CA144210]
FX This work was supported by U. S. National Institutes of Health grants
R01-AR40352, RC1-CA146337, R01-CA160998, and P01-CA084203 to T. H. and
F32-CA144210 to B. Q. S.
NR 39
TC 1
Z9 1
U1 1
U2 5
PU SPIE-SOC PHOTO-OPTICAL INSTRUMENTATION ENGINEERS
PI BELLINGHAM
PA 1000 20TH ST, PO BOX 10, BELLINGHAM, WA 98225 USA
SN 1083-3668
EI 1560-2281
J9 J BIOMED OPT
JI J. Biomed. Opt.
PD JUN
PY 2014
VL 19
IS 6
AR 066006
DI 10.1117/1.JBO.19.6.066006
PG 5
WC Biochemical Research Methods; Optics; Radiology, Nuclear Medicine &
Medical Imaging
SC Biochemistry & Molecular Biology; Optics; Radiology, Nuclear Medicine &
Medical Imaging
GA AN2RL
UT WOS:000340432900013
PM 24919449
ER
PT J
AU Chang, G
Meadows, ME
Smallwood, JA
Antin, JH
Orav, EJ
AF Chang, Grace
Meadows, Mary-Ellen
Smallwood, Jennifer A.
Antin, Joseph H.
Orav, E. John
TI Cognitive and Other Predictors of Change in Quality of Life One Year
After Treatment for Chronic Myelogenous Leukemia or Myelodysplastic
Syndrome
SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
LA English
DT Article
ID BONE-MARROW-TRANSPLANTATION; CANCER-PATIENTS; CELL TRANSPLANTATION;
MENTAL-HEALTH; SURVIVORS; ASSOCIATION; DIAGNOSIS; SYSTEM; MEMORY; SF-36
AB The role of cognitive function in quality of life is important among the growing numbers of survivors after cancer treatment. The authors conducted a prospective cohort study of 106 adults evaluated 5.6 months (median) after diagnosis and 77 of 83 (93%) survivors 12 months later with neuropsychological assessments yielding information about simple reaction time to stimuli and other aspects of cognitive function and with two quality of life measures. The two most consistent predictors of change in quality of life were baseline quality of life ratings and simple reaction time. This novel finding about simple reaction time warrants further confirmation.
C1 [Chang, Grace; Meadows, Mary-Ellen; Antin, Joseph H.; Orav, E. John] Harvard Med Sch, Boston, MA 02115 USA.
[Chang, Grace; Meadows, Mary-Ellen; Smallwood, Jennifer A.; Antin, Joseph H.; Orav, E. John] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Chang, Grace] VA Boston Healthcare Syst, Brockton, MA USA.
[Antin, Joseph H.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Chang, G (reprint author), Harvard Med Sch, Boston, MA 02115 USA.
EM grace.chang2@va.gov
FU American Cancer Society [RSG-01-246-01]; National Institute on Alcohol
Abuse and Alcoholism [K24AA00289]
FX This study was funded by grants from the American Cancer Society
(RSG-01-246-01, GC) and the National Institute on Alcohol Abuse and
Alcoholism (K24AA00289, GC). Study sponsors had no involvement in study
design; data acquisition, analysis, or interpretation; writing or
submission of the manuscript.
NR 41
TC 1
Z9 1
U1 0
U2 0
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0895-0172
EI 1545-7222
J9 J NEUROPSYCH CLIN N
JI J. Neuropsychiatr. Clin. Neurosci.
PD SUM
PY 2014
VL 26
IS 3
BP 249
EP 257
PG 9
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AN3ML
UT WOS:000340492100043
PM 24817387
ER
PT J
AU Mendez, MF
Shapira, JS
AF Mendez, Mario F.
Shapira, Jill S.
TI Kissing or "Osculation" in Frontotemporal Dementia
SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES
LA English
DT Article
ID KLUVER-BUCY-SYNDROME; TEMPORAL-LOBE EPILEPSY
AB The authors investigated the neuropsychiatry of kissing in frontotemporal dementia. Among 15 patients, two had compulsive social kissing, bitemporal involvement, and Kluver-Bucy symptoms, and four pursued kissing with sexually disinhibited behavior. Future research should clarify the neuropsychiatric significance of kissing behavior.
C1 [Mendez, Mario F.; Shapira, Jill S.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90089 USA.
[Mendez, Mario F.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehavioral Sci, Los Angeles, CA USA.
[Mendez, Mario F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA.
RP Mendez, MF (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90089 USA.
EM mmendez@ucla.edu
FU NIA [R01AG034499-03]
FX Supported by NIA grant # R01AG034499-03.
NR 12
TC 0
Z9 0
U1 0
U2 6
PU AMER PSYCHIATRIC PUBLISHING, INC
PI ARLINGTON
PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA
SN 0895-0172
EI 1545-7222
J9 J NEUROPSYCH CLIN N
JI J. Neuropsychiatr. Clin. Neurosci.
PD SUM
PY 2014
VL 26
IS 3
BP 258
EP 261
PG 4
WC Clinical Neurology; Neurosciences; Psychiatry
SC Neurosciences & Neurology; Psychiatry
GA AN3ML
UT WOS:000340492100044
PM 24922478
ER
PT J
AU Byrd, JK
Smith, KJ
de Almeida, JR
Albergotti, WG
Davis, KS
Kim, SW
Johnson, JT
Ferris, RL
Duvvuri, U
AF Byrd, J. Kenneth
Smith, Kenneth J.
de Almeida, John R.
Albergotti, W. Greer
Davis, Kara S.
Kim, Seungwon W.
Johnson, Jonas T.
Ferris, Robert L.
Duvvuri, Umamaheswar
TI Transoral Robotic Surgery and the Unknown Primary: A Cost-Effectiveness
Analysis
SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY
LA English
DT Article
DE transoral robotic surgery; TORS; occult primary; cost-effectiveness
analysis
ID SQUAMOUS-CELL CARCINOMA; LYMPH-NODE METASTASES; PRIMARY TUMORS; RADICAL
PROSTATECTOMY; EXTRACAPSULAR SPREAD; NECK; HEAD; TECHNOLOGY; MANAGEMENT;
PARADIGM
AB Objective. To evaluate the cost-effectiveness of transoral robotic surgery (TORS) for the diagnosis and treatment of cervical unknown primary squamous cell carcinoma (CUP).
Study Design. Case series with chart review.
Setting. Tertiary academic hospital.
Subjects and Methods. A retrospective chart review was performed on patients with new occult primary squamous cell carcinoma of the head and neck with nondiagnostic imaging and/or endoscopy who were treated with TORS at a tertiary hospital between 2009 and 2012. Direct costs were obtained from the hospital's billing system, and national data were used for inpatient hospital costs and physician fees. The proportion of tumors found in 3 strategies was used as effectiveness to calculate the incremental cost-effectiveness ratio.
Results. In total, 206 head and neck robotic cases were performed at our institution between December 2009 and December 2012. Three surgeons performed TORS on 22 patients for occult primary squamous cell carcinoma. The primary tumor was located in 19 of 22 patients (86.4%). The incremental cost-effectiveness ratio for sequential and simultaneous examination under anesthesia with tonsillectomy (EUA) and TORS base of tongue resection was $8619 and $5774 per additional primary identified, respectively.
Conclusion. Sequential EUA followed by TORS is associated with an incremental cost-effectiveness ratio of $8619 compared with traditional EUA alone. Bilateral base of tongue resection should be considered in the workup of these patients, particularly if the palatine tonsils have already been removed.
C1 [Byrd, J. Kenneth; Albergotti, W. Greer; Davis, Kara S.; Kim, Seungwon W.; Johnson, Jonas T.; Ferris, Robert L.; Duvvuri, Umamaheswar] Univ Pittsburgh, Med Ctr, Dept Otolaryngol, Pittsburgh, PA 15213 USA.
[Smith, Kenneth J.] Univ Pittsburgh, Med Ctr, Dept Med, Pittsburgh, PA 15213 USA.
[de Almeida, John R.] Univ Toronto, Dept Otolaryngol Head & Neck Surg, Toronto, ON, Canada.
[Duvvuri, Umamaheswar] VA Pittsburgh Hlth Syst, Pittsburgh, PA USA.
RP Byrd, JK (reprint author), Univ Pittsburgh, Med Ctr, Dept Otolaryngol, 200 Lothrop St,Suite 500, Pittsburgh, PA 15213 USA.
EM byrdjk@upmc.edu
FU Department of Veterans Affairs
FX This work was supported in part by funds from the Department of Veterans
Affairs; this work does not reflect the views of the U.S. government or
the Department of Veterans Affairs.
NR 22
TC 17
Z9 17
U1 0
U2 4
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0194-5998
EI 1097-6817
J9 OTOLARYNG HEAD NECK
JI Otolaryngol. Head Neck Surg.
PD JUN
PY 2014
VL 150
IS 6
BP 976
EP 982
DI 10.1177/0194599814525746
PG 7
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA AN2YC
UT WOS:000340451000014
PM 24618502
ER
PT J
AU Priesol, AJ
Valko, Y
Merfeld, DM
Lewis, RF
AF Priesol, Adrian J.
Valko, Yulia
Merfeld, Daniel M.
Lewis, Richard F.
TI Motion Perception in Patients with Idiopathic Bilateral Vestibular
Hypofunction
SO OTOLARYNGOLOGY-HEAD AND NECK SURGERY
LA English
DT Article
DE motion; orientation; perception; psychophysics; vestibular
ID CANAL FUNCTION
AB We measured vestibular perceptual thresholds in patients with idiopathic bilateral vestibulopathy to assess the distribution of peripheral vestibular damage in this disorder. Thresholds were measured with standard psychometric techniques in 4 patients and compared with thresholds in normal subjects and patients with completely absent peripheral vestibular function. Motion paradigms included yaw rotation (testing the lateral canals), interaural translation (testing the utricles), superior-inferior translation (testing the saccules), and roll tilt (testing the vertical semicircular canals and the otolith organs). We found that perceptual thresholds were abnormally elevated in the patients with idiopathic bilateral vestibulopathy for yaw rotation at all frequencies and for interaural translation at only the lower frequencies. Thresholds were normal for the other 2 motion paradigms. The results demonstrate that the distribution of vestibular dysfunction in this disorder is not uniform but, rather, can affect lateral canal and utricular thresholds while relatively sparing vertical canal and saccular function.
C1 [Priesol, Adrian J.; Merfeld, Daniel M.; Lewis, Richard F.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02114 USA.
[Priesol, Adrian J.; Valko, Yulia; Merfeld, Daniel M.; Lewis, Richard F.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Jenks Vestibular Physiol Lab, Boston, MA 02114 USA.
[Lewis, Richard F.] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02114 USA.
RP Lewis, RF (reprint author), Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, 243 Charles St, Boston, MA 02114 USA.
EM richard_lewis@meei.harvard.edu
FU NIH [NIH/NIDCD R01-DC04158]
FX Funding source: NIH (NIH/NIDCD R01-DC04158).
NR 9
TC 11
Z9 11
U1 0
U2 1
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0194-5998
EI 1097-6817
J9 OTOLARYNG HEAD NECK
JI Otolaryngol. Head Neck Surg.
PD JUN
PY 2014
VL 150
IS 6
BP 1040
EP 1042
DI 10.1177/0194599814526557
PG 3
WC Otorhinolaryngology; Surgery
SC Otorhinolaryngology; Surgery
GA AN2YC
UT WOS:000340451000023
PM 24647642
ER
PT J
AU Fritsch, EF
Rajasagi, M
Ott, PA
Brusic, V
Hacohen, N
Wu, CJ
AF Fritsch, Edward F.
Rajasagi, Mohini
Ott, Patrick A.
Brusic, Vladimir
Hacohen, Nir
Wu, Catherine J.
TI HLA-Binding Properties of Tumor Neoepitopes in Humans
SO CANCER IMMUNOLOGY RESEARCH
LA English
DT Article
ID CYTOLYTIC T-LYMPHOCYTES; MINOR HISTOCOMPATIBILITY ANTIGEN;
ACTIVE-SPECIFIC IMMUNOTHERAPY; COLONY-STIMULATING FACTOR; RENAL-CELL
CARCINOMA; POINT MUTATION; HUMAN-MELANOMA; METASTATIC MELANOMA;
LUNG-CARCINOMA; HIGH-FREQUENCY
AB Cancer genome sequencing has enabled the rapid identification of the complete repertoire of coding sequence mutations within a patient's tumor and facilitated their use as personalized immunogens. Although a variety of techniques are available to assist in the selection of mutation-defined epitopes to be included within the tumor vaccine, the ability of the peptide to bind to patient MHC is a key gateway to peptide presentation. With advances in the accuracy of predictive algorithms for MHC class I binding, choosing epitopes on the basis of predicted affinity provides a rapid and unbiased approach to epitope prioritization. We show herein the retrospective application of a prediction algorithm to a large set of bona fide T cell-defined mutated human tumor antigens that induced immune responses, most of which were associated with tumor regression or long-term disease stability. The results support the application of this approach for epitope selection and reveal informative features of these naturally occurring epitopes to aid in epitope prioritization for use in tumor vaccines. (C) 2014 AACR.
C1 [Fritsch, Edward F.; Rajasagi, Mohini; Brusic, Vladimir; Wu, Catherine J.] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02115 USA.
[Fritsch, Edward F.; Rajasagi, Mohini; Ott, Patrick A.; Wu, Catherine J.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Hacohen, Nir] Massachusetts Gen Hosp, Dept Med, Div Allergy Immunol & Rheumatol, Boston, MA 02114 USA.
[Ott, Patrick A.; Brusic, Vladimir; Wu, Catherine J.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
[Fritsch, Edward F.; Hacohen, Nir] Broad Inst MIT & Harvard, Cambridge, MA USA.
RP Wu, CJ (reprint author), Dana Farber Canc Inst, Dana 540B,450 Brookline Ave, Boston, MA 02115 USA.
EM cwu@partners.org
FU Blavatnik Family Foundation; NIH [NHLBI:5 R01 HL103532-03,
NCI:1R01CA155010-02]
FX The work on neoepitope-based vaccines was financially supported by the
Blavatnik Family Foundation and the NIH (NHLBI:5 R01 HL103532-03;
NCI:1R01CA155010-02).
NR 54
TC 41
Z9 41
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 2326-6066
EI 2326-6074
J9 CANCER IMMUNOL RES
JI Cancer Immunol. Res.
PD JUN
PY 2014
VL 2
IS 6
BP 522
EP 529
DI 10.1158/2326-6066.CIR-13-0227
PG 8
WC Oncology; Immunology
SC Oncology; Immunology
GA AM7HC
UT WOS:000340035300004
PM 24894089
ER
PT J
AU Morgenroth, DC
Medverd, JR
Seyedali, M
Czerniecki, JM
AF Morgenroth, David C.
Medverd, Jonathan R.
Seyedali, Mahyo
Czerniecki, Joseph M.
TI The relationship between knee joint loading rate during walking and
degenerative changes on magnetic resonance imaging
SO CLINICAL BIOMECHANICS
LA English
DT Article
DE Osteoarthritis; Knee; Gait
ID TRANS-TIBIAL AMPUTATION; ADDUCTION MOMENT; TIBIOFEMORAL OSTEOARTHRITIS;
DISEASE SEVERITY; IN-VITRO; CARTILAGE; GAIT; BONE; IMPACT; STRENGTH
AB Background: While animal study and cadaveric study have demonstrated an association between knee joint loading rate and joint degeneration, the relationship between knee joint loading rate during walking and osteoarthritis has not yet been sufficiently studied in humans.
Methods: Twenty-eight participants (14 transfemoral amputees and 14 age and body mass matched controls) underwent knee MRI with subsequent assessment using the semiquantitative Whole-Organ Magnetic Resonance Image Score. Each subject also underwent gait analysis in order to determine knee adduction moment loading rate, peak, and impulse and an exploratory measure, knee adduction moment rate * magnitude.
Findings; Significant correlations were found between medial tibiofemoral joint degeneration and knee adduction moment peak (slope = 0.42 [SE 0.20]; P = .037), loading rate (slope = 12.3 [SE 3.2]; P = .0004), and rate * magnitude (slope = 437 [SE 100]; P < .0001). These relationships continued to be significant after adjusting for body mass or subject type. The relationship between medial knee semiquantitative MRI score and knee adduction moment loading rate and rate * magnitude continued to be significant even after adjusting for peak moment (P < .0001), however, the relationship between medial knee semiquantitative MRI score and peak moment was no longer significant after adjusting for either loading rate or rate * magnitude (P > .2 in both cases).
Interpretation; This study suggests an independent relationship between knee adduction moment loading rate and medial tibiofemoral joint degeneration. Our results support the hypothesis that rate of loading, represented by the knee adduction moment loading rate, is strongly associated with medial tibiofemoral joint degeneration independent of knee adduction moment peak and impulse. Published by Elsevier Ltd.
C1 [Morgenroth, David C.; Seyedali, Mahyo; Czerniecki, Joseph M.] VAPSHCS, Dept Vet Affairs, Rehabil Res & Dev Ctr Excellence, Seattle, WA USA.
[Medverd, Jonathan R.] VAPSHCS, Dept Vet Affairs, Dept Radiol, Seattle, WA USA.
[Morgenroth, David C.; Czerniecki, Joseph M.] Univ Washington, Dept Rehabil Med, Seattle, WA 98195 USA.
[Medverd, Jonathan R.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA.
RP Morgenroth, DC (reprint author), VA Puget Sound Hlth Care Syst, RCS 117,1660 S Columbian Way, Seattle, WA 98108 USA.
EM dmorgen@uw.edu
FU U.S. Department of Veterans Affairs, Office of Research and Development
(RRD Center) [A4843C]; National Institutes of Health (NIH) [K12
HD001097]
FX This material is based on work supported in part by the U.S. Department
of Veterans Affairs, Office of Research and Development (RR&D Center
Grant A4843C). Additionally, David Morgenroth's work on this project was
supported by the National Institutes of Health (NIH grant K12 HD001097).
None of the authors have any conflicts of interest related to this work.
The content is solely the responsibility of the authors and does not
necessarily represent the official views of the National Institutes of
Health.
NR 43
TC 6
Z9 6
U1 0
U2 9
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 0268-0033
EI 1879-1271
J9 CLIN BIOMECH
JI Clin. Biomech.
PD JUN
PY 2014
VL 29
IS 6
BP 664
EP 670
DI 10.1016/j.clinbiomech.2014.04.008
PG 7
WC Engineering, Biomedical; Orthopedics; Sport Sciences
SC Engineering; Orthopedics; Sport Sciences
GA AN1KH
UT WOS:000340340700010
PM 24820134
ER
PT J
AU Wawer, MJ
Jaramillo, DE
Dancik, V
Fass, DM
Haggarty, SJ
Shamji, AF
Wagner, BK
Schreiber, SL
Clemons, PA
AF Wawer, Mathias J.
Jaramillo, David E.
Dancik, Vlado
Fass, Daniel M.
Haggarty, Stephen J.
Shamji, Alykhan F.
Wagner, Bridget K.
Schreiber, Stuart L.
Clemons, Paul A.
TI Automated Structure-Activity Relationship Mining: Connecting Chemical
Structure to Biological Profiles
SO JOURNAL OF BIOMOLECULAR SCREENING
LA English
DT Article
DE structure-activity relationships; small-molecule profiling; high-content
screening; frequent-itemset mining; association-rule mining
ID HISTONE DEACETYLASE INHIBITORS; DIVERSITY-ORIENTED SYNTHESIS; SMALL
MOLECULES; DRUG DISCOVERY; STRATEGY; CANCER; DIFFERENTIATION;
IDENTIFICATION; MECHANISM; RESOURCE
AB Understanding the structure-activity relationships (SARs) of small molecules is important for developing probes and novel therapeutic agents in chemical biology and drug discovery. Increasingly, multiplexed small-molecule profiling assays allow simultaneous measurement of many biological response parameters for the same compound (e. g., expression levels for many genes or binding constants against many proteins). Although such methods promise to capture SARs with high granularity, few computational methods are available to support SAR analyses of high-dimensional compound activity profiles. Many of these methods are not generally applicable or reduce the activity space to scalar summary statistics before establishing SARs. In this article, we present a versatile computational method that automatically extracts interpretable SAR rules from high-dimensional profiling data. The rules connect chemical structural features of compounds to patterns in their biological activity profiles. We applied our method to data from novel cell-based gene-expression and imaging assays collected on more than 30,000 small molecules. Based on the rules identified for this data set, we prioritized groups of compounds for further study, including a novel set of putative histone deacetylase inhibitors.
C1 [Wawer, Mathias J.; Jaramillo, David E.; Dancik, Vlado; Fass, Daniel M.; Haggarty, Stephen J.; Shamji, Alykhan F.; Wagner, Bridget K.; Schreiber, Stuart L.; Clemons, Paul A.] Broad Inst, Ctr Sci Therapeut, Cambridge, MA 02142 USA.
[Fass, Daniel M.; Haggarty, Stephen J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Chem Neurobiol Lab,Ctr Human Genet Res,Dept Neuro, Boston, MA USA.
[Fass, Daniel M.; Haggarty, Stephen J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Chem Neurobiol Lab,Ctr Human Genet Res,Dept Psych, Boston, MA USA.
RP Clemons, PA (reprint author), Broad Inst, Ctr Sci Therapeut, 7 Cambridge Ctr, Cambridge, MA 02142 USA.
EM pclemons@broadinstitute.org
OI Haggarty, Stephen J./0000-0002-7872-168X
FU National Institute of General Medical Sciences as part of the Center of
Excellence for Chemical Methodology and Library Development
[P50-GM069721]; National Institutes of Health (NIH) RoadMap Molecular
Libraries Initiative [U54-HG005032]
FX The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article:
Cheminformatics and data-mining work was supported by the National
Institute of General Medical Sciences (P50-GM069721, awarded to S. L.
S.), as part of the Center of Excellence for Chemical Methodology and
Library Development. Profiling measurements were supported as part of
the National Institutes of Health (NIH) RoadMap Molecular Libraries
Initiative (U54-HG005032, awarded to S. L. S.). Associated data can be
accessed at
http://www.broadinstitute.org/scientific-community/science/programs/csof
t/thera peutics-platform/mlpcn/accessing-mlpcn-data. D.M.F. and S.J.H.
NR 33
TC 8
Z9 8
U1 0
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1087-0571
EI 1552-454X
J9 J BIOMOL SCREEN
JI J. Biomol. Screen
PD JUN
PY 2014
VL 19
IS 5
SI SI
BP 738
EP 748
DI 10.1177/1087057114530783
PG 11
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
Chemistry, Analytical
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Chemistry
GA AM9OG
UT WOS:000340210300013
PM 24710340
ER
PT J
AU Vempati, UD
Chung, C
Mader, C
Koleti, A
Datar, N
Vidovic, D
Wrobel, D
Erickson, S
Muhlich, JL
Berriz, G
Benes, CH
Subramanian, A
Pillai, A
Shamu, CE
Schurer, SC
AF Vempati, Uma D.
Chung, Caty
Mader, Chris
Koleti, Amar
Datar, Nakul
Vidovic, Dusica
Wrobel, David
Erickson, Sean
Muhlich, Jeremy L.
Berriz, Gabriel
Benes, Cyril H.
Subramanian, Aravind
Pillai, Ajay
Shamu, Caroline E.
Schuerer, Stephan C.
TI Metadata Standard and Data Exchange Specifications to Describe, Model,
and Integrate Complex and Diverse High-Throughput Screening Data from
the Library of Integrated Network-based Cellular Signatures (LINCS)
SO JOURNAL OF BIOMOLECULAR SCREENING
LA English
DT Article
DE database and data management; data standards; metadata; cell-based
assays; enzyme assays or enzyme kinetics; gene expression
ID MINIMUM INFORMATION; ONTOLOGY; INHIBITOR; PROJECT
AB The National Institutes of Health Library of Integrated Network-based Cellular Signatures (LINCS) program is generating extensive multidimensional data sets, including biochemical, genome-wide transcriptional, and phenotypic cellular response signatures to a variety of small-molecule and genetic perturbations with the goal of creating a sustainable, widely applicable, and readily accessible systems biology knowledge resource. Integration and analysis of diverse LINCS data sets depend on the availability of sufficient metadata to describe the assays and screening results and on their syntactic, structural, and semantic consistency. Here we report metadata specifications for the most important molecular and cellular components and recommend them for adoption beyond the LINCS project. We focus on the minimum required information to model LINCS assays and results based on a number of use cases, and we recommend controlled terminologies and ontologies to annotate assays with syntactic consistency and semantic integrity. We also report specifications for a simple annotation format (SAF) to describe assays and screening results based on our metadata specifications with explicit controlled vocabularies. SAF specifically serves to programmatically access and exchange LINCS data as a prerequisite for a distributed information management infrastructure. We applied the metadata specifications to annotate large numbers of LINCS cell lines, proteins, and small molecules. The resources generated and presented here are freely available.
C1 [Vempati, Uma D.; Chung, Caty; Mader, Chris; Koleti, Amar; Datar, Nakul; Vidovic, Dusica; Schuerer, Stephan C.] Univ Miami, Ctr Computat Sci, Miami, FL 33154 USA.
[Wrobel, David; Erickson, Sean; Shamu, Caroline E.] Harvard Univ, Sch Med, ICCB Longwood Screening Facil, Boston, MA USA.
[Muhlich, Jeremy L.; Berriz, Gabriel; Shamu, Caroline E.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA.
[Benes, Cyril H.] Massachusetts Gen Hosp, Ctr Mol Therapeut, Boston, MA 02114 USA.
[Subramanian, Aravind] Broad Inst, Cambridge, MA USA.
[Pillai, Ajay] NHGRI, NIH, Rockville, MD USA.
[Schuerer, Stephan C.] Univ Miami, Dept Mol & Cellular Pharmacol, Miami, FL 33154 USA.
RP Schurer, SC (reprint author), Univ Miami, Dept Mol & Cellular Pharmacol, Ctr Computat Sci, 610D Clin Res Bldg,LC-213, Miami, FL 33154 USA.
EM sschurer@med.miami.edu
OI Pillai, Ajay/0000-0002-9789-7189
FU LINCS project [1U01HL111561, 3U01HL111561-01S1, 3U01HL111561-02S1,
U54HG006097, U54 HG006093]
FX The authors disclosed receipt of the following financial support for the
research, authorship, and/or publication of this article: This work was
funded by the LINCS project grants 1U01HL111561, 3U01HL111561-01S1, and
3U01HL111561-02S1, U54HG006097, U54 HG006093.
NR 26
TC 22
Z9 22
U1 0
U2 5
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1087-0571
EI 1552-454X
J9 J BIOMOL SCREEN
JI J. Biomol. Screen
PD JUN
PY 2014
VL 19
IS 5
SI SI
BP 803
EP 816
DI 10.1177/1087057114522514
PG 14
WC Biochemical Research Methods; Biotechnology & Applied Microbiology;
Chemistry, Analytical
SC Biochemistry & Molecular Biology; Biotechnology & Applied Microbiology;
Chemistry
GA AM9OG
UT WOS:000340210300019
PM 24518066
ER
PT J
AU Ceppi, F
Langlois-Pelletier, C
Gagne, V
Rousseau, J
Ciolino, C
De Lorenzo, S
Kevin, KM
Cijov, D
Sallan, SE
Silverman, LB
Neuberg, D
Kutok, JL
Sinnett, D
Laverdiere, C
Krajinovic, M
AF Ceppi, Francesco
Langlois-Pelletier, Chloe
Gagne, Vincent
Rousseau, Julie
Ciolino, Claire
De Lorenzo, Samanta
Kevin, Kojok M.
Cijov, Diana
Sallan, Stephen E.
Silverman, Lewis B.
Neuberg, Donna
Kutok, Jeffery L.
Sinnett, Daniel
Laverdiere, Caroline
Krajinovic, Maja
TI Polymorphisms of the vincristine pathway and response to treatment in
children with childhood acute lymphoblastic leukemia
SO PHARMACOGENOMICS
LA English
DT Article
DE childhood leukemia; peripheral neurotoxicity; pharmacogenetics;
polymorphisms; treatment outcome; vincristine
ID MULTIDRUG-RESISTANCE; MDR1 GENE; SEQUENCE DIVERSITY; CYP3A5 EXPRESSION;
PHARMACOKINETICS; C3435T; CELLS; IDENTIFICATION; DISPOSITION;
ASSOCIATION
AB Background: Vincristine (VCR) is a standard component in the treatment of childhood acute lymphoblastic leukemia (ALL). VCR cytotoxicity is primarily due to its ability to disrupt the formation of microtubules of the mitotic spindle. Patients & methods: A total of 17 polymorphisms in regulatory and coding regions of genes controlling VCR targets (TUBB1, MAP4, ACTG1 and CAPG) or potentially influencing VCR levels (ABCB1 and CYP3A5) were investigated for an association with peripheral neuropathy and outcome in childhood ALL patients. Results: High-grade neurotoxicity was more frequent in carriers of the A allele of synonymous (Ala310) G to A (rs1135989) variation in the ACTG1 gene. Substitution (rs4728709) in the promoter of the ABCB1 gene had a protective effect against lower grade neurotoxicity and C to A variation (rs3770102) located 17 nucleotides upstream from the transcription start site had a protective effect against high-grade neurotoxicity. Patients with the ABCB1 3435TT genotype had lower event-free survival; the association with event-free survival was not supported by the analysis in the replication patient set. Conclusion: The polymorphisms in the ACTG1, CAPG and ABCB1 genes may modulate VCR-related neurotoxicity, whereas the risk of relapse seems not to be affected by the genes of the VCR pathway.
C1 [Ceppi, Francesco; Langlois-Pelletier, Chloe; Gagne, Vincent; Rousseau, Julie; Ciolino, Claire; De Lorenzo, Samanta; Kevin, Kojok M.; Cijov, Diana; Sinnett, Daniel; Laverdiere, Caroline; Krajinovic, Maja] CHU St Justine, Res Ctr, Montreal, PQ H3T 1C5, Canada.
[Sallan, Stephen E.; Silverman, Lewis B.] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA USA.
[Sallan, Stephen E.; Silverman, Lewis B.] Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
[Neuberg, Donna] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA USA.
[Kutok, Jeffery L.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
[Sinnett, Daniel; Laverdiere, Caroline; Krajinovic, Maja] Univ Montreal, Dept Pediat, Montreal, PQ H3C 3J7, Canada.
[Krajinovic, Maja] Univ Montreal, Dept Pharmacol, Montreal, PQ H3C 3J7, Canada.
RP Krajinovic, M (reprint author), CHU St Justine, Res Ctr, 3175 Chemin Cote Ste Catherine, Montreal, PQ H3T 1C5, Canada.
EM maja.krajinovic@umontreal.ca
FU Canadian Institutes of Health Research; Leukemia Lymphoma Society of
Canada; Charles Bruneau Foundation; Centre d'excellence en Oncologie
pediatrique et en soins palliatifs; National Cancer Institute/NIH [5
P01CA06848]
FX Canadian Institutes of Health Research, Leukemia Lymphoma Society of
Canada, Charles Bruneau Foundation, and Centre d'excellence en Oncologie
pediatrique et en soins palliatifs supported this study. Dana-Farber
Cancer Institute ALL treatment protocols are supported by the National
Cancer Institute/NIH grant 5 P01CA06848. The authors have no other
relevant affiliations or financial involvement with any organization or
entity with a financial interest in or financial conflict with the
subject matter or materials discussed in the manuscript apart from those
disclosed.
NR 52
TC 7
Z9 8
U1 0
U2 6
PU FUTURE MEDICINE LTD
PI LONDON
PA UNITEC HOUSE, 3RD FLOOR, 2 ALBERT PLACE, FINCHLEY CENTRAL, LONDON, N3
1QB, ENGLAND
SN 1462-2416
EI 1744-8042
J9 PHARMACOGENOMICS
JI Pharmacogenomics
PD JUN
PY 2014
VL 15
IS 8
BP 1105
EP 1116
DI 10.2217/PGS.14.68
PG 12
WC Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AM9YJ
UT WOS:000340236900009
PM 25084203
ER
PT J
AU Galland-Girodet, S
Maire, JP
De-Mones, E
Benech, J
Bouhoreira, K
Protat, B
Demeaux, H
Darrouzet, V
Huchet, A
AF Galland-Girodet, Sigolene
Maire, Jean-Philippe
De-Mones, Erwan
Benech, Julie
Bouhoreira, Kheireddine
Protat, Benoit
Demeaux, Helene
Darrouzet, Vincent
Huchet, Aymeri
TI The role of radiation therapy in the management of head and neck
paragangliomas: Impact of quality of life versus treatment response
SO RADIOTHERAPY AND ONCOLOGY
LA English
DT Article
DE Head and neck paragangliomas; Quality of life; Radiation therapy; Tumor
response
ID GLOMUS-JUGULARE TUMORS; INTENSITY-MODULATED RADIOTHERAPY; LOCAL-CONTROL;
EUROPEAN-ORGANIZATION; CANCER PATIENTS; TEMPORAL BONE; VAGALE TUMORS;
EORTC QLQ-C30; SURGERY; TOXICITY
AB Purpose: To assess the impact of radiotherapy in paragangliomas (PGLs) with regard to overall survival, local control, volumetric response and particularly quality of life (QoL).
Materials and methods: From 1985 to 2010, 130 cases of head and neck (H&N) PGLs were managed at Bordeaux University Hospital. With a median follow-up of 7.6 years, we retrospectively present a cohort of 30 consecutive patients treated with radiation therapy for H&N PGLs. QoL was evaluated for 20 patients by the EORTC QLQ-C30 and H&N35 questionnaires through a cross-sectional study.
Results: The 5-year overall survival and local control were 95% and 96% respectively. QoL is altered following management of PGLs. The H&N35 score is lower after combined modality therapy (surgery +/- embolization and radiation therapy) for speech and hearing (p = 0.004), trismus (p = 0.003) and total score (p = 0.01) than after radiotherapy alone. Tumor shrinkage was significant at 2 and 3 years after radiotherapy (p = 0.018; p = 0.043).
Conclusion: Ultimate QoL should be a major goal of any treatment strategy for this benign disease. Definitive radiotherapy should be considered as a reasonable alternative to multimodality treatment as it provides comparable disease control with an apparent improvement in QoL. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
C1 [Galland-Girodet, Sigolene; Maire, Jean-Philippe; Darrouzet, Vincent] Univ Bordeaux, Bordeaux, France.
[Galland-Girodet, Sigolene; Maire, Jean-Philippe; Benech, Julie; Bouhoreira, Kheireddine; Protat, Benoit; Demeaux, Helene; Huchet, Aymeri] CHU Bordeaux, Dept Radiat Oncol, Bordeaux, France.
[De-Mones, Erwan; Darrouzet, Vincent] CHU Bordeaux, Dept Otorhinolaryngol & Skull Base Surg, Bordeaux, France.
[Galland-Girodet, Sigolene] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiat Oncol, Boston, MA USA.
RP Galland-Girodet, S (reprint author), Polyclin Bordeaux Nord Aquitaine, Serv Radiotherapie Oncol Med, 15 Rue Claude Boucher, F-33000 Bordeaux, France.
EM dr.sgalland@bordeauxnord.com
NR 39
TC 2
Z9 2
U1 0
U2 1
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0167-8140
J9 RADIOTHER ONCOL
JI Radiother. Oncol.
PD JUN
PY 2014
VL 111
IS 3
BP 463
EP 467
DI 10.1016/j.radonc.2014.06.002
PG 5
WC Oncology; Radiology, Nuclear Medicine & Medical Imaging
SC Oncology; Radiology, Nuclear Medicine & Medical Imaging
GA AN0VO
UT WOS:000340302300023
PM 24996453
ER
PT J
AU Cattaneo, Z
Bona, S
Bauer, C
Silvanto, J
Herbert, AM
Vecchi, T
Merabet, LB
AF Cattaneo, Zaira
Bona, Silvia
Bauer, Corinna
Silvanto, Juha
Herbert, Andrew M.
Vecchi, Tomaso
Merabet, Lotfi B.
TI Symmetry Detection in Visual Impairment: Behavioral Evidence and Neural
Correlates
SO SYMMETRY-BASEL
LA English
DT Review
DE symmetry detection; blind; visual impairment; haptic; plasticity
ID LATERAL OCCIPITAL COMPLEX; MIRROR SYMMETRY; ELECTROPHYSIOLOGICAL
INDEXES; BILATERAL SYMMETRY; HAPTIC DISCRIMINATION; UNFAMILIAR DISPLAYS;
PROCESSING SYMMETRY; AMBLYOPIC VISION; WORKING-MEMORY; HUMAN BRAIN
AB Bilateral symmetry is an extremely salient feature for the human visual system. An interesting issue is whether the perceptual salience of symmetry is rooted in normal visual development. In this review, we discuss empirical work on visual and tactile symmetry detection in normally sighted and visually impaired individuals. On the one hand, available evidence suggests that efficient visual symmetry detection may need normal binocular vision development. On the other hand, converging evidence suggests that symmetry can develop as a principle of haptic perceptual organization in individuals lacking visual experience. Certain features of visual symmetry detection, however, such as the higher salience of the patterns containing a vertical axis of symmetry, do not systematically apply to the haptic modality. The neural correlates (revealed with neuroimaging) associated with visual and haptic symmetry detection are also discussed.
C1 [Cattaneo, Zaira] Univ Milano Bicocca, Dept Psychol, I-20126 Milan, Italy.
[Cattaneo, Zaira; Vecchi, Tomaso] Natl Neurol Inst C Mondino, Brain Connect Ctr, I-27100 Pavia, Italy.
[Bona, Silvia; Silvanto, Juha] Aalto Univ, Sch Sci, OV Lounasmaa Lab, Brain Res Unit, Espoo 02150, Finland.
[Bauer, Corinna; Merabet, Lotfi B.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Dept Ophthalmol,Lab Visual Neuroplast, Boston, MA 02115 USA.
[Silvanto, Juha] Univ Westminster, Fac Sci & Technol, Dept Psychol, London W1W 6UW, England.
[Herbert, Andrew M.] Rochester Inst Technol, Dept Psychol, Rochester, NY 14623 USA.
[Vecchi, Tomaso] Univ Pavia, Dept Brain & Behav Sci, I-27100 Pavia, Italy.
RP Cattaneo, Z (reprint author), Univ Milano Bicocca, Dept Psychol, I-20126 Milan, Italy.
EM zaira.cattaneo@unimib.it; silvia.bona@aalto.fi;
Corinna_Bauer@meei.harvard.edu; J.Silvanto@westminster.ac.uk;
amhgss@rit.edu; vecchi@unipv.it; Lotfi_Merabet@meei.harvard.edu
FU NIH/NEI [EY019924]; MIUR FIRB [RBFR12F0BD]
FX This work was supported by an NIH/NEI RO1 Grant EY019924 (L.B.M.) and by
a MIUR FIRB Grant RBFR12F0BD (Z.C.).
NR 74
TC 3
Z9 3
U1 1
U2 6
PU MDPI AG
PI BASEL
PA POSTFACH, CH-4005 BASEL, SWITZERLAND
SN 2073-8994
J9 SYMMETRY-BASEL
JI Symmetry-Basel
PD JUN
PY 2014
VL 6
IS 2
BP 427
EP 443
DI 10.3390/sym6020427
PG 17
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AM9KH
UT WOS:000340200000016
ER
PT J
AU Raffetto, JD
Mannello, F
AF Raffetto, J. D.
Mannello, F.
TI Pathophysiology of chronic venous disease
SO INTERNATIONAL ANGIOLOGY
LA English
DT Review
DE Genetics; Inflammation; Varicose veins; Venous ulcer; Microcirculation;
Extracellular matrix
ID VARICOSE-VEIN FORMATION; SMOOTH-MUSCLE-CELLS; CHRONIC LEG ULCERS;
MATRIX-METALLOPROTEINASE ACTIVITY; COLLAGEN TYPE-III;
EXTRACELLULAR-MATRIX; ELEVATED EXPRESSION; GENE POLYMORPHISMS; CYTOKINE
LEVELS; INSUFFICIENCY
AB Chronic venous disease (CVD) is a debilitating condition with a prevalence between 60-70%. The disease pathophysiology is complex and involves genetic susceptibility and environmental factors, with individuals developing visible telengiectasias, reticular veins, and varicose veins. Patient with significant lower extremity symptoms have pain, dermal irritation, swelling, skin changes, and are at risk of developing debilitating venous ulceration. The signature of CVD is an increase in venous pressure referred to as venous hypertension. The various symptoms presenting in CVD and the clinical signs that are observed indicate that there is inflammation, secondary to venous hypertension, and it leads to a number of inflammatory pathways that become activated. The endothelium and glycocalyx via specialized receptors are critical at sensing changes in shear stress, and expression of adhesion molecules allows the activation of leukocytes leading to endothelial attachment, diapedisis, and transmigration into the venous wall/valves resulting in venous wall injury and inflammatory cells in the interstitial tissues. There is a complex of cytokines, chemokines, growth factors, proteases and proteinases, produced by activated leukocytes, that are expressed and unbalanced resulting in an environment of persistent inflammation with the clinical changes that are commonly seen, consisting of varicose veins to more advanced presentations of skin changes and venous ulceration. The structural integrity of protein and the extracellular matrix is altered, enhancing the progressive events of CVD. Work focusing on metabolic changes, miRNA regulation, inflammatory modulation and the glycocalyx will further our knowledge in the pathophysiology of CVD, and provide answers critical to treatment and prevention.
C1 [Raffetto, J. D.] VA Boston Healthcare Syst, Div Vasc Surg, West Roxbury, MA USA.
[Raffetto, J. D.] Brigham & Womens Hosp, Div Vasc & Endovasc Surg, Boston, MA 02115 USA.
[Raffetto, J. D.] Harvard Univ, Sch Med, Boston, MA USA.
[Mannello, F.] Univ Carlo Bo, Sect Clin Biochem & Cell Biol, Dept Biomol Sci, Urbino, Italy.
RP Raffetto, JD (reprint author), VA Boston HCS, 1400 VFW Pkwy, West Roxbury, MA 02132 USA.
EM joseph.raffetto@med.va.gov
NR 59
TC 11
Z9 11
U1 0
U2 6
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 0392-9590
EI 1827-1839
J9 INT ANGIOL
JI Int. Angiol.
PD JUN
PY 2014
VL 33
IS 3
BP 212
EP 221
PG 10
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AM4XN
UT WOS:000339859600002
PM 24755829
ER
PT J
AU Mannello, F
Ligi, D
Raffetto, JD
AF Mannello, F.
Ligi, D.
Raffetto, J. D.
TI Glycosaminoglycan sulodexide modulates inflammatory pathways in chronic
venous disease
SO INTERNATIONAL ANGIOLOGY
LA English
DT Article
DE Glycosaminoglycans; Glycocalyx; Inflammation; Macrophages; Lymphocytes;
Interleukins; Cytokines Chemokines
ID HUMAN ENDOTHELIAL-CELLS; VARICOSE-VEINS; GLYCOCALYX; PATHOGENESIS;
ISCHEMIA/REPERFUSION; HYPERPOLARIZATION; INSUFFICIENCY; INFILTRATION;
HYPERTENSION; MECHANISMS
AB Inflammation represents an important epiphenomenon in the etiopathogenesis of chronic venous disease, a worldwide debilitating condition affecting millions of subjects. The pathophysiology of chronic venous disease (CVD) is based on the hemodynamic abnormalities in conjunction to alterations in cellular and extracellular matrix biocompounds. The endothelial dysfunction results from early perturbation in the endothelium linked to glycocalyx injury and promoted by inflammatory cells and mediators (such as matrix metalloproteinases and interleukins), which lead to progressive dilation of the vein resulting in chronic venous insufficiency. Activated leukocytes during the inflammatory process release enzymes, free radicals, chemokines and inflammatory cytokines in the vessel microenvironment, which are responsible for the changes of the venous wall and venous valve, reflux and venous hypertension, and the development/progression of tissue destruction and skin changes. Sulodexide, a highly purified mixture of glycosaminoglycans composed by 80% fast moving heparin and 20% of dermatan sulphate, exhibits anti-thrombotic and profibrinolytic properties, restoring also the essential endothelial glycocalyx. Glycosaminoglycan sulodexide has been also characterized to reduce the release of inflammatory cytokines/chemokines and to inhibit the matrix metalloproteinases-related proteolytic cascades, counteracting endothelial dysfunctions. The pleiotropic effects of sulodexide set the basis for a very promising agent in treating the spectrum of CVD.
C1 [Mannello, F.; Ligi, D.] Univ Carlo Bo, Sect Clin Biochem & Cell Biol, Dept Biomol Sci, Urbino, Italy.
[Raffetto, J. D.] VA Boston Healthcare Syst, Div Vasc Surg, West Roxbury, MA USA.
[Raffetto, J. D.] Brigham & Womens Hosp, Div Vasc & Endovasc Surg, Boston, MA 02115 USA.
[Raffetto, J. D.] Harvard Univ, Sch Med, Boston, MA USA.
RP Mannello, F (reprint author), Univ Carlo Bo, Sect Clin Biochem & Cell Biol, Dept Biomol Sci, Urbino, Italy.
EM ferdinando.mannello@uniurb.it
NR 53
TC 12
Z9 12
U1 0
U2 0
PU EDIZIONI MINERVA MEDICA
PI TURIN
PA CORSO BRAMANTE 83-85 INT JOURNALS DEPT., 10126 TURIN, ITALY
SN 0392-9590
EI 1827-1839
J9 INT ANGIOL
JI Int. Angiol.
PD JUN
PY 2014
VL 33
IS 3
BP 236
EP 242
PG 7
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AM4XN
UT WOS:000339859600005
PM 24936532
ER
PT J
AU Petryshen, T
AF Petryshen, T.
TI Roles of genetics-based animal models in drug development in bipolar
disorder
SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
LA English
DT Meeting Abstract
CT 29th CINP World Congress of Neuropsychopharmacology
CY JUN 22-26, 2014
CL Vancouver, CANADA
SP CINP
C1 [Petryshen, T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1461-1457
EI 1469-5111
J9 INT J NEUROPSYCHOPH
JI Int. J. Neuropsychopharmacol.
PD JUN
PY 2014
VL 17
SI 1
MA S-03-002
BP 5
EP 5
PG 1
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA AM3RB
UT WOS:000339769200017
ER
PT J
AU Fava, M
Lophaven, S
Olsen, C
AF Fava, M.
Lophaven, S.
Olsen, C.
TI Effects of vortioxetine on cognitive symptoms of major depressive
disorder (MDD)
SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
LA English
DT Meeting Abstract
CT 29th CINP World Congress of Neuropsychopharmacology
CY JUN 22-26, 2014
CL Vancouver, CANADA
SP CINP
C1 [Fava, M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Lophaven, S.; Olsen, C.] H Lundbeck & Co AS, Valby, Denmark.
NR 0
TC 1
Z9 1
U1 0
U2 3
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1461-1457
EI 1469-5111
J9 INT J NEUROPSYCHOPH
JI Int. J. Neuropsychopharmacol.
PD JUN
PY 2014
VL 17
SI 1
MA P-04-026
BP 61
EP 61
PG 1
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA AM3RB
UT WOS:000339769200243
ER
PT J
AU English, B
Johnstone, J
Johe, K
Gertsik, L
Sherman, M
Fava, M
Ereshefsky, L
AF English, B.
Johnstone, J.
Johe, K.
Gertsik, L.
Sherman, M.
Fava, M.
Ereshefsky, L.
TI Effects of NSI-189, a neurogenic compound, on quantitative
electroencephalography (qEEG) in patients with major depressive disorder
(MDD) during a phase 1b randomized, double-blind, placebo controlled,
multiple ascending dose study
SO INTERNATIONAL JOURNAL OF NEUROPSYCHOPHARMACOLOGY
LA English
DT Meeting Abstract
CT 29th CINP World Congress of Neuropsychopharmacology
CY JUN 22-26, 2014
CL Vancouver, CANADA
SP CINP
C1 [English, B.; Sherman, M.; Ereshefsky, L.] PAREXEL Int, Glendale, MA USA.
[Johnstone, J.] Q Metrx, Glendale, MA USA.
[Johe, K.] Neuralstem Inc, Rockville, MD USA.
[Gertsik, L.] Calif Clin Trials, Glendale, MA USA.
[Fava, M.] Massachusetts Gen Hosp, Dept Psychiat, MGH Clin Trials Network, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 2
U2 5
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1461-1457
EI 1469-5111
J9 INT J NEUROPSYCHOPH
JI Int. J. Neuropsychopharmacol.
PD JUN
PY 2014
VL 17
SI 1
MA P-32-003
BP 119
EP 119
PG 1
WC Clinical Neurology; Neurosciences; Pharmacology & Pharmacy; Psychiatry
SC Neurosciences & Neurology; Pharmacology & Pharmacy; Psychiatry
GA AM3RB
UT WOS:000339769200466
ER
PT J
AU Soltis, K
Acierno, R
Gros, DF
Yoder, M
Tuerk, PW
AF Soltis, Kathryn
Acierno, Ron
Gros, Daniel F.
Yoder, Matthew
Tuerk, Peter W.
TI Post-Traumatic Stress Disorder: Ethical and Legal Relevance to the
Criminal Justice System
SO JOURNAL OF LAW MEDICINE & ETHICS
LA English
DT Article
ID NATIONAL COMORBIDITY SURVEY; INTERNATIONAL CONSENSUS GROUP;
COGNITIVE-PROCESSING THERAPY; MENTAL-HEALTH-SERVICES; PROLONGED
EXPOSURE; PSYCHIATRIC-DISORDERS; MILITARY PERSONNEL; RISK-FACTORS; US
VETERANS; GULF-WAR
C1 [Soltis, Kathryn] Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, Charleston, SC 29425 USA.
[Acierno, Ron; Tuerk, Peter W.] Ralph H Johnson VA Med Ctr, PTSD Clin Team, Charleston, SC USA.
[Acierno, Ron] Med Univ S Carolina, Coll Nursing, Charleston, SC USA.
[Gros, Daniel F.] Ralph H Johnson VAMC, Mental Hlth Primary Care Integrat Program, Charleston, SC USA.
[Gros, Daniel F.; Yoder, Matthew; Tuerk, Peter W.] MUSC, Dept Psychiat & Behav Sci, Charleston, SC USA.
[Yoder, Matthew] Ralph H Johnson Vet Affairs Med Ctr, Posttraumat Stress Clin, Charleston, SC USA.
[Tuerk, Peter W.] APA Accredited MUSC VA Psychol Internship Program, Charleston, SC USA.
RP Soltis, K (reprint author), Med Univ S Carolina, Natl Crime Victims Res & Treatment Ctr, Charleston, SC 29425 USA.
NR 81
TC 2
Z9 2
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1073-1105
EI 1748-720X
J9 J LAW MED ETHICS
JI J. Law Med. Ethics
PD SUM
PY 2014
VL 42
IS 2
SI SI
BP 147
EP 154
DI 10.1111/jlme.12130
PG 8
WC Ethics; Law; Medical Ethics; Medicine, Legal
SC Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal
Medicine
GA AM2XI
UT WOS:000339714400006
PM 25040378
ER
PT J
AU Hamner, MB
AF Hamner, Mark B.
TI The Role of PTSD in Adjudicating Violent Crimes
SO JOURNAL OF LAW MEDICINE & ETHICS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; DOMESTIC VIOLENCE; ABUSE; PREVALENCE;
VICTIMS
C1 [Hamner, Mark B.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Hamner, Mark B.] Ralph H Johnson VA Med Ctr, PTSD Clin, Charleston, SC USA.
[Hamner, Mark B.] Amer Psychiat Assoc, Washington, DC 20005 USA.
RP Hamner, MB (reprint author), Med Univ S Carolina, Charleston, SC 29425 USA.
NR 19
TC 2
Z9 2
U1 1
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1073-1105
EI 1748-720X
J9 J LAW MED ETHICS
JI J. Law Med. Ethics
PD SUM
PY 2014
VL 42
IS 2
SI SI
BP 155
EP 160
DI 10.1111/jlme.12131
PG 6
WC Ethics; Law; Medical Ethics; Medicine, Legal
SC Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal
Medicine
GA AM2XI
UT WOS:000339714400007
PM 25040379
ER
PT J
AU Wangelin, BC
Tuerk, PW
AF Wangelin, Bethany C.
Tuerk, Peter W.
TI PTSD in Active Combat Soldiers: To Treat or Not to Treat
SO JOURNAL OF LAW MEDICINE & ETHICS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; PROLONGED EXPOSURE THERAPY; OPERATION
IRAQI FREEDOM; NATIONAL-GUARD SOLDIERS; HEALTH TREATMENT-SEEKING;
MENTAL-HEALTH; PSYCHOLOGICAL SYMPTOMS; MARITAL SATISFACTION; TREATMENT
SERVICES; VIETNAM VETERANS
C1 [Wangelin, Bethany C.; Tuerk, Peter W.] Ralph H Johnson VA Med Ctr, PTSD Clin Team, Charleston, SC 29401 USA.
[Tuerk, Peter W.] Med Univ S Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA.
[Tuerk, Peter W.] APA Accredited MUSC VA Psychol Internship Program, Charleston, SC USA.
RP Wangelin, BC (reprint author), Ralph H Johnson VA Med Ctr, PTSD Clin Team, Charleston, SC 29401 USA.
NR 81
TC 2
Z9 2
U1 1
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1073-1105
EI 1748-720X
J9 J LAW MED ETHICS
JI J. Law Med. Ethics
PD SUM
PY 2014
VL 42
IS 2
SI SI
BP 161
EP 170
DI 10.1111/jlme.12132
PG 10
WC Ethics; Law; Medical Ethics; Medicine, Legal
SC Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal
Medicine
GA AM2XI
UT WOS:000339714400008
PM 25040380
ER
PT J
AU Hwong, AR
Qaragholi, N
Carpenter, D
Joffe, S
Campbell, EG
Lehmann, LS
AF Hwong, Alison R.
Qaragholi, Noor
Carpenter, Daniel
Joffe, Steven
Campbell, Eric G.
Lehmann, Lisa Soleymani
TI A Systematic Review of State and Manufacturer Physician Payment
Disclosure Websites: Implications for Implementation of the Sunshine Act
SO JOURNAL OF LAW MEDICINE & ETHICS
LA English
DT Article
ID CONFLICTS-OF-INTEREST; INDUSTRY; TRANSPARENCY; LAWS
C1 [Hwong, Alison R.; Campbell, Eric G.; Lehmann, Lisa Soleymani] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Hwong, Alison R.] Harvard Univ, Grad Sch Arts & Sci, Cambridge, MA 02138 USA.
[Hwong, Alison R.] Harvard Univ, Edmond J Safra Ctr Eth, Cambridge, MA 02138 USA.
[Qaragholi, Noor] Univ Virginia, Charlottesville, VA USA.
[Carpenter, Daniel] Harvard Univ, Radcliffe Inst, Cambridge, MA 02138 USA.
[Joffe, Steven] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Campbell, Eric G.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA.
[Lehmann, Lisa Soleymani] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Hwong, AR (reprint author), Harvard Univ, Sch Med, Boston, MA 02115 USA.
OI Joffe, Steven/0000-0002-0667-7384
FU NIH [1UL1RR025758-01]; Safra Center for Ethics, Harvard University;
Brigham and Women's Hospital Department of Medicine
FX Supported by NIH 1UL1RR025758-01 (LSL, SJ), the Safra Center for Ethics,
Harvard University (LSL, DC) and Brigham and Women's Hospital Department
of Medicine (LSL).
NR 22
TC 4
Z9 4
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1073-1105
EI 1748-720X
J9 J LAW MED ETHICS
JI J. Law Med. Ethics
PD SUM
PY 2014
VL 42
IS 2
SI SI
BP 208
EP 219
DI 10.1111/jlme.12136
PG 12
WC Ethics; Law; Medical Ethics; Medicine, Legal
SC Social Sciences - Other Topics; Government & Law; Medical Ethics; Legal
Medicine
GA AM2XI
UT WOS:000339714400012
PM 25040384
ER
PT J
AU Healy, DY
Leopold, DA
Gray, ST
Holbrook, EH
AF Healy, David Y., Jr.
Leopold, Donald A.
Gray, Stacey T.
Holbrook, Eric H.
TI The Perforation Technique: A Modification to the Frontal Sinus
Osteoplastic Flap
SO LARYNGOSCOPE
LA English
DT Editorial Material
DE Frontal sinus; external approaches; bossing
ID FAT OBLITERATION; OPERATIONS; SURGERY
C1 [Healy, David Y., Jr.; Gray, Stacey T.; Holbrook, Eric H.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol Head & Neck Surg, Boston, MA 02114 USA.
[Healy, David Y., Jr.; Gray, Stacey T.; Holbrook, Eric H.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
[Leopold, Donald A.] Univ Vermont, Dept Otolaryngol Head & Neck Surg, Burlington, VT USA.
RP Healy, DY (reprint author), Naval Med Ctr Portsmouth, Dept Otolaryngol Head & Neck Surg, 620 John Paul Jones Circle, Portsmouth, VA 23708 USA.
EM dyhealy@hotmail.com
NR 6
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0023-852X
EI 1531-4995
J9 LARYNGOSCOPE
JI Laryngoscope
PD JUN
PY 2014
VL 124
IS 6
BP 1314
EP 1317
DI 10.1002/lary.24460
PG 4
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA AL9SF
UT WOS:000339480400018
PM 24122789
ER
PT J
AU Carter, MS
Lookabaugh, S
Lee, DJ
AF Carter, Margaret S.
Lookabaugh, Sarah
Lee, Daniel J.
TI Endoscopic-Assisted Repair of Superior Canal Dehiscence Syndrome
SO LARYNGOSCOPE
LA English
DT Editorial Material
DE superior canal dehiscence syndrome; SCD; SCDS; endoscopy; middle fossa
craniotomy
ID SURGICAL-MANAGEMENT; SKULL BASE; BONE; SURGERY
C1 [Carter, Margaret S.; Lookabaugh, Sarah; Lee, Daniel J.] Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Boston, MA 02114 USA.
[Carter, Margaret S.; Lookabaugh, Sarah; Lee, Daniel J.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
RP Lee, DJ (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, 243 Charles St, Boston, MA 02114 USA.
EM daniel_lee@meei.harvard.edu
NR 17
TC 8
Z9 8
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0023-852X
EI 1531-4995
J9 LARYNGOSCOPE
JI Laryngoscope
PD JUN
PY 2014
VL 124
IS 6
BP 1464
EP 1468
DI 10.1002/lary.24523
PG 5
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA AL9SF
UT WOS:000339480400043
PM 24403248
ER
PT J
AU Phelan, E
Schneider, R
Lorenz, K
Dralle, H
Kamani, D
Potenza, A
Sritharan, N
Shin, J
Randolph, GW
AF Phelan, Eimear
Schneider, Rick
Lorenz, Kerstin
Dralle, Henning
Kamani, Dipti
Potenza, Andre
Sritharan, Niranjan
Shin, Jenifer
Randolph, Gregory W.
TI Continuous Vagal IONM Prevents Recurrent Laryngeal Nerve Paralysis by
Revealing Initial EMG Changes of Impending Neuropraxic Injury: A
Prospective, Multicenter Study
SO LARYNGOSCOPE
LA English
DT Article
DE Continuous vagal monitoring; CIONM; vagal electrodes; recurrent
laryngeal nerve paralysis; recurrent laryngeal nerve injury; vocal cord
paralysis; adverse EMG changes; neuromonitoring; IONM; thyroid surgery;
combined events; amplitude and latency changes
ID THYROID-SURGERY; PARATHYROID SURGERY; ENDOCRINE SURGEONS; ANCHOR
ELECTRODE; STIMULATION; PALSY; IDENTIFICATION; COMPLICATIONS;
ASSOCIATION; STATEMENT
AB Objectives/Hypothesis: Existing intraoperative neuromonitoring (IONM) formats stimulate the recurrent laryngeal nerve (RLN) intermittently, exposing it to risk for injury in between stimulations. We report electrophysiologic parameters of continuous vagal monitoring, utilizing a novel real-time IONM format, and relate these parameters to intraoperative surgical maneuvers that delineate nascent adverse but reversible electrophysiologic parameters to prevent nerve injury. These results are correlated with postoperative vocal cord functional outcome.
Study Design: Prospective multicenter tertiary study.
Method: Evoked vagal nerve waveform amplitude and latency changes during 102 thyroidectomies were recorded. Adverse electrophysiologic response was categorized into 1-concordant amplitude reduction and latency increase events (combined events) and 2-loss of signal (LOS). Surgical maneuvers were modified when adverse electrophysiologic findings were noted. All patients underwent preoperative and postoperative laryngoscopy; intraoperative electrophysiologic findings were correlated with postoperative laryngeal function.
Results: Continuous vagal monitoring did not result in stimulation-evoked nerve injury or intraoperative adverse cardiac, pulmonary, or gastrointestinal effects. Both intraoperative combined events and LOS were associated with development of vocal cord paralysis (VCP) (P=0.001 and P >0.001 respectively). Combined events had a positive predictive value (PPV) of 33%, negative predictive value (NPV) of 97%, and were reversible in 73%. LOS had a PPV of 83%, NPV of 98%, and was reversible in only 17%. Milder combined events and isolated amplitude or latency changes were not associated with VCP.
Conclusions: Continuous vagal monitoring is safe and provides real-time RLN evaluation during surgical maneuvers. Combined events and LOS, both easily identifiable intraoperatively, are related to the development of VCP. A combined event represents a largely reversible electrophysiologic change when the associated surgical maneuver is aborted. If allowed to continue, it can advance to LOS (which typically is significantly less reversible) and to postoperative VCP. Continuous vagal monitoring has utility in identifying real-time adverse concordant amplitude and latency changes (combined events), which can prompt modification of the associated surgical maneuver and may prevent RLN paralysis during thyroidectomy.
C1 [Phelan, Eimear; Kamani, Dipti; Potenza, Andre; Sritharan, Niranjan; Shin, Jenifer; Randolph, Gregory W.] Massachusetts Eye & Ear Infirm, Dept Otol & Laryngol, Div Thyroid & Parathyroid Surg, Boston, MA 02114 USA.
[Randolph, Gregory W.] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp,Div Surg Oncol, Boston, MA 02115 USA.
[Schneider, Rick; Dralle, Henning] Univ Halle Wittenberg, Div Gen Visceral & Vasc Surg, D-06108 Halle, Germany.
RP Randolph, GW (reprint author), Massachusetts Eye & Ear Infirm, Dept Otolaryngol, Div Thyroid & Parathyroid Surg, 243 Charles St, Boston, MA 02114 USA.
EM Gregory_Randolph@meei.harvard.edu
RI Shin, Jennifer/A-3169-2016
NR 43
TC 33
Z9 33
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0023-852X
EI 1531-4995
J9 LARYNGOSCOPE
JI Laryngoscope
PD JUN
PY 2014
VL 124
IS 6
BP 1498
EP 1505
DI 10.1002/lary.24550
PG 8
WC Medicine, Research & Experimental; Otorhinolaryngology
SC Research & Experimental Medicine; Otorhinolaryngology
GA AL9SF
UT WOS:000339480400049
PM 24307596
ER
PT J
AU Fritsch, EF
Hacohen, N
Wu, CJ
AF Fritsch, Edward F.
Hacohen, Nir
Wu, Catherine J.
TI Personal neoantigen cancer vaccines The momentum builds
SO ONCOIMMUNOLOGY
LA English
DT Editorial Material
DE neoantigen; vaccine; personalized; central tolerance; T cells
ID T-CELLS; PATIENT
AB Neoantigen-based cancer vaccines designed to target the unique immunogenic mutations arising in each patient's tumor are breathing new life into a struggling approach. Data continue to demonstrate the importance of neoantigens in immune control of cancer. Despite manufacturing complexity, outstanding questions and desired further improvements, neoantigen vaccines are currently undergoing clinical evaluation.
C1 [Fritsch, Edward F.; Hacohen, Nir; Wu, Catherine J.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
[Fritsch, Edward F.; Wu, Catherine J.] Dana Farber Canc Inst, Canc Vaccine Ctr, Dept Med Oncol, Boston, MA 02115 USA.
[Hacohen, Nir] Massachusetts Gen Hosp, Dept Med, Div Allergy Immunol & Rheumatol, Boston, MA 02114 USA.
[Wu, Catherine J.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dept Med, Boston, MA USA.
RP Wu, CJ (reprint author), Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
EM cwu@partners.org
NR 11
TC 16
Z9 16
U1 3
U2 9
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 2162-4011
EI 2162-402X
J9 ONCOIMMUNOLOGY
JI OncoImmunology
PD JUN
PY 2014
VL 3
IS 6
AR e29311
DI 10.4161/onci.29311
PG 3
WC Oncology; Immunology
SC Oncology; Immunology
GA AM6EX
UT WOS:000339957200021
PM 25101225
ER
PT J
AU Miller, DM
Flaherty, KT
Tsao, H
AF Miller, David M.
Flaherty, Keith T.
Tsao, Hensin
TI Current status and future directions of molecularly targeted therapies
and immunotherapies for melanoma
SO SEMINARS IN CUTANEOUS MEDICINE AND SURGERY
LA English
DT Article
ID T-LYMPHOCYTE ANTIGEN-4; STAGE-III MELANOMA; METASTATIC MELANOMA;
ADJUVANT THERAPY; RAF INHIBITORS; PHASE-II; PEGYLATED
INTERFERON-ALPHA-2B; RECOMBINANT INTERLEUKIN-2; TUMOR MICROENVIRONMENT;
CANCER-IMMUNOTHERAPY
AB Key molecular and immunological insights over the past decade have radically changed the face of therapy in melanoma. Whereas 5 years ago, treatment for advanced melanoma was restricted to the alkylating agent da-carbazine and the immunostimulants interleukin-2 and interferon-alpha-2b, today the therapeutic menu includes precise therapies that target key determinants in oncogenic pathways and immune checkpoints. In this chapter, we will review the current status and future directions of targeted therapies for melanoma directed at mitogen-activated pathways and immune checkpoints. (C) 2014 Frontline Medical Communications
C1 [Miller, David M.] Columbia Univ, Dept Dermatol, Med Ctr, New York, NY 10027 USA.
[Flaherty, Keith T.] Massachusetts Gen Hosp, Ctr Canc, Div Hematol Oncol, Boston, MA 02114 USA.
[Tsao, Hensin] Massachusetts Gen Hosp, Wellman Ctr Photomed, Boston, MA 02114 USA.
[Tsao, Hensin] Massachusetts Gen Hosp, MGH Canc Ctr, Dept Dermatol, Boston, MA 02114 USA.
RP Tsao, H (reprint author), Massachusetts Gen Hosp, Edwards 211,55 Fruit St, Boston, MA 02114 USA.
EM htsao@partners.org
NR 90
TC 6
Z9 6
U1 0
U2 2
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1085-5629
EI 1558-0768
J9 SEMIN CUTAN MED SURG
JI Semin. Cutan. Med. Surg.
PD JUN
PY 2014
VL 33
IS 2
BP 60
EP 67
PG 8
WC Dermatology; Surgery
SC Dermatology; Surgery
GA AM2VG
UT WOS:000339708300002
PM 25085663
ER
PT J
AU Steensma, DP
Montori, VM
Shampo, MA
Kyle, RA
AF Steensma, David P.
Montori, Victor M.
Shampo, Marc A.
Kyle, Robert A.
TI Daniel Alcides Carrion - Peruvian Hero and Medical Martyr
SO MAYO CLINIC PROCEEDINGS
LA English
DT Editorial Material
C1 [Steensma, David P.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Steensma, David P.] Harvard Univ, Sch Med, Boston, MA USA.
[Montori, Victor M.; Shampo, Marc A.; Kyle, Robert A.] Mayo Clin, Rochester, MN USA.
RP Steensma, DP (reprint author), Dana Farber Canc Inst, Boston, MA 02115 USA.
OI Montori, Victor/0000-0003-0595-2898
NR 0
TC 0
Z9 0
U1 0
U2 0
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0025-6196
EI 1942-5546
J9 MAYO CLIN PROC
JI Mayo Clin. Proc.
PD JUN
PY 2014
VL 89
IS 6
BP E55
EP E56
DI 10.1016/j.mayocp.2013.08.025
PG 2
WC Medicine, General & Internal
SC General & Internal Medicine
GA AL0VZ
UT WOS:000338846400002
PM 24943706
ER
PT J
AU Kraft, S
Granter, SR
AF Kraft, Stefan
Granter, Scott R.
TI Molecular Pathology of Skin Neoplasms of the Head and Neck
SO ARCHIVES OF PATHOLOGY & LABORATORY MEDICINE
LA English
DT Article
ID MERKEL-CELL-CARCINOMA; MUIR-TORRE-SYNDROME; TUMOR-SUPPRESSOR GENE;
BROOKE-SPIEGLER-SYNDROME; CUTANEOUS MALIGNANT-MELANOMA; IN-SITU
HYBRIDIZATION; NF-KAPPA-B; COMPARATIVE GENOMIC HYBRIDIZATION;
NONPOLYPOSIS COLORECTAL-CANCER; DNA MISMATCH REPAIR
AB Context.-Skin neoplasms include the most common malignancies affecting humans. Many show an ultraviolet (UV)-induced pathogenesis and often affect the head and neck region.
Objective.-To review literature on cutaneous neoplasms that show a predilection for the head and neck region and that are associated with molecular alterations.
Data Sources.-Literature review.
Conclusions.-Common nonmelanoma skin cancers, such as basal and squamous cell carcinomas, show a UV-induced pathogenesis. Basal cell carcinomas are characterized by molecular alterations of the Hedgehog pathway, affecting patched and smoothened genes. While squamous cell carcinomas show UV-induced mutations in several genes, driver mutations are only beginning to be identified. In addition, certain adnexal neoplasms also predominantly affect the head and neck region and show interesting, recently discovered molecular abnormalities, or are associated with hereditary conditions whose molecular genetic pathogenesis is well understood. Furthermore, recent advances have led to an increased understanding of the molecular pathogenesis of melanoma. Certain melanoma subtypes, such as lentigo maligna melanoma and desmoplastic melanoma, which are more often seen on the chronically sun-damaged skin of the head and neck, show differences in their molecular signature when compared to the other more common subtypes, such as superficial spreading melanoma, which are more prone to occur at sites with acute intermittent sun damage. In summary, molecular alterations in cutaneous neoplasms of the head and neck are often related to UV exposure. Their molecular footprint often reflects the histologic tumor type, and familiarity with these changes will be increasingly necessary for diagnostic and therapeutic considerations.
C1 [Kraft, Stefan] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Kraft, Stefan; Granter, Scott R.] Harvard Univ, Sch Med, Boston, MA USA.
[Granter, Scott R.] Brigham & Womens Hosp, Dept Pathol, Boston, MA 02115 USA.
RP Kraft, S (reprint author), Univ Med Ctr Hamburg Eppendorf, Dept Pathol, Martinistr 52, D-20246 Hamburg, Germany.
EM stefkraft@hotmail.com
NR 513
TC 10
Z9 10
U1 1
U2 7
PU COLL AMER PATHOLOGISTS
PI NORTHFIELD
PA C/O KIMBERLY GACKI, 325 WAUKEGAN RD, NORTHFIELD, IL 60093-2750 USA
SN 0003-9985
EI 1543-2165
J9 ARCH PATHOL LAB MED
JI Arch. Pathol. Lab. Med.
PD JUN
PY 2014
VL 138
IS 6
BP 759
EP 787
DI 10.5858/arpa.2013-0157-RA
PG 29
WC Medical Laboratory Technology; Medicine, Research & Experimental;
Pathology
SC Medical Laboratory Technology; Research & Experimental Medicine;
Pathology
GA AM1FP
UT WOS:000339592100009
PM 24878016
ER
PT J
AU Menendez, ME
Bot, AGJ
Neuhaus, V
Ring, D
Johnson, AH
AF Menendez, Mariano E.
Bot, Arjan G. J.
Neuhaus, Valentin
Ring, David
Johnson, A. Holly
TI Factors Influencing Discharge Disposition After Ankle Arthrodesis
SO FOOT & ANKLE INTERNATIONAL
LA English
DT Article
DE ankle arthrodesis; ankle fusion; discharge; hospital stay; risk factors
ID CARE RESOURCE UTILIZATION; UNITED-STATES; RISK-FACTORS;
PERIOPERATIVE-OUTCOMES; SURGERY EPIDEMIOLOGY; METABOLIC SYNDROME;
PATIENT OUTCOMES; HIP-ARTHROPLASTY; ELDERLY-PATIENTS; SPINE FUSION
AB Background: Although functional and morbidity outcomes following ankle arthrodesis have been widely studied, patterns of health care resource utilization remain unclear. The purpose of this study was to identify preoperative and postoperative risk factors for nonroutine discharge following ankle arthrodesis. A secondary study aim was to determine risk factors associated with prolonged hospital stay.
Methods: Using the National Health Discharge Survey (NHDS) database for the years 2001 through 2007, an estimated 40 941 patients having undergone ankle arthrodesis were identified and separated into those who were discharged to home (routine discharge) and those who were discharged to rehabilitation facilities (nonroutine discharge). Factors influencing discharge disposition and hospital length of stay were determined using multivariable binary logistic regression analysis.
Results: Risk factors for nonroutine discharge were increasing age, male sex, diabetes mellitus, atrial fibrillation, more than 1 general or surgery-related complication, additional days of care, and the 2005 to 2007 time period. Risk factors associated with prolonged hospital stay were advanced age, female sex, diabetes mellitus, more than 1 general or surgery-related complication, and the 2001 to 2004 time period.
Conclusion: Early identification of these factors might prove useful for better allocation of resources and implementation of effective strategies aimed at preventing longer hospitalizations and nonroutine discharges in selected patients at risk.
Level of Evidence: Level II, prognostic study.
C1 [Menendez, Mariano E.; Bot, Arjan G. J.; Neuhaus, Valentin] Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, Boston, MA 02114 USA.
[Ring, David] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Johnson, A. Holly] Harvard Univ, Sch Med, Boston, MA USA.
RP Menendez, ME (reprint author), Massachusetts Gen Hosp, Orthopaed Hand & Upper Extrem Serv, 55 Fruit St,Ste 2100, Boston, MA 02114 USA.
EM marianofurrer@gmail.com
OI Neuhaus, Valentin/0000-0003-4012-5628
NR 50
TC 3
Z9 3
U1 0
U2 2
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1071-1007
EI 1944-7876
J9 FOOT ANKLE INT
JI Foot Ankle Int.
PD JUN
PY 2014
VL 35
IS 6
BP 578
EP 583
DI 10.1177/1071100714528499
PG 6
WC Orthopedics
SC Orthopedics
GA AL7QN
UT WOS:000339329800007
PM 24677223
ER
PT J
AU Klinge, SA
McClure, P
Fellars, T
DiGiovanni, CW
AF Klinge, Stephen A.
McClure, Philip
Fellars, Todd
DiGiovanni, Christopher W.
TI Modification of the Weil/Maceira Metatarsal Osteotomy for Coronal Plane
Malalignment During Crossover Toe Correction: Case Series
SO FOOT & ANKLE INTERNATIONAL
LA English
DT Article
DE metatarsophalangeal joint; crossover toe deformity; instability;
metatarsal osteotomy
ID METATARSOPHALANGEAL JOINT INSTABILITY; BREVIS TENDON TRANSFER; 2ND TOE;
DEFORMITY; EXTENSOR; FLEXOR; PLATE; TIP
AB Background: Metatarsophalangeal joint (MPJ) instability, which often involves the second ray, may result in dorsal translation and coronal drift of the proximal phalanx, with subsequent crossover of the first and second toe. After traditionally described soft tissue and osteotomy procedures are used to treat this deformity, coronal plane malalignment may persist, but few additional surgical options have been described to address this problem.
Methods: We present a retrospective series of 5 patients who underwent a supplemental technique to augment coronal plane MPJ realignment. All patients underwent preplanned concomitant procedures. Crossover angulation of the second MPJ, amount of coronal translation required, and overall first-second ray alignment were compared pre- and postoperatively.
Results: Depending on the severity of refractory deformity after soft tissue release and decompressive metatarsal osteotomy, 1.5 to 4.5 mm of coronal plane metatarsal head translation was required to achieve 3 to 20 degrees of overall valgus correction at the MPJ and complete correction of the crossover toe deformity. All patients were satisfied and had good function at last follow-up, a mean of 10.2 months, although 3 patients exhibited some level of second MPJ stiffness. One patient ended up with a component of residual floating toe deformity that was considered more of an incomplete correction of dorsal MPJ subluxation rather than any technical complication of this translational osteotomy modification designed to primarily correct coronal plane malalignment. A second patient had asymptomatic angular malalignment through partial (coronal plane) malrotation of the metatarsal osteotomy before it had healed.
Conclusions: We have found this technique modification to be a very effective and simple means of treating recalcitrant lesser MPJ coronal plane malalignment when traditional soft tissue and bony techniques fail to fully restore anatomic MPJ position.
Level of Evidence: Level IV, retrospective case series.
C1 [Klinge, Stephen A.; McClure, Philip; Fellars, Todd] Brown Univ, Warren Alpert Sch Med, Providence, RI 02912 USA.
[DiGiovanni, Christopher W.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP DiGiovanni, CW (reprint author), Harvard Univ, Sch Med, Dept Orthopaed Surg, Yawkey Ctr Outpatient Care 55 Fruit St,Yaw 3F, Boston, MA 02114 USA.
EM CWDiGiovanni@MGH.Harvard.edu
NR 16
TC 1
Z9 1
U1 0
U2 3
PU SAGE PUBLICATIONS INC
PI THOUSAND OAKS
PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA
SN 1071-1007
EI 1944-7876
J9 FOOT ANKLE INT
JI Foot Ankle Int.
PD JUN
PY 2014
VL 35
IS 6
BP 584
EP 591
DI 10.1177/1071100714527745
PG 8
WC Orthopedics
SC Orthopedics
GA AL7QN
UT WOS:000339329800008
PM 24651712
ER
PT J
AU Thase, ME
AF Thase, Michael E.
TI Combining Cognitive Therapy and Pharmacotherapy for Depressive
Disorders: A Review of Recent Developments
SO INTERNATIONAL JOURNAL OF COGNITIVE THERAPY
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; BEHAVIORAL-ANALYSIS SYSTEM; MAJOR
DEPRESSION; RECURRENT DEPRESSION; BIPOLAR DISORDER; CHRONIC FORMS;
PSYCHOTHERAPY; MEDICATION; PREVENTION; NEFAZODONE
AB Cognitive Behavior Therapy (CBT) and pharmacotherapy, including antidepressants for depressive disorders and mood stabilizers for bipolar disorders, are effective and widely disseminated treatments that often are considered the first line of therapy for these common, yet potentially disabling conditions. Given the imperfect and often unpredictable effects of these treatments, as well as the obvious differences in the aspects of depressive syndromes that they target, there has been a longstanding and widespread belief that these strategies will have additive effects. After 30-plus years of research-and slow progress-it now seems reasonably clear that CBT and pharmacotherapy have a partially additive benefit for patients with depressive disorders; this effect is proposed to be largely explained by improving outcomes for patients who are less responsive to one or both of the monotherapies. This article summarizes the research literature, including newer studies that examining differential impact on neural circuits and the metabolic activity of relevant brain regions.
C1 [Thase, Michael E.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Thase, Michael E.] Univ Penn, Med Ctr, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.
RP Thase, ME (reprint author), 3535 Market St,Suite 670, Philadelphia, PA 19104 USA.
EM thase@mail.med.upenn.edu
NR 38
TC 1
Z9 1
U1 2
U2 23
PU GUILFORD PUBLICATIONS INC
PI NEW YORK
PA 72 SPRING STREET, NEW YORK, NY 10012 USA
SN 1937-1209
EI 1937-1217
J9 INT J COGN THER
JI Int. J. Cogn. Ther.
PD JUN
PY 2014
VL 7
IS 2
BP 108
EP 121
PG 14
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA AM1NI
UT WOS:000339612800002
ER
PT J
AU Crnej, A
Omoto, M
Dohlman, TH
Graney, JM
Dohlman, CH
Drnovsek-Olup, B
Dana, R
AF Crnej, Alja
Omoto, Masahiro
Dohlman, Thomas H.
Graney, John M.
Dohlman, Claes H.
Drnovsek-Olup, Brigita
Dana, Reza
TI A Novel Murine Model for Keratoprosthesis
SO INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE
LA English
DT Article
DE keratoprosthesis; murine model
ID BOSTON TYPE-1 KERATOPROSTHESIS; I KERATOPROSTHESIS; GLAUCOMA; SURGERY;
EYES; ENDOPHTHALMITIS; MULTICENTER; OUTCOMES; RISK
AB PURPOSE. To establish a murine model for keratoprosthesis.
METHODS. A miniature keratoprosthesis (m-KPro) device was created consisting of a poly[methyl methacrylate] front part and a titanium back plate, designed after the Boston KPro, which is in widespread clinical use. BALB/c mice were used and a 2 mm in diameter donor cornea was punched out. After 2-mm trepanation of the syngeneic recipient cornea, extracapsular crystalline lens extraction was performed. The m-KPro was assembled onto the cornea button in a similar manner to human KPro implantation. The cornea-device complex was secured to the recipient bed with eight interrupted 11-0 sutures. All mice (n = 10) were followed up for 8 weeks postoperatively.
RESULTS. All m-KPros were successfully implanted and retained in all 10 animals. There were no critical complications such as endophthalmitis, corneal melting, device extrusions, leakage, extensive inflammation, or weight loss in the animals. We observed mild to moderate donor and host corneal neovascularization in all cases throughout the follow-up period.
CONCLUSIONS. We have established a novel murine model of KPro implantation that we anticipate will serve as a good experimental system for evaluating host responses after KPro surgery.
C1 [Crnej, Alja; Omoto, Masahiro; Dohlman, Thomas H.; Dohlman, Claes H.; Dana, Reza] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA USA.
[Crnej, Alja; Omoto, Masahiro; Dohlman, Thomas H.; Dohlman, Claes H.; Dana, Reza] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA.
[Graney, John M.] JG Machine Co Inc, Wilmington, MA USA.
[Drnovsek-Olup, Brigita] Univ Eye Hosp, Univ Med Ctr, Ljubljana, Slovenia.
RP Dana, R (reprint author), Schepens Eye Res Inst, 20 Staniford St, Boston, MA 02114 USA.
EM reza_dana@meei.harvard.edu
FU Boston-KPro research fund; National Institutes of Health [EY12963]
FX Supported by the Boston-KPro research fund and the National Institutes
of Health (EY12963). The authors alone are responsible for the content
and writing of the paper.
NR 25
TC 3
Z9 3
U1 0
U2 1
PU ASSOC RESEARCH VISION OPHTHALMOLOGY INC
PI ROCKVILLE
PA 12300 TWINBROOK PARKWAY, ROCKVILLE, MD 20852-1606 USA
SN 0146-0404
EI 1552-5783
J9 INVEST OPHTH VIS SCI
JI Invest. Ophthalmol. Vis. Sci.
PD JUN
PY 2014
VL 55
IS 6
BP 3681
EP 3685
DI 10.1167/iovs.14-14058
PG 5
WC Ophthalmology
SC Ophthalmology
GA AL9TX
UT WOS:000339485800038
PM 24833747
ER
PT J
AU Kondo, K
Ishikado, A
Morino, K
Nishio, Y
Ugi, S
Kajiwara, S
Kurihara, M
Iwakawa, H
Nakao, K
Uesaki, S
Shigeta, Y
Imanaka, H
Yoshizaki, T
Sekine, O
Makino, T
Maegawa, H
King, GL
Kashiwagi, A
AF Kondo, Keiko
Ishikado, Atsushi
Morino, Katsutaro
Nishio, Yoshihiko
Ugi, Satoshi
Kajiwara, Sadae
Kurihara, Mika
Iwakawa, Hiromi
Nakao, Keiko
Uesaki, Syoko
Shigeta, Yasutami
Imanaka, Hiromichi
Yoshizaki, Takeshi
Sekine, Osamu
Makino, Taketoshi
Maegawa, Hiroshi
King, George L.
Kashiwagi, Atsunori
TI A high-fiber, low-fat diet improves periodontal disease markers in
high-risk subjects: a pilot study
SO NUTRITION RESEARCH
LA English
DT Article
DE Dietary fiber; Periodontal diseases; Obesity; Glucose tolerance test;
Prediabetic state; Intervention study
ID C-REACTIVE PROTEIN; ADIPONECTIN CONCENTRATION; DIABETES-MELLITUS;
NATIONAL-HEALTH; GLYCEMIC INDEX; OLDER-ADULTS; WEIGHT-LOSS; OBESITY;
JAPANESE; ATHEROSCLEROSIS
AB Periodontal disease is related to aging, smoking habits, diabetes mellitus, and systemic inflammation. However, there remains limited evidence about causality from intervention studies. An effective diet for prevention of periodontal disease has not been well established. The current study was an intervention study examining the effects of a high-fiber, low-fat diet on periodontal disease markers in high-risk subjects. Forty-seven volunteers were interviewed for recruitment into the study. Twenty-one volunteers with a body mass index of at least 25.0 kg/m(2) or with impaired glucose tolerance were enrolled in the study. After a 2- to 3-week run-in period, subjects were provided with a test meal consisting of high fiber and low fat (30 kcal/kg of ideal body weight) 3 times a day for 8 weeks and followed by a regular diet for 24 weeks. Four hundred twenty-five teeth from 17 subjects were analyzed. Periodontal disease markers assessed as probing depth (2.28 vs 2.21 vs 2.13 mm; P < .0001), clinical attachment loss (6.11 vs 6.06 vs 5.98 mm; P < .0001), and bleeding on probing (16.2 vs 13.2 vs 14.6%; P = .005) showed significant reductions after the test-meal period, and these improvements persisted until the follow-up period. Body weight (P < .0001), HbA1c (P < .0001), and high-sensitivity C-reactive protein (P = .038) levels showed improvement after the test-meal period; they returned to baseline levels after the follow-up period. In conclusion, treatment with a high-fiber, low-fat diet for 8 weeks effectively improved periodontal disease markers as well as metabolic profiles, at least in part, by effects other than the reduction of total energy intake. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Kondo, Keiko; Ishikado, Atsushi; Morino, Katsutaro; Ugi, Satoshi; Nakao, Keiko; Yoshizaki, Takeshi; Sekine, Osamu; Maegawa, Hiroshi; Kashiwagi, Atsunori] Shiga Univ Med Sci, Dept Med, Div Endocrinol & Metab, Otsu, Shiga 5202192, Japan.
[Ishikado, Atsushi; Uesaki, Syoko; Shigeta, Yasutami; Imanaka, Hiromichi; Makino, Taketoshi] Sunstar Inc, R&D Dept, Takatsuki, Osaka 5691195, Japan.
[Nishio, Yoshihiko] Kagoshima Univ, Dept Grad Sch Med & Dent Sci, Div Endocrinol Diabet & Metab, Kagoshima 8908544, Japan.
[Kajiwara, Sadae] Sunstar Fdn Oral Hlth Promot, Takatsuki, Osaka 5691195, Japan.
[Kurihara, Mika; Iwakawa, Hiromi] Shiga Univ Med Sci, Div Clin Nutr, Otsu, Shiga 5202192, Japan.
[King, George L.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Sect Vasc Cell Biol,Res Div, Boston, MA 02215 USA.
RP Ishikado, A (reprint author), Shiga Univ Med Sci, Dept Med, Div Endocrinol & Metab, Seta Tsuldnowa Cho, Otsu, Shiga 5202192, Japan.
EM kon@belle.shiga-med.ac.jp; ishikado@belle.shiga-med.ac.jp;
morino@belle.shiga-med.ac.jp; ynishio@m3.kufm.kagoshima-u.ac.jp;
sugi@belle.shiga-med.ac.jp; sadae.kajiwara@jp.sunstar.com;
kuri@belle.shiga-med.ac.jp; iwakawa@belle.shiga-med.ac.jp;
kein@belle.shiga-med.ac.jp; syoko.uesaki@jp.sunstar.com;
yasutami.shigeta@jp.sunstar.com; hiromichi.imanaka@jp.sunstar.com;
yosizaki@belle.shiga-med.ac.jp; sekine@belle.shiga-med.ac.jp;
taketoshi.makino@jp.sunstar.com; maegawa@belle.shiga-med.ac.jp;
george.king@joslin.harvard.edu; kasiwagi@belle.shiga-med.ac.jp
FU Department of Medicine, Shiga University of Medical Science; Sunstar;
Astellas Pharma; Boehringer-Mannheim; Dainippon Sumitomo Pharma;
Mitsubishi Tanabe Pharma Corporation; MSD; Pfizer; Sanofi; Takeda
Pharmaceutical Company; Teijin Pharma
FX We thank Mayumi Yamanaka and Shinya Koshinuma for their expert technical
assistance and the volunteers for their participation. This study was
funded by the Department of Medicine, Shiga University of Medical
Science, and also partially supported by Sunstar. The Department of
Medicine, Shiga University of Medical Science, received research
promotion grants (Shougaku Kifukin) from Astellas Pharma,
Boehringer-Mannheim, Dainippon Sumitomo Pharma, Mitsubishi Tanabe Pharma
Corporation, MSD, Pfizer, Sanofi, Takeda Pharmaceutical Company, and
Teijin Pharma. The research topics of these donation grants are not
restricted.
NR 38
TC 7
Z9 7
U1 1
U2 10
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0271-5317
J9 NUTR RES
JI Nutr. Res.
PD JUN
PY 2014
VL 34
IS 6
BP 491
EP 498
DI 10.1016/j.nutres.2014.06.001
PG 8
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AM1XF
UT WOS:000339641900004
PM 25026916
ER
PT J
AU Doran, KM
Curry, LA
Vashi, AA
Platis, S
Rowe, M
Gang, M
Vaca, FE
AF Doran, Kelly M.
Curry, Leslie A.
Vashi, Anita A.
Platis, Stephanie
Rowe, Michael
Gang, Maureen
Vaca, Federico E.
TI "Rewarding and Challenging at the Same Time": Emergency Medicine
Residents' Experiences Caring for Patients Who Are Homeless
SO ACADEMIC EMERGENCY MEDICINE
LA English
DT Article
ID SAFETY-NET EMERGENCY; STUDENTS ATTITUDES; CARE; PEOPLE; URBAN;
POPULATION; DEPARTMENTS; INTERVENTION; PHYSICIANS; LEARNERS
AB Objectives: The objectives were to examine how emergency medicine (EM) residents learn to care for patients in the emergency department (ED) who are homeless and how providing care for patients who are homeless influences residents' education and professional development as emergency physicians.
Methods: We conducted in-depth, one-on-one interviews with EM residents from two programs. A random sample of residents stratified by training year was selected from each site. Interviews were digitally recorded and professionally transcribed. A team of researchers with diverse content-relevant expertise reviewed transcripts independently and applied codes to text segments using a grounded theory approach. The team met regularly to reconcile differences in code interpretations. Data collection and analysis occurred iteratively, and interviews continued until theoretical saturation was achieved.
Results: Three recurring themes emerged from 23 resident interviews. First, residents learn unique aspects of EM by caring for patients who are homeless. This learning encompasses both specific knowledge and skills (e. g., disease processes infrequently seen in other populations) and professional development as an emergency physician (e. g., the core value of service in EM). Second, residents learn how to care for patients who are homeless through experience and informal teaching rather than through a formal curriculum. Residents noted little formal curricular time dedicated to homelessness and instead learned during clinical shifts through personal experience and by observing more senior physicians. One unique method of learning was through stories of "misses," in which patients who were homeless had bad outcomes. Third, caring for patients who are homeless affects residents emotionally in complex, multifaceted ways. Emotions were dominated by feelings of frustration. This frustration was often related to feelings of futility in truly helping homeless patients, particularly for patients who were frequent visitors to the ED and who had concomitant alcohol dependence.
Conclusions: Caring for ED patients who are homeless is an important part of EM residency training. Our findings suggest the need for increased formal curricular time dedicated to the unique medical and social challenges inherent in treating patients who are homeless, as well as enhanced support and resources to improve the ability of residents to care for this vulnerable population. Future research is needed to determine if such interventions improve EM resident education and, ultimately, result in improved care for ED patients who are homeless. (C) 2014 by the Society for Academic Emergency Medicine
C1 [Doran, Kelly M.; Vashi, Anita A.] Yale Univ, Sch Med, Robert Wood Johnson Fdn Clin Scholars Program, New Haven, CT USA.
[Doran, Kelly M.; Vashi, Anita A.] US Dept Vet Affairs, New Haven, CT USA.
[Doran, Kelly M.; Vashi, Anita A.; Vaca, Federico E.] Yale Univ, Sch Med, Dept Emergency Med, New Haven, CT USA.
[Curry, Leslie A.; Platis, Stephanie] Yale Univ, Sch Publ Hlth, New Haven, CT USA.
[Curry, Leslie A.] Yale Univ, Sch Med, Robert Wood Johnson Fdn RWJF Clin Scholars Progra, New Haven, CT USA.
[Rowe, Michael] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Doran, Kelly M.; Gang, Maureen] NYU, Bellevue Hosp Ctr, Sch Med, Dept Emergency Med, New York, NY 10016 USA.
RP Doran, KM (reprint author), NYU, Bellevue Hosp Ctr, Sch Med, Dept Emergency Med, New York, NY 10016 USA.
EM kelly.doran@nyumc.org
FU RWJF; U.S. Department of Veterans Affairs through the RWJF Clinical
Scholars Program
FX Financial support for this study was received from the RWJF and the U.S.
Department of Veterans Affairs through the RWJF Clinical Scholars
Program. The funder had no role in the study conduct or presentation of
the results.
NR 44
TC 1
Z9 1
U1 1
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1069-6563
EI 1553-2712
J9 ACAD EMERG MED
JI Acad. Emerg. Med.
PD JUN
PY 2014
VL 21
IS 6
BP 673
EP 679
DI 10.1111/acem.12388
PG 7
WC Emergency Medicine
SC Emergency Medicine
GA AL5GR
UT WOS:000339162200009
PM 25039552
ER
PT J
AU Li, PY
Tsai, TY
Li, JS
Zhang, Y
Kwon, YM
Rubash, HE
Li, GA
AF Li, Pingyue
Tsai, Tsung-Yuan
Li, Jing-Sheng
Zhang, Yu
Kwon, Young-Min
Rubash, Harry E.
Li, Guoan
TI Morphological measurement of the knee : race and sex effects
SO ACTA ORTHOPAEDICA BELGICA
LA English
DT Article
ID ANTHROPOMETRIC MEASUREMENTS; TIBIAL COMPONENT; PROXIMAL TIBIA;
ARTHROPLASTY; POPULATION; DESIGN; PROSTHESES; MORPHOMETRY; REPLACEMENT;
ANATOMY
AB Three-dimensional knee models of 148 Chinese (61 males, 87 female) and of 127 Caucasian (79 male, 48 female) were constructed. The anteroposterior (fAP, tAP) and mediolateral (fML, tML) dimensions of cross-section of the femur and tibia after simulated TKA bony resection were measured. Females have smaller femoral aspect ratios (fML/fAP) than males (Chinese : 1.22 +/- 0.05 vs 1.29 +/- 0.04; Caucasians : 1.18 +/- 0.05 vs 1.25 +/- 0.05) (P < 0.05). The tibial aspect ratios (tML/tAP) of the Chinese males (1.56 +/- 0.07) and the Caucasian females (1.54 +/- 0.07) are smaller than that of the Caucasian males (1.61 +/- 0.08) (P < 0.05). In regression analysis, for the same fAP or tAP dimension, females have narrower femoral condyles or tibia platforms than males; the Caucasian males have narrower femoral condyle or wider tibial platform than the Chinese males. For the same fAP dimension, males have lager tibial platforms than females; the Chinese males have larger tibial platforms than the Caucasian males. Racial and sex differences of the resected femur and tibia surfaces were found between a Chinese population and a Caucasian population. The relationship between the femur and tibia also showed racial and sex differences. These results may provide guidelines for future development of sex-specific as well as race-specific total knee replacement surgeries.
C1 [Li, Pingyue; Zhang, Yu] Guangzhou Gen Hosp Guangzhou Mil Command, Dept Orthopaed Surg, Guangzhou, Guangdong, Peoples R China.
[Tsai, Tsung-Yuan; Li, Jing-Sheng; Kwon, Young-Min; Rubash, Harry E.; Li, Guoan] Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA.
[Tsai, Tsung-Yuan; Li, Jing-Sheng; Kwon, Young-Min; Rubash, Harry E.; Li, Guoan] Harvard Univ, Sch Med, Boston, MA USA.
RP Li, GA (reprint author), Massachusetts Gen Hosp, Dept Orthopaed Surg, 55 Fruit St,GRJ 1215, Boston, MA 02114 USA.
EM Li.Guoan@mgh.harvard.edu
OI Tsai, Tsung-Yuan/0000-0003-1522-2987
NR 30
TC 3
Z9 4
U1 0
U2 1
PU ACTA MEDICA BELGICA
PI BRUSSELS
PA AVENUE WINSTON CHURCHILL, WINSTON CHURCHILL-LAAN, 11 BOX 30, B-1180
BRUSSELS, BELGIUM
SN 0001-6462
J9 ACTA ORTHOP BELG
JI Acta Orthop. Belg.
PD JUN
PY 2014
VL 80
IS 2
BP 260
EP 268
PG 9
WC Orthopedics
SC Orthopedics
GA AL8UL
UT WOS:000339415100017
PM 25090801
ER
PT J
AU Myaskovsky, L
Pleis, J
Dew, M
Switzer, G
Shapiro, R
AF Myaskovsky, L.
Pleis, J.
Dew, M.
Switzer, G.
Shapiro, R.
TI Race, Experience of Discrimination, and Other Non-Medical Factors
Predict Differences in Acceptance for Kidney Transplantation.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Myaskovsky, L.; Pleis, J.; Switzer, G.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Myaskovsky, L.; Pleis, J.; Dew, M.; Switzer, G.; Shapiro, R.] Univ Pittsburgh, Pittsburgh, PA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA B1197
BP 827
EP 827
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033303588
ER
PT J
AU Myaskovsky, L
Pleis, J
Ramkumar, M
Langone, A
Saha, S
Thomas, C
AF Myaskovsky, L.
Pleis, J.
Ramkumar, M.
Langone, A.
Saha, S.
Thomas, C.
TI Fewer Race Disparities in the National VA Kidney Transplant Program.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Myaskovsky, L.; Pleis, J.; Ramkumar, M.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Myaskovsky, L.; Pleis, J.; Ramkumar, M.] Univ Pittsburgh, Pittsburgh, PA USA.
[Langone, A.] VA Tennessee Valley Healthcare Syst, Nashville, TN USA.
[Saha, S.] Portland VA Med Ctr, Portland, OR 97239 USA.
[Thomas, C.] Iowa City VA Healthcare Syst, Iowa City, IA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA B1196
BP 827
EP 827
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033303587
ER
PT J
AU Blumenthal, KG
Youngster, I
Shenoy, ES
Banerji, A
Nelson, SB
AF Blumenthal, Kimberly G.
Youngster, Ilan
Shenoy, Erica S.
Banerji, Aleena
Nelson, Sandra B.
TI Tolerability of Cefazolin after Immune-Mediated Hypersensitivity
Reactions to Nafcillin in the Outpatient Setting
SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY
LA English
DT Article
ID PARENTERAL ANTIMICROBIAL THERAPY; STAPHYLOCOCCUS-AUREUS BACTEREMIA;
PENICILLIN-ALLERGIC PATIENTS; TOXIC EPIDERMAL NECROLYSIS;
STEVENS-JOHNSON SYNDROME; ACUTE INTERSTITIAL NEPHRITIS; BETA-LACTAM
ANTIBIOTICS; ADVERSE DRUG-REACTIONS; NONIMMEDIATE REACTIONS;
METHICILLIN-RESISTANT
AB The objective of the present study was to assess the safety and tolerability of cefazolin therapy among patients with methicillin-sensitive Gram-positive bacterial infections who develop non-IgE-mediated hypersensitivity reactions (HSRs) to nafcillin. In this retrospective cohort analysis of the Outpatient Parenteral Antimicrobial Therapy program at the Massachusetts General Hospital from 2007 through 2013, we identified patients switched from nafcillin to cefazolin after an immune-mediated HSR. We reviewed patient demographics, details about the original HSR, and outcomes after the switch to cefazolin therapy. HSRs were classified by reaction type and likely mechanism. There were 467 patients treated with nafcillin, of which 60 (12.8%) were switched to cefazolin during their prescribed course. Of the 60 patients who transitioned to cefazolin, 17 (28.3%) were switched because of non-IgE-mediated HSRs. HSRs included maculopapular rash (n = 10), immune-mediated nephritis (n = 3), isolated eosinophilia (n = 2), immune-mediated hepatitis (n = 1), and a serum sickness-like reaction (n = 1). All but one patient (94.1%) who switched to cefazolin tolerated the drug with resolution of the HSR and completed their therapy with cefazolin. No patient experienced worsening of their rash or progressive organ dysfunction. With appropriate monitoring, therapy with cefazolin after non-IgE-mediated HSRs to nafcillin appears to be safe.
C1 [Blumenthal, Kimberly G.; Banerji, Aleena] Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA.
[Blumenthal, Kimberly G.; Shenoy, Erica S.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Boston, MA 02114 USA.
[Blumenthal, Kimberly G.; Shenoy, Erica S.; Banerji, Aleena; Nelson, Sandra B.] Harvard Univ, Sch Med, Boston, MA USA.
[Youngster, Ilan] Boston Childrens Hosp, Dept Pediat, Div Infect Dis, Boston, MA USA.
[Youngster, Ilan; Shenoy, Erica S.; Nelson, Sandra B.] Massachusetts Gen Hosp, Dept Med, Div Infect Dis, Boston, MA 02114 USA.
[Shenoy, Erica S.] Massachusetts Gen Hosp, Infect Control Unit, Boston, MA 02114 USA.
RP Blumenthal, KG (reprint author), Massachusetts Gen Hosp, Dept Med, Div Rheumatol Allergy & Immunol, Boston, MA 02114 USA.
EM kblumenthal1@partners.org
RI Youngster, Ilan/J-5047-2014
OI Youngster, Ilan/0000-0001-5233-1213
FU NIAID NIH HHS [K01 AI110524]
NR 67
TC 4
Z9 4
U1 0
U2 0
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 0066-4804
EI 1098-6596
J9 ANTIMICROB AGENTS CH
JI Antimicrob. Agents Chemother.
PD JUN
PY 2014
VL 58
IS 6
BP 3137
EP 3143
DI 10.1128/AAC.02504-13
PG 7
WC Microbiology; Pharmacology & Pharmacy
SC Microbiology; Pharmacology & Pharmacy
GA AK9VP
UT WOS:000338776900018
PM 24637693
ER
PT J
AU Somarouthu, BS
Shinagare, AB
Rosenthal, MH
Tirumani, H
Hornick, JL
Ramaiya, NH
Tirumani, SH
AF Somarouthu, B. S.
Shinagare, A. B.
Rosenthal, M. H.
Tirumani, H.
Hornick, J. L.
Ramaiya, N. H.
Tirumani, S. H.
TI Multimodality imaging features, metastatic pattern and clinical outcome
in adult extraskeletal Ewing sarcoma: experience in 26 patients
SO BRITISH JOURNAL OF RADIOLOGY
LA English
DT Article
ID PRIMITIVE NEUROECTODERMAL TUMORS; FAMILY; DISEASE; PET/CT
AB Objective: To describe the multimodality imaging features, metastatic pattern and clinical outcome in adult extraskeletal Ewing sarcoma (EES).
Methods: In this institutional reviewboard-approved, health insurance portability and accountability act-compliant retrospective study, we included 26 patients (17 females and 9 males; mean age, 36 years; range, 18-85 years) with pathologically confirmed EES seen at our institute between 1999 and 2011, who had imaging of primary tumour. Imaging of primary tumour in all 26 patients and follow-up imaging in 23 was reviewed by two radiologists in consensus. Clinical data were extracted from electronic medical records.
Results: The most common primary sites were the torso (n = 13), extremities (n = 10) and head and neck (HN) region (n = 3). The mean tumour size was 9 cm (range, 3-22 cm); tumours of the torso were larger than those of other areas (p > 0.05). Compared with the skeletal muscle, tumours were isodense on CT (21/21), hypointense (n = 5) to isointense (n = 14) on T-1 weighted image, hyperintense on T-2 weighted image (19/19) and were fluorine-18 fludeoxyglucose (F-18-FDG)-avid [10/10; mean maximum standardized uptake value of 7 (range, 3-11)]. Necrosis (15/26), haemorrhage (5/26) and adjacent organ invasion (14/26) were present without calcification. Median follow-up was 16 months. 5 patients had local recurrence (torso, 3; extremity, 1; and HN, 1). Metastases developed in 11 patients (torso, 7; extremities, 3; and HN, 1;p > 0.05); 8 at presentation, most commonly to lung (9/11), peritoneum (4/11), muscles (4/11) and lymph nodes (4/11). Nine patients (torso, 7; extremity, 1; and HN, 1) died (10 months median survival) (p > 0.05).
Conclusion: Adult EESs are large tumours, which frequently invade adjacent organs and metastasize to the lung. EESs of the torso are larger, have more frequent metastases and poorer outcomes.
Advances in knowledge: Adult EESs of the torso have poor outcomes compared with other EESs.
C1 [Somarouthu, B. S.; Shinagare, A. B.; Rosenthal, M. H.; Tirumani, H.; Ramaiya, N. H.; Tirumani, S. H.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging, Boston, MA 02115 USA.
[Shinagare, A. B.; Rosenthal, M. H.; Ramaiya, N. H.; Tirumani, S. H.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Radiol, Boston, MA 02115 USA.
[Hornick, J. L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Tirumani, SH (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Imaging, 44 Binney St, Boston, MA 02115 USA.
EM sreeharsha_tirumani@DFCI.harvard.edu
RI Rosenthal, Michael/D-4080-2015
NR 21
TC 5
Z9 5
U1 0
U2 0
PU BRITISH INST RADIOLOGY
PI LONDON
PA 36 PORTLAND PLACE, LONDON W1N 4AT, ENGLAND
SN 0007-1285
EI 1748-880X
J9 BRIT J RADIOL
JI Br. J. Radiol.
PD JUN
PY 2014
VL 87
IS 1038
AR 20140123
DI 10.1259/bjr.20140123
PG 6
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AL6QC
UT WOS:000339256600019
PM 24734938
ER
PT J
AU Uher, R
Payne, JL
Pavlova, B
Perlis, RH
AF Uher, Rudolf
Payne, Jennifer L.
Pavlova, Barbara
Perlis, Roy H.
TI MAJOR DEPRESSIVE DISORDER IN DSM-5: IMPLICATIONS FOR CLINICAL PRACTICE
AND RESEARCH OF CHANGES FROM DSM-IV
SO DEPRESSION AND ANXIETY
LA English
DT Review
DE major depressive disorder; persistent depressive disorder;
classification; psychopathology; assessment; diagnosis
ID PREMENSTRUAL DYSPHORIC DISORDER; BEREAVEMENT-RELATED DEPRESSION;
POSTTRAUMATIC-STRESS-DISORDER; TEST-RETEST RELIABILITY; BIPOLAR
DISORDER; ANTIDEPRESSANT TREATMENT; HOPELESSNESS DEPRESSION; CHILDHOOD
MALTREATMENT; PSYCHIATRIC-DISORDERS; PERINATAL DEPRESSION
AB The changes in diagnostic criteria for major depressive disorder (MDD) from the fourth to the fifth edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM) may appear small but have important consequences for how the diagnosis is used. In DSM-5, MDD is part of the new "Depressive disorders" section, which is separate from "Bipolar disorders", marking a division in what had been known as "Mood disorders". A small wording change has expanded the core mood criterion to include hopelessness, potentially broadening the diagnosis. The replacement of an operationalized bereavement exclusion with a call for clinical judgment in distinguishing normal reactions to significant loss from a disorder in need of clinical attention makes the diagnosis less objective and complicates investigations of the relationship between adversity and depression. A new persistent depressive disorder category is intended to encompass both dysthymia and chronic depression, but its relationship to MDD is ambiguous with conflicting statements on whether the two diagnoses should be concurrent if both sets of criteria are fulfilled. Clarification is also needed on whether MDD can be concurrent with the new broad "other specified bipolar and related disorders". New specifiers of MDD "with anxious distress" and "with mixed features" allow characterization of additional symptoms. The specifier "with perinatal onset" expands on the DSM-IV "postnatal onset" to include onset during pregnancy. We review the changes in MDD definition, provide guidance on their implementation and discuss their implications for clinical practice and research. Depression and Anxiety 31: 459-471, 2014. (C) 2013 Wiley Periodicals, Inc.
C1 [Uher, Rudolf; Pavlova, Barbara] Dalhousie Univ, Dept Psychiat, Halifax, NS, Canada.
[Uher, Rudolf] Kings Coll London, Inst Psychiat, London WC2R 2LS, England.
[Payne, Jennifer L.] Johns Hopkins Sch Med, Dept Psychiat, Baltimore, MD USA.
[Perlis, Roy H.] Massachusetts Gen Hosp, Dept Psychiat, Ctr Expt Drugs & Diagnost, Boston, MA 02114 USA.
[Perlis, Roy H.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
RP Uher, R (reprint author), Mood Disorders Program, Abbie J Lane Bldg,3rd Floor,5909 Vet Mem Lane, Halifax, NS B3H 2E2, Canada.
EM uher@dal.ca
OI Uher, Rudolf/0000-0002-2998-0546
FU Corcept; Canada Research Chairs program
FX Contract grant sponsor: Corcept. Dr. Uher is supported by the Canada
Research Chairs program (http://www.chairs-chaires.gc.ca/)
NR 78
TC 32
Z9 34
U1 6
U2 51
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1091-4269
EI 1520-6394
J9 DEPRESS ANXIETY
JI Depress. Anxiety
PD JUN
PY 2014
VL 31
IS 6
BP 459
EP 471
DI 10.1002/da.22217
PG 13
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA AL3XZ
UT WOS:000339066600001
PM 24272961
ER
PT J
AU Stein, DJ
McLaughlin, KA
Koenen, KC
Atwoli, L
Friedman, MJ
Hill, ED
Maercker, A
Petukhova, M
Shahly, V
van Ommeren, M
Alonso, J
Borges, G
de Girolamo, G
de Jonge, P
Demyttenaere, K
Florescu, S
Karam, EG
Kawakami, N
Matschinger, H
Okoliyski, M
Posada-Villa, J
Scott, KM
Viana, MC
Kessler, RC
AF Stein, Dan J.
McLaughlin, Katie A.
Koenen, Karestan C.
Atwoli, Lukoye
Friedman, Matthew J.
Hill, Eric D.
Maercker, Andreas
Petukhova, Maria
Shahly, Victoria
van Ommeren, Mark
Alonso, Jordi
Borges, Guilherme
de Girolamo, Giovanni
de Jonge, Peter
Demyttenaere, Koen
Florescu, Silvia
Karam, Elie G.
Kawakami, Norito
Matschinger, Herbert
Okoliyski, Michail
Posada-Villa, Jose
Scott, Kate M.
Viana, Maria Carmen
Kessler, Ronald C.
TI DSM-5 AND ICD-11 DEFINITIONS OF POSTTRAUMATIC STRESS DISORDER:
INVESTIGATING "NARROW" AND "BROAD" APPROACHES
SO DEPRESSION AND ANXIETY
LA English
DT Article
DE Posttraumatic stress disorder; World Mental Health Surveys;
epidemiology; nosology; DSM-IV; DSM-5; ICD-10; ICD-11
ID CLINICAL-SIGNIFICANCE CRITERION; CONFIRMATORY FACTOR-ANALYSIS;
MENTAL-HEALTH; FRIEDMAN 2013; PTSD; SYMPTOMS; IMPACT; CLASSIFICATION;
COMORBIDITY; PROPOSALS
AB Background: The development of the Diagnostic and Statistical Manual of Mental Disorders 5th edition (DSM-5) and ICD-11 has led to reconsideration of diagnostic criteria for posttraumatic stress disorder (PTSD). The World Mental Health (WMH) Surveys allow investigation of the implications of the changing criteria compared to DSM-IV and ICD-10. Methods: WMH Surveys in 13 countries asked respondents to enumerate all their lifetime traumatic events (TEs) and randomly selected one TE per respondent for PTSD assessment. DSM-IV and ICD-10 PTSD were assessed for the 23,936 respondents who reported lifetime TEs in these surveys with the fully structured Composite International Diagnostic Interview (CIDI). DSM-5 and proposed ICD-11 criteria were approximated. Associations of the different criteria sets with indicators of clinical severity (distress-impairment, suicidality, comorbid fear-distress disorders, PTSD symptom duration) were examined to investigate the implications of using the different systems. Results: A total of 5.6% of respondents met criteria for "broadly defined" PTSD (i.e., full criteria in at least one diagnostic system), with prevalence ranging from 3.0% with DSM-5 to 4.4% with ICD-10. Only one-third of broadly defined cases met criteria in all four systems and another one third in only one system (narrowly defined cases). Between-system differences in indicators of clinical severity suggest that ICD-10 criteria are least strict and DSM-IV criteria most strict. The more striking result, though, is that significantly elevated indicators of clinical significance were found even for narrowly defined cases for each of the four diagnostic systems. Conclusions: These results argue for a broad definition of PTSD defined by any one of the different systems to capture all clinically significant cases of PTSD in future studies. Depression and Anxiety 31: 494-505, 2014. (C) 2014 Wiley Periodicals, Inc.
C1 [Stein, Dan J.] Univ Cape Town, Dept Psychiat & Mental Hlth, ZA-7925 Cape Town, South Africa.
[McLaughlin, Katie A.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA.
[Koenen, Karestan C.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA.
[Atwoli, Lukoye] Moi Univ, Dept Psychiat, Eldoret, Kenya.
[Friedman, Matthew J.] US Dept Vet Affairs, Natl Ctr PTSD, VA Med Ctr, White River Jct, VT USA.
[Hill, Eric D.; Petukhova, Maria; Kessler, Ronald C.] Harvard Univ, Sch Med, Dept Hlth Care Policy, Boston, MA 02115 USA.
[Maercker, Andreas; Shahly, Victoria] Univ Zurich, Dept Psychol, Div Psychopathol, CH-8006 Zurich, Switzerland.
[van Ommeren, Mark] WHO, Dept Mental Hlth & Subst Abuse, CH-1211 Geneva, Switzerland.
[Alonso, Jordi] Hosp Mar, IMIM, Hlth Serv Res Unit, Barcelona, Spain.
[Alonso, Jordi] CIBER Epidemol & Salud Publ CIBERESP, Barcelona, Spain.
[Borges, Guilherme] Natl Inst Psychiat Mexico, Dept Epidemiol Res, Div Epidemiol & Psychosocial Res, Mexico City, DF, Mexico.
[Borges, Guilherme] Metropolitan Autonomous Univ, Mexico City, DF, Mexico.
[de Girolamo, Giovanni] IRCCS Ctr S Giovanni Dio Fatebenefratelli, Brescia, Italy.
[de Jonge, Peter] Univ Groningen, Univ Med Ctr Groningen, Dept Psychiat PdJ, NL-9713 AV Groningen, Netherlands.
[Demyttenaere, Koen] Univ Hosp Gasthuisberg, Dept Psychiat, Leuven, Belgium.
[Florescu, Silvia] Natl Sch Publ Hlth Management & Profess Dev, Hlth Serv Res & Evaluat Ctr, Bucharest, Romania.
[Karam, Elie G.] Balamand Univ, St George Hosp Univ Med Ctr, Fac Med, IDRAAC,MIND, Beirut, Lebanon.
[Kawakami, Norito] Univ Tokyo, Sch Publ Hlth, Dept Mental Hlth, Tokyo, Japan.
[Matschinger, Herbert] Univ Leipzig, Inst Social Med Occupat Hlth & Publ Hlth, Publ Hlth Res Unit HM, D-04109 Leipzig, Germany.
[Okoliyski, Michail] Minist Hlth, Natl Ctr Publ Hlth & Anal, Dept Mental Hlth, Sofia, Bulgaria.
[Posada-Villa, Jose] Pontificia Univ Javeriana, Inst Colombiano Sistema Nervioso, Bogota, Colombia.
[Scott, Kate M.] Univ Otago, Dept Psychol Med, Dunedin, New Zealand.
[Viana, Maria Carmen] Univ Fed Espirito Santo, Dept Social Med, Vitoria, Brazil.
RP Stein, DJ (reprint author), Univ Cape Town, Groote Schuur Hosp, Dept Psychiat, J2,Anzio Rd, ZA-7925 Cape Town, South Africa.
EM dan.stein@uct.ac.za
RI Stein, Dan/A-1752-2008; Alonso, Jordi/A-5514-2010;
OI Stein, Dan/0000-0001-7218-7810; Alonso, Jordi/0000-0001-8627-9636;
Borges, Guilherme/0000-0002-3269-0507; Atwoli,
Lukoye/0000-0001-7710-9723; McLaughlin, Katie/0000-0002-1362-2410
FU United States National Institute of Mental Health [R01MH070884]; John D.
and Catherine T. MacArthur Foundation; Pfizer Foundation; US Public
Health Service [R13-MH066849, R01-MH069864, R01-MH092526, R01-DA016558];
Fogarty International Center [FIRCA R03-TW006481]; Pan American Health
Organization; Eli Lilly & Company Foundation; Ortho-McNeil
Pharmaceutical, Inc.; GlaxoSmithKline; Bristol-Myers Squibb; Shire
Pharmaceuticals; State of Sao Paulo Research Foundation (FAPESP)
[03/00204-3]; European Commission [QLG5-1999-01042, SANCO 2004123];
Piedmont Region; Fondo de Investigacion Sanitaria; Instituto de Salud
Carlos III [FIS 00/0028, CIBER CB06/02/0046, RETICS RD06/0011 REM-TAP];
Ministerio de Ciencia y Tecnologia, Spain [SAF 2000-158-CE]; Departament
de Salut, Generalitat de Catalunya; Japan Ministry of Health, Labour and
Welfare [H13-SHOGAI-023, H14-TOKUBETSU-026, H16-KOKORO-013]; National
Institute of Health/Fogarty International Center [R03 TW006481-01];
Astra Zeneca; Hikma Pharm; Janssen Cilag; MSD; Novartis; Sanofi Aventis;
Servier; National Institute of Psychiatry Ramon de la Fuente [INPRFMDIES
4280]; National Council on Science and Technology [CONACyT-G30544-H];
Health & Social Care Research & Development Division; Champalimaud
Foundation; Gulbenkian Foundation; Foundation for Science and Technology
(FCT); Ministry of Health; Ministry of Public Health; National Institute
of Mental Health (NIMH) [U01-MH60220]
FX Contract grant sponsor: United States National Institute of Mental
Health; Contract grant number: R01MH070884; Contract grant sponsor: John
D. and Catherine T. MacArthur Foundation; Contract grant sponsor: The
Pfizer Foundation; Contract grant sponsor: The US Public Health Service;
Contract grant numbers: R13-MH066849, R01-MH069864, R01-MH092526, and
R01-DA016558; Contract grant sponsor: Fogarty International Center;
Contract grant number: FIRCA R03-TW006481; Contract grant sponsor: The
Pan American Health Organization; Contract grant sponsor: the Eli Lilly
& Company Foundation; Contract grant sponsor: Ortho-McNeil
Pharmaceutical, Inc.; Contract grant sponsor: GlaxoSmithKline; Contract
grant sponsor: Bristol-Myers Squibb; Contract grant sponsor: Shire
Pharmaceuticals; Contract grant sponsor: State of Sao Paulo Research
Foundation (FAPESP) Thematic Project; Contract grant number: 03/00204-3;
Contract grant sponsor: European Commission; Contract grant numbers:
QLG5-1999-01042 and SANCO 2004123; Contract grant sponsor: The Piedmont
Region; Contract grant sponsor: Fondo de Investigacion Sanitaria;
Contract grant sponsor: Instituto de Salud Carlos III; Contract grant
number: FIS 00/0028; Contract grant sponsor: Ministerio de Ciencia y
Tecnologia, Spain; Contract grant number: SAF 2000-158-CE; Contract
grant sponsor: Departament de Salut, Generalitat de Catalunya; Contract
grant sponsor: Instituto de Salud Carlos III; Contract grant numbers:
CIBER CB06/02/0046 and RETICS RD06/0011 REM-TAP; Contract grant sponsor:
Japan Ministry of Health, Labour and Welfare; Contract grant numbers:
H13-SHOGAI-023, H14-TOKUBETSU-026, and H16-KOKORO-013; Contract grant
sponsor: National Institute of Health/Fogarty International Center;
Contract grant number: R03 TW006481-01; Contract grant sponsor: Astra
Zeneca; Contract grant sponsor: Hikma Pharm; Contract grant sponsor:
Janssen Cilag; Contract grant sponsor: MSD; Contract grant sponsor:
Novartis; Contract grant sponsor: Sanofi Aventis; Contract grant
sponsor: Servier; Contract grant sponsor: The National Institute of
Psychiatry Ramon de la Fuente; Contract grant number: INPRFMDIES 4280;
Contract grant sponsor: National Council on Science and Technology;
Contract grant number: CONACyT-G30544-H; Contract grant sponsor: Health
& Social Care Research & Development Division; Contract grant sponsor:
Champalimaud Foundation; Contract grant sponsor: Gulbenkian Foundation;
Contract grant sponsor: Foundation for Science and Technology (FCT);
Contract grant sponsor: Ministry of Health; Contract grant sponsor:
Ministry of Public Health (former Ministry of Health); Contract grant
sponsor: National Institute of Mental Health (NIMH); Contract grant
number: U01-MH60220.
NR 40
TC 30
Z9 30
U1 5
U2 37
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1091-4269
EI 1520-6394
J9 DEPRESS ANXIETY
JI Depress. Anxiety
PD JUN
PY 2014
VL 31
IS 6
BP 494
EP 505
DI 10.1002/da.22279
PG 12
WC Psychology, Clinical; Psychiatry; Psychology
SC Psychology; Psychiatry
GA AL3XZ
UT WOS:000339066600005
PM 24894802
ER
PT J
AU West, AM
Bittner, EA
Ortiz, VE
AF West, Amy M.
Bittner, Edward A.
Ortiz, Vilma E.
TI The effects of preoperative, video-assisted anesthesia education in
Spanish on Spanish-speaking patients' anxiety, knowledge, and
satisfaction: a pilot study
SO JOURNAL OF CLINICAL ANESTHESIA
LA English
DT Article
DE General anesthesia; Limited English proficiency (LEP); Patient anxiety,
preoperative; Preoperative interview; Spanish-speaking patients; Video
instruction
ID RANDOMIZED CONTROLLED-TRIAL; INFORMATION; INTERVIEW
AB We studied the effect of an instructional video in Spanish on self-reported anxiety, knowledge about general anesthesia procedures, and satisfaction with the preoperative anesthesia process in patients requiring a Spanish interpreter. This prospective, randomized, nonblinded pilot study took place at Massachusetts General Hospital (MGH), a university-affiliated tertiary-care hospital. Twenty adult, ASA physical status 1, 2, and 3 patients, scheduled for elective surgery (gynecological, orthopedic, and intrabdominal surgery) during general anesthesia were studied. Anxiety, knowledge, and patient satisfaction were assessed using a visual analog scale (VAS). There was a significant reduction in anxiety score in patients who viewed the video compared with those who did not (median reduction 2 vs 0; P = 0.020). There was an increase in satisfaction score in the video group (median increase 2 vs 0; P = 0.046). There was no difference in reported knowledge-improvement scores between the two groups (3.5 vs 4; P = 0.908). In Spanish-speaking patients, the addition of an instructional video in Spanish to a preanesthesia interview decreased anxiety and increased patient satisfaction. (C) 2014 Elsevier Inc. All rights reserved.
C1 [West, Amy M.; Bittner, Edward A.; Ortiz, Vilma E.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Bittner, Edward A.; Ortiz, Vilma E.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
RP West, AM (reprint author), 154 Harvard St,Apt 7, Brookline, MA 02446 USA.
EM amy_west@hms.harvard.edu
FU Student National Medical Association, Washington, DC [20011]; summer
internship at the Department of Anesthesia, Critical Care, and Pain
Medicine, Massachusetts General Hospital, Boston, MA
FX Supported by a David E. Satcher, MD, PhD fellowship, Student National
Medical Association, Washington, DC 20011; and a summer internship at
the Department of Anesthesia, Critical Care, and Pain Medicine,
Massachusetts General Hospital, Boston, MA.
NR 13
TC 2
Z9 2
U1 1
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0952-8180
EI 1873-4529
J9 J CLIN ANESTH
JI J. Clin. Anesth.
PD JUN
PY 2014
VL 26
IS 4
BP 325
EP 329
DI 10.1016/j.jclinane.2013.12.008
PG 5
WC Anesthesiology
SC Anesthesiology
GA AL7IL
UT WOS:000339307300014
PM 24882604
ER
PT J
AU Brown, MC
AF Brown, M. Christian
TI Single-unit labeling of medial olivocochlear neurons: the cochlear
frequency map for efferent axons
SO JOURNAL OF NEUROPHYSIOLOGY
LA English
DT Article
DE cochlear amplifier; outer hair cell; masking; acoustic protection;
descending system
ID AUDITORY-NERVE FIBERS; GUINEA-PIG COCHLEA; BASILAR-MEMBRANE MOTION;
EMISSION FINE-STRUCTURE; 2-TONE SUPPRESSION; TONOTOPIC ORGANIZATION;
RESPONSE PROPERTIES; STIMULUS VARIABLES; STIMULATION; CAT
AB Medial olivocochlear (MOC) neurons are efferent neurons that project axons from the brain to the cochlea. Their action on outer hair cells reduces the gain of the "cochlear amplifier," which shifts the dynamic range of hearing and reduces the effects of noise masking. The MOC effects in one ear can be elicited by sound in that ipsilateral ear or by sound in the contralateral ear. To study how MOC neurons project onto the cochlea to mediate these effects, single-unit labeling in guinea pigs was used to study the mapping of MOC neurons for neurons responsive to ipsilateral sound vs. those responsive to contralateral sound. MOC neurons were sharply tuned to sound frequency with a well-defined characteristic frequency (CF). However, their labeled termination spans in the organ of Corti ranged from narrow to broad, innervating between 14 and 69 outer hair cells per axon in a "patchy" pattern. For units responsive to ipsilateral sound, the midpoint of innervation was mapped according to CF in a relationship generally similar to, but with more variability than, that of auditory-nerve fibers. Thus, based on CF mappings, most of the MOC terminations miss outer hair cells involved in the cochlear amplifier for their CF, which are located more basally. Compared with ipsilaterally responsive neurons, contralaterally responsive neurons had an apical offset in termination and a larger span of innervation (an average of 10.41% cochlear distance), suggesting that when contralateral sound activates the MOC reflex, the actions are different than those for ipsilateral sound.
C1 [Brown, M. Christian] Massachusetts Eye & Ear Infirm, Eaton Peabody Labs, Boston, MA 02114 USA.
[Brown, M. Christian] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
RP Brown, MC (reprint author), Massachusetts Eye & Ear Infirm, Eaton Peabody Lab, 243 Charles St, Boston, MA 02114 USA.
EM Chris_Brown@meei.harvard.edu
FU National Institute of Child Health and Human Development [DC-01089]
FX This work was supported by National Institute of Child Health and Human
Development Grant DC-01089.
NR 69
TC 8
Z9 8
U1 2
U2 7
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3077
EI 1522-1598
J9 J NEUROPHYSIOL
JI J. Neurophysiol.
PD JUN
PY 2014
VL 111
IS 11
BP 2177
EP 2186
DI 10.1152/jn.00045.2014
PG 10
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA AL5JX
UT WOS:000339171000003
PM 24598524
ER
PT J
AU Karmali, F
Lim, K
Merfeld, DM
AF Karmali, Faisal
Lim, Koeun
Merfeld, Daniel M.
TI Visual and vestibular perceptual thresholds each demonstrate better
precision at specific frequencies and also exhibit optimal integration
SO JOURNAL OF NEUROPHYSIOLOGY
LA English
DT Article
DE vision; semicircular canals; otoliths; roll tilt; psychophysics; human
ID QUALITATIVELY DIFFERENT MECHANISMS; SELF-MOTION PERCEPTION; WHOLE-BODY;
VESTIBULOOCULAR REFLEX; CUE INTEGRATION; INERTIAL CUES; VERTICAL AXIS;
TILT; DIRECTION; ROLL
AB Prior studies show that visual motion perception is more precise than vestibular motion perception, but it is unclear whether this is universal or the result of specific experimental conditions. We compared visual and vestibular motion precision over a broad range of temporal frequencies by measuring thresholds for vestibular (subject motion in the dark), visual (visual scene motion) or visual-vestibular (subject motion in the light) stimuli. Specifically, thresholds were measured for motion frequencies spanning a two-decade physiological range (0.05-5 Hz) using single-cycle sinusoidal acceleration roll tilt trajectories (i.e., distinguishing left-side down from right-side down). We found that, while visual and vestibular thresholds were broadly similar between 0.05 and 5.0 Hz, each cue is significantly more precise than the other at certain frequencies. Specifically, we found that 1) visual and vestibular thresholds were indistinguishable at 0.05 Hz and 2 Hz (i.e., similarly precise); 2) visual thresholds were lower (i.e., vision more precise) than vestibular thresholds between 0.1 Hz and 1 Hz; and 3) visual thresholds were higher (i.e., vision less precise) than vestibular thresholds above 2 Hz. This shows that vestibular perception can be more precise than visual perception at physiologically relevant frequencies. We also found that sensory integration of visual and vestibular information is consistent with static Bayesian optimal integration of visual-vestibular cues. In contrast with most prior work that degraded or altered sensory cues, we demonstrated static optimal integration using natural cues.
C1 [Karmali, Faisal; Lim, Koeun; Merfeld, Daniel M.] Massachusetts Eye & Ear Infirm, Jenks Vestibular Physiol Lab, Boston, MA 02114 USA.
[Karmali, Faisal; Merfeld, Daniel M.] Harvard Univ, Sch Med, Dept Otol & Laryngol, Boston, MA 02115 USA.
RP Karmali, F (reprint author), Massachusetts Eye & Ear Infirm, Jenks Vestibular Physiol Lab, 243 Charles St, Boston, MA 02114 USA.
EM faisal_karmali@yahoo.com
OI Karmali, Faisal/0000-0002-1140-4954
FU National Institute of Deafness and Other Communications Disorders
[R01-DC04158]
FX This research was supported by National Institute of Deafness and Other
Communications Disorders Grant R01-DC04158.
NR 64
TC 7
Z9 7
U1 6
U2 13
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-3077
EI 1522-1598
J9 J NEUROPHYSIOL
JI J. Neurophysiol.
PD JUN
PY 2014
VL 111
IS 12
BP 2393
EP 2403
DI 10.1152/jn.00332.2013
PG 11
WC Neurosciences; Physiology
SC Neurosciences & Neurology; Physiology
GA AL5KE
UT WOS:000339171700001
PM 24371292
ER
PT J
AU Enzinger, AC
Zhang, BH
Weeks, JC
Prigerson, HG
AF Enzinger, Andrea C.
Zhang, Baohui
Weeks, Jane C.
Prigerson, Holly G.
TI Clinical Trial Participation as Part of End-of-Life Cancer Care:
Associations With Medical Care and Quality of Life Near Death
SO JOURNAL OF PAIN AND SYMPTOM MANAGEMENT
LA English
DT Article
DE Palliative care; end-of-life care; clinical trials; cancer
ID PHASE-1 ONCOLOGY TRIALS; CELL LUNG-CANCER; PALLIATIVE CARE; THERAPEUTIC
MISCONCEPTION; INVESTIGATIONAL THERAPY; INITIAL VALIDATION;
INFORMED-CONSENT; BENEFIT; PREFERENCES; DISCUSSIONS
AB Context. Clinical trials are a common therapeutic option for patients with advanced incurable cancer.
Objectives. To examine the associations between trial participation and end-of-life (EOL) outcomes, including aggressive care and quality of life (QOL).
Methods. Coping with Cancer, a multicenter prospective cohort study of patients with metastatic cancer, progressed after at least first-line chemotherapy. Baseline chart review documented clinical trial participation. Baseline interviews assessed psychosocial characteristics and EOL preferences. Caregiver interview and chart review assessed medical care and QOL near death. The primary outcome was aggressive EOL care (ventilation, resuscitation, or intensive care unit admission in last week of life). Propensity score weighting balanced patient characteristics that differed by trial participation, including care preferences and EOL discussion. Propensity scoreeweighted regression models estimated the effect of trial participation on outcomes.
Results. Of 352 patients followed to death, 37 were enrolled in a clinical trial at baseline. In propensity scoreeweighted analyses, trial participation was significantly associated with aggressive EOL care (21.6% vs. 12.0%, adjusted odds ratio [AOR] 2.04, 95% confidence interval [CI] 1.00e4.15), late hospice enrollment (51.4% vs. 42.2%, AOR 1.96, 95% CI 1.10e3.50), hospital death (48.6% vs. 25.7%, AOR 2.74, 95% CI 1.37e5.47), intensive care unit death (16.2% vs. 6.3%, AOR 3.53, 95% CI 1.29e9.65), and inferior QOL near death (least squares mean 5.93 vs. 7.69, P < 0.001). Controlling for EOL care, trial enrollment was no longer associated with QOL near death (P 0.342).
Conclusion. Clinical trial participation is associated with aggressive EOL care. Aggressive EOL care appears to explain the association between trial participation and QOL near death. (C) 2014 U. S. Cancer Pain Relief Committee. Published by Elsevier Inc. All rights reserved.
C1 [Enzinger, Andrea C.; Zhang, Baohui; Prigerson, Holly G.] Dana Farber Canc Inst, Ctr Psychosocial Epidemiol & Outcomes Res, Boston, MA 02215 USA.
[Enzinger, Andrea C.; Weeks, Jane C.; Prigerson, Holly G.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Enzinger, Andrea C.; Zhang, Baohui; Weeks, Jane C.; Prigerson, Holly G.] Dana Farber Canc Inst, McGraw Patterson Ctr Populat Sci, Boston, MA 02215 USA.
[Enzinger, Andrea C.; Weeks, Jane C.; Prigerson, Holly G.] Harvard Univ, Sch Med, Boston, MA USA.
RP Prigerson, HG (reprint author), Dana Farber Canc Inst, Dept Med Oncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM holly_prigerson@dfci.harvard.edu
FU National Institute of Mental Health [MH 63892]; National Cancer
Institute [CA 156732]; Fetzer Foundation; National Institutes of Health
[IH T32 CA009172-38]
FX This research was supported by grant MH 63892 from the National
Institute of Mental Health, grants CA 106370 and CA 156732 from the
National Cancer Institute (H. G. P.), the Fetzer Foundation (H. G. P.),
and National Institutes of Health grant IH T32 CA009172-38 (A. C. E.).
The funding organizations neither had a role in the design or conduct of
the study nor did they play any role in the collection, management,
analysis, or interpretation of the data or the preparation, review, or
approval of the manuscript. Dr. H. G. P. and Dr. A. C. E. had full
access to all the data in the study and take full responsibility for the
integrity of the data and accuracy of the data analysis. None of the
authors have a relationship with any entity having financial interest in
this topic.
NR 52
TC 8
Z9 8
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0885-3924
EI 1873-6513
J9 J PAIN SYMPTOM MANAG
JI J. Pain Symptom Manage.
PD JUN
PY 2014
VL 47
IS 6
BP 1078
EP 1090
DI 10.1016/j.jpainsymman.2013.07.004
PG 13
WC Health Care Sciences & Services; Medicine, General & Internal; Clinical
Neurology
SC Health Care Sciences & Services; General & Internal Medicine;
Neurosciences & Neurology
GA AL0YO
UT WOS:000338853200016
PM 24099894
ER
PT J
AU Kirchhoff, AC
Hart, G
Campbell, EG
AF Kirchhoff, Anne C.
Hart, Gary
Campbell, Eric G.
TI Rural and Urban Primary Care Physician Professional Beliefs and Quality
Improvement Behaviors
SO JOURNAL OF RURAL HEALTH
LA English
DT Article
DE primary care physicians; professionalism; quality; rural; urban
ID PATIENT; COMMUNITY; HOSPITALS; AMERICA; ACCESS; ACT
AB Purpose: We evaluated whether primary care physicians (PCPs) from urban and rural practices differ on attitudes and behaviors related to quality improvement (QI) activities, patient relationships, and professionalism/self-regulation.
Methods: Data from a national survey that assessed physician attitudes and behaviors based on the Physician Charter on Medical Professionalism were used. Of the 1,891 survey respondents, N = 840 were PCPs (n = 274 family medicine (response rate = 67.5%); n = 257 general internal medicine (60.8%); and n = 309 pediatricians (72.7%)). Using Rural-Urban Commuting Area (RUCA) codes, PCPs were classified as urban and rural according to their practice ZIP code.
Findings: A total of n = 691 physicians were urban and n = 127 rural. Attitudes regarding participating in QI did not differ by practice location; however, rural PCPs were more likely to have reviewed an other physician's records for QI than urban PCPs (65.6% vs 48.0%, P < .001). Rural physicians were more likely to agree that physicians should talk with their patients about the cost of care than urban PCPs (40.5% vs 29.2%, P = .02). While all PCPs endorsed attitudes regarding the importance of professional behaviors (eg, reporting impaired/incompetent colleagues, disclosing medical errors) at generally similar levels, their behaviors differed. More rural physicians had a personal knowledge of an impaired/incompetent physician than urban physicians (20.7% vs 12.7%, P = .02).
Conclusions: PCPs from rural and urban areas share similar attitudes regarding the importance of participating in QI and fulfilling professional responsibilities. However, certain behaviors (eg, knowledge of impaired colleagues) do differ. These results should be confirmed in larger studies of rural PCPs.
C1 [Kirchhoff, Anne C.] Univ Utah, Sch Med, Dept Pediat, Salt Lake City, UT USA.
[Hart, Gary] Huntsman Canc Inst, Salt Lake City, UT USA.
[Hart, Gary] Univ N Dakota, Sch Med & Hlth Sci, Ctr Rural Hlth, Grand Forks, ND 58201 USA.
[Campbell, Eric G.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA.
[Campbell, Eric G.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
RP Kirchhoff, AC (reprint author), 2000 Circle Hope, Salt Lake City, UT 84103 USA.
EM anne.kirchhoff@hci.utah.edu
FU Institute on Medicine as a Profession at Columbia University
FX This study was supported by a grant from the Institute on Medicine as a
Profession at Columbia University.
NR 28
TC 1
Z9 1
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0890-765X
EI 1748-0361
J9 J RURAL HEALTH
JI J. Rural Health
PD SUM
PY 2014
VL 30
IS 3
BP 235
EP 243
DI 10.1111/jrh.12067
PG 9
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA AL3TT
UT WOS:000339052900002
PM 24528129
ER
PT J
AU Britton, WB
Lepp, NE
Niles, HF
Rocha, T
Fisher, NE
Gold, JS
AF Britton, Willoughby B.
Lepp, Nathaniel E.
Niles, Halsey F.
Rocha, Tomas
Fisher, Nathan E.
Gold, Jonathan S.
TI A randomized controlled pilot trial of classroom-based mindfulness
meditation compared to an active control condition in sixth-grade
children
SO JOURNAL OF SCHOOL PSYCHOLOGY
LA English
DT Article
DE Children; Pre-adolescent; Mindfulness meditation; Contemplative
education; School; Social and emotional learning
ID MENTAL-HEALTH-SERVICES; TRAIT ANXIETY INVENTORY; NONSUICIDAL
SELF-INJURY; VISUAL ANALOG SCALES; SUICIDAL IDEATION; STRESS REDUCTION;
PSYCHIATRIC-DISORDERS; EXECUTIVE FUNCTION; COGNITIVE THERAPY; EARLY
ADOLESCENCE
AB The current study is a pilot trial to examine the effects of a nonelective, classroom-based, teacher-implemented, mindfulness meditation intervention on standard clinical measures of mental health and affect in middle school children. A total of 101 healthy sixth-grade students (55 boys, 46 girls) were randomized to either an Asian history course with daily mindfulness meditation practice (intervention group) or an African history course with a matched experiential activity (active control group). Self-reported measures included the Youth Self Report (YSR), a modified Spielberger State-Trait Anxiety Inventory, and the Cognitive and Affective Mindfulness Measure Revised. Both groups decreased significantly on clinical syndrome subscales and affect but did not differ in the extent of their improvements. Meditators were significantly less likely to develop suicidal ideation or thoughts of self-harm than controls. These results suggest that mindfulness training may yield both unique and non-specific benefits that are shared by other novel activities. (C) 2014 Society for the Study of School Psychology. Published by Elsevier Ltd. All rights reserved.
C1 [Britton, Willoughby B.; Lepp, Nathaniel E.; Niles, Halsey F.; Rocha, Tomas; Fisher, Nathan E.; Gold, Jonathan S.] Brown Univ Contemplat Studies Initiat, Providence, RI USA.
[Niles, Halsey F.] Massachusetts Gen Hosp, Benson Henry Inst Mind Body Med, Boston, MA 02114 USA.
[Rocha, Tomas] Mind & Life Inst, Boulder, CO USA.
[Gold, Jonathan S.] Moses Brown Sch, Providence, RI USA.
[Britton, Willoughby B.; Fisher, Nathan E.] Brown Univ, Sch Med, Dept Psychiat & Human Behav, Providence, RI 02906 USA.
RP Britton, WB (reprint author), Brown Univ, Warren Alpert Med Sch, Dept Psychiat & Human Behav, 185 Brown St, Providence, RI 02906 USA.
EM Willoughby_Britton@Brown.edu
FU NCCIH NIH HHS [K23-AT006328-01A1, T32-AT001287, T32 AT001287, K23
AT006328]; NIMH NIH HHS [MH067553-05, T32 MH067553]
NR 163
TC 21
Z9 21
U1 18
U2 107
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0022-4405
EI 1873-3506
J9 J SCHOOL PSYCHOL
JI J. Sch. Psychol.
PD JUN
PY 2014
VL 52
IS 3
BP 263
EP 278
DI 10.1016/j.jsp.2014.03.002
PG 16
WC Psychology, Educational
SC Psychology
GA AL5AC
UT WOS:000339144900002
PM 24930819
ER
PT J
AU Aerts, HJWL
Velazquez, ER
Leijenaar, RTH
Parmar, C
Grossmann, P
Cavalho, S
Bussink, J
Monshouwer, R
Haibe-Kains, B
Rietveld, D
Hoebers, F
Rietbergen, MM
Leemans, CR
Dekker, A
Quackenbush, J
Gillies, RJ
Lambin, P
AF Aerts, Hugo J. W. L.
Velazquez, Emmanuel Rios
Leijenaar, Ralph T. H.
Parmar, Chintan
Grossmann, Patrick
Cavalho, Sara
Bussink, Johan
Monshouwer, Rene
Haibe-Kains, Benjamin
Rietveld, Derek
Hoebers, Frank
Rietbergen, Michelle M.
Leemans, C. Rene
Dekker, Andre
Quackenbush, John
Gillies, Robert J.
Lambin, Philippe
TI Decoding tumour phenotype by noninvasive imaging using a quantitative
radiomics approach
SO NATURE COMMUNICATIONS
LA English
DT Article
ID CELL LUNG-CANCER; HETEROGENEITY; VARIABILITY; EVOLUTION; SURVIVAL;
RECIST; STAGE
AB uman cancers exhibit strong phenotypic differences that can be visualized noninvasively by medical imaging. Radiomics refers to the comprehensive quantification of tumour phenotypes by applying a large number of quantitative image features. Here we present a radiomic analysis of 440 features quantifying tumour image intensity, shape and texture, which are extracted from computed tomography data of 1,019 patients with lung or head-and-neck cancer. We find that a large number of radiomic features have prognostic power in independent data sets of lung and head-and-neck cancer patients, many of which were not identified as significant before. Radiogenomics analysis reveals that a prognostic radiomic signature, capturing intratumour heterogeneity, is associated with underlying gene-expression patterns. These data suggest that radiomics identifies a general prognostic phenotype existing in both lung and head-and-neck cancer. This may have a clinical impact as imaging is routinely used in clinical practice, providing an unprecedented opportunity to improve decision-support in cancer treatment at low cost.
C1 [Aerts, Hugo J. W. L.; Velazquez, Emmanuel Rios; Leijenaar, Ralph T. H.; Parmar, Chintan; Cavalho, Sara; Hoebers, Frank; Dekker, Andre; Lambin, Philippe] Maastricht Univ, Res Inst GROW, Dept Radiat Oncol MAASTRO, NL-6229 ET Maastricht, Netherlands.
[Aerts, Hugo J. W. L.; Velazquez, Emmanuel Rios; Parmar, Chintan; Grossmann, Patrick] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Inst,Dept Radiat Oncol, Boston, MA 02215 USA.
[Aerts, Hugo J. W. L.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Dana Farber Canc Inst,Dept Radiol, Boston, MA 02215 USA.
[Aerts, Hugo J. W. L.; Quackenbush, John] Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Bussink, Johan; Monshouwer, Rene] Radboud Univ Nijmegen, Med Ctr, Dept Radiat Oncol, NL-6500 HB Nijmegen, Netherlands.
[Haibe-Kains, Benjamin] Univ Toronto, Princess Margaret Canc Ctr, Univ Hlth Network, Toronto, ON M5G 1L7, Canada.
[Haibe-Kains, Benjamin] Univ Toronto, Dept Med Biophys, Toronto, ON M5G 1L7, Canada.
[Rietveld, Derek] Vrije Univ Amsterdam, Med Ctr, Dept Radiat Oncol, NL-1081 HZ Amsterdam, Netherlands.
[Rietbergen, Michelle M.; Leemans, C. Rene] Vrije Univ Amsterdam, Med Ctr, Dept Otolaryngol Head & Neck Surg, NL-1081 HZ Amsterdam, Netherlands.
[Gillies, Robert J.] H Lee Moffitt Canc Ctr & Res Inst, Dept Canc Imaging & Metab, Tampa, FL 33612 USA.
RP Aerts, HJWL (reprint author), Maastricht Univ, Res Inst GROW, Dept Radiat Oncol MAASTRO, NL-6229 ET Maastricht, Netherlands.
EM Hugo_Aerts@dfci.harvard.edu
RI Bussink, Jan/N-3584-2014; Monshouwer, R./L-4527-2015; Aerts,
Hugo/P-6350-2015; Haibe-Kains, Benjamin/D-3702-2011;
OI Aerts, Hugo/0000-0002-2122-2003; Haibe-Kains,
Benjamin/0000-0002-7684-0079; , Patrick/0000-0003-4918-6902; Dekker,
Andre/0000-0002-0422-7996; Gillies, Robert/0000-0002-8888-7747
FU National Institute of Health (Radiomics of NSCLC) [NIH-USA U01 CA
143062-01]; CTMM (AIRFORCE project) [030-103]; EU 6th program (METOXIA,
EURECA, ARTFORCE); EU 7th program (METOXIA, EURECA, ARTFORCE); euroCAT
(IVA); Dutch Cancer Society [KWF UM 2011-5020, KWF UM 2009-4454];
Innovative Medicines Initiative Joint Undertaking; 7th framework program
abd EFPIA companies' kind contribution [115151]
FX We acknowledge financial support from the National Institute of Health
(NIH-USA U01 CA 143062-01, Radiomics of NSCLC), the CTMM framework
(AIRFORCE project, grant 030-103), EU 6th and 7th framework program
(METOXIA, EURECA, ARTFORCE), euroCAT (IVA Interreg-www.eurocat.info),
and the Dutch Cancer Society (KWF UM 2011-5020, KWF UM 2009-4454). We
also acknowledge financial support from the Innovative Medicines
Initiative Joint Undertaking (www.imi.europa.eu), based on resources
from the 7th framework program abd EFPIA companies' kind contribution
(Grant agreement No. 115151).
NR 28
TC 187
Z9 194
U1 25
U2 95
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUN
PY 2014
VL 5
AR 4006
DI 10.1038/ncomms5006
PG 8
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AL0SE
UT WOS:000338836200003
PM 24892406
ER
PT J
AU Kang, S
Singh, J
Melo, MV
Gulur, P
AF Kang, Stanley
Singh, Jagmeet
Melo, Marcos Vidal
Gulur, Padma
TI Spinal Cord Stimulation for Intercostal Neuralgia in a Patient With
Implantable Cardiac Defibrillator and Biventricular Pacing
SO NEUROMODULATION
LA English
DT Letter
DE ICD; implantable cardiac defibrillator; SCS; spinal cord stimulator
ID CARDIOVERTER-DEFIBRILLATOR; REFRACTORY ANGINA; PACEMAKER
C1 [Kang, Stanley; Singh, Jagmeet; Melo, Marcos Vidal; Gulur, Padma] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Singh, Jagmeet; Melo, Marcos Vidal; Gulur, Padma] Harvard Univ, Sch Med, Boston, MA USA.
RP Gulur, P (reprint author), 15 Parkman St,WACC 330, Boston, MA USA.
EM pgulur@partners.org
NR 10
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1094-7159
EI 1525-1403
J9 NEUROMODULATION
JI Neuromodulation
PD JUN
PY 2014
VL 17
IS 4
BP 386
EP 388
DI 10.1111/ner.12082
PG 3
WC Medicine, Research & Experimental; Clinical Neurology
SC Research & Experimental Medicine; Neurosciences & Neurology
GA AL6KQ
UT WOS:000339241700026
PM 23837496
ER
PT J
AU Wang, YY
Li, WD
Patel, SS
Cong, J
Zhang, N
Sabbatino, F
Liu, XY
Qi, Y
Huang, PG
Lee, H
Taghian, A
Li, JJ
DeLeo, AB
Ferrone, S
Epperly, MW
Ferrone, CR
Ly, A
Brachtel, EF
Wang, XH
AF Wang, Yangyang
Li, Wende
Patel, Shalin S.
Cong, Juan
Zhang, Nan
Sabbatino, Francesco
Liu, Xiaoyan
Qi, Yuan
Huang, Peigen
Lee, Hang
Taghian, Alphonse
Li, Jian-Jian
DeLeo, Albert B.
Ferrone, Soldano
Epperly, Michael W.
Ferrone, Cristina R.
Ly, Amy
Brachtel, Elena F.
Wang, Xinhui
TI Blocking the formation of radiation-induced breast cancer stem cells
SO ONCOTARGET
LA English
DT Article
DE Breast Cancer; Radiation; Cancer Stem Cells; NF-kappaB Stemness genes
ID TRACE-ELEMENTS; ALDEHYDE DEHYDROGENASE; INITIATING CELLS; DISULFIRAM;
COPPER; IDENTIFICATION; EXPRESSION; TISSUE; SERUM; TUMORIGENESIS
AB The goal of adjuvant (post-surgery) radiation therapy (RT) for breast cancer (BC) is to eliminate residual cancer cells, leading to better local tumor control and thus improving patient survival. However, radioresistance increases the risk of tumor recurrence and negatively affects survival. Recent evidence shows that breast cancer stem cells (BCSCs) are radiation-resistant and that relatively differentiated BC cells can be reprogrammed into induced BCSCs (iBCSCs) via radiation-induced re-expression of the stemness genes. Here we show that in irradiation (IR)-treated mice bearing syngeneic mammary tumors, IR-induced stemness correlated with increased spontaneous lung metastasis (51.7%). However, IR-induced stemness was blocked by targeting the NF-kappa B- stemness gene pathway with disulfiram (DSF) and Copper (Cu2+). DSF is an inhibitor of aldehyde dehydrogenase (ALDH) and an FDA-approved drug for treating alcoholism. DSF binds to Cu2+ to form DSF-Cu complexes (DSF/Cu), which act as a potent apoptosis inducer and an effective proteasome inhibitor, which, in turn, inhibits NF-kappa B activation. Treatment of mice with RT and DSF significantly inhibited mammary primary tumor growth (79.4%) and spontaneous lung metastasis (89.6%) compared to vehicle treated mice. This anti-tumor efficacy was associated with decreased stem cell properties (or stemness) in tumors. We expect that these results will spark clinical investigation of RT and DSF as a novel combinatorial treatment for breast cancer.
C1 [Wang, Yangyang; Cong, Juan; Zhang, Nan; Sabbatino, Francesco; Liu, Xiaoyan; Qi, Yuan; Ferrone, Soldano; Wang, Xinhui] Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA.
[Li, Wende; Huang, Peigen; Taghian, Alphonse] Massachusetts Gen Hosp, Dept Radiat Oncol, Boston, MA 02114 USA.
[Patel, Shalin S.; Ferrone, Soldano] Massachusetts Gen Hosp, Dept Orthopaed, Boston, MA 02114 USA.
[Lee, Hang] Massachusetts Gen Hosp, Dept Biostat Ctr, Boston, MA 02114 USA.
[Li, Jian-Jian] Univ Calif Davis, Dept Radiat Oncol, Sacramento, CA 95817 USA.
[DeLeo, Albert B.] Univ Pittsburgh, Dept Pathol, Pittsburgh, PA USA.
[Epperly, Michael W.] Univ Pittsburgh, Dept Radiat Oncol, Pittsburgh, PA USA.
[Ferrone, Cristina R.] Massachusetts Gen Hosp, Dept Surg, Div Gen & Gastrointestinal Surg, Boston, MA 02114 USA.
[Ly, Amy; Brachtel, Elena F.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Wang, Yangyang; Li, Wende; Patel, Shalin S.; Cong, Juan; Zhang, Nan; Sabbatino, Francesco; Huang, Peigen; Lee, Hang; Taghian, Alphonse; Ferrone, Soldano; Ferrone, Cristina R.; Ly, Amy; Brachtel, Elena F.; Wang, Xinhui] Harvard Univ, Sch Med, Boston, MA USA.
RP Wang, XH (reprint author), Massachusetts Gen Hosp, Div Surg Oncol, Boston, MA 02114 USA.
EM xwang30@mgh.harvard.edu
RI Sabbatino, Francesco/F-4992-2014
OI Sabbatino, Francesco/0000-0001-6431-8278
FU NIH [RO3 CA141086, R01-1CA138188, 2P50CA121973-06, 7R01CA110249-06];
Susan G. Komen Postdoctoral Fellowship [KG111486]
FX This study was supported by NIH grant RO3 CA141086 (X.W.), Susan G.
Komen Postdoctoral Fellowship KG111486 (Y.W.) and NIH grants
R01-1CA138188 (S. F.), 2P50CA121973-06 (S. F.) and 7R01CA110249-06 (S.
F.).
NR 47
TC 19
Z9 22
U1 0
U2 4
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUN
PY 2014
VL 5
IS 11
BP 3743
EP 3755
PG 13
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA AL3UG
UT WOS:000339054500027
PM 25003837
ER
PT J
AU Borre, PV
Gunda, V
McFadden, DG
Sadow, PM
Varmeh, S
Bernasconi, M
Parangi, S
AF Borre, Pierre Vanden
Gunda, Viswanath
McFadden, David G.
Sadow, Peter M.
Varmeh, Shohreh
Bernasconi, Maria
Parangi, Sareh
TI Combined BRAF(V600E-) and SRC-inhibition induces apoptosis, evokes an
immune response and reduces tumor growth in an immunocompetent
orthotopic mouse model of anaplastic thyroid cancer
SO ONCOTARGET
LA English
DT Article
DE Thyroid; BRAF; SRC
ID FOCAL ADHESION KINASE; BRAF INHIBITION; BREAST-CANCER; RAF INHIBITORS;
METASTATIC MELANOMA; FEEDBACK INHIBITION; TARGETING SRC; CELL-LINES;
WILD-TYPE; PHASE-II
AB Anaplastic (ATC) and refractory papillary thyroid cancer (PTC) lack effective treatments. Inhibition of either oncogenic BRAF or SRC has marked anti-tumor effects in mouse models of thyroid cancer, however, neither drug induces notable apoptosis. Here we report that the SRC-inhibitor dasatinib further sensitizes BRAF(V600E)-positive thyroid cancer cells to the BRAF(V600E)-inhibitor PLX4720. Combined treatment with PLX4720 and dasatinib synergistically inhibited proliferation and reduced migration in PTC and ATC cells. Whereas PLX4720 did not induce robust apoptosis in thyroid cancer cells, combined treatment with dasatinib induced apoptosis in 4 of 6 lines. In an immunocompetent orthotopic mouse model of ATC, combined PLX4720 and dasatinib treatment significantly reduced tumor volume relative to PLX4720 treatment alone. Immune cell infiltration was increased by PLX4720 treatment and this effect was maintained in mice treated with both PLX4720 and dasatinib. Further, combined treatment significantly increased caspase 3 cleavage in vivo relative to control or either treatment alone. In conclusion, combined PLX4720 and dasatinib treatment induces apoptosis, increases immune cell infiltration and reduces tumor volume in a preclinical model of ATC, suggesting that the combination of these FDA-approved drugs may have potential for the treatment of patients with ATC or refractory PTC.
C1 [Borre, Pierre Vanden; Gunda, Viswanath; Sadow, Peter M.; Varmeh, Shohreh; Bernasconi, Maria; Parangi, Sareh] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[McFadden, David G.] Massachusetts Gen Hosp, Dept Med, Thyroid Unit, Boston, MA 02114 USA.
RP Parangi, S (reprint author), Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA.
EM sparangi@partners.org
FU National Institute of Health [R01CA149738, F32CA177282]; American
College of Surgeons; American Thyroid Association
FX Supported by National Institute of Health Grants R01CA149738 (to SP) and
F32CA177282 (to PVB). Sareh Parangi is additionally funded through the
American College of Surgeons and the American Thyroid Association.
NR 63
TC 4
Z9 4
U1 0
U2 6
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUN
PY 2014
VL 5
IS 12
BP 3996
EP 4010
PG 15
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA AL3UM
UT WOS:000339055200004
ER
PT J
AU Kushwaha, D
Ramakrishnan, V
Ng, K
Steed, T
Nguyen, T
Futalan, D
Akers, JC
Sarkaria, J
Jiang, T
Chowdhury, D
Carter, BS
Chen, CC
AF Kushwaha, Deepa
Ramakrishnan, Valya
Ng, Kimberly
Steed, Tyler
Thien Nguyen
Futalan, Diahnn
Akers, Johnny C.
Sarkaria, Jann
Jiang, Tao
Chowdhury, Dipanjan
Carter, Bob S.
Chen, Clark C.
TI A genome-wide miRNA screen revealed miR-603 as a MGMT-regulating miRNA
in glioblastomas
SO ONCOTARGET
LA English
DT Article
DE microRNA; Glioblastoma; MGMT; Temozolomide; miRNA cooperativity
ID PROMOTER METHYLATION; METHYLTRANSFERASE MGMT; O-6-METHYLGUANINE-DNA
METHYLTRANSFERASE; ADJUVANT TEMOZOLOMIDE; PROTEIN EXPRESSION; TARGET
PREDICTION; MICRORNA TARGETS; PHASE-3 TRIAL; DNA; RADIOTHERAPY
AB MGMT expression is a critical determinant for therapeutic resistance to DNA alkylating agents. We previously demonstrated that MGMT expression is post-transcriptionally regulated by miR-181d and other miRNAs. Here, we performed a genome-wide screen to identify MGMT regulating miRNAs. Candidate miRNAs were further tested for inverse correlation with MGMT expression in clinical specimens. We identified 15 candidate miRNAs and characterized the top candidate, miR-603. Transfection of miR-603 suppressed MGMT mRNA/protein expression in vitro and in vivo; this effect was reversed by transfection with antimiR-603. miR-603 affinity-precipitated with MGMT mRNA and suppressed luciferase activity in an MGMT-3'UTR-luciferase assay, suggesting direct interaction between miR-603 and MGMT 3'UTR. miR-603 transfection enhanced the temozolomide (TMZ) sensitivity of MGMT-expressing glioblastoma cell lines. Importantly, miR-603 mediated MGMT suppression and TMZ resistance were reversed by expression of an MGMT cDNA. In a collection of 74 clinical glioblastoma specimens, both miR-603 and miR-181d levels inversely correlated with MGMT expression. Moreover, a combined index of the two miRNAs better reflected MGMT expression than each individually. These results suggest that MGMT is co-regulated by independent miRNAs. Characterization of these miRNAs should contribute toward strategies for enhancing the efficacy of DNA alkylating agents.
C1 [Kushwaha, Deepa; Ng, Kimberly; Chowdhury, Dipanjan] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[Ramakrishnan, Valya; Steed, Tyler; Thien Nguyen; Futalan, Diahnn; Akers, Johnny C.; Carter, Bob S.; Chen, Clark C.] Univ Calif San Diego, Div Neurosurg, Moores Canc Ctr, Ctr Theoret & Appl Neurooncol, San Diego, CA 92103 USA.
[Sarkaria, Jann] Mayo Clin, Dept Radiat Oncol, Rochester, MN USA.
[Jiang, Tao] Tiantan Med Ctr, Dept Neurosurg, Beijing, Peoples R China.
RP Chen, CC (reprint author), Univ Calif San Diego, Div Neurosurg, Moores Canc Ctr, Ctr Theoret & Appl Neurooncol, San Diego, CA 92103 USA.
EM clarkchen@ucsd.edu
RI Jiang, Tao/N-8142-2014; RAMAKRISHNAN, VALYA/L-6415-2016
FU NIAID NIH HHS [R01 AI101897]; NIGMS NIH HHS [T32 GM007198]
NR 51
TC 26
Z9 26
U1 2
U2 4
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUN
PY 2014
VL 5
IS 12
BP 4026
EP 4039
PG 14
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA AL3UM
UT WOS:000339055200006
PM 24994119
ER
PT J
AU Shahbazi, J
Scarlett, CJ
Norris, MD
Liu, B
Haber, M
Tee, AE
Carrier, A
Biankin, AV
London, WB
Marshall, GM
Lock, RB
Liu, T
AF Shahbazi, Jeyran
Scarlett, Christopher J.
Norris, Murray D.
Liu, Bing
Haber, Michelle
Tee, Andrew E.
Carrier, Alice
Biankin, Andrew V.
London, Wendy B.
Marshall, Glenn M.
Lock, Richard B.
Liu, Tao
TI Histone Deacetylase 2 and N-Myc reduce p53 protein phosphorylation at
serine 46 by repressing gene transcription of tumor protein 53-induced
nuclear protein 1
SO ONCOTARGET
LA English
DT Article
DE N-Myc; HDAC2; p53; TP53INP1
ID BET BROMODOMAIN INHIBITION; C-MYC; NEUROBLASTOMA; EXPRESSION; APOPTOSIS;
TARGET; LEUKEMIA; CANCER; DIFFERENTIATION; CELLS
AB Myc oncoproteins and histone deacetylases (HDACs) exert oncogenic effects by modulating gene transcription. Paradoxically, N-Myc induces p53 gene expression. Tumor protein 53-induced nuclear protein 1 (TP53INP1) phosphorylates p53 protein at serine 46, leading to enhanced p53 activity, transcriptional activation of p53 target genes and programmed cell death. Here we aimed to identify the mechanism through which N-Myc overexpressing p53 wild-type neuroblastoma cells acquired resistance to apoptosis. TP53INP1 was found to be one of the genes most significantly repressed by HDAC2 and N-Myc according to Affymetrix microarray gene expression datasets. HDAC2 and N-Myc reduced TP53INP1 gene expression by direct binding to the TP53INP1 gene promoter, leading to transcriptional repression of TP53INP1, p53 protein de-phosphorylation at serine 46, neuroblastoma cell proliferation and survival. Moreover, low levels of TP53INP1 expression in human neuroblastoma tissues correlated with high levels of N-Myc expression and poor patient outcome, and the BET bromodomain inhibitors JQ1 and I-BET151 reduced N-Myc expression and reactivated TP53INP1 expression in neuroblastoma cells. These findings identify TP53INP1 repression as an important co-factor for N-Myc oncogenesis, and provide further evidence for the potential application of BET bromodomain inhibitors in the therapy of N-Myc-induced neuroblastoma.
C1 [Shahbazi, Jeyran; Norris, Murray D.; Liu, Bing; Haber, Michelle; Tee, Andrew E.; Marshall, Glenn M.; Lock, Richard B.; Liu, Tao] Childrens Canc Inst Australia Med Res, Sydney, NSW, Australia.
[Shahbazi, Jeyran] Univ New S Wales, UNSW Sci, Sch Biotechnol & Biomol Sci, Sydney, NSW, Australia.
[Scarlett, Christopher J.] Univ Newcastle, Sch Environm & Life Sci, Ourimbah, Australia.
[Scarlett, Christopher J.; Biankin, Andrew V.] Garvan Inst Med Res, Canc Res Program, Sydney, NSW, Australia.
[Carrier, Alice] Univ Aix Marseille, CRCM Stress Cellulaire, INSERM, U1068, F-13009 Marseille, France.
[Biankin, Andrew V.] Univ Glasgow, Wolfson Wohl Canc Res Ctr, Glasgow, Lanark, Scotland.
[Biankin, Andrew V.] Glasgow Royal Infirm, Glasgow G4 0SF, Lanark, Scotland.
[London, Wendy B.] Dana Farber Canc Inst, Childrens Oncol Grp Stat, Boston, MA 02115 USA.
[London, Wendy B.] Dana Farber Canc Inst, Ctr Data, Boston, MA 02115 USA.
[London, Wendy B.] Dana Farber Canc Inst, Boston Childrens Hosp, Boston, MA 02115 USA.
[Marshall, Glenn M.] Sydney Childrens Hosp, Kids Canc Ctr, Sydney, NSW, Australia.
[Liu, Tao] Univ New S Wales, UNSW Med, Sch Womens & Childrens Hlth, Sydney, NSW, Australia.
RP Liu, T (reprint author), Childrens Canc Inst Australia Med Res, Sydney, NSW, Australia.
EM tliu@ccia.unsw.edu.au
RI Liu, Tao/A-3922-2015; Lock, Richard/G-4253-2013;
OI Biankin, Andrew/0000-0002-0362-5597
FU National Health and Medical Research Council; Cancer Council NSW; Cancer
Institute NSW; Cancer Australia; Cure Cancer Australia Foundation; ARC
Future Fellowship
FX The authors were supported by National Health and Medical Research
Council, Cancer Council NSW, Cancer Institute NSW, Cancer Australia and
Cure Cancer Australia Foundation grants. T. Liu is a recipient of an ARC
Future Fellowship. Children's Cancer Institute Australia is affiliated
with University of New South Wales and Sydney Children's Hospitals
Network.
NR 41
TC 15
Z9 15
U1 1
U2 9
PU IMPACT JOURNALS LLC
PI ALBANY
PA 6211 TIPTON HOUSE, STE 6, ALBANY, NY 12203 USA
SN 1949-2553
J9 ONCOTARGET
JI Oncotarget
PD JUN
PY 2014
VL 5
IS 12
BP 4257
EP 4268
PG 12
WC Oncology; Cell Biology
SC Oncology; Cell Biology
GA AL3UM
UT WOS:000339055200024
PM 24952595
ER
PT J
AU Podlaha, O
De, S
Gonen, M
Michor, F
AF Podlaha, Ondrej
De, Subhajyoti
Gonen, Mithat
Michor, Franziska
TI Histone Modifications Are Associated with Transcript Isoform Diversity
in Normal and Cancer Cells
SO PLOS COMPUTATIONAL BIOLOGY
LA English
DT Article
ID HUMAN GENOME; CHROMATIN STATE; DNA METHYLATION; PROSTATE-CANCER; PWWP
DOMAIN; RNA-SEQ; LANDSCAPE; ARCHITECTURE; RECOGNITION; RECRUITMENT
AB Mechanisms that generate transcript diversity are of fundamental importance in eukaryotes. Although a large fraction of human protein-coding genes and lincRNAs produce more than one mRNA isoform each, the regulation of this phenomenon is still incompletely understood. Much progress has been made in deciphering the role of sequence-specific features as well as DNA-and RNA-binding proteins in alternative splicing. Recently, however, several experimental studies of individual genes have revealed a direct involvement of epigenetic factors in alternative splicing and transcription initiation. While histone modifications are generally correlated with overall gene expression levels, it remains unclear how histone modification enrichment affects relative isoform abundance. Therefore, we sought to investigate the associations between histone modifications and transcript diversity levels measured by the rates of transcription start-site switching and alternative splicing on a genome-wide scale across protein-coding genes and lincRNAs. We found that the relationship between enrichment levels of epigenetic marks and transcription start-site switching is similar for protein-coding genes and lincRNAs. Furthermore, we found associations between splicing rates and enrichment levels of H2az, H3K4me1, H3K4me2, H3K4me3, H3K9ac, H3K9me3, H3K27ac, H3K27me3, H3K36me3, H3K79me2, and H4K20me, marks traditionally associated with enhancers, transcription initiation, transcriptional repression, and others. These patterns were observed in both normal and cancer cell lines. Additionally, we developed a novel computational method that identified 840 epigenetically regulated candidate genes and predicted transcription start-site switching and alternative exon splicing with up to 92% accuracy based on epigenetic patterning alone. Our results suggest that the epigenetic regulation of transcript isoform diversity may be a relatively common genome-wide phenomenon representing an avenue of deregulation in tumor development.
C1 [Podlaha, Ondrej; Michor, Franziska] Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
[Podlaha, Ondrej; Michor, Franziska] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[De, Subhajyoti] Univ Colorado, Dept Med, Sch Med, Aurora, CO USA.
[De, Subhajyoti] Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA.
[De, Subhajyoti] Univ Colorado, Mol Oncol Program, Ctr Canc, Aurora, CO USA.
[Gonen, Mithat] Mem Sloan Kettering Canc Ctr, Dept Epidemiol & Biostat, New York, NY 10021 USA.
RP Podlaha, O (reprint author), Harvard Univ, Sch Publ Hlth, Dana Farber Canc Inst, Dept Biostat & Computat Biol, Boston, MA 02115 USA.
EM michor@jimmy.harvard.edu
FU NIH [NIH U54CA143798]
FX NIH grant: NIH U54CA143798: Evolutionary Dynamics of Brain, Lung, and
Hematopoietic Tumors. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 48
TC 5
Z9 5
U1 1
U2 12
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-734X
EI 1553-7358
J9 PLOS COMPUT BIOL
JI PLoS Comput. Biol.
PD JUN
PY 2014
VL 10
IS 6
AR e1003611
DI 10.1371/journal.pcbi.1003611
PG 13
WC Biochemical Research Methods; Mathematical & Computational Biology
SC Biochemistry & Molecular Biology; Mathematical & Computational Biology
GA AL0WP
UT WOS:000338848100005
PM 24901363
ER
PT J
AU Juraeva, D
Haenisch, B
Zapatka, M
Frank, J
Witt, SH
Muhleisen, T
Treutlein, J
Strohmaier, J
Meier, S
Degenhardt, F
Giegling, I
Ripke, S
Leber, M
Lange, C
Schulze, T
Mossner, R
Nenadic, I
Sauer, H
Rujescu, D
Maier, W
Borglum, A
Ophoff, R
Cichon, S
Nothen, M
Rietschel, M
Mattheisen, M
Brors, B
AF Juraeva, Dilafruz
Haenisch, Britta
Zapatka, Marc
Frank, Josef
Witt, Stephanie H.
Muehleisen, ThomasW.
Treutlein, Jens
Strohmaier, Jana
Meier, Sandra
Degenhardt, Franziska
Giegling, Ina
Ripke, Stephan
Leber, Markus
Lange, Christoph
Schulze, ThomasG.
Moessner, Rainald
Nenadic, Igor
Sauer, Heinrich
Rujescu, Dan
Maier, Wolfgang
Borglum, Anders
Ophoff, Roel
Cichon, Sven
Noethen, MarkusM.
Rietschel, Marcella
Mattheisen, Manuel
Brors, Benedikt
CA GRP Investigators
iPSYCH-GEMS SCZ Working Grp
TI Integrated Pathway-Based Approach Identifies Association between Genomic
Regions at CTCF and CACNB2 and Schizophrenia
SO PLOS GENETICS
LA English
DT Article
ID WIDE ASSOCIATION; ENRICHMENT ANALYSIS; GENE-EXPRESSION; COMMON VARIANTS;
ANNOTATION; TRANSPORT; DISEASES; HAPMAP; GAMMA; MOTIF
AB In the present study, an integrated hierarchical approach was applied to: (1) identify pathways associated with susceptibility to schizophrenia; (2) detect genes that may be potentially affected in these pathways since they contain an associated polymorphism; and (3) annotate the functional consequences of such single-nucleotide polymorphisms (SNPs) in the affected genes or their regulatory regions. The Global Test was applied to detect schizophrenia-associated pathways using discovery and replication datasets comprising 5,040 and 5,082 individuals of European ancestry, respectively. Information concerning functional gene-sets was retrieved from the Kyoto Encyclopedia of Genes and Genomes, Gene Ontology, and the Molecular Signatures Database. Fourteen of the gene-sets or pathways identified in the discovery dataset were confirmed in the replication dataset. These include functional processes involved in transcriptional regulation and gene expression, synapse organization, cell adhesion, and apoptosis. For two genes, i.e. CTCF and CACNB2, evidence for association with schizophrenia was available (at the gene-level) in both the discovery study and published data from the Psychiatric Genomics Consortium schizophrenia study. Furthermore, these genes mapped to four of the 14 presently identified pathways. Several of the SNPs assigned to CTCF and CACNB2 have potential functional consequences, and a gene in close proximity to CACNB2, i.e. ARL5B, was identified as a potential gene of interest. Application of the present hierarchical approach thus allowed: (1) identification of novel biological gene-sets or pathways with potential involvement in the etiology of schizophrenia, as well as replication of these findings in an independent cohort; (2) detection of genes of interest for future follow-up studies; and (3) the highlighting of novel genes in previously reported candidate regions for schizophrenia.
C1 [Juraeva, Dilafruz; Brors, Benedikt] German Canc Res Ctr, Div Theoret Bioinformat, Heidelberg, Germany.
[Haenisch, Britta; Lange, Christoph] German Ctr Neurodegenerat Dis DZNE, Bonn, Germany.
[Haenisch, Britta; Muehleisen, ThomasW.; Degenhardt, Franziska; Cichon, Sven; Noethen, MarkusM.] Univ Bonn, Inst Human Genet, Bonn, Germany.
[Haenisch, Britta] Fed Inst Drugs & Med Devices BfArM, Bonn, Germany.
[Haenisch, Britta] Univ Bonn, Dept Psychiat, Bonn, Germany.
[Zapatka, Marc] German Canc Res Ctr, Div Mol Genet, Heidelberg, Germany.
[Frank, Josef; Witt, Stephanie H.; Treutlein, Jens; Strohmaier, Jana; Meier, Sandra; Rietschel, Marcella] Heidelberg Univ, Med Fac Mannheim, Cent Inst Mental Hlth, Dept Genet Epidemiol Psychiat, Mannheim, Germany.
[Muehleisen, ThomasW.; Degenhardt, Franziska; Cichon, Sven; Noethen, MarkusM.; Mattheisen, Manuel] Univ Bonn, Dept Genom, Life & Brain Ctr, Bonn, Germany.
[Muehleisen, ThomasW.; Cichon, Sven] Res Ctr Juelich, Inst Neurosci & Med INM 1, Julich, Germany.
[Meier, Sandra] Aarhus Univ, Dept Econ & Business, NCRR, Aarhus, Denmark.
[Giegling, Ina; Rujescu, Dan] Univ Munich, Dept Psychiat, Div Mol & Clin Neurobiol, D-80539 Munich, Germany.
[Giegling, Ina; Rujescu, Dan] Univ Halle Wittenberg, Dept Psychiat, D-06108 Halle, Germany.
[Ripke, Stephan] Massachusetts Gen Hosp, Dept Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Ripke, Stephan] Broad Inst MIT & Harvard, Cambridge, MA USA.
[Leber, Markus] Univ Bonn, Inst Med Biometry Informat & Epidemiol, Bonn, Germany.
[Lange, Christoph; Mattheisen, Manuel] Univ Bonn, Dept Genom Math, Bonn, Germany.
[Lange, Christoph; Mattheisen, Manuel] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Schulze, ThomasG.] Univ Gottingen, Univ Med Ctr, Dept Psychiat & Psychotherapy, D-37073 Gottingen, Germany.
[Moessner, Rainald; Maier, Wolfgang] Univ Bonn, Dept Psychiat, Bonn, Germany.
[Nenadic, Igor; Sauer, Heinrich] Jena Univ Hosp, Dept Psychiat & Psychotherapy, Jena, Germany.
[Borglum, Anders; Mattheisen, Manuel] Aarhus Univ, Dept Biomed, Aarhus C, Denmark.
[Borglum, Anders; Mattheisen, Manuel] iSEQ, Ctr Integrated Sequencing, Aarhus, Denmark.
[Borglum, Anders; Mattheisen, Manuel] iPSYCH, Lundbeck Fdn Initiat Integrat Psychiat Res, Aarhus, Denmark.
[Borglum, Anders; Mattheisen, Manuel] iPSYCH, Lundbeck Fdn Initiat Integrat Psychiat Res, Copenhagen, Denmark.
[Borglum, Anders] Aarhus Univ Hosp, Ctr Psychiat Res, Risskov, Denmark.
[Ophoff, Roel] UCLA Ctr Neurobehav Genet, Los Angeles, CA USA.
[Ophoff, Roel] Univ Med Ctr Utrecht, Rudolf Magnus Inst Neurosci, Dept Psychiat, Utrecht, Netherlands.
[Cichon, Sven] Univ Basel Hosp, Dept Med Genet, CH-4031 Basel, Switzerland.
RP Juraeva, D (reprint author), German Canc Res Ctr, Div Theoret Bioinformat, Heidelberg, Germany.
EM d.juraeva@dkfz-heidelberg.de
RI Myin-Germeys, Inez /L-5106-2014; Brors, Benedikt/E-5620-2013; Mortensen,
Preben/D-2358-2015; Mattheisen, Manuel/B-4949-2012;
OI Brors, Benedikt/0000-0001-5940-3101; Mortensen,
Preben/0000-0002-5230-9865; Mattheisen, Manuel/0000-0002-8442-493X;
Myin-Germeys, Inez/0000-0002-3731-4930; Grove,
Jakob/0000-0003-2284-5744; Bruggeman, Richard/0000-0002-3238-8471;
Nothen, Markus/0000-0002-8770-2464
FU BMBF through the Integrated Genome Research Network (IG) MooDS under
National Genome Research Network plus (NGFNplus) [01GS08144, 01GS08147,
01GS08149]; European Community's Seventh Framework Programme (FP7)
[279227]; European Union Seventh Framework Programme (FP7) [242257];
DFG; Junior Scientist Grant (Rotationsstelle) of IZKF, Jena University
Hospital
FX This study was supported by the German Federal Ministry of Education and
Research (BMBF) through the Integrated Genome Research Network (IG)
MooDS (Systematic Investigation of the Molecular Causes of Major Mood
Disorders and Schizophrenia; grant 01GS08144 to MMN and SC, grant
01GS08147 to MR, grant 01GS08149 to BB), under the auspices of the
National Genome Research Network plus (NGFNplus). The research leading
to these results has received funding from the European Community's
Seventh Framework Programme (FP7/2007-2013) under grant agreement no
279227 (CRESTAR). Further funding came from the European Union Seventh
Framework Programme (FP7/2007-2011) under grant agreement no. 242257
(ADAMS). The Heinz Nixdorf Recall cohort was established with the
support of the Heinz Nixdorf Foundation (Dr G Schmidt, Chairman). MMN is
a member of the DFG-funded Excellence Cluster ImmunoSensation. IN was
supported by a Junior Scientist Grant (Rotationsstelle) of IZKF, Jena
University Hospital. The funders had no role in study design, data
collection and analysis, decision to publish, or preparation of the
manuscript.
NR 63
TC 10
Z9 10
U1 2
U2 9
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7390
EI 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD JUN
PY 2014
VL 10
IS 6
AR e1004345
DI 10.1371/journal.pgen.1004345
PG 11
WC Genetics & Heredity
SC Genetics & Heredity
GA AL0WL
UT WOS:000338847700004
PM 24901509
ER
PT J
AU Kemp, JP
Medina-Gomez, C
Estrada, K
St Pourcain, B
Heppe, DHM
Warrington, NM
Oei, L
Ring, SM
Kruithof, CJ
Timpson, NJ
Wolber, LE
Reppe, S
Gautvik, K
Grundberg, E
Ge, B
van der Eerden, B
van de Peppel, J
Hibbs, MA
Ackert-Bicknell, CL
Choi, K
Koller, DL
Econs, MJ
Williams, FMK
Foroud, T
Zillikens, MC
Ohlsson, C
Hofman, A
Uitterlinden, AG
Smith, GD
Jaddoe, VWV
Tobias, JH
Rivadeneira, F
Evans, DM
AF Kemp, John P.
Medina-Gomez, Carolina
Estrada, Karol
St Pourcain, Beate
Heppe, Denise H. M.
Warrington, Nicole M.
Oei, Ling
Ring, Susan M.
Kruithof, Claudia J.
Timpson, Nicholas J.
Wolber, Lisa E.
Reppe, Sjur
Gautvik, Kaare
Grundberg, Elin
Ge, Bing
van der Eerden, Bram
van de Peppel, Jeroen
Hibbs, Matthew A.
Ackert-Bicknell, Cheryl L.
Choi, Kwangbom
Koller, Daniel L.
Econs, Michael J.
Williams, Frances M. K.
Foroud, Tatiana
Zillikens, M. Carola
Ohlsson, Claes
Hofman, Albert
Uitterlinden, Andre G.
Smith, George Davey
Jaddoe, Vincent W. V.
Tobias, Jonathan H.
Rivadeneira, Fernando
Evans, David M.
TI Phenotypic Dissection of Bone Mineral Density Reveals Skeletal Site
Specificity and Facilitates the Identification of Novel Loci in the
Genetic Regulation of Bone Mass Attainment
SO PLOS GENETICS
LA English
DT Article
ID GENOME-WIDE ASSOCIATION; PREMENOPAUSAL WOMEN; METAANALYSIS; FRACTURES;
SNPS; TOOL; MAP; ANNOTATION; DISEASES; PROJECT
AB Heritability of bone mineral density (BMD) varies across skeletal sites, reflecting different relative contributions of genetic and environmental influences. To quantify the degree to which common genetic variants tag and environmental factors influence BMD, at different sites, we estimated the genetic (r(g)) and residual (r(e)) correlations between BMD measured at the upper limbs (UL-BMD), lower limbs (LL-BMD) and skull (SK-BMD), using total-body DXA scans of,4,890 participants recruited by the Avon Longitudinal Study of Parents and their Children (ALSPAC). Point estimates of r(g) indicated that appendicular sites have a greater proportion of shared genetic architecture (LL-/UL-BMD r(g) = 0.78) between them, than with the skull (UL-/SK-BMD r(g) = 0.58 and LL-/SK-BMD r(g) = 0.43). Likewise, the residual correlation between BMD at appendicular sites (r(e) = 0.55) was higher than the residual correlation between SK-BMD and BMD at appendicular sites (r(e) = 0.20-0.24). To explore the basis for the observed differences in r(g) and r(e), genome-wide association meta-analyses were performed (n similar to 9,395), combining data from ALSPAC and the Generation R Study identifying 15 independent signals from 13 loci associated at genome-wide significant level across different skeletal regions. Results suggested that previously identified BMD-associated variants may exert site-specific effects (i.e. differ in the strength of their association and magnitude of effect across different skeletal sites). In particular, variants at CPED1 exerted a larger influence on SK-BMD and UL-BMD when compared to LL-BMD (P = 2.01x10(-37)), whilst variants at WNT16 influenced UL-BMD to a greater degree when compared to SK- and LL-BMD (P = 2.31x10(-14)). In addition, we report a novel association between RIN3 (previously associated with Paget's disease) and LL-BMD (rs754388: beta = 0.13, SE = 0.02, P = 1.4x10(-10)). Our results suggest that BMD at different skeletal sites is under a mixture of shared and specific genetic and environmental influences. Allowing for these differences by performing genome-wide association at different skeletal sites may help uncover new genetic influences on BMD.
C1 [Kemp, John P.; St Pourcain, Beate; Ring, Susan M.; Timpson, Nicholas J.; Smith, George Davey; Evans, David M.] Univ Bristol, MRC Integrat Epidemiol Unit, Bristol, Avon, England.
[Kemp, John P.; Warrington, Nicole M.; Evans, David M.] Univ Queensland, Diamantina Inst, Translat Res Inst, Brisbane, Qld, Australia.
[Medina-Gomez, Carolina; Oei, Ling; van der Eerden, Bram; van de Peppel, Jeroen; Zillikens, M. Carola; Uitterlinden, Andre G.; Rivadeneira, Fernando] Erasmus Univ, Med Ctr, Dept Internal Med, Rotterdam, Netherlands.
[Medina-Gomez, Carolina; Heppe, Denise H. M.; Kruithof, Claudia J.; Hofman, Albert; Uitterlinden, Andre G.; Jaddoe, Vincent W. V.; Rivadeneira, Fernando] Erasmus Univ, Med Ctr, Generat Study Grp R, Rotterdam, Netherlands.
[Medina-Gomez, Carolina; Heppe, Denise H. M.; Oei, Ling; Kruithof, Claudia J.; Hofman, Albert; Uitterlinden, Andre G.; Jaddoe, Vincent W. V.; Rivadeneira, Fernando] Erasmus Univ, Med Ctr, Dept Epidemiol, Rotterdam, Netherlands.
[Estrada, Karol] Massachusetts Gen Hosp, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[St Pourcain, Beate] Univ Bristol, Sch Oral & Dent Sci, Bristol, Avon, England.
[St Pourcain, Beate] Univ Bristol, Sch Expt Psychol, Bristol, Avon, England.
[Heppe, Denise H. M.; Jaddoe, Vincent W. V.] Erasmus Univ, Med Ctr, Dept Paediat, Rotterdam, Netherlands.
[Wolber, Lisa E.; Williams, Frances M. K.] Kings Coll London, Dept Twin Res & Genet Epidemiol, London, England.
[Reppe, Sjur; Gautvik, Kaare] Oslo Univ Hosp, Dept Med Biochem, Oslo, Norway.
[Gautvik, Kaare] Oslo Deacon Hosp, Dept Med Biochem, Oslo, Norway.
[Grundberg, Elin] McGill Univ, Dept Human Genet, Montreal, PQ, Canada.
[Grundberg, Elin; Ge, Bing] McGill Univ, Montreal, PQ, Canada.
[Grundberg, Elin; Ge, Bing] Genome Quebec Innovat Ctr, Montreal, PQ, Canada.
[Hibbs, Matthew A.] Trinity Univ, Dept Comp Sci, San Antonio, TX USA.
[Hibbs, Matthew A.; Ackert-Bicknell, Cheryl L.; Choi, Kwangbom] Jackson Lab, Bar Harbor, ME 04609 USA.
[Koller, Daniel L.; Econs, Michael J.; Foroud, Tatiana] Indiana Univ Sch Med, Dept Med & Mol Genet, Indianapolis, IN 46202 USA.
[Econs, Michael J.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA.
[Ohlsson, Claes] Univ Gothenburg, Sahlgrenska Acad, Inst Med, Ctr Bone & Arthrit Res, Gothenburg, Sweden.
[Tobias, Jonathan H.] Univ Bristol, Sch Clin Sci, Bristol, Avon, England.
RP Kemp, JP (reprint author), Univ Bristol, MRC Integrat Epidemiol Unit, Bristol, Avon, England.
EM j.p.kemp@bristol.ac.uk
RI Warrington, Nicole/P-4868-2014; Rivadeneira, Fernando/O-5385-2015; Fox,
Laura /C-6249-2016; Oei, Ling/E-8163-2013; Davey Smith,
George/A-7407-2013;
OI Evans, David/0000-0003-0663-4621; Timpson, Nicholas/0000-0002-7141-9189;
Warrington, Nicole/0000-0003-4195-775X; Rivadeneira,
Fernando/0000-0001-9435-9441; Medina-Gomez,
Carolina/0000-0001-7999-5538; Kemp, John/0000-0002-9105-2249; Oei,
Ling/0000-0003-3523-458X; Davey Smith, George/0000-0002-1407-8314;
Williams, Frances/0000-0002-2998-2744; St Pourcain,
Beate/0000-0002-4680-3517
FU Medical Research Council [MC_UU_12013/4]; Australian Research Council
[FT130101709]; Wellcome Trust [WT083431MA, 092731]; UK Medical Research
Council; University of Bristol; 23andMe; European Commission
[HEALTH-F2-2008-201865-GEFOS]; German Bundesministerium fuer Forschung
und Technology [01 AK 803 A-H, 01 IG 07015 G]; Erasmus Medical Center,
Rotterdam; Erasmus University Rotterdam; Netherlands Organization for
Health Research and Development (ZonMw); Netherlands Organisation for
Scientific Research (NWO); Ministry of Health, Welfare and Sport;
Netherlands Organization for Health Research and Development (VWVJ)
[ZonMw 907.00303, ZonMw 916.10159, ZonMw VIDI 016.136.367]; European
Commission; Genetic Laboratory of the Department of Internal Medicine,
Erasmus MC Rotterdam; NIH [R01 AG041517, M01 RR-00750, R01 AR43351-11,
U01HL072515-06, F32 AR059469, R01 AR/AG 41398, R01 AR 050066]; National
Heart, Lung, and Blood Institute's Framingham Heart Study [N01 HC
25195]; Robert Dawson Evans Endowment of the Department of Medicine at
Boston University School of Medicine and Boston Medical Center
FX ALSPAC: This work was supported by the Medical Research Council
MC_UU_12013/4. DME is funded by an Australian Research Council Future
Fellowship (FT130101709). JPK is funded by a Wellcome Trust 4-year PhD
studentship in molecular, genetic, and life course epidemiology
(WT083431MA). The UK Medical Research Council and the Wellcome Trust
(Grant ref: 092731) and the University of Bristol provide core support
for ALSPAC. 23andMe funded the generation of the ALSPAC GWA data.
Funding to pay the Open Access publication charges for this article was
provided by the Wellcome Trust. Generation R Study: The musculoskeletal
research of the Generation R Study is partly supported by the European
Commission grant HEALTH-F2-2008-201865-GEFOS. The grid resources used by
this study were funded by the German Bundesministerium fuer Forschung
und Technologyunder grants #01 AK 803 A-H and #01 IG 07015 G. The
general design of Generation R Study is made possible by financial
support from the Erasmus Medical Center, Rotterdam, the Erasmus
University Rotterdam, the Netherlands Organization for Health Research
and Development (ZonMw), the Netherlands Organisation for Scientific
Research (NWO), and the Ministry of Health, Welfare and Sport. VWVJ and
FR received additional grants from the Netherlands Organization for
Health Research and Development (VWVJ: ZonMw 907.00303, ZonMw 916.10159
and FR: ZonMw VIDI 016.136.367). CMG is supported by the European
Commission's EACEA within the framework of the Erasmus Mundus
Partnerships programme Erasmus-Columbus (ERACOL) and by the Genetic
Laboratory of the Department of Internal Medicine, Erasmus MC Rotterdam.
Miscellaneous: Participants in the premenopausal BMD meta-analysis study
were funded by NIH grants R01 AG041517, M01 RR-00750, R01 AR43351-11,
U01HL072515-06, F32 AR059469, R01 AR/AG 41398, and R01 AR 050066.
Genotyping was provided by CIDR (NIH HHSN268200782096C) and the Azar
Foundation. The Framingham Heart Study of the National Heart, Lung, and
Blood Institute of the National Institutes of Health and Boston
University School of Medicine were supported by the National Heart,
Lung, and Blood Institute's Framingham Heart Study (N01 HC 25195) and
its contract with Affymetrix, Inc. for genotyping services (N02 HL
64278). Analyses reflect intellectual input and resource development
from the Framingham Heart Study investigators participating in the SNP
Health Association Resource (SHARe) project. A portion of this research
was conducted using the Linux Cluster for Genetic Analysis (LinGA-II)
funded by the Robert Dawson Evans Endowment of the Department of
Medicine at Boston University School of Medicine and Boston Medical
Center. Please note that in all cases, the funders had no role in study
design, data collection and analysis, decision to publish, or
preparation of the manuscript.
NR 51
TC 35
Z9 35
U1 0
U2 6
PU PUBLIC LIBRARY SCIENCE
PI SAN FRANCISCO
PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA
SN 1553-7404
J9 PLOS GENET
JI PLoS Genet.
PD JUN
PY 2014
VL 10
IS 6
AR e1004423
DI 10.1371/journal.pgen.1004423
PG 18
WC Genetics & Heredity
SC Genetics & Heredity
GA AL0WL
UT WOS:000338847700039
PM 24945404
ER
PT J
AU Yu, HH
Cheng, L
Cho, KS
AF Yu, Honghua
Cheng, Lin
Cho, Kin-Sang
TI The potential of stem cell-based therapy for retinal repair
SO NEURAL REGENERATION RESEARCH
LA English
DT Article
ID MACULAR DEGENERATION; PROGENITOR CELLS; SUBRETINAL SPACE;
CLINICAL-TRIALS; GANGLION-CELLS; DIFFERENTIATION; TRANSPLANTATION;
INTEGRATION; LINES; DEATH
AB Like injured neurons in the brain or spinal cord, neurons in the retina are incapable to regenerate following injury and ultimately would lead to irreversible neuronal loss and vision impairment. Over decades, extensive effort has been made to develop strategies to protect retinal neurons from death; however, the outcome is limited (Pettmann and Henderson, 1998; Bahr, 2000; Lagali and Picketts, 2011). Replacing the degenerated retinal neurons by newly generated and functional neurons would be an ideal scenario. The rapid development of stem cell biology has recently demonstrated that stem cells could be a potential source of cells for cell replacement therapy because these cells have the self-renewal capacity and could be differentiated into many cell types. This review will discuss the therapeutic potential of stem cell-based therapy to retinal degenerative diseases.
C1 [Yu, Honghua] Gen Hosp Guangzhou Mil Command PLA, Dept Ophthalmol, Guangzhou, Guangdong, Peoples R China.
[Cheng, Lin] Cent S Univ, Dept Clin Pharmacol, Xiangya Hosp, Changsha, Hunan, Peoples R China.
[Cheng, Lin] Cent S Univ, Inst Clin Pharmacol, Changsha, Hunan, Peoples R China.
[Cheng, Lin] Hunan Key Lab Pharmacogenet, Changsha, Hunan, Peoples R China.
[Yu, Honghua; Cheng, Lin; Cho, Kin-Sang] Harvard Univ, Sch Med, Schepens Eye Res Inst, Massachusetts Eye & Ear Infirm,Dept Ophthalmol, Boston, MA 02114 USA.
RP Cho, KS (reprint author), Harvard Univ, Sch Med, Schepens Eye Res Inst, Massachusetts Eye & Ear Infirm,Dept Ophthalmol, 20 Staniford St, Boston, MA 02114 USA.
EM Kinsang_Cho@meei.harvard.edu
OI Cheng, Lin/0000-0002-4960-8186
NR 76
TC 0
Z9 0
U1 0
U2 5
PU SHENYANG EDITORIAL DEPT NEURAL REGENERATION RES
PI SHENYANG
PA PO BOX 1234, SHENYANG, LIAONING 110004, PEOPLES R CHINA
SN 1673-5374
J9 NEURAL REGEN RES
JI Neural Regen. Res.
PD JUN
PY 2014
VL 9
IS 11
BP 1100
EP 1103
DI 10.4103/1673-5374.135311
PG 4
WC Cell Biology; Neurosciences
SC Cell Biology; Neurosciences & Neurology
GA AL0FX
UT WOS:000338803900003
PM 25206766
ER
PT J
AU Glick, AR
Khan, IA
Sher, L
AF Glick, Amy R.
Khan, Imran A.
Sher, Leo
TI Treatment of Antipsychotic-Induced Sialorrhea
SO PSYCHIATRIC ANNALS
LA English
DT Editorial Material
ID CLOZAPINE-INDUCED SIALORRHEA; STRATEGIES
C1 [Glick, Amy R.; Sher, Leo] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
[Khan, Imran A.; Sher, Leo] James J Peters VA Med Ctr, New York, NY USA.
RP Glick, AR (reprint author), Icahn Sch Med Mt Sinai, One Gustave L Levy Pl, New York, NY 10029 USA.
EM amy.glick@mountsinai.org
NR 10
TC 0
Z9 0
U1 0
U2 3
PU SLACK INC
PI THOROFARE
PA 6900 GROVE RD, THOROFARE, NJ 08086 USA
SN 0048-5713
EI 1938-2456
J9 PSYCHIAT ANN
JI Psychiatr. Ann.
PD JUN
PY 2014
VL 44
IS 6
BP 267
EP 269
DI 10.3928/00485713-20140609-02
PG 3
WC Psychiatry
SC Psychiatry
GA AL0PB
UT WOS:000338827700002
ER
PT J
AU Vacanti, JP
Kulig, KM
AF Vacanti, Joseph P.
Kulig, Katherine M.
TI Liver cell therapy and tissue engineering for transplantation
SO SEMINARS IN PEDIATRIC SURGERY
LA English
DT Article
DE Hepatocytes; Liver transplantation alternatives; Organ engineering; Stem
cells; Tissue engineering; Xenotransplantation; Regenerative medicine
ID EMBRYONIC STEM-CELLS; HEPATOCYTE-LIKE CELLS; IN-VITRO DIFFERENTIATION;
BIOARTIFICIAL LIVER; ASSIST DEVICE; CONTROLLED-TRIAL; CORD BLOOD;
HEPATIC DIFFERENTIATION; PROGENITOR CELLS; SUPPORT-SYSTEM
AB Liver transplantation remains the only definitive treatment for liver failure and is available to only a tiny fraction of patients with end-stage liver diseases. Major limitations for the procedure include donor organ shortage, high cost, high level of required expertise, and long-term consequences of immune suppression. Alternative cell-based liver therapies could potentially greatly expand the number of patients provided with effective treatment Investigative research into augmenting or replacing liver function extends into three general strategies. Bioartificial livers (BALs) are extracorporeal devices that utilize cartridges of primary hepatocytes or cell lines to process patient plasma. Injection of liver cell suspensions aims to foster organ regeneration or provide a missing metabolic function arising from a genetic defect. Tissue engineering recreates the organ in vitro for subsequent implantation to augment or replace patient liver function. Translational models and clinical trials have highlighted both the immense challenges involved and some striking examples of success. (C) 2014 Published by Elsevier Inc.
C1 [Vacanti, Joseph P.; Kulig, Katherine M.] Massachusetts Gen Hosp, Ctr Regenerat Med, Boston, MA 02114 USA.
[Vacanti, Joseph P.; Kulig, Katherine M.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Vacanti, Joseph P.; Kulig, Katherine M.] MassGen Hosp Children, Dept Pediat Surg, Boston, MA USA.
[Vacanti, Joseph P.] Harvard Univ, Sch Med, Boston, MA USA.
RP Vacanti, JP (reprint author), Massachusetts Gen Hosp, Dept Surg, 55 Fruit St,WRN 1151, Boston, MA 02114 USA.
EM jvacanti@partners.org
NR 63
TC 9
Z9 9
U1 3
U2 22
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1055-8586
EI 1532-9453
J9 SEMIN PEDIATR SURG
JI Semin. Pediatr. Surg.
PD JUN
PY 2014
VL 23
IS 3
BP 150
EP 155
DI 10.1053/j.sempedsurg.2014.05.001
PG 6
WC Pediatrics; Surgery
SC Pediatrics; Surgery
GA AL1SL
UT WOS:000338906300008
PM 24994529
ER
PT J
AU Sharkey, KM
Crawford, SL
Kim, S
Joffe, H
AF Sharkey, Katherine M.
Crawford, Sybil L.
Kim, Semmie
Joffe, Hadine
TI Objective sleep interruption and reproductive hormone dynamics in the
menstrual cycle
SO SLEEP MEDICINE
LA English
DT Article
DE Menstrual cycle; Progesterone; Estradiol; Estrone; Sleep; Premenopausal;
Polysomnography
ID PREMENSTRUAL DYSPHORIC DISORDER; POSTMENOPAUSAL WOMEN; ESTROGEN
REPLACEMENT; BODY TEMPERATURES; MASS-SPECTROMETRY; HYPOGONADAL WOMEN;
HEALTHY WOMEN; PROGESTERONE; ESTRADIOL; THERAPY
AB Objectives: Women report greater sleep disturbance during the premenstrual phase of the menstrual cycle and during menses. However, the putative hormonal basis of perceived menstrual cycle-related sleep disturbance has not been investigated directly. We examined associations, of objective measures of sleep fragmentation with reproductive hormone levels in healthy, premenopausal women.
Methods: Twenty-seven women with monthly menses had hormone levels measured at two time points during a single menstrual cycle: the follicular phase and the peri-ovulatory to mid-luteal phase. A single night of home polysomnography (PSG) was recorded on the day of the peri-ovulatory/mid-luteal-phase blood draw. Serum progesterone, estradiol, and estrone levels concurrent with PSG and rate of change in progesterone (PROGslope) from the follicular blood draw to PSG were correlated with log-transformed wake after sleep onset (InWASO%) and number of wakes/hour of sleep (InWake-Index) using linear regression.
Results: Sleep was more fragmented in association with a steeper PROGslope (InWASO% p = 0.016; InWake-Index p = 0.08) and higher concurrent estrone level (InWASO% p = 0.03; InWake-Index p = 0.01), but the effect of estrone on WASO was lost after accounting for PROGslope. WASO% and Wake-Index were not associated with concomitant progesterone or estradiol levels.
Conclusions: A steeper rate of rise in progesterone levels from the follicular phase through the mid-luteal phase was associated with significantly greater WASO, establishing a link between reproductive hormone dynamics and sleep fragmentation in the luteal phase of the menstrual cycle. (C) 2014 Elsevier B.V. All rights reserved.
C1 [Sharkey, Katherine M.] Brown Univ, Rhode Isl Hosp, Alpert Med Sch, Dept Med, Providence, RI 02903 USA.
[Sharkey, Katherine M.] Brown Univ, Rhode Isl Hosp, Alpert Med Sch, Dept Psychiat & Human Behav, Providence, RI 02903 USA.
[Crawford, Sybil L.] Univ Massachusetts, Sch Med, Dept Med, Div Prevent & Behav Med, Worcester, MA 01655 USA.
[Kim, Semmie; Joffe, Hadine] Harvard Univ, Sch Med, Brigham & Womens Hosp, Womens Hormones & Aging Res Program,Dept Psychiat, Boston, MA 02115 USA.
[Joffe, Hadine] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Psychosocial Oncol & Palliat Care, Boston, MA 02115 USA.
RP Joffe, H (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Womens Hormones & Aging Res Program,Dept Psychiat, 75 Francis St, Boston, MA 02115 USA.
EM hjoffe@partners.org
FU NIH (United States); Cephalon/Teva; [5 R01 MH082922]; [K23 MH086689]
FX The authors thank Susan Regan, Ph.D, for her valuable contributions to
this study. This work was supported by 5 R01 MH082922 (HJ) and K23
MH086689 (KMS). KMS, SK, and SC have no conflicts to report. HJ receives
research funding from NIH (United States) and Cephalon/Teva, and serves
as a consultant for Noven and as an unpaid consultant to Sunovion.
NR 38
TC 2
Z9 2
U1 0
U2 2
PU ELSEVIER SCIENCE BV
PI AMSTERDAM
PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS
SN 1389-9457
EI 1878-5506
J9 SLEEP MED
JI Sleep Med.
PD JUN
PY 2014
VL 15
IS 6
BP 688
EP 693
DI 10.1016/j.sleep.2014.02.003
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA AK7PW
UT WOS:000338621200017
PM 24841109
ER
PT J
AU Varghese, M
Ho, L
Wang, J
Zhao, W
Levine, S
Ono, K
Mannino, S
Pasinetti, GM
AF Varghese, Merina
Ho, Lap
Wang, Jun
Zhao, Wei
Levine, Samara
Ono, Kenjiro
Mannino, Salvatore
Pasinetti, Giulio Maria
TI Green coffee as a novel agent for Alzheimer's disease prevention by
attenuating diabetes
SO TRANSLATIONAL NEUROSCIENCE
LA English
DT Article
DE Coffee; Alzheimer's disease; Diabetes; Diabetes type 2; Brain; Energy
metabolism
ID INDUCED INSULIN-RESISTANCE; AMYLOID-BETA LEVELS; COGNITIVE IMPAIRMENT;
DECAFFEINATED COFFEE; CHLOROGENIC ACID; MOUSE MODEL; CAFFEINE; MICE;
RISK; CONSUMPTION
AB Diabetes type 2, caused mainly by insulin resistance, is growing in incidence worldwide. In addition to being a major public health concern, type 2 diabetes is also a risk factor for dementia, including Alzheimer's disease type dementia. Coffee consumption is reported to have protective effects in both diabetes and Alzheimer's disease. We review here the reported beneficial effects of coffee in both disease conditions and the previously identified active ingredients of coffee. Furthermore, we revisit our recent findings of improved glucose utilization in the periphery and in the brain in a mouse model of high-fat diet induced type 2 diabetes after treatment with a decaffeinated green coffee preparation. Overall, consumption of coffee appears to improve diabetes and reduce the risk of dementia, although future studies are required to further identify the active components and the type of coffee that is most effective in addressing these conditions.
C1 [Varghese, Merina; Ho, Lap; Wang, Jun; Zhao, Wei; Levine, Samara; Pasinetti, Giulio Maria] Mt Sinai Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA.
[Ho, Lap; Wang, Jun; Zhao, Wei; Pasinetti, Giulio Maria] James J Peters Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY 10468 USA.
[Ono, Kenjiro] Kanazawa Univ, Grad Sch Med Sci, Dept Neurol & Neurobiol & Aging, Kanazawa, Ishikawa 9209640, Japan.
[Mannino, Salvatore] Osped Alzano, Geriatr Output Unit, Bergamo, Italy.
RP Varghese, M (reprint author), Mt Sinai Icahn Sch Med Mt Sinai, Dept Neurol, New York, NY 10029 USA.
EM giulio.pasinetti@mssm.edu
OI Varghese, Merina/0000-0002-1517-3903
NR 44
TC 2
Z9 2
U1 4
U2 20
PU DE GRUYTER OPEN LTD
PI WARSAW
PA SOLIPSKA 14A-1, 02-482 WARSAW, POLAND
SN 2081-3856
EI 2081-6936
J9 TRANSL NEUROSCI
JI Transl. Neurosci.
PD JUN
PY 2014
VL 5
IS 2
BP 111
EP 116
DI 10.2478/s13380-014-0213-y
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA AK8AV
UT WOS:000338650400001
ER
PT J
AU Lin, JJ
Mahindra, A
Santo, L
Amin, S
Sohani, AR
Raje, N
AF Lin, J. J.
Mahindra, A.
Santo, L.
Amin, S.
Sohani, A. R.
Raje, N.
TI MicroRNA expression patterns in medullary and extramedullary
plasmacytoma
SO BLOOD CANCER JOURNAL
LA English
DT Letter
ID MULTIPLE-MYELOMA; BONE; PROLIFERATION; ANGIOGENESIS
C1 [Lin, J. J.; Mahindra, A.; Santo, L.; Amin, S.; Sohani, A. R.; Raje, N.] Massachusetts Gen Hosp, Ctr Canc, Ctr Multiple Myeloma, Boston, MA 02114 USA.
RP Lin, JJ (reprint author), Massachusetts Gen Hosp, Ctr Canc, Ctr Multiple Myeloma, Boston, MA 02114 USA.
EM nraje@partners.org
OI Amin, Samir/0000-0002-3207-9505
NR 15
TC 0
Z9 0
U1 0
U2 0
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2044-5385
J9 BLOOD CANCER J
JI Blood Cancer J.
PD JUN
PY 2014
VL 4
AR e223
DI 10.1038/bcj.2014.41
PG 3
WC Oncology
SC Oncology
GA AL0VP
UT WOS:000338845400007
PM 24972152
ER
PT J
AU Bah, N
Maillet, L
Ryan, J
Dubreil, S
Gautier, F
Letai, A
Juin, P
Barille-Nion, S
AF Bah, N.
Maillet, L.
Ryan, J.
Dubreil, S.
Gautier, F.
Letai, A.
Juin, P.
Barille-Nion, S.
TI Bcl-xL controls a switch between cell death modes during mitotic arrest
SO CELL DEATH & DISEASE
LA English
DT Article
ID PACLITAXEL-INDUCED APOPTOSIS; BREAST-CANCER; PHOSPHORYLATION SITE;
CHECKPOINT; IDENTIFICATION; CHEMOTHERAPY; INHIBITOR; SENSITIVITY;
DEPENDENCY; BCL-X(L)
AB Antimitotic agents such as microtubule inhibitors (paclitaxel) are widely used in cancer therapy while new agents blocking mitosis onset are currently in development. All these agents impose a prolonged mitotic arrest in cancer cells that relies on sustained activation of the spindle assembly checkpoint and may lead to subsequent cell death by incompletely understood molecular events. We have investigated the role played by anti-apoptotic Bcl-2 family members in the fate of mitotically arrested mammary tumor cells treated with paclitaxel, or depleted in Cdc20, the activator of the anaphase promoting complex. Under these conditions, a weak and delayed mitotic cell death occurs that is caspase-and Bax/Bak-independent. Moreover, BH3 profiling assays indicate that viable cells during mitotic arrest are primed to die by apoptosis and that Bcl-xL is required to maintain mitochondrial integrity. Consistently, Bcl-xL depletion, or treatment with its inhibitor ABT-737 (but not with the specific Bcl-2 inhibitor ABT-199), during mitotic arrest converts cell response to antimitotics to efficient caspase and Bax-dependent apoptosis. Apoptotic priming under conditions of mitotic arrest relies, at least in part, on the phosphorylation on serine 62 of Bcl-xL, which modulates its interaction with Bax and its sensitivity to ABT-737. The phospho-mimetic S62D-Bcl-xL mutant is indeed less efficient than the corresponding phospho-deficient S62A-Bcl-xL mutant in sequestrating Bax and in protecting cancer cells from mitotic cell death or yeast cells from Bax-induced growth inhibition. Our results provide a rationale for combining Bcl-xL targeting to antimitotic agents to improve clinical efficacy of antimitotic strategy in cancer therapy.
C1 [Bah, N.; Maillet, L.; Dubreil, S.; Gautier, F.; Juin, P.; Barille-Nion, S.] Univ Nantes, Inst Rech Sante, Team Cell Survival & Tumor Escape Breast Canc 8, INSERM,UMR 892,CNRS 6299, F-44007 Nantes, France.
[Ryan, J.; Letai, A.] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Gautier, F.; Juin, P.] Ctr Lutte Canc Rene Gauducheau, ICO, F-44805 St Herblain, France.
[Gautier, F.] Univ Nantes, Inst Rech Sante, Plateforme IMPACT Biogenouest, F-44007 Nantes 1, France.
RP Barille-Nion, S (reprint author), Univ Nantes, Inst Rech Sante, Team Cell Survival & Tumor Escape Breast Canc 8, INSERM,UMR 892,CNRS 6299, 8 Quai Moncousu,BP 70721, F-44007 Nantes, France.
EM sophie.barille@inserm.fr
RI Barille-Nion, sophie/K-8057-2015; Gautier, Fabien/K-9119-2015; JUIN,
Philippe/H-3636-2014; MAILLET, Laurent/K-7959-2015
OI JUIN, Philippe/0000-0002-4997-3888; MAILLET, Laurent/0000-0002-8169-060X
FU la Ligue contre le Cancer de Loire-Atlantique; la Ligue Regionale contre
le Cancer Grand-Ouest; French Society of Cancer
FX We thank Philippe Hulin for his technical support in Cellular and
Tissular Imaging Core Facility of Nantes University (MicroPICell). We
also thank the Cytometry Facilty Cytocell from Nantes for expert
technical assistance. We thank Claude Prigent and Francois Paris for
fruitful discussions. We thank Sophie de Carne for providing us the
MCF-7-YFP and MCF-7-YFP-Bcl-xL cell lines. N Bah was supported by la
Ligue contre le Cancer de Loire-Atlantique. We thank la Ligue Regionale
contre le Cancer Grand-Ouest and the French Society of Cancer for their
financial support.
NR 34
TC 17
Z9 18
U1 3
U2 15
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-4889
J9 CELL DEATH DIS
JI Cell Death Dis.
PD JUN
PY 2014
VL 5
AR e1291
DI 10.1038/cddis.2014.251
PG 12
WC Cell Biology
SC Cell Biology
GA AK9WE
UT WOS:000338778500019
PM 24922075
ER
PT J
AU Udell, JA
Braunwald, E
Antman, EM
Murphy, SA
Montalescot, G
Wiviott, SD
AF Udell, Jacob A.
Braunwald, Eugene
Antman, Elliot M.
Murphy, Sabina A.
Montalescot, Gilles
Wiviott, Stephen D.
TI Prasugrel Versus Clopidogrel in Patients With ST-Segment Elevation
Myocardial Infarction According to Timing of Percutaneous Coronary
Intervention A TRITON-TIMI 38 Subgroup Analysis (Trial to Assess
Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition
with Prasugrel-Thrombolysis In Myocardial Infarction 38)
SO JACC-CARDIOVASCULAR INTERVENTIONS
LA English
DT Article
DE antiplatelet therapy; myocardial infarction; periprocedural myocardial
injury; prasugrel; primary percutaneous coronary intervention
ID UNIVERSAL DEFINITION; CLASSIFICATION-SYSTEM; REPERFUSION THERAPY;
AMERICAN-COLLEGE; HEART; PRETREATMENT; TICAGRELOR; CARDIOLOGY; SOCIETY;
INJURY
AB Objectives This study sought to evaluate the efficacy of prasugrel versus clopidogrel in ST-segment elevation myocardial infarction (STEMI) by the timing of percutaneous coronary intervention (PCI).
Background Treatment strategies and outcomes for patients with STEMI may differ when treated with primary compared with secondary PCI.
Methods STEMI patients in the TRITON-TIMI 38 (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis In Myocardial Infarction 38) were randomized to prasugrel or clopidogrel on presentation if primary PCI was intended or later during secondary PCI. Primary PCI was defined as within 12 h of symptom onset. The primary endpoint was cardiovascular death, myocardial infarction (MI), or stroke. Because periprocedural MI is difficult to assess in the setting of STEMI, we performed analyses excluding these events.
Results Reductions in the primary endpoint with prasugrel versus clopidogrel (hazard ratio [HR]: 0.79; 95% confidence interval [CI]: 0.65 to 0.97; p = 0.022) were consistent between primary and secondary PCI patients at 15 months (HR: 0.89; 95% CI: 0.69 to 1.13 vs. HR: 0.65; 95% CI: 0.46 to 0.93; p interaction = 0.15). However, a tendency toward a difference in treatment effect at 30 days (HR: 0.68; 95% CI: 0.54 to 0.87; p = 0.002) was observed between primary and secondary PCI patients (HR: 0.81; 95% CI: 0.60 to 1.09 vs. HR: 0.51; 95% CI: 0.34 to 0.76; p interaction = 0.06). When periprocedural MI was excluded, the efficacy of prasugrel remained consistent among primary and secondary PCI patients at 30 days (HR: 0.53; 95% CI: 0.34 to 0.81 vs. HR: 0.44; 95% CI: 0.22 to 0.88; p interaction = 0.68) and 15 months (HR: 0.76; 95% CI: 0.56 to 1.03 vs. HR: 0.75; 95% CI: 0.46 to 1.21; p interaction = 0.96).
Conclusions The efficacy of prasugrel versus clopidogrel was consistent irrespective of the timing of PCI, particularly in preventing nonprocedural events. (Trial to Assess Improvement in Therapeutic Outcomes by Optimizing Platelet Inhibition with Prasugrel-Thrombolysis in Myocardial Infarction 38; NCT00097591) (C) 2014 by the American College of Cardiology Foundation
C1 [Udell, Jacob A.] Univ Toronto, Womens Coll Hosp, Womens Coll Res Inst, Toronto, ON, Canada.
[Udell, Jacob A.] Univ Toronto, Womens Coll Hosp, Dept Med, Cardiovasc Div, Toronto, ON, Canada.
[Braunwald, Eugene; Antman, Elliot M.; Murphy, Sabina A.; Wiviott, Stephen D.] Harvard Univ, Brigham & Womens Hosp, TIMI Study Grp, Cardiovasc Div,Dept Med,Med Sch, Boston, MA 02115 USA.
[Montalescot, Gilles] Univ Paris 06, INSERM, Hop La Pitie Salpetriere, AP HP,ACT Study Grp,Inst Cardiol,UMRS 1166, Paris, France.
RP Wiviott, SD (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
EM swiviott@partners.org
FU Eli Lilly and Company; Daiichi Sankyo Company Ltd.; Canadian Institutes
of Health Research (Ottawa, Ontario, Canada); Canadian Foundation for
Women's Health (Ottawa, Ontario, Canada); Eli Lilly; Daiichi Sankyo;
Abbott Vascular; Accumetrics; AstraZeneca; Biotronik; Bristol-Myers
Squibb; Federation Francaise de Cardiologie; Fondation de France;
INSERM; Institut de France; Medtronic; Menarini; Nanospheres; Pfizer;
Roche; Sanofi-Aventis; Stentys; Societe Francaise de Cardiologie;
Medicines Company; Bayer; Boehringer-Ingelheim; Duke Institute; Europa;
GlaxoSmithKline; Iroko; Lead Up; Novartis; Springer; TIMI Study Group;
WebMD; Wolters; Arena; Bristol-Myers-Squibb; Eisai; Merck; Aegerion;
Angelmed; Boston Clinical Research Institute; ICON Clinical; Janssen;
Xoma
FX TRITON-TIMI 38 received funding from Eli Lilly and Company and Daiichi
Sankyo Company Ltd. No additional funding for this analysis was
provided. Dr. Udell was supported in part by a Postdoctoral Research
Fellowship from the Canadian Institutes of Health Research (Ottawa,
Ontario, Canada) and the Canadian Foundation for Women's Health (Ottawa,
Ontario, Canada). The TIMI Study Group has received significant research
grant support from Eli Lilly and Daiichi Sankyo. Dr. Braunwald has
received significant research grant support from Eli Lilly and Daiichi
Sankyo; and lecture honoraria from Daiichi Sankyo. Dr. Antman has
received significant research grant support from Eli Lilly and Daiichi
Sankyo. Ms. Murphy has received research funding from Eli Lilly. Dr.
Montalescot and his research units have received significant research
grant support from Abbott Vascular, Accumetrics, AstraZeneca, Biotronik,
Bristol-Myers Squibb, Daiichi Sankyo, Eli Lilly, Federation Francaise de
Cardiologie, Fondation de France, INSERM, Institut de France, Medtronic,
Menarini, Nanospheres, Pfizer, Roche, Sanofi-Aventis, Stentys, Societe
Francaise de Cardiologie, and The Medicines Company; and consulting fees
from AstraZeneca, Accumetrics, Bayer, Biotronik, Bristol-Myers Squibb,
Boehringer-Ingelheim, Duke Institute, Eli Lilly, Europa,
GlaxoSmithKline, Iroko, Lead Up, Medtronic, Menarini, Novartis, Pfizer,
Roche, Sanofi-Aventis, Springer, The Medicines Company, TIMI Study
Group, WebMD, and Wolters. S. A. Murphy has received research funding
from Eli Lilly. Dr Wiviott has received significant research grants from
Arena, AstraZeneca, Bristol-Myers-Squibb, Daiichi Sankyo, Eisai, Eli
Lilly, Merck, and Sanofi-Aventis; and consulting fees from Aegerion,
Angelmed, Arena, AstraZeneca, Boston Clinical Research Institute,
Bristol-Myers-Squibb, Daiichi Sankyo, Eisai, Eli Lilly, ICON Clinical,
Janssen, and Xoma. Dr. Udell has reported that he has no relationships
relevant to the contents of this paper to disclose.
NR 25
TC 17
Z9 17
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-8798
EI 1876-7605
J9 JACC-CARDIOVASC INTE
JI JACC-Cardiovasc. Interv.
PD JUN
PY 2014
VL 7
IS 6
BP 604
EP 612
DI 10.1016/j.jcin.2014.01.160
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AL2HI
UT WOS:000338946200013
PM 24947719
ER
PT J
AU Hu, SN
Jia, HB
Vergallo, R
Abtahian, F
Tian, JW
Soeda, T
Rosenfield, K
Jang, IK
AF Hu, Sining
Jia, Haibo
Vergallo, Rocco
Abtahian, Farhad
Tian, Jinwei
Soeda, Tsunenari
Rosenfield, Kenneth
Jang, Ik-Kyung
TI Plaque Erosion In Vivo Diagnosis and Treatment Guided by Optical
Coherence Tomography
SO JACC-CARDIOVASCULAR INTERVENTIONS
LA English
DT Editorial Material
DE acute coronary syndrome; optical coherence tomography; plaque erosion
ID SUDDEN CORONARY DEATH
C1 [Hu, Sining; Jia, Haibo; Tian, Jinwei] Harbin Med Univ, Key Lab Myocardial Ischemia, Chinese Minist Educ, Dept Cardiol,Affiliated Hosp 2, Harbin, Peoples R China.
[Hu, Sining; Jia, Haibo; Vergallo, Rocco; Abtahian, Farhad; Tian, Jinwei; Soeda, Tsunenari; Rosenfield, Kenneth; Jang, Ik-Kyung] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiol Div, Boston, MA USA.
RP Jang, IK (reprint author), Massachusetts Gen Hosp, Div Cardiol, 55 Fruit St GRB 800, Boston, MA 02114 USA.
EM ijang@partners.org
NR 4
TC 2
Z9 3
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-8798
EI 1876-7605
J9 JACC-CARDIOVASC INTE
JI JACC-Cardiovasc. Interv.
PD JUN
PY 2014
VL 7
IS 6
BP E63
EP E64
DI 10.1016/j.jcin.2013.10.024
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AL2HI
UT WOS:000338946200007
PM 24947729
ER
PT J
AU Hall, JA
Tabata, M
Rodgers, JT
Puigserver, P
AF Hall, Jessica A.
Tabata, Mitsuhisa
Rodgers, Joseph T.
Puigserver, Pere
TI USP7 Attenuates Hepatic Gluconeogenesis Through Modulation of FoxO1 Gene
Promoter Occupancy
SO MOLECULAR ENDOCRINOLOGY
LA English
DT Article
ID FORKHEAD TRANSCRIPTION FACTOR; PHOSPHOENOLPYRUVATE CARBOXYKINASE GENE;
UBIQUITIN-SPECIFIC PROTEASE; BINDING PROTEIN-1 PROMOTER;
INSULIN-RESPONSE SEQUENCE; DNA-BINDING; FACTOR FKHR;
SUBCELLULAR-LOCALIZATION; NUCLEAR EXCLUSION; COACTIVATOR PGC-1
AB Hepatic forkhead protein FoxO1 is a key component of systemic glucose homeostasis via its ability to regulate the transcription of rate-limiting enzymes in gluconeogenesis. Important in the regulation of FoxO1 transcriptional activity are the modifying/demodifying enzymes that lead to posttranslational modification. Here, we demonstrate the functional interaction and regulation of FoxO1 by herpesvirus-associated ubiquitin-specific protease 7 (USP7; also known as herpesvirus-associated ubiquitin-specific protease, HAUSP), a deubiquitinating enzyme. We show that USP7-mediated mono-deubiquitination of FoxO1 results in suppression of FoxO1 transcriptional activity through decreased FoxO1 occupancy on the promoters of gluconeogenic genes. Knockdown of USP7 in primary hepatocytes leads to increased expression of FoxO1-target gluconeogenic genes and elevated glucose production. Consistent with this, USP7 gain-of-function suppresses the fasting/cAMP-induced activation of gluconeogenic genes in hepatocyte cells and in mouse liver, resulting in decreased hepatic glucose production. Notably, we show that the effects of USP7 on hepatic glucose metabolism depend on FoxO1. Together, these results place FoxO1 under the intimate regulation of deubiquitination and glucose metabolic control with important implication in diseases such as diabetes.
C1 [Hall, Jessica A.; Tabata, Mitsuhisa; Rodgers, Joseph T.; Puigserver, Pere] Harvard Univ, Sch Med, Dana Farber Canc Inst & Cell Biol, Dept Canc Biol, Boston, MA 02115 USA.
RP Puigserver, P (reprint author), Dana Farber Canc Inst, 450 Brookline Ave CLSB-11144, Boston, MA 02215 USA.
EM Pere_Puigserver@dfci.harvard.edu
FU American Heart Association; American Diabetes Association; National
Institute of Health (NIH)/National Institute of Diabetes and Digestive
and Kidney Diseases (NIDDK) [R01 069966]
FX This work was supported by an American Heart Association predoctoral
fellowship (J.A.H.) and postdoctoral fellowship (M. T.). P. P. received
support from American Diabetes Association and National Institute of
Health (NIH)/National Institute of Diabetes and Digestive and Kidney
Diseases (NIDDK) (R01 069966).
NR 66
TC 8
Z9 8
U1 0
U2 7
PU ENDOCRINE SOC
PI WASHINGTON
PA 2055 L ST NW, SUITE 600, WASHINGTON, DC 20036 USA
SN 0888-8809
J9 MOL ENDOCRINOL
JI Mol. Endocrinol.
PD JUN
PY 2014
VL 28
IS 6
BP 912
EP 924
DI 10.1210/me.2013-1420
PG 13
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AK8SL
UT WOS:000338698200011
PM 24694308
ER
PT J
AU Huang, P
Schulz, TJ
Beauvais, A
Tseng, YH
Gussoni, E
AF Huang, Ping
Schulz, Tim J.
Beauvais, Ariane
Tseng, Yu-Hua
Gussoni, Emanuela
TI Intramuscular adipogenesis is inhibited by myo-endothelial progenitors
with functioning Bmpr1a signalling
SO NATURE COMMUNICATIONS
LA English
DT Article
ID MUSCLE SATELLITE CELLS; BONE MORPHOGENETIC PROTEIN; ADULT
SKELETAL-MUSCLE; STEM-CELLS; FIBRO/ADIPOGENIC PROGENITORS; MYOGENIC
DIFFERENTIATION; LINEAGE ANALYSIS; SELF-RENEWAL; GENE MYF-5;
REGENERATION
AB Developing human muscle contains inter-myofibre progenitors expressing Bmp-receptor 1a (Bmpr1a) and Myf5 that respond to stimulation with Bmp4. Here we ablate Bmpr1a in Myf5- and MyoD-expressing cells in vivo. Mutant mice reveal increased intramuscular fat and reduced myofibre size in selected muscles, or following muscle injury. Myo-endothelial progenitors are the most affected cell type: clonal studies demonstrate that ablation of Bmpr1a in myo-endothelial cells results in decreased myogenic activity, while adipogenic differentiation is significantly increased. Downstream phospho-Smad 1, 5, 8 signalling is also severely decreased in mutant myo-endothelial cells. Lineage tracing of endothelial cells using VE-cadherin(Cre) driver failed to reveal a significant contribution of these cells to developing or injured skeletal muscle. Thus, myo-endothelial progenitors with functioning Bmpr1a signalling demonstrate myogenic potential, but their main function in vivo is to inhibit intramuscular adipogenesis, both through a cell-autonomous and a cell-cell interaction mechanism.
C1 [Huang, Ping; Beauvais, Ariane; Gussoni, Emanuela] Boston Childrens Hosp, Div Genet, Boston, MA 02115 USA.
[Schulz, Tim J.; Tseng, Yu-Hua] Joslin Diabet Ctr, Sect Integrat Physiol & Metab, Boston, MA 02115 USA.
RP Gussoni, E (reprint author), Boston Childrens Hosp, Div Genet, Boston, MA 02115 USA.
EM gussoni@enders.tch.harvard.edu
RI Schulz, Tim/F-4842-2013
OI Schulz, Tim/0000-0002-8413-3972
FU NICHD; Scientist Development Grant from AHA [0730285N]; NIH/NINDS [2R01
NS047727]
FX We thank the Dana Farber Hematologic Neoplasia Flow Cytometry Core for
their outstanding services. We also thank Dr. Paul B. Yu for helpful
discussions and for the pSmad 2 and pSmad 1,3 antibodies. The Pax7
antibody (DSHB, University of Iowa) was developed under the auspices of
the NICHD. P.H. was supported by a Scientist Development Grant from AHA
(0730285N). This work was supported by NIH/NINDS 2R01 NS047727 grant to
E.G.
NR 68
TC 9
Z9 9
U1 0
U2 10
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUN
PY 2014
VL 5
AR 4063
DI 10.1038/ncomms5063
PG 16
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AL0SV
UT WOS:000338838000007
PM 24898859
ER
PT J
AU Lim, EJ
Ober, TJ
Edd, JF
Desai, SP
Neal, D
Bong, KW
Doyle, PS
McKinley, GH
Toner, M
AF Lim, Eugene J.
Ober, Thomas J.
Edd, Jon F.
Desai, Salil P.
Neal, Douglas
Bong, Ki Wan
Doyle, Patrick S.
McKinley, Gareth H.
Toner, Mehmet
TI Inertio-elastic focusing of bioparticles in microchannels at high
throughput
SO NATURE COMMUNICATIONS
LA English
DT Article
ID PARTICLE IMAGE VELOCIMETRY; OLDROYD-B FLUIDS; POISEUILLE FLOW;
SEPARATION; TURBULENCE; SPHERE; INSTABILITY; TECHNOLOGY; MIGRATION;
BREAKUP
AB Controlled manipulation of particles from very large volumes of fluid at high throughput is critical for many biomedical, environmental and industrial applications. One promising approach is to use microfluidic technologies that rely on fluid inertia or elasticity to drive lateral migration of particles to stable equilibrium positions in a microchannel. Here, we report on a hydrodynamic approach that enables deterministic focusing of beads, mammalian cells and anisotropic hydrogel particles in a microchannel at extremely high flow rates. We show that on addition of micromolar concentrations of hyaluronic acid, the resulting fluid viscoelasticity can be used to control the focal position of particles at Reynolds numbers up to Re approximate to 10,000 with corresponding flow rates and particle velocities up to 50 ml min(-1) and 130 ms(-1). This study explores a previously unattained regime of inertio-elastic fluid flow and demonstrates bioparticle focusing at flow rates that are the highest yet achieved.
C1 [Lim, Eugene J.; Edd, Jon F.; Desai, Salil P.; Bong, Ki Wan; Toner, Mehmet] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med & Surg Serv, Charlestown, MA 02129 USA.
[Lim, Eugene J.] MIT, Dept Elect Engn & Comp Sci, Cambridge, MA 02139 USA.
[Ober, Thomas J.; McKinley, Gareth H.] MIT, Dept Mech Engn, Cambridge, MA 02139 USA.
[Neal, Douglas] LaVision Inc, Ypsilanti, MI 48197 USA.
[Bong, Ki Wan] Korea Univ, Dept Chem & Biol Engn, Seoul 136713, South Korea.
[Doyle, Patrick S.] MIT, Dept Chem Engn, Cambridge, MA 02139 USA.
RP McKinley, GH (reprint author), MIT, Dept Mech Engn, Cambridge, MA 02139 USA.
EM gareth@mit.edu; mehmet_toner@hms.harvard.edu
FU National Institutes of Biomedical Imaging and Bioengineering (P41
BioMicroElectroMechanical Systems Resource Center) [P41 EB002503]; NSF;
Institute for Collaborative Biotechnologies from the U.S. Army Research
Office [W911NF-09-0001]
FX We thank Bashar Hamza for his cell culture work, Bavand Keshavarz for
rheological measurements of test fluids and Patrick Nash for assembling
the fluidic circuit. We also thank Octavio Hurtado and A.J. Aranyosi for
the coordination of the research lab and guidance. This work was
supported in part by the National Institutes of Biomedical Imaging and
Bioengineering (P41 BioMicroElectroMechanical Systems Resource Center,
P41 EB002503). T.J.O. acknowledges the NSF Graduate Research Fellowship
for funding. P.S.D. and K.W.B. were supported by the Institute for
Collaborative Biotechnologies through grant W911NF-09-0001 from the U.S.
Army Research Office. The content of the information does not
necessarily reflect the position or the policy of the Government, and no
official endorsement should be inferred.
NR 59
TC 35
Z9 35
U1 8
U2 83
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUN
PY 2014
VL 5
AR 4120
DI 10.1038/ncomms5120
PG 9
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AL0SY
UT WOS:000338838300015
PM 24939508
ER
PT J
AU Zhou, XZ
Menche, J
Barabasi, AL
Sharma, A
AF Zhou, XueZhong
Menche, Joerg
Barabasi, Albert-Laszlo
Sharma, Amitabh
TI Human symptoms-disease network
SO NATURE COMMUNICATIONS
LA English
DT Article
ID ELECTRONIC HEALTH RECORDS; INFLAMMATORY-BOWEL-DISEASE;
PARKINSONS-DISEASE; PHENOTYPE ONTOLOGY; ALZHEIMERS-DISEASE; GENES;
INFORMATION; MODEL; INTERACTOME; DISCOVERY
AB In the post-genomic era, the elucidation of the relationship between the molecular origins of diseases and their resulting phenotypes is a crucial task for medical research. Here, we use a large-scale biomedical literature database to construct a symptom-based human disease network and investigate the connection between clinical manifestations of diseases and their underlying molecular interactions. We find that the symptom-based similarity of two diseases correlates strongly with the number of shared genetic associations and the extent to which their associated proteins interact. Moreover, the diversity of the clinical manifestations of a disease can be related to the connectivity patterns of the underlying protein interaction network. The comprehensive, high-quality map of disease-symptom relations can further be used as a resource helping to address important questions in the field of systems medicine, for example, the identification of unexpected associations between diseases, disease etiology research or drug design.
C1 [Zhou, XueZhong] Beijing Jiaotong Univ, Sch Comp & Informat Technol, Beijing 100044, Peoples R China.
[Zhou, XueZhong] Beijing Jiaotong Univ, Beijing Key Lab Traff Data Anal & Min, Beijing 100044, Peoples R China.
[Zhou, XueZhong; Menche, Joerg; Barabasi, Albert-Laszlo; Sharma, Amitabh] Northeastern Univ, Dept Phys, Ctr Complex Network Res, Boston, MA 02115 USA.
[Zhou, XueZhong; Menche, Joerg; Barabasi, Albert-Laszlo; Sharma, Amitabh] Dana Farber Canc Inst, Ctr Canc Syst Biol, Boston, MA 02215 USA.
[Menche, Joerg; Barabasi, Albert-Laszlo] Budapest Univ Technol & Econ, Dept Theoret Phys, H-1111 Budapest, Hungary.
[Barabasi, Albert-Laszlo] Cent European Univ, Ctr Network Sci, H-1051 Budapest, Hungary.
[Barabasi, Albert-Laszlo; Sharma, Amitabh] Harvard Univ, Sch Med, Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA.
RP Zhou, XZ (reprint author), Beijing Jiaotong Univ, Sch Comp & Informat Technol, Beijing 100044, Peoples R China.
EM xzzhou@bjtu.edu.cn; amitabh.sharma@channing.harvard.edu
RI Menche, Jorg/G-3994-2015
OI Menche, Jorg/0000-0002-1583-6404
FU National Science Foundation of China [61105055, 81230086]; National
Basic Research Program of China [2014CB542903]; National Key Technology
RD Program [2013BAI02B01, 2013BAI13B04]; National S&T Major Special
Project [2012ZX09503-001-003]; Beijing Municipal S&T Program of China
[Z131110002813118]; MapGen grant [1U01HL108630-01]; EC-FP7 Program,
Synergy-COPD [270086]; U.S. National Institutes of Health [HL066289,
HL105339]
FX We thank Baoyan Liu, Chaoming Song, Dashun Wang and Andrew Michaelson
for useful discussions and suggestions, and especially Lili Xu, Guangli
Song, Haixun Qi, Minghui Lv, Yiwei Wang, Xiaofeng Zhou and Hongwei Chu
for the manual validation of the selected PubMed records. X.Z. was
supported by the National Science Foundation of China (61105055,
81230086), National Basic Research Program of China (2014CB542903),
National Key Technology R&D Program (2013BAI02B01, 2013BAI13B04),
National S&T Major Special Project (2012ZX09503-001-003) and Beijing
Municipal S&T Program of China (Z131110002813118). This work was
supported by MapGen grant (1U01HL108630-01) and by the EC-FP7 Program,
Synergy-COPD, GA no 270086. Additional support was provided by HL066289
and HL105339 grants from the U.S. National Institutes of Health.
NR 69
TC 49
Z9 51
U1 3
U2 34
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 2041-1723
J9 NAT COMMUN
JI Nat. Commun.
PD JUN
PY 2014
VL 5
AR 4212
DI 10.1038/ncomms5212
PG 10
WC Multidisciplinary Sciences
SC Science & Technology - Other Topics
GA AL0TI
UT WOS:000338839300001
PM 24967666
ER
PT J
AU Tewari, KS
Sill, MW
Long, HJ
Penson, RT
Huang, H
Ramondetta, LM
Landrum, LM
Oaknin, A
Reid, TJ
Leitao, MM
Michael, HE
Monk, BJ
AF Tewari, Krishnansu S.
Sill, Michael W.
Long, Harry J., III
Penson, Richard T.
Huang, Helen
Ramondetta, Lois M.
Landrum, Lisa M.
Oaknin, Ana
Reid, Thomas J.
Leitao, Mario M.
Michael, Helen E.
Monk, Bradley J.
TI Improved Survival With Bevacizumab in Advanced Cervical Cancer
SO OBSTETRICAL & GYNECOLOGICAL SURVEY
LA English
DT Editorial Material
C1 [Tewari, Krishnansu S.] Univ Calif Irvine, Med Ctr, Orange, CA 92697 USA.
[Sill, Michael W.; Huang, Helen] SUNY Buffalo, Roswell Pk Canc Inst, Buffalo, NY 14260 USA.
[Long, Harry J., III] Mayo Clin, Rochester, MN USA.
[Penson, Richard T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Ramondetta, Lois M.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Landrum, Lisa M.] Univ Oklahoma, Oklahoma City, OK USA.
[Oaknin, Ana] Vall dHebron Univ Hosp, Barcelona, Spain.
[Reid, Thomas J.] Univ Cincinnati, Coll Med, Womens Canc Ctr Kettering, Kettering, OH USA.
[Leitao, Mario M.] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Michael, Helen E.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA.
[Monk, Bradley J.] Univ Arizona, Ctr Canc, Phoenix, AZ USA.
[Monk, Bradley J.] Creighton Univ, St Josephs Hosp & Med Ctr, Phoenix, AZ USA.
RP Tewari, KS (reprint author), Univ Calif Irvine, Med Ctr, Orange, CA 92697 USA.
NR 0
TC 0
Z9 0
U1 1
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0029-7828
EI 1533-9866
J9 OBSTET GYNECOL SURV
JI Obstet. Gynecol. Surv.
PD JUN
PY 2014
VL 69
IS 6
BP 331
EP 332
PG 2
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA AK9WS
UT WOS:000338779900013
ER
PT J
AU Scott, JC
Pietrzak, RH
Southwick, SM
Jordan, J
Silliker, N
Brandt, CA
Haskell, SG
AF Scott, J. Cobb
Pietrzak, Robert H.
Southwick, Steven M.
Jordan, Jessica
Silliker, Norman
Brandt, Cynthia A.
Haskell, Sally G.
TI Military Sexual Trauma Interacts With Combat Exposure to Increase Risk
for Posttraumatic Stress Symptomatology in Female Iraq and Afghanistan
Veterans
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID MALE VIETNAM VETERANS; MENTAL-HEALTH; GENDER-DIFFERENCES; NATIONAL
SAMPLE; WOMEN VETERANS; CHILD-ABUSE; LIFE EVENTS; GULF-WAR; DISORDER;
SYMPTOMS
AB Objective: Sexual trauma during military service is increasingly recognized as a substantial public health problem and is associated with detrimental effects on veteran mental health. In this study, we examined associations between childhood trauma, military sexual trauma (MST), combat exposure, and military-related posttraumatic stress symptomatology (PTSS) in the Women Veterans Cohort Study (WVCS), a community-based sample of veterans who served in the recent conflicts in Iraq and Afghanistan.
Method: From July 2008 to December 2011, 365 female veterans completed a survey that assessed combat exposure, military sexual trauma, military-related PTSS (assessed using the PTSD [posttraumatic stress disorder] Checklist-Military Version), and demographic, life history, and other psychopathology variables.
Results: High rates of childhood trauma (59.7%) and MST (sexual assault = 14.7%; sexual harassment = 34.8%) were observed in this sample. A hierarchical regression revealed that active duty status, childhood trauma, combat exposure, and MST were independently associated with increased severity of military-related PTSS (Ps < .05). Moreover, a significant interaction emerged between MST and combat exposure in predicting military-related PTSS (P = .030), suggesting that the relationship between combat exposure and PTSS was altered by MST status. Specifically, under conditions of high combat exposure, female veterans with MST had significantly higher PTSS compared to female veterans without MST.
Conclusions: Taken together, results suggest that exposure to multiple traumas during military service may have synergistic effects on posttraumatic stress symptoms in female veterans. Moreover, our findings highlight the importance of prevention efforts to protect female veterans from the detrimental effects of MST, particularly those who are exposed to high levels of combat. (C) Copyright 2014 Physicians Postgraduate Press, Inc.
C1 [Scott, J. Cobb; Pietrzak, Robert H.; Southwick, Steven M.; Jordan, Jessica] VA Connecticut Healthcare Syst, Clin Neurosci Div, Natl Ctr Posttraumat Stress Disorder, West Haven, CT USA.
[Scott, J. Cobb; Pietrzak, Robert H.; Southwick, Steven M.; Jordan, Jessica] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA.
[Scott, J. Cobb] Philadelphia VA Med Ctr, Vet Integrated Serv Network VISN, Mental Illness Res Educ & Clin Ctr MIRECC 4, Philadelphia, PA 19104 USA.
[Silliker, Norman; Brandt, Cynthia A.; Haskell, Sally G.] VA Connecticut Healthcare Syst, West Haven, CT USA.
[Brandt, Cynthia A.] Dept Emergency Med, New Haven, CT USA.
[Brandt, Cynthia A.] Yale Ctr Med Informat, New Haven, CT USA.
[Haskell, Sally G.] Yale Univ, Sch Med, Dept Internal Med, New Haven, CT 06510 USA.
RP Scott, JC (reprint author), Philadelphia VA Med Ctr, MIRECC 116,3900 Woodland Ave, Philadelphia, PA 19104 USA.
EM scott1@mail.med.upenn.edu
FU Veterans Administration (VA) Health Services Research and Development
Service (HSRD) [DHI07-065]; Clinical Neurosciences Division of the
National Center for Posttraumatic Stress Disorder; VA Clinical Science &
Research Developmental Award [IK2 CX000772]
FX Funding for this study was provided by Veterans Administration (VA)
Health Services Research and Development Service (HSR&D) grant
#DHI07-065 to Drs Haskell and Brandt. Preparation of this report was
also supported in part by the Clinical Neurosciences Division of the
National Center for Posttraumatic Stress Disorder and a VA Clinical
Science & Research Developmental Award (IK2 CX000772) to Dr Scott.
NR 64
TC 12
Z9 12
U1 3
U2 29
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
EI 1555-2101
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD JUN
PY 2014
VL 75
IS 6
BP 637
EP 643
DI 10.4088/JCP.13m08808
PG 7
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA AK5IO
UT WOS:000338458200015
ER
PT J
AU van der Kolk, BA
Stone, L
West, J
Rhodes, A
Emerson, D
Suvak, M
Spinazzola, J
AF van der Kolk, Bessel A.
Stone, Laura
West, Jennifer
Rhodes, Alison
Emerson, David
Suvak, Michael
Spinazzola, Joseph
TI Yoga as an Adjunctive Treatment for Posttraumatic Stress Disorder: A
Randomized Controlled Trial
SO JOURNAL OF CLINICAL PSYCHIATRY
LA English
DT Article
ID ADVERSE CHILDHOOD EXPERIENCES; LOW-BACK-PAIN; BRAIN GABA LEVELS;
MINDFULNESS MEDITATION; PSYCHOMETRIC PROPERTIES; CLINICAL-IMPLICATIONS;
EXPOSURE THERAPY; EXTREME STRESS; ANXIETY; PTSD
AB Background: More than a third of the approximately 10 million women with histories of interpersonal violence in the United States develop posttraumatic stress disorder (PTSD). Currently available treatments for this population have a high rate of incomplete response, in part because problems in affect and impulse regulation are major obstacles to resolving PTSD. This study explored the efficacy of yoga to increase affect tolerance and to decrease PTSD symptomatology.
Method: Sixty-four women with chronic, treatment-resistant PTSD were randomly assigned to either trauma-informed yoga or supportive women's health education, each as a weekly 1-hour class for 10 weeks. Assessments were conducted at pretreatment, midtreatment, and posttreatment and included measures of DSM-IV PTSD, affect regulation, and depression. The study ran from 2008 through 2011.
Results: The primary outcome measure was the Clinician-Administered PTSD Scale (CAPS). At the end of the study, 16 of 31 participants (52%) in the yoga group no longer met criteria for PTSD compared to 6 of 29 (21%) in the control group (n = 60, chi(2)(1) = 6.17, P = .013). Both groups exhibited significant decreases on the CAPS, with the decrease falling in the large effect size range for the yoga group (d = 1.07) and the medium to large effect size decrease for the control group (d = 0.66). Both the yoga (b = -9.21, t = -2.34, P = .02, d = -0.37) and control (b = -22.12, t = -3.39, P = .001, d = -0.54) groups exhibited significant decreases from pretreatment to the midtreatment assessment. However, a significant group x quadratic trend interaction (d = -0.34) showed that the pattern of change in Davidson Trauma Scale significantly differed across groups. The yoga group exhibited a significant medium effect size linear (d = -0.52) trend. In contrast, the control group exhibited only a significant medium effect size quadratic trend (d = 0.46) but did not exhibit a significant linear trend (d = -0.29). Thus, both groups exhibited significant decreases in PTSD symptoms during the first half of treatment, but these improvements were maintained in the yoga group, while the control group relapsed after its initial improvement.
Discussion: Yoga significantly reduced PTSD symptomatology, with effect sizes comparable to well-researched psychotherapeutic and psychopharmacologic approaches. Yoga may improve the functioning of traumatized individuals by helping them to tolerate physical and sensory experiences associated with fear and helplessness and to increase emotional awareness and affect tolerance. (C) Copyright 2014 Physicians Postgraduate Press, Inc.
C1 [van der Kolk, Bessel A.; Stone, Laura; West, Jennifer; Rhodes, Alison; Emerson, David; Spinazzola, Joseph] Justice Resource Inst, Ctr Trauma, Brookline, MA 02446 USA.
[van der Kolk, Bessel A.; Spinazzola, Joseph] Natl Child Traumat Stress Network, Brookline, MA USA.
[van der Kolk, Bessel A.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
[Suvak, Michael] Suffolk Univ, Natl Ctr PTSD, Boston, MA 02114 USA.
[Suvak, Michael] Suffolk Univ, Dept Psychol, Boston, MA 02114 USA.
RP van der Kolk, BA (reprint author), Justice Resource Inst, Ctr Trauma, 1269 Beacon St, Brookline, MA 02446 USA.
EM bessel1@mac.com
FU US National Center for Complementary and Alternative Medicine (NCCAM)
[1R21AT003905-01A2]
FX This study was supported by grant 1R21AT003905-01A2 from the US National
Center for Complementary and Alternative Medicine (NCCAM).
NR 67
TC 22
Z9 22
U1 16
U2 81
PU PHYSICIANS POSTGRADUATE PRESS
PI MEMPHIS
PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA
SN 0160-6689
EI 1555-2101
J9 J CLIN PSYCHIAT
JI J. Clin. Psychiatry
PD JUN
PY 2014
VL 75
IS 6
BP E559
EP E565
DI 10.4088/JCP.13m08561
PG 7
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA AK5IO
UT WOS:000338458200003
PM 25004196
ER
PT J
AU Kagan, VE
Kapralov, AA
St Croix, CM
Watkins, SC
Kisin, ER
Kotchey, GP
Balasubramanian, K
Vlasova, II
Yu, J
Kim, K
Seo, W
MallampaIli, RK
Star, A
Shvedova, AA
AF Kagan, Valerian E.
Kapralov, Alexandr A.
St Croix, Claudette M.
Watkins, Simon C.
Kisin, Elena R.
Kotchey, Gregg P.
Balasubramanian, Krishnakumar
Vlasova, Irina I.
Yu, Jaesok
Kim, Kang
Seo, Wanji
MallampaIli, Rama K.
Star, Alexander
Shvedova, Anna A.
TI Lung Macrophages "Digest" Carbon Nanotubes Using a
Superoxide/Peroxynitrite Oxidative Pathway
SO ACS NANO
LA English
DT Article
DE single-walled carbon nanotubes; peroxynitrite; biodegradation; lung
ID DARK-FIELD MICROSCOPY; IN-VIVO; NITRIC-OXIDE; PULMONARY INFLAMMATION;
REACTIVE OXYGEN; PEROXYNITRITE; CELLS; NANOPARTICLES; NANOMATERIALS;
NEUTROPHILS
AB In contrast to short-lived neutrophils, macrophages display persistent presence in the lung of animals after pulmonary exposure to carbon nanotubes. While effective in the clearance of bacterial pathogens and injured host cells, the ability of macrophages to "digest" carbonaceous nanoparticles has not been documented. Here, we used chemical, biochemical, and cell and animal models and demonstrated oxidative biodegradation of oxidatively functionalized single-walled carbon nanotubes via superoxide/NO* -> peroxynitrite-driven oxidative pathways of activated macrophages facilitating clearance of nanoparticles from the lung.
C1 [Kagan, Valerian E.; Kapralov, Alexandr A.; Balasubramanian, Krishnakumar; Vlasova, Irina I.] Univ Pittsburgh, Ctr Free Rad & Antioxidant Hlth, Pittsburgh, PA 15260 USA.
[MallampaIli, Rama K.] Univ Pittsburgh, Acute Lung Injury Ctr Excellence, Pittsburgh, PA USA.
[Kagan, Valerian E.; Kapralov, Alexandr A.; St Croix, Claudette M.; Balasubramanian, Krishnakumar; Vlasova, Irina I.] Univ Pittsburgh, Dept Environm & Occupat Hlth, Pittsburgh, PA USA.
[Watkins, Simon C.] Univ Pittsburgh, Dept Physiol & Cell Biol, Pittsburgh, PA USA.
[Kotchey, Gregg P.; Seo, Wanji; Star, Alexander] Univ Pittsburgh, Dept Chem, Pittsburgh, PA 15260 USA.
[Yu, Jaesok; Kim, Kang; MallampaIli, Rama K.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[MallampaIli, Rama K.] Vet Affairs Pittsburgh Healthcare Syst, Med Specialty Serv Line, Pittsburgh, PA USA.
[Shvedova, Anna A.] NIOSH, Pathol & Physiol Res Branch, Hlth Effects Lab Div, Morgantown, WV USA.
[Vlasova, Irina I.] Res Inst Physicochem Med, Moscow 119495, Russia.
RP Kagan, VE (reprint author), Univ Pittsburgh, Ctr Free Rad & Antioxidant Hlth, Pittsburgh, PA 15260 USA.
EM kagan@pitt.edu
OI Kapralov, Oleksandr/0000-0002-3006-916X
FU National Institute for Occupational Safety and Health (NIOSH)
[OH008282]; National Institutes of Health, NIEHS [R01ES019304,
U19AI068021, PO1HL114453]; RFBR [12-04-01293]; EPA STAR Graduate
Fellowship [FP-91713801]
FX This work was supported by the National Institute for Occupational
Safety and Health (NIOSH), OH008282, and National Institutes of Health,
NIEHS R01ES019304, U19AI068021, PO1HL114453, and RFBR 12-04-01293.
G.P.K. acknowledges an EPA STAR Graduate Fellowship, FP-91713801.
NR 50
TC 46
Z9 46
U1 0
U2 26
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1936-0851
EI 1936-086X
J9 ACS NANO
JI ACS Nano
PD JUN
PY 2014
VL 8
IS 6
BP 5610
EP 5621
DI 10.1021/nn406484b
PG 12
WC Chemistry, Multidisciplinary; Chemistry, Physical; Nanoscience &
Nanotechnology; Materials Science, Multidisciplinary
SC Chemistry; Science & Technology - Other Topics; Materials Science
GA AK0FV
UT WOS:000338089200025
PM 24871084
ER
PT J
AU Shore, S
Carey, EP
Turakhia, MP
Jackevicius, CA
Cunningham, F
Pilote, L
Bradley, SM
Maddox, TM
Grunwald, GK
Baron, AE
Rumsfeld, JS
Varosy, PD
Schneider, PM
Marzec, LN
Ho, PM
AF Shore, Supriya
Carey, Evan P.
Turakhia, Mintu P.
Jackevicius, Cynthia A.
Cunningham, Fran
Pilote, Louise
Bradley, Steven M.
Maddox, Thomas M.
Grunwald, Gary K.
Baron, Anna E.
Rumsfeld, John S.
Varosy, Paul D.
Schneider, Preston M.
Marzec, Lucas N.
Ho, P. Michael
TI Adherence to dabigatran therapy and longitudinal patient outcomes:
Insights from the Veterans Health Administration
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID ATRIAL-FIBRILLATION; ANTITHROMBOTIC TREATMENT; MEDICATION ADHERENCE;
CLINICAL-PRACTICE; WARFARIN; ANTICOAGULATION; ETEXILATE; CARE;
UNDERTREATMENT; CHALLENGES
AB Background Dabigatran is a novel oral anti-coagulant (NOAC) that reduces risk of stroke in patients with non-valvular atrial fibrillation (NVAF). It does not require routine monitoring with laboratory testing which may have an adverse impact on adherence. We aimed to describe adherence to dabigatran in the first year after initiation and assess the association between non-adherence to dabigatran and clinical outcomes in a large integrated healthcare system.
Methods We studied a national cohort of 5,376 patients with NVAF, initiated on dabigatran between October-2010 and September-2012 at all Veterans Affairs hospitals. Adherence to dabigatran was calculated as proportion of days covered (PDC) and association between PDC and outcomes was assessed using standard regression techniques.
Results Mean age of the study cohort was 71.3 +/- 9.7 years; 98.3% were men and mean CHADS(2) score was 2.4 +/- 1.2 (mean CHA(2)DS(2)VASc score 3.2 +/- 1.4). Median PDC was 94% (IQR 76%-100%; mean PDC 84% +/- 22%) over a median follow-up of 244 days (IQR 140-351). A total of 1,494 (27.8%) patients had a PDC <80% and were classified as non-adherent. After multivariable adjustment, lower adherence was associated with increased risk for combined all-cause mortality and stroke (HR 1.13, 95% CI 1.07-1.19 per 10% decrease in PDC). Adherence to dabigatran was not associated with non-fatal bleeding or myocardial infarction.
Conclusions In the year after initiation, adherence to dabigatran for a majority of patients is very good. However, 28% of patients in our cohort had poor adherence. Furthermore, lower adherence to dabigatran was associated with increased adverse outcomes. Concerted efforts are needed to optimize adherence to NOACs.
C1 [Shore, Supriya; Carey, Evan P.; Bradley, Steven M.; Maddox, Thomas M.; Grunwald, Gary K.; Rumsfeld, John S.; Varosy, Paul D.; Schneider, Preston M.; Marzec, Lucas N.; Ho, P. Michael] Vet Affairs Eastern Colorado Hlth Care Syst, Denver, CO USA.
[Shore, Supriya; Bradley, Steven M.; Maddox, Thomas M.; Rumsfeld, John S.; Varosy, Paul D.; Schneider, Preston M.; Marzec, Lucas N.; Ho, P. Michael] Univ Colorado, Sch Med, Aurora, CO USA.
[Shore, Supriya; Carey, Evan P.; Bradley, Steven M.; Maddox, Thomas M.; Rumsfeld, John S.; Varosy, Paul D.; Schneider, Preston M.; Marzec, Lucas N.; Ho, P. Michael] Colorado Cardiovasc Outcomes Res Consortium, Denver, CO USA.
[Carey, Evan P.; Grunwald, Gary K.; Baron, Anna E.] Univ Colorado, Sch Publ Hlth, Aurora, CO USA.
[Turakhia, Mintu P.] Vet Affairs Palo Alto Hlth Care Syst, Palo Alto, CA USA.
[Turakhia, Mintu P.] Stanford Univ, Sch Med, Stanford, CA 94305 USA.
[Jackevicius, Cynthia A.] Vet Affairs Greater Angeles Hlth Care Syst, Los Angeles, CA USA.
[Jackevicius, Cynthia A.] Western Univ Hlth Sci, Pomona, CA USA.
[Cunningham, Fran] US Dept Vet Affairs, Pharm Benefits Management Serv, Hines, IL USA.
[Cunningham, Fran] Ctr Medicat Safety, Hines, IL USA.
[Pilote, Louise] McGill Univ, Ctr Hlth, Montreal, PQ, Canada.
RP Ho, PM (reprint author), VA Eastern Colorado Hlth Care Syst, Cardiol Sect, 111B,1055 Clermont St, Denver, CO 80220 USA.
EM michael.ho@va.gov
FU NHLBI NIH HHS [T32 HL007822]
NR 28
TC 47
Z9 47
U1 1
U2 11
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
EI 1097-5330
J9 AM HEART J
JI Am. Heart J.
PD JUN
PY 2014
VL 167
IS 6
BP 810
EP 817
DI 10.1016/j.ahj.2014.03.023
PG 8
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AK3US
UT WOS:000338350800009
PM 24890529
ER
PT J
AU Meijers, WC
Januzzi, JL
deFilippi, C
Adourian, AS
Shah, SJ
van Veldhuisen, DJ
de Boer, RA
AF Meijers, Wouter C.
Januzzi, James L.
deFilippi, Christopher
Adourian, Aram S.
Shah, Sanjiv J.
van Veldhuisen, Dirk J.
de Boer, Rudolf A.
TI Elevated plasma galectin-3 is associated with near-term
rehospitalization in heart failure: A pooled analysis of 3 clinical
trials
SO AMERICAN HEART JOURNAL
LA English
DT Article
ID NATRIURETIC PEPTIDE ASSAY; SYSTOLIC DYSFUNCTION; PROGNOSTIC VALUE;
HF-ACTION; DYSPNEA; HOSPITALIZATION; MORTALITY; FIBROSIS; DISEASE;
MARKER
AB Background Rehospitalization is a major cause for heart failure (HF)-related morbidity and is associated with considerable loss of quality of life and costs. The rate of unplanned rehospitalization in patients with HF is unacceptably high; current risk stratification to identify patients at risk for rehospitalization is inadequate. We evaluated whether measurement of galectin-3 would be helpful in identifying patients at such risk.
Methods We analyzed pooled data from patients (n = 902) enrolled in 3 cohorts (COACH, n = 592; PRIDE, n = 181; and UMD H-23258, n = 129) originally admitted because of HF. Mean patient age was between 61.6 and 72.9 years across the cohorts, with a wide range of left ventricular ejection fraction. Galectin-3 levels were measured during index admission. We used fixed and random-effects models, as well as continuous and categorical reclassification statistics to assess the association of baseline galectin-3 levels with risk of postdischarge rehospitalization at different time points and the composite end point all-cause mortality and rehospitalization.
Results Compared with patients with galectin-3 concentrations less than 17.8 ng/mL, those with results exceeding this value were significantly more likely to be rehospitalized for HF at 30, 60, 90, and 120 days after discharge, with odds ratios (ORs) of 2.80 (95% CI 1.41-5.57), 2.61 (95% CI 1.46-4.65), 3.01 (95% CI 1.79-5.05), and 2.79 (95% CI 1.75-4.45), respectively. After adjustment for age, gender, New York Heart Association class, renal function (estimated glomerular filtration rate), left ventricular ejection fraction, and B-type natriuretic peptide, galectin-3 remained an independent predictor of HF rehospitalization. The addition of galectin-3 to risk models significantly reclassified patient risk of postdischarge rehospitalization and fatal event at each time point (continuous net reclassification improvement at 30 days of +42.6% [95% CI + 19.9%-65.4%], P < .001).
Conclusions Among patients hospitalized for HF, plasma galectin-3 concentration is useful for the prediction of near-term rehospitalization.
C1 [Meijers, Wouter C.; van Veldhuisen, Dirk J.; de Boer, Rudolf A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands.
[Januzzi, James L.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[deFilippi, Christopher] Univ Maryland, Sch Med, Dept Med, Baltimore, MD 21201 USA.
[Adourian, Aram S.] BG Med, Waltham, MA USA.
[Shah, Sanjiv J.] Northwestern Univ, Feinberg Sch Med, Div Cardiol, Chicago, IL 60611 USA.
RP de Boer, RA (reprint author), Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, POB 30-001, Groningen, Netherlands.
EM r.a.de.boer@umcg.nl
FU BG Medicine; Critical Diagnostics; Roche; Singulex; Abbott; AstraZeneca;
Novartis; Pfizer; Baxter; Radiometer; Healtcare Diagnostics Laboratory;
Siemens
FX J.L.J. and R.A.d.B. have received grant support from BG Medicine. J.L.J.
and C.d.F. have received grants from Critical Diagnostics, Roche, and
Singulex. C.d.F. has received consultancies from Radiometer, Healtcare
Diagnostics Laboratory, and Siemens. R.A.d.B. received research grants
and or speaker's fees from Abbott, BG Medicine, AstraZeneca, Novartis,
Pfizer, Baxter, and Novartis. The University Medical Center Groningen,
where W.C.M., D.J.v.V., and R.A.d.B. are employed, has received research
grants from BG Medicine. A.S.A. is employed by BG Medicine and has
ownership interest.
NR 44
TC 39
Z9 39
U1 0
U2 5
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-8703
EI 1097-5330
J9 AM HEART J
JI Am. Heart J.
PD JUN
PY 2014
VL 167
IS 6
BP 853
EP U117
DI 10.1016/j.ahj.2014.02.011
PG 12
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AK3US
UT WOS:000338350800015
PM 24890535
ER
PT J
AU Sacks, GD
Diggs, BS
Hadjizacharia, P
Green, D
Salim, A
Malinoski, DJ
AF Sacks, Greg D.
Diggs, Brian S.
Hadjizacharia, Pantelis
Green, Donald
Salim, Ali
Malinoski, Darren J.
TI Reducing the rate of catheter-associated bloodstream infections in a
surgical intensive care unit using the Institute for Healthcare
Improvement central line bundle
SO AMERICAN JOURNAL OF SURGERY
LA English
DT Article
DE Catheter-associated line infections; Infection control; Central venous
catheters; Quality improvement; Healthcare cost; Checklist
ID PRACTICE GUIDELINES; PREVENTION; QUALITY
AB BACKGROUND: Central line-associated bloodstream infections (CLABSIs) are a significant source of morbidity and mortality. This study sought to determine whether implementation of the Institute for Healthcare Improvement (IHI) Central Line Bundle would reduce the incidence of CLABSIs.
METHODS: The IHI Central Line Bundle was implemented in a surgical intensive care unit. Patient demographics and the rate of CLABSIs per 1,000 catheter days were compared between the pre- and postintervention groups. Contemporaneous infection rates in an adjacent ICU were measured.
RESULTS: Baseline demographics were similar between the pre- and postintervention groups. The rate of CLABSIs per catheter days decreased from 19/3,784 to 3/1,870 after implementation of the IHI Bundle (1.60 vs 5.02 CLABSIs per 1,000 catheter days; rate ratio .32 [.08 to .99, P < .05]). There was no significant change in CLABSIs in the control ICU.
CONCLUSIONS: Implementation of the IHI Central Line Bundle reduced the incidence of CLABSIs in our SICU by 68%, preventing 12 CLABSIs, 2.5 deaths, and saving $198,600 annually. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Sacks, Greg D.] Univ Calif Los Angeles, Dept Surg, Los Angeles, CA 90024 USA.
[Diggs, Brian S.; Malinoski, Darren J.] Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA.
[Hadjizacharia, Pantelis; Green, Donald] Univ Arizona, Dept Surg, Tucson, AZ USA.
[Salim, Ali] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
[Malinoski, Darren J.] Portland VA Med Ctr, Sect Surg Crit Care, Portland, OR USA.
RP Malinoski, DJ (reprint author), Oregon Hlth & Sci Univ, Dept Surg, Portland, OR 97201 USA.
EM darren.malinoski@va.gov
NR 24
TC 14
Z9 15
U1 0
U2 8
PU EXCERPTA MEDICA INC-ELSEVIER SCIENCE INC
PI BRIDGEWATER
PA 685 ROUTE 202-206 STE 3, BRIDGEWATER, NJ 08807 USA
SN 0002-9610
EI 1879-1883
J9 AM J SURG
JI Am. J. Surg.
PD JUN
PY 2014
VL 207
IS 6
BP 817
EP 823
DI 10.1016/j.amjsurg.2013.08.041
PG 7
WC Surgery
SC Surgery
GA AK5BY
UT WOS:000338440100003
PM 24576582
ER
PT J
AU Kim, J
Lee, K
Stott, R
Zhao, G
SooHoo, J
Xiong, W
Lian, M
Fitzgerald, L
Shi, S
Deng, S
Yeh, H
Markmann, J
AF Kim, J.
Lee, K.
Stott, R.
Zhao, G.
SooHoo, J.
Xiong, W.
Lian, M.
Fitzgerald, L.
Shi, S.
Deng, S.
Yeh, H.
Markmann, J.
TI TGF-b-Producing Regulatory B Cells Induce Regulatory T Cells and Promote
Transplantation Tolerance.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Kim, J.; Lee, K.; Stott, R.; Zhao, G.; SooHoo, J.; Xiong, W.; Lian, M.; Fitzgerald, L.; Shi, S.; Deng, S.; Yeh, H.; Markmann, J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Zhao, G.; Xiong, W.; Deng, S.] Sichuan Prov Peoples Hosp, Chengdu, Sichuan, Peoples R China.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA 658
BP 20
EP 20
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033300059
ER
PT J
AU Kim, J
Lee, K
Stott, R
SooHoo, J
Yeh, H
Markmann, J
AF Kim, J.
Lee, K.
Stott, R.
SooHoo, J.
Yeh, H.
Markmann, J.
TI NKT Cells May Play a Role in B Cell-Dependent Transplant Tolerance.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA 1414
BP 28
EP 28
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033300087
ER
PT J
AU Oura, T
Hotta, K
Cosimi, B
Benichou, G
Kawai, T
AF Oura, T.
Hotta, K.
Cosimi, B.
Benichou, G.
Kawai, T.
TI Suppression of CD8(+) Memory T Cell Proliferation and Expansion of T
Regulatory Cells By Bone Marrow Derived Autologous Mesenchymal Stem
Cells in Nonhuman Primates
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Oura, T.; Hotta, K.; Cosimi, B.; Benichou, G.; Kawai, T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplant Ctr, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA 2274
BP 43
EP 43
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033300146
ER
PT J
AU Boneschansker, L
Bruneau, S
Nakayama, H
Yan, J
Wong, E
Irimia, D
Klagsbrun, M
Briscoe, D
AF Boneschansker, L.
Bruneau, S.
Nakayama, H.
Yan, J.
Wong, E.
Irimia, D.
Klagsbrun, M.
Briscoe, D.
TI Netrin-1 Is a Novel Molecule That Elicits Chemoattraction of Activated
CD4+T-Lymphocytes Via Interactions With Neogenin.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Boneschansker, L.; Bruneau, S.; Nakayama, H.; Klagsbrun, M.; Briscoe, D.] Boston Childrens Hosp, Boston, MA USA.
[Yan, J.; Wong, E.; Irimia, D.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA 2899
BP 47
EP 47
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033300160
ER
PT J
AU Tonsho, M
Boskovic, S
Lee, S
Aoyama, A
Smith, N
Colvin, R
Kawai, T
Madsen, J
Benichou, G
Allan, J
AF Tonsho, M.
Boskovic, S.
Lee, S.
Aoyama, A.
Smith, N.
Colvin, R.
Kawai, T.
Madsen, J.
Benichou, G.
Allan, J.
TI Successful Tolerance Induction of Lung Allografts in Non-Human Primates
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 Massachusetts Gen Hosp, Transplant Ctr, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA 2946
BP 48
EP 48
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033300164
ER
PT J
AU Farkash, E
Nicole, B
Nickeleit, V
Papadimitriou, J
Roberts, I
Emerson, L
McDaid, J
Colvin, R
AF Farkash, E.
Nicole, B.
Nickeleit, V.
Papadimitriou, J.
Roberts, I.
Emerson, L.
McDaid, J.
Colvin, R.
TI T Antigen Dependent Oncogenic Pathways Are Active in Post-Transplant
Tumors Driven By BK Polyoma Virus.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Farkash, E.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Farkash, E.; Nicole, B.; McDaid, J.; Colvin, R.] Mass Gen Hosp, Boston, MA USA.
[Nickeleit, V.] Univ N Carolina, Chapel Hill, NC USA.
[Papadimitriou, J.] Univ Maryland, Baltimore, MD 21201 USA.
[Roberts, I.] Oxford Univ Hosp, Oxford, England.
[Emerson, L.] Univ Utah, Salt Lake City, UT USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA 732
BP 86
EP 87
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033300268
ER
PT J
AU Saidi, R
Hertl, M
Cosimi, A
AF Saidi, R.
Hertl, M.
Cosimi, A.
TI Outcomes of Full-Right-Full Left Split Liver Transplantation in Adults
in US: A Propensity-Score Matched Ananlysis
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Saidi, R.] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA.
[Hertl, M.; Cosimi, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA 614
BP 157
EP 157
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033300474
ER
PT J
AU op den Dries, S
Westerkamp, A
Karimian, N
Gouw, A
Bruinsma, B
Markmann, J
Lisman, T
Yeh, H
Uygun, K
Martins, P
Porte, R
AF op den Dries, S.
Westerkamp, A.
Karimian, N.
Gouw, A.
Bruinsma, B.
Markmann, J.
Lisman, T.
Yeh, H.
Uygun, K.
Martins, P.
Porte, R.
TI Injury to Peribiliary Glands and Vascular Plexus Before Liver
Transplantation Predicts Formation of Non-Anastomotic Biliary Strictures
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [op den Dries, S.; Westerkamp, A.; Karimian, N.; Lisman, T.; Porte, R.] Univ Groningen, Univ Med Ctr Groningen, Dept Surg, Sect Hepatobiliary Surg & Liver Transplantat, Groningen, Netherlands.
[op den Dries, S.; Markmann, J.; Yeh, H.; Martins, P.] Harvard Univ, Sch Med, Dept Surg, Div Transplantat,Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Gouw, A.] Univ Groningen, Dept Pathol, Univ Med Ctr Groningen, Groningen, Netherlands.
[Bruinsma, B.; Uygun, K.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Engn Med Surg Serv, Boston, MA USA.
[Bruinsma, B.; Uygun, K.] Shriners Burns Hosp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA 2117
BP 175
EP 175
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033300536
ER
PT J
AU Axelrod, D
Smith, K
Chaidarun, S
Markmann, J
Lei, J
Freeman, R
Gardner, T
AF Axelrod, D.
Smith, K.
Chaidarun, S.
Markmann, J.
Lei, J.
Freeman, R.
Gardner, T.
TI Total Pancreatectomy With Auto Islet Transplantation Using Offsite
Recovery of Islets.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Axelrod, D.; Smith, K.; Freeman, R.] Dartmouth Hitchcock, Surg, Lebanon, NH USA.
[Chaidarun, S.; Gardner, T.] Dartmouth Hitchcock, Med, Lebanon, NH USA.
[Markmann, J.; Lei, J.] Mass Gen Hosp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA 597
BP 210
EP 210
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033300625
ER
PT J
AU De Wolf, S
Morris, H
Robins, H
Kawai, T
Shen, Y
Sykes, M
AF De Wolf, S.
Morris, H.
Robins, H.
Kawai, T.
Shen, Y.
Sykes, M.
TI Role of Deletion of Donor-Reactive T Cells in Long-Term Human Allograft
Tolerance Achieved Via Combined Kidney and Bone Marrow Transplantation
(CKBMT).
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [De Wolf, S.; Morris, H.; Shen, Y.; Sykes, M.] Columbia Univ, Med Ctr, New York, NY USA.
[Robins, H.] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Kawai, T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA 591
BP 221
EP 222
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301004
ER
PT J
AU Yamada, Y
Ohura, T
Hotta, K
Tonsho, M
Dehnadi, A
Bernard-Stoecklin, S
Smith, R
Colvin, R
Benichou, G
Cosimi, B
Kawai, T
AF Yamada, Y.
Ohura, T.
Hotta, K.
Tonsho, M.
Dehnadi, A.
Bernard-Stoecklin, S.
Smith, R.
Colvin, R.
Benichou, G.
Cosimi, B.
Kawai, T.
TI Novel ELISPOT-Based Assay to Detect Insidious Anti-Donor B Cell Response
in Non-Human Primate Recipients Tolerant of MHC Mismatched Kidney
Allografts.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Yamada, Y.; Ohura, T.; Hotta, K.; Tonsho, M.; Dehnadi, A.; Bernard-Stoecklin, S.; Smith, R.; Colvin, R.; Benichou, G.; Cosimi, B.; Kawai, T.] Massachusetts Gen Hosp, Transplant Ctr, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA 592
BP 222
EP 222
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301005
ER
PT J
AU Hor, K
Diefenbach, E
Anderson, P
Nankivell, B
Chapman, J
Alexander, S
Rosales, I
Colvin, R
Murphy, B
Webster, A
O'Connell, P
AF Hor, K.
Diefenbach, E.
Anderson, P.
Nankivell, B.
Chapman, J.
Alexander, S.
Rosales, I.
Colvin, R.
Murphy, B.
Webster, A.
O'Connell, P.
TI Proteomic Analysis Identified Urine Proteins Predictive of Chronic
Allograft Injury.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Hor, K.; Diefenbach, E.; Anderson, P.; Nankivell, B.; Chapman, J.; Alexander, S.; Webster, A.; O'Connell, P.] Westmead Millennium Inst, Sydney, NSW, Australia.
[Rosales, I.; Colvin, R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Murphy, B.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA 1334
BP 224
EP 224
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301014
ER
PT J
AU Gao, B
Moore, C
Porcheray, F
Rong, C
Abidoglu, C
DeVito, J
Paine, R
Girouard, T
Saidman, S
Schoenfeld, D
Levin, B
Wong, W
Fu, Y
Zom, E
AF Gao, B.
Moore, C.
Porcheray, F.
Rong, C.
Abidoglu, C.
DeVito, J.
Paine, R.
Girouard, T.
Saidman, S.
Schoenfeld, D.
Levin, B.
Wong, W.
Fu, Y.
Zom, E.
TI Pre-Transplant IgG Reactivity to Apoptotic Cells Correlates With Late
Kidney Allograft Loss.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Gao, B.; Moore, C.; Porcheray, F.; Rong, C.; Abidoglu, C.; DeVito, J.; Paine, R.; Girouard, T.; Saidman, S.; Schoenfeld, D.; Zom, E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Gao, B.; Fu, Y.] Jilin Univ, Hosp 1, Changchun 130023, Peoples R China.
[Rong, C.] Changchun Univ Chinese Med, Affiliated Hosp, Changchun, Peoples R China.
[Levin, B.] Columbia Univ, Mailman Sch Publ Hlth, New York, NY USA.
[Wong, W.] Columbia Univ, New York Presbyterian Hosp, New York, NY USA.
NR 0
TC 1
Z9 1
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA 1435
BP 225
EP 225
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301017
ER
PT J
AU Gao, B
Rong, C
Porcheray, F
Moore, C
Girouard, T
Saidman, S
Wong, W
Zorn, E
AF Gao, B.
Rong, C.
Porcheray, F.
Moore, C.
Girouard, T.
Saidman, S.
Wong, W.
Zorn, E.
TI Polyreactive Antibodies Crossreactive to HLA and Self-Antigens
Contribute to Overall Serum Reactivity.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Gao, B.; Rong, C.; Porcheray, F.; Moore, C.; Girouard, T.; Saidman, S.; Zorn, E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Gao, B.] Jilin Univ, Hosp 1, Changchun 130023, Peoples R China.
[Rong, C.] Changchun Univ Chinese Med, Affiliated Hosp, Changchun, Peoples R China.
[Wong, W.] Columbia Univ Med Ctr, New York Presbyterian Hosp, Div Nephrol, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA 1437
BP 226
EP 226
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301019
ER
PT J
AU Chen, G
Ko, D
Wang, C
Yuan, X
Qin, J
Han, M
Lai, X
He, X
Chen, L
AF Chen, G.
Ko, D.
Wang, C.
Yuan, X.
Qin, J.
Han, M.
Lai, X.
He, X.
Chen, L.
TI Impact of Machine Perfusion On Outcomes of Kidney Transplantation From
Donation After Cardiac Death: A Prospective Randomized Controlled Trial.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Chen, G.; Wang, C.; Yuan, X.; Qin, J.; Han, M.; Lai, X.; He, X.; Chen, L.] Sun Yat Sen Univ, Affiliated Hosp 1, Organ Transplant Ctr, Guangzhou 510275, Guangdong, Peoples R China.
[Ko, D.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Urol, Boston, MA 02115 USA.
[Ko, D.] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp,Div Transplantat, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA D2675
BP 267
EP 267
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301168
ER
PT J
AU Boneschansker, L
Yan, J
Wong, E
Irimia, D
Briscoe, D
AF Boneschansker, L.
Yan, J.
Wong, E.
Irimia, D.
Briscoe, D.
TI Analyzing Chemorepulsion: A Critical Leukocyte Migration Pattern With
Potential to Protect the Graft Microenvironment
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Boneschansker, L.; Briscoe, D.] Boston Childrens Hosp, Transplant Res Program, Boston, MA USA.
[Yan, J.; Wong, E.; Irimia, D.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA A96
BP 292
EP 292
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301263
ER
PT J
AU Bruinsma, B
Ozer, S
Geerts, S
Chen, Y
Golberg, A
Weeder, P
Rodriguez, D
Uygun, K
Yarmush, M
Uygun, B
AF Bruinsma, B.
Ozer, S.
Geerts, S.
Chen, Y.
Golberg, A.
Weeder, P.
Rodriguez, D.
Uygun, K.
Yarmush, M.
Uygun, B.
TI Tissue Engineered Human Liver Grafts
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Bruinsma, B.; Ozer, S.; Geerts, S.; Chen, Y.; Golberg, A.; Weeder, P.; Rodriguez, D.; Uygun, K.; Yarmush, M.; Uygun, B.] Massachusetts Gen Hosp, Ctr Engn Med, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA A557
BP 301
EP 301
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301297
ER
PT J
AU Galan, Y
Marina, J
Trowell, A
Tocco, G
Benichou, G
AF Galan, Y.
Marina, J.
Trowell, A.
Tocco, G.
Benichou, G.
TI Effects of Lymphangiogenesis Blockade On Cell Trafficking, Alloimmunity
and Rejection After Skin or Heart Transplantation.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Galan, Y.; Marina, J.; Trowell, A.; Tocco, G.; Benichou, G.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA B758
BP 306
EP 307
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301316
ER
PT J
AU Gans, J
Ndishabandi, D
Shinoda, K
Madsen, J
Colvin, R
Alessandrini, A
AF Gans, J.
Ndishabandi, D.
Shinoda, K.
Madsen, J.
Colvin, R.
Alessandrini, A.
TI Allogeneic Murine Plasmacytold Dendritic Cells Induce Regulatory T Cells
In Vitro Which Can Prolong Cardiac Allograft Survival In Vivo
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Gans, J.; Ndishabandi, D.; Shinoda, K.; Madsen, J.; Colvin, R.; Alessandrini, A.] Massachusetts Gen Hosp, Transplant Ctr, Boston, MA 02114 USA.
[Gans, J.] Sarnoff Cardiovasc Res Fdn, Great Falls, VA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA B761
BP 307
EP 307
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301319
ER
PT J
AU Marino, J
Tocco, G
Mordecai, S
Benichou, G
AF Marino, J.
Tocco, G.
Mordecai, S.
Benichou, G.
TI Trafficking of Infra-Graft Donor T Cells After Skin Transplantation in
Mice.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Marino, J.; Tocco, G.; Benichou, G.] Massachusetts Gen Hosp, Dept Surg, Transplantat Res Ctr, Boston, MA 02114 USA.
[Marino, J.; Tocco, G.; Mordecai, S.; Benichou, G.] Harvard Univ, Sch Med, Boston, MA USA.
[Mordecai, S.] Massachusetts Gen Hosp, Dept Pathol, Flow & Imaging Cytometry Core, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA B759
BP 307
EP 307
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301317
ER
PT J
AU Madariaga, M
Michel, S
La Muraglia, G
Harrington, E
Connolly, J
Selkirk, W
Farkash, E
Allan, J
Chen, Y
Sachs, D
Wang, Z
Madsen, J
Huang, C
AF Madariaga, M.
Michel, S.
La Muraglia, G., II
Harrington, E., Jr.
Connolly, J.
Selkirk, W.
Farkash, E.
Allan, J.
Chen, Y.
Sachs, D.
Wang, Z.
Madsen, J.
Huang, C.
TI Depletion of T Regulatory Cells By Novel Bivalent IL2 Fusion Toxin in
Miniature Swine
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Madariaga, M.; Michel, S.; La Muraglia, G., II; Harrington, E., Jr.; Connolly, J.; Selkirk, W.; Farkash, E.; Allan, J.; Sachs, D.; Wang, Z.; Madsen, J.; Huang, C.] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA.
[Madariaga, M.; Michel, S.; La Muraglia, G., II; Harrington, E., Jr.; Connolly, J.; Selkirk, W.; Farkash, E.; Allan, J.; Chen, Y.; Sachs, D.; Wang, Z.; Madsen, J.; Huang, C.] Harvard Univ, Sch Med, Boston, MA USA.
[Chen, Y.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA B1143
BP 314
EP 314
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301345
ER
PT J
AU Schuetz, C
Lei, J
Machaidze, Z
Saidman, S
Yeh, H
Kim, J
Shi, S
Zhang, X
Wei, L
Soohoo, J
Wang, T
Markmann, J
AF Schuetz, C.
Lei, J.
Machaidze, Z.
Saidman, S.
Yeh, H.
Kim, J.
Shi, S.
Zhang, X.
Wei, L.
Soohoo, J.
Wang, T.
Markmann, J.
TI Challenges in Pre-Clinical Transplantation of Encapsulated Xenogenic
Islets
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Schuetz, C.; Lei, J.; Machaidze, Z.; Yeh, H.; Kim, J.; Shi, S.; Zhang, X.; Wei, L.; Soohoo, J.; Markmann, J.] Massachusetts Gen Hosp, Transplant Surg Div, Boston, MA 02114 USA.
[Saidman, S.] Massachusetts Gen Hosp, Histocompatibil Lab, Boston, MA 02114 USA.
[Shi, S.; Wang, T.] Vanderbilt Univ, Sch Engn, Nashville, TN 37235 USA.
RI Schuetz, Christian/K-5234-2013
OI Schuetz, Christian/0000-0002-6828-4543
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA C1559
BP 332
EP 332
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301414
ER
PT J
AU Karimian, N
op den Dries, S
Westerkamp, A
Gouw, A
Markmann, J
Lisman, T
Yeh, H
Uygun, K
Martins, P
Porte, R
AF Karimian, N.
op den Dries, S.
Westerkamp, A.
Gouw, A.
Markmann, J.
Lisman, T.
Yeh, H.
Uygun, K.
Martins, P.
Porte, R.
TI Injury of Peribiliary Glands and Vascular Plexus Before Liver
Transplantation Predicts Formation of Non-Anastomotic Biliary Strictures
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Karimian, N.; op den Dries, S.; Westerkamp, A.; Lisman, T.; Porte, R.] Univ Med Ctr Groningen, Dept Surg, Sect Hepatopancreatobiliary Surg & Liver Transpla, Groningen, Netherlands.
[Gouw, A.] Univ Med Ctr Groningen, Dept Pathol, Groningen, Netherlands.
[op den Dries, S.; Markmann, J.; Yeh, H.; Uygun, K.; Martins, P.] Harvard Univ, Sch Med, Dept Surg, Massachusetts Gen Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA C1651
BP 342
EP 342
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301453
ER
PT J
AU Schuetz, C
Patti, M
Cagliero, E
Crisalli, K
Yeh, H
Lillemoe, K
Markmann, J
AF Schuetz, C.
Patti, M.
Cagliero, E.
Crisalli, K.
Yeh, H.
Lillemoe, K.
Markmann, J.
TI Recurrent Hypoglycemia Following Total Pancreatectomy and Islet
Autotransplantation.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Schuetz, C.; Crisalli, K.; Yeh, H.; Markmann, J.] Massachusetts Gen Hosp, Transplant Surg Div, Boston, MA 02114 USA.
[Lillemoe, K.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Cagliero, E.] Massachusetts Gen Hosp, Diabet Ctr, Boston, MA 02114 USA.
[Patti, M.] Joslin Diabet Ctr, Boston, MA 02215 USA.
RI Schuetz, Christian/K-5234-2013
OI Schuetz, Christian/0000-0002-6828-4543
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA C1708
BP 358
EP 358
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301510
ER
PT J
AU Michel, S
La Muraglia, G
Madariaga, M
Allan, J
Titus, J
Selig, M
Farkash, E
Anderson, L
Madsen, J
AF Michel, S.
La Muraglia, G., II
Madariaga, M.
Allan, J.
Titus, J.
Selig, M.
Farkash, E.
Anderson, L.
Madsen, J.
TI Superior Donor Heart Preservation Using Hypothermic Oxygenated
Perfusion.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Michel, S.; La Muraglia, G., II; Madariaga, M.; Allan, J.; Titus, J.; Madsen, J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA USA.
[Selig, M.; Farkash, E.] Harvard Univ, Sch Med, Dept Pathol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Anderson, L.] Paragonix Technol, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA C2053
BP 370
EP 370
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301555
ER
PT J
AU Bruinsma, B
Sridharan, G
Weeder, P
Izamis, M
Martins, P
Yeh, H
Uygun, K
AF Bruinsma, B.
Sridharan, G.
Weeder, P.
Izamis, M.
Martins, P.
Yeh, H.
Uygun, K.
TI Indicators of Liver Viability in the Ex Vivo Perfused Human Liver.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Bruinsma, B.; Sridharan, G.; Weeder, P.; Izamis, M.; Uygun, K.] Massachusetts Gen Hosp, Ctr Engn Med, Boston, MA 02114 USA.
[Martins, P.] Massachusetts Gen Hosp, Transplant Unit, Boston, MA 02114 USA.
[Yeh, H.] UMass Mem, Transplant Surg, Worcester, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA C2065
BP 373
EP 374
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301567
ER
PT J
AU Farris, A
Farkash, E
Della Pelle, P
Collins, A
Smith, R
Colvin, R
AF Farris, A.
Farkash, E.
Della Pelle, P.
Collins, A.
Smith, R.
Colvin, R.
TI Activated NK Cells in Glomeruli Are Characteristic of Chronic Antibody
Mediated Rejection
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Farris, A.] Emory Univ, Atlanta, GA 30322 USA.
[Farkash, E.] Univ Michigan, Ann Arbor, MI 48109 USA.
[Della Pelle, P.; Collins, A.; Smith, R.; Colvin, R.] Harvard Univ, Massachusetts Gen Hosp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA D2310
BP 381
EP 382
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301596
ER
PT J
AU Marino, J
Trowell, A
Singh, P
Benichou, G
AF Marino, J.
Trowell, A.
Singh, P.
Benichou, G.
TI B Cell Depletion Prevents the Development of Memory T Cell Direct
Alloreactivity After Allotransplantation
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Marino, J.; Trowell, A.; Singh, P.; Benichou, G.] Harvard Univ, Sch Med, Dept Surg, Transplantat Res Ctr,Massachusetts Gen Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA D2324
BP 386
EP 386
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301610
ER
PT J
AU Marino, J
Galan, Y
Trowell, A
Benichou, G
AF Marino, J.
Galan, Y.
Trowell, A.
Benichou, G.
TI B Cell Depletion Promotes the Development of Donor Hematopoietic
Chimerism
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Marino, J.; Galan, Y.; Trowell, A.; Benichou, G.] Harvard Univ, Sch Med, Dept Surg, Transplantat Res Ctr,Massachusetts Gen Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA D2329
BP 387
EP 387
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301615
ER
PT J
AU Navarro-Alvarez, N
Zhu, A
Arellano, R
Randolph, M
Duggan, M
Am, J
Sachs, D
Vagefi, P
AF Navarro-Alvarez, N.
Zhu, A.
Arellano, R.
Randolph, M.
Duggan, M.
Am, J.
Sachs, D.
Vagefi, P.
TI Post-Natal B-Cell Tolerance Following In-Utero Intraportal Injection of
Xenogeneic Cells
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Navarro-Alvarez, N.; Zhu, A.; Arellano, R.; Randolph, M.; Duggan, M.; Am, J.; Sachs, D.; Vagefi, P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Transplantat Biol Res Ctr, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA D2333
BP 388
EP 388
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301619
ER
PT J
AU McDaid, J
Markmann, J
Kim, J
AF McDaid, J.
Markmann, J.
Kim, J.
TI Bespoke Immunosuppression: Targeting Alloreactive T-Cells Using c-FLIP
siRNA Prolongs Allograft Survival
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [McDaid, J.] Queens Univ Belfast, Belfast, Antrim, North Ireland.
[Markmann, J.; Kim, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA D2757
BP 392
EP 392
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301634
ER
PT J
AU Kim, J
Stott, R
Soohoo, J
Lee, K
Zhao, G
Yeh, H
Deng, S
Markmann, J
AF Kim, J.
Stott, R.
Soohoo, J.
Lee, K.
Zhao, G.
Yeh, H.
Deng, S.
Markmann, J.
TI Elevated Levels of Interferon-gamma Production By Memory T Cells Do Not
Promote Transplant Tolerance Resistance in Aged Recipients
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Kim, J.; Stott, R.; Soohoo, J.; Lee, K.; Zhao, G.; Yeh, H.; Deng, S.; Markmann, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kim, J.; Stott, R.; Soohoo, J.; Lee, K.; Zhao, G.; Yeh, H.; Deng, S.; Markmann, J.] Harvard Univ, Sch Med, Boston, MA USA.
[Zhao, G.; Deng, S.] Sichuan Prov Peoples Hosp, Chengdu, Sichuan, Peoples R China.
[Zhao, G.; Deng, S.] Sichuan Acad Med Sci, Chengdu, Sichuan, Peoples R China.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA D2768
BP 395
EP 395
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301645
ER
PT J
AU Cameron, A
Wesson, R
Singer, A
Wang, Y
Hu, X
Okabayashi, T
Sachs, D
Arn, S
Abdullah, K
Delone, P
Ruben, D
Montgomery, R
Williams, M
Sun, Z
AF Cameron, A.
Wesson, R.
Singer, A.
Wang, Y.
Hu, X.
Okabayashi, T.
Sachs, D.
Arn, S.
Abdullah, K.
Delone, P.
Ruben, D.
Montgomery, R.
Williams, M.
Sun, Z.
TI Endogenous Stem Cell Mobilization Via CXCR4 Antagonism Allows for Drug
Free Kidney Transplantation in a Large Animal Preclinical Model.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Cameron, A.; Wesson, R.; Singer, A.; Wang, Y.; Hu, X.; Okabayashi, T.; Ruben, D.; Montgomery, R.; Williams, M.; Sun, Z.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA.
[Abdullah, K.; Delone, P.] Genzyme Sanofi, Cambridge, MA USA.
[Sachs, D.; Arn, S.] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Cambridge, MA USA.
NR 0
TC 0
Z9 0
U1 3
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA D2780
BP 397
EP 398
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301657
ER
PT J
AU Kato, Y
Griesemer, A
Duran-Struuck, R
Wu, A
Woodland, D
Weiner, J
Ohmura, Y
Martinez, M
Alonso, P
Baker, S
Karolewski, B
Lefkowitch, J
Kawai, T
Kato, T
Sykes, M
AF Kato, Y.
Griesemer, A.
Duran-Struuck, R.
Wu, A.
Woodland, D.
Weiner, J.
Ohmura, Y.
Martinez, M.
Alonso, P.
Baker, S.
Karolewski, B.
Lefkowitch, J.
Kawai, T.
Kato, T.
Sykes, M.
TI The First Tolerance Induction Model for Combined Liver and Donor Bone
Marrow Transplantation in Cynomolgus Monkey
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Kato, Y.; Griesemer, A.; Woodland, D.; Weiner, J.; Ohmura, Y.; Kato, T.] Columbia Univ Coll Phys & Surg, New York, NY 10032 USA.
[Kato, Y.; Griesemer, A.; Duran-Struuck, R.; Wu, A.; Woodland, D.; Weiner, J.; Ohmura, Y.; Alonso, P.; Sykes, M.] Columbia Univ, Columbia Ctr Translat Immunol, New York, NY USA.
[Martinez, M.; Lefkowitch, J.] Columbia Univ, New York, NY USA.
[Duran-Struuck, R.; Baker, S.; Karolewski, B.] Columbia Univ, Inst Comparat Med, New York, NY USA.
[Kawai, T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA D2782
BP 398
EP 398
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301659
ER
PT J
AU Madariaga, M
Michel, S
La Muraglia, G
Villani, V
Sejikima, M
Leonard, D
Powell, H
Farkash, E
Colvin, R
Allan, J
Cetrulo, C
Huang, C
Sachs, D
Yamada, K
Madsen, J
AF Madariaga, M.
Michel, S.
La Muraglia, G., II
Villani, V.
Sejikima, M.
Leonard, D.
Powell, H.
Farkash, E.
Colvin, R.
Allan, J.
Cetrulo, C., Jr.
Huang, C.
Sachs, D.
Yamada, K.
Madsen, J.
TI Assessing the Renal Elements Responsible for Kidney-Induced Cardiac
Allograft Tolerance in Miniature Swine
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA D2781
BP 398
EP 398
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301658
ER
PT J
AU Tonsho, M
Benichou, G
Boskovic, S
Nadazdin, O
Smith, N
Allan, J
Colvin, R
Sachs, D
Cosimi, A
Kawai, T
Madsen, J
AF Tonsho, M.
Benichou, G.
Boskovic, S.
Nadazdin, O.
Smith, N.
Allan, J.
Colvin, R.
Sachs, D.
Cosimi, A.
Kawai, T.
Madsen, J.
TI Delayed Induction of Mixed Chimerism Permits Kidney-Induced Cardiac
Allograft Tolerance to Be Applied to Recipients of Cadaveric Heart
Allografts
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Tonsho, M.; Benichou, G.; Boskovic, S.; Nadazdin, O.; Smith, N.; Allan, J.; Colvin, R.; Cosimi, A.; Kawai, T.; Madsen, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Tonsho, M.; Benichou, G.; Boskovic, S.; Nadazdin, O.; Smith, N.; Allan, J.; Colvin, R.; Sachs, D.; Cosimi, A.; Kawai, T.; Madsen, J.] Harvard Univ, Sch Med, Boston, MA USA.
[Allan, J.; Sachs, D.; Madsen, J.] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA D2783
BP 398
EP 398
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301660
ER
PT J
AU Shinoda, K
Akiyoshi, T
Chase, C
Farkash, E
Russell, P
Madsen, J
Colvin, R
Alessandrini, A
AF Shinoda, K.
Akiyoshi, T.
Chase, C.
Farkash, E.
Russell, P.
Madsen, J.
Colvin, R.
Alessandrini, A.
TI Depletion of Foxp3(+) T Cells Abrogates Tolerance of Organ Allografts in
Murine Mixed Chimeras Without Inducing Recipient Reactivity to Donor
Hematopoietic Cells
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Shinoda, K.; Akiyoshi, T.; Chase, C.; Farkash, E.; Russell, P.; Madsen, J.; Colvin, R.; Alessandrini, A.] Massachusetts Gen Hosp, Transplant Ctr, Boston, MA 02114 USA.
[Shinoda, K.; Chase, C.; Farkash, E.; Russell, P.; Madsen, J.; Colvin, R.; Alessandrini, A.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA D2785
BP 399
EP 399
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301662
ER
PT J
AU La Muraglia, G
Madariaga, M
Michel, S
Mordecai, K
Preffer, F
Hanekamp, I
Madsen, J
AF La Muraglia, G., II
Madariaga, M.
Michel, S.
Mordecai, K.
Preffer, F.
Hanekamp, I.
Madsen, J.
TI A Novel Approach to the Quantification and Characterization of Cell
Mediated Cytotoxicity Using the Amnis ImageStream(x)
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [La Muraglia, G., II; Madariaga, M.; Michel, S.; Hanekamp, I.; Madsen, J.] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA.
[Michel, S.] Univ Munich, Munich, Germany.
[Mordecai, K.; Preffer, F.; Madsen, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[La Muraglia, G., II; Madariaga, M.; Michel, S.; Hanekamp, I.; Madsen, J.] Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA D2794
BP 401
EP 401
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301671
ER
PT J
AU Hotta, K
Aoyama, A
Oura, T
Tonsho, M
Yamada, Y
Allan, J
Madsen, J
Cosimi, B
Kawai, T
AF Hotta, K.
Aoyama, A.
Oura, T.
Tonsho, M.
Yamada, Y.
Allan, J.
Madsen, J.
Cosimi, B.
Kawai, T.
TI Donor Specific Regulatory T-Cell Expansion Is Associated With the
Maintenance of Allograft Tolerance Induced By Transient Mixed Chimerism
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Hotta, K.; Aoyama, A.; Oura, T.; Tonsho, M.; Yamada, Y.; Allan, J.; Madsen, J.; Cosimi, B.; Kawai, T.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA D2806
BP 404
EP 405
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301683
ER
PT J
AU Madariaga, M
Michel, S
La Muraglia, G
Sihag, S
Leonard, D
Powell, H
Farkash, E
Colvin, R
Cetrulo, C
Huang, C
Sachs, D
Madsen, J
Allan, J
AF Madariaga, M.
Michel, S.
La Muraglia, G., II
Sihag, S.
Leonard, D.
Powell, H.
Farkash, E.
Colvin, R.
Cetrulo, C., Jr.
Huang, C.
Sachs, D.
Madsen, J.
Allan, J.
TI Recipient-Matching of Passenger Leukocytes Prolongs Survival of Donor
Lung Allografts in Miniature Swine
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA D2809
BP 405
EP 405
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301686
ER
PT J
AU Villani, V
Scalea, J
Gillon, B
Sekijima, M
Tasaki, M
Cormack, T
Sachs, D
Yamada, K
AF Villani, V.
Scalea, J.
Gillon, B.
Sekijima, M.
Tasaki, M.
Cormack, T.
Sachs, D.
Yamada, K.
TI Adoptive Transfer of Renal Allograft Tolerance in a Large Animal Model
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Villani, V.; Scalea, J.; Gillon, B.; Sekijima, M.; Tasaki, M.; Cormack, T.; Sachs, D.; Yamada, K.] Massachusetts Gen Hosp, Transplantat Biol Res Ctr, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA D2807
BP 405
EP 405
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301684
ER
PT J
AU Yeh, H
Machaidze, Z
Wamala, I
Navarro-Alvarez, N
Shi, S
Zhu, A
Hertl, M
Elias, N
Farkash, E
Fraser, J
Vagefi, P
Smith, R
Robson, S
Van Cott, E
Sachs, D
Markmann, J
AF Yeh, H.
Machaidze, Z.
Wamala, I.
Navarro-Alvarez, N.
Shi, S.
Zhu, A.
Hertl, M.
Elias, N.
Farkash, E.
Fraser, J.
Vagefi, P.
Smith, R.
Robson, S.
Van Cott, E.
Sachs, D.
Markmann, J.
TI Increased Transfusion-Free Survival Following Auxiliary Liver
Xenotransplantation.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Yeh, H.; Machaidze, Z.; Wamala, I.; Navarro-Alvarez, N.; Shi, S.; Zhu, A.; Hertl, M.; Elias, N.; Farkash, E.; Fraser, J.; Vagefi, P.; Smith, R.; Van Cott, E.; Sachs, D.; Markmann, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Robson, S.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA D2845
BP 415
EP 415
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301722
ER
PT J
AU Alvarez, NN
Machaidze, Z
Hertl, M
Vagefi, P
Elias, N
Buhler, L
Sachs, D
Markmann, J
Yeh, H
AF Alvarez, N. Navarro
Machaidze, Z.
Hertl, M.
Vagefi, P.
Elias, N.
Buhler, L.
Sachs, D.
Markmann, J.
Yeh, H.
TI Auxiliary Liver Xenotransplantation Improves Liver Regeneration and
Survival in 90% Hepatectomy Model of Liver Failure in Baboons.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Alvarez, N. Navarro; Machaidze, Z.; Hertl, M.; Vagefi, P.; Elias, N.; Sachs, D.; Markmann, J.; Yeh, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Buhler, L.] Univ Geneva, Sch Med, CH-1211 Geneva, Switzerland.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA D2849
BP 416
EP 416
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301726
ER
PT J
AU Tena, A
Leonard, D
Tasaki, M
Mallard, C
Germana, S
Farkash, E
Mastroianni, M
Sachs, D
Hawley, R
AF Tena, A.
Leonard, D.
Tasaki, M.
Mallard, C.
Germana, S.
Farkash, E.
Mastroianni, M.
Sachs, D.
Hawley, R.
TI Initial Evidence for Functional Immune Modulation in Primate Recipients
of Porcine Skin Grafts Following Conditioning With Human CD47 Transgenic
Pig Hematopoietic Stem Cells.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Tena, A.; Leonard, D.; Tasaki, M.; Mallard, C.; Germana, S.; Farkash, E.; Mastroianni, M.; Sachs, D.; Hawley, R.] Massachusetts Gen Hosp, Transplant Biol Res Ctr, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA D2854
BP 417
EP 417
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033301731
ER
PT J
AU Elias, N
Ko, D
Farrell, M
Shao, S
Crisalli, K
Tolkoff-Rubin, N
Cosimi, B
AF Elias, N.
Ko, D.
Farrell, M.
Shao, S.
Crisalli, K.
Tolkoff-Rubin, N.
Cosimi, B.
TI Dactinomycin Based Immunosuppression Maintains Long Term Renal Graft
Survival.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Elias, N.; Ko, D.; Farrell, M.; Shao, S.; Crisalli, K.; Tolkoff-Rubin, N.; Cosimi, B.] Massachusetts Gen Hosp, Transplant Unit, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA A217
BP 462
EP 462
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033302096
ER
PT J
AU Farkash, E
Brousades, N
Farrell, M
Della Pelle, T
Colvin, R
AF Farkash, E.
Brousades, N.
Farrell, M.
Della Pelle, T.
Colvin, R.
TI BK Polyoma Virus Drives a Subset of Kidney and Bladder Cancers in Solid
Organ Transplant Recipients
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Farkash, E.; Brousades, N.; Farrell, M.; Della Pelle, T.; Colvin, R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Farkash, E.] Univ Michigan, Ann Arbor, MI 48109 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA B1017
BP 555
EP 555
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033302423
ER
PT J
AU Chandran, S
Arroyo, D
Vagefi, P
Wojciechowski, D
AF Chandran, S.
Arroyo, D.
Vagefi, P.
Wojciechowski, D.
TI Adjuvant Ciprofloxacin Therapy for Refractory BK Polyomavirus Infection
in Kidney Transplant Recipients.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Chandran, S.; Wojciechowski, D.] UCSF, San Francisco, CA USA.
[Arroyo, D.] Univ Gregorio Maranon, Gen Hosp, Madrid, Spain.
[Vagefi, P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA B1037
BP 560
EP 560
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033302443
ER
PT J
AU Cardarelli, F
Kandula, P
Greka, A
Mundel, P
Weins, A
Riella, L
AF Cardarelli, F.
Kandula, P.
Greka, A.
Mundel, P.
Weins, A.
Riella, L.
TI Analysis of Glomerular B7-1 Staining in Renal Allograft Biopsies.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA C1787
BP 577
EP 577
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033302506
ER
PT J
AU Adler, J
Yeh, H
Markmann, J
AF Adler, J.
Yeh, H.
Markmann, J.
TI Risk Factors Associated With Renal Allograft Thrombosis and Obstacles to
Re-Transplantation
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Adler, J.; Yeh, H.; Markmann, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA D2531
BP 644
EP 644
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033302745
ER
PT J
AU Satomi, M
Bracamonte-Baran, W
Jankowska-Gan, E
Shea, S
Benichou, G
Burlingham, W
AF Satomi, M.
Bracamonte-Baran, W.
Jankowska-Gan, E.
Shea, S.
Benichou, G.
Burlingham, W.
TI Can Bi-Directional Regulation Play a Beneficial Role in Skin Allograft
Survival?
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Satomi, M.] Osaka City Univ, Dept Surg, Osaka 558, Japan.
[Satomi, M.; Bracamonte-Baran, W.; Jankowska-Gan, E.; Burlingham, W.] Univ Wisconsin, Dept Surg, Madison, WI USA.
[Shea, S.; Benichou, G.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA A2973
BP 660
EP 660
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033303002
ER
PT J
AU Faustman, D
Mera, T
AF Faustman, D.
Mera, T.
TI Removal of Donor HLA Class I Proteins with Papain: Translation for
Possible Whole Organ Practices
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 Massachusetts Gen Hosp, Immunobiol Labs, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA C3039
BP 678
EP 678
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033303067
ER
PT J
AU Weeder, P
op den Dries, S
Yeh, H
Markmann, J
Uygun, K
Porte, R
Martins, P
AF Weeder, P.
op den Dries, S.
Yeh, H.
Markmann, J.
Uygun, K.
Porte, R.
Martins, P.
TI Identification of Donor Factors Associated With Pretransplant Injury of
The Donor Bile Duct and The Occurence of Non-Anastomotic Biliary
Strictures After Liver Transplantation
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Weeder, P.; op den Dries, S.; Porte, R.] Univ Med Ctr Groningen, NL-9713 AV Groningen, Netherlands.
[Weeder, P.; Yeh, H.; Markmann, J.] Massachusetts Gen Hosp, Transplant Div, Boston, MA 02114 USA.
[Weeder, P.; Uygun, K.] Harvard Univ, Sch Med, Ctr Engn Med, Boston, MA USA.
[Martins, P.] Umass Mem Med Ctr, Worcester, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA B1074
BP 722
EP 722
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033303227
ER
PT J
AU Adler, J
Dong, N
Nguyen, L
Schoenfeld, D
Markmann, J
Yeh, H
AF Adler, J.
Dong, N.
Nguyen, L.
Schoenfeld, D.
Markmann, J.
Yeh, H.
TI Longer Liver Transplant Waiting Lists Associated With Sicker Patients in
Donor Service Areas
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Adler, J.; Dong, N.; Markmann, J.; Yeh, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Nguyen, L.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Schoenfeld, D.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA B1089
BP 726
EP 727
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033303242
ER
PT J
AU Schaenman, J
Morris, M
Kotton, C
Danziger-Isakov, L
Kumar, D
AF Schaenman, J.
Morris, M.
Kotton, C.
Danziger-Isakov, L.
Kumar, D.
TI Medical Center Support for Transplant Infectious Diseases Programs
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Schaenman, J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Infect Dis, Los Angeles, CA 90095 USA.
[Morris, M.] Univ Miami, Miller Sch Med, Div Infect Dis, Dept Med, Miami, FL 33136 USA.
[Kotton, C.] Mass Gen Hosp, Div Infect Dis, Dept Med, Boston, MA USA.
[Danziger-Isakov, L.] Cincinnati Childrens, Dept Pediat, Cincinnati, OH USA.
[Kumar, D.] Univ Hlth Network, Multi Organ Transplant Program, Toronto, ON, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA D2395
BP 771
EP 772
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033303403
ER
PT J
AU Donnelly, J
Wang, H
Locke, J
Mannon, R
Baddley, J
AF Donnelly, J.
Wang, H.
Locke, J.
Mannon, R.
Baddley, J.
TI Healthcare Facility-Associated Clostridium difficile Infection in Solid
Organ Transplant Recipients
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Donnelly, J.; Wang, H.] Univ Alabama Birmingham, Dept Emergency Med, Birmingham, AL USA.
[Locke, J.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA.
[Mannon, R.; Baddley, J.] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA.
[Baddley, J.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA D2397
BP 772
EP 772
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033303405
ER
PT J
AU Yeh, H
Markmann, J
Hunsicker, L
AF Yeh, H.
Markmann, J.
Hunsicker, L.
TI Higher Income Associated With Lower Risk of Liver Disease But Higher
Likelihood of Listing for Liver Transplantation.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Yeh, H.; Markmann, J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Hunsicker, L.] Univ Iowa, Iowa City, IA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA B827
BP 816
EP 816
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033303548
ER
PT J
AU Adler, J
Pratt, J
Werger, N
Marquez, A
McLaughlin, E
Markmann, J
Yeh, H
AF Adler, J.
Pratt, J.
Werger, N.
Marquez, A.
McLaughlin, E.
Markmann, J.
Yeh, H.
TI Psychosocial and Economic Differences Between Donors and Recipients.
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Adler, J.; Pratt, J.; Werger, N.; Marquez, A.; McLaughlin, E.; Markmann, J.; Yeh, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA B842
BP 820
EP 820
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033303563
ER
PT J
AU Adler, J
Nguyen, L
Markmann, J
Yeh, H
AF Adler, J.
Nguyen, L.
Markmann, J.
Yeh, H.
TI Socioeconomic Disparities Among Deceased Donors and Renal Transplant
Recipients
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Adler, J.; Markmann, J.; Yeh, H.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Nguyen, L.] Brigham & Womens Hosp, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA B1226
BP 835
EP 836
PG 2
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033303617
ER
PT J
AU Asselbergs, F
Lord, G
Snyder, M
Birdwell, K
Schadt, E
Oetting, W
Petersdorf, E
MacArthur, D
Shaked, A
Keating, B
AF Asselbergs, F.
Lord, G.
Snyder, M.
Birdwell, K.
Schadt, E.
Oetting, W.
Petersdorf, E.
MacArthur, D.
Shaked, A.
Keating, B.
TI The International Genomics & Translational Research in Transplantation
Network (iGeneTrain).
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Asselbergs, F.] Univ Med Ctr Utrecht, Utrecht, Netherlands.
[Lord, G.] Guys & St Thomas Hosp, London SE1 9RT, England.
[Lord, G.] Kings Coll London, London WC2R 2LS, England.
[Snyder, M.] Stanford Univ, Stanford, CA 94305 USA.
[Birdwell, K.] Vanderbilt Univ, Nashville, TN 37235 USA.
[Schadt, E.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
[Oetting, W.] Univ Minnesota, Sch Pharm, Minneapolis, MN 55455 USA.
[Petersdorf, E.] Univ Washington, Dept Hematol & Oncol, Seattle, WA 98195 USA.
[MacArthur, D.] Harvard Univ, Sch Med, Broad Inst, Cambridge, MA 02138 USA.
[MacArthur, D.] Massachusetts Gen Hosp, Cambridge, MA USA.
[Shaked, A.; Keating, B.] Univ Penn, Transplant Inst, Philadelphia, PA 19104 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA A521
BP 891
EP 891
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033304071
ER
PT J
AU Gao, B
Rong, C
Moore, C
Porcheray, F
Wong, W
Kawai, T
Sykes, M
Cosimi, B
Sachs, D
Zorn, E
AF Gao, B.
Rong, C.
Moore, C.
Porcheray, F.
Wong, W.
Kawai, T.
Sykes, M.
Cosimi, B.
Sachs, D.
Zorn, E.
TI Dynamics of B Cell Recovery in Tolerant Recipients of Combined Kidney
Bone Marrow Transplantation
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Meeting Abstract
CT World Transplant Congress
CY JUL 26-31, 2014
CL San Francisco, CA
C1 [Gao, B.; Rong, C.; Moore, C.; Porcheray, F.; Wong, W.; Kawai, T.; Cosimi, B.; Sachs, D.; Zorn, E.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
[Gao, B.] Jilin Univ, Hosp 1, Changchun 130023, Peoples R China.
[Rong, C.] Changchun Univ Chinese Med, Affiliated Hosp, Changchun, Peoples R China.
[Sykes, M.] Columbia Univ, Med Ctr, New York, NY USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
SU 3
MA B787
BP 896
EP 896
PG 1
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ9LU
UT WOS:000338033304089
ER
PT J
AU Saxena, R
Bjonnes, A
Prescott, J
Dib, P
Natt, P
Lane, J
Lerner, M
Cooper, JA
Ye, YQ
Li, KW
Maubaret, CG
Codd, V
Brackett, D
Mirabello, L
Kraft, P
Dinney, CP
Stowell, D
Peyton, M
Ralhan, S
Wander, GS
Mehra, NK
Salpea, KD
Gu, J
Wu, XF
Mangino, M
Hunter, DJ
De Vivo, I
Humphries, SE
Samani, NJ
Spector, TD
Savage, SA
Sanghera, DK
AF Saxena, Richa
Bjonnes, Andrew
Prescott, Jennifer
Dib, Patrick
Natt, Praveen
Lane, Jacqueline
Lerner, Megan
Cooper, Jackie A.
Ye, Yuanqing
Li, Ka Wah
Maubaret, Cecilia G.
Codd, Veryan
Brackett, Daniel
Mirabello, Lisa
Kraft, Peter
Dinney, Colin P.
Stowell, Donald
Peyton, Marvin
Ralhan, Sarju
Wander, Gurpreet S.
Mehra, Narinder K.
Salpea, Klelia D.
Gu, Jian
Wu, Xifeng
Mangino, Massimo
Hunter, David J.
De Vivo, Immaculata
Humphries, Steve E.
Samani, Nilesh J.
Spector, Tim D.
Savage, Sharon A.
Sanghera, Dharambir K.
TI Genome-Wide Association Study Identifies Variants in Casein Kinase II
(CSNK2A2) to be Associated With Leukocyte Telomere Length in a Punjabi
Sikh Diabetic Cohort
SO CIRCULATION-CARDIOVASCULAR GENETICS
LA English
DT Article
DE cardiovascular diseases; diabetes mellitus, type 2; genome-wide
association study; telomere length
ID CORONARY-HEART-DISEASE; ASIAN INDIAN SIKHS; WHITE BLOOD-CELLS;
GENETIC-VARIATION; GENOTYPE IMPUTATION; ATHEROSCLEROSIS; LOCUS; RISK;
SHORTER; PROTEIN
AB Background-Telomere length is a heritable trait, and short telomere length has been associated with multiple chronic diseases. We investigated the relationship of relative leukocyte telomere length with cardiometabolic risk and performed the first genome-wide association study and meta-analysis to identify variants influencing relative telomere length in a population of Sikhs from South Asia.
Methods and Results-Our results revealed a significant independent association of shorter relative telomere length with type 2 diabetes mellitus and heart disease. Our discovery genome-wide association study (n=1616) was followed by stage 1 replication of 25 top signals (P<10(-6)) in an additional Sikhs (n=2397). On combined discovery and stage 1 metaanalysis (n=4013), we identified a novel relative telomere length locus at chromosome 16q21 represented by an intronic variant (rs74019828) in the CSNK2A2 gene (beta=-0.38; P=4.5x10(-8)). We further tested 3 top variants by genotyping in UK cardiovascular disease (UKCVD) (whites n=2952) for stage 2. Next, we performed in silico replication of 139 top signals (P<10(-5)) in UK Twin, Nurses Heart Study, Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial, and MD Anderson Cancer Controls (n=10033) and joint meta-analysis (n=16998). The observed signal in CSNK2A2 was confined to South Asians and could not be replicated in whites because of significant difference in allele frequencies (P<0.001). CSNK2A2 phosphorylates telomeric repeat binding factor 1 and plays an important role for regulation of telomere length homoeostasis.
Conclusions-By identification of a novel signal in telomere pathway genes, our study provides new molecular insight into the underlying mechanism that may regulate telomere length and its association with human aging and cardiometabolic pathophysiology.
C1 [Saxena, Richa; Bjonnes, Andrew; Lane, Jacqueline] Massachusetts Gen Hosp, Ctr Human Genet Res, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Prescott, Jennifer; Hunter, David J.; De Vivo, Immaculata] Brigham & Womens Hosp, Channing Div Network Med, Dept Med, Boston, MA 02115 USA.
[Prescott, Jennifer; Hunter, David J.; De Vivo, Immaculata] Harvard Univ, Sch Med, Boston, MA USA.
[Saxena, Richa; Bjonnes, Andrew; Lane, Jacqueline; Hunter, David J.] Massachusetts Inst Technol & Harvard, Broad Ins, Cambridge, MA USA.
[Dib, Patrick; Natt, Praveen; Sanghera, Dharambir K.] Univ Oklahoma, Dept Pediat, Coll Med, Hlth Sci Ctr, Oklahoma City, OK 73104 USA.
[Lerner, Megan; Brackett, Daniel; Stowell, Donald; Peyton, Marvin] Univ Oklahoma, Dept Surg, Hlth Sci Ctr, Oklahoma City, OK 73104 USA.
[Prescott, Jennifer; Kraft, Peter; Hunter, David J.; De Vivo, Immaculata] Harvard Univ, Sch Publ Hlth, Program Mol & Genet Epidemiol, Dept Epidemiol, Boston, MA 02115 USA.
[Kraft, Peter] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Cooper, Jackie A.; Li, Ka Wah; Maubaret, Cecilia G.; Salpea, Klelia D.; Humphries, Steve E.] UCL, BHF Labs, Inst Cardiovasc Sci, London, England.
[Ye, Yuanqing; Gu, Jian; Wu, Xifeng] Univ Texas MD Anderson Canc Ctr, Dept Epidemiol, Houston, TX 77030 USA.
[Codd, Veryan; Mangino, Massimo; Samani, Nilesh J.; Spector, Tim D.] Glenfield Hosp, Natl Inst Hlth Res, Leicester Cardiovasc Biomed Res Unit, Leicester, Leics, England.
[Mirabello, Lisa; Savage, Sharon A.] NCI, Div Canc Epidemiol & Genet, NIH, US Dept HHS, Bethesda, MD 20892 USA.
[Dinney, Colin P.] Univ Texas MD Anderson Canc Ctr, Dept Urol, Houston, TX 77030 USA.
[Ralhan, Sarju; Wander, Gurpreet S.] Hero DMC Heart Inst, Ludhiana, Punjab, India.
[Mehra, Narinder K.] All India Inst Med Sci & Res, New Delhi, India.
RP Sanghera, DK (reprint author), Univ Oklahoma, Dept Pediat, Coll Med, Hlth Sci Ctr, 940 Stanton L Young Blvd,Rm 317 BMSB, Oklahoma City, OK 73104 USA.
EM Dharambir-sanghera@ouhsc.edu
RI Savage, Sharon/B-9747-2015; mangino, massimo/F-5134-2011;
OI Savage, Sharon/0000-0001-6006-0740; mangino,
massimo/0000-0002-2167-7470; Humphries, Stephen E/0000-0002-8221-6547
FU National Institutes of Health - National Institute of Diabetes and
Digestive and Kidney Diseases [R01DK082766]; National Genome Research
Institute [NOT-HG-11-009]; Vice President for Research Bridge grant from
University of Oklahoma Health Sciences Center, Oklahoma City, OK
FX This work was partly supported by National Institutes of Health
grants-R01DK082766 funded by the National Institute of Diabetes and
Digestive and Kidney Diseases and NOT-HG-11-009 funded by National
Genome Research Institute and Vice President for Research Bridge grant
from University of Oklahoma Health Sciences Center, Oklahoma City, OK.
The genotyping and analysis for UKCVD was supported by the British Heart
Foundation (PG08/008). Study-specific funding sources for the
replication studies are provided in the Material in the Data Supplement.
NR 53
TC 7
Z9 7
U1 0
U2 13
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1942-325X
EI 1942-3268
J9 CIRC-CARDIOVASC GENE
JI Circ.-Cardiovasc. Genet.
PD JUN
PY 2014
VL 7
IS 3
BP 287
EP 295
DI 10.1161/CIRCGENETICS.113.000412
PG 9
WC Cardiac & Cardiovascular Systems; Genetics & Heredity
SC Cardiovascular System & Cardiology; Genetics & Heredity
GA AK1VY
UT WOS:000338207300009
PM 24795349
ER
PT J
AU Guan, WH
Steffen, BT
Lemaitre, RN
Wu, JHY
Tanaka, T
Manichaikul, A
Foy, M
Rich, SS
Wang, L
Nettleton, JA
Tang, WH
Gu, X
Bandinelli, S
King, IB
McKnight, B
Psaty, BM
Siscovick, D
Djousse, L
Chen, YDI
Ferrucci, L
Fornage, M
Mozafarrian, D
Tsai, MY
Steffen, LM
AF Guan, Weihua
Steffen, Brian T.
Lemaitre, Rozenn N.
Wu, Jason H. Y.
Tanaka, Toshiko
Manichaikul, Ani
Foy, Millennia
Rich, Stephen S.
Wang, Lu
Nettleton, Jennifer A.
Tang, Weihong
Gu, Xiangjun
Bandinelli, Stafania
King, Irena B.
McKnight, Barbara
Psaty, Bruce M.
Siscovick, David
Djousse, Luc
Chen, Yii-Der Ida
Ferrucci, Luigi
Fornage, Myriam
Mozafarrian, Dariush
Tsai, Michael Y.
Steffen, Lyn M.
TI Genome-Wide Association Study of Plasma N6 Polyunsaturated Fatty Acids
Within the Cohorts for Heart and Aging Research in Genomic Epidemiology
Consortium
SO CIRCULATION-CARDIOVASCULAR GENETICS
LA English
DT Article
DE epidemiology; genome-wide association study; N6 fatty acids;
polyunsaturated fatty acids
ID ACUTE MYOCARDIAL-INFARCTION; FADS GENETIC-VARIANTS; ARACHIDONIC-ACID;
ADIPOSE-TISSUE; DISEASE; POPULATION; ATHEROSCLEROSIS; DIETARY; DESIGN;
GENOTYPES
AB Background-Omega6 (n6) polyunsaturated fatty acids (PUFAs) and their metabolites are involved in cell signaling, inflammation, clot formation, and other crucial biological processes. Genetic components, such as variants of fatty acid desaturase (FADS) genes, determine the composition of n6 PUFAs.
Methods and Results-To elucidate undiscovered biological pathways that may influence n6 PUFA composition, we conducted genome-wide association studies and meta-analyses of associations of common genetic variants with 6 plasma n6 PUFAs in 8631 white adults (55% women) across 5 prospective studies. Plasma phospholipid or total plasma fatty acids were analyzed by similar gas chromatography techniques. The n6 fatty acids linoleic acid (LA), gamma-linolenic acid (GLA), dihomo-GLA, arachidonic acid, and adrenic acid were expressed as percentage of total fatty acids. We performed linear regression with robust SEs to test for single-nucleotide polymorphism-fatty acid associations, with pooling using inverse-variance-weighted meta-analysis. Novel regions were identified on chromosome 10 associated with LA (rs10740118; P=8.1x10(-9); near NRBF2), on chromosome 16 with LA, GLA, dihomo-GLA, and arachidonic acid (rs16966952; P=1.2x10(-15), 5.0x10(-11), 7.6x10(-65), and 2.4x10(-10), respectively; NTAN1), and on chromosome 6 with adrenic acid after adjustment for arachidonic acid (rs3134950; P=2.1x10(-10); AGPAT1). We confirmed previous findings of the FADS cluster on chromosome 11 with LA and arachidonic acid, and further observed novel genome-wide significant association of this cluster with GLA, dihomo-GLA, and adrenic acid (P=2.3x10(-72), 2.6x10(-151), and 6.3x10(-140), respectively).
Conclusions-Our findings suggest that along with the FADS gene cluster, additional genes may influence n6 PUFA composition.
C1 [Guan, Weihua] Univ Minnesota, Div Biostat, Sch Publ Hlth, Minneapolis, MN 55454 USA.
[Steffen, Brian T.; Tsai, Michael Y.] Univ Minnesota, Sch Publ Med, Minneapolis, MN 55454 USA.
[Tang, Weihong; Steffen, Lyn M.] Univ Minnesota, Div Epidemiol & Community Hlth, Sch Publ Hlth, Minneapolis, MN 55454 USA.
[Lemaitre, Rozenn N.; McKnight, Barbara; Psaty, Bruce M.; Siscovick, David] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
[Lemaitre, Rozenn N.; McKnight, Barbara; Psaty, Bruce M.; Siscovick, David] Univ Washington, Dept Med, Seattle, WA USA.
[Psaty, Bruce M.; Siscovick, David] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Psaty, Bruce M.; Siscovick, David] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Wu, Jason H. Y.; Wang, Lu; Mozafarrian, Dariush] Harvard Univ, Sch Publ Hlth, Dept Epidemiol & Nutr, Boston, MA 02115 USA.
[Mozafarrian, Dariush] Harvard Univ, Sch Publ Hlth, Dept Epidemiol, Boston, MA 02115 USA.
[Wu, Jason H. Y.] Univ Western Australia, Sch Med & Pharmacol, Perth, WA 6009, Australia.
[Tanaka, Toshiko; Ferrucci, Luigi] NIA, Clin Res Branch, NIH, Baltimore, MD 21224 USA.
[Manichaikul, Ani; Rich, Stephen S.] Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA USA.
[Manichaikul, Ani] Univ Virginia, Div Biostat & Epidemiol, Charlottesville, VA USA.
[Foy, Millennia; Gu, Xiangjun; Fornage, Myriam] Univ Texas Hlth Sci Ctr Houston, Inst Mol Med, Houston, TX 77030 USA.
[Nettleton, Jennifer A.] Univ Texas Hlth Sci Ctr Houston, Div Epidemiol Human Genet & Environm Sci, Houston, TX 77030 USA.
[Bandinelli, Stafania] ASF, Geriatr Rehabil Unit, Florence, Italy.
[King, Irena B.] Univ New Mexico, Dept Internal Med, Albuquerque, NM 87131 USA.
[Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA.
[Djousse, Luc] Harvard Univ, Sch Med, Div Aging, Brigham & Womens Hosp,Dept Med, Cambridge, MA 02138 USA.
[Djousse, Luc] Boston VA Healthcare Syst, Boston, MA USA.
[Chen, Yii-Der Ida] Cedars Sinai Med Ctr, Med Genet Res Inst, Los Angeles, CA 90048 USA.
[Mozafarrian, Dariush] Harvard Univ, Brigham & Womens Hosp, Div Cardiovasc Med, Sch Med, Boston, MA 02115 USA.
RP Steffen, LM (reprint author), Univ Minnesota, Div Epidemiol & Community Hlth, Sch Publ Hlth, 1300 South Second St,Suite 300, Minneapolis, MN 55454 USA.
EM steffen@umn.edu
RI Djousse, Luc/F-5033-2017
OI Djousse, Luc/0000-0002-9902-3047
FU National Heart, Lung, and Blood Institute (NHLBI) [HL105756]; NHLBI
[HHSN268201100005C, HHSN268201100006C, HHSN268201100007C,
HHSN268201100008C, HHSN268201100009C]; National Human Genome Research
Institute (NHGRI) [U01HG004402]; National Institutes of Health (NIH)
[HSN268200625226C]; NIH Roadmap for Medical Research [UL1RR025005];
National Institute of Neurological Disorders and Stroke; National
Institute on Aging (NIA) [AG023629]; National Center for Advancing
Translational Sciences, CTSI [UL1TR000124]; National Institute of
Diabetes and Digestive and Kidney Disease Diabetes Research Center
[DK063491]; NHGRI [U01-HG-004729, U01-HG-004446, U01-HG-004424]; Italian
Ministry of Health [ICS110.1/RF97.71]; US NIA [263 MD 9164, 263 MD
821336]; Intramural research program of the NIA, NIH, Baltimore, MD; K01
from the National Institute of Diabetes and Digestive and Kidney
Diseases (NIKDD) [5K01DK082729-02]; NHLBI. [HL105756, N01HC85086,
HL080295, HL087652, HL085710, N01-HC-95095, N01-HC-48047, N01-HC-48048,
N01-HC-48049, N01-HC-48050, N01-HC-45134, N01-HC-05187, N01-HC-45205,
N01-HC-45204, R01-HL-084099, N01-HC-95159, N01-HC-95160]; The NHLBI
[HHSN268201100010C, HHSN268201100011C, HHSN268201100012C, R01HL087641,
R01HL59367, R01HL086694]; The NHLBI. [N01-HC-95161, N01-HC-95162,
N01-HC-95163, N01-HC-95164, N01-HC-95165, N01-HC-95166, N01-HC-95167,
N01-HC-95168, N01-HC-95169, RR-024156, N02HL64278, HHSN268201200036C,
HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081,
N01HC85082, N01HC85083]
FX Infrastructure for the Cohorts for Heart and Aging Research in Genomic
Epidemiology Consortium is supported, in part, by the National Heart,
Lung, and Blood Institute (NHLBI) grant HL105756. The Atherosclerosis
Risk in Communities (ARIC) Study is performed as a collaborative study
supported by NHLBI contracts HHSN268201100005C, HHSN268201100006C,
HHSN268201100007C, HHSN268201100008C, HHSN268201100009C,
HHSN268201100010C, HHSN268201100011C, HHSN268201100012C, R01HL087641,
R01HL59367, and R01HL086694; National Human Genome Research Institute
(NHGRI) contract U01HG004402; and National Institutes of Health (NIH)
contract HSN268200625226C. Infrastructure was partly supported by grant
number UL1RR025005, a component of the NIH Roadmap for Medical Research.
The Cardiovascular Health Study (CHS) was supported by contracts
HHSN268201200036C, HHSN268200800007C, N01HC55222, N01HC85079,
N01HC85080, N01HC85081, N01HC85082, N01HC85083, and N01HC85086 and
grants HL080295, HL087652, and HL105756 from the NHLBI, with additional
contribution from the National Institute of Neurological Disorders and
Stroke. Additional support was provided by AG023629 from the National
Institute on Aging (NIA). The provision of genotyping data was supported
in part by the National Center for Advancing Translational Sciences,
CTSI grant UL1TR000124, and the National Institute of Diabetes and
Digestive and Kidney Disease Diabetes Research Center grant DK063491 to
the Southern California Diabetes Endocrinology Research Center. The
fatty acid measurements were supported by grant HL085710 from NHLBI. The
Coronary Artery Risk Development in Young Adults (CARDIA) study is
funded by contracts N01-HC-95095, N01-HC-48047, N01-HC-48048,
N01-HC-48049, N01-HC-48050, N01-HC-45134, N01-HC-05187, N01-HC-45205,
and N01-HC-45204 from the NHLBI to the CARDIA investigators. Genotyping
of the CARDIA participants was supported by grants U01-HG-004729,
U01-HG-004446, and U01-HG-004424 from the NHGRI and R01-HL-084099 from
the NHLBI to Dr Foy. The Invecchiare in Chianti (InCHIANTI) study
baseline (1998-2000) was supported as a targeted project
(ICS110.1/RF97.71) by the Italian Ministry of Health and in part by the
US NIA Contracts 263 MD 9164 and 263 MD 821336 and was supported, in
part, by the Intramural research program of the NIA, NIH, Baltimore, MD.
The Multi-Ethnic Study of Atherosclerosis (MESA) and MESA SNP Health
Association Resource (SHARe) were supported by contracts N01-HC-95159
through N01-HC-95169 and RR-024156 from the NHLBI. Funding for MESA
SHARe genotyping was provided by NHLBI Contract N02HL64278. Dr Nettleton
was supported by a K01 from the National Institute of Diabetes and
Digestive and Kidney Diseases (NIKDD) (5K01DK082729-02).
NR 49
TC 9
Z9 9
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1942-325X
EI 1942-3268
J9 CIRC-CARDIOVASC GENE
JI Circ.-Cardiovasc. Genet.
PD JUN
PY 2014
VL 7
IS 3
BP 321
EP 331
DI 10.1161/CIRCGENETICS.113.000208
PG 11
WC Cardiac & Cardiovascular Systems; Genetics & Heredity
SC Cardiovascular System & Cardiology; Genetics & Heredity
GA AK1VY
UT WOS:000338207300013
PM 24823311
ER
PT J
AU Bis, JC
White, CC
Franceschini, N
Brody, J
Zhang, XL
Muzny, D
Santibanez, J
Gibbs, R
Liu, XM
Lin, HH
Boerwinkle, E
Psaty, BM
North, KE
Cupples, LA
O'Donnell, CJ
AF Bis, Joshua C.
White, Charles C.
Franceschini, Nora
Brody, Jennifer
Zhang, Xiaoling
Muzny, Donna
Santibanez, Jireh
Gibbs, Richard
Liu, Xiaoming
Lin, Honghuang
Boerwinkle, Eric
Psaty, Bruce M.
North, Kari E.
Cupples, L. Adrienne
O'Donnell, Christopher J.
CA CHARGE Subclinical Atherosclerosis
TI Sequencing of 2 Subclinical Atherosclerosis Candidate Regions in 3669
Individuals Cohorts for Heart and Aging Research in Genomic Epidemiology
(CHARGE) Consortium Targeted Sequencing Study
SO CIRCULATION-CARDIOVASCULAR GENETICS
LA English
DT Article
DE atherosclerosis; carotid artery, common; epidemiology; genetics; plaque,
atherosclerotic; sequence analysis, DNA
ID INTIMA-MEDIA THICKNESS; KERNEL ASSOCIATION TEST; WIDE ASSOCIATION;
TASK-FORCE; METAANALYSIS; VARIANTS; RISK; LOCI; DESIGN; FRAMINGHAM
AB Background-Atherosclerosis, the precursor to coronary heart disease and stroke, is characterized by an accumulation of fatty cells in the arterial intimal-medial layers. Common carotid intima media thickness (cIMT) and plaque are subclinical atherosclerosis measures that predict cardiovascular disease events. Previously, genome-wide association studies demonstrated evidence for association with cIMT (SLC17A4) and plaque (PIK3CG).
Methods and Results-We sequenced 120 kb around SLC17A4 (6p22.2) and 251 kb around PIK3CG (7q22.3) among 3669 European ancestry participants from the Atherosclerosis Risk in Communities (ARIC) study, Cardiovascular Health Study (CHS), and Framingham Heart Study (FHS) in Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium. Primary analyses focused on 438 common variants (minor allele frequency >= 1%), which were independently meta-analyzed. A 3' untranslated region CCDC71L variant (rs2286149), upstream from PIK3CG, was the most significant finding in cIMT (P=0.00033) and plaque (P=0.0004) analyses. A SLC17A4 intronic variant was also associated with cIMT (P=0.008). Both were in low linkage disequilibrium with the genome-wide association study single nucleotide polymorphisms. Gene-based tests including T1 count and sequence kernel association test for rare variants (minor allele frequency <1%) did not yield statistically significant associations. However, we observed nominal associations for rare variants in CCDC71L and SLC17A3 with cIMT and of the entire 7q22 region with plaque (P=0.05).
Conclusions-Common and rare variants in PIK3CG and SLC17A4 regions demonstrated modest association with subclinical atherosclerosis traits. Although not conclusive, these findings may help to understand the genetic architecture of regions previously implicated by genome-wide association studies and identify variants within these regions for further investigation in larger samples.
C1 [Bis, Joshua C.; Brody, Jennifer; Psaty, Bruce M.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98101 USA.
[Bis, Joshua C.; Brody, Jennifer; Psaty, Bruce M.] Univ Washington, Dept Med, Seattle, WA 98101 USA.
[Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Seattle, WA 98101 USA.
[Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98101 USA.
[White, Charles C.; Zhang, Xiaoling; Lin, Honghuang; Cupples, L. Adrienne; O'Donnell, Christopher J.] NHLBI, Framingham Heart Study, Framingham, MA USA.
[White, Charles C.; Cupples, L. Adrienne] Boston Univ, Dept Biostat, Sch Publ Hlth, Boston, MA 02215 USA.
[Franceschini, Nora; North, Kari E.] Univ N Carolina, Dept Epidemiol, Chapel Hill, NC USA.
[North, Kari E.] Univ N Carolina, Carolina Ctr Genome Sci, Chapel Hill, NC USA.
[Muzny, Donna; Santibanez, Jireh; Gibbs, Richard; Boerwinkle, Eric] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA.
[Liu, Xiaoming; Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, Houston, TX 77030 USA.
[Lin, Honghuang] Boston Univ, Dept Med, Sch Med, Boston, MA 02215 USA.
[Psaty, Bruce M.] Grp Hlth, Grp Hlth Res Inst, Seattle, WA USA.
[Liu, Xiaoming; O'Donnell, Christopher J.] NHLBI, Div Intramural Res, Bethesda, MD 20892 USA.
[O'Donnell, Christopher J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiol Div,Dept Med, Boston, MA USA.
RP Bis, JC (reprint author), Univ Washington, Cardiovasc Hlth Res Unit, 1730 Minor Ave,Suite 1360, Seattle, WA 98101 USA.
EM joshbis@uw.edu
OI Lin, Honghuang/0000-0003-3043-3942
FU National Institutes of Health through the American Recovery and
Reinvestment Act [5RC2HL102419]; National Heart, Lung, and Blood
Institute (NHLBI) [HHSN268201100005C, HHSN268201100006C,
HHSN268201100007C, HHSN268201100 008C, HHSN268201100009C,
HHSN2682011000010C, HHSN268 2011000011C, HHSN2682011000012C]; Boston
University [N01-HC-25195]; Affymetrix, Inc [N02-HL-6-4278]; National
Institute on Aging (NIA) [AG023629]; National Center for Advancing
Translational Sciences, CTSI [UL1TR000124]; National Institute of
Diabetes and Digestive and Kidney Disease Diabetes Research Center (DRC)
[DK063491]; the NHLBI [N01-HC-25195, HHSN268201200036C,
HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081,
N01HC85082, N01HC85083, N01HC85086, N01HC85085, N01HC45133]; NHLBI
[HL080295, HL087652, HL105756, HL103612, HL120393]; [R01HL087641];
[R01HL59367]; [R01HL086694]
FX Funding support for Building on GWAS for NHLBI-Diseases: The US CHARGE
Consortium was provided by the National Institutes of Health through the
American Recovery and Reinvestment Act of 2009 (5RC2HL102419). Data for
Building on GWAS for NHLBI-Diseases: The US CHARGE Consortium were
provided by Eric Boerwinkle on behalf of the Atherosclerosis Risk in
Communities (ARIC) study; L. Adrienne Cupples, principal investigator
for the Framingham Heart Study (FHS); and Bruce Psaty, principal
investigator for the Cardiovascular Health Study. Sequencing was
performed at the Baylor Genome Center (U54 HG003273). The ARIC study is
performed as a collaborative study supported by National Heart, Lung,
and Blood Institute (NHLBI) contracts (HHSN268201100005C,
HHSN268201100006C, HHSN268201100007C, HHSN268201100 008C,
HHSN268201100009C, HHSN2682011000010C, HHSN268 2011000011C, and
HHSN2682011000012C), R01HL087641, R01HL59367, and R01HL086694. The
authors thank the staff and participants of the ARIC study for their
important contributions. The FHS is conducted and supported by the NHLBI
in collaboration with Boston University (contract no. N01-HC-25195), and
its contract with Affymetrix, Inc, for genome-wide genotyping services
(contract no. N02-HL-6-4278), for quality control by FHS investigators
using genotypes in the SNP Health Association Resource (SHARe) project.
A portion of this research was conducted using the Linux Cluster for
Genetic Analysis (LinGA) computing resources at Boston University
Medical Campus. This Cardiovascular Health Study research was supported
by NHLBI contracts HHSN268201200036C, HHSN268200800007C, N01HC55222,
N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086,
N01HC85085, N01HC45133; and NHLBI grants HL080295, HL087652, HL105756,
HL103612, and HL120393 with additional contribution from the National
Institute of Neurological Disorders and Stroke (NINDS). Additional
support was provided through AG023629 from the National Institute on
Aging (NIA). A full list of principal CHS investigators and institutions
can be found at CHS-NHLBI.org/. The provision of genotyping data was
supported in part by the National Center for Advancing Translational
Sciences, CTSI grant UL1TR000124, and the National Institute of Diabetes
and Digestive and Kidney Disease Diabetes Research Center (DRC) grant
DK063491 to the Southern California Diabetes Endocrinology Research
Center. The content is solely the responsibility of the authors and does
not necessarily represent the official views of the National Institutes
of Health.
NR 31
TC 3
Z9 3
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1942-325X
EI 1942-3268
J9 CIRC-CARDIOVASC GENE
JI Circ.-Cardiovasc. Genet.
PD JUN
PY 2014
VL 7
IS 3
BP 359
EP 364
DI 10.1161/CIRCGENETICS.113.000116
PG 6
WC Cardiac & Cardiovascular Systems; Genetics & Heredity
SC Cardiovascular System & Cardiology; Genetics & Heredity
GA AK1VY
UT WOS:000338207300018
PM 24951662
ER
PT J
AU Magnani, JW
Brody, JA
Prins, BP
Arking, DE
Lin, HH
Yin, XY
Liu, CT
Morrison, AC
Zhang, F
Spector, TD
Alonso, A
Bis, JC
Heckbert, SR
Lumley, T
Sitlani, CM
Cupples, A
Lubitz, SA
Soliman, EZ
Pulit, SL
Newton-Cheh, C
O'Donnell, CJ
Ellinor, PT
Benjamin, EJ
Muzny, DM
Gibbs, RA
Santibanez, J
Taylor, HA
Rotter, JI
Lange, LA
Psaty, BM
Jackson, R
Rich, SS
Boerwinkle, E
Jamshidi, Y
Sotoodehnia, N
AF Magnani, Jared W.
Brody, Jennifer A.
Prins, Bram P.
Arking, Dan E.
Lin, Honghuang
Yin, Xiaoyan
Liu, Ching-Ti
Morrison, Alanna C.
Zhang, Feng
Spector, Tim D.
Alonso, Alvaro
Bis, Joshua C.
Heckbert, Susan R.
Lumley, Thomas
Sitlani, Colleen M.
Cupples, Adrienne
Lubitz, Steven A.
Soliman, Elsayed Z.
Pulit, Sara L.
Newton-Cheh, Christopher
O'Donnell, Christopher J.
Ellinor, Patrick T.
Benjamin, Emelia J.
Muzny, Donna M.
Gibbs, Richard A.
Santibanez, Jireh
Taylor, Herman A.
Rotter, Jerome I.
Lange, Leslie A.
Psaty, Bruce M.
Jackson, Rebecca
Rich, Stephen S.
Boerwinkle, Eric
Jamshidi, Yalda
Sotoodehnia, Nona
CA CHARGE Consortium
NHLBIs Exome Sequencing
UK10K
TI Sequencing of SCN5A Identifies Rare and Common Variants Associated With
Cardiac Conduction: Cohorts for Heart and Aging Research in Genomic
Epidemiology (CHARGE) Consortium
SO CIRCULATION-CARDIOVASCULAR GENETICS
LA English
DT Article
DE electrocardiography; genomics
ID SICK SINUS SYNDROME; LONG QT SYNDROME; SODIUM-CHANNEL; QRS DURATION; PR
INTERVAL; DILATED CARDIOMYOPATHY; WIDE ASSOCIATION; CODING VARIANTS;
MUTATIONS; DISEASE
AB Background-The cardiac sodium channel SCN5A regulates atrioventricular and ventricular conduction. Genetic variants in this gene are associated with PR and QRS intervals. We sought to characterize further the contribution of rare and common coding variation in SCN5A to cardiac conduction.
Methods and Results-In Cohorts for Heart and Aging Research in Genomic Epidemiology (CHARGE) Consortium Targeted Sequencing Study, we performed targeted exonic sequencing of SCN5A (n=3699, European ancestry individuals) and identified 4 common (minor allele frequency >1%) and 157 rare variants. Common and rare SCN5A coding variants were examined for association with PR and QRS intervals through meta-analysis of European ancestry participants from CHARGE, National Heart, Lung, and Blood Institute's Exome Sequencing Project (n=607), and the UK10K (n=1275) and by examining Exome Sequencing Project African ancestry participants (n=972). Rare coding SCN5A variants in aggregate were associated with PR interval in European and African ancestry participants (P=1.3x10(-3)). Three common variants were associated with PR and QRS interval duration among European ancestry participants and one among African ancestry participants. These included 2 well-known missense variants: rs1805124 (H558R) was associated with PR and QRS shortening in European ancestry participants (P=6.25x10(-4) and P=5.2x10(-3), respectively) and rs7626962 (S1102Y) was associated with PR shortening in those of African ancestry (P=2.82x10(-3)). Among European ancestry participants, 2 novel synonymous variants, rs1805126 and rs6599230, were associated with cardiac conduction. Our top signal, rs1805126 was associated with PR and QRS lengthening (P=3.35x10(-7) and P=2.69x10(-4), respectively) and rs6599230 was associated with PR shortening (P=2.67x10(-5)).
Conclusions-By sequencing SCN5A, we identified novel common and rare coding variants associated with cardiac conduction.
C1 [Magnani, Jared W.; Lin, Honghuang; Yin, Xiaoyan; Liu, Ching-Ti; Cupples, Adrienne; Newton-Cheh, Christopher; O'Donnell, Christopher J.; Benjamin, Emelia J.] NHLBI, Framingham, MA USA.
[Magnani, Jared W.; Lin, Honghuang; Yin, Xiaoyan; Liu, Ching-Ti; Cupples, Adrienne; Newton-Cheh, Christopher; O'Donnell, Christopher J.; Benjamin, Emelia J.] Boston Univ, Framingham Heart Study, Boston, MA 02118 USA.
[Magnani, Jared W.; Benjamin, Emelia J.] Boston Univ, Sch Med, Sect Cardiovasc Med, Boston, MA 02118 USA.
[Lin, Honghuang] Boston Univ, Sch Med, Sect Computat Biomed, Boston, MA 02118 USA.
[Brody, Jennifer A.; Bis, Joshua C.; Heckbert, Susan R.; Sitlani, Colleen M.; Psaty, Bruce M.; Sotoodehnia, Nona] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Heckbert, Susan R.; Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA.
[Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Sotoodehnia, Nona] Univ Washington, Div Cardiol, Seattle, WA 98195 USA.
[Prins, Bram P.; Zhang, Feng; Jamshidi, Yalda] St Georges Univ London, Human Genet Res Ctr, London, England.
[Arking, Dan E.] Johns Hopkins Univ, Sch Med, McKusick Nathans Inst Genet Med, Baltimore, MD USA.
[Yin, Xiaoyan; Liu, Ching-Ti; Cupples, Adrienne] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02118 USA.
[Morrison, Alanna C.; Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Ctr Human Genet, Houston, TX 77030 USA.
[Zhang, Feng; Spector, Tim D.] Kings Coll London, Dept Twin Res, St Thomas Hosp, London WC2R 2LS, England.
[Zhang, Feng; Spector, Tim D.] Kings Coll London, Genet Epidemiol Unit, St Thomas Hosp, London WC2R 2LS, England.
[Alonso, Alvaro] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
[Lumley, Thomas] Univ Auckland, Dept Stat, Auckland 1, New Zealand.
[Lubitz, Steven A.; Pulit, Sara L.; Newton-Cheh, Christopher; Ellinor, Patrick T.] Massachusetts Gen Hosp, Cardiovasc Res Ctr, Charlestown, MA USA.
[Lubitz, Steven A.; Newton-Cheh, Christopher; O'Donnell, Christopher J.; Ellinor, Patrick T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol,Dept Med, Boston, MA USA.
[Soliman, Elsayed Z.] Wake Forest Univ, Bowman Gray Sch Med, Epidemiol Cardiol Res Ctr, Winston Salem, NC USA.
[Pulit, Sara L.; Newton-Cheh, Christopher] Broad Inst, Cambridge, MA USA.
[Benjamin, Emelia J.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Benjamin, Emelia J.] Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA.
[Muzny, Donna M.; Gibbs, Richard A.; Santibanez, Jireh; Boerwinkle, Eric] Baylor Coll Med, Human Genome Sequencing Ctr, Houston, TX 77030 USA.
[Taylor, Herman A.] Univ Mississippi, Med Ctr, Jackson, MI USA.
[Rotter, Jerome I.] Harbor UCLA Med Ctr, Los Angeles Biomed Res Inst, Inst Translat Genom & Populat Sci, Torrance, CA 90509 USA.
[Lange, Leslie A.] Univ N Carolina, Dept Genet, Chapel Hill, NC USA.
[Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA.
[Jackson, Rebecca] Ohio State Univ, Dept Med, Wexner Med Ctr, Columbus, OH 43210 USA.
[Rich, Stephen S.] Univ Virginia, Ctr Publ Hlth Genom, Charlottesville, VA USA.
RP Magnani, JW (reprint author), Boston Univ, Sch Med, Sect Cardiovasc Med, 88 E Newton St, Boston, MA 02118 USA.
EM jmagnani@bu.edu; nsotoo@uw.edu
RI Alonso, Alvaro/A-4917-2010;
OI Alonso, Alvaro/0000-0002-2225-8323; Jamshidi, Yalda/0000-0003-0151-6482;
Lin, Honghuang/0000-0003-3043-3942; Benjamin, Emelia/0000-0003-4076-2336
FU National Institutes of Health (NIH) through the American Recovery and
Reinvestment Act [5RC2HL102419]; NHLBI [HHSN268201100005C,
HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN26820110
0009C, HHSN2682011000010C, HHSN2682011000011C, HHSN2682011000012C];
Boston University [N01-HC-25195]; Affymetrix, Inc [N02-HL-6-4278];
Boston University School of Medicine Department of Medicine Career
Investment Award; Robert Dawson Evans Endowment of the Department of
Medicine at Boston University School of Medicine; Boston Medical Center;
National Institute on Aging [AG023629]; Wellcome Trust [WT091310];
ENGAGE project [HEALTH-F4-2007-201413]; Department of Health via the
National Institute for Health Research (NIHR); British Heart Foundation
[PG/12/38/29615]; the NHLBI [N01-HC-25195, HHSN268201200036C,
HHSN268200800007C, N01HC55222, N01HC85079]; NHLBI. [N01HC85080,
N01HC85081, N01HC85082, N01HC85083, N01HC85086, HL080295, HL087652,
HL105756]; [6R01-NS 17950NIH]; [1RO1HL092577]; [1R01 HL102214l];
[1RC1HL101056]; [5R21DA027021]; [1RO1HL104156]; [K23HL11472];
[1K24HL105780]; [1R03AG045075]
FX Funding support for building on Genome-wide association studies (GWAS)
for National Heart, Lung, and Blood Institute (NHLBI) diseases: the US
Cohorts for Heart and Aging Research in Genetic Epidemiology (CHARGE)
Consortium Targeted Sequencing Study was provided by the National
Institutes of Health (NIH) through the American Recovery and
Reinvestment Act of 2009 (5RC2HL102419). Data for building on GWAS for
NHLBI diseases: the US CHARGE Consortium was provided by Dr Boerwinkle
on behalf of the Atherosclerosis Risk in Communities (ARIC) Study, Dr
Cupples, principal investigator for the Framingham Heart Study, and Dr
Psaty, principal investigator for the Cardiovascular Health Study. The
ARIC Study is performed as a collaborative study supported by NHLBI
contracts (HHSN268201100005C, HHSN268201100006C, HHSN268201100007C,
HHSN268201100008C, HHSN26820110 0009C, HHSN2682011000010C,
HHSN2682011000011C, and HHSN2682011000012C). The Framingham Heart Study
is conducted and supported by the NHLBI in collaboration with Boston
University (contract No. N01-HC-25195) and its contract with Affymetrix,
Inc, for genome-wide genotyping services (contract No. N02-HL-6-4278),
for quality control by Framingham Heart Study investigators using
genotypes in the SNP Health Association Resource (SHARe) project. This
project was supported by 6R01-NS 17950NIH, 1RO1HL092577, 1R01 HL102214l,
1RC1HL101056, 5R21DA027021, 1RO1HL104156, K23HL11472, 1K24HL105780, and
1R03AG045075. Dr Magnani is further supported by a Boston University
School of Medicine Department of Medicine Career Investment Award. A
portion of this research was conducted using the Linux Cluster for
Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment
of the Department of Medicine at Boston University School of Medicine
and Boston Medical Center. Cardiovascular Health Study (CHS): This CHS
research was supported by NHLBI contracts HHSN268201200036C,
HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081,
N01HC85082, N01HC85083, and N01HC85086 and NHLBI grants HL080295,
HL087652, and HL105756 with additional contribution from the National
Institute of Neurological Disorders and Stroke. Additional support was
provided through AG023629 from the National Institute on Aging. A full
list of CHS investigators and institutions can be found at
http://www.chs-nhlbi.org/pi.htm. UK10K: The UK10K project was funded by
the Wellcome Trust award WT091310. Twins UK (TUK): TUK was funded by the
Wellcome Trust and ENGAGE project grant agreement HEALTH-F4-2007-201413.
The study also receives support from the Department of Health via the
National Institute for Health Research (NIHR)-funded BioResource,
Clinical Research Facility and Biomedical Research Centre based at Guy's
and St. Thomas' NHS Foundation Trust in partnership with King's College
London. Dr Spector is an NIHR senior Investigator and ERC Senior
Researcher. Funding for the project was also provided by the British
Heart Foundation grant PG/12/38/29615 (Dr Jamshidi).
NR 46
TC 3
Z9 3
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1942-325X
EI 1942-3268
J9 CIRC-CARDIOVASC GENE
JI Circ.-Cardiovasc. Genet.
PD JUN
PY 2014
VL 7
IS 3
BP 365
EP 373
DI 10.1161/CIRCGENETICS.113.000098
PG 9
WC Cardiac & Cardiovascular Systems; Genetics & Heredity
SC Cardiovascular System & Cardiology; Genetics & Heredity
GA AK1VY
UT WOS:000338207300019
PM 24951663
ER
PT J
AU Cornes, BK
Brody, JA
Nikpoor, N
Morrison, AC
Dang, HCP
Ahn, BS
Wang, S
Dauriz, M
Barzilay, JI
Dupuis, J
Florez, JC
Coresh, J
Gibbs, RA
Kao, WHL
Liu, CT
McKnight, B
Muzny, D
Pankow, JS
Reid, JG
White, CC
Johnson, AD
Wong, TY
Psaty, BM
Boerwinkle, E
Rotter, JI
Siscovick, DS
Sladek, R
Meigs, JB
AF Cornes, Belinda K.
Brody, Jennifer A.
Nikpoor, Naghmeh
Morrison, Alanna C.
Huan Chu Pham Dang
Ahn, Byung Soo
Wang, Shuai
Dauriz, Marco
Barzilay, Joshua I.
Dupuis, Josee
Florez, Jose C.
Coresh, Josef
Gibbs, Richard A.
Kao, W. H. Linda
Liu, Ching-Ti
McKnight, Barbara
Muzny, Donna
Pankow, James S.
Reid, Jeffrey G.
White, Charles C.
Johnson, Andrew D.
Wong, Tien Y.
Psaty, Bruce M.
Boerwinkle, Eric
Rotter, Jerome I.
Siscovick, David S.
Sladek, Robert
Meigs, James B.
TI Association of Levels of Fasting Glucose and Insulin With Rare Variants
at the Chromosome 11p11.2-MADD Locus Cohorts for Heart and Aging
Research in Genomic Epidemiology (CHARGE) Consortium Targeted Sequencing
Study
SO CIRCULATION-CARDIOVASCULAR GENETICS
LA English
DT Article
DE genetic epidemiology; glucose; human genetics; insulin; molecular
genetics
ID HUMAN GENE-EXPRESSION; TRANSCRIPTION FACTOR; CARDIOVASCULAR HEALTH; WIDE
ASSOCIATION; GLYCEMIC TRAITS; BETA-CELL; DNA; POPULATION; RISK;
PATHOPHYSIOLOGY
AB Background-Common variation at the 11p11.2 locus, encompassing MADD, ACP2, NR1H3, MYBPC3, and SPI1, has been associated in genome-wide association studies with fasting glucose and insulin (FI). In the Cohorts for Heart and Aging Research in Genomic Epidemiology Targeted Sequencing Study, we sequenced 5 gene regions at 11p11.2 to identify rare, potentially functional variants influencing fasting glucose or FI levels.
Methods and Results-Sequencing (mean depth, 38x) across 16.1 kb in 3566 individuals without diabetes mellitus identified 653 variants, 79.9% of which were rare (minor allele frequency <1%) and novel. We analyzed rare variants in 5 gene regions with FI or fasting glucose using the sequence kernel association test. At NR1H3, 53 rare variants were jointly associated with FI (P=2.73x10(-3)); of these, 7 were predicted to have regulatory function and showed association with FI (P=1.28x10(-3)). Conditioning on 2 previously associated variants at MADD (rs7944584, rs10838687) did not attenuate this association, suggesting that there are >2 independent signals at 11p11.2. One predicted regulatory variant, chr11: 47227430 (hg18; minor allele frequency=0.00068), contributed 20.6% to the overall sequence kernel association test score at NR1H3, lies in intron 2 of NR1H3, and is a predicted binding site for forkhead box A1 (FOXA1), a transcription factor associated with insulin regulation. In human HepG2 hepatoma cells, the rare chr11: 47227430 A allele disrupted FOXA1 binding and reduced FOXA1-dependent transcriptional activity.
Conclusions-Sequencing at 11p11.2-NR1H3 identified rare variation associated with FI. One variant, chr11: 47227430, seems to be functional, with the rare A allele reducing transcription factor FOXA1 binding and FOXA1-dependent transcriptional activity.
C1 [Cornes, Belinda K.; Dauriz, Marco; Meigs, James B.] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
[Florez, Jose C.] Massachusetts Gen Hosp, Ctr Human Genet Res, Diabet Unit, Boston, MA 02114 USA.
[Cornes, Belinda K.; Dauriz, Marco; Florez, Jose C.; Meigs, James B.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Brody, Jennifer A.; McKnight, Barbara; Siscovick, David S.] Univ Washington, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
[McKnight, Barbara] Univ Washington, Dept Biostat, Seattle, WA 98195 USA.
[McKnight, Barbara] Univ Washington, Dept Med, Seattle, WA USA.
[Siscovick, David S.] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA 98195 USA.
[Nikpoor, Naghmeh; Huan Chu Pham Dang; Ahn, Byung Soo; Sladek, Robert] McGill Univ, Fac Med, Dept Human Genet, Montreal, PQ, Canada.
[Nikpoor, Naghmeh; Huan Chu Pham Dang; Ahn, Byung Soo; Sladek, Robert] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Ctr Human Genet, Houston, TX 77030 USA.
[Gibbs, Richard A.; Muzny, Donna; Boerwinkle, Eric] Univ Texas Hlth Sci Ctr Houston, Human Genome Sequencing Ctr, Baylor Coll Med, Houston, TX 77030 USA.
[Wang, Shuai; Dupuis, Josee; Liu, Ching-Ti; White, Charles C.] Boston Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02215 USA.
[Dauriz, Marco] Univ Verona, Div Endocrinol Diabet & Metab, Dept Med, Sch Med, I-37100 Verona, Italy.
[Dauriz, Marco] Hosp Trust Verona, Verona, Italy.
[Barzilay, Joshua I.] Kaiser Permanente Georgia, Div Endocrinol, Atlanta, GA USA.
[Barzilay, Joshua I.] Emory Univ, Sch Med, Atlanta, GA USA.
[Dupuis, Josee; Johnson, Andrew D.] NHLBI, Framingham Heart Study, Cardiovasc Epidemiol & Human Genom Ctr, Framingham, MA USA.
[Florez, Jose C.] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA USA.
[Coresh, Josef] Johns Hopkins Med Inst, Dept Med, Baltimore, MD 21205 USA.
[Coresh, Josef; Kao, W. H. Linda; Reid, Jeffrey G.] Johns Hopkins Univ, Dept Epidemiol, Johns Hopkins Univ Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Pankow, James S.] Univ Minnesota, Div Epidemiol & Community Hlth, Minneapolis, MN USA.
[Wong, Tien Y.] Duke NUS Grad Med Sch, Singapore Eye Res Inst, Singapore Natl Eye Ctr, Singapore, Singapore.
[Wong, Tien Y.] Natl Univ Singapore, Dept Ophthalmol, Yong Loo Lin Sch Med, Singapore 117548, Singapore.
[Psaty, Bruce M.] Univ Washington, Dept Med, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Psaty, Bruce M.] Univ Washington, Dept Epidemiol, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Psaty, Bruce M.] Univ Washington, Dept Hlth Serv, Cardiovasc Hlth Res Unit, Seattle, WA USA.
[Psaty, Bruce M.] Grp Hlth Cooperat Puget Sound, Grp Hlth Res Inst, Seattle, WA USA.
[Rotter, Jerome I.] Harbor UCLA Med Ctr Torrance, Inst Translat Genom & Populat Sci, Los Angeles Biomed Reasearch Inst, Torrance, CA USA.
[Rotter, Jerome I.] Harbor UCLA Med Ctr Torrance, Dept Pediat, Torrance, CA USA.
RP Meigs, JB (reprint author), Massachusetts Gen Hosp, Div Gen Med, 50 Staniford St,9th Floor, Boston, MA 02114 USA.
EM jmeigs@partners.org
RI Johnson, Andrew/G-6520-2013; Dauriz, Marco/S-5843-2016;
OI Dauriz, Marco/0000-0002-5542-5941; Sladek, Robert/0000-0002-2730-1204;
Pankow, James/0000-0001-7076-483X
FU National Institutes of Health (NIH) through the American Recovery and
Reinvestment Act (ARRA) [5RC2HL102419]; Baylor Genome Center [U54
HG003273]; National Heart, Lung, and Blood Institute (NHLBI)
[HHSN268201100005C, HHSN268201100006C, HHSN268201100007C,
HHSN268201100008C, HHSN2682011 00009C, HHSN2682011000010C,
HHSN2682011000011C, HHSN2682011000012C]; Boston University
[N01-HC-25195]; Affymetrix, Inc [N02-HL-6-4278]; Robert Dawson Evans
Endowment of the Department of Medicine at Boston University School of
Medicine; Boston Medical Center; American Diabetes Association Mentored
Post Doctoral Fellowship Award; National Institute on Aging (NIA)
[AG023629]; the NHLBI [N01-HC-25195, HHSN268201200036C,
HHSN268200800007C, N01HC55222, N01HC85079, N01HC85080]; NHLBI.
[N01HC85081, N01HC85082, N01HC85083, N01HC85086, HL080295, HL087652,
HL105756]; [R01DK078616]; [K24 DK080140]
FX Funding support for Building on GWAS for NHLBI-diseases: the US CHARGE
Consortium was provided by the National Institutes of Health (NIH)
through the American Recovery and Reinvestment Act of 2009 (ARRA;
5RC2HL102419). Data for Building on GWAS for NHLBI-diseases: the US
CHARGE Consortium was provided by Dr Boerwinkle on behalf of the ARIC
study, L. Adrienne Cupples, principal investigator for the FHS, and Dr
Psaty, principal investigator for the CHS. Support was also received
from the Baylor Genome Center (U54 HG003273). The ARIC study is
performed as a collaborative study supported by National Heart, Lung,
and Blood Institute (NHLBI) contracts (HHSN268201100005C,
HHSN268201100006C, HHSN268201100007C, HHSN268201100008C, HHSN2682011
00009C, HHSN2682011000010C, HHSN2682011000011C, and HHSN2682011000012C).
The FHS is conducted and supported by the NHLBI in collaboration with
Boston University (contract No. N01-HC-25195), and its contract with
Affymetrix, Inc, for genome-wide genotyping services (contract No.
N02-HL-6-4278) and for quality control by FHS investigators using
genotypes in the SNP Health Association Resource (SHARe) project. A
portion of this research was conducted using the Linux Cluster for
Genetic Analysis (LinGA-II) funded by the Robert Dawson Evans Endowment
of the Department of Medicine at Boston University School of Medicine
and Boston Medical Center. This research is also supported by
R01DK078616, K24 DK080140 and an American Diabetes Association Mentored
Post Doctoral Fellowship Award (Dr Meigs). This CHS research was
supported by NHLBI contracts HHSN268201200036C, HHSN268200800007C,
N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083,
N01HC85086; and NHLBI grants HL080295, HL087652, HL105756 with
additional contribution from the National Institute of Neurological
Disorders and Stroke (NINDS). Additional support was provided through
AG023629 from the National Institute on Aging (NIA). A full list of CHS
investigators and institutions can be found at https://chs-nhlbi.org/pi.
NR 46
TC 4
Z9 4
U1 1
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1942-325X
EI 1942-3268
J9 CIRC-CARDIOVASC GENE
JI Circ.-Cardiovasc. Genet.
PD JUN
PY 2014
VL 7
IS 3
BP 374
EP 382
DI 10.1161/CIRCGENETICS.113.000169
PG 9
WC Cardiac & Cardiovascular Systems; Genetics & Heredity
SC Cardiovascular System & Cardiology; Genetics & Heredity
GA AK1VY
UT WOS:000338207300020
PM 24951664
ER
PT J
AU Nattel, S
Guasch, E
Savelieva, I
Cosio, FG
Valverde, I
Halperin, JL
Conroy, JM
Al-Khatib, SM
Hess, PL
Kirchhof, P
De Bono, J
Lip, GYH
Banerjee, A
Ruskin, J
Blendea, D
Camm, AJ
AF Nattel, Stanley
Guasch, Eduard
Savelieva, Irina
Cosio, Francisco G.
Valverde, Irene
Halperin, Jonathan L.
Conroy, Jennifer M.
Al-Khatib, Sana M.
Hess, Paul L.
Kirchhof, Paulus
De Bono, Joseph
Lip, Gregory Y. H.
Banerjee, Amitava
Ruskin, Jeremy
Blendea, Dan
Camm, A. John
TI Early management of atrial fibrillation to prevent cardiovascular
complications
SO EUROPEAN HEART JOURNAL
LA English
DT Review
DE Atrial fibrillation; Post-operative AF; Atrial remodelling; Integrated
care pathways; Anticoagulation; Rhythm control; Natural history
ID ACUTE MYOCARDIAL-INFARCTION; COMPREHENSIVE RISK REDUCTION; HEART RHYTHM
ASSOCIATION; FOLLOW-UP; EUROPEAN-SOCIETY; POTASSIUM CURRENT;
CARDIAC-SURGERY; MOLECULAR-MECHANISMS; CONSENSUS CONFERENCE; UPSTREAM
THERAPIES
AB Atrial fibrillation (AF) is generally considered a progressive disease, typically evolving from paroxysmal through persistent to 'permanent' forms, a process attributed to electrical and structural remodelling related to both the underlying disease and AF itself. Medical treatment has yet to demonstrate clinical efficacy in preventing progression. Large clinical trials performed to date have failed to show benefit of rhythm control compared with rate control, but these trials primarily included patients at late stages in the disease process. One possible explanation is that intervention at only an early stage of progression may improve prognosis. Evolving observations about the progressive nature of AF, along with the occurrences of major complications such as strokes upon AF presentation, led to the notion that earlier and more active approaches to AF detection, rhythm-reversion, and maintenance of sinus rhythm may be a useful strategy in AF management. Approaches to early and sustained rhythm control include measures that prevent development of the AF substrate, earlier catheter ablation, and novel antiarrhythmic drugs. Improved classifications of AF mechanism, pathogenesis, and remodelling may be helpful to enable patient-specific pathophysiological diagnosis and therapy. Potential novel therapeutic options under development include microRNA-modulation, heatshock protein inducers, agents that influence Ca2+ handling, vagal stimulators, and more aggressive mechanism-based ablation strategies. In this review, of research into the basis and management of AF in acute and early settings, it is proposed that progression from paroxysmal to persistent AF can be interrupted, with potentially favourable prognostic impact.
C1 [Nattel, Stanley; Guasch, Eduard] Montreal Heart Inst, Montreal, PQ H1T 1C8, Canada.
[Savelieva, Irina; Camm, A. John] St Georges Univ London, Div Clin Sci, London SW17 0RE, England.
[Cosio, Francisco G.; Valverde, Irene] Hosp Univ Getafe, Dept Cardiol, Madrid, Spain.
[Halperin, Jonathan L.; Conroy, Jennifer M.] Mt Sinai Sch Med, Zena & Michael A Wiener Cardiovasc Inst, New York, NY USA.
[Al-Khatib, Sana M.; Hess, Paul L.] Duke Univ, Med Ctr, Div Cardiol, Dept Med, Durham, NC 27710 USA.
[Lip, Gregory Y. H.; Banerjee, Amitava] Univ Birmingham, Ctr Cardiovasc Sci, City Hosp, Birmingham, W Midlands, England.
[De Bono, Joseph] Univ Hosp Birmingham NHS Trust, Birmingham, W Midlands, England.
[Kirchhof, Paulus] Univ Birmingham, Ctr Cardiovasc Sci, Birmingham, W Midlands, England.
[Kirchhof, Paulus] Sandwell & West Birmingham NHS Trust, Birmingham, W Midlands, England.
[Kirchhof, Paulus] Hosp Univ Munster, Dept Cardiol & Angiol, Munster, Germany.
[Kirchhof, Paulus] German Atrial Fibrillat Competence NETwork AFNET, Munster, Germany.
[Ruskin, Jeremy; Blendea, Dan] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
RP Camm, AJ (reprint author), St Georges Univ London, Div Clin Sci, Cranmer Terrace, London SW17 0RE, England.
EM jcamm@sgul.ac.uk
RI Banerjee, Amitava/D-4381-2014;
OI Banerjee, Amitava/0000-0001-8741-3411; Guasch,
Eduard/0000-0003-4238-5319; Kirchhof, Paulus/0000-0002-1881-0197
FU Astellas Pharma, USA; Atricure/Boston Biomedical Associates;
AstraZeneca; Bayer AG HealthCare; Boehringer Ingelheim, Pharmaceuticals,
Inc.; Bristol Meyers-Squibb; Daiichi-Sankyo; Ortho-McNeil-Janssen
Pharmaceuticals, Inc.; Johnson& Johnson, Pfizer, Inc.; Sanofi and
Biotronik, Inc.; 3M Medica; MEDA Pharma; Medtronic; Merck; MSD; Otsuka
Pharma; Pfizer/BMS; Sanofi; Servier; Siemens; TAKEDA; 3M Medica/MEDA
Pharma; Cardiovascular Therapeutics; OMRON; St Jude Medical; German
Federal Ministry for Education and Research; Fondation Leducq; German
Research Foundation; European Union; BMS; Boston Scientific
FX S.N.: Consultant/advisor to Xention, listed as inventor on the following
patents awarded or pending belonging to the Montreal Heart Institute:
Preventing atrial fibrillation with the use of statin drugs; TRPC3
channels are critical for regulating fibroblast proliferation in the
heart; MiR21 as a target in prevention of atrial fibrillation. E. G. I.
V., J.M.C., P. L. H., A. B., and D. B. have no conflict of interest to
declare. I. S.: Advisor/speaker/investigator for Sanofi, Bristol-Myers
Squibb (BMS), Takeda, Daiichi, Boehringer Ingelheim, Servier,
Astrazeneca, Astellas, Mitsubishi Pharma and Merck. F. G. C. Fellowship
program support by Medtronic and Sorin. Speaker's honoraria from Sanofi,
St Jude. J.L.H.: Consulting fees from Astellas Pharma, USA,
Atricure/Boston Biomedical Associates, AstraZeneca, Bayer AG HealthCare,
Boehringer Ingelheim, Pharmaceuticals, Inc., Bristol Meyers-Squibb,
Daiichi-Sankyo, Ortho-McNeil-Janssen Pharmaceuticals, Inc., Johnson&
Johnson, Pfizer, Inc., Sanofi and Biotronik, Inc. S. M. Al-K. has no
conflicts of interest to declare and did not receive any honoraria for
her participation in the meetings that led to development of this
manuscript. P. K.: Consulting fees and honoraria from 3M Medica, MEDA
Pharma, AstraZeneca, Bayer Healthcare, Boehringer Ingelheim,
Daicchi-Sankyo, MEDA Pharma, Medtronic, Merck, MSD, Otsuka Pharma,
Pfizer/BMS, Sanofi, Servier, Siemens, and TAKEDA. Research Grants from
3M Medica/MEDA Pharma, Cardiovascular Therapeutics, Medtronic, OMRON,
Sanofi, St Jude Medical, German Federal Ministry for Education and
Research, Fondation Leducq, German Research Foundation and the European
Union. Travel support received from the European Society of Cardiology,
the European Heart Rhythm Association and from the German Atrial
Fibrillation Competence NETwork. J.d.B.: Research funding from BMS and
travel funding from St Jude Medical, Boston Scientific and Medtronic.
G.Y.H.L.: Consultant for Bayer, Astellas, Merck, AstraZeneca, Sanofi,
BMS/Pfizer, Daiichi-Sankyo, Biotronik, Portola and Boehringer Ingelheim.
Speaker for Bayer, BMS/Pfizer, Boehringer Ingelheim, and Sanofi. J.R.:
Consultant-Atricure Inc., Arrhythmia Education Inc., Astellas/Cardiome,
BiosenseWebster, Inc., Bristol-Myers Squibb, CardioInsight, InfoBionic
(equity), Medtronic, Inc., Pfizer, Portola (equity), Sanofi Aventis, and
Third Rock Ventures; Fellowship Support-Biosense Webster, Inc., Boston
Scientific Corp., Medtronic, Inc., and St Jude Medical. A.J.C.:
Consultant/advisor to St Jude, Medtronic, Boston Scientific, Sanofi,
Cardiome, Pfizer, BMS, Bayer, Boehringer Ingelheim.
NR 100
TC 44
Z9 45
U1 1
U2 18
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD JUN
PY 2014
VL 35
IS 22
BP 1448
EP U32
DI 10.1093/eurheartj/ehu028
PG 11
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AJ8SE
UT WOS:000337976800012
PM 24536084
ER
PT J
AU Gupta, DK
Shah, AM
Giugliano, RP
Ruff, CT
Antman, EM
Grip, LT
Deenadayalu, N
Hoffman, E
Patel, I
Shi, M
Mercuri, M
Mitrovic, V
Braunwald, E
Solomon, SD
AF Gupta, Deepak K.
Shah, Amil M.
Giugliano, Robert P.
Ruff, Christian T.
Antman, Elliott M.
Grip, Laura T.
Deenadayalu, Naveen
Hoffman, Elaine
Patel, Indravadan
Shi, Minggao
Mercuri, Michele
Mitrovic, Veselin
Braunwald, Eugene
Solomon, Scott D.
CA ENGAGE AF-TIMI 48 Echocardiograp
TI Left atrial structure and function in atrial fibrillation: ENGAGE
AF-TIMI 48
SO EUROPEAN HEART JOURNAL
LA English
DT Article
DE Atrial fibrillation; ENGAGE AF-TIMI 48; Left atrium; Echocardiography;
Stroke
ID CATHETER-BASED TECHNIQUES; MAZE III OPERATION; EURO HEART SURVEY; RISK
STRATIFICATION; MECHANICAL FUNCTION; PREDICTING STROKE;
CONTROLLED-TRIALS; FOLLOW-UP; THERAPY; ECHOCARDIOGRAPHY
AB Aims The complex relationship between left atrial (LA) structure and function, electrical burden of atrial fibrillation (AF) and stroke risk is not well understood. We aimed to describe LA structure and function in AF.
Methods and results Left atrial structure and function was assessed in 971 subjects enrolled in the echocardiographic substudy of ENGAGE AF-TIMI 48. Left atrial size, emptying fraction (LAEF), and contractile function were compared across AF types (paroxysmal, persistent, or permanent) and CHADS(2) scores as an estimate of stroke risk. The majority of AF patients (55%) had both LA enlargement and reduced LAEF, with an inverse relationship between LA size and LAEF (R = -0.57, P < 0.001). With an increasing electrical burden of AF and higher CHADS(2) scores, LA size increased and LAEF declined. Moreover, 19% of AF subjects had impaired LAEF despite normal LA size, and LA contractile dysfunction was present even among the subset of AF subjects in sinus rhythm at the time of echocardiography.
Conclusions In a contemporary AF population, LA structure and function were increasingly abnormal with a greater electrical burden of AF and higher stroke risk estimated by the CHADS(2) score. Moreover, LA dysfunction was present despite normal LA size and sinus rhythm, suggesting that the assessment of LA function may add important incremental information in the evaluation of AF patients.
C1 [Gupta, Deepak K.; Shah, Amil M.; Solomon, Scott D.] Harvard Univ, Brigham andWomens Hosp, Cardiovasc Div, Dept Med,Sch Med, Boston, MA 02115 USA.
[Giugliano, Robert P.; Ruff, Christian T.; Antman, Elliott M.; Grip, Laura T.; Deenadayalu, Naveen; Hoffman, Elaine; Braunwald, Eugene] Harvard Univ, Brigham andWomens Hosp, Cardiovasc Div, Dept Med,Sch Med,TIMI Study Grp, Boston, MA 02115 USA.
[Patel, Indravadan; Shi, Minggao; Mercuri, Michele] Daiichi Sankyo Pharma Dev, Edison, NJ USA.
[Mitrovic, Veselin] Kerckhoff Clin Nauheim, Bad Nauheim, Germany.
RP Gupta, DK (reprint author), Harvard Univ, Brigham andWomens Hosp, Cardiovasc Div, Dept Med,Sch Med, 75 Francis St, Boston, MA 02115 USA.
EM ssolomon@rics.bwh.harvard.edu
FU Daiichi Sankyo Pharma Development (Edison, NJ, USA); NIH [T32
HL094301-02]
FX The ENGAGE AF-TIMI 48 study was funded by Daiichi Sankyo Pharma
Development (Edison, NJ, USA). Support was provided by the NIH training
grant (T32 HL094301-02).
NR 42
TC 34
Z9 40
U1 1
U2 6
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD JUN
PY 2014
VL 35
IS 22
BP 1457
EP 1465
DI 10.1093/eurheartj/eht500
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AJ8SE
UT WOS:000337976800013
PM 24302269
ER
PT J
AU Troughton, RW
Frampton, CM
Brunner-La Rocca, HP
Pfisterer, M
Eurlings, LWM
Erntell, H
Persson, H
O'Connor, CM
Moertl, D
Karlstrom, P
Dahlstrom, U
Gaggin, HK
Januzzi, JL
Berger, R
Richards, AM
Pinto, YM
Nicholls, MG
AF Troughton, Richard W.
Frampton, Christopher M.
Brunner-La Rocca, Hans-Peter
Pfisterer, Matthias
Eurlings, Luc W. M.
Erntell, Hans
Persson, Hans
O'Connor, Christopher M.
Moertl, Deddo
Karlstrom, Patric
Dahlstrom, Ulf
Gaggin, Hanna K.
Januzzi, James L.
Berger, Rudolf
Richards, A. Mark
Pinto, Yigal M.
Nicholls, M. Gary
TI Effect of B-type natriuretic peptide-guided treatment of chronic heart
failure on total mortality and hospitalization: an individual patient
meta-analysis
SO EUROPEAN HEART JOURNAL
LA English
DT Article
DE Natriuretic peptides; B-type Natriuretic peptide; Heart failure
AB Aims Natriuretic peptide-guided (NP-guided) treatment of heart failure has been tested against standard clinically guided care in multiple studies, but findings have been limited by study size. We sought to perform an individual patient data meta-analysis to evaluate the effect of NP-guided treatment of heart failure on all-cause mortality.
Methods and results ligible randomized clinical trials were identified from searches of Medline and EMBASE databases and the Cochrane Clinical Trials Register. The primary pre-specified outcome, all-cause mortality was tested using a Cox proportional hazards regression model that included study of origin, age (< 75 or >= 75 years), and left ventricular ejection fraction (LVEF, <= 45 or > 45%) as covariates. Secondary endpoints included heart failure or cardiovascular hospitalization. Of 11 eligible studies, 9 provided individual patient data and 2 aggregate data. For the primary endpoint individual data from 2000 patients were included, 994 randomized to clinically guided care and 1006 to NP-guided care. All-cause mortality was significantly reduced by NP-guided treatment [hazard ratio = 0.62 (0.45-0.86); P = 0.004] with no heterogeneity between studies or interaction with LVEF. The survival benefit from NP-guided therapy was seen in younger (< 75 years) patients [0.62 (0.45-0.85); P = 0.004] but not older (>= 75 years) patients [0.98 (0.75-1.27); P = 0.96]. Hospitalization due to heart failure [0.80 (0.67-0.94); P = 0.009] or cardiovascular disease [0.82 (0.67-0.99); P = 0.048] was significantly lower in NP-guided patients with no heterogeneity between studies and no interaction with age or LVEF.
Conclusion Natriuretic peptide-guided treatment of heart failure reduces all-cause mortality in patients aged < 75 years and overall reduces heart failure and cardiovascular hospitalization.
C1 [Troughton, Richard W.; Frampton, Christopher M.; Nicholls, M. Gary] Univ Otago, Christchurch Hosp, Dept Med, Christchurch 8140, New Zealand.
[Richards, A. Mark] Natl Univ Heart Ctr Singapore, Singapore, Singapore.
[Pfisterer, Matthias] Univ Basel Hosp, Dept Cardiol, CH-4031 Basel, Switzerland.
[Brunner-La Rocca, Hans-Peter; Eurlings, Luc W. M.] Maastricht Univ Med Ctr, Dept Cardiol, Maastricht, Netherlands.
[Erntell, Hans; Persson, Hans] Danderyd Hosp, Karolinska Inst, Dept Clin Sci, Stockholm, Sweden.
[O'Connor, Christopher M.] Duke Univ, Med Ctr, Duke Clin Res Inst, Durham, NC USA.
[Berger, Rudolf] Med Univ Vienna, Dept Cardiol, Vienna, Austria.
[Moertl, Deddo] LKH, Dept Cardiol, St Polten, Austria.
[Karlstrom, Patric] Cty Hosp Ryhov, Dept Med, Div Cardiol, Jonkoping, Sweden.
[Dahlstrom, Ulf] Linkoping Univ, Cty Council Ostergotland, Dept Cardiol, Dept Med & Hlth Sci, Linkoping, Sweden.
[Gaggin, Hanna K.; Januzzi, James L.] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Pinto, Yigal M.] Univ Amsterdam, Acad Med Ctr, NL-1105 AZ Amsterdam, Netherlands.
RP Troughton, RW (reprint author), Univ Otago, Christchurch Hosp, Dept Med, POB 4345, Christchurch 8140, New Zealand.
EM richard.troughton@cdhb.health.nz
FU Christchurch Heart Institute at the University of Otago, Christchurch
FX None specific to the meta-analysis. Funding related to the original
studies included in the meta-analysis is outlined in the attached
appendix. Funding to pay the Open Access publication charges for this
article was provided by the Christchurch Heart Institute at the
University of Otago, Christchurch.
NR 0
TC 62
Z9 65
U1 2
U2 10
PU OXFORD UNIV PRESS
PI OXFORD
PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND
SN 0195-668X
EI 1522-9645
J9 EUR HEART J
JI Eur. Heart J.
PD JUN
PY 2014
VL 35
IS 23
BP 1559
EP 1567
DI 10.1093/eurheartj/ehu090
PG 9
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AK0OF
UT WOS:000338112700016
PM 24603309
ER
PT J
AU Kang, JH
Loomis, SJ
Yaspan, BL
Bailey, JC
Weinreb, RN
Lee, RK
Lichter, PR
Budenz, DL
Liu, Y
Realini, T
Gaasterland, D
Gaasterland, T
Friedman, DS
McCarty, CA
Moroi, SE
Olson, L
Schuman, JS
Singh, K
Vollrath, D
Wollstein, G
Zack, DJ
Brilliant, M
Sit, AJ
Christen, WG
Fingert, J
Forman, JP
Buys, ES
Kraft, P
Zhang, K
Allingham, RR
Pericak-Vance, MA
Richards, JE
Hauser, MA
Haines, JL
Wiggs, JL
Pasquale, LR
AF Kang, J. H.
Loomis, S. J.
Yaspan, B. L.
Bailey, J. C.
Weinreb, R. N.
Lee, R. K.
Lichter, P. R.
Budenz, D. L.
Liu, Y.
Realini, T.
Gaasterland, D.
Gaasterland, T.
Friedman, D. S.
McCarty, C. A.
Moroi, S. E.
Olson, L.
Schuman, J. S.
Singh, K.
Vollrath, D.
Wollstein, G.
Zack, D. J.
Brilliant, M.
Sit, A. J.
Christen, W. G.
Fingert, J.
Forman, J. P.
Buys, E. S.
Kraft, P.
Zhang, K.
Allingham, R. R.
Pericak-Vance, M. A.
Richards, J. E.
Hauser, M. A.
Haines, J. L.
Wiggs, J. L.
Pasquale, L. R.
TI Vascular tone pathway polymorphisms in relation to primary open-angle
glaucoma
SO EYE
LA English
DT Article
ID NITRIC-OXIDE SYNTHASE; OPTIC-NERVE HEAD; RETINAL BLOOD-FLOW; OCULAR
PERFUSION-PRESSURE; CENTRAL CORNEAL THICKNESS; HIGH-TENSION GLAUCOMA;
VISUAL-FIELD DEFECTS; ENDOTHELIAL DYSFUNCTION; INTRAOCULAR-PRESSURE;
HEALTHY-SUBJECTS
AB Aims Vascular perfusion may be impaired in primary open-angle glaucoma (POAG); thus, we evaluated a panel of markers in vascular tone-regulating genes in relation to POAG.
Methods We used Illumina 660W-Quad array genotype data and pooled P-values from 3108 POAG cases and 3430 controls from the combined National Eye Institute Glaucoma Human Genetics Collaboration consortium and Glaucoma Genes and Environment studies. Using information from previous literature and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathways, we compiled single-nucleotide polymorphisms (SNPs) in 186 vascular tone-regulating genes. We used the 'Pathway Analysis by Randomization Incorporating Structure' analysis software, which performed 1000 permutations to compare the overall pathway and selected genes with comparable randomly generated pathways and genes in their association with POAG.
Results The vascular tone pathway was not associated with POAG overall or POAG subtypes, defined by the type of visual field loss (early paracentral loss (n = 224 cases) or only peripheral loss (n 993 cases)) (permuted P>0.20). In gene-based analyses, eight were associated with POAG overall at permuted P<0.001: PRKAA1, CAV1, ITPR3, EDNRB, GNB2, DNM2, HFE, and MYL9. Notably, six of these eight (the first six listed) code for factors involved in the endothelial nitric oxide synthase activity, and three of these six (CAV1, ITPR3, and EDNRB) were also associated with early paracentral loss at P<0.001, whereas none of the six genes reached P<0.001 for peripheral loss only.
Discussion Although the assembled vascular tone SNP set was not associated with POAG, genes that code for local factors involved in setting vascular tone were associated with POAG.
C1 [Kang, J. H.; Christen, W. G.; Forman, J. P.; Pasquale, L. R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med,Dept Med, Boston, MA 02115 USA.
[Loomis, S. J.; Wiggs, J. L.; Pasquale, L. R.] Dept Ophthalmol, Boston, MA USA.
[Yaspan, B. L.] Genentech Inc, San Francisco, CA 94080 USA.
[Bailey, J. C.; Olson, L.; Haines, J. L.] Vanderbilt Univ, Sch Med, Ctr Human Genet Res, Nashville, TN 37212 USA.
[Weinreb, R. N.; Zhang, K.] Univ Calif San Diego, Dept Ophthalmol, San Diego, CA 92103 USA.
[Weinreb, R. N.; Zhang, K.] Univ Calif San Diego, Hamilton Glaucoma Ctr, San Diego, CA 92103 USA.
[Lee, R. K.; Pericak-Vance, M. A.] Univ Miami, Miller Sch Med, Bascom Palmer Eye Inst & Human Genom, Miami, FL 33136 USA.
[Lichter, P. R.; Moroi, S. E.; Richards, J. E.] Univ Michigan, Dept Ophthalmol & Visual Sci, Ann Arbor, MI 48109 USA.
[Budenz, D. L.] Univ N Carolina, Dept Ophthalmol, Chapel Hill, NC USA.
[Liu, Y.; Allingham, R. R.; Hauser, M. A.] Duke Univ, Med Ctr, Dept Ophthalmol, Durham, NC 27710 USA.
[Liu, Y.; Hauser, M. A.] Duke Univ, Med Ctr, Dept Med, Durham, NC 27710 USA.
[Realini, T.] West Virginia Univ Eye Inst, Dept Ophthalmol, Morgantown, WV USA.
[Gaasterland, T.] Univ Calif San Diego, Scripps Genome Ctr, San Diego, CA 92103 USA.
[Friedman, D. S.; Zack, D. J.] Johns Hopkins Univ Hosp, Wilmer Eye Inst, Baltimore, MD 21205 USA.
[McCarty, C. A.] Essentia Inst Rural Hlth, Duluth, MN USA.
[Schuman, J. S.; Wollstein, G.] Univ Pittsburgh, Dept Ophthalmol, UPMC Eye Ctr, Pittsburgh, PA 15260 USA.
[Singh, K.] Stanford Univ, Dept Ophthalmol, Palo Alto, CA 94304 USA.
[Vollrath, D.] Stanford Univ, Dept Genet, Palo Alto, CA 94304 USA.
[Brilliant, M.] Marshfield Clin Res Fdn, Ctr Human Genet, Marshfield, WI USA.
[Sit, A. J.] Mayo Clin, Dept Ophthalmol, Rochester, MN USA.
[Fingert, J.] Univ Iowa, Coll Med, Dept Ophthalmol, Iowa City, IA 52242 USA.
[Fingert, J.] Univ Iowa, Coll Med, Dept Anat Cell Biol, Iowa City, IA USA.
[Buys, E. S.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02115 USA.
[Kraft, P.] Harvard Univ, Dept Biostat & Epidemiol, Sch Med, Boston, MA 02115 USA.
RP Kang, JH (reprint author), Harvard Univ, Brigham & Womens Hosp, Sch Med, Channing Div Network Med,Dept Med, 181 Longwood Ave, Boston, MA 02115 USA.
EM nhjhk@channing.harvard.edu
OI Sit, Arthur/0000-0002-3904-2625; Zack, Don/0000-0002-7966-1973
FU Allergan (Irvine, CA, USA); The Harvard Glaucoma Center of Excellence, a
Harvard Department of Ophthalmology; Research to Prevent Blindness Inc.
(New York, NY, USA); The Arthur Ashley Foundation; The Glaucoma Research
Foundation (San Francisco, CA, USA); American Health Assistance
Foundation (Clarksburg, MD, USA); Glaucoma Foundation (New York, NY,
USA); NIH [R01EY022746]; National Institutes of Health [P01 CA87969,
CA49449, UM1 CA167552, HL35464, HHSN268200782096C]; National Human
Genome Research Institute (Bethesda, MD, USA) [HG004728, HG004424,
HG004446]; National Eye Institute [HG005259-01]; The National Eye
Institute (Bethesda, MD) through ARRA [3R01EY015872-05S1,
3R01EY019126-02S1]; National Institutes of Health (Bethesda, MD)
[EY015543, EY006827, HL073389, EY13315, EY09611, EY015473, EY009149,
HG004608, EY008208, EY012118, EY015682, EY011671, EY09580, EY013178,
EY010886, EY009847, EY011008, EY144428, EY144448, EY18660, UL1TR000427,
U01HG006389, P30 EY014104, R01 EY022305, R21 EY022766]
FX A Horizon Grant to MEEI from Allergan (Irvine, CA, USA) supported the
collection of some glaucoma feature data. The Harvard Glaucoma Center of
Excellence, a Harvard Department of Ophthalmology Scholar Award, and
Margolis fund (Boston, MA) support LRP and JLW. LRP, JER, and JLW are
also supported by Research to Prevent Blindness Inc. (New York, NY,
USA). The Arthur Ashley Foundation also supports Dr Pasquale. The
Glaucoma Research Foundation (San Francisco, CA, USA), American Health
Assistance Foundation (Clarksburg, MD, USA), and the Glaucoma Foundation
(New York, NY, USA) support YL. EB is supported by NIH Grant
R01EY022746. The following National Institutes of Health grants support
the maintenance of the NHS and Health Professionals Follow-up, allowing
these health professionals to contribute to this analysis: P01 CA87969,
CA49449, UM1 CA167552, and HL35464. The following grants from the
National Human Genome Research Institute (Bethesda, MD, USA) supported
GLAUGEN: HG004728 (LRP), HG004424 (Broad Institute to support
genotyping), and HG004446 (C Laurie, U Washington, to support genotype
data cleaning and analysis). Genotyping services for the NEIGHBOR study
were provided by the Center for Inherited Disease Research (CIDR) and
were supported by the National Eye Institute through Grant HG005259-01
(JLW). In addition, CIDR is funded through a federal contract from the
National Institutes of Health to The Johns Hopkins University, contract
number HHSN268200782096C. The National Eye Institute (Bethesda, MD)
through ARRA Grants 3R01EY015872-05S1 (JLW) and 3R01EY019126-02S1 (MAH)
supported the collection and processing of samples for the NEIGHBOR data
set. Funding for the collection of cases and controls was provided by
National Institutes of Health (Bethesda, MD) Grants: EY015543 (RRA),
EY006827 (DG), HL073389 (E Hauser); EY13315 (MAH); EY09611 (S
Hankinson), EY015473 (LRP), EY009149 (PRL), HG004608 (CAM), EY008208 (P
Medeiros), EY012118 (MAP-V), EY015682 (TR), EY011671 (JER), EY09580
(JER), EY013178 (JSS), EY010886 (JLW), EY009847 (JLW), EY011008 (L
Zangwill), EY144428 (KZ), EY144448 (KZ), EY18660 (KZ), UL1TR000427 (MHB)
and U01HG006389 (CAM), P30 EY014104, R01 EY022305, and R21 EY022766.
NR 73
TC 6
Z9 6
U1 0
U2 5
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0950-222X
EI 1476-5454
J9 EYE
JI Eye
PD JUN
PY 2014
VL 28
IS 6
BP 662
EP 671
DI 10.1038/eye.2014.42
PG 10
WC Ophthalmology
SC Ophthalmology
GA AK3QQ
UT WOS:000338340200004
PM 24603425
ER
PT J
AU Qazi, Y
Aggarwal, S
Hamrah, P
AF Qazi, Yureeda
Aggarwal, Shruti
Hamrah, Pedram
TI Image-guided evaluation and monitoring of treatment response in patients
with dry eye disease
SO GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY
LA English
DT Review
DE IVCM; OCT; Dry eye disease; Meibomian gland dysfunction; Confocal
microscopy
ID MEIBOMIAN GLAND DYSFUNCTION; OPTICAL COHERENCE TOMOGRAPHY; VIVO CONFOCAL
MICROSCOPY; QUALITY-OF-LIFE; ANTERIOR-CHAMBER PARAMETERS; MENISCUS
HEIGHT MEASUREMENT; PRIMARY SJOGRENS-SYNDROME; AQUEOUS TEAR DEFICIENCY;
CONTACT-LENS WEARERS; HIGH-SCHOOL-STUDENTS
AB Background Dry eye disease (DED) is one of the most common ocular disorders worldwide. The pathophysiological mechanisms involved in the development of DED are not well-understood, and thus treating DED has been a significant challenge for ophthalmologists. Most of the currently available diagnostic tests demonstrate low correlation to patient symptoms and have low reproducibility.
Methods Recently, sophisticated in vivo imaging modalities have become available for patient care, namely, in vivo confocal microscopy (IVCM) and optical coherence tomography (OCT). These emerging modalities are powerful and non-invasive, allowing real-time visualization of cellular and anatomical structures of the cornea and ocular surface. Here we discuss how, by providing both qualitative and quantitative assessment, these techniques can be used to demonstrate early subclinical disease, grade layer-by-layer severity, and allow monitoring of disease severity by cellular alterations. Imaging-guided stratification of patients may also be possible in conjunction with clinical examination methods.
Conclusions Visualization of subclinical changes and stratification of patients in vivo allows objective image-guided evaluation of tailored treatment response based on cellular morphological alterations specific to each patient. This image-guided approach to DED may ultimately improve patient outcomes and make it possible to study the efficacy of novel therapies in clinical trials.
C1 [Qazi, Yureeda; Aggarwal, Shruti; Hamrah, Pedram] Massachusetts Eye & Ear Infirm, Cornea & Refract Surg Serv, Cornea Serv, Ocular Surface Imaging Ctr, Boston, MA 02114 USA.
[Qazi, Yureeda; Aggarwal, Shruti; Hamrah, Pedram] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA 02114 USA.
RP Hamrah, P (reprint author), Massachusetts Eye & Ear Infirm, Cornea & Refract Surg Serv, Cornea Serv, Ocular Surface Imaging Ctr, 243 Charles St, Boston, MA 02114 USA.
EM pedram_hamrah@meei.harvard.edu
FU National Institute of Health [NIH K08-EY020575]; Research to Prevent
Blindness Career Development Award; Falk Medical Research Foundation
FX We would like to thank our sponsors for their generous support through
grants from the National Institute of Health (NIH K08-EY020575 to PH),
Research to Prevent Blindness Career Development Award (PH) and Falk
Medical Research Foundation (PH).
NR 231
TC 6
Z9 6
U1 1
U2 9
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0721-832X
EI 1435-702X
J9 GRAEF ARCH CLIN EXP
JI Graefes Arch. Clin. Exp. Ophthalmol.
PD JUN
PY 2014
VL 252
IS 6
BP 857
EP 872
DI 10.1007/s00417-014-2618-2
PG 16
WC Ophthalmology
SC Ophthalmology
GA AK5UN
UT WOS:000338492000001
PM 24696045
ER
PT J
AU Dupree, JM
Patel, K
Singer, SJ
West, M
Wang, R
Zinner, MJ
Weissman, JS
AF Dupree, James M.
Patel, Kavita
Singer, Sara J.
West, Mallory
Wang, Rui
Zinner, Michael J.
Weissman, Joel S.
TI Attention To Surgeons And Surgical Care Is Largely Missing From Early
Medicare Accountable Care Organizations
SO HEALTH AFFAIRS
LA English
DT Article
ID HEALTH-CARE
AB The Affordable Care Act supports the growth of accountable care organizations (ACOs) as a potentially powerful model for health care delivery and payment. The model focuses on primary care. However, surgeons and other specialists have a large role to play in caring for ACOs' patients. No studies have yet investigated the role of surgical care in the ACO model. Using case studies and a survey, we examined the early experience of fifty-nine Medicare-approved ACOs in providing surgical care. We found that ACOs have so far devoted little attention to surgical care. Instead, they have emphasized coordinating care for patients with chronic conditions and reducing unnecessary hospital readmissions and ED visits. In the years to come, ACOs will likely focus more on surgical care. Some ACOs have the ability to affect surgical practice patterns through referral pressures, but local market conditions may limit ACOs' abilities to alter surgeons' behavior. Policy makers, ACO administrators, and surgeons need to be aware of these trends because they have the potential to affect the surgical care provided to ACO patients as well as the success of ACOs themselves.
C1 [Dupree, James M.] Amer Coll Surg, Chicago, IL USA.
[Patel, Kavita] Brookings Inst, Engelberg Ctr Hlth Care Reform, Washington, DC 20036 USA.
[Singer, Sara J.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.
[Singer, Sara J.] Massachusetts Gen Hosp, Mongan Inst Hlth Policy, Boston, MA 02114 USA.
[West, Mallory] Brookings Inst, Washington, DC 20036 USA.
[Wang, Rui; Zinner, Michael J.; Weissman, Joel S.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
[Weissman, Joel S.] Brigham & Womens Hosp, Ctr Surg & Publ Hlth, Boston, MA 02115 USA.
RP Dupree, JM (reprint author), Baylor Coll Med, Scott Dept Urol, Houston, TX 77030 USA.
EM jim.dupree@gmail.com
FU American College of Surgeons
FX This study was funded by a grant from the American College of Surgeons.
Findings from this research were presented at the 2013 AcademyHealth
Annual Research Meeting in Baltimore, Maryland, June 24, 2013. Kathy
Corso provided valuable research assistance for this project.
NR 14
TC 27
Z9 27
U1 2
U2 5
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD JUN
PY 2014
VL 33
IS 6
BP 972
EP 979
DI 10.1377/hlthaff.2013.1300
PG 8
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA AK1PL
UT WOS:000338187200008
PM 24889946
ER
PT J
AU Hebert, PL
Liu, CF
Wong, ES
Hernandez, SE
Batten, A
Lo, S
Lemon, JM
Conrad, DA
Grembowski, D
Nelson, K
Fihn, SD
AF Hebert, Paul L.
Liu, Chuan-Fen
Wong, Edwin S.
Hernandez, Susan E.
Batten, Adam
Lo, Sophie
Lemon, Jaclyn M.
Conrad, Douglas A.
Grembowski, David
Nelson, Karin
Fihn, Stephan D.
TI Patient-Centered Medical Home Initiative Produced Modest Economic
Results For Veterans Health Administration, 2010-12
SO HEALTH AFFAIRS
LA English
DT Article
ID PRIMARY-CARE; COST SAVINGS; GROWTH; ACCESS
AB In 2010 the Veterans Health Administration (VHA) began a nationwide initiative called Patient Aligned Care Teams (PACT) that reorganized care at all VHA primary care clinics in accordance with the patient-centered medical home model. We analyzed data for fiscal years 2003-12 to assess how trends in health care use and costs changed after the implementation of PACT. We found that PACT was associated with modest increases in primary care visits and with modest decreases in both hospitalizations for ambulatory care-sensitive conditions and outpatient visits with mental health specialists. We estimated that these changes avoided $596 million in costs, compared to the investment in PACT of $774 million, for a potential net loss of $178 million in the study period. Although PACT has not generated a positive return, it is still maturing, and trends in costs and use are favorable. Adopting patient-centered care does not appear to have been a major financial risk for the VHA.
C1 [Hebert, Paul L.] VA Puget Sound Hlth Care Syst, Vet Affairs VA Hlth Serv Res & Dev Ctr Vet Ctr, Value Driven Hlth, Seattle, WA 98108 USA.
[Hebert, Paul L.; Liu, Chuan-Fen; Hernandez, Susan E.] Univ Washington, Dept Hlth Serv, Sch Publ Hlth, Seattle, WA 98195 USA.
[Liu, Chuan-Fen; Wong, Edwin S.; Batten, Adam; Nelson, Karin] Value Driven Hlth, VA Hlth Serv Res & Dev Ctr Vet Ctr, Seattle, WA USA.
[Lo, Sophie] Vet Hlth Adm Off Analyt & Business Intelligence, Bedford, MA USA.
[Lemon, Jaclyn M.] Univ Washington, Sch Med, Seattle, WA 98195 USA.
[Conrad, Douglas A.] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA.
[Grembowski, David] Univ Washington, Seattle, WA 98195 USA.
[Nelson, Karin; Fihn, Stephan D.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA.
[Fihn, Stephan D.] VA Puget Sound Hlth Care Syst, VHA Off Analyt & Business Intelligence, Seattle, WA USA.
RP Hebert, PL (reprint author), VA Puget Sound Hlth Care Syst, Vet Affairs VA Hlth Serv Res & Dev Ctr Vet Ctr, Value Driven Hlth, Seattle, WA 98108 USA.
EM paul.hebert2@va.gov
FU Veterans Health Administration (VHA) Patient Centered Medical Home
Demonstration Laboratory Coordination Center [XVA-61-041]; VHA Health
Services Research and Development Career Development Award [CDA 13-024]
FX This research was presented at the Society of General Internal Medicine
Annual Meeting, Denver, Colorado, April 23, 2013; and the AcademyHealth
Annual Research Meeting, Baltimore, Maryland, June 23, 2013. This work
was funded by the Veterans Health Administration (VHA) Patient Centered
Medical Home Demonstration Laboratory Coordination Center (Grant No.
XVA-61-041). Edwin Wong is supported by a VHA Health Services Research
and Development Career Development Award (Grant No. CDA 13-024). The
views expressed herein are those of the authors and do not necessary
represent the views of the Department of Veterans Affairs or other
affiliated institutions.
NR 21
TC 13
Z9 13
U1 1
U2 3
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD JUN
PY 2014
VL 33
IS 6
BP 980
EP 987
DI 10.1377/hlthaff.2013.0893
PG 8
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA AK1PL
UT WOS:000338187200009
PM 24889947
ER
PT J
AU Guy, GP
Yabroff, KR
Ekwueme, DU
Smith, AW
Dowling, EC
Rechis, R
Nutt, S
Richardson, LC
AF Guy, Gery P., Jr.
Yabroff, K. Robin
Ekwueme, Donatus U.
Smith, Ashley Wilder
Dowling, Emily C.
Rechis, Ruth
Nutt, Stephanie
Richardson, Lisa C.
TI Estimating The Health And Economic Burden Of Cancer Among Those
Diagnosed As Adolescents And Young Adults
SO HEALTH AFFAIRS
LA English
DT Article
ID UNITED-STATES; SURVIVORS; PRODUCTIVITY; PREVALENCE; IMPACT; CHALLENGES;
COSTS; CARE
AB Adolescent and young adult cancer survivors-those who were ages 15-39 at their first cancer diagnosis-have important health limitations. These survivors are at risk for higher health care expenditures and lost productivity, compared to adults without a history of cancer. Using Medical Expenditure Panel Survey data, we present nationally representative estimates of the economic burden among people who were diagnosed with cancer in adolescence or young adulthood. Our findings demonstrate that surviving cancer at this age is associated with a substantial economic burden. Compared to adults without a history of cancer, adolescent and young adult cancer survivors had excess annual medical expenditures of $3,170 per person and excess annual productivity losses of $2,250 per person. Multifaceted prevention strategies, including education and sustained intervention programs to ensure access to lifelong risk-based follow-up care, may be effective ways to improve the economic outcomes associated with cancer survivorship in this population.
C1 [Guy, Gery P., Jr.] Ctr Dis Control & Prevent CDC, Div Canc Prevent & Control, Atlanta, GA 30333 USA.
[Yabroff, K. Robin; Smith, Ashley Wilder] NCI, Div Canc Control & Populat Sci, Bethesda, MD 20892 USA.
[Ekwueme, Donatus U.] CDC, Div Canc Prevent & Control, Atlanta, GA 30333 USA.
[Dowling, Emily C.] Massachusetts Gen Hosp, Inst Technol Assessment, Boston, MA 02114 USA.
[Rechis, Ruth] LIVESTRONG Fdn, Austin, TX USA.
[Nutt, Stephanie] LIVESTRONG Fdn, Res & Evaluat Team, Austin, TX USA.
[Richardson, Lisa C.] CDC, Div Blood Disorders, Atlanta, GA 30333 USA.
RP Guy, GP (reprint author), Ctr Dis Control & Prevent CDC, Div Canc Prevent & Control, Atlanta, GA 30333 USA.
EM irm2@cdc.gov
FU Intramural CDC HHS [CC999999]
NR 31
TC 17
Z9 18
U1 7
U2 14
PU PROJECT HOPE
PI BETHESDA
PA 7500 OLD GEORGETOWN RD, STE 600, BETHESDA, MD 20814-6133 USA
SN 0278-2715
J9 HEALTH AFFAIR
JI Health Aff.
PD JUN
PY 2014
VL 33
IS 6
BP 1024
EP 1031
DI 10.1377/hlthaff.2013.1425
PG 8
WC Health Care Sciences & Services; Health Policy & Services
SC Health Care Sciences & Services
GA AK1PL
UT WOS:000338187200014
PM 24889952
ER
PT J
AU Choi, HR
Bedair, H
AF Choi, Ho-Rim
Bedair, Hany
TI Mortality Following Revision Total Knee Arthroplasty: A Matched Cohort
Study of Septic versus Aseptic Revisions
SO JOURNAL OF ARTHROPLASTY
LA English
DT Article
DE total knee arthroplasty; septic revision; aseptic revision; mortality;
longer-term
ID PATIENT SURVIVAL; REPLACEMENT; INFECTION
AB We report the medium-term mortality after septic versus aseptic revision total knee arthroplasty (TKA) and factors that can contribute to mortality in revision TKA. Mortality rates of 88 patients undergoing septic revision (septic group) were compared with age-and year of surgery-matched 88 patients of aseptic revision (aseptic group). The overall mortality after revision TKA was 10.7% at a median of 4 years of follow-up (range, 2-7 years). However, the mortality after septic revision (18%, 16/88) was six times higher than that of aseptic revision (3%, 3/88) (P = 0.003). Infections with Staphylococcus aureus and/or methicillin resistance was not associated with higher mortality rates. Multivariate analysis indicated that increased age (P < 0.001), higher ASA class (P = 0.002), and septic revision (P < 0.001) were identified as independent predictors of increased mortality after revision TKA. (C) 2014 Elsevier Inc. All rights reserved.
C1 Massachusetts Gen Hosp, Harris Orthoped Lab, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Dept Orthopaed Surg, Boston, MA 02114 USA.
RP Bedair, H (reprint author), Massachusetts Gen Hosp, Dept Orthoped Surg, Boston, MA 02114 USA.
NR 17
TC 4
Z9 4
U1 0
U2 0
PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
PI PHILADELPHIA
PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA
SN 0883-5403
EI 1532-8406
J9 J ARTHROPLASTY
JI J. Arthroplast.
PD JUN
PY 2014
VL 29
IS 6
BP 1216
EP 1218
DI 10.1016/j.arth.2013.11.026
PG 3
WC Orthopedics
SC Orthopedics
GA AK0PC
UT WOS:000338115400029
PM 24405619
ER
PT J
AU Altenburger, EM
Tung, ES
Keuthen, NJ
AF Altenburger, Erin M.
Tung, Esther S.
Keuthen, Nancy J.
TI Body esteem in adolescent hair pullers
SO JOURNAL OF BEHAVIORAL ADDICTIONS
LA English
DT Article
DE hair pulling; trichotillomania; body esteem
ID SELF-ESTEEM; TRICHOTILLOMANIA; DEPRESSION; CHILDREN; SCALE
AB Background and aims: Trichotillomania (TTM) often first presents in adolescence, a developmental period marked by vulnerability in body image. To date, no one has studied the relationship between this disorder and body esteem. Methods: 49 adolescents with DSM-IV TTM or chronic hair pulling (HP) and 23 control adolescents were administered diagnostic assessments and self-report measures of hair pulling and body esteem. Results: HP youth vs. controls reported lower levels of body esteem on all Body-Esteem Scale for Adolescents and Adults (BESAA) subscales (appearance, attribution and weight satisfaction). HP contributed to lowered body esteem, independent of comorbid anxiety or depression. As expected, HP youth with vs. without comorbid anxiety or depression reported lowered levels of body esteem. Further, greater HP severity and distress were significantly associated with lower levels of body esteem. HP severity alone but not distress/impairment predicted lower levels of body esteem, independent of comorbid anxiety and depression. Conclusions: Both hair pulling and comorbid anxiety and depression can independently impact body esteem in adolescent hair pullers.
C1 [Altenburger, Erin M.] Ohio State Univ, Columbus, OH 43210 USA.
[Tung, Esther S.; Keuthen, Nancy J.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA USA.
RP Altenburger, EM (reprint author), Ohio State Univ, Dept Psychol, 181 Psychol Bldg,1835 Neil Ave, Columbus, OH 43210 USA.
EM altenburger.20@buckeyemail.osu.edu
FU Greater Kansas City Foundation
FX This research was financially supported by a grant from the Greater
Kansas City Foundation. The funding sponsor had no role in study design,
data collection, data analysis or interpretation, manuscript preparation
or the decision to submit the manuscript for publication.
NR 15
TC 3
Z9 3
U1 0
U2 1
PU AKADEMIAI KIADO RT
PI BUDAPEST
PA PRIELLE K U 19, PO BOX 245,, H-1117 BUDAPEST, HUNGARY
SN 2062-5871
EI 2063-5303
J9 J BEHAV ADDICT
JI J. Behav. Addict.
PD JUN
PY 2014
VL 3
IS 2
BP 124
EP 127
DI 10.1556/JBA.3.2014.010
PG 4
WC Psychiatry
SC Psychiatry
GA AK3KC
UT WOS:000338321100006
PM 25215223
ER
PT J
AU Ho, CH
Ho, MG
Ho, SP
Ho, HH
AF Ho, Cynthia H.
Ho, Michael G.
Ho, Shin-Pin
Ho, Helen H.
TI BITTER BOTTLE GOURD (LAGENARIA SICERARIA) TOXICITY
SO JOURNAL OF EMERGENCY MEDICINE
LA English
DT Article
DE Cucurbitaceae; cucurbitacin; hematemesis; food-borne illness; food
poisoning
ID CUCURBITACIN-B; CANCER CELLS
AB Background: Bottle gourd (Lagenaria siceraria) is an edible plant in the Cucurbitaceae family. When extremely bitter, ingestion of bottle gourd can cause rapid onset diarrhea, vomiting, gastrointestinal bleeding, and hypotension due to release of a substance named cucurbitacin. Objective: Our aim was to increase physician awareness of cucurbitacin poisoning in order to facilitate accurate diagnosis and appropriate management. Case Report: Five adult patients presented with nausea, vomiting, and diarrhea within 5 to 25 min of ingesting cooked bitter bottle gourd. One patient developed severe diarrhea, hematemesis, and hypotension requiring hospitalization. All patients improved within a few days with intravenous fluids and proton pump inhibitors. To our knowledge, this is the first reported group of patients with toxicity due to ingestion of bottle gourd in the United States (US). Conclusions: Physicians should be suspicious of cucurbitacin toxicity in patients who present with symptoms within minutes of ingestion of a plant in the Cucurbitaceae family. Patients should be asked if the plant tasted unusually bitter. The most common symptoms include diarrhea and hematemesis. More than half of patients develop hypotension. There is no known antidote for bottle gourd poisoning; treatment is supportive. Proton pump inhibitors should be given to patients with gastrointestinal mucosal injury. (C) 2014 Elsevier Inc.
C1 [Ho, Cynthia H.] Univ So Calif, Dept Internal Med, Los Angeles Cty Univ Southen Calif Med Ctr, Los Angeles, CA 90033 USA.
[Ho, Cynthia H.] Univ So Calif, Dept Pediat, Los Angeles Cty Univ Southen Calif Med Ctr, Los Angeles, CA 90033 USA.
[Ho, Michael G.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Ho, Shin-Pin] Henry Mayo Newhall Mem Hosp, Newhall, CA USA.
[Ho, Helen H.] White Mem Med Ctr, Dept Emergency Med, Los Angeles, CA USA.
RP Ho, CH (reprint author), Univ So Calif, Dept Internal Med, 2020 Zonal Ave,IRD Room 109, Los Angeles, CA 90033 USA.
OI Ho, Michael/0000-0002-4893-3016
NR 14
TC 3
Z9 3
U1 0
U2 13
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0736-4679
EI 1090-1280
J9 J EMERG MED
JI J. Emerg. Med.
PD JUN
PY 2014
VL 46
IS 6
BP 772
EP 775
DI 10.1016/j.jemermed.2013.08.106
PG 4
WC Emergency Medicine
SC Emergency Medicine
GA AK1UB
UT WOS:000338201100016
PM 24360122
ER
PT J
AU Walling, AM
Dy, SM
AF Walling, Anne M.
Dy, Sydney M.
TI The Importance of a Comprehensive, Patient-Centered Approach to
End-of-Life Care
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Editorial Material
ID DISCUSSIONS; PREFERENCES; OUTCOMES
C1 [Walling, Anne M.] Univ Calif Los Angeles, David Geffen Sch Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA.
[Walling, Anne M.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA.
[Dy, Sydney M.] Johns Hopkins Bloomberg Sch Publ Hlth, Dept Hlth Policy & Management, Baltimore, MD USA.
[Dy, Sydney M.] Johns Hopkins Kimmel Canc Ctr, Harry J Duffey Family Pain & Palliat Care Program, Baltimore, MD USA.
RP Dy, SM (reprint author), Rm 609,624 N Broadway, Baltimore, MD 21205 USA.
EM sdy@jhsph.edu
FU NCATS NIH HHS [UL1 TR000124, KL2 TR000122, KL2TR000122]
NR 14
TC 1
Z9 1
U1 3
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2014
VL 29
IS 6
BP 822
EP 823
DI 10.1007/s11606-013-2757-x
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AK1VS
UT WOS:000338206600002
PM 24420868
ER
PT J
AU Bailey, FA
Williams, BR
Woodby, LL
Goode, PS
Redden, DT
Houston, TK
Granstaff, US
Johnson, TM
Pennypacker, LC
Haddock, KS
Painter, JM
Spencer, JM
Hartney, T
Burgio, KL
AF Bailey, F. Amos
Williams, Beverly R.
Woodby, Lesa L.
Goode, Patricia S.
Redden, David T.
Houston, Thomas K.
Granstaff, U. Shanette
Johnson, Theodore M., II
Pennypacker, Leslye C.
Haddock, K. Sue
Painter, John M.
Spencer, Jessie M.
Hartney, Thomas
Burgio, Kathryn L.
TI Intervention to Improve Care at Life's End in Inpatient Settings: The
BEACON Trial
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE palliative care; end-of-life care; palliative medicine; hospice;
inpatient
ID ILL CANCER-PATIENTS; SMALL-SAMPLE ADJUSTMENTS; PALLIATIVE CARE; OF-LIFE;
INTENSIVE-CARE; PAIN MANAGEMENT; HOSPICE CARE; LAST HOURS; DEATH;
OPPORTUNITIES
AB BACKGROUND: Widespread implementation of palliative care treatment plans could reduce suffering in the last days of life by adopting best practices of traditionally home-based hospice care in inpatient settings.
OBJECTIVE: To evaluate the effectiveness of a multi-modal intervention strategy to improve processes of end-of-life care in inpatient settings.
DESIGN: Implementation trial with an intervention staggered across hospitals using a multiple-baseline, stepped wedge design.
PARTICIPANTS: Six Veterans Affairs Medical Centers (VAMCs).
INTERVENTION: Staff training was targeted to all hospital providers and focused on identifying actively dying patients and implementing best practices from home-based hospice care, supported with an electronic order set and paper-based educational tools.
MAIN MEASURES: Several processes of care were identified as quality endpoints for end-of-life care (last 7 days) and abstracted from electronic medical records of veterans who died before or after intervention (n=6,066). Primary endpoints were proportion with an order for opioid pain medication at time of death, do-not-resuscitate order, location of death, nasogastric tube, intravenous line infusing, and physical restraints. Secondary endpoints were administration of opioids, order/administration of antipsychotics, benzodiazepines, and scopolamine (for death rattle); sublingual administration; advance directives; palliative care consultations; and pastoral care services. Generalized estimating equations were conducted adjusting for longitudinal trends.
KEY RESULTS: Significant intervention effects were observed for orders for opioid pain medication (OR: 1.39), antipsychotic medications (OR: 1.98), benzodiazepines (OR: 1.39), death rattle medications (OR: 2.77), sublingual administration (OR: 4.12), nasogastric tubes (OR: 0.71), and advance directives (OR: 1.47). Intervention effects were not significant for location of death, do-not-resuscitate orders, intravenous lines, or restraints.
CONCLUSIONS: This broadly targeted intervention strategy led to modest but statistically significant changes in several processes of care, indicating its potential for widespread dissemination to improve end-of-life care for thousands of patients who die each year in inpatient settings. (C) Society of General Internal Medicine 2014
C1 [Bailey, F. Amos; Williams, Beverly R.; Woodby, Lesa L.; Goode, Patricia S.; Redden, David T.; Granstaff, U. Shanette; Burgio, Kathryn L.] Birmingham Atlanta Geriatr Res Educ & Clin Ctr GR, Dept Vet Affairs, Birmingham, AL USA.
[Bailey, F. Amos; Williams, Beverly R.; Woodby, Lesa L.; Goode, Patricia S.; Redden, David T.; Granstaff, U. Shanette; Burgio, Kathryn L.] Univ Alabama Birmingham, Birmingham, AL USA.
[Houston, Thomas K.] US Dept Vet Affairs, VA eHlth Qual Enhancement Res Initiat, Bedford, MA USA.
[Houston, Thomas K.] Univ Massachusetts Med Sch, Worcester, MA USA.
[Johnson, Theodore M., II] Birmingham Atlanta Geriatr Res Educ & Clin Ctr GR, Decatur, GA USA.
[Johnson, Theodore M., II] Emory Univ, Atlanta, GA 30322 USA.
[Pennypacker, Leslye C.] Malcom Randall VA Med Ctr, Gainesville, FL USA.
[Haddock, K. Sue] William Jennings Bryan Dorn VA Med Ctr, Columbia, SC USA.
[Painter, John M.] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
[Spencer, Jessie M.] GV Sonny Montgomery VA Med Ctr, Jackson, MS USA.
[Hartney, Thomas] Charlie Norwood VA Med Ctr, Augusta, GA USA.
RP Burgio, KL (reprint author), Birmingham VA Med Ctr, Birmingham Atlanta Geriatr Res Educ & Clin Ctr, 11G,700 South 19th St, Birmingham, AL 35233 USA.
EM kburgio@uabmc.edu
FU Department of Veterans Affairs, Veterans Health Administration, Office
of Research and Development, Health Services Research and Development
Service [IIR 03-126]
FX This research was supported by a Merit Review grant from the Department
of Veterans Affairs, Veterans Health Administration, Office of Research
and Development, Health Services Research and Development Service (IIR
03-126 "Intervention to Improve Care at Life's End in VA Medical
Centers;" PI: KL Burgio, Co-PI: FA Bailey). The funding source had no
role in the design and conduct of the study; collection, management,
analysis, and interpretation of the data; preparation, review, or
approval of the manuscript.
NR 62
TC 14
Z9 14
U1 2
U2 12
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2014
VL 29
IS 6
BP 836
EP 843
DI 10.1007/s11606-013-2724-6
PG 8
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AK1VS
UT WOS:000338206600008
PM 24449032
ER
PT J
AU Wald, HL
Leykum, LK
Mattison, MLP
Vasilevskis, EE
Meltzer, DO
AF Wald, Heidi L.
Leykum, Luci K.
Mattison, Melissa L. P.
Vasilevskis, Eduard E.
Meltzer, David O.
TI Road Map to a Patient-Centered Research Agenda at the Intersection of
Hospital Medicine and Geriatric Medicine
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE geriatrics; hospitals; hospitalists; patient-centered care; research
ID OLDER PATIENTS; CARE; ADULTS
AB As the United States ages, the patient population in acute care hospitals is increasingly older and more medically complex. Despite evidence of a high burden of disease, high costs, and often poor outcomes of care, there is limited understanding of the presentation, diagnostic strategies, and management of acute illness in older adults. In this paper, we present a strategy for the development of a research agenda at the intersection of hospital and geriatric medicine. This approach is informed by the Patient-Centered Outcomes Research Institute (PCORI) framework for identification and prioritization of research areas, emphasizing input from patients and caregivers. The framework's four components are: 1) Topic generation, 2) Gap Analysis in Systematic Review, 3) Value of information (VOI) analysis, and 4) Peer Review. An inclusive process for topic generation requiring the systematic engagement of multiple stakeholders, especially patients, is emphasized. In subsequent steps, researchers and stakeholders prioritize research topics in order to identify areas that optimize patient-centeredness, population impact, impact on clinical decision making, ease of implementation, and durability. Finally, next steps for dissemination of the research agenda and evaluation of the impact of the patient-centered research prioritization process are described. (C) Society of General Internal Medicine 2014
C1 [Wald, Heidi L.] Univ Colorado Sch Med, Div Hlth Care Policy & Res, Aurora, CO USA.
[Leykum, Luci K.] Univ Texas Hlth Sci Ctr San Antonio, South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA.
[Mattison, Melissa L. P.] Beth Israel Deaconess Med Ctr, Boston, MA USA.
[Mattison, Melissa L. P.] Harvard Univ, Sch Med, Boston, MA USA.
[Vasilevskis, Eduard E.] Vanderbilt Univ, Div Gen Internal Med & Publ Hlth, Sect Hosp Med, Nashville, TN 37235 USA.
[Vasilevskis, Eduard E.] Vanderbilt Univ, Ctr Qual Aging, Nashville, TN 37235 USA.
[Vasilevskis, Eduard E.] GRECC, Nashville, TN USA.
[Meltzer, David O.] Univ Chicago, Chicago, IL 60637 USA.
RP Wald, HL (reprint author), Div Hlth Care Policy & Res, Dept Med, Campus Box F480 13199 E Moniview Blvd,Suite 400, Aurora, CO 80024 USA.
EM Heidi.wald@ucdenver.edu
RI Meltzer, David/C-2926-2009
OI Meltzer, David/0000-0003-2790-7393
FU American Association of Instructors of Medicine/Association of Specialty
Providers; John A. Hartford Foundation; Paul Beeson Career Development
Award in Aging (NIA) [5 K23 AG034544]; Rx Foundation; Department of
Veterans Affairs, Veterans Health Administration, Health Services
Research and Development Service [REA 05-129, CDA 07-022]; South Texas
Veterans Health Care System; National Institute On Aging of the National
Institutes of Health [K23AG040157]; Veterans Affairs Clinical Research
Center of Excellence; Geriatric Research, Education and Clinical Center
(GRECC)
FX This work was supported by the American Association of Instructors of
Medicine/Association of Specialty Providers, and the John A. Hartford
Foundation. Dr. Wald is supported by a Paul Beeson Career Development
Award in Aging (NIA 5 K23 AG034544). Dr. Mattison acknowledges the
support of Rx Foundation. This work was also supported by the Department
of Veterans Affairs, Veterans Health Administration, Health Services
Research and Development Service (REA 05-129, CDA 07-022). Investigator
salary support (to Dr. Leykum) is provided through this funding, and
through the South Texas Veterans Health Care System. Dr. Vasilevskis was
supported by the National Institute On Aging of the National Institutes
of Health (K23AG040157) and the Veterans Affairs Clinical Research
Center of Excellence, and the Geriatric Research, Education and Clinical
Center (GRECC).
NR 23
TC 5
Z9 5
U1 0
U2 4
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2014
VL 29
IS 6
BP 926
EP 931
DI 10.1007/s11606-014-2777-1
PG 6
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AK1VS
UT WOS:000338206600023
PM 24557516
ER
PT J
AU Arbaje, AI
Kansagara, DL
Salanitro, AH
Englander, HL
Kripalani, S
Jencks, SF
Lindquist, LA
AF Arbaje, Alicia I.
Kansagara, Devan L.
Salanitro, Amanda H.
Englander, Honora L.
Kripalani, Sunil
Jencks, Stephen F.
Lindquist, Lee A.
TI Regardless of Age: Incorporating Principles from Geriatric Medicine to
Improve Care Transitions for Patients with Complex Needs
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE care transitions; geriatrics; utilization; healthcare delivery;
vulnerable populations
ID CONGESTIVE-HEART-FAILURE; OLDER-ADULTS; HOSPITAL READMISSION;
RANDOMIZED-TRIAL; RISK; INTERVENTION; CAREGIVERS; SETTINGS;
REHOSPITALIZATIONS; DEMENTIA
AB With its focus on holistic approaches to patient care, caregiver support, and delivery system redesign, geriatrics has advanced our understanding of optimal care during transitions. This article provides a framework for incorporating geriatrics principles into care transition activities by discussing the following elements: (1) identifying factors that make transitions more complex, (2) engaging care "receivers" and tailoring home care to meet patient needs, (3) building "recovery plans" into transitional care, (4) predicting and avoiding preventable readmissions, and (5) adopting a palliative approach, when appropriate, that optimizes patient and family goals of care. The article concludes with a discussion of practical aspects of designing, implementing, and evaluating care transitions programs for those with complex care needs, as well as implications for public policy. (C) Society of General Internal Medicine 2014
C1 [Arbaje, Alicia I.] Johns Hopkins Univ, Dept Med, Div Geriatr Med & Gerontol, Baltimore, MD 21224 USA.
[Kansagara, Devan L.] Oregon Hlth & Sci Univ, Sect Gen Internal Med, Portland VA Med Ctr, Portland, OR 97201 USA.
[Salanitro, Amanda H.] Vanderbilt Univ Sch Med, Nashville, TN USA.
[Englander, Honora L.] Oregon Hlth & Sci Univ, Div Hosp Med, Portland, OR 97201 USA.
[Kripalani, Sunil] Vanderbilt Univ Sch Med, Div Gen Internal Med & Publ Hlth, Sect Hosp Med, Nashville, TN USA.
[Jencks, Stephen F.] Healthcare Safety & Qual, Baltimore, MD USA.
[Lindquist, Lee A.] Northwestern Univ Feinberg Sch Med, Sect Gen Internal Med & Geriatr, Dept Med, Chicago, IL USA.
RP Arbaje, AI (reprint author), Johns Hopkins Univ, Dept Med, Div Geriatr Med & Gerontol, Mason F Lord Bldg,Ctr Tower,5200 Eastern Ave,7th, Baltimore, MD 21224 USA.
EM aarbaje@jhmi.edu
FU Association of Specialty Professors
FX The Association of Specialty Professors provided funding for the
conceptualization of priority areas for publication, of which this
manuscript is one. The views expressed in this article are those of the
authors and do not necessarily reflect the position or policy of the
Department of Veterans Affairs or the United States government.
NR 49
TC 2
Z9 2
U1 3
U2 11
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2014
VL 29
IS 6
BP 932
EP 939
DI 10.1007/s11606-013-2729-1
PG 8
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AK1VS
UT WOS:000338206600024
PM 24557511
ER
PT J
AU Edwards, ST
Mafi, JN
Landon, BE
AF Edwards, Samuel T.
Mafi, John N.
Landon, Bruce E.
TI Trends and Quality of Care in Outpatient Visits to Generalist and
Specialist Physicians Delivering Primary Care in the United States,
1997-2010
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Article
DE primary health care; primary care physicians; specialization; health
manpower; patient-centered care
ID CENTERED MEDICAL HOME; INTERNAL-MEDICINE; AMBULATORY-CARE; HEALTH;
SERVICES; WORKFORCE; OUTCOMES; SYSTEM; WILL
AB BACKGROUND: Although many specialists serve as primary care physicians (PCPs), the type of patients they serve, the range of services they provide, and the quality of care they deliver is uncertain.
OBJECTIVE: To describe trends in patient, physician, and visit characteristics, and compare visit-based quality for visits to generalists and specialists self-identified as PCPs.
DESIGN: Cross-sectional study and time trend analysis.
DATA: Nationally representative sample of visits to office-based physicians from the National Ambulatory Medical Care Survey, 1997-2010.
MAIN MEASURES: Proportions of primary care visits to generalist and specialists, patient characteristics, principal diagnoses, and quality.
KEY RESULTS: Among 84,041 visits to self-identified PCPs representing an estimated 4.0 billion visits, 91.5 % were to generalists, 5.9 % were to medical specialists and 2.6 % were to obstetrician/gynecologists. The proportion of PCP visits to generalists increased from 88.4 % in 1997 to 92.4 % in 2010, but decreased for medical specialists from 8.0 % to 4.8 %, p=0.04). The proportion of medical specialist visits in which the physician self-identified as the patient's PCP decreased from 30.6 % in 1997 to 9.8 % in 2010 (p<0.01). Medical specialist PCPs take care of older patients (mean age 61 years), and dedicate most of their visits to chronic disease management (51.0 %), while generalist PCPs see younger patients (mean age 55.4 years) most commonly for new problems (40.5 %). Obstetrician/gynecologists self-identified as PCPs see younger patients (mean age 38.3 p<0.01), primarily for preventive care (54.0 %, p<0.01). Quality of care for cardiovascular disease was better in visits to cardiologists than in visits to generalists, but was similar or better in visits to generalists compared to visits to other medical specialists.
CONCLUSIONS: Medical specialists are less frequently serving as PCPs for their patients over time. Generalist, medical specialist, and obstetrician/gynecologist PCPs serve different primary care roles for different populations. Delivery redesign efforts must account for the evolving role of generalist and specialist PCPs in the delivery of primary care.
C1 [Edwards, Samuel T.] Vet Affairs VA Boston Healthcare Syst, Sect Gen Internal Med, Boston, MA USA.
[Edwards, Samuel T.] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Boston, MA USA.
[Edwards, Samuel T.; Mafi, John N.] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Mafi, John N.; Landon, Bruce E.] Beth Israel Deaconess Med Ctr, Div Gen Med & Primary Care, Boston, MA 02215 USA.
[Landon, Bruce E.] Harvard Univ, Dept Hlth Care Policy, Sch Med, Boston, MA 02115 USA.
RP Landon, BE (reprint author), Harvard Univ, Dept Hlth Care Policy, Sch Med, 180 Longwood Ave, Boston, MA 02115 USA.
EM landon@hcp.med.harvard.edu
FU Massachusetts Veteran's Epidemiology Research and Information Center, VA
Boston Healthcare System, Boston, MA; US Health Services and Research
Administration [T32HP12706]; Ryoichi Sasakawa Fellowship Fund
FX Dr. Edwards was supported by the Massachusetts Veteran's Epidemiology
Research and Information Center, VA Boston Healthcare System, Boston,
MA. Dr. Mafi was supported by a National Research Service Award training
grant T32HP12706 from the US Health Services and Research Administration
and by the Ryoichi Sasakawa Fellowship Fund.
NR 32
TC 12
Z9 12
U1 1
U2 6
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2014
VL 29
IS 6
BP 947
EP 955
DI 10.1007/s11606-014-2808-y
PG 9
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AK1VS
UT WOS:000338206600026
PM 24567201
ER
PT J
AU Chiovaro, JC
Gaggar, A
AF Chiovaro, Joseph C.
Gaggar, Anuj
TI Crystalline Bone Marrow in Systemic Oxalosis
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Editorial Material
ID PRIMARY HYPEROXALURIA
C1 [Chiovaro, Joseph C.] Portland VA Med Ctr, Portland, OR USA.
[Chiovaro, Joseph C.] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
[Gaggar, Anuj] Univ Calif San Francisco, San Francisco, CA 94143 USA.
RP Chiovaro, JC (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Dept Med, 3710 Southwest US Vet Hosp Rd, Portland, OR 97239 USA.
EM jchiovaro@gmail.com
NR 3
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2014
VL 29
IS 6
BP 961
EP 961
DI 10.1007/s11606-013-2618-7
PG 1
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AK1VS
UT WOS:000338206600028
PM 24078429
ER
PT J
AU Wakeman, SE
AF Wakeman, Sarah E.
TI One Shot
SO JOURNAL OF GENERAL INTERNAL MEDICINE
LA English
DT Editorial Material
C1 [Wakeman, Sarah E.] Massachusetts Gen Hosp, Div Gen Med, Dept Med, Boston, MA 02114 USA.
[Wakeman, Sarah E.] Harvard Univ, Sch Med, Boston, MA USA.
RP Wakeman, SE (reprint author), Massachusetts Gen Hosp, Div Gen Med, Dept Med, 101 Merrimac St,6th Floor, Boston, MA 02114 USA.
EM swakeman@partners.org
NR 2
TC 0
Z9 0
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0884-8734
EI 1525-1497
J9 J GEN INTERN MED
JI J. Gen. Intern. Med.
PD JUN
PY 2014
VL 29
IS 6
BP 968
EP 969
DI 10.1007/s11606-013-2715-7
PG 2
WC Health Care Sciences & Services; Medicine, General & Internal
SC Health Care Sciences & Services; General & Internal Medicine
GA AK1VS
UT WOS:000338206600032
PM 24366396
ER
PT J
AU Cardo, LF
Coto, E
Ribacoba, R
Mata, IF
Moris, G
Menendez, M
Alvarez, V
AF Cardo, Lucia F.
Coto, Eliecer
Ribacoba, Rene
Mata, Ignacio F.
Moris, German
Menendez, Manuel
Alvarez, Victoria
TI The screening of the 3 ' UTR sequence of LRRK2 identified an association
between the rs66737902 polymorphism and Parkinson's disease
SO JOURNAL OF HUMAN GENETICS
LA English
DT Article
DE DNA polymorphisms; genetic risk; LRRK2 gene; microRNAs; Parkinson's
disease
ID MUTATION; VARIANTS; BRAIN; SNCA; GENE
AB Mutations in the leucine-rich repeat kinase 2 gene (LRRK2) are the most common genetic determinants of familial and sporadic Parkinson's disease (PD). Most of the mutational screenings analyzed the exon-coding sequence. Our aim was to determine whether LRRK2 3' untranslated region (UTR) variants were associated with the risk of developing PD in a large cohort of patients (n = 743) and controls (n = 523) from Spain. We identified a total of 12 3'UTR variants (two new). Single-nucleotide polymorphism (SNP) rs66737902 C allele was overrepresented in patients (P = 0.005; odds ratio = 1.47). This SNP was in linkage disequilibrium with the p.R1441G mutation, but the association remained significant among mutation-negative cases. We found a significant lower level of the LRRK2 transcript in the Substantia nigra (SN) of PD postmortem donors (n = 9) who were rs66737902 C carriers (P = 0.01). This SNP was predicted to affect a binding site for miR-138-2-3p. We showed that this microRNA was expressed in all the SN samples. In conclusion, we found a significant association between SNP rs66737902 and the risk of developing PD. This effect on PD risk could be explained by differences in LRRK2 transcript levels between the two alleles.
C1 [Cardo, Lucia F.; Coto, Eliecer; Alvarez, Victoria] Hosp Univ Cent Asturias, Genet Mol Lab Med, Oviedo 33006, Spain.
[Coto, Eliecer] Univ Oviedo, Dept Med, Oviedo, Spain.
[Ribacoba, Rene; Moris, German; Menendez, Manuel] Hosp Univ Cent Asturias & Alvarez Buylla Mieres, Asturias, Spain.
[Mata, Ignacio F.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA.
[Mata, Ignacio F.] Univ Washington, Sch Med, Dept Neurol, Seattle, WA USA.
RP Alvarez, V (reprint author), Hosp Univ Cent Asturias, Genet Mol Lab Med, Oviedo 33006, Spain.
EM victoria.alvarez@sespa.princast.es
FU 'Fundacion Parkinson Asturias'; 'Obra Social Cajastur'; Spanish 'Fondo
de Investigaciones Sanitarias-Fondos FEDER' European Union [FIS
11/0093]; FICYT-Principado de Asturias
FX We thank Dr Claire Troakes and the London Neurodegenerative Diseases
Brain Bank for supplying all post mortem brain samples. We also thank
the 'Fundacion Parkinson Asturias' and 'Obra Social Cajastur' for their
support. This work was supported by grants from the Spanish 'Fondo de
Investigaciones Sanitarias-Fondos FEDER' European Union (FIS 11/0093).
LFC is a predoctoral fellowship from FICYT-Principado de Asturias.
NR 17
TC 2
Z9 2
U1 0
U2 4
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1434-5161
EI 1435-232X
J9 J HUM GENET
JI J. Hum. Genet.
PD JUN
PY 2014
VL 59
IS 6
BP 346
EP 348
DI 10.1038/jhg.2014.26
PG 3
WC Genetics & Heredity
SC Genetics & Heredity
GA AK1PC
UT WOS:000338186000010
PM 24758914
ER
PT J
AU Miyamoto, N
Pham, LDD
Maki, T
Liang, AC
Arai, K
AF Miyamoto, Nobukazu
Pham, Loc-Duyen D.
Maki, Takakuni
Liang, Anna C.
Arai, Ken
TI A radical scavenger edaravone inhibits matrix metalloproteinase-9
upregulation and blood-brain barrier breakdown in a mouse model of
prolonged cerebral hypoperfusion
SO NEUROSCIENCE LETTERS
LA English
DT Article
DE White matter injury; Prolonged cerebral hypoperfusion; Matrix
metalloproteinase-9; Blood-brain barrier; Edaravone
ID GENE KNOCK-OUT; MATRIX-METALLOPROTEINASE; NEUROVASCULAR UNIT;
ENDOTHELIAL-CELLS; FOCAL ISCHEMIA; INJURY; MECHANISMS; STROKE;
OLIGODENDROCYTE; HEALTH
AB Matrix metalloproteinase-9 (MMP-9) plays key roles in the brain pathophysiology, especially in blood-brain barrier (BBB) breakdown. Therefore, inhibiting MMP-9 activity may be a promising therapy for protecting brains in cerebrovascular diseases. Here we show that in a mouse prolonged cerebral hypoperfusion model, a clinically proven radical scavenger edaravone suppressed MMP-9 and reduced BBB damage in cerebral white matter. Prolonged cerebral hypoperfusion was induced by bilateral common carotid artery stenosis in male adult C57BL/6J mice (10 weeks old). After 7 days of cerebral hypoperfusion, white matter region (e.g. corpus callosum) exhibited significant BBB leakage, assessed by IgG staining. Correspondingly, immunostaining and western blotting showed that MMP-9 was upregulated in the white matter. Edaravone treatment (3 mg/kg, i.p. at days 0 and 3) inhibited both BBB leakage and MMP-9 increase. Under the early phase of cerebral hypoperfusion conditions, oligodendrocyte precursor cells (OPCs) mainly contribute to the MMP-9 increase, but our immunostaining data showed that very little OPCs expressed MMP-9 in the edaravone-treated animals at day 7. Therefore, in vitro studies with primary rat OPCs were conducted to examine whether edaravone would directly suppressed MMP-9 expressions in OPCs. OPC cultures were exposed to sub-lethal CoCl2 for 7 days to induce prolonged chemical hypoxic stress. Prolonged chemical hypoxic stress increased MMP-9 expression in OPCs, and radical scavenging with edaravone (10 mu M for 7 days) ameliorated the increase. Taken together, our proof-of-concept study demonstrates that radical scavengers may provide a potential therapeutic approach for white matter injury by suppressing BBB damage. (C) 2014 Elsevier Ireland Ltd. All rights reserved.
C1 Massachusetts Gen Hosp, Dept Radiol, Neuroprotect Res Lab, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
RP Arai, K (reprint author), Neuroprotect Res Lab, MGH East 149-2401, Charlestown, MA 02129 USA.
EM karai@partners.org
FU National Institutes of Health, Research Abroad from the Uehara Memorial
Foundation
FX Supported in part by National Institutes of Health, Research Abroad from
the Uehara Memorial Foundation. We thank Dr. Eng H. Lo for many helpful
discussions.
NR 49
TC 2
Z9 5
U1 0
U2 4
PU ELSEVIER IRELAND LTD
PI CLARE
PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000,
IRELAND
SN 0304-3940
EI 1872-7972
J9 NEUROSCI LETT
JI Neurosci. Lett.
PD JUN
PY 2014
VL 573
BP 40
EP 45
DI 10.1016/j.neulet.2014.05.005
PG 6
WC Neurosciences
SC Neurosciences & Neurology
GA AK4MV
UT WOS:000338399700008
PM 24820542
ER
PT J
AU Nguyen, PL
AF Nguyen, Paul L.
TI The Role of Radical Prostatectomy and Lymph Node Dissection in the
Treatment of Young Men With High-Grade Node-Positive Prostate Cancer:
Less Is More-the Benefits of Surgery Do Not Yet Outweigh Potential Harms
SO ONCOLOGY-NEW YORK
LA English
DT Editorial Material
ID PELVIC LYMPHADENECTOMY
C1 [Nguyen, Paul L.] Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02215 USA.
[Nguyen, Paul L.] Harvard Univ, Sch Med, Boston, MA USA.
RP Nguyen, PL (reprint author), Dana Farber Brigham & Womens Canc Ctr, Dept Radiat Oncol, Boston, MA 02215 USA.
NR 4
TC 0
Z9 0
U1 0
U2 0
PU UBM MEDICA
PI NORWALK
PA 535 CONNECTICUT AVE, STE 300, NORWALK, CT 06854 USA
SN 0890-9091
J9 ONCOLOGY-NY
JI Oncology-NY
PD JUN
PY 2014
VL 28
IS 6
BP 523
EP +
PG 2
WC Oncology
SC Oncology
GA AK0FL
UT WOS:000338088200011
PM 25134329
ER
PT J
AU Joseph, NT
Kamarck, TW
Muldoon, MF
Manuck, SB
AF Joseph, Nataria Tennille
Kamarck, Thomas W.
Muldoon, Matthew F.
Manuck, Stephen B.
TI Daily Marital Interaction Quality and Carotid Artery Intima-Medial
Thickness in Healthy Middle-Aged Adults
SO PSYCHOSOMATIC MEDICINE
LA English
DT Article
DE marital quality; marital interaction; ecological momentary assessment;
intima-media thickness; cardiovascular disease
ID CORONARY-HEART-DISEASE; BLOOD-PRESSURE; CARDIOVASCULAR-DISEASE;
DAILY-LIFE; WOMEN; RISK; ASSOCIATION; STRESS; SAMPLE; PROGRESSION
AB Objective: To examine the association between marital interaction quality during daily life and subclinical cardiovascular disease (CVD). Studies have shown that marital status and quality of marriage are associated with cardiovascular health. However, little is known about the role of marital interaction quality during daily life in contributing to these effects. Methods: The sample consisted of 281 healthy, employed middle-aged adults who were married or living with a partner in a marital-like relationship (mean age = 42.0 years, 88% white, 52% men). Marital interaction quality was assessed using hourly real-time ecological momentary assessments for 4 days, with participants rating their current or recent partner interactions on positive and negative characteristics (e. g., agreeableness and conflict). Carotid artery intima-medial thickness (IMT) was assessed using ultrasound imaging. Results: Adjusting for demographics, positive marital interaction was inversely associated with IMT (b = -0.02, F(1,275) = 9.18, p = .002), and negative marital interaction was positively associated with IMT (b = 0.02 F(1,275) = 10.29, p = .001). These associations were not accounted for by behavioral and biological CVD risk factors and were consistent across age, sex, race, and education. The associations were also independent of marital interaction frequency, nonmarital social interaction quality, and personality factors. Global reports of marital quality, in contrast, were not associated with IMT. Conclusions: Marital quality as measured during real-time interactions between partners was associated with subclinical CVD in healthy middle-aged adults. This study supports the use of real-time social interaction assessment for characterizing links between social relationships and cardiovascular health.
C1 [Joseph, Nataria Tennille] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
[Kamarck, Thomas W.] Univ Pittsburgh, Dept Psychiat & Psychol, Pittsburgh, PA USA.
[Muldoon, Matthew F.] Univ Pittsburgh, Dept Med, Pittsburgh, PA USA.
[Manuck, Stephen B.] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA.
RP Joseph, NT (reprint author), VA Greater Los Angeles Healthcare Syst, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM nataria.joseph@va.gov
FU National Institutes of Health [P01 HL040962, T32 HL007560]; VA Office of
Academic Affiliations' Women's Health Fellowship Program
FX This research was supported by National Institutes of Health Grants P01
HL040962 awarded to Drs. Manuck, Kamarck, and Muldoon and T32 HL007560
(fellowship) awarded to Dr. Joseph. Dr. Joseph is currently supported by
the VA Office of Academic Affiliations' Women's Health Fellowship
Program. The authors have no conflicts of interest to disclose.
NR 49
TC 11
Z9 11
U1 1
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0033-3174
EI 1534-7796
J9 PSYCHOSOM MED
JI Psychosom. Med.
PD JUN
PY 2014
VL 76
IS 5
BP 347
EP 354
DI 10.1097/PSY.0000000000000071
PG 8
WC Psychiatry; Psychology; Psychology, Multidisciplinary
SC Psychiatry; Psychology
GA AK0TQ
UT WOS:000338128800004
PM 24915293
ER
PT J
AU Wallace, ZS
Deshpande, V
Stone, JH
AF Wallace, Zachary S.
Deshpande, Vikram
Stone, John H.
TI Ophthalmic manifestations of IgG4-related disease: Single-center
experience and literature review
SO SEMINARS IN ARTHRITIS AND RHEUMATISM
LA English
DT Review
DE IgG4-related disease; Orbital pseudotumor; Dacryoadenitis; Myositis;
Idiopathic inflammation; Rituximab
ID IDIOPATHIC ORBITAL INFLAMMATION; INFRAORBITAL NERVE ENLARGEMENT;
SYSTEMIC SCLEROSING DISEASE; OCULAR ADNEXA; TEMPORAL BONE; IGG4 DISEASE;
FEATURES; PACHYMENINGITIS; NOMENCLATURE; PSEUDOTUMOR
AB Objectives: IgG4-related disease (IgG4-RD) is an inflammatory disorder responsible for fibrosing, tumefactive lesions that can involve the lacrimal gland as well as the extraocular muscles, orbital soft tissues, sclera, and local nerves. We reviewed IgG4-related ophthalmic disease (IgG4-ROD), including the natural history, pathology, and treatment, based on our center's experience and that reported in the literature.
Methods: We identified 27 patients with orbital manifestations from our IgG4-RD registry; six were excluded because no pathology was available for review. All 21 cases included had histopathologically confirmed diagnoses of IgG4-RD, 11 of which were of the orbital tissue. Other data were obtained by a retrospective medical records review. MEDLINE and PubMed literature searches in English were conducted to identify articles for a literature review on the topic.
Results: Patients with IgG4-ROD were predominantly male (57%) and had an average age at symptom onset of 50 years (range: 21-79 years). The lacrimal gland was the most commonly involved structure (62%). Most patients (71%) had bilateral disease and extra-orbital involvement (71%); these patients also had elevated serum IgG4 concentrations compared to those with unilateral disease and no extra-orbital disease. Ten patients improved following rituximab treatment.
Conclusions: Ophthalmic involvement is a common manifestation of IgG4-RD and can affect nearly every orbital structure. Consideration of IgG4-RD and accurate diagnosis by biopsy have important implications for prognosis and treatment following the distinction of this condition from the Sjogren syndrome (SjS), granulomatosis with polyangiitis (CPA, formerly Wegener's), sarcoidosis, lymphoma, infection, and other disorders. Rituximab holds promise as an effective steroid-sparing agent or therapy for steroid-resistant cases. (C) 2014 Published by Elsevier Inc.
C1 [Wallace, Zachary S.; Stone, John H.] Massachusetts Gen Hosp, Div Allergy Immunol & Rheumatol, Boston, MA 02114 USA.
[Wallace, Zachary S.; Deshpande, Vikram; Stone, John H.] Harvard Univ, Sch Med, Boston, MA USA.
[Wallace, Zachary S.; Stone, John H.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Deshpande, Vikram] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Stone, JH (reprint author), Massachusetts Gen Hosp, Rheumatol Unit Yawkey 2, 55 Fruit St, Boston, MA 02114 USA.
EM jhstone@partners.org
FU Genentech
FX Dr. Stone has received funding from Genentech for an
investigator-initiated study evaluating the use of rituximab in IgG4-RD.
NR 62
TC 33
Z9 36
U1 1
U2 10
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0049-0172
EI 1532-866X
J9 SEMIN ARTHRITIS RHEU
JI Semin. Arthritis Rheum.
PD JUN
PY 2014
VL 43
IS 6
BP 806
EP 817
DI 10.1016/j.semarthrit.2013.11.008
PG 12
WC Rheumatology
SC Rheumatology
GA AK1KK
UT WOS:000338173800015
PM 24513111
ER
PT J
AU Prapruttam, D
Hedgire, SS
Mani, SE
Chandramohan, A
Shyamkumar, NK
Harisinghani, K
AF Prapruttam, Duangkamon
Hedgire, Sandeep S.
Mani, Sunithi Elizabeth
Chandramohan, Anuradha
Shyamkumar, N. K.
Harisinghani, Kukesh
TI Tuberculosis-The Great Mimicker
SO SEMINARS IN ULTRASOUND CT AND MRI
LA English
DT Article
ID CONTRAST-ENHANCED CT; RADIOLOGIC-PATHOLOGICAL CORRELATION; FOCAL SPLENIC
LESIONS; ABDOMINAL LYMPH-NODES; PANCREATIC TUBERCULOSIS; PULMONARY
TUBERCULOSIS; GENITOURINARY TUBERCULOSIS; IMMUNOCOMPETENT PATIENT;
HEPATIC TUBERCULOSIS; ADRENAL TUBERCULOSIS
AB Tuberculosis is 'an immense health problem in the developing world, and it remains a health care challenge in the developed world. It can affect virtually any organ system in the body. Diagnosis of tuberculosis is often difficult. Many patients with tuberculosis present with nonspecific symptoms, negative purified protein derivative skin test result, and negative findings on culture specimens. Cross-sectional imaging with ultrasound, multidetector computed tomography, and magnetic resonance imaging plays an important role in the diagnosis of tuberculosis. Tuberculosis demonstrates a variety of radiologic features depending on the organ involved and can mimic a number of other disease entities. Cross-sectional imaging alone is insufficient in reaching a conclusive diagnosis. Tuberculosis is a great mimicker as its radiologic manifestations can simulate numerous other diseases across the body systems. However, recognition and understanding of the common and uncommon radiologic manifestations of tuberculosis should alert considering tuberculosis in the high-risk population and correct clinical setting to enable appropriate treatment. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Prapruttam, Duangkamon; Hedgire, Sandeep S.; Harisinghani, Kukesh] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Abdominal Imaging & Intervent, Boston, MA 02114 USA.
[Mani, Sunithi Elizabeth; Chandramohan, Anuradha; Shyamkumar, N. K.] Christian Med Coll & Hosp, Dept Radiol, Vellore, Tamil Nadu, India.
RP Hedgire, SS (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Abdominal Imaging & Intervent, 55 Fruit St,White 270, Boston, MA 02114 USA.
EM Hedgire.Sandeep@mgh.harvard.edu
NR 87
TC 6
Z9 6
U1 1
U2 5
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0887-2171
EI 1558-5034
J9 SEMIN ULTRASOUND CT
JI Semin. Ultrasound CT MRI
PD JUN
PY 2014
VL 35
IS 3
BP 195
EP 214
DI 10.1053/j.sult.2014.02.002
PG 20
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AK2RX
UT WOS:000338268300002
PM 24929261
ER
PT J
AU Diyabalanage, HVK
Van de Bittner, GC
Ricq, EL
Hooker, JM
AF Diyabalanage, Himashinie V. K.
Van de Bittner, Genevieve C.
Ricq, Emily L.
Hooker, Jacob M.
TI A Chemical Strategy for the Cell-Based Detection of HDAC Activity
SO ACS CHEMICAL BIOLOGY
LA English
DT Article
ID HISTONE DEACETYLASE INHIBITORS; ACTIVITY-BASED PROBES;
FLUORESCENT-PROBES; CANCER; EPIGENETICS; DISEASE; ACETYLTRANSFERASES;
ACETYLATION; VORINOSTAT; DISORDERS
AB A strategy for activity-based enzyme detection using a novel enamide-based chemical strategy is described. Enzymatic cleavage of an amide bond results in the formation of an aldehyde. The interaction of this aldehyde with proteins increases retention in cells that express the enzyme. Proof of concept for this enamide-based strategy is demonstrated by detecting histone deacetylase (HDAC) activity in He La cells. The modular design of this strategy makes it amenable to in vitro and in vivo detection.
C1 [Diyabalanage, Himashinie V. K.; Van de Bittner, Genevieve C.; Ricq, Emily L.; Hooker, Jacob M.] Harvard Univ, Massachusetts Gen Hosp, Dept Radiol, Sch Med,Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
RP Hooker, JM (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Radiol, Sch Med,Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
EM hooker@nmr.mgh.harvard.edu
FU NIH [2T32CA009502, R01DA030321]
FX This research was supported by the NIH (2T32CA009502 and R01DA030321).
C. Sheridan and M. Granda are acknowledged for technical assistance in
cell culture studies. The authors would like to thank members of the
Hooker and Haggarty laboratories at MGH for helpful discussions.
NR 38
TC 3
Z9 3
U1 4
U2 21
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1554-8929
EI 1554-8937
J9 ACS CHEM BIOL
JI ACS Chem. Biol.
PD JUN
PY 2014
VL 9
IS 6
BP 1257
EP 1262
DI 10.1021/cb500248r
PG 6
WC Biochemistry & Molecular Biology
SC Biochemistry & Molecular Biology
GA AJ7IN
UT WOS:000337870500006
PM 25056147
ER
PT J
AU Gordon, M
Greene, M
Frumento, P
Rolfson, O
Garellick, G
Stark, A
AF Gordon, Max
Greene, Meridith
Frumento, Paolo
Rolfson, Ola
Garellick, Garan
Stark, Andre
TI Age- and health-related quality of life after total hip replacement
Decreasing gains in patients above 70 years of age
SO ACTA ORTHOPAEDICA
LA English
DT Article
ID JOINT ARTHROPLASTY; PROGNOSTIC-FACTORS; KNEE ARTHROPLASTY; CUTPOINTS;
OUTCOMES; VALUES
AB Background - While age is a common confounder, its impact on health-related quality of life (HRQoL) after total hip replacement is uncertain. This could be due to improper statistical modeling of age in previous studies, such as treating age as a linear variable or by using age categories. We hypothesized that there is a non-linear association between age and HRQoL.
Methods - We selected a nationwide cohort from the Swedish Hip Arthroplasty Register of patients operated with total hip replacements due to primary osteoarthritis between 2008 and 2010. For estimating HRQoL, we used the generic health outcome questionnaire EQ-5D of the EuroQol group that consits or 2 parts: the EQ-5D index and the EQ VAS estimates.
Using linear regression, we modeled the EQ-5D index and the EQ VAS against age 1 year after surgery. Instead of using a straight line for age, we applied a method called restricted cubic splines that allows the line to bend in a controlled manner. Confounding was controlled by adjusting for preoperative HRQoL, sex, previous contralateral hip surgery, pain, and Charnley classification.
Results - Complete data on 27,245 patients were available for analysis. Both the EQ-5D index and EQ VAS showed a non-linear relationship with age. They were fairly unaffected by age until the patients were in their late sixties, after which age had a negative effect.
Interpretation - There is a non-linear relationship between age and HRQoL, with improvement decreasing in the elderly.
C1 [Gordon, Max; Greene, Meridith; Rolfson, Ola; Garellick, Garan] Swedish Hip Arthroplasty Register, Gothenburg, Sweden.
[Gordon, Max; Stark, Andre] Karolinska Inst, Danderyd Hosp, Dept Clin Sci, Stockholm, Sweden.
[Greene, Meridith] Massachusetts Gen Hosp, Orthopaed Lab, Boston, MA 02114 USA.
[Frumento, Paolo] Karolinska Inst, Inst Environm Med IMM, Stockholm, Sweden.
[Rolfson, Ola; Garellick, Garan] Univ Gothenburg, Sahlgrenska Acad, Inst Clin Sci, Dept Orthopaed, Gothenburg, Sweden.
RP Gordon, M (reprint author), Swedish Hip Arthroplasty Register, Gothenburg, Sweden.
EM max@gforge.se
RI Gordon, Max/M-4330-2014;
OI Rolfson, Ola/0000-0001-6534-1242; Gordon, Max/0000-0002-8080-5815;
Stark, Andre/0000-0002-8665-2899
NR 33
TC 8
Z9 8
U1 0
U2 4
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 1745-3674
EI 1745-3682
J9 ACTA ORTHOP
JI Acta Orthop.
PD JUN
PY 2014
VL 85
IS 3
BP 244
EP 249
DI 10.3109/17453674.2014.916492
PG 6
WC Orthopedics
SC Orthopedics
GA AJ6ZI
UT WOS:000337845000007
PM 24786908
ER
PT J
AU Goldvasser, D
Hansen, VJ
Noz, ME
Maguire, GQ
Zeleznik, MP
Olivecrona, H
Bragdon, CR
Weidenhielm, L
Malchau, H
AF Goldvasser, Dov
Hansen, Viktor J.
Noz, Marilyn E.
Maguire, Gerald Q., Jr.
Zeleznik, Michael P.
Olivecrona, Henrik
Bragdon, Charles R.
Weidenhielm, Lars
Malchau, Henrik
TI In vivo and ex vivo measurement of polyethylene wear in total hip
arthroplasty
SO ACTA ORTHOPAEDICA
LA English
DT Article
ID CROSS-LINKED POLYETHYLENE; COMPUTED-TOMOGRAPHY; CT; TRIAL
AB Background - Determination of the amount of wear in a polyethylene liner following total hip arthroplasty (THA) is important for both the clinical care of individual patients and the development of new types of liners.
Patients and methods - We measured in vivo wear of the polyethylene liner using computed tomography (CT) (obtained in the course of regular clinical care) and compared it to coordinate-measuring machine (CMM) readings. Also, changes in liner thickness of the same retrieved polyethylene liner were measured using a micrometer, and were compared to CT and CMM measurements. The distance between the centers of the acetabular cup and femoral head component was measured in 3D CT, using a semi-automatic analysis method. CMM readings were performed on each acetabular liner and data were analyzed using 3D computer-aided design software. Micrometer readings compared the thickest and thinnest regions of the liner. We analyzed 10 THA CTs and retrievals that met minimal requirements for CT slice thickness and explanted cup condition.
Results - For the 10 cups, the mean difference between the CT readings and the CMM readings was -0.09 (-0.38 to 0.20) mm. This difference was not statistically significant (p = 0.6). Between CT and micrometer, the mean difference was 0.11 (-0.33 to 0.55) mm. This difference was not statistically significant (p = 0.6).
Interpretation - Our results show that CT imaging is ready to be used as a tool in clinical wear measurement of polyethylene liners used in THA.
C1 [Goldvasser, Dov; Hansen, Viktor J.; Bragdon, Charles R.; Malchau, Henrik] Massachusetts Gen Hosp, Harris Orthopaed Lab, Boston, MA 02114 USA.
[Noz, Marilyn E.] NYU, Dept Radiol, New York, NY USA.
[Maguire, Gerald Q., Jr.] KTH Royal Inst Technol, Sch Informat & Commun Technol, Kista, Sweden.
[Zeleznik, Michael P.] Saya Syst Inc, Salt Lake City, UT USA.
[Goldvasser, Dov; Olivecrona, Henrik; Weidenhielm, Lars] Karolinska Inst, Dept Mol Med & Surg, Sect Orthopaed & Sports Med, Stockholm, Sweden.
RP Goldvasser, D (reprint author), Massachusetts Gen Hosp, Harris Orthopaed Lab, Boston, MA 02114 USA.
EM dov.goldvasser@mgh.harvard.edu
RI Maguire, Gerald/G-4584-2011
OI Maguire, Gerald/0000-0002-6066-746X
FU Harris Orthopaedic Laboratory, Massachusetts General Hospital, Boston MA
USA
FX No competing interests declared. The project was funded by the Harris
Orthopaedic Laboratory, Massachusetts General Hospital, Boston MA USA
NR 15
TC 3
Z9 3
U1 2
U2 11
PU INFORMA HEALTHCARE
PI NEW YORK
PA 52 VANDERBILT AVE, NEW YORK, NY 10017 USA
SN 1745-3674
EI 1745-3682
J9 ACTA ORTHOP
JI Acta Orthop.
PD JUN
PY 2014
VL 85
IS 3
BP 271
EP 275
DI 10.3109/17453674.2014.913225
PG 5
WC Orthopedics
SC Orthopedics
GA AJ6ZI
UT WOS:000337845000011
PM 24758322
ER
PT J
AU Bera, A
Das, F
Ghosh-Choudhury, N
Li, XN
Pal, S
Gorin, Y
Kasinath, BS
Abboud, HE
Choudhury, GG
AF Bera, Amit
Das, Falguni
Ghosh-Choudhury, Nandini
Li, Xiaonan
Pal, Sanjay
Gorin, Yves
Kasinath, Balakuntalam S.
Abboud, Hanna E.
Choudhury, Goutam Ghosh
TI A positive feedback loop involving Erk5 and Akt turns on mesangial cell
proliferation in response to PDGF
SO AMERICAN JOURNAL OF PHYSIOLOGY-CELL PHYSIOLOGY
LA English
DT Article
DE Akt kinase; cell proliferation; MAP kinase; receptor tyrosine kinase;
renal physiology
ID METANEPHRIC MESENCHYMAL CELLS; ACTIVATED PROTEIN-KINASE; INDUCED
DNA-SYNTHESIS; GROWTH-FACTOR; PHOSPHATIDYLINOSITOL 3-KINASE; CYCLIN D1;
TRANSGENIC MICE; EXPRESSION; RECEPTOR; GLOMERULONEPHRITIS
AB Platelet-derived growth factor BB and its receptor (PDGFR beta) play a pivotal role in the development of renal glomerular mesangial cells. Their roles in increased mesangial cell proliferation during mesangioproliferative glomerulonephritis have long been noted, but the operating logic of signaling mechanisms regulating these changes remains poorly understood. We examined the role of a recently identified MAPK, Erk5, in this process. PDGF increased the activating phosphorylation of Erk5 and tyrosine phosphorylation of proteins in a time-dependent manner. A pharmacologic inhibitor of Erk5, XMD8-92, abrogated PDGF-induced DNA synthesis and mesangial cell proliferation. Similarly, expression of dominant negative Erk5 or siRNAs against Erk5 blocked PDGF-stimulated DNA synthesis and proliferation. Inhibition of Erk5 attenuated expression of cyclin D1 mRNA and protein, resulting in suppression of CDK4-mediated phosphorylation of the tumor suppressor protein pRb. Expression of cyclin D1 or CDK4 prevented the dominant negative Erk5-or siErk5 mediated inhibition of DNA synthesis and mesangial cell proliferation induced by PDGF. We have previously shown that phosphatidylinositol 3-kinase (PI3-kinase) contributes to PDGF-induced proliferation of mesangial cells. Inhibition of PI3-kinase blocked PDGF-induced phosphorylation of Erk5. Since PI3-kinase acts through Akt, we determined the role of Erk5 on Akt phosphorylation. XMD8-92, dominant negative Erk5, and siErk5 inhibited phosphorylation of Akt by PDGF. Interestingly, we found inhibition of PDGF-induced Erk5 phosphorylation by a pharmacological inhibitor of Akt kinase and kinase dead Akt in mesangial cells. Thus our data unfold the presence of a positive feedback microcircuit between Erk5 and Akt downstream of PI3-kinase nodal point for PDGF-induced mesangial cell proliferation.
C1 [Ghosh-Choudhury, Nandini; Kasinath, Balakuntalam S.; Abboud, Hanna E.; Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Vet Adm Res Serv, San Antonio, TX USA.
[Ghosh-Choudhury, Nandini] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA.
[Bera, Amit; Das, Falguni; Li, Xiaonan; Pal, Sanjay; Gorin, Yves; Kasinath, Balakuntalam S.; Abboud, Hanna E.; Choudhury, Goutam Ghosh] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
[Choudhury, Goutam Ghosh] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX USA.
RP Choudhury, GG (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.
EM choudhuryg@uthscsa.edu
FU Veterans Affairs Service Merit Review [5I01BX000926]; National Institute
of Diabetes and Digestive and Kidney Diseases [RO1-DK-50190]; National
Institutes of Health and Veterans Affairs Research Service grants;
Cancer Therapy and Research Center at San Antonio; Veterans Affairs
Research Service Merit Review grant; Veterans Affairs Senior Research
Career Scientist Award
FX The results described in this manuscript are the work supported by
Veterans Affairs Service Merit Review Grant 5I01BX000926 and National
Institute of Diabetes and Digestive and Kidney Diseases Grant
RO1-DK-50190 (to G. G. Choudhury). G. G. Choudhury is a recipient of
Veterans Affairs Senior Research Career Scientist Award. B. S. Kasinath,
Y. Gorin, and H. E. Abboud are supported by National Institutes of
Health and Veterans Affairs Research Service grants (B. S. Kasinath and
H. E. Abboud). N. Ghosh-Choudhury is supported by Veterans Affairs
Research Service Merit Review grant and a pilot grant from Cancer
Therapy and Research Center at San Antonio.
NR 45
TC 7
Z9 7
U1 0
U2 4
PU AMER PHYSIOLOGICAL SOC
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0363-6143
EI 1522-1563
J9 AM J PHYSIOL-CELL PH
JI Am. J. Physiol.-Cell Physiol.
PD JUN
PY 2014
VL 306
IS 11
BP C1089
EP C1100
DI 10.1152/ajpcell.00387.2013
PG 12
WC Cell Biology; Physiology
SC Cell Biology; Physiology
GA AJ7SL
UT WOS:000337897300012
PM 24740537
ER
PT J
AU Bateman, BT
Tsen, LC
AF Bateman, Brian T.
Tsen, Lawrence C.
TI Anesthesiologist as Epidemiologist Insights from Registry Studies of
Obstetric Anesthesia-related Complications
SO ANESTHESIOLOGY
LA English
DT Editorial Material
ID DELIVERY
C1 [Bateman, Brian T.] Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
[Bateman, Brian T.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Pharmacoepidemiol & Pharmacoecon,Dept Med, Boston, MA 02115 USA.
[Tsen, Lawrence C.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Anesthesiol Perioperat & Pain Med, Boston, MA 02115 USA.
RP Bateman, BT (reprint author), Massachusetts Gen Hosp, Dept Anesthesia Crit Care & Pain Med, Boston, MA 02114 USA.
EM bbateman@-partners.org
OI Tsen, Lawrence/0000-0002-1964-723X
NR 10
TC 2
Z9 2
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0003-3022
EI 1528-1175
J9 ANESTHESIOLOGY
JI Anesthesiology
PD JUN
PY 2014
VL 120
IS 6
BP 1311
EP 1312
DI 10.1097/ALN.0000000000000252
PG 2
WC Anesthesiology
SC Anesthesiology
GA AJ5UF
UT WOS:000337753900004
PM 24845916
ER
PT J
AU Huang, LW
Lipschutz, JH
AF Huang, Liwei
Lipschutz, Joshua H.
TI Cilia and Polycystic Kidney Disease, Kith and Kin
SO BIRTH DEFECTS RESEARCH PART C-EMBRYO TODAY-REVIEWS
LA English
DT Review
DE polycystic kidney disease; cilia; planar cell polarity; exocyst
ID PLANAR CELL POLARITY; LEFT-RIGHT AXIS; SMOOTH-MUSCLE-CELLS;
INTRAFLAGELLAR TRANSPORT; EPITHELIAL-CELLS; CYSTIC KIDNEY; RENAL CILIA;
INTRACELLULAR CALCIUM; PRIMARY CILIOGENESIS; MEMBRANE-PROTEIN
AB In the past decade, cilia have been found to play important roles in renal cystogenesis. Many genes, such as PKD1 and PKD2 which, when mutated, cause autosomal dominant polycystic kidney disease (ADPKD), have been found to localize to primary cilia. The cilium functions as a sensor to transmit extracellular signals into the cell. Abnormal cilia structure and function are associated with the development of polyscystic kidney disease (PKD). Cilia assembly includes centriole migration to the apical surface of the cell, ciliary vesicle docking and fusion with the cell membrane at the intended site of cilium outgrowth, and microtubule growth from the basal body. This review summarizes the most recent advances in cilia and PKD research, with special emphasis on the mechanisms of cytoplasmic and intraciliary protein transport during ciliogenesis. (C) 2014 Wiley Periodicals, Inc.
C1 Eastern Virginia Med Sch, Dept Med, Norfolk, VA 23501 USA.
Philadelphia Vet Affairs Med Ctr, Dept Med, Philadelphia, PA USA.
Univ Penn, Dept Med, Philadelphia, PA 19104 USA.
RP Huang, LW (reprint author), Lewis Hall Rm 2124,740 W Olney Rd, Norfolk, VA 23501 USA.
EM huangle@evms.edu
FU Veterans Affairs (Merit Award); NIH [DK093625, 5P30 DK047757-18]
FX Supported by a grant from the Veterans Affairs (Merit Award to J.H.L.),
and NIH (DK093625 to L. H., and 5P30 DK047757-18 pilot award to J.H.L.).
NR 96
TC 3
Z9 4
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1542-975X
EI 1542-9768
J9 BIRTH DEFECTS RES C
JI Birth Defects Res. Part C-Embryo Today-Rev.
PD JUN
PY 2014
VL 102
IS 2
BP 174
EP 185
DI 10.1002/bdrc.21066
PG 12
WC Developmental Biology; Reproductive Biology
SC Developmental Biology; Reproductive Biology
GA AJ8PG
UT WOS:000337967700005
PM 24898006
ER
PT J
AU Weingart, SN
Hsieh, C
Lane, S
Cleary, AM
AF Weingart, Saul N.
Hsieh, Candace
Lane, Sharon
Cleary, Angela M.
TI Standardizing Central Venous Catheter Care by Using Observations From
Patients With Cancer
SO CLINICAL JOURNAL OF ONCOLOGY NURSING
LA English
DT Article
DE central venous catheter; central line-associated bloodstream infection;
practice variation; patient and family engagement; quality improvement
ID BLOOD-STREAM INFECTIONS; ONCOLOGY; PREVENTION; GUIDELINES; SOCIETY
AB To understand the vulnerability of patients with cancer to central line-associated bloodstream infections related to tunneled central venous catheters (CVCs), patients were asked to describe their line care at home and in clinic and to characterize their knowledge and experience managing CVCs. Forty-five adult patients with cancer were recruited to participate. Patients were interviewed about the type of line, duration of use, and observations of variations in line care. They also were asked about differences between line care at home and in the clinic, precautions taken when bathing, and their education regarding line care. Demographic information and primary cancer diagnosis were taken from the patients' medical records. Patients with hematologic and gastrointestinal malignancies were heavily represented. The majority had tunneled catheters with subcutaneous implanted ports. Participants identified variations in practice among nurses who cared for them. Although many participants expressed confidence in their knowledge of line care, some were uncertain about what to do if the dressing became loose or wet, or how to recognize an infection. Patients seemed to be astute observers of their own care and offered insights into practice variation. Their observations show that CVC care practices should be standardized, and educational interventions should be created to address patients' knowledge deficits.
C1 [Weingart, Saul N.] Tufts Med Ctr, Boston, MA 02111 USA.
[Hsieh, Candace] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Lane, Sharon; Cleary, Angela M.] Dana Farber Canc Inst, Ctr Patient Safety, Boston, MA 02115 USA.
RP Weingart, SN (reprint author), Tufts Med Ctr, Boston, MA 02111 USA.
EM sweingart@tuftsmedicalcenter.org
NR 14
TC 3
Z9 3
U1 1
U2 8
PU ONCOLOGY NURSING SOC
PI PITTSBURGH
PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA
SN 1092-1095
EI 1538-067X
J9 CLIN J ONCOL NURS
JI Clin. J. Oncol. Nurs.
PD JUN
PY 2014
VL 18
IS 3
BP 321
EP 326
DI 10.1188/14.CJON.321-326
PG 6
WC Oncology; Nursing
SC Oncology; Nursing
GA AJ0HQ
UT WOS:000337331900009
PM 24867112
ER
PT J
AU Boucher, J
Habin, K
Underhill, M
AF Boucher, Jean
Habin, Karleen
Underhill, Meghan
TI Cancer Genetics and Genomics: Essentials for Oncology Nurses
SO CLINICAL JOURNAL OF ONCOLOGY NURSING
LA English
DT Article
DE genetics; genomics; biology of cancer; biotherapy; targeted therapy;
staff development; staff education
ID HEALTH-CARE; DISEASE PREVENTION; RISK-ASSESSMENT; SOCIETY; INTEGRATION;
STATEMENT; BARRIERS
AB Cancer genetics and genomics are rapidly evolving, with new discoveries emerging in genetic mutations, variants, genomic sequencing, risk-reduction methods, and targeted therapies. To educate patients and families, state-of-the-art care requires nurses to understand terminology, scientific and technological advances, and pharmacogenomics. Clinical application of cancer genetics and genomics involves working in interdisciplinary teams to properly identify patient risk through assessing family history, facilitating genetic testing and counseling services, applying risk-reduction methods, and administering and monitoring targeted therapies.
C1 [Boucher, Jean] Univ Massachusetts, Sch Med, Grad Sch Nursing, Worcester, MA 01605 USA.
[Habin, Karleen] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Habin, Karleen] Canc Resource Fdn Inc, Marlborough, MA USA.
[Underhill, Meghan] Dana Farber Canc Inst, Phyllis F Cantor Ctr Res Nursing & Patient Care S, Boston, MA 02115 USA.
RP Boucher, J (reprint author), Univ Massachusetts, Sch Med, Grad Sch Nursing, Worcester, MA 01605 USA.
EM jean.boucher@umassmed.edu
FU NCI NIH HHS [U54 CA156732]
NR 34
TC 0
Z9 0
U1 2
U2 6
PU ONCOLOGY NURSING SOC
PI PITTSBURGH
PA 125 ENTERPRISE DR, PITTSBURGH, PA 15275 USA
SN 1092-1095
EI 1538-067X
J9 CLIN J ONCOL NURS
JI Clin. J. Oncol. Nurs.
PD JUN
PY 2014
VL 18
IS 3
BP 355
EP 359
DI 10.1188/14.CJON.355-359
PG 5
WC Oncology; Nursing
SC Oncology; Nursing
GA AJ0HQ
UT WOS:000337331900014
PM 24867117
ER
PT J
AU Clark, DG
Kapur, P
Geldmacher, DS
Brockington, JC
Harrell, L
DeRamus, TP
Blanton, PD
Lokken, K
Nicholas, AP
Marson, DC
AF Clark, D. G.
Kapur, P.
Geldmacher, D. S.
Brockington, J. C.
Harrell, L.
DeRamus, T. P.
Blanton, P. D.
Lokken, K.
Nicholas, A. P.
Marson, D. C.
TI Latent information in fluency lists predicts functional decline in
persons at risk for Alzheimer disease
SO CORTEX
LA English
DT Article
DE Alzheimer's disease; Cognitive neuropsychology; Dementia; MCI (mild
cognitive impairment); Machine learning; Random forests
ID MILD COGNITIVE IMPAIRMENT; VERBAL FLUENCY; FINANCIAL ABILITIES;
CONVERSION; DEMENTIA; DIAGNOSIS; CAPACITY; INFERIOR; ATROPHY
AB Objective: We constructed random forest classifiers employing either the traditional method of scoring semantic fluency word lists or new methods. These classifiers were then compared in terms of their ability to diagnose Alzheimer disease (AD) or to prognosticate among individuals along the continuum from cognitively normal (CN) through mild cognitive impairment (MCI) to AD.
Method: Semantic fluency lists from 44 cognitively normal elderly individuals, 80 MCI patients, and 41 AD patients were transcribed into electronic text files and scored by four methods: traditional raw scores, clustering and switching scores, "generalized" versions of clustering and switching, and a method based on independent components analysis (ICA). Random forest classifiers based on raw scores were compared to "augmented" classifiers that incorporated newer scoring methods. Outcome variables included AD diagnosis at baseline, MCI conversion, increase in Clinical Dementia Rating-Sum of Boxes (CDR-SOB) score, or decrease in Financial Capacity Instrument (FCI) score. Receiver operating characteristic (ROC) curves were constructed for each classifier and the area under the curve (AUC) was calculated. We compared AUC between raw and augmented classifiers using Delong's test and assessed validity and reliability of the augmented classifier.
Results: Augmented classifiers outperformed classifiers based on raw scores for the outcome measures AD diagnosis (AUC .97 vs .95), MCI conversion (AUC .91 vs .77), CDR-SOB increase (AUC .90 vs .79), and FCI decrease (AUC .89 vs .72). Measures of validity and stability over time support the use of the method.
Conclusion: Latent information in semantic fluency word lists is useful for predicting cognitive and functional decline among elderly individuals at increased risk for developing AD. Modem machine learning methods may incorporate latent information to enhance the diagnostic value of semantic fluency raw scores. These methods could yield information valuable for patient care and clinical trial design with a relatively small investment of time and money. Published by Elsevier Ltd.
C1 [Clark, D. G.; Blanton, P. D.; Lokken, K.; Nicholas, A. P.] Birmingham VA Med Ctr, Birmingham, AL 35233 USA.
[Clark, D. G.; Geldmacher, D. S.; Brockington, J. C.; Harrell, L.; Nicholas, A. P.; Marson, D. C.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL USA.
[Kapur, P.] Georgia Hlth Sci Univ, Dept Biomed Sci, Augusta, GA USA.
[DeRamus, T. P.] Univ Alabama Birmingham, Dept Psychol & Behav Neurosci, Birmingham, AL USA.
RP Clark, DG (reprint author), 1720,7th Ave South,SC 620C, Birmingham, AL 35294 USA.
EM dgclark@uab.edu
FU Department of Veterans Affairs, Veterans Health Administration,
Rehabilitation Research and Development Service [E6553W]; Alzheimer's
Disease Research Center (Marson, PI) [2R01 AG021927, 1P50 AG16582]
FX The research reported here was supported by the Department of Veterans
Affairs, Veterans Health Administration, Rehabilitation Research and
Development Service (E6553W, PI David Clark, Department of Neurology).
In addition, the work was supported by grants 2R01 AG021927 (Marson, PI)
and 1P50 AG16582 (Alzheimer's Disease Research Center) (Marson, PI).
NR 57
TC 3
Z9 3
U1 0
U2 13
PU ELSEVIER MASSON
PI MILANO
PA VIA PALEOCAPA 7, 20121 MILANO, ITALY
SN 0010-9452
EI 1973-8102
J9 CORTEX
JI Cortex
PD JUN
PY 2014
VL 55
SI SI
BP 202
EP 218
DI 10.1016/j.cortex.2013.12.013
PG 17
WC Behavioral Sciences; Neurosciences
SC Behavioral Sciences; Neurosciences & Neurology
GA AJ5ZY
UT WOS:000337770700017
PM 24556551
ER
PT J
AU Everhart, RS
Mitchell, DK
Friedman, D
Kopel, S
Canino, G
Fritz, G
McQuaid, EL
AF Everhart, Robin S.
Mitchell, Daphne Koinis
Friedman, Deborah
Kopel, Sheryl
Canino, Glorisa
Fritz, Gregory
McQuaid, Elizabeth L.
TI Pediatric Asthma Management Within Latino and Non-Latino White Families
SO FAMILIES SYSTEMS & HEALTH
LA English
DT Article
DE pediatric asthma; management; family; balanced integration; ethnic
minority
ID QUALITY-OF-LIFE; MEDICATION ADHERENCE; ETHNIC-DIFFERENCES; PUERTO-RICAN;
SYSTEM SCALE; CHILDREN; MORBIDITY; DISPARITIES; BELIEFS; ACCULTURATION
AB Pediatric asthma disparities exist with Latino children, especially from Island Puerto Rico (PR), experiencing greater asthma prevalence and morbidity than non-Latino White (NLW) children. Families must balance attention to child asthma with other child and family needs, defined as the "balanced integration of asthma." This study examined the impact of culturally related factors on the balanced integration of asthma in NLW and Latino families in Rhode Island (RI) and PR, as well as associations between balanced integration and asthma morbidity. Participants included 601 caregivers and their children with asthma (7-16 years) from NLW and Latino backgrounds in RI and PR. Caregivers and children completed interview-administered assessments and a semistructured interview related to family asthma management. Balanced integration of asthma differed significantly by ethnic group/site (p < .001), with Island PR families having the lowest levels of balanced integration. Higher balanced integration was associated with fewer concerns about asthma medications, higher levels of Spanish proficiency in RI Latino families, lower levels of functional limitation, and no emergency department visits in the last year (all ps < .05). Findings suggest that Latino families may experience more difficulty adjusting to child asthma in the context of other child and family demands. Medication beliefs and language proficiency may begin to explain these differences. Our study suggests the importance of continuing to understand how families balance asthma with other aspects of daily life, as culturally appropriate interventions to improve family adjustment to asthma may serve to reduce child asthma morbidity.
C1 [Everhart, Robin S.] Virginia Commonwealth Univ, Dept Psychol, Richmond, VA 23284 USA.
[Mitchell, Daphne Koinis; Kopel, Sheryl; Fritz, Gregory; McQuaid, Elizabeth L.] Brown Univ, Alpert Med Sch, Bradley Hasbro Childrens Res Ctr, Providence, RI 02912 USA.
[Friedman, Deborah] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Canino, Glorisa] Univ Puerto Rico, Behav Sci Res Inst, San Juan, PR 00936 USA.
RP Everhart, RS (reprint author), Virginia Commonwealth Univ, Dept Psychol, POB 842018, Richmond, VA 23284 USA.
EM reverhart@vcu.edu
FU National Heart, Lung, and Blood Institute [U01 HL072438]
FX This study was funded by a grant from the National Heart, Lung, and
Blood Institute (U01 HL072438) to Gregory G. Fritz and Glorisa Canino,
principal investigators.
NR 32
TC 2
Z9 2
U1 2
U2 3
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 1091-7527
EI 1939-0602
J9 FAM SYST HEALTH
JI Fam. Syst. Health
PD JUN
PY 2014
VL 32
IS 2
BP 167
EP 175
DI 10.1037/fsh0000005
PG 9
WC Health Care Sciences & Services; Family Studies; Public, Environmental &
Occupational Health
SC Health Care Sciences & Services; Family Studies; Public, Environmental &
Occupational Health
GA AJ8HI
UT WOS:000337943600013
PM 24611719
ER
PT J
AU Chen, S
Qin, T
Seidel, J
Ferrari, M
van den Maagden, A
Ayata, C
Eikermann-Haerter, K
AF Chen, S.
Qin, T.
Seidel, J.
Ferrari, M.
van den Maagden, A.
Ayata, C.
Eikermann-Haerter, K.
TI Inhibition of the p2x7 Receptor-Pannexin1 Pore Suppresses Spreading
Depression and Inflammatory Downstream Mechanisms
SO HEADACHE
LA English
DT Meeting Abstract
CT 56th Annual Scientific Meeting of the American-Headache-Society
CY JUN 26-29, 2014
CL Los Angeles, CA
SP Amer Headache Soc
C1 [Chen, S.; Qin, T.; Seidel, J.; Ayata, C.; Eikermann-Haerter, K.] Massachusetts Gen Hosp, Neurovasc Res Lab, Charlestown, MA USA.
[Ferrari, M.; van den Maagden, A.] Leiden Univ, Med Ctr, Dept Neurol, Leiden, Netherlands.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0017-8748
EI 1526-4610
J9 HEADACHE
JI Headache
PD JUN
PY 2014
VL 54
SU 1
SI SI
MA OR3
BP 2
EP 2
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AJ8JX
UT WOS:000337950600004
ER
PT J
AU Yalcin, N
Yu, E
Atalay, Y
Ayata, C
Eikermann-Haerter, K
AF Yalcin, N.
Yu, E.
Atalay, Y.
Ayata, C.
Eikermann-Haerter, K.
TI The Migraine Trigger Caffeine Increases Susceptibility to Spreading
Depolarization
SO HEADACHE
LA English
DT Meeting Abstract
CT 56th Annual Scientific Meeting of the American-Headache-Society
CY JUN 26-29, 2014
CL Los Angeles, CA
SP Amer Headache Soc
C1 [Yalcin, N.; Yu, E.; Atalay, Y.; Ayata, C.; Eikermann-Haerter, K.] Massachusetts Gen Hosp, Charlestown, MA USA.
NR 0
TC 0
Z9 0
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0017-8748
EI 1526-4610
J9 HEADACHE
JI Headache
PD JUN
PY 2014
VL 54
SU 1
SI SI
MA P27
BP 25
EP 25
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AJ8JX
UT WOS:000337950600048
ER
PT J
AU Siebert, U
Arvandi, M
Gothe, RM
Bornschein, B
Eccleston, D
Walters, DL
Rankin, J
De Bruyne, B
Fearon, WF
Pijls, NH
Harper, R
AF Siebert, Uwe
Arvandi, Marjan
Gothe, Raffaella M.
Bornschein, Bernhard
Eccleston, David
Walters, Darren L.
Rankin, James
De Bruyne, Bernard
Fearon, William F.
Pijls, Nico H.
Harper, Richard
TI Improving the Quality of Percutaneous Revascularisation in Patients with
Multivessel Disease in Australia: Cost-Effectiveness, Public Health
Implications, and Budget Impact of FFR-Guided PCI
SO HEART LUNG AND CIRCULATION
LA English
DT Article
DE Coronary artery disease; Flow reserve; Cost-benefit analysis;
Percutaneous coronary intervention (PCI); Multivessel disease
ID FRACTIONAL FLOW RESERVE; CORONARY INTERVENTION; ECONOMIC-EVALUATION;
TASK-FORCE; ANGIOGRAPHY; FAME
AB Purpose Cross Mark The international multicentre FAME Study (n=1,005) demonstrated significant health benefits for patients undergoing multivessel percutaneous coronary intervention (PCI) guided by fractional flow reserve (FFR) measurement compared with angiography guidance alone (ANGIO). We determined the cost-effectiveness and the public health/budget impact for Australia.
Methods We performed a prospective economic evaluation comparing FFR vs. ANGIO in patients with multivessel disease based on original patient-level FAME data. We used Australian utilities (EQ-5D) and costs to calculate quality-adjusted life years (QALYs) and incremental cost-effectiveness adopting the societal perspective. The public health and budget impact from the payer's perspective was based on Australian PCI registries. Uncertainty was explored using deterministic sensitivity analyses and the bootstrap method (n=5,000 samples).
Results The cost-effectiveness analysis showed that FFR was cost-saving and reduces costs by 1,776 AUD per patient during one year. Over a two-year time horizon, the public health impact ranged from 7.8 to 73.9 QALYs gained and the budget impact from 1.8 to 14.5 million AUD total cost savings. Sensitivity analyses demonstrated that FFR was cost-saving over a wide range of assumptions.
Conclusions FFR-guided PCI in patients with multivessel coronary disease substantially reduces cardiac events, improves QALYs and is cost-saving in the Australian health care system.
C1 [Siebert, Uwe; Arvandi, Marjan; Gothe, Raffaella M.; Bornschein, Bernhard] UMIT Univ Hlth Sci, Dept Publ Hlth & Hlth Technol Assessment, Hall In Tirol, Austria.
[Siebert, Uwe] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Ctr Hlth Decis Sci, Boston, MA 02115 USA.
[Siebert, Uwe] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Inst Technol Assessment, Boston, MA USA.
[Siebert, Uwe] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Radiol, Boston, MA USA.
[Eccleston, David] Univ Melbourne, Royal Melbourne Hosp, Melbourne, Vic 3050, Australia.
[Walters, Darren L.] Univ Queensland, Prince Charles Hosp, Brisbane, Qld, Australia.
[Rankin, James] Royal Perth Hosp, Perth, WA 6001, Australia.
[De Bruyne, Bernard] Cardiovasc Ctr Aalst, Aalst, Belgium.
[Fearon, William F.] Stanford Univ, Med Ctr, Cardiovasc Inst, Stanford, CA 94305 USA.
[Pijls, Nico H.] Catharina Hosp, Dept Cardiol, Eindhoven, Netherlands.
[Harper, Richard] Monash Univ, Monash Med Ctr, Monash Heart, Melbourne, Vic 3004, Australia.
RP Siebert, U (reprint author), UMIT, Hall In Tirol, Austria.
EM uwe.siebert@umit.at
FU St. Jude Medical
FX This project was supported in part by an unrestricted research grant
from St. Jude Medical. The authors had complete and independent control
over study design, collection of data, analysis and interpretation of
data, report writing, and publication, regardless of results.
NR 14
TC 4
Z9 4
U1 2
U2 5
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1443-9506
EI 1444-2892
J9 HEART LUNG CIRC
JI Heart Lung Circ.
PD JUN
PY 2014
VL 23
IS 6
BP 527
EP 533
DI 10.1016/j.hlc.2013.12.009
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AJ7EK
UT WOS:000337859800006
PM 24560401
ER
PT J
AU Hodi, FS
AF Hodi, F. Stephen
TI Preface
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Editorial Material
C1 Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Immunooncol, Boston, MA 02215 USA.
RP Hodi, FS (reprint author), Harvard Univ, Sch Med, Dana Farber Canc Inst, Ctr Immunooncol, 450 Brookline Ave, Boston, MA 02215 USA.
EM Stephen_Hodi@dfci.harvard.edu
NR 0
TC 1
Z9 1
U1 0
U2 0
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
EI 1558-1977
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD JUN
PY 2014
VL 28
IS 3
BP XIII
EP XIV
DI 10.1016/j.hoc.2014.04.001
PG 2
WC Oncology; Hematology
SC Oncology; Hematology
GA AJ8UG
UT WOS:000337982700001
PM 24880951
ER
PT J
AU Sullivan, RJ
Fisher, DE
AF Sullivan, Ryan J.
Fisher, David E.
TI Understanding the Biology of Melanoma and Therapeutic Implications
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE BRAF; NRAS; Immunotherapy; Targeted therapy; MITF
ID ACTIVATED PROTEIN-KINASE; RECOMBINANT INTERLEUKIN-2 THERAPY; UNTREATED
METASTATIC MELANOMA; RANDOMIZED PHASE-II; CELL-LINES; CUTANEOUS
MELANOMA; UVEAL MELANOMA; MALIGNANT-MELANOMA; MULTIKINASE INHIBITOR;
IMATINIB MESYLATE
AB From 1976 to 2010, only 2 medications were approved for treating metastatic melanoma. Between 2011 and 2013, 4 agents were approved and other therapies have shown great promise in clinical trials. Fundamental discoveries, such as the identification of oncogenic mutations in most melanomas, the elucidation of the molecular signaling resulting from these mutations, and the revelation that several cell surface molecules serve as regulators of immune activation, have been instrumental in this progress. This article summarizes the molecular pathogenesis of melanoma, describes the current efforts to target oncogene-driven signaling, and presents the rationale for combining immune and molecular targeting.
C1 [Sullivan, Ryan J.] Harvard Univ, Massachusetts Gen Hosp, Ctr Melanoma, Canc Ctr,Med Sch, Boston, MA 02114 USA.
[Fisher, David E.] Harvard Univ, Massachusetts Gen Hosp, Dept Dermatol, Canc Ctr,Med Sch, Boston, MA 02114 USA.
RP Fisher, DE (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Dermatol, Canc Ctr,Med Sch, Bartlett 6,55 Fruit St, Boston, MA 02114 USA.
EM dfisher3@partners.org
FU NCI NIH HHS [R21 CA175907, P01 CA163222, R01 CA150226]; NIAMS NIH HHS
[R01 AR043369, R01 AR045662]
NR 122
TC 8
Z9 8
U1 0
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
EI 1558-1977
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD JUN
PY 2014
VL 28
IS 3
BP 437
EP +
DI 10.1016/j.hoc.2014.02.007
PG 18
WC Oncology; Hematology
SC Oncology; Hematology
GA AJ8UG
UT WOS:000337982700003
PM 24880940
ER
PT J
AU Ott, PA
Fritsch, EF
Wu, CJ
Dranoff, G
AF Ott, Patrick A.
Fritsch, Edward F.
Wu, Catherine J.
Dranoff, Glenn
TI Vaccines and Melanoma
SO HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Melanoma; Vaccine; Immunotherapy; Neoantigen
ID COLONY-STIMULATING FACTOR; REFRACTORY PROSTATE-CANCER; CYTOLYTIC
T-LYMPHOCYTES; EXOME ANALYSIS REVEALS; HLA-DR MOLECULES; PHASE-II TRIAL;
METASTATIC MELANOMA; PEPTIDE VACCINE; CELLULAR IMMUNOTHERAPY; DENDRITIC
CELLS
AB The potential for therapeutic efficacy of a melanoma vaccine has been evident preclinically for many years. In melanoma patients, vaccines have resulted in the induction of immune responses, although clinical benefit has not been clearly documented. The recent achievements with immune-checkpoint blockade have shown that immunotherapy can be a powerful tool in cancer therapy. With increased understanding of tumor immunity, the limitations of previous cancer vaccination approaches have become evident. Rapid progress in technologies that enable better vaccine design raise the expectation that these limitations can be overcome, thus leading to a clinically effective melanoma vaccine in the near future.
C1 [Ott, Patrick A.; Fritsch, Edward F.; Wu, Catherine J.; Dranoff, Glenn] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02215 USA.
[Ott, Patrick A.] Dana Farber Canc Inst, Melanoma Dis Ctr, Boston, MA 02215 USA.
[Ott, Patrick A.] Dana Farber Canc Inst, Ctr Immunooncol, Boston, MA 02215 USA.
[Ott, Patrick A.; Wu, Catherine J.; Dranoff, Glenn] Harvard Univ, Dept Med, Brigham & Womens Hosp, Sch Med, Boston, MA 02215 USA.
[Fritsch, Edward F.] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
[Wu, Catherine J.; Dranoff, Glenn] Dana Farber Canc Inst, Canc Vaccine Ctr, Boston, MA 02215 USA.
RP Ott, PA (reprint author), Harvard Univ, Dana Farber Canc Inst, Melanoma Dis Ctr, Ctr Immunooncol,Med Sch, 450 Brookline Ave, Boston, MA 02215 USA.
EM Patrick_Ott@DFCI.harvard.edu
NR 42
TC 9
Z9 9
U1 1
U2 6
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8588
EI 1558-1977
J9 HEMATOL ONCOL CLIN N
JI Hematol. Oncol. Clin. North Am.
PD JUN
PY 2014
VL 28
IS 3
BP 559
EP +
DI 10.1016/j.hoc.2014.02.008
PG 12
WC Oncology; Hematology
SC Oncology; Hematology
GA AJ8UG
UT WOS:000337982700010
PM 24880947
ER
PT J
AU O'Reilly, M
Federoff, HJ
Fong, YM
Kohn, DB
Patterson, AP
Ahmed, N
Asokan, A
Boye, SE
Crystal, RG
De Oliveira, S
Gargiulo, L
Harper, SQ
Ikeda, Y
Jambou, R
Montgomery, M
Prograis, L
Rosenthal, E
Sterman, DH
Vandenberghe, LH
Zoloth, L
Abedi, M
Adair, J
Adusumilli, PS
Goins, WF
Gray, J
Monahan, P
Popplewell, L
Sena-Esteves, M
Tannous, B
Weber, T
Wierda, W
Gopal-Srivastava, R
McDonald, CL
Rosenblum, D
Corrigan-Curay, J
AF O'Reilly, Marina
Federoff, Howard J.
Fong, Yuman
Kohn, Donald B.
Patterson, Amy P.
Ahmed, Nabil
Asokan, Aravind
Boye, Shannon E.
Crystal, Ronald G.
De Oliveira, Satiro
Gargiulo, Linda
Harper, Scott Q.
Ikeda, Yasuhiro
Jambou, Robert
Montgomery, Maureen
Prograis, Lawrence
Rosenthal, Eugene
Sterman, Daniel H.
Vandenberghe, Luk H.
Zoloth, Laurie
Abedi, Mehrdad
Adair, Jennifer
Adusumilli, Prasad S.
Goins, William F.
Gray, Jhanelle
Monahan, Paul
Popplewell, Leslie
Sena-Esteves, Miguel
Tannous, Bakhos
Weber, Thomas
Wierda, William
Gopal-Srivastava, Rashmi
McDonald, Cheryl L.
Rosenblum, Daniel
Corrigan-Curay, Jacqueline
TI Gene Therapy: Charting a Future Course-Summary of a National Institutes
of Health Workshop, April 12, 2013
SO HUMAN GENE THERAPY
LA English
DT Review
ID LEBER CONGENITAL AMAUROSIS; CHIMERIC ANTIGEN RECEPTOR; HEMATOPOIETIC
STEM/PROGENITOR CELLS; MODIFIED T-CELLS; ADENOASSOCIATED VIRUS;
CANCER-IMMUNOTHERAPY; HEMOPHILIA-B; EFFICACY; SAFETY; EXPRESSION
AB Recently, the gene therapy field has begun to experience clinical successes in a number of different diseases using various approaches and vectors. The workshop Gene Therapy: Charting a Future Course, sponsored by the National Institutes of Health (NIH) Office of Biotechnology Activities, brought together early and mid-career researchers to discuss the key scientific challenges and opportunities, ethical and communication issues, and NIH and foundation resources available to facilitate further clinical advances.
C1 [O'Reilly, Marina; Patterson, Amy P.; Gargiulo, Linda; Jambou, Robert; Montgomery, Maureen; Rosenthal, Eugene; Corrigan-Curay, Jacqueline] Off Director, Off Sci Policy, Bethesda, MD 20892 USA.
[Prograis, Lawrence] NIAID, Bethesda, MD 20892 USA.
[Gopal-Srivastava, Rashmi; Rosenblum, Daniel] Natl Ctr Adv Translat Sci, Bethesda, MD 20892 USA.
[McDonald, Cheryl L.] NHLBI, NIH, Bethesda, MD 20892 USA.
[Federoff, Howard J.] Georgetown Univ, Med Ctr, Washington, DC 20057 USA.
[Fong, Yuman; Popplewell, Leslie] City Hope Natl Med Ctr, Duarte, CA 91010 USA.
[Kohn, Donald B.; De Oliveira, Satiro] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA.
[Ahmed, Nabil] Baylor Coll Med, Ctr Cell & Gene Therapy, Houston, TX 77030 USA.
[Asokan, Aravind; Monahan, Paul] Univ N Carolina, Chapel Hill, NC 27599 USA.
[Boye, Shannon E.] Univ Florida, Gainesville, FL 32605 USA.
[Crystal, Ronald G.] Weill Cornell Med Coll, Dept Med Genet, New York, NY 10065 USA.
[Harper, Scott Q.] Ohio State Univ, Coll Med, Nationwide Childrens Hosp, Res Inst, Columbus, OH 43205 USA.
[Ikeda, Yasuhiro] Mayo Clin, Rochester, MN 55905 USA.
[Sterman, Daniel H.] Univ Penn, Med Ctr, Philadelphia, PA 19104 USA.
[Vandenberghe, Luk H.] Harvard Univ, Sch Med, Schepens Eye Res Inst, Boston, MA 02114 USA.
[Vandenberghe, Luk H.] Harvard Univ, Sch Med, Massachusetts Eye & Ear Infirm, Boston, MA 02114 USA.
[Zoloth, Laurie] Northwestern Univ, Evanston, IL 60208 USA.
[Abedi, Mehrdad] Univ Calif Davis, Ctr Comprehens Canc, Sacramento, CA 95817 USA.
[Adair, Jennifer] Fred Hutchinson Canc Res Ctr, Seattle, WA 98102 USA.
[Adusumilli, Prasad S.] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.
[Goins, William F.] Univ Pittsburgh, Pittsburgh, PA 15219 USA.
[Gray, Jhanelle] H Lee Mofitt Canc Ctr & Res Inst, Tampa, FL 33612 USA.
[Sena-Esteves, Miguel] Univ Massachusetts, Sch Med, Worcester, MA 01605 USA.
[Tannous, Bakhos] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Charlestown, MA 02129 USA.
[Weber, Thomas] Icahn Sch Med Mt Sinai, New York, NY 10029 USA.
[Wierda, William] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
RP Corrigan-Curay, J (reprint author), NIH, Off Biotechnol Act, 6705 Rockledge Dr,Suite 750, Bethesda, MD 20892 USA.
EM corrigaja@od.nih.gov
RI Weber, Thomas/A-2363-2008; De Oliveira, Satiro/D-8860-2014; Kohn,
Donald/N-5085-2016
OI Weber, Thomas/0000-0002-0494-0484; De Oliveira,
Satiro/0000-0002-8181-7316; Kohn, Donald/0000-0003-1840-6087
FU Foundation Fighting Blindness; Massachusetts Eye and Ear Infirmary
(Boston, MA); Genelux; Roche; Asklepios Biopharmaceutical; Baxter
Biologics
FX N.A. has patent applications in the field of T-cell and gene-modified
T-cell therapy for cancer. The Center for Cell and Gene Therapy (CAGT)
has research collaboration with Celgene Inc. to develop CAR-based
therapeutics that is administered by Baylor College of Medicine. L. H.
V. is inventor on gene therapy-related patents that are licensed to
various pharmaceutical and biotechnological companies, holds equity in
GenSight Biologics, consults for Novartis and GenSight Biologics, and
receives funding from the Foundation Fighting Blindness and the
Massachusetts Eye and Ear Infirmary (Boston, MA). He has been employed
by the University of Pennsylvania and the Massachusetts Eye and Ear
Infirmary. Y.F. is a paid advisor for Genelux and consultant to Roche.
H.F. is a founder and advisor to MedGenesis. P.M.'s university receives
or has received funding to support basic science research work in the
author's laboratory from Asklepios Biopharmaceutical and Baxter
Biologics. He has received remuneration for consulting work and for
speaking from Asklepios Biopharmaceutical and Baxter Biologics.
NR 47
TC 8
Z9 8
U1 1
U2 17
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1043-0342
EI 1557-7422
J9 HUM GENE THER
JI Hum. Gene Ther.
PD JUN
PY 2014
VL 25
IS 6
BP 488
EP 497
DI 10.1089/hum.2014.045
PG 10
WC Biotechnology & Applied Microbiology; Genetics & Heredity; Medicine,
Research & Experimental
SC Biotechnology & Applied Microbiology; Genetics & Heredity; Research &
Experimental Medicine
GA AJ8JR
UT WOS:000337949900004
PM 24773122
ER
PT J
AU Bakaeen, FG
Reda, DJ
Gelijns, AC
Cornwell, L
Omer, S
Al Jurdi, R
Kougias, P
Anaya, D
Berger, DH
Huang, GD
AF Bakaeen, Faisal G.
Reda, Domenic J.
Gelijns, Annetine C.
Cornwell, Lorraine
Omer, Shuab
Al Jurdi, Rayan
Kougias, Panos
Anaya, Daniel
Berger, David H.
Huang, Grant D.
TI Department of Veterans Affairs Cooperative Studies Program Network of
Dedicated Enrollment Sites Implications for Surgical Trials
SO JAMA SURGERY
LA English
DT Article
ID PERCUTANEOUS CORONARY INTERVENTION; OUTCOMES RESEARCH-INSTITUTE;
ARTERY-BYPASS SURGERY; RANDOMIZED-TRIAL; VALVE-REPLACEMENT; ON-PUMP;
REPAIR
AB IMPORTANCE Surgical clinical trials have played a critical role in shaping clinical practice, yet their launch and conduct remain challenging. Innovative approaches to carrying out such studies can not only help transform how trials produce definitive evidence but also move the field toward increased participation in trials.
OBJECTIVE To review a recently launched pilot program aimed at enhancing patient enrollment and improving surgical trial operations at individual sites and nationally.
SETTING AND PARTICIPANTS After a solicitation to create a national network focused on making the conduct of clinical trials more efficient, 10 Department of Veterans Affairs (VA) sites were selected. These sites, collectively called the Cooperative Studies Program (CSP) Network of Dedicated Enrollment Sites (NODES), were evaluated with regard to their previous participation in CSP multisite trials, the strength of the local clinical research environment, and presentation of innovative plans to coordinate and enhance the operations of local CSP studies and share best practices with other centers. Node accountability was also emphasized and involved metrics that tracked productivity and efficiency.
RESULTS Building from available CSP experience in a range of clinical trials, including ones involving surgical interventions, NODES provides VA surgeons with resources for facilitating timely study initiation, determining patient availability, and addressing enrollment barriers. Such resources are particularly important for surgical studies, which often face challenges in patient recruitment and retention. In addition, NODES can maintain qualified and trained personnel at sites to support surgeons with limited time to fulfill the numerous administrative and regulatory responsibilities that often fall to the investigators.
CONCLUSIONS AND RELEVANCE The VA's approach to enhancing trial efficiency may reinvigorate interest in surgical trials by offering a redesigned cooperative framework that builds on a core of high-yield sites and could mitigate traditional limitations of surgical trials.
C1 [Bakaeen, Faisal G.; Cornwell, Lorraine; Omer, Shuab; Kougias, Panos; Anaya, Daniel; Berger, David H.] Baylor Coll Med, Michael E DeBakey VA Med Ctr, Dept Surg, Houston, TX 77030 USA.
[Bakaeen, Faisal G.] Texas Heart Inst, Dept Cardiovasc Surg, Houston, TX 77025 USA.
[Reda, Domenic J.; Huang, Grant D.] US Dept Vet Affairs, Cooperat Studies Program Cent Off, Washington, DC USA.
[Gelijns, Annetine C.] Mt Sinai Sch Med, Dept Hlth Evidence & Policy, New York, NY USA.
[Al Jurdi, Rayan] Michael E DeBakey VA Med Ctr, Houston, TX USA.
RP Bakaeen, FG (reprint author), Michael E DeBakey VA Med Ctr, Div Cardiothorac Surg, Mail Stop OCL 112,2002 Holcombe Blvd, Houston, TX 77030 USA.
EM fbakaeen@bcm.edu
FU Department of Veterans Affairs Cooperative Studies Program
FX This work was supported by the Department of Veterans Affairs
Cooperative Studies Program.
NR 25
TC 2
Z9 2
U1 0
U2 0
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6254
EI 2168-6262
J9 JAMA SURG
JI JAMA Surg.
PD JUN
PY 2014
VL 149
IS 6
BP 507
EP 513
DI 10.1001/jamasurg.2013.4150
PG 7
WC Surgery
SC Surgery
GA AJ7WB
UT WOS:000337909900005
PM 24647851
ER
PT J
AU Mavros, MN
Economopoulos, KP
Alexiou, VG
Pawlik, TM
AF Mavros, Michael N.
Economopoulos, Konstantinos P.
Alexiou, Vangelis G.
Pawlik, Timothy M.
TI Treatment and Prognosis for Patients With Intrahepatic
Cholangiocarcinoma Systematic Review and Meta-analysis
SO JAMA SURGERY
LA English
DT Article
ID TRANSCATHETER ARTERIAL CHEMOEMBOLIZATION; OUTCOME FOLLOWING RESECTION;
SINGLE-CENTER EXPERIENCE; LYMPH-NODE METASTASES; B-VIRUS INFECTION;
MASS-FORMING TYPE; CLINICOPATHOLOGICAL FACTORS; LIVER-TRANSPLANTATION;
PREDICTIVE FACTORS; SURGICAL-TREATMENT
AB IMPORTANCE Data on outcomes following surgical management of intrahepatic cholangiocarcinoma (ICC) are limited. The incidence of ICC is increasing and it has a poor prognosis. No consensus has been reached regarding the optimal treatment modalities.
OBJECTIVE To systematically review and synthesize the available evidence regarding treatment and prognosis in patients with ICC. DATA SOURCES The PubMed database was searched for relevant articles published between January 1, 2000, and April 1, 2013.
STUDY SELECTION Only studies assessing predictors of survival or recurrence in patients undergoing curative-intent surgical treatment of ICC were included. Small series, studies reporting on mixed types of cholangiocarcinoma, or exclusively on hepatolithiasis-associated cholangiocarcinoma, and those published in a language other than English, French, German, Italian, or Greek, were excluded. Fifty-seven of 960 articles were analyzed.
DATA EXTRACTION AND SYNTHESIS Data on preoperative, intraoperative, and postoperative variables were extracted by 3 independent reviewers. Multiple studies reporting on the same population were excluded. Data were pooled using a random-effects model.
MAIN OUTCOMES AND MEASURES We hypothesized that preoperative variables and tumor characteristics affect patient survival. The outcomes of the study were overall survival and recurrence-free survival. The hypothesis was formulated before data collection.
RESULTS Fifty-seven studies (4756 patients) were included in the review. Median patient age ranged from 49 to 67 years, and 57% were male. Most patients had a solitary (69%), large (median size, 4.5-8.0 cm) tumor of the mass-forming type (86%). Approximately one-third of the patients had lymph node metastasis (34%) or vascular (38%), perineural (29%), or biliary invasion (29%). Most underwent a major hepatectomy (82%), often accompanied by lymphadenectomy (67%) and sometimes by extrahepatic bile duct resection (23%). Median and 5-year overall survival (OS) generally were approximately 28 months (range, 9-53 months) and 30% (range, 5%-56%), respectively; factors predicting shorter OS included large tumor size, multiple tumors, lymph node metastasis, and vascular invasion. Adjuvant chemotherapy or radiotherapy did not appear to be beneficial. Seven studies (2132 patients) provided data for the meta-analysis. Factors associated with shorter OS included older age (pooled hazard ratio, 1.10; 95% CI, 1.03-1.17), larger tumor size (1.09; 1.02-1.16), presence of multiple tumors (1.70; 1.43-2.02), lymph node metastasis (2.09; 1.80-2.43), vascular invasion (1.87; 1.44-2.42), and poor tumor differentiation (1.41; 1.17-1.71).
CONCLUSIONS AND RELEVANCE The prognosis of ICC is dictated mainly by tumor factors. Future research could focus on the usefulness of adjuvant treatment as well as other multidisciplinary treatment modalities.
C1 [Mavros, Michael N.] Medstar Washington Hosp Ctr, Dept Surg, Washington, DC USA.
[Mavros, Michael N.; Alexiou, Vangelis G.] Alfa Inst Biomed Sci, Dept Surg, Athens, Greece.
[Mavros, Michael N.; Economopoulos, Konstantinos P.] Soc Jr Doctors, Athens, Greece.
[Economopoulos, Konstantinos P.] Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Economopoulos, Konstantinos P.] Harvard Univ, Sch Med, Boston, MA USA.
[Pawlik, Timothy M.] Johns Hopkins Univ, Sch Med, Dept Surg, Div Surg Oncol, Baltimore, MD USA.
RP Pawlik, TM (reprint author), Johns Hopkins Univ, Sch Med, Dept Surg, Div Surg Oncol, Blalock Room 688,600 N Wolfe St, Baltimore, MD 21287 USA.
EM tpawlik1@jhmi.edu
OI Economopoulos, Konstantinos/0000-0003-4856-0405
NR 68
TC 43
Z9 52
U1 0
U2 7
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6254
EI 2168-6262
J9 JAMA SURG
JI JAMA Surg.
PD JUN
PY 2014
VL 149
IS 6
BP 565
EP 574
DI 10.1001/jamasurg.2013.5137
PG 10
WC Surgery
SC Surgery
GA AJ7WB
UT WOS:000337909900017
PM 24718873
ER
PT J
AU Rosenberg, SM
Partridge, AH
AF Rosenberg, Shoshana M.
Partridge, Ann H.
TI Contralateral Prophylactic Mastectomy An Opportunity for Shared Decision
Making
SO JAMA SURGERY
LA English
DT Editorial Material
ID BREAST-CANCER; WOMEN
C1 [Rosenberg, Shoshana M.; Partridge, Ann H.] Dana Farber Canc Inst, Boston, MA 02215 USA.
RP Partridge, AH (reprint author), Dana Farber Canc Inst, 450 Brookline Ave, Boston, MA 02215 USA.
EM ann_partridge@dfci.harvard.edu
FU NCI NIH HHS [R25 CA057711, 5 R25 CA057711]
NR 5
TC 4
Z9 4
U1 0
U2 3
PU AMER MEDICAL ASSOC
PI CHICAGO
PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA
SN 2168-6254
EI 2168-6262
J9 JAMA SURG
JI JAMA Surg.
PD JUN
PY 2014
VL 149
IS 6
BP 589
EP 590
DI 10.1001/jamasurg.2013.5713
PG 3
WC Surgery
SC Surgery
GA AJ7WB
UT WOS:000337909900020
PM 24848646
ER
PT J
AU Han, SC
Castro, F
Lee, LO
Charney, ME
Marx, BP
Brailey, K
Proctor, SP
Vasterling, JJ
AF Han, Sohyun C.
Castro, Frank
Lee, Lewina O.
Charney, Meredith E.
Marx, Brian P.
Brailey, Kevin
Proctor, Susan P.
Vasterling, Jennifer J.
TI Military unit support, postdeployment social support, and PTSD symptoms
among active duty and National Guard soldiers deployed to Iraq
SO JOURNAL OF ANXIETY DISORDERS
LA English
DT Article
DE Social support; Unit support; Posttraumatic stress disorder; Military
personnel; Deployment; Longitudinal
ID POSTTRAUMATIC-STRESS-DISORDER; MENTAL-HEALTH PROBLEMS; RISK-FACTORS;
LIFE EVENTS; RESILIENCE; PERSONNEL; VETERANS; EXPLANATIONS; AFGHANISTAN;
EXPERIENCES
AB Research suggests that military unit support and community postdeployment social support are associated with fewer PTSD symptoms following military deployment. This study extended prior research by examining the associations among predeployment unit support and PTSD symptoms before Iraq deployment as well as unit support, PTSD symptoms, and postdeployment social support after deployment among 835 U.S. Army and 173 National Guard soldiers. Multiple regression analyses indicated that predeployment unit support was not significantly associated with postdeployment PTSD severity in either group of soldiers, whereas higher unit support during deployment was significantly associated with lower postdeployment PTSD severity among active duty soldiers only. Among both groups, higher levels of postdeployment social support were associated with lower levels of postdeployment PTSD symptom severity. These findings suggest that postdeployment social support is a particularly strong buffer against postdeployment PTSD symptoms among both groups of soldiers whereas the effects of unit support may be limited. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Han, Sohyun C.; Castro, Frank; Lee, Lewina O.; Marx, Brian P.; Proctor, Susan P.; Vasterling, Jennifer J.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA.
[Charney, Meredith E.; Brailey, Kevin] VA Boston Healthcare Syst, Boston, MA 02130 USA.
[Lee, Lewina O.; Marx, Brian P.; Brailey, Kevin; Vasterling, Jennifer J.] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Proctor, Susan P.] US Army Res Inst Environm Med, Natick, MA USA.
[Lee, Lewina O.; Proctor, Susan P.] Boston Univ, Sch Publ Hlth, Boston, MA 02118 USA.
RP Vasterling, JJ (reprint author), VA Boston Healthcare Syst 116B 4, 150 South Huntington Ave, Boston, MA 02130 USA.
EM jennifer.vasterling@va.gov
FU NIA NIH HHS [AG032037, AG039343]
NR 31
TC 6
Z9 6
U1 3
U2 18
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-6185
EI 1873-7897
J9 J ANXIETY DISORD
JI J. Anxiety Disord.
PD JUN
PY 2014
VL 28
IS 5
BP 446
EP 453
DI 10.1016/j.janxdis.2014.04.004
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA AJ8WS
UT WOS:000337989400003
PM 24846492
ER
PT J
AU Goetter, EM
Herbert, JD
Forman, EM
Yuen, EK
Thomas, JG
AF Goetter, Elizabeth M.
Herbert, James D.
Forman, Evan M.
Yuen, Erica K.
Thomas, J. Graham
TI An open trial of videoconference-mediated exposure and ritual prevention
for obsessive-compulsive disorder
SO JOURNAL OF ANXIETY DISORDERS
LA English
DT Article
DE Obsessive-compulsive disorder; Exposure and ritual prevention;
Telehealth; Telemental health; Telepsychology; Videoconferencing
ID THERAPY; SCALE
AB The gold-standard treatment for OCD is exposure and ritual prevention (ERP), yet despite its well-established efficacy, only a small percentage of OCD patients have access to this treatment. Remote treatments (e.g., videoconferencing) are becoming increasingly popular avenues for treatment delivery and show promise in increasing patient access to evidence-based mental health care. The current pilot study utilized an open trial to examine the feasibility and preliminary efficacy of videoconference-mediated, twice weekly, ERP for adults (n = 15) with OCD. Results revealed that ERP was associated with significant improvements in OCD symptoms and large within-group effect sizes. Among the 10 individuals who completed a 3-month follow-up assessment, 30% of participants no longer met DSM-IV-TR criteria for OCD and 80% of participants were rated as very much or much improved on the CGI. This study adds to the growing body of literature suggesting that videoconference-based interventions are viable alternatives to face-to-face treatment. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Goetter, Elizabeth M.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Goetter, Elizabeth M.; Herbert, James D.; Forman, Evan M.] Drexel Univ, Philadelphia, PA 19104 USA.
[Yuen, Erica K.] Univ Tampa, Tampa, FL 33606 USA.
[Thomas, J. Graham] Brown Univ, Warren Alpert Med Sch, Providence, RI 02912 USA.
RP Goetter, EM (reprint author), Massachusetts Gen Hosp, Dept Psychiat, One Bowdoin Sq,6th Floor, Boston, MA 02114 USA.
EM egoetter@mgh.harvard.edu
NR 19
TC 5
Z9 5
U1 0
U2 3
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-6185
EI 1873-7897
J9 J ANXIETY DISORD
JI J. Anxiety Disord.
PD JUN
PY 2014
VL 28
IS 5
BP 460
EP 462
DI 10.1016/j.janxdis.2014.05.004
PG 3
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA AJ8WS
UT WOS:000337989400005
PM 24873883
ER
PT J
AU Reardon, AF
Hein, CL
Wolf, EJ
Prince, LB
Ryabchenko, K
Miller, MW
AF Reardon, Annemarie F.
Hein, Christina L.
Wolf, Erika J.
Prince, Lauren B.
Ryabchenko, Karen
Miller, Mark W.
TI Intermittent explosive disorder: Associations with PTSD and other Axis I
disorders in a US military veteran sample
SO JOURNAL OF ANXIETY DISORDERS
LA English
DT Article
DE Posttraumatic stress disorder; Intermittent explosive disorder;
Comorbidity
ID POSTTRAUMATIC-STRESS-DISORDER; COMMON MENTAL-DISORDERS; DSM-IV; COMBAT
VETERANS; CRIME VICTIMS; ANGER; COMORBIDITY; AGGRESSION; PREVALENCE;
PERSONALITY
AB This study examined the prevalence of intermittent explosive disorder (IED) and its associations with trauma exposure, posttraumatic stress disorder (PTSD), and other psychiatric diagnoses in a sample of trauma-exposed veterans (n = 232) with a high prevalence of PTSD. Structural associations between IED and latent dimensions of internalizing and externalizing psychopathology were also modeled to examine the location of IED within this influential structure. Twenty-four percent of the sample met criteria for a lifetime IED diagnosis and those with the diagnosis were more likely to meet criteria for lifetime PTSD than those without (30.3% vs. 14.3% respectively). Furthermore, regression analyses revealed lifetime PTSD severity to be a significant predictor of IED severity after controlling for combat, trauma exposure, and age. Finally, confirmatory factor analysis revealed significant cross-loadings of IED on both the externalizing and distress dimensions of psychopathology, suggesting that the association between IED and other psychiatric disorders may reflect underlying tendencies toward impulsivity and aggression and generalized distress and negative emotionality, respectively. Published by Elsevier Ltd.
C1 [Reardon, Annemarie F.; Hein, Christina L.; Wolf, Erika J.; Prince, Lauren B.; Ryabchenko, Karen; Miller, Mark W.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA.
[Hein, Christina L.; Wolf, Erika J.; Prince, Lauren B.; Ryabchenko, Karen; Miller, Mark W.] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02215 USA.
RP Reardon, AF (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA 02130 USA.
EM annemarie.reardon@va.gov; mark.miller5@va.gov
RI Miller, Mark/G-7322-2011;
OI Miller, Mark/0000-0001-6393-8563; Wolf, Erika/0000-0003-2666-2435
FU CSRD VA [I01 CX000431]; Intramural VA [CDA-2-067-10S]; NIMH NIH HHS [R01
MH079806]
NR 50
TC 2
Z9 2
U1 4
U2 21
PU PERGAMON-ELSEVIER SCIENCE LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND
SN 0887-6185
EI 1873-7897
J9 J ANXIETY DISORD
JI J. Anxiety Disord.
PD JUN
PY 2014
VL 28
IS 5
BP 488
EP 494
DI 10.1016/j.janxdis.2014.05.001
PG 7
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA AJ8WS
UT WOS:000337989400009
PM 24907536
ER
PT J
AU Mitchell, JD
Mahmood, F
Bose, R
Hess, PE
Wong, V
Matyal, R
AF Mitchell, John D.
Mahmood, Feroze
Bose, Ruma
Hess, Philip E.
Wong, Vanessa
Matyal, Robina
TI Novel, Multimodal Approach for Basic Transesophageal Echocardiographic
Teaching
SO JOURNAL OF CARDIOTHORACIC AND VASCULAR ANESTHESIA
LA English
DT Article
DE echocardiography; simulation; education; TEE
ID MEDICAL-EDUCATION; SURGICAL SIMULATION; SKILLS; UTILITY; AUTOMATICITY;
PROFICIENCY; PERFORMANCE; COLONOSCOPY
AB Objectives: Web and simulation technology may help in creating a transesophageal echocardiography (TEE) curriculum. The authors discuss the educational principles applied to developing and implementing a multimodal TEE curriculum.
Design and Setting: The authors modified a pilot course based on principles for effective simulation-based education. Key curricular elements were consistent with principles for effective simulation-based education: (1) clear goals and carefully structured objectives, (2) conveniently accessed, graduated, longitudinal instruction, (3) a protected and optimal learning environment, (4) repetition of concepts and technical skills, (5) progressive expectations for understanding and skill development, (6) introduction of abnormalities after understanding of normal anatomy and probe manipulation is achieved, (7) live learning sessions that are customizable to meet learner needs and individualized proctoring in skill sessions, (8) use of multiple approaches to teaching, (9) regular and relevant feedback, and (10) application of performance and compliance measures.
Participants: Fifty-five learners participated in a curriculum with web-based modules, live teaching, and simulation practice between August 2011 and May 2013.
Conclusion: It is possible to develop and implement an integrated, multimodal TEE curriculum supported by educational theory. The authors will explore the transferability of this approach to intraoperative TEE on live patients. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Mitchell, John D.; Mahmood, Feroze; Bose, Ruma; Hess, Philip E.; Matyal, Robina] Harvard Univ, Sch Med, Boston, MA USA.
[Mitchell, John D.; Mahmood, Feroze; Bose, Ruma; Hess, Philip E.; Wong, Vanessa; Matyal, Robina] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
RP Mitchell, JD (reprint author), Beth Deaconess Med Ctr, Dept Anesthesia Crit Care & Pain Med, 1 Deaconess Rd,CC-470, Boston, MA 02215 USA.
EM jdmitche@bidmc.harvard.edu
RI Mahmood, Feroze/B-1383-2008; Hess, Philip/A-8577-2013
OI Mahmood, Feroze/0000-0002-7071-0476; Hess, Philip/0000-0002-1206-0102
NR 41
TC 2
Z9 2
U1 1
U2 1
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 1053-0770
EI 1532-8422
J9 J CARDIOTHOR VASC AN
JI J. Cardiothorac. Vasc. Anesth.
PD JUN
PY 2014
VL 28
IS 3
BP 800
EP 809
DI 10.1053/j.jvca.2014.01.006
PG 10
WC Anesthesiology; Cardiac & Cardiovascular Systems; Respiratory System;
Peripheral Vascular Disease
SC Anesthesiology; Cardiovascular System & Cardiology; Respiratory System
GA AK0GI
UT WOS:000338090500054
PM 24746594
ER
PT J
AU Imel, ZE
Baldwin, SA
Baer, JS
Hartzler, B
Dunn, C
Rosengren, DB
Atkins, DC
AF Imel, Zac E.
Baldwin, Scott A.
Baer, John S.
Hartzler, Bryan
Dunn, Chris
Rosengren, David B.
Atkins, David C.
TI Evaluating Therapist Adherence in Motivational Interviewing by Comparing
Performance With Standardized and Real Patients
SO JOURNAL OF CONSULTING AND CLINICAL PSYCHOLOGY
LA English
DT Article
DE motivational interviewing; therapist adherence; mixed models;
standardized patients
ID ALLIANCE-OUTCOME CORRELATION; COMPETENCE; CLINICIAN; DEPENDABILITY;
VARIABILITY; ASSESSMENTS; SESSIONS; BEHAVIOR; LARGER; THINK
AB Objective: The goal of measuring therapist adherence is to determine whether a therapist can perform a given treatment. Yet, the evaluation of therapist behaviors in most clinical trials is limited. Typically, randomized trials have few therapists and minimize therapist variability through training and supervision. Furthermore, therapist adherence is confounded with uncontrolled differences in patients across therapists. Consequently, the extent to which adherence measures capture differences in actual therapist adherence versus other sources of variance is unclear. Method: We estimated intra-class correlations (ICCs) for therapist adherence in sessions with real and standardized patients (RPs and SPs), using ratings from a motivational interviewing (MI) dissemination trial (Baer et al., 2009) in which 189 therapists recorded 826 sessions with both patient types. We also examined the correlations of therapist adherence between SP and RP sessions, and the reliability of therapist level adherence scores with generalizability coefficients (GCs). Results: ICCs for therapist adherence were generally large (average ICC for SPs = .44; average ICC for RPs = .40), meaning that a given therapist's adherence scores were quite similar across sessions. Both ICCs and GCs were larger for SP sessions compared to RPs on global measures of MI adherence, such as Empathy and MI Spirit. Correlations between therapist adherence with real and standardized patients were moderate to large on 3 of 5 adherence measures. Conclusion: Differences in therapist-level adherence ratings were substantial, and standardized patients have promise as tools to evaluate therapist behavior.
C1 [Imel, Zac E.] Univ Utah, Dept Educ Psychol, Salt Lake City, UT 84112 USA.
[Baldwin, Scott A.] Brigham Young Univ, Dept Psychol, Provo, UT 84602 USA.
[Baer, John S.] Univ Washington, Dept Psychol, Seattle, WA 98195 USA.
[Baer, John S.] VA Puget Sound Healthcare Syst, CESATE, Seattle, WA USA.
[Hartzler, Bryan] Univ Washington, Alcohol Drug Abuse Inst, Seattle, WA 98195 USA.
[Dunn, Chris; Atkins, David C.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Rosengren, David B.] Prevent Res Inst, Lexington, KY USA.
RP Imel, ZE (reprint author), Univ Utah, Dept Educ Psychol, 1705 Campus Ctr Dr,Room 327, Salt Lake City, UT 84112 USA.
EM zac.imel@utah.edu
OI imel, zachary/0000-0001-9645-7184; Atkins, David/0000-0002-5781-9880
FU NIAAA NIH HHS [R01 AA018673, R01/AA018673]; NIDA NIH HHS [R34/DA034860,
R01/DA016360, R34 DA034860, U10 DA013714]
NR 28
TC 13
Z9 13
U1 0
U2 6
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0022-006X
EI 1939-2117
J9 J CONSULT CLIN PSYCH
JI J. Consult. Clin. Psychol.
PD JUN
PY 2014
VL 82
IS 3
BP 472
EP 481
DI 10.1037/a0036158
PG 10
WC Psychology, Clinical
SC Psychology
GA AJ7SF
UT WOS:000337896700009
PM 24588405
ER
PT J
AU Naeser, MA
Zafonte, R
Krengel, MH
Martin, PI
Frazier, J
Hamblin, MR
Knight, JA
Meehan, WP
Baker, EH
AF Naeser, Margaret A.
Zafonte, Ross
Krengel, Maxine H.
Martin, Paula I.
Frazier, Judith
Hamblin, Michael R.
Knight, Jeffrey A.
Meehan, William P., III
Baker, Errol H.
TI Significant Improvements in Cognitive Performance Post-Transcranial,
Red/Near-Infrared Light-Emitting Diode Treatments in Chronic, Mild
Traumatic Brain Injury: Open-Protocol Study
SO JOURNAL OF NEUROTRAUMA
LA English
DT Article
DE executive function; mTBI; photobiomodulation; treatment for mTBI
ID LEVEL LASER THERAPY; CYTOCHROME-C-OXIDASE; CEREBRAL-BLOOD-FLOW;
CLOSED-HEAD-INJURY; WORKING-MEMORY; NEUROLOGICAL DEFICITS; FUNCTIONAL
MRI; FOLLOW-UP; TBI; DYSFUNCTION
AB This pilot, open-protocol study examined whether scalp application of red and near-infrared (NIR) light-emitting diodes (LED) could improve cognition in patients with chronic, mild traumatic brain injury (mTBI). Application of red/NIR light improves mitochondrial function (especially in hypoxic/compromised cells) promoting increased adenosine triphosphate (ATP) important for cellular metabolism. Nitric oxide is released locally, increasing regional cerebral blood flow. LED therapy is noninvasive, painless, and non-thermal (cleared by the United States Food and Drug Administration [FDA], an insignificant risk device). Eleven chronic, mTBI participants (26-62 years of age, 6 males) with nonpenetrating brain injury and persistent cognitive dysfunction were treated for 18 outpatient sessions (Monday, Wednesday, Friday, for 6 weeks), starting at 10 months to 8 years post-mTBI (motor vehicle accident [MVA] or sports-related; and one participant, improvised explosive device [IED] blast injury). Four had a history of multiple concussions. Each LED cluster head (5.35 cm diameter, 500mW, 22.2 mW/cm(2)) was applied for 10 min to each of 11 scalp placements (13 J/cm(2)). LEDs were placed on the midline from front-to-back hairline; and bilaterally on frontal, parietal, and temporal areas. Neuropsychological testing was performed pre-LED, and at 1 week, and 1 and 2 months after the 18th treatment. A significant linear trend was observed for the effect of LED treatment over time for the Stroop test for Executive Function, Trial 3 inhibition (p = 0.004); Stroop, Trial 4 inhibition switching (p = 0.003); California Verbal Learning Test (CVLT)-II, Total Trials 1-5 (p = 0.003); and CVLT-II, Long Delay Free Recall (p = 0.006). Participants reported improved sleep, and fewer post-traumatic stress disorder (PTSD) symptoms, if present. Participants and family reported better ability to perform social, interpersonal, and occupational functions. These open-protocol data suggest that placebo-controlled studies are warranted.
C1 [Naeser, Margaret A.; Krengel, Maxine H.; Martin, Paula I.; Baker, Errol H.] VA Boston Healthcare Syst, Boston, MA USA.
[Naeser, Margaret A.; Krengel, Maxine H.; Martin, Paula I.] Boston Univ, Sch Med, Dept Neurol, Boston, MA 02118 USA.
[Zafonte, Ross; Frazier, Judith] Spaulding Rehabil Hosp, Dept Phys Med & Rehabil, Charlestown, MA USA.
[Zafonte, Ross] Harvard Univ, Sch Med, Dept Phys Med & Rehabil,Brigham & Womens Hosp, Massachusetts Gen Hosp,Red Sox MGH Home Base Prog, Boston, MA USA.
[Hamblin, Michael R.] Harvard Univ, Sch Med, Wellman Ctr Photomed,Massachusetts Gen Hosp, Harvard Mit Div Hlth Sci & Technol,Dept Dermatol, Cambridge, MA 02138 USA.
[Knight, Jeffrey A.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA.
[Meehan, William P., III] Micheli Ctr Sports Injury Prevent, Waltham, MA USA.
[Meehan, William P., III] Harvard Univ, Sch Med, Boston Childrens Hosp, Sports Concuss Clin, Boston, MA USA.
RP Naeser, MA (reprint author), VA Boston Healthcare Syst 12A, 150 So Huntington Ave, Boston, MA 02130 USA.
EM mnaeser@bu.edu
OI Hamblin, Michael/0000-0001-6431-4605
FU Clinical Sciences Research and Development, Department of Veterans
Affairs; United States National Institutes of Health (NIH)
[R01AI050875]; American Medical Society for Sports Medicine (AMSSM)
Young Investigator Award; American College of Sports Medicine-American
Medical Society for Sports Medicine Foundation Award
FX M. Naeser was supported by the Clinical Sciences Research and
Development, Department of Veterans Affairs. M. R. Hamblin was supported
by United States National Institutes of Health (NIH) grant R01AI050875.
W. P. Meehan was supported by an American Medical Society for Sports
Medicine (AMSSM) Young Investigator Award and an American College of
Sports Medicine-American Medical Society for Sports Medicine Foundation
Award. The authors thank Laura Burns for assistance with participant
enrollment, Iris Monge for the LED treatments, Anita Saltmarche for
assistance with acquisition of the LED units and LED methodology, and
Michael D. Ho for assistance with manuscript preparation.
NR 72
TC 26
Z9 26
U1 9
U2 29
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
EI 1557-9042
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JUN 1
PY 2014
VL 31
IS 11
BP 1008
EP 1017
DI 10.1089/neu.2013.3244
PG 10
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA AJ7RS
UT WOS:000337895300003
PM 24568233
ER
PT J
AU Watts, LT
Long, JA
Chemello, J
Van Koughnet, S
Fernandez, A
Huang, SL
Shen, Q
Duong, TQ
AF Watts, Lora Talley
Long, Justin Alexander
Chemello, Jonathan
Van Koughnet, Samantha
Fernandez, Angelica
Huang, Shiliang
Shen, Qiang
Duong, Timothy Q.
TI Methylene Blue Is Neuroprotective against Mild Traumatic Brain Injury
SO JOURNAL OF NEUROTRAUMA
LA English
DT Article
DE antioxidant; mitochondria; MRI; oxidative stress; vasogenic edema
ID SPINAL-CORD-INJURY; CYCLOSPORINE-A; NEURONAL DEGENERATION;
OXYGEN-CONSUMPTION; CEREBRAL-ISCHEMIA; REACTIVE GLIOSIS; FLUORO-JADE;
MECHANISMS; GENERATION; PERFUSION
AB Traumatic brain injury (TBI) is a leading cause of death and disability worldwide. Methylene blue (MB) has known energy-enhancing and antioxidant properties. This study tested the hypothesis that MB treatment reduces lesion volume and behavioral deficits in a rat model of mild TBI. In a randomized double-blinded design, animals received either MB (n = 5) or vehicle (n = 6) after TBI. Studies were performed on 0, 1, 2, 7, and 14 days following an impact to the primary forelimb somatosensory cortex. MRI lesion was not apparent 1 h after TBI, became apparent 3 h after TBI, and peaked at 2 days for both groups. The MB-treated animals showed significantly smaller MRI lesion volume than the vehicle-treated animals at all time points studied. The MB-treated animals exhibited significantly improved scores on forelimb placement asymmetry and foot fault tests than did the vehicle-treated animals at all time points studied. Smaller numbers of dark-stained Nissl cells and Fluoro-Jade (R) positive cells were observed in the MB-treated group than in vehicle-treated animals 14 days post-TBI. In conclusion, MB treatment minimized lesion volume, behavioral deficits, and neuronal degeneration following mild TBI. MB is already approved by the United States Food and Drug Administration (FDA) to treat a number of indications, likely expediting future clinical trials in TBI.
C1 [Watts, Lora Talley; Long, Justin Alexander; Chemello, Jonathan; Van Koughnet, Samantha; Fernandez, Angelica; Huang, Shiliang; Shen, Qiang; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
[Watts, Lora Talley] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular & Struct Biol, San Antonio, TX 78229 USA.
[Watts, Lora Talley; Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Duong, Timothy Q.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Duong, TQ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, 8403 Floyd Curl Dr, San Antonio, TX 78229 USA.
EM wattsl@uthscsa.edu; duongt@uthscsa.edu
NR 45
TC 14
Z9 15
U1 4
U2 10
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0897-7151
EI 1557-9042
J9 J NEUROTRAUM
JI J. Neurotrauma
PD JUN 1
PY 2014
VL 31
IS 11
BP 1063
EP 1071
DI 10.1089/neu.2013.3193
PG 9
WC Critical Care Medicine; Clinical Neurology; Neurosciences
SC General & Internal Medicine; Neurosciences & Neurology
GA AJ7RS
UT WOS:000337895300009
ER
PT J
AU von Mehren, M
Randall, RL
Benjamin, RS
Boles, S
Bui, MM
Casper, ES
Conrad, EU
DeLaney, TF
Ganjoo, KN
George, S
Gonzalez, RJ
Heslin, MJ
Kane, JM
Mayerson, J
McGarry, SV
Meyer, C
O'Donnell, RJ
Pappo, AS
Paz, IB
Pfeifer, JD
Riedel, RF
Schuetze, S
Schupak, KD
Schwartz, HS
Van Tine, BA
Wayne, JD
Bergman, MA
Sundar, H
AF von Mehren, Margaret
Randall, R. Lor
Benjamin, Robert S.
Boles, Sarah
Bui, Marilyn M.
Casper, Ephraim S.
Conrad, Ernest U., III
DeLaney, Thomas F.
Ganjoo, Kristen N.
George, Suzanne
Gonzalez, Ricardo J.
Heslin, Martin J.
Kane, John M., III
Mayerson, Joel
McGarry, Sean V.
Meyer, Christian
O'Donnell, Richard J.
Pappo, Alberto S.
Paz, I. Benjamin
Pfeifer, John D.
Riedel, Richard F.
Schuetze, Scott
Schupak, Karen D.
Schwartz, Herbert S.
Van Tine, Brian A.
Wayne, Jeffrey D.
Bergman, Mary Anne
Sundar, Hema
TI Gastrointestinal Stromal Tumors, Version 2.2014
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID FRENCH SARCOMA GROUP; IMATINIB MESYLATE; PHASE-III;
SUCCINATE-DEHYDROGENASE; FUNCTION MUTATIONS; KINASE INHIBITOR; TYROSINE
KINASE; KIT MUTATIONS; DOSE IMATINIB; SUNITINIB
AB Gastrointestinal stromal tumors (GIST) are the most common soft tissue sarcoma of the gastrointestinal tract, resulting most commonly from KIT or platelet-derived growth factor receptor a (PDGFR alpha)-activating mutations. These NCCN Guideline Insights highlight the important updates to the NCCN Guidelines for Soft Tissue Sarcoma specific to the management of patients with GIST experiencing disease progression while on imatinib and/or sunitinib.
C1 [von Mehren, Margaret] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Randall, R. Lor] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
[Benjamin, Robert S.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
[Boles, Sarah] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
[Bui, Marilyn M.; Gonzalez, Ricardo J.] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Casper, Ephraim S.; Schupak, Karen D.] Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Conrad, Ernest U., III] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA USA.
[DeLaney, Thomas F.] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Ganjoo, Kristen N.] Stanford Canc Inst, Stanford, CA USA.
[George, Suzanne] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
[Heslin, Martin J.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA.
[Kane, John M., III] Roswell Pk Canc Inst, Buffalo, NY USA.
[Mayerson, Joel] Ohio State Univ, James Canc Hosp, Ctr Comprehens Canc, Columbus, OH 43210 USA.
[Mayerson, Joel] Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA.
[McGarry, Sean V.] Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE USA.
[Meyer, Christian] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
[O'Donnell, Richard J.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
[Pappo, Alberto S.] Univ Tennessee, St Jude Childrens Res Hosp, Hlth Sci Ctr, Knoxville, TN 37996 USA.
[Paz, I. Benjamin] City Hope Comprehens Canc Ctr, Duarte, CA USA.
[Pfeifer, John D.; Van Tine, Brian A.] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA.
[Pfeifer, John D.; Van Tine, Brian A.] Washington Univ, Sch Med, St Louis, MO 63130 USA.
[Riedel, Richard F.] Duke Canc Inst, Durham, NC USA.
[Schuetze, Scott] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Schwartz, Herbert S.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Wayne, Jeffrey D.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
RP von Mehren, M (reprint author), Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
FU Prometheus Laboratories, Inc.; Bayer HealthCare; Onyx Pharmaceuticals,
Inc.; Algeta US; Exelixis, Inc.; Genentech; Genomic Health, Inc.;
NOVOCURE; Merck Sharp Dohme Corp.
FX Supported by an independent educational grant from Prometheus
Laboratories, Inc., and by educational grants from Bayer HealthCare,
Onyx Pharmaceuticals, Inc., and Algeta US; Exelixis, Inc.; Genentech;
Genomic Health, Inc.; NOVOCURE; and Merck Sharp & Dohme Corp.
NR 50
TC 27
Z9 27
U1 1
U2 8
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
EI 1540-1413
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD JUN
PY 2014
VL 12
IS 6
BP 853
EP 862
PG 10
WC Oncology
SC Oncology
GA AJ5GF
UT WOS:000337710000003
PM 24925196
ER
PT J
AU Bichakjian, CK
Olencki, T
Alam, M
Andersen, JS
Berg, D
Bowen, GM
Cheney, RT
Daniels, GA
Glass, LF
Grekin, RC
Grossman, K
Ho, AL
Lewis, KD
Lydiatt, DD
Morrison, WH
Nehal, KS
Nelson, KC
Nghiem, P
Perlis, CS
Shaha, AR
Thorstad, WL
Tuli, M
Urist, MM
Wang, TS
Werchniak, AE
Wong, SL
Zic, JA
McMillian, N
Hoffman, K
Ho, M
AF Bichakjian, Christopher K.
Olencki, Thomas
Alam, Murad
Andersen, James S.
Berg, Daniel
Bowen, Glen M.
Cheney, Richard T.
Daniels, Gregory A
Glass, L. Frank
Grekin, Roy C.
Grossman, Kenneth
Ho, Alan L.
Lewis, Karl D
Lydiatt, Daniel D.
Morrison, William H.
Nehal, Kishwer S.
Nelson, Kelly C.
Nghiem, Paul
Perlis, Clifford S.
Shaha, Ashok R
Thorstad, Wade L
Tuli, Malika
Urist, Marshall M.
Wang, Timothy S.
Werchniak, Andrew E.
Wong, Sandra L.
Zic, John A.
McMillian, Nicole
Hoffman, Karin
Ho, Maria
TI Dermatofibrosarcoma Protuberans, Version 1.2014
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID GROWTH-FACTOR-B; IMATINIB MESYLATE; DIFFERENTIAL-DIAGNOSIS; USEFUL
MARKER; FACTOR-XIIIA; CD34; EXPRESSION; TISSUE; TUMOR
AB Dermatofibrosarcoma protuberans (DFSP) is an uncommon soft tissue tumor characterized by a relatively high risk of local recurrence and low risk of metastasis. The NCCN Guidelines for DFSP provide multidisciplinary recommendations on the management of patients with this rare disease. These NCCN Guidelines Insights highlight the addition of the Principles of Pathology section, which provides recommendations on the pathologic assessment of DFSP. Because DFSP can mimic other lesions, immunohistochemical studies are often required to establish diagnosis. Cytogenetic testing for the characteristic translocation t(17;22)(q22;q13) can also be valuable in the differential diagnosis of DF5P with other histologically similar tumors.
C1 [Bichakjian, Christopher K.; Wong, Sandra L.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Olencki, Thomas] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA.
[Olencki, Thomas] Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA.
[Alam, Murad] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
[Andersen, James S.] City Hope Comprehens Canc Ctr, Duarte, CA USA.
[Berg, Daniel] Univ Washington, Seattle Canc Care Alliance, Seattle, WA 98195 USA.
[Bowen, Glen M.; Grossman, Kenneth] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
[Cheney, Richard T.] Roswell Pk Canc Inst, Buffalo, NY USA.
[Daniels, Gregory A] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
[Glass, L. Frank] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Grekin, Roy C.] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
[Ho, Alan L.; Nehal, Kishwer S.; Shaha, Ashok R] Mem Sloan Kettering Canc Ctr, New York, NY USA.
[Lewis, Karl D] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA.
[Lydiatt, Daniel D.] Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE USA.
[Morrison, William H.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
[Nelson, Kelly C.] Duke Canc Inst, Durham, NC USA.
[Perlis, Clifford S.] Fox Chase Canc Ctr, Philadelphia, PA USA.
[Thorstad, Wade L] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA.
[Thorstad, Wade L] Washington Univ, Sch Med, St Louis, MO 63130 USA.
[Tuli, Malika] Univ Tennessee, St Jude Childrens Res Hosp, Hlth Sci Ctr, Knoxville, TN 37996 USA.
[Urist, Marshall M.] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA.
[Wang, Timothy S.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
[Werchniak, Andrew E.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
[Zic, John A.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
RP Bichakjian, CK (reprint author), Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
FU Prometheus Laboratories, Inc.; Bayer HealthCare; Onyx Pharmaceuticals,
Inc.; Algeta US; Exelixis, Inc.; Genentech; Genomic Health, Inc.;
NOVOCURE; Merck Sharp Dohme Corp.
FX Supported by an independent educational grant from Prometheus
Laboratories, Inc., and by educational grants from Bayer HealthCare,
Onyx Pharmaceuticals, Inc., and Algeta US; Exelixis, Inc.; Genentech;
Genomic Health, Inc.; NOVOCURE; and Merck Sharp & Dohme Corp.
NR 24
TC 8
Z9 12
U1 0
U2 0
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
EI 1540-1413
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD JUN
PY 2014
VL 12
IS 6
BP 863
EP 868
PG 6
WC Oncology
SC Oncology
GA AJ5GF
UT WOS:000337710000004
PM 24925197
ER
PT J
AU Denlinger, CS
Ligibel, JA
Are, M
Baker, KS
Demark-Wahnefried, W
Friedman, DL
Goldman, M
Friedman, DL
Goldman, M
Jones, L
King, A
Ku, GH
Kvale, E
Langbaum, TS
Leonardi-Warren, K
McCabe, MS
Melisko, M
Montoya, JG
Mooney, K
Morgan, MA
Moslehi, JJ
O'Connor, T
Overholser, L
Paskett, ED
Raza, M
Syrjala, KL
Urba, SG
Wakabayashi, MT
Zee, P
McMillian, N
Freedman-Cass, D
AF Denlinger, Crystal S.
Ligibel, Jennifer A.
Are, Madhuri
Baker, K. Scott
Demark-Wahnefried, Wendy
Friedman, Debra L.
Goldman, Mindy
Friedman, Debra L.
Goldman, Mindy
Jones, Lee
King, Allison
Ku, Grace H.
Kvale, Elizabeth
Langbaum, Terry S.
Leonardi-Warren, Kristin
McCabe, Mary S.
Melisko, Michelle
Montoya, Jose G.
Mooney, Kathi
Morgan, Mary Ann
Moslehi, Javid J.
O'Connor, Tracey
Overholser, Linda
Paskett, Electra D.
Raza, Muhammad
Syrjala, Karen L.
Urba, Susan G.
Wakabayashi, Mark T.
Zee, Phyllis
McMillian, Nicole
Freedman-Cass, Deborah
TI Survivorship: Fatigue, Version 1.2014
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID CANCER-RELATED FATIGUE; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL;
COGNITIVE-BEHAVIOR THERAPY; LONG-TERM SURVIVORS; BREAST-CANCER;
CLINICAL-TRIAL; INSOMNIA; METAANALYSIS; EXERCISE
AB Many cancer survivors report that fatigue is a disruptive symptom even after treatment ends. Persistent cancer-related fatigue affects quality of life, because individuals become too tired to fully participate in the roles and activities that make life meaningful. Identification and management of fatigue remains an unmet need for many cancer survivors. This section of the NCCN Guidelines for Survivorship provides screening, evaluation, and management recommendations for fatigue in survivors. Management includes education and counseling, physical activity, psychosocial interventions, and pharmacologic treatments.
C1 [Denlinger, Crystal S.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Ligibel, Jennifer A.; Moslehi, Javid J.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
[Are, Madhuri] Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE USA.
[Baker, K. Scott; Syrjala, Karen L.] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA USA.
[Demark-Wahnefried, Wendy; Kvale, Elizabeth] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA.
[Friedman, Debra L.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Goldman, Mindy; Melisko, Michelle] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
[Jones, Lee; McCabe, Mary S.] Mem Sloan Kettering Canc Ctr, New York, NY USA.
[King, Allison] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA.
[King, Allison] Washington Univ, Sch Med, St Louis, MO 63130 USA.
[Ku, Grace H.] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
[Langbaum, Terry S.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
[Leonardi-Warren, Kristin; Overholser, Linda] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA.
[Montoya, Jose G.] Stanford Canc Inst, Stanford, CA USA.
[Mooney, Kathi] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
[Morgan, Mary Ann] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[O'Connor, Tracey] Roswell Pk Canc Inst, Buffalo, NY USA.
[Paskett, Electra D.] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA.
[Paskett, Electra D.] Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA.
[Raza, Muhammad] Univ Tennessee, St Jude Childrens Res Hosp, Hlth Sci Ctr, Knoxville, TN 37996 USA.
[Urba, Susan G.] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Wakabayashi, Mark T.] City Hope Comprehens Canc Ctr, Duarte, CA USA.
[Zee, Phyllis] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
[McMillian, Nicole; Freedman-Cass, Deborah] NCCN, Ft Washington, PA USA.
RP Denlinger, CS (reprint author), Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
FU NCI NIH HHS [UM1 CA173642]
NR 58
TC 9
Z9 9
U1 2
U2 8
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
EI 1540-1413
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD JUN
PY 2014
VL 12
IS 6
BP 876
EP 886
PG 11
WC Oncology
SC Oncology
GA AJ5GF
UT WOS:000337710000005
PM 24925198
ER
PT J
AU Zelenetz, AD
Gordon, LI
Wierda, WG
Abramson, JS
Advani, RH
Andreadis, CB
Bartlett, N
Bellam, N
Byrd, JC
Czuczman, MS
Fayad, LE
Fisher, RI
Glenn, MJ
Harris, NL
Hoppe, RT
Horwitz, SM
Kelsey, CR
Kim, YH
Krivacic, S
LaCasce, AS
Nademanee, A
Porcu, P
Press, O
Rabinovitch, R
Reddy, N
Reid, E
Sokol, L
Swinnen, LJ
Tsien, C
Vose, JM
Yahalom, J
Zafar, N
Dwyer, M
Sundar, H
AF Zelenetz, Andrew D.
Gordon, Leo I.
Wierda, William G.
Abramson, Jeremy S.
Advani, Ranjana H.
Andreadis, C. Babis
Bartlett, Nancy
Bellam, Naresh
Byrd, John C.
Czuczman, Myron S.
Fayad, Luis E.
Fisher, Richard I.
Glenn, Martha J.
Harris, Nancy Lee
Hoppe, Richard T.
Horwitz, Steven M.
Kelsey, Christopher R.
Kim, Youn H.
Krivacic, Susan
LaCasce, Ann S.
Nademanee, Auayporn
Porcu, Pierluigi
Press, Oliver
Rabinovitch, Rachel
Reddy, Nishitha
Reid, Erin
Sokol, Lubomir
Swinnen, Lode J.
Tsien, Christina
Vose, Julie M.
Yahalom, Joachim
Zafar, Nadeem
Dwyer, Mary
Sundar, Hema
TI Non-Hodgkin's Lymphomas, Version 2.2014
SO JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK
LA English
DT Article
ID POSITRON-EMISSION-TOMOGRAPHY; PHASE-II TRIAL; TERM-FOLLOW-UP; STAGE
FOLLICULAR LYMPHOMA; B-CELL LYMPHOMA; IBRITUMOMAB TIUXETAN
RADIOIMMUNOTHERAPY; ANTI-CD20 MONOCLONAL-ANTIBODY; RANDOMIZED
CONTROLLED-TRIAL; HIGH-TUMOR BURDEN; TOSITUMOMAB/IODINE I-131
TOSITUMOMAB
AB Non-Hodgkin's lymphomas (NHLs) are a heterogeneous group of lymphoproliferative disorders originating in B lymphocytes, T lymphocytes, or natural killer cells. Follicular lymphoma (FL) is the most common subtype of indolent NHL, accounting for approximately 22% of all newly diagnosed cases of NHL. The incorporation of rituximab to chemotherapy regimens has become a widely accepted standard of care for first-line therapy for patients with FL. Maintenance and consolidation therapy with rituximab and radioimmunotherapy have also been associated with improved progression-free survival in patients experiencing response to first-line therapy. Despite therapeutic advances that have improved outcomes, FL is generally considered a chronic disease characterized by multiple recurrences with current therapies. This manuscript discusses the recommendations outlined in the NCCN Guidelines for the diagnosis and management of patients with FL.
C1 [Zelenetz, Andrew D.; Horwitz, Steven M.; Yahalom, Joachim] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.
[Gordon, Leo I.] Northwestern Univ, Robert H Lurie Comprehens Canc Ctr, Evanston, IL 60208 USA.
[Wierda, William G.; Fayad, Luis E.] Univ Texas MD Anderson Canc Ctr, Houston, TX USA.
[Abramson, Jeremy S.; Harris, Nancy Lee] Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Advani, Ranjana H.; Horwitz, Steven M.; Kim, Youn H.] Stanford Canc Inst, Stanford, CA USA.
[Andreadis, C. Babis] Univ Calif San Francisco, Helen Diller Family Comprehens Canc Ctr, San Francisco, CA 94143 USA.
[Bartlett, Nancy] Barnes Jewish Hosp, Siteman Canc Ctr, St Louis, MO USA.
[Bartlett, Nancy] Washington Univ, Sch Med, St Louis, MO 63130 USA.
[Bellam, Naresh] Univ Alabama Birmingham, Ctr Comprehens Canc, Birmingham, AL USA.
[Byrd, John C.; Porcu, Pierluigi] Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Columbus, OH 43210 USA.
[Byrd, John C.; Porcu, Pierluigi] Ohio State Univ, Solove Res Inst, Columbus, OH 43210 USA.
[Czuczman, Myron S.] Roswell Pk Canc Inst, Buffalo, NY USA.
[Fisher, Richard I.] Fox Chase Canc Ctr, Philadelphia, PA USA.
[Glenn, Martha J.] Univ Utah, Huntsman Canc Inst, Salt Lake City, UT 84112 USA.
[Kelsey, Christopher R.] Duke Canc Inst, Durham, NC USA.
[Krivacic, Susan; LaCasce, Ann S.] Dana Farber Brigham & Womens Canc Ctr, Boston, MA USA.
[Nademanee, Auayporn] City Hope Comprehens Canc Ctr, Duarte, CA USA.
[Press, Oliver] Fred Hutchinson Canc Res Ctr, Seattle Canc Care Alliance, Seattle, WA USA.
[Rabinovitch, Rachel] Univ Colorado, Ctr Canc, Boulder, CO 80309 USA.
[Reddy, Nishitha] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
[Reid, Erin] Univ Calif San Diego, Moores Canc Ctr, La Jolla, CA 92093 USA.
[Sokol, Lubomir] H Lee Moffitt Canc Ctr & Res Inst, Tampa, FL USA.
[Swinnen, Lode J.] Sidney Kimmel Comprehens Canc Ctr Johns Hopkins, Baltimore, MD USA.
[Tsien, Christina] Univ Michigan, Ctr Comprehens Canc, Ann Arbor, MI 48109 USA.
[Vose, Julie M.] Nebraska Med Ctr, Fred & Pamela Buffett Canc Ctr, Omaha, NE USA.
[Zafar, Nadeem] Univ Tennessee, St Jude Childrens Res Hosp, Hlth Sci Ctr, Knoxville, TN 37996 USA.
[Dwyer, Mary; Sundar, Hema] NCCN, Ft Washington, PA USA.
RP Zelenetz, AD (reprint author), Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.
FU NCI NIH HHS [P30 CA016672]
NR 127
TC 19
Z9 22
U1 0
U2 7
PU HARBORSIDE PRESS
PI COLD SPRING HARBOR
PA 37 MAIN ST, COLD SPRING HARBOR, NY 11724 USA
SN 1540-1405
EI 1540-1413
J9 J NATL COMPR CANC NE
JI J. Natl. Compr. Cancer Netw.
PD JUN
PY 2014
VL 12
IS 6
BP 916
EP 945
PG 30
WC Oncology
SC Oncology
GA AJ5GF
UT WOS:000337710000009
PM 24925202
ER
PT J
AU Scheiner, DL
Keilp, J
Mindt, MR
Burke, AK
Oquendo, MA
Mann, JJ
AF Scheiner, Diane L.
Keilp, John
Mindt, Monica Rivera
Burke, Ainsley K.
Oquendo, Maria A.
Mann, J. John
TI Verbal Learning Deficits in Posttraumatic Stress Disorder and Depression
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID PSYCHIATRIC-DISORDERS; HOLOCAUST SURVIVORS; MEMORY PERFORMANCE; SUICIDE
ATTEMPTERS; MAJOR DEPRESSION; COMBAT VETERANS; PTSD; ATTENTION;
COMORBIDITY; DYSFUNCTION
AB Verbal learning and memory deficits are frequently reported in posttraumatic stress disorder (PTSD), but may be a product of its psychiatric comorbidities, especially major depressive disorder (MDD). To evaluate this hypothesis, 25 medication-free patients with PTSD and comorbid MDD were compared to 148 medication-free patients with equally severe MDD alone and to 96 nonpatients on a measure of verbal learning and memory. Additional measures of attention, working memory, and executive function were administered to evaluate their contribution to verbal memory impairment. Patients with comorbid PTSD and MDD demonstrated the greatest deficit in verbal learning compared to both MDD patients and nonpatients (omnibus effect sizes ranged d = 0.41 to 0.50), one that was not accounted for by other cognitive deficits. Findings suggest that a current diagnosis of PTSD makes a contribution to verbal learning deficits beyond the effect of depression alone.
C1 [Scheiner, Diane L.; Mindt, Monica Rivera] Fordham Univ, Dept Psychol, Bronx, NY 10458 USA.
[Keilp, John; Burke, Ainsley K.; Oquendo, Maria A.; Mann, J. John] Columbia Univ, Dept Psychiat, New York, NY USA.
[Keilp, John; Burke, Ainsley K.; Oquendo, Maria A.; Mann, J. John] New York State Psychiat Inst & Hosp, Div Mol Imaging & Neuropathol, New York, NY 10032 USA.
RP Scheiner, DL (reprint author), West Los Angeles Healthcare Ctr, VA Greater Los Angeles Healthcare Syst, Psychol Dept 116B, Bldg 256,Room 204,11301 Wilshire Blvd, Los Angeles, CA 90073 USA.
EM dscheiner@fordham.edu
FU NIMH NIH HHS [MH-62155, 5P50 MH-62185]
NR 55
TC 2
Z9 2
U1 3
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
EI 1573-6598
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD JUN
PY 2014
VL 27
IS 3
BP 291
EP 298
DI 10.1002/jts.21921
PG 8
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA AJ8JM
UT WOS:000337949300006
PM 24850268
ER
PT J
AU Vogt, D
Fox, AB
Di Leone, BAL
AF Vogt, Dawne
Fox, Annie B.
Di Leone, Brooke A. L.
TI Mental Health Beliefs and Their Relationship With Treatment Seeking
Among U.S. OEF/OIF Veterans
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID MILITARY PERSONNEL; PRIMARY-CARE; STIGMA; IRAQ; BARRIERS; SOLDIERS;
AFGHANISTAN; INVENTORY; ATTITUDES; REDUCE
AB Many veterans who would benefit from mental health care do not seek treatment. The current study provided an in-depth examination of mental health-related beliefs and their relationship with mental health and substance abuse service use in a national sample of 640 U.S. Operation Enduring Freedom and Operation Iraqi Freedom (OEF/OIF) veterans. Both concerns about mental health stigma from others and personal beliefs about mental illness and mental health treatment were examined. Data were weighted to adjust for oversampling of women and nonresponse bias. Results revealed substantial variation in the nature of OEF/OIF veterans' mental health beliefs, with greater anticipated stigma in the workplace (M = 23.74) than from loved ones (M = 19.30), and stronger endorsement of negative beliefs related to mental health treatment-seeking (M = 21.78) than either mental illness (M = 18.56) or mental health treatment (M = 20.34). As expected, individuals with probable mental health problems reported more negative mental health-related beliefs than those without these conditions. Scales addressing negative personal beliefs were related to lower likelihood of seeking care (ORs = 0.80-0.93), whereas scales addressing anticipated stigma were not associated with service use. Findings can be applied to address factors that impede treatment seeking.
C1 [Vogt, Dawne; Fox, Annie B.; Di Leone, Brooke A. L.] VA Boston Healthcare Syst, Natl Ctr Posttraumat Stress Disorder, Womens Hlth Sci Div, Boston, MA USA.
[Vogt, Dawne] Boston Univ, Sch Med, Dept Psychiat, Boston, MA 02118 USA.
RP Vogt, D (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD 116B 3, 150 South Huntington Ave, Boston, MA 02130 USA.
EM Dawne.Vogt@va.gov
NR 30
TC 6
Z9 6
U1 0
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
EI 1573-6598
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD JUN
PY 2014
VL 27
IS 3
BP 307
EP 313
DI 10.1002/jts.21919
PG 7
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA AJ8JM
UT WOS:000337949300008
PM 24839077
ER
PT J
AU Price, M
Davidson, TM
Ruggiero, KJ
Acierno, R
Resnick, HS
AF Price, Matthew
Davidson, Tatiana M.
Ruggiero, Kenneth J.
Acierno, Ron
Resnick, Heidi S.
TI Predictors of Using Mental Health Services After Sexual Assault
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID POSTTRAUMATIC-STRESS-DISORDER; NATIONAL COMORBIDITY SURVEY; RAPE
MEDICAL-CARE; SUBSTANCE USE; EARLY INTERVENTION; TREATMENT-SEEKING;
TRAUMATIC INJURY; RECENT VICTIMS; UNITED-STATES; HELP-SEEKING
AB Sexual assault increases the risk for psychopathology. Despite the availability of effective interventions, relatively few victims who need treatment receive care in the months following an assault. Prior work identified several factors associated with utilizing care, including ethnicity, insurance, and posttraumatic stress disorder (PTSD) symptoms. Few studies, however, have examined predictors of treatment utilization prospectively from the time of assault. The present study hypothesized that White racial status, younger age, being partnered, having health insurance, having previously received mental health treatment, and having more PTSD and depression symptoms would predict utilization of care in the 6 months postassault. This was examined in a sample of 266 female sexual assault victims with an average age of 26.2 years, of whom 62.0% were White and 38.0% were African American assessed at 1.5 and 6 months postassault. Available information on utilizing care varied across assessments (1.5 months, n = 214; 3 months, n = 126; 6 months, n = 204). Significant predictors included having previously received mental health treatment (OR = 4.09), 1 day depressive symptoms (OR = 1.06), and having private insurance (OR = 2.24) or Medicaid (OR = 2.19). Alcohol abuse and prior mental health care were associated with a substantial increase in treatment utilization (OR = 4.07). The findings highlight the need to help victims at risk obtain treatment after sexual assault.
C1 [Price, Matthew] Univ Vermont, Dept Psychol, Burlington, VT 05405 USA.
[Davidson, Tatiana M.; Ruggiero, Kenneth J.; Acierno, Ron; Resnick, Heidi S.] Med Univ S Carolina, Natl Crime Victims Ctr, Charleston, SC 29425 USA.
[Ruggiero, Kenneth J.; Acierno, Ron] Ralph H Johnson VA Med Ctr, Charleston, SC USA.
RP Resnick, HS (reprint author), Med Univ S Carolina, Natl Crime Victims Ctr, Natl Crime Victims Res & Treatment Ctr, 67 President St, Charleston, SC 29425 USA.
EM resnickh@musc.edu
FU NIDA NIH HHS [R01DA11158, R01 DA011158, R01 DA023099, R01DA023099]; NIMH
NIH HHS [T32MH018869, T32 MH018869]
NR 54
TC 10
Z9 10
U1 5
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
EI 1573-6598
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD JUN
PY 2014
VL 27
IS 3
BP 331
EP 337
DI 10.1002/jts.21915
PG 7
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA AJ8JM
UT WOS:000337949300011
PM 24852357
ER
PT J
AU Gradus, JL
Bozi, I
Antonsen, S
Svensson, E
Lash, TL
Resick, PA
Hansen, JG
AF Gradus, Jaimie L.
Bozi, Imre
Antonsen, Sussie
Svensson, Elisabeth
Lash, Timothy L.
Resick, Patricia A.
Hansen, Jens Georg
TI Severe Stress and Adjustment Disorder Diagnoses in the Population of
Denmark
SO JOURNAL OF TRAUMATIC STRESS
LA English
DT Article
ID NATIONAL COMORBIDITY SURVEY; DSM-IV DISORDERS; LIFETIME PREVALENCE;
SURVEY REPLICATION; COMPLETED SUICIDE; SEX-DIFFERENCES; ONSET
AB We created a registry of Danish-born citizens of Denmark with incident International Classification of Diseases (10th ed.; ICD-10) severe stress and adjustment disorder diagnoses between 1995 and 2011. A unique personal identifier was used to retrieve and merge data on demographic characteristics and diagnoses (ICD-10 codes F43.x). Here we report on the incidence of these disorders and the demographic characteristics of the subset of the Danish population who have received 1 of these diagnoses: 111,844 adults and children received a first diagnosis between 1995 and 2011. More women than men (60.1% vs. 39.9%) received a diagnosis. Diagnoses increased during the late teens through early 30s. Adjustment disorder was the most common diagnosis (65.7% of adults and 64% of children). Reaction to severe stress unspecified was the second most common (19.8% of adults and 23.8% of children), and there was a large increase in both, as well as acute stress reaction diagnoses, in 2007 (3,717-5,141, 1,248-2,520, and 348-1,024 in 2006 to 2007, respectively). Findings regarding gender and age of onset are similar to other westernized countries. This registry can be used for future research programs, contributing to the study of stress and trauma.
C1 [Gradus, Jaimie L.; Resick, Patricia A.] VA Boston Healthcare Syst, Natl Ctr PTSD, Boston, MA USA.
[Gradus, Jaimie L.; Resick, Patricia A.] Boston Univ, Dept Psychiat, Boston, MA 02215 USA.
[Bozi, Imre; Antonsen, Sussie; Svensson, Elisabeth; Lash, Timothy L.; Hansen, Jens Georg] Aarhus Univ Hosp, Dept Clin Epidemiol, DK-8000 Aarhus, Denmark.
[Lash, Timothy L.] Emory Univ, Dept Epidemiol, Atlanta, GA 30322 USA.
[Resick, Patricia A.] Boston Univ, Dept Psychol, Boston, MA 02215 USA.
RP Gradus, JL (reprint author), 150 S Huntington Ave,116B-3, Boston, MA 02130 USA.
EM Jaimie.gradus@va.gov
OI Gradus, Jaimie/0000-0003-1459-5327; Svensson,
Elisabeth/0000-0001-6706-6336
FU NIMH NIH HHS [1R21MH094551-01A1]
NR 15
TC 7
Z9 7
U1 2
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0894-9867
EI 1573-6598
J9 J TRAUMA STRESS
JI J. Trauma Stress
PD JUN
PY 2014
VL 27
IS 3
BP 370
EP 374
DI 10.1002/jts.21926
PG 5
WC Psychology, Clinical; Psychiatry
SC Psychology; Psychiatry
GA AJ8JM
UT WOS:000337949300017
PM 24948539
ER
PT J
AU Tang, Y
Gellad, WF
Men, A
Donohue, JM
AF Tang, Yan
Gellad, Walid F.
Men, Aiju
Donohue, Julie M.
TI Impact of Medicare Part D Plan Features on Use of Generic Drugs
SO MEDICAL CARE
LA English
DT Article
DE Medicare Part D; cost-sharing; prior authorization; step therapy;
generic drugs
ID D BENEFICIARIES; HEART-FAILURE; ADHERENCE; COST; COPAYMENT; PHYSICIAN;
PERCEPTIONS; PROGRAM; CHOICE
AB Background:Little is known about how Medicare Part D plan features influence choice of generic versus brand drugs.Objectives:To examine the association between Part D plan features and generic medication use.Methods:Data from a 2009 random sample of 1.6 million fee-for-service, Part D enrollees aged 65 years and above, who were not dually eligible or receiving low-income subsidies, were used to examine the association between plan features (generic cost-sharing, difference in brand and generic copay, prior authorization, step therapy) and choice of generic antidepressants, antidiabetics, and statins. Logistic regression models accounting for plan-level clustering were adjusted for sociodemographic and health status.Results:Generic cost-sharing ranged from $0 to $9 for antidepressants and statins, and from $0 to $8 for antidiabetics (across 5th-95th percentiles). Brand-generic cost-sharing differences were smallest for statins (5th-95th percentiles: $16-$37) and largest for antidepressants ($16-$64) across plans. Beneficiaries with higher generic cost-sharing had lower generic use [adjusted odds ratio (OR)=0.97, 95% confidence interval (CI), 0.95-0.98 for antidepressants; OR=0.97, 95% CI, 0.96-0.98 for antidiabetics; OR=0.94, 95% CI, 0.92-0.95 for statins]. Larger brand-generic cost-sharing differences and prior authorization were significantly associated with greater generic use in all categories. Plans could increase generic use by 5-12 percentage points by reducing generic cost-sharing from the 75th ($7) to 25th percentiles ($4-$5), increasing brand-generic cost-sharing differences from the 25th ($25-$26) to 75th ($32-$33) percentiles, and using prior authorization and step therapy.Conclusions:Cost-sharing features and utilization management tools were significantly associated with generic use in 3 commonly used medication categories.
C1 [Tang, Yan; Men, Aiju; Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15261 USA.
[Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Gellad, Walid F.] Univ Pittsburgh, Div Gen Med, Pittsburgh, PA 15261 USA.
[Gellad, Walid F.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA 15261 USA.
[Gellad, Walid F.] RAND Hlth, Pittsburgh, PA USA.
RP Tang, Y (reprint author), Univ Pittsburgh, Grad Sch Publ Hlth, Dept Hlth Policy & Management, 130 DeSoto St,Crabtree Hall A663, Pittsburgh, PA 15261 USA.
EM yat11@pitt.edu
OI Donohue, Julie/0000-0003-2418-6017
FU RAND-University of Pittsburgh Health Initiative (RUPHI); Clinical and
Translational Science Institute at the University of Pittsburgh;
National Institutes of Health (NIH) Clinical and Translational Science
Award (CTSA) program [UL1RR024153, UL1TR000005]; VA HSR&D Career
Development Award [CDA09-207]
FX Supported by a pilot grant funded by both RAND-University of Pittsburgh
Health Initiative (RUPHI) and the Clinical and Translational Science
Institute at the University of Pittsburgh, which is supported by the
National Institutes of Health (NIH) Clinical and Translational Science
Award (CTSA) program (grants UL1RR024153 and UL1TR000005). W. F. G. is
additionally supported by a VA HSR&D Career Development Award
(CDA09-207).
NR 46
TC 1
Z9 1
U1 1
U2 7
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0025-7079
EI 1537-1948
J9 MED CARE
JI Med. Care
PD JUN
PY 2014
VL 52
IS 6
BP 541
EP 548
DI 10.1097/MLR.0000000000000142
PG 8
WC Health Care Sciences & Services; Health Policy & Services; Public,
Environmental & Occupational Health
SC Health Care Sciences & Services; Public, Environmental & Occupational
Health
GA AJ5LK
UT WOS:000337723900012
PM 24824538
ER
PT J
AU Schrey, D
Malietzis, G
Chi, S
Dufour, C
Lafay-Cousin, L
Marshall, L
Carceller, F
Moreno, L
Zacharoulis, S
AF Schrey, Dominik
Malietzis, George
Chi, Susan
Dufour, Christelle
Lafay-Cousin, Lucie
Marshall, Lynley
Carceller, Fernando
Moreno, Lucas
Zacharoulis, Stergios
TI IMPACT OF HIGH DOSE CHEMOTHERAPY ON SURVIVAL OF NEWLY DIAGNOSED PATIENTS
WITH ATYPICAL TERATOID RHABDOID TUMOUR (ATRT) - A SYSTEMATIC REVIEW AND
RE-ANALYSIS OF MULTIMODAL THERAPY
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO)
CY JUN 28-JUL 02, 2014
CL Singapore, SINGAPORE
C1 [Schrey, Dominik; Marshall, Lynley; Carceller, Fernando; Moreno, Lucas; Zacharoulis, Stergios] Royal Marsden Hosp, Inst Canc Res, Sutton, Surrey, England.
[Malietzis, George] St Marks Hosp, Harrow, Middx, England.
[Chi, Susan] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Dufour, Christelle] Inst Cancerol Gustave Roussy, Paris, France.
[Lafay-Cousin, Lucie] Alberta Childrens Prov Gen Hosp, Calgary, AB, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2014
VL 16
SU 1
MA AT-014
BP 4
EP 4
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA AJ8AK
UT WOS:000337924200015
ER
PT J
AU Kieran, M
Fontebasso, A
Papillon-Cavanagh, S
Schwartzentruber, J
Nikbakht, H
Gerges, N
Fiset, PO
Bechet, D
Faury, D
De Jay, N
Ramkissoon, L
Corcoran, A
Jones, D
Sturm, D
Johann, P
Tomita, T
Goldman, S
Nagib, M
Bendel, A
Goumnerova, L
Bowers, DC
Leonard, JR
Rubin, JB
Alden, T
DiPatri, A
Browd, S
Leary, S
Jallo, G
Cohen, K
Prados, MD
Banerjee, A
Carret, AS
Ellezam, B
Crevier, L
Klekner, A
Bognar, L
Hauser, P
Garami, M
Myseros, J
Dong, ZF
Siegel, PM
Gump, W
Ayyanar, K
Ragheb, J
Khatib, Z
Krieger, M
Kiehna, E
Robison, N
Harter, D
Gardner, S
Handler, M
Foreman, N
Brahma, B
MacDonald, T
Malkin, H
Chi, S
Manley, P
Bandopadhayay, P
Greenspan, L
Ligon, A
Albrecht, S
Pfister, SM
Ligon, KL
Majewski, J
Gupta, N
Jabado, N
AF Kieran, Mark
Fontebasso, Adam
Papillon-Cavanagh, Simon
Schwartzentruber, Jeremy
Nikbakht, Hamid
Gerges, Noha
Fiset, Pierre-Oliver
Bechet, Denise
Faury, Damien
De Jay, Nicolas
Ramkissoon, Lori
Corcoran, Aoife
Jones, David
Sturm, Dominik
Johann, Pascal
Tomita, Tadanori
Goldman, Stewart
Nagib, Mahmoud
Bendel, Anne
Goumnerova, Liliana
Bowers, Daniel C.
Leonard, Jeffrey R.
Rubin, Joshua B.
Alden, Tord
DiPatri, Arthur
Browd, Samuel
Leary, Sarah
Jallo, George
Cohen, Kenneth
Prados, Michael D.
Banerjee, Anuradha
Carret, Anne-Sophie
Ellezam, Benjamin
Crevier, Louis
Klekner, Almos
Bognar, Laszlo
Hauser, Peter
Garami, Miklos
Myseros, John
Dong, Zhifeng
Siegel, Peter M.
Gump, William
Ayyanar, Kanyalakshmi
Ragheb, John
Khatib, Ziad
Krieger, Mark
Kiehna, Erin
Robison, Nathan
Harter, David
Gardner, Sharon
Handler, Michael
Foreman, Nicholas
Brahma, Barunashish
MacDonald, Tobey
Malkin, Hayley
Chi, Susan
Manley, Peter
Bandopadhayay, Pratiti
Greenspan, Lianne
Ligon, Azra
Albrecht, Steffen
Pfister, Stefan M.
Ligon, Keith L.
Majewski, Jacek
Gupta, Nalin
Jabado, Nada
TI THE BATS DIPG STUDY: A NATIONAL CLINICAL TRIAL OF UPFRONT BIOPSY AND
TREATMENT STRATIFICATION FOR NEWLY DIAGNOSED DIFFUSE INTRINSIC PONTINE
GLIOMA (DFCI # 10-321)
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO)
CY JUN 28-JUL 02, 2014
CL Singapore, SINGAPORE
C1 [Kieran, Mark; Ramkissoon, Lori; Corcoran, Aoife; Malkin, Hayley; Chi, Susan; Manley, Peter; Bandopadhayay, Pratiti; Greenspan, Lianne; Ligon, Azra; Ligon, Keith L.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Goumnerova, Liliana] Boston Childrens Hosp, Boston, MA USA.
[Fontebasso, Adam; Papillon-Cavanagh, Simon; Schwartzentruber, Jeremy; Nikbakht, Hamid; Gerges, Noha; Fiset, Pierre-Oliver; Bechet, Denise; Faury, Damien; De Jay, Nicolas; Albrecht, Steffen; Majewski, Jacek; Jabado, Nada] Montreal Childrens Hosp, Montreal, PQ, Canada.
[Jones, David; Sturm, Dominik; Johann, Pascal; Pfister, Stefan M.] German Canc Res Ctr, Heidelberg, Germany.
[Tomita, Tadanori; Goldman, Stewart; Alden, Tord; DiPatri, Arthur] Ann & Robert H Lurie Childrens Hosp, Chicago, IL USA.
[Nagib, Mahmoud; Bendel, Anne] Childrens Hosp & Clin Minnesota, Minneapolis, MN USA.
[Bowers, Daniel C.] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA.
[Leonard, Jeffrey R.; Rubin, Joshua B.] Washington Univ, Sch Med, St Louis, MO USA.
[Browd, Samuel; Leary, Sarah] Seattle Childrens Hosp, Seattle, WA USA.
[Jallo, George; Cohen, Kenneth] Johns Hopkins Univ Hosp, Baltimore, MD 21287 USA.
[Prados, Michael D.; Banerjee, Anuradha; Gupta, Nalin] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Carret, Anne-Sophie; Ellezam, Benjamin; Crevier, Louis] CHU Ste Justine, Montreal, PQ, Canada.
[Klekner, Almos; Bognar, Laszlo] Med & Hlth Sci Ctr, Debrecen, Hungary.
[Hauser, Peter; Garami, Miklos] Semmelweis Univ, H-1085 Budapest, Hungary.
[Myseros, John] Childrens Natl Med Ctr, Washington, DC 20010 USA.
[Dong, Zhifeng; Siegel, Peter M.] Rosalind & Morris Goodman Canc Res Ctr, Montreal, PQ, Canada.
[Gump, William; Ayyanar, Kanyalakshmi] Univ Louisville, Louisville, KY 40292 USA.
[Ragheb, John; Khatib, Ziad] Miami Childrens Hosp, Miami, FL USA.
[Krieger, Mark; Kiehna, Erin; Robison, Nathan] Childrens Hosp Los Angeles, Los Angeles, CA 90027 USA.
[Harter, David; Gardner, Sharon] NYU, Med Ctr, New York, NY 10016 USA.
[Handler, Michael; Foreman, Nicholas] Childrens Hosp Colorado, Aurora, CO USA.
[Brahma, Barunashish; MacDonald, Tobey] Childrens Healthcare Atlanta, Atlanta, GA USA.
RI Pfister, Stefan/F-6860-2013
OI Pfister, Stefan/0000-0002-5447-5322
NR 0
TC 0
Z9 0
U1 0
U2 3
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2014
VL 16
SU 1
MA HG-066
BP 56
EP 57
PG 2
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA AJ8AK
UT WOS:000337924200213
ER
PT J
AU Bergthold, G
Bandopadhayay, P
Rich, B
Chan, J
Santagata, S
Hoshida, Y
Ramkissoon, S
Ramkissoon, L
Golub, T
Tabak, B
Ferrer-Luna, R
Weng, PY
Stiles, C
Grill, J
Kieran, MW
Ligon, KL
Beroukhim, R
AF Bergthold, Guillaume
Bandopadhayay, Pratiti
Rich, Benjamin
Chan, Jennifer
Santagata, Sandro
Hoshida, Yujin
Ramkissoon, Shakti
Ramkissoon, Lori
Golub, Todd
Tabak, Barbara
Ferrer-Luna, Ruben
Weng, Patrick Y.
Stiles, Charles
Grill, Jacques
Kieran, Mark W.
Ligon, Keith L.
Beroukhim, Rameen
TI GENE EXPRESSION ANALYSIS OF 151 PEDIATRIC LOW-GRADE GLIOMAS REVEALS
UNDERLYING MOLECULAR HETEROGENEITY
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO)
CY JUN 28-JUL 02, 2014
CL Singapore, SINGAPORE
C1 [Bergthold, Guillaume; Bandopadhayay, Pratiti; Ferrer-Luna, Ruben; Stiles, Charles; Kieran, Mark W.; Beroukhim, Rameen] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Rich, Benjamin; Chan, Jennifer; Santagata, Sandro; Ramkissoon, Shakti; Ramkissoon, Lori; Weng, Patrick Y.; Ligon, Keith L.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Hoshida, Yujin; Golub, Todd; Tabak, Barbara] Broad Inst MIT & Harvard, Cambridge, MA USA.
[Grill, Jacques] Inst Gustave Roussy, Villejuif, France.
[Grill, Jacques] Univ Paris 11, Villejuif, France.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2014
VL 16
SU 1
MA LG-011
BP 62
EP 62
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA AJ8AK
UT WOS:000337924200235
ER
PT J
AU Hwang, E
Mun, A
Kilburn, L
Chi, S
Knipstein, J
Oren, M
Dvir, R
Hardy, K
Rood, B
Packer, R
AF Hwang, Eugene
Mun, Alissa
Kilburn, Lindsay
Chi, Susan
Knipstein, Jeffrey
Oren, Michal
Dvir, Rina
Hardy, Kristina
Rood, Brian
Packer, Roger
TI A MULTI-INSTITUTIONAL PHASE II STUDY OF VINORELBINE IN CHILDREN WITH
RECURRENT OR PROGRESSIVE LOW-GRADE GLIOMAS
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO)
CY JUN 28-JUL 02, 2014
CL Singapore, SINGAPORE
C1 [Hwang, Eugene; Mun, Alissa; Kilburn, Lindsay; Hardy, Kristina; Rood, Brian; Packer, Roger] Childrens Natl Med Ctr, Washington, DC 20010 USA.
[Chi, Susan] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Knipstein, Jeffrey] INOVA Fairfax, Fairfax, VA USA.
[Oren, Michal] Chaim Sheba Med Ctr, IL-52621 Tel Hashomer, Israel.
[Dvir, Rina] Tel Aviv Med Ctr & Sch Med, Dana Childrens Hosp, IL-64239 Tel Aviv, Israel.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2014
VL 16
SU 1
MA LG-009
BP 62
EP 62
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA AJ8AK
UT WOS:000337924200233
ER
PT J
AU Sun, Y
Buhrlage, S
Pilarz, C
Alberta, J
Stiles, C
Gray, N
AF Sun, Yu
Buhrlage, Sara
Pilarz, Catherine
Alberta, John
Stiles, Charles
Gray, Nathanael
TI TARGETING BRAF MUTANTS FOR PEDIATRIC LOW-GRADE ASTROCYTOMAS
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO)
CY JUN 28-JUL 02, 2014
CL Singapore, SINGAPORE
C1 [Sun, Yu; Buhrlage, Sara; Pilarz, Catherine; Alberta, John; Stiles, Charles; Gray, Nathanael] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2014
VL 16
SU 1
MA LG-024
BP 65
EP 65
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA AJ8AK
UT WOS:000337924200248
ER
PT J
AU Bandopadhayay, P
Bergthold, G
Sauer, N
Green, A
Malkin, H
Dabscheck, G
Marcus, K
Ullrich, N
Goumnerova, L
Chi, S
Beroukhim, R
Kieran, M
Manley, P
AF Bandopadhayay, Pratiti
Bergthold, Guillaume
Sauer, Nadine
Green, Adam
Malkin, Hayley
Dabscheck, Gabriel
Marcus, Karen
Ullrich, Nicole
Goumnerova, Liliana
Chi, Susan
Beroukhim, Rameen
Kieran, Mark
Manley, Peter
TI PEDIATRIC PATIENTS WITH DIFFUSE ASTROCYTOMAS HAVE A DISTINCT CLINICAL
COURSE TO THOSE DIAGNOSED AS ADULTS, WITH EXCELLENT VERY LONG TERM
SURVIVAL
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO)
CY JUN 28-JUL 02, 2014
CL Singapore, SINGAPORE
C1 Boston Childrens Hosp, Dana Farber Canc Inst, Boston, MA USA.
Harvard Univ, Sch Med, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2014
VL 16
SU 1
MA LG-032
BP 67
EP 67
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA AJ8AK
UT WOS:000337924200256
ER
PT J
AU Sauer, N
Dodgshun, A
Malkin, H
Bergthold, G
Manley, P
Chi, S
Ramkissoon, S
MacGregor, D
Beroukhim, R
Kieran, M
Sullivan, M
Ligon, K
Bandopadhayay, P
Hansford, J
AF Sauer, Nadine
Dodgshun, Andrew
Malkin, Hayley
Bergthold, Guillaume
Manley, Peter
Chi, Susan
Ramkissoon, Shakti
MacGregor, Duncan
Beroukhim, Rameen
Kieran, Mark
Sullivan, Michael
Ligon, Keith
Bandopadhayay, Pratiti
Hansford, Jordan
TI BRAF MUTATIONS IDENTIFIED IN DISSEMINATED OLIGODENDROGLIAL-LIKE
LEPTOMENINGEAL TUMOR OF CHILDHOOD
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO)
CY JUN 28-JUL 02, 2014
CL Singapore, SINGAPORE
C1 [Sauer, Nadine; Malkin, Hayley; Bergthold, Guillaume; Manley, Peter; Chi, Susan; Ramkissoon, Shakti; Beroukhim, Rameen; Kieran, Mark; Ligon, Keith; Bandopadhayay, Pratiti] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Dodgshun, Andrew; MacGregor, Duncan; Sullivan, Michael; Hansford, Jordan] Royal Chlidrens Hosp, Melbourne, Vic, Australia.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2014
VL 16
SU 1
MA LG-037
BP 68
EP 69
PG 2
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA AJ8AK
UT WOS:000337924200261
ER
PT J
AU Lafay-Cousin, L
Chi, S
Madden, J
Smith, A
Wells, E
Owens, E
Strother, D
Foreman, N
Packer, R
Bouffet, E
AF Lafay-Cousin, Lucie
Chi, Susan
Madden, Jennifer
Smith, Amy
Wells, Elisabeth
Owens, Emily
Strother, Douglas
Foreman, Nicholas
Packer, Roger
Bouffet, Eric
TI LONG TERM FOLLOW UP OF INFANTS WITH MEDULLOBLASTOMA TREATED WITH
SEQUENTIAL HIGH DOSE CHEMOTHERAPY
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO)
CY JUN 28-JUL 02, 2014
CL Singapore, SINGAPORE
C1 [Lafay-Cousin, Lucie; Strother, Douglas] Alberta Children Hosp, Calgary, AB, Canada.
[Chi, Susan] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Madden, Jennifer; Foreman, Nicholas] Childrens Hosp Colorado, Denver, CO USA.
[Smith, Amy; Owens, Emily] Arnold Palmer Hosp Children, Orlando, CA USA.
[Wells, Elisabeth; Packer, Roger] Childrens Natl Med Ctr, Washington, DC 20010 USA.
[Bouffet, Eric] Hosp Sick Children, Toronto, ON M5G 1X8, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2014
VL 16
SU 1
MA MB-007
BP 72
EP 72
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA AJ8AK
UT WOS:000337924200273
ER
PT J
AU Fay-McClymont, T
Walsh, K
Mabbott, D
Smith, A
Wells, E
Madden, J
Chi, S
Owens, E
Strother, D
Packer, R
Foreman, N
Bouffet, E
Lafay-Cousin, L
AF Fay-McClymont, Taryn
Walsh, Karin
Mabbott, Donald
Smith, Amy
Wells, Elizabeth
Madden, Jennifer
Chi, Susan
Owens, Emily
Strother, Douglas
Packer, Roger
Foreman, Nicholas
Bouffet, Eric
Lafay-Cousin, Lucie
TI LONG TERM NEUROPSYCHOLOGICAL FOLLOW-UP OF YOUNG CHILDREN WITH
MEDULLOBLASTOMA TREATED ACCORDING TO THE CCG 99703 REGIMEN
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO)
CY JUN 28-JUL 02, 2014
CL Singapore, SINGAPORE
C1 [Fay-McClymont, Taryn; Strother, Douglas; Lafay-Cousin, Lucie] Alberta Childrens Prov Gen Hosp, Calgary, AB, Canada.
[Mabbott, Donald; Bouffet, Eric] Hosp Sick Children, Toronto, ON, Canada.
[Walsh, Karin; Wells, Elizabeth; Packer, Roger] Childrens Natl Med Ctr, Washington, DC 20010 USA.
[Smith, Amy; Owens, Emily] Arnold Palmer Hosp Children, Orlando, FL USA.
[Madden, Jennifer; Foreman, Nicholas] Childrens Hosp Colorado, Denver, CO USA.
[Chi, Susan] Dana Farber Canc Inst, Boston, MA 02115 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2014
VL 16
SU 1
MA MB-019
BP 75
EP 75
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA AJ8AK
UT WOS:000337924200285
ER
PT J
AU Ecker, J
Oehme, I
Mazitschek, R
Korshunov, A
Kool, M
Lodrini, M
Deubzer, HE
von Deimling, A
Kulozik, AE
Pfister, SM
Witt, O
Milde, T
AF Ecker, Jonas
Oehme, Ina
Mazitschek, Ralph
Korshunov, Andrey
Kool, Marcel
Lodrini, Marco
Deubzer, Hedwig E.
von Deimling, Andreas
Kulozik, Andreas E.
Pfister, Stefan M.
Witt, Olaf
Milde, Till
TI TARGETING CLASS I HISTONE DEACETYLASES IN HIGH RISK MEDULLOBLASTOMA -
ANALYSIS OF MOLECULAR MECHANISMS AND TRANSLATIONAL IMPLICATIONS
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO)
CY JUN 28-JUL 02, 2014
CL Singapore, SINGAPORE
C1 [Ecker, Jonas; Oehme, Ina; Lodrini, Marco; Deubzer, Hedwig E.; Witt, Olaf; Milde, Till] German Canc Res Ctr, Clin Cooperat Unit Pediat Oncol G340, Heidelberg, Germany.
[Mazitschek, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Korshunov, Andrey; von Deimling, Andreas] Univ Heidelberg Hosp, Dept Neuropathol, Heidelberg, Germany.
[Kool, Marcel; Pfister, Stefan M.] German Canc Res Ctr, Div Pediat Neurooncol B062, Heidelberg, Germany.
[Kulozik, Andreas E.] Univ Heidelberg Hosp, Sect Pediat Brain Tumors, Dept Pediat Oncol Hematol & Immunol, Heidelberg, Germany.
RI Kool, Marcel/H-2541-2013; Pfister, Stefan/F-6860-2013
OI Pfister, Stefan/0000-0002-5447-5322
NR 0
TC 0
Z9 0
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2014
VL 16
SU 1
MA MB-037
BP 80
EP 80
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA AJ8AK
UT WOS:000337924200303
ER
PT J
AU Bandopadhayay, P
Bergthold, G
Nguyen, B
Schubert, S
Gholamin, S
Tang, YJ
Bolin, S
Schumacher, S
Zeid, R
Masoud, S
Yu, FR
Vue, N
Gibson, W
Paolella, B
Mitra, S
Cheshier, S
Qi, J
Liu, KW
Wechsler-Reya, R
Weiss, W
Swartling, FJ
Kieran, MW
Bradner, JE
Beroukhim, R
Cho, YJ
AF Bandopadhayay, Pratiti
Bergthold, Guillaume
Nguyen, Brian
Schubert, Simone
Gholamin, Sharareh
Tang, Yujie
Bolin, Sara
Schumacher, Steven
Zeid, Rhamy
Masoud, Sabran
Yu, Furong
Vue, Nujsaubnusi
Gibson, William
Paolella, Brenton
Mitra, Siddhartha
Cheshier, Samuel
Qi, Jun
Liu, Kun-Wei
Wechsler-Reya, Robert
Weiss, William
Swartling, Fredrik J.
Kieran, Mark W.
Bradner, James E.
Beroukhim, Rameen
Cho, Yoon-Jae
TI MEDULLOBLASTOMA MODELS WHICH HARBOR AMPLIFICATIONS OF MYC FAMILY MEMBERS
ARE SENSITIVE TO BET-BROMODOMAIN INHIBITION
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO)
CY JUN 28-JUL 02, 2014
CL Singapore, SINGAPORE
C1 [Bandopadhayay, Pratiti; Bergthold, Guillaume; Kieran, Mark W.] Boston Childrens Hosp, Dana Farber Canc Inst, Boston, MA USA.
[Bandopadhayay, Pratiti; Bergthold, Guillaume; Kieran, Mark W.] Harvard Univ, Sch Med, Boston, MA USA.
[Nguyen, Brian; Schubert, Simone; Gholamin, Sharareh; Tang, Yujie; Masoud, Sabran; Yu, Furong; Vue, Nujsaubnusi; Mitra, Siddhartha; Cheshier, Samuel; Cho, Yoon-Jae] Stanford Univ, Sch Med, Stanford Canc Inst, Stanford, CA 94305 USA.
[Bolin, Sara; Swartling, Fredrik J.] Uppsala Univ, Uppsala, Sweden.
[Schumacher, Steven; Zeid, Rhamy; Gibson, William; Paolella, Brenton; Qi, Jun; Bradner, James E.; Beroukhim, Rameen] Harvard Univ, Sch Med, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Schumacher, Steven; Zeid, Rhamy; Gibson, William; Paolella, Brenton; Qi, Jun; Bradner, James E.; Beroukhim, Rameen] Broad Inst MIT & Harvard, Boston, MA USA.
[Liu, Kun-Wei; Wechsler-Reya, Robert] Sanford Burnham Med Res Inst, La Jolla, CA USA.
[Weiss, William] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Weiss, William] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA.
[Weiss, William] Univ Calif San Francisco, Dept Neurosurg, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2014
VL 16
SU 1
MA MB-075
BP 90
EP 90
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA AJ8AK
UT WOS:000337924200341
ER
PT J
AU Wells, EM
Ullrich, NJ
Seidel, K
Leisenring, W
Sklar, C
Armstrong, GT
Diller, L
King, A
Krull, K
Neglia, JP
Stovall, M
Whelan, K
Robison, LL
Packer, RJ
AF Wells, Elizabeth M.
Ullrich, Nicole J.
Seidel, Kristy
Leisenring, Wendy
Sklar, Charles
Armstrong, Gregory T.
Diller, Lisa
King, Allison
Krull, Kevin
Neglia, Joseph P.
Stovall, Marilyn
Whelan, Kimberly
Robison, Leslie L.
Packer, Roger J.
TI NEUROLOGIC SEQUELAE IN BRAIN TUMOR SURVIVORS IN THE CHILDHOOD CANCER
SURVIVOR STUDY (CCSS)
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO)
CY JUN 28-JUL 02, 2014
CL Singapore, SINGAPORE
C1 [Wells, Elizabeth M.; Packer, Roger J.] Childrens Natl, Washington, DC USA.
[Ullrich, Nicole J.] Harvard Univ, Boston Childrens, Boston, MA 02115 USA.
[Seidel, Kristy; Leisenring, Wendy] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA.
[Sklar, Charles] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Armstrong, Gregory T.; Krull, Kevin; Stovall, Marilyn] St Jude Canc Res Ctr, Memphis, TN USA.
[Diller, Lisa] Dana Farber Canc Inst, Boston, MA 02115 USA.
[King, Allison] Washington Univ, St Louis, MO USA.
[Neglia, Joseph P.] Univ Minnesota, Minneapolis, MN USA.
[Whelan, Kimberly] MD Anderson, Houston, TX USA.
[Robison, Leslie L.] Univ Alabama Birmingham, Birmingham, AL USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2014
VL 16
SU 1
MA QL-006
BP 112
EP 112
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA AJ8AK
UT WOS:000337924200430
ER
PT J
AU Chi, SN
Bandopadhayay, P
Janeway, K
Pinches, N
Malkin, H
Kieran, MW
Manley, PE
Green, A
Goumnerova, L
Ramkissoon, S
Harris, MH
Ligon, KL
AF Chi, Susan N.
Bandopadhayay, Pratiti
Janeway, Katherine
Pinches, Nathan
Malkin, Hayley
Kieran, Mark W.
Manley, Peter E.
Green, Adam
Goumnerova, Liliana
Ramkissoon, Shakti
Harris, Marian H.
Ligon, Keith L.
TI PROFILE: FEASIBILITY OF AN INSTITUTE-WIDE PROJECT IN PERSONALIZED
MEDICINE FOR CHILDREN WITH BRAIN TUMORS
SO NEURO-ONCOLOGY
LA English
DT Meeting Abstract
CT 16th International Symposium on Pediatric Neuro-Oncology (ISPNO)
CY JUN 28-JUL 02, 2014
CL Singapore, SINGAPORE
C1 [Chi, Susan N.; Bandopadhayay, Pratiti; Janeway, Katherine; Pinches, Nathan; Malkin, Hayley; Kieran, Mark W.; Manley, Peter E.; Green, Adam] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Ramkissoon, Shakti; Ligon, Keith L.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Goumnerova, Liliana; Harris, Marian H.] Boston Childrens Hosp, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 1522-8517
EI 1523-5866
J9 NEURO-ONCOLOGY
JI Neuro-Oncology
PD JUN
PY 2014
VL 16
SU 1
MA TB-029
BP 143
EP 143
PG 1
WC Oncology; Clinical Neurology
SC Oncology; Neurosciences & Neurology
GA AJ8AK
UT WOS:000337924200554
ER
PT J
AU Hoyos-Bachiloglu, R
Morales, PS
Cerda, J
Talesnik, E
Gonzalez, G
Camargo, CA
Borzutzky, A
AF Hoyos-Bachiloglu, Rodrigo
Morales, Pamela S.
Cerda, Jaime
Talesnik, Eduardo
Gonzalez, Gilberto
Camargo, Carlos A., Jr.
Borzutzky, Arturo
TI Higher latitude and lower solar radiation influence on anaphylaxis in
Chilean children
SO PEDIATRIC ALLERGY AND IMMUNOLOGY
LA English
DT Article
DE allergy; anaphylaxis; food allergy; latitude; solar radiation; vitamin D
ID EMERGENCY-DEPARTMENT VISITS; VITAMIN-D; FOOD ALLERGY;
REGIONAL-VARIATION; PRESCRIPTIONS; AUSTRALIA; PREVALENCE
AB Background: Recent studies suggest an association between higher latitude, a proxy of vitamin D (VD) status, and allergic diseases. Chile provides an ideal setting to study this association due to its latitude span and high rates of VD deficiency in southern regions. The aim of this study is to explore the associations of latitude and solar radiation with anaphylaxis admission rates.
Methods: We reviewed anaphylaxis admissions in Chile's hospital discharge database between 2001 and 2010 and investigated associations with latitude and solar radiation.
Results: 2316 anaphylaxis admissions were registered. Median age of patients was 41 yr; 53% were female. National anaphylaxis admission rate was 1.41 per 100,000 persons per year. We observed a strong north-south increasing gradient of anaphylaxis admissions (beta 0.04, p = 0.01), with increasing rates south of latitude 34 degrees S. A significant association was also observed between solar radiation and anaphylaxis admissions (beta -0.11, p = 0.009). Latitude was associated with food-induced (beta 0.05, p = 0.02), but not drug-induced (beta -0.002, p = 0.27), anaphylaxis. The association between latitude and food-induced anaphylaxis was significant in children (beta 0.01, p = 0.006), but not adults (beta 0.003, p = 0.16). Anaphylaxis admissions were not associated with regional sociodemographic factors like poverty, rurality, educational level, ethnicity, or physician density.
Conclusions: Anaphylaxis admission rates in Chile are highest at higher latitudes and lower solar radiation, used as proxies of VD status. The associations appear driven by food-induced anaphylaxis. Our data support a possible role of VD deficiency as an etiological factor in the high anaphylaxis admission rates found in southern Chile.
C1 [Hoyos-Bachiloglu, Rodrigo; Morales, Pamela S.; Talesnik, Eduardo; Borzutzky, Arturo] Pontificia Univ Catolica Chile, Div Pediat, Sch Med, Immunol Allergy & Rheumatol Unit, Santiago 8330074, Chile.
[Hoyos-Bachiloglu, Rodrigo; Borzutzky, Arturo] Pontificia Univ Catolica Chile, Sch Med, Millennium Inst Immunol & Immunotherapy, Santiago 8330074, Chile.
[Cerda, Jaime] Pontificia Univ Catolica Chile, Sch Med, Dept Publ Hlth, Santiago 8330074, Chile.
[Gonzalez, Gilberto] Pontificia Univ Catolica Chile, Sch Med, Dept Endocrinol, Santiago 8330074, Chile.
[Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Emergency Med, Boston, MA USA.
[Camargo, Carlos A., Jr.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Rheumatol Allergy & Immunol,Dept Med, Boston, MA USA.
RP Borzutzky, A (reprint author), Pontificia Univ Catolica Chile, Div Pediat, Lira 85, Santiago 8330074, Chile.
EM arturobor@med.puc.cl
RI Osborne, Nicholas/N-4915-2015;
OI Osborne, Nicholas/0000-0002-6700-2284; Borzutzky,
Arturo/0000-0002-7904-262X
FU FONDECYT [1130615]; NIH [U01 AI-87881]
FX Dr Borzutzky was supported by FONDECYT grant 1130615. Dr Camargo was
supported by NIH U01 AI-87881.
NR 29
TC 14
Z9 14
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0905-6157
EI 1399-3038
J9 PEDIAT ALLERG IMM-UK
JI Pediatr. Allergy Immunol.
PD JUN
PY 2014
VL 25
IS 4
BP 338
EP 343
DI 10.1111/pai.12211
PG 6
WC Allergy; Immunology; Pediatrics
SC Allergy; Immunology; Pediatrics
GA AJ9NB
UT WOS:000338037100006
PM 24628618
ER
PT J
AU Jordan, AH
Litz, BT
AF Jordan, Alexander H.
Litz, Brett T.
TI Prolonged Grief Disorder: Diagnostic, Assessment, and Treatment
Considerations
SO PROFESSIONAL PSYCHOLOGY-RESEARCH AND PRACTICE
LA English
DT Article
DE prolonged grief; complicated grief; pathological grief; traumatic grief;
psychotherapy
ID RANDOMIZED CONTROLLED-TRIAL; COGNITIVE-BEHAVIORAL THERAPY;
INTERNET-BASED INTERVENTION; TREATING COMPLICATED GRIEF;
POSTTRAUMATIC-STRESS; LATER LIFE; BEREAVEMENT; PSYCHOTHERAPY;
DEPRESSION; ANXIETY
AB Normative bereavement reactions are contrasted with prolonged grief disorder (PGD). Diagnostic criteria for PGD are reviewed. PGD is distinguished from other problems occurring after loss, namely depression and PTSD. Assessment approaches are described. Recent clinical trials are reviewed, and recommendations for the psychotherapeutic treatment of PGD are developed. Consideration of medication referral is also recommended, especially in the case of co-occurring depression.
C1 [Jordan, Alexander H.] VA Boston Healthcare Syst, Boston, MA USA.
[Litz, Brett T.] VA Boston Healthcare Syst, Massachusetts Vet Epidemiol Res & Informat Ctr, Mental Hlth Core, Boston, MA USA.
[Jordan, Alexander H.; Litz, Brett T.] Boston Univ, Sch Med, Boston, MA 02215 USA.
RP Jordan, AH (reprint author), VA Boston Healthcare Syst 116B 4, 150 South Huntington Ave, Boston, MA 02130 USA.
EM jordan.alexander.h@gmail.com
NR 55
TC 5
Z9 5
U1 5
U2 35
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 0735-7028
EI 1939-1323
J9 PROF PSYCHOL-RES PR
JI Prof. Psychol.-Res. Pract.
PD JUN
PY 2014
VL 45
IS 3
BP 180
EP 187
DI 10.1037/a0036836
PG 8
WC Psychology, Multidisciplinary
SC Psychology
GA AJ7TN
UT WOS:000337900300004
ER
PT J
AU Kaufmann, VG
O'Farrell, TJ
Murphy, CM
Murphy, MM
Muchowski, P
AF Kaufmann, Vyga G.
O'Farrell, Timothy J.
Murphy, Christopher M.
Murphy, Marie M.
Muchowski, Patrice
TI Alcohol Consumption and Partner Violence Among Women Entering Substance
Use Disorder Treatment
SO PSYCHOLOGY OF ADDICTIVE BEHAVIORS
LA English
DT Article
DE partner violence; alcohol consumption; female alcoholic patients
ID ABUSE TREATMENT; AGGRESSION; MEN; DRINKING; CONFLICT; SCALES
AB To test the hypothesized role of alcohol consumption as a proximal risk factor for partner violence, a within-subjects analysis compared levels of alcohol consumption in violent versus nonviolent conflict events among substance-abusing women and their male partners. Participants were married or cohabiting women (N = 145) who had recently begun a substance abuse treatment program and reported both a violent and a nonviolent relationship conflict event with their male partner in the prior 6 months. The average age was 38, and 83% were White. Male partners did not participate in the study. The female participant provided information about the male partner. Women were interviewed regarding a violent conflict event in which physical violence occurred and a nonviolent conflict event in which psychological aggression occurred without physical violence. The interview assessed quantity of alcohol consumed and use of other drugs prior to each conflict. Alcohol consumption was significantly greater prior to violent versus nonviolent conflict events for all measures of women's alcohol consumption examined: any drinking, heavy drinking, number of drinks in the 12 hr preceding the conflict event, and estimated blood alcohol concentration at time of the event. Male partners' alcohol consumption showed similar results. Use of other drugs in women, but not men, was significantly more likely prior to physical conflicts. These within-subject comparisons help to rule out individual difference explanations for the alcohol-violence association and indicate that the quantity of alcohol consumption is an important proximal risk factor for partner violence in substance-abusing women and their male partners.
C1 [Kaufmann, Vyga G.; O'Farrell, Timothy J.; Murphy, Marie M.] VA Boston Healthcare Syst, Dept Psychiat, Families & Addict Program, Brockton, MA USA.
[Kaufmann, Vyga G.; O'Farrell, Timothy J.; Murphy, Marie M.] Harvard Univ, Sch Med, Brockton, MA 02301 USA.
[Murphy, Christopher M.] Univ Maryland Baltimore Cty, Dept Psychol, Baltimore, MD 21228 USA.
[Muchowski, Patrice] AdCare Hosp Worcester Inc, Worcester, MA USA.
RP O'Farrell, TJ (reprint author), Harvard Univ, Sch Med, Dept Psychiat, VA Boston Healthcare Syst, VAMC 116B1,940 Belmont St, Brockton, MA 02301 USA.
EM timothy_ofarrell@hms.harvard.edu
FU NIAAA NIH HHS [R01AA12834]
NR 33
TC 2
Z9 2
U1 1
U2 9
PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA
SN 0893-164X
EI 1939-1501
J9 PSYCHOL ADDICT BEHAV
JI Psychol. Addict. Behav.
PD JUN
PY 2014
VL 28
IS 2
BP 313
EP 321
DI 10.1037/a0034971
PG 9
WC Substance Abuse; Psychology, Multidisciplinary
SC Substance Abuse; Psychology
GA AJ7XW
UT WOS:000337915800001
PM 24955661
ER
PT J
AU Byrne, T
Fargo, JD
Montgomery, AE
Munley, E
Culhane, DP
AF Byrne, Thomas
Fargo, Jamison D.
Montgomery, Ann Elizabeth
Munley, Ellen
Culhane, Dennis P.
TI The Relationship between Community Investment in Permanent Supportive
Housing and Chronic Homelessness
SO SOCIAL SERVICE REVIEW
LA English
DT Article
ID NEW-YORK-CITY; MENTAL-ILLNESS; RENT CONTROL; COST-EFFECTIVENESS;
HEALTH-CARE; SERVICE USE; PHILADELPHIA; PROGRAM; ADULTS; INDIVIDUALS
AB In recent years, permanent supportive housing (PSH) has emerged as the preferred intervention for addressing chronic homelessness in the United States. However, almost all prior studies examining the effectiveness of PSH have been conducted at the individual level, with only minimal attempts to empirically test the relationship between PSH and chronic homelessness at the community level. This study uses longitudinal data collected by the US Department of Housing and Urban Development (HUD) and several other sources to model the relationship between measures of community investment in PSH and rates of chronic homelessness. The results show modest negative associations between increased investment in PSH and rates of chronic homelessness over time. We discuss the implications of these findings for ongoing efforts to address chronic homelessness and future research.
C1 [Byrne, Thomas; Culhane, Dennis P.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA.
[Byrne, Thomas; Fargo, Jamison D.; Montgomery, Ann Elizabeth; Munley, Ellen; Culhane, Dennis P.] US Dept Vet Affairs, Washington, DC USA.
[Fargo, Jamison D.] Utah State Univ, Logan, UT 84322 USA.
RP Byrne, T (reprint author), Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA.
NR 54
TC 6
Z9 6
U1 5
U2 29
PU UNIV CHICAGO PRESS
PI CHICAGO
PA 1427 E 60TH ST, CHICAGO, IL 60637-2954 USA
SN 0037-7961
EI 1537-5404
J9 SOC SERV REV
JI Soc. Serv. Rev.
PD JUN
PY 2014
VL 88
IS 2
BP 234
EP 263
DI 10.1086/676142
PG 30
WC Social Work
SC Social Work
GA AJ5QV
UT WOS:000337741600002
ER
PT J
AU Brahmbhatt, R
Carter, SA
Hicks, SC
Berger, DH
Liang, MK
AF Brahmbhatt, Reshma
Carter, Stacey A.
Hicks, Stephanie C.
Berger, David H.
Liang, Mike K.
TI Identifying Risk Factors for Surgical Site Complications after
Laparoscopic Ventral Hernia Repair: Evaluation of the Ventral Hernia
Working Group Grading System
SO SURGICAL INFECTIONS
LA English
DT Article
ID INCISIONAL HERNIA; WOUND-INFECTION; MESH; HERNIORRHAPHY; METAANALYSIS;
RECURRENCE; OUTCOMES
AB Background: In 2010, the Ventral Hernia Working Group (VHWG) published a grading system to assess the risk of surgical site complications in patients undergoing ventral hernia repair. This study evaluated the predictive value of the VHWG classification for the surgical outcomes of laparoscopic ventral hernia repair (LVHR) and identified independent factors associated with surgical site infection (SSI) and surgical site occurrence (SSO). Methods: A retrospective review was performed of all patients who underwent LVHR over a 10-year period at two institutions. The U.S. Centers for Disease Control and Prevention definition of SSI and the VHWG definition of SSO were used. Univariable analysis was performed using the Student t-test, analysis of variance, chi-square test, or Fisher exact test, as appropriate. Multivariable analysis was used to identify independent factors associated with SSI and SSO. Results: Differences in American Society of Anesthesiologists class, body mass index, diabetes mellitus, chronic obstructive pulmonary disease, tobacco use, hernia type, prior abdominal surgery, prior ventral hernia repair, hernia size, and total infections were identified by grade. There was no difference in SSI or SSO by grade. Multivariable analysis revealed institution and number of prior abdominal operations to be associated with SSI. Institution, prostate disease, and prior ventral hernia repair were associated with SSO. Conclusions: The VHWG classification was unable to predict SSI and SSO and may not be applicable in LVHR. This study identified independent factors associated with SSI and SSO in LVHR. Although further study is warranted to validate these results, the factors presented may be a useful tool to stratify patient risk of SSI and SSO with LVHR.
C1 [Brahmbhatt, Reshma; Carter, Stacey A.; Berger, David H.; Liang, Mike K.] Baylor Coll Med, Michael E DeBakey Vet Affairs Med Ctr, Michael E DeBakey Dept Surg, Houston, TX 77030 USA.
[Hicks, Stephanie C.] Rice Univ, Dept Stat, Houston, TX 77251 USA.
RP Liang, MK (reprint author), Michael E DeBakey VAMC, 2002 Holcombe Blvd,OCL 112, Houston, TX 77030 USA.
EM ml3@bcm.edu
RI Liang, Mike/L-8493-2015;
OI Liang, Mike/0000-0001-7063-7291; Hicks, Stephanie/0000-0002-7858-0231
FU Lifecell; KCI; Acell
FX R.B., S.A.C., S.C.H., and D.H.B. declare no competing financial
interests. M. K. L. has held research grants from Lifecell and
unrestricted education grants from Lifecell, KCI, and Acell.
NR 40
TC 7
Z9 7
U1 1
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1096-2964
EI 1557-8674
J9 SURG INFECT
JI Surg. Infect.
PD JUN
PY 2014
VL 15
IS 3
BP 187
EP 193
DI 10.1089/sur.2012.179
PG 7
WC Infectious Diseases; Surgery
SC Infectious Diseases; Surgery
GA AJ9EI
UT WOS:000338009600006
PM 24773169
ER
PT J
AU deLemos, AS
Chung, RT
AF deLemos, Andrew S.
Chung, Raymond T.
TI Hepatitis C treatment: an incipient therapeutic revolution
SO TRENDS IN MOLECULAR MEDICINE
LA English
DT Review
DE hepatitis C; pegylated interferon; NS3-4A serine protease inhibitors;
direct-acting antivirals (DAAs); sofosbuvir; simeprevir
ID HCV GENOTYPE 1; TREATMENT-NAIVE PATIENTS; PHASE-III TRIAL; SOFOSBUVIR
PLUS RIBAVIRIN; TREATMENT-EXPERIENCED PATIENTS; PEGYLATED INTERFERON
ALPHA-2A; GENOME-WIDE ASSOCIATION; VIRUS-INFECTION; SIMEPREVIR TMC435;
GENETIC-VARIATION
AB An exciting paradigm shift is occurring in the treatment of hepatitis C virus (HCV). We now have the capacity to specifically target therapy to HCV proteins, and thereby directly interrupt the viral life cycle. The first direct-acting antivirals (DAAs), the NS3-4A serine protease inhibitors boceprevir and telaprevir, improved the rate of sustained virologic response (SVR), but their toxicities combined with PEG-IFN and RBV limited their overall efficacy. Sofosbuvir, a nucleotide HCV polymerase inhibitor, is now available and offers better tolerability and efficacy across all HCV genotypes. The next phase of therapy will be combining several classes of DAAs without IFN in order to make sustained clearance of hepatitis C deliverable to a much larger number of infected individuals.
C1 [deLemos, Andrew S.] Carolinas Med Ctr, Ctr Liver Dis & Transplantat, Dept Med, Charlotte, NC 28203 USA.
[Chung, Raymond T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Liver Ctr, Boston, MA 02114 USA.
[Chung, Raymond T.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Gastrointestinal Div, Boston, MA 02114 USA.
RP deLemos, AS (reprint author), Carolinas Med Ctr, Ctr Liver Dis & Transplantat, Dept Med, Charlotte, NC 28203 USA.
EM andrew.delemos@carolinas.org; rtchung@partners.org
FU Gilead; Mass Biologics; Vertex
FX R.T.C. has received grant support from Gilead (clinical trial), Mass
Biologics (clinical trial), and Vertex (clinical trial), and has
consulted for Abbvie.
NR 45
TC 25
Z9 25
U1 0
U2 16
PU ELSEVIER SCI LTD
PI OXFORD
PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND
SN 1471-4914
EI 1471-499X
J9 TRENDS MOL MED
JI Trends Mol. Med
PD JUN
PY 2014
VL 20
IS 6
BP 315
EP 321
DI 10.1016/j.molmed.2014.02.002
PG 7
WC Biochemistry & Molecular Biology; Cell Biology; Medicine, Research &
Experimental
SC Biochemistry & Molecular Biology; Cell Biology; Research & Experimental
Medicine
GA AJ7LG
UT WOS:000337877600003
PM 24636306
ER
PT J
AU Orton, LP
Cohan, RH
Davenport, MS
Parker, RA
Parameswaran, A
Caoili, EM
Kaza, RK
Francis, IR
Ellis, JH
Wolf, JS
Hafez, K
AF Orton, Lorenzo P.
Cohan, Richard H.
Davenport, Matthew S.
Parker, Robert A.
Parameswaran, Aishwarya
Caoili, Elaine M.
Kaza, Ravi K.
Francis, Isaac R.
Ellis, James H.
Wolf, J. Stuart
Hafez, Khaled
TI Variability in computed tomography diameter measurements of solid renal
masses
SO ABDOMINAL IMAGING
LA English
DT Article
DE Renal mass measurements; Computed tomography; Solid renal mass
ID NATURAL-HISTORY; INTEROBSERVER VARIABILITY; RISING INCIDENCE; HELICAL
CT; INTRAOBSERVER; MANAGEMENT; TUMORS; SIZE
AB To determine whether the frequency of intra-observer measurement discrepancies a parts per thousand yen5 mm for solid renal masses varies by renal mass characteristics and CT contrast phase.
This HIPAA-compliant retrospective study was approved by our IRB. We selected single CT images performed during the nephrographic phase (NP) of renal enhancement in 97 patients, each with a single solid renal mass. Mass location, margin, heterogeneity, and growth pattern were assessed. Six readers measured each mass on two occasions > 3 weeks apart. Readers also measured the masses on images in 50 patients who had corticomedullary phase (CMP) images obtained during the same study. Results were assessed using Chi-square/Fisher's exact and Wilcoxon Signed Rank tests, and logistic regression analyses.
For NP to NP comparisons, intra-reader measurement differences a parts per thousand yen5 mm were seen for 3.7% (17/463) of masses < 4 cm, but increased to 16.8% (20/119) for masses > 4 cm (p < 0.0001). Masses with poorly defined margins (15.9% [22/138] vs. 3.4% [15/444] for well-defined margins, p < 0.0001) and heterogeneity (15.3% [22/144], vs. 5.0% [14/282] for minimally heterogeneous, vs. 0.6% [1/156] for homogeneous, p < 0.0001), were more frequently associated with measurement differences a parts per thousand yen5 mm. Differences a parts per thousand yen5 mm were more frequent when only CMP images were utilized (14% [42/299]), or when CMP images were compared with NP images (26% [77/299]).
A a parts per thousand yen5 mm intra-reader variation in measured size of solid renal masses < 4 cm is uncommon for NP to NP comparisons. Variation increases when masses are a parts per thousand yen4 cm, poorly defined, or heterogeneous; or when CMP images are utilized.
C1 [Orton, Lorenzo P.; Cohan, Richard H.; Davenport, Matthew S.; Parameswaran, Aishwarya; Caoili, Elaine M.; Kaza, Ravi K.; Francis, Isaac R.; Ellis, James H.] Univ Michigan Hosp, Dept Radiol, Ann Arbor, MI 48109 USA.
[Parker, Robert A.] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Directory Biometry, Boston, MA 02114 USA.
[Wolf, J. Stuart; Hafez, Khaled] Univ Michigan Hosp, Dept Urol, Ann Arbor, MI 48109 USA.
RP Cohan, RH (reprint author), Univ Michigan Hosp, Dept Radiol, 1500 East Med Ctr Dr,Room B1D502G, Ann Arbor, MI 48109 USA.
EM rcohan@umich.edu
NR 26
TC 1
Z9 1
U1 0
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0942-8925
EI 1432-0509
J9 ABDOM IMAGING
JI Abdom. Imaging
PD JUN
PY 2014
VL 39
IS 3
BP 533
EP 542
DI 10.1007/s00261-014-0088-y
PG 10
WC Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical
Imaging
SC Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical
Imaging
GA AJ5RA
UT WOS:000337742200012
PM 24535480
ER
PT J
AU Sainani, NI
Schlett, CL
Hahn, PF
Gervais, DA
Mueller, PR
Arellano, RS
AF Sainani, Nisha I.
Schlett, Christopher L.
Hahn, Peter F.
Gervais, Debra A.
Mueller, Peter R.
Arellano, Ronald S.
TI Computed tomography-guided percutaneous biopsy of isoattenuating focal
liver lesions
SO ABDOMINAL IMAGING
LA English
DT Article
DE Liver; Focal; Biopsy; Computed tomography
ID FINE-NEEDLE BIOPSY; HEPATIC-LESIONS; HEPATOCELLULAR-CARCINOMA;
CIRRHOSIS; CT; DIAGNOSIS; ULTRASOUND
AB The purpose of this study was to evaluate the efficacy of CT-guided percutaneous biopsy of isoattenuating liver lesions using anatomic landmarks (ALs) to guide needle placement and added value of intravenous (IV) contrast.
An interventional radiology database was reviewed to identify patients with CT-guided percutaneous biopsy of isoattenuating focal liver lesions using ALs to guide needle placement. The cohort was further divided into two groups: lesions biopsied using ALs only and lesions biopsied using ALs and intravenous contrast (AL+IV). Pathology results or follow-up imaging served as reference standard. Sensitivity and accuracy were calculated, Student's t test and Fisher's exact test were used for statistical comparison between the two groups.
Between January 2000 and December 2011, CT-guided percutaneous biopsy of 133 isoattenuating focal liver lesions was performed in 133 patients. The AL group included 54 patients (M:F = 29:25) with 54 lesions (size range 7-90 mm, mean 32.1 +/- A 18.1) and AL+IV group included 79 patients (M:F = 44:35) with 79 lesions (size range 7-100 mm, mean 25.6 +/- A 15.0). AL group included 23 (43%) benign and 31 (57%) malignant lesions; AL+IV group included 31 (39%) benign and 48 (61%) malignant lesions. Sensitivity and accuracy for CT-guided biopsy of focal isoattenuating liver lesions were, overall 94% and 96%, AL group 97% and 98% and AL+IV group 92% and 94%, with no statistical significant difference between the AL and AL+IV groups (P = 0.88-1.00).
Accurate planning and utilizing of internal reference ALs is successful in yielding a diagnostic sample for CT-guided percutaneous biopsy of isoattenuating focal liver lesion. The confidence of accurate targeting can be enhanced by administering IV contrast, however, since the visualization provided by IV contrast can be short-lived; use of IV contrast does not obviate the need for precise planning based on ALs.
C1 [Sainani, Nisha I.] Harvard Univ, Brigham & Womens Hosp, Div Abdominal Imaging & Intervent, Sch Med,Dept Radiol, Boston, MA 02115 USA.
[Hahn, Peter F.; Gervais, Debra A.; Mueller, Peter R.; Arellano, Ronald S.] Harvard Univ, Massachusetts Gen Hosp, Div Abdominal Imaging & Intervent, Sch Med,Dept Radiol, Boston, MA 02115 USA.
[Schlett, Christopher L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cardiac MR PET CT Program,Dept Radiol, Boston, MA 02115 USA.
[Schlett, Christopher L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA 02115 USA.
[Schlett, Christopher L.] Univ Heidelberg Hosp, Dept Diagnost & Intervent Radiol, Heidelberg, Germany.
RP Sainani, NI (reprint author), Harvard Univ, Brigham & Womens Hosp, Div Abdominal Imaging & Intervent, Sch Med,Dept Radiol, 75 Francis St, Boston, MA 02115 USA.
EM nsainani@partners.org
NR 29
TC 2
Z9 2
U1 1
U2 5
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0942-8925
EI 1432-0509
J9 ABDOM IMAGING
JI Abdom. Imaging
PD JUN
PY 2014
VL 39
IS 3
BP 633
EP 644
DI 10.1007/s00261-014-0089-x
PG 12
WC Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical
Imaging
SC Gastroenterology & Hepatology; Radiology, Nuclear Medicine & Medical
Imaging
GA AJ5RA
UT WOS:000337742200021
PM 24531352
ER
PT J
AU Kil, KE
Zhu, AJ
Zhang, ZD
Choi, JK
Kura, S
Gong, CY
Brownell, AL
AF Kil, Kun-Eek
Zhu, Aijun
Zhang, Zhaoda
Choi, Ji-Kyung
Kura, Sreekanth
Gong, Chunyu
Brownell, Anna-Liisa
TI Development of [I-123]IPEB and [I-123]IMPEB as SPECT Radioligands for
Metabotropic Glutamate Receptor Subtype 5
SO ACS MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE metabotropic glutamate receptor subtype S (mGlu(5)); negative allosteric
modulator (NAM); single photon emission computed tomography (SPECT); in
vivo imaging; [I-123]IPEB; [I-123]IMPEB
ID POSITRON-EMISSION-TOMOGRAPHY; SIGNAL-TRANSDUCTION; RADIATION-DOSIMETRY;
PET; MGLUR5; BRAIN; PHARMACOLOGY; ANTAGONISTS;
METABOTROPIC-GLUTAMATE-RECEPTOR-SUBTYPE-5; RADIOTRACERS
AB mGlus play an important role in physiology and pathology to various central nervous system (CNS) diseases. Several positron emission tomography (PET) radiotracers have been developed to explore the role of mGlus in brain disorders. However, there are no single photon emission computed tomography (SPECT) radioligands for mGlus. Here we report development of [I-123]IPEB ([I-123]1) and [I-123]IMPEB ([I-123]2) as mGlu(5) radioligands for SPECT. [I-123]1 and [I-123]2 were produced by copper(I) mediated aromatic halide displacement reactions. The SPECT imaging using mouse models demonstrated that [I-123]1 readily entered the brain and accumulated specifically in mGlus-rich regions of the brain such as striatum and hippocampus. However, in comparison to the corresponding PET tracer [F-18]FPEB, [I-123]1 showed faster washout from the brain. The binding ratios of the striatum and the hippocampus compared to the cerebellum for [I-123]1 and [F-18]FPEB were similar despite unfavorable pharmacokinetics of [I-123]1. Further structural optimization of 1 may lead to more viable SPECT radiotracers for the imaging of mGlus.
C1 [Kil, Kun-Eek; Zhu, Aijun; Zhang, Zhaoda; Choi, Ji-Kyung; Kura, Sreekanth; Gong, Chunyu; Brownell, Anna-Liisa] Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
RP Brownell, AL (reprint author), Massachusetts Gen Hosp, Dept Radiol, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
EM abrownell@mgh.harvard.edu
FU [NIBIB-R01EB012864]; [NIMH-R01MH91684]; [1S10RR029495-01];
[1S10RR026666-01]; [1S10RR023452-01]
FX Funding was provided by NIBIB-R01EB012864 and NIMH-R01MH91684 to A.-L.B.
Authors would like to acknowledge supporting grants for the
instrumentation 1S10RR029495-01, 1S10RR026666-01, and 1S10RR023452-01.
NR 35
TC 5
Z9 5
U1 0
U2 5
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-5875
J9 ACS MED CHEM LETT
JI ACS Med. Chem. Lett.
PD JUN
PY 2014
VL 5
IS 6
BP 652
EP 656
DI 10.1021/ml500007z
PG 5
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA AJ2OM
UT WOS:000337497200010
PM 24944738
ER
PT J
AU Rotstein, BH
Hooker, JM
Woo, J
Collier, TL
Brady, TJ
Liang, SH
Vasdev, N
AF Rotstein, Benjamin H.
Hooker, Jacob M.
Woo, Jiyeon
Collier, Thomas Lee
Brady, Thomas J.
Liang, Steven H.
Vasdev, Neil
TI Synthesis of [C-11]Bexarotene by Cu-Mediated [C-11]Carbon Dioxide
Fixation and Preliminary PET Imaging
SO ACS MEDICINAL CHEMISTRY LETTERS
LA English
DT Article
DE Bexarotene; targretin; positron emission tomography; carbon-11; carbon
dioxide fixation; retinoid X receptor; Alzheimer's disease
ID AD MOUSE MODELS; REVERSE DEFICITS; ALZHEIMERS-DISEASE; BETA; RECEPTORS;
RAT; C-11
AB Bexarotene (Targretin) is a retinoid X receptor (RXR) agonist that has applications for treatment of T cell lymphoma and proposed mechanisms of action in Alzheimer's disease that have been the subject of recent controversy. Carbon-11 labeled bexarotene ([11C_ carbony1]4-[1-(3,5,5,8,8-pentamethylietralin-2-yOethenyllbenzoic acid) was synthesized using a Cu-mediated cross-coupling reaction employing an arylboronate precursor 1 and [C-11]carbon dioxide under atmospheric pressure in 15 +/- 2% uncorrected radiochemical yield (n = 3), based on [C-11]CO2. Judicious choice of solvents, catalysts, and additives, as well as precursor concentration and purity of [11C]CO2, enabled the preparation of this C-11-labeled carboxylic acid. Formulated [11C]bexarotene was isolated (>37 mCi) with >99% radiochemical purity in 32 mm. Preliminary positron emission tomography magnetic resonance imaging revealed rapid brain uptake in nonhuman primate in the first 75 s following intravenous administration of the radiotracer (specific activity >0.3 Ci/mu mol at time of injection), followed by slow clearance (Delta = 43%) over 60 min. Modest uptake (SUV = 0.8) was observed in whole brain and regions with high RXR expression.
C1 [Rotstein, Benjamin H.; Woo, Jiyeon; Collier, Thomas Lee; Brady, Thomas J.; Liang, Steven H.; Vasdev, Neil] Massachusetts Gen Hosp, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA.
[Rotstein, Benjamin H.; Woo, Jiyeon; Collier, Thomas Lee; Brady, Thomas J.; Liang, Steven H.; Vasdev, Neil] Massachusetts Gen Hosp, Ctr Adv Med Imaging Sci, Boston, MA 02114 USA.
[Rotstein, Benjamin H.; Hooker, Jacob M.; Collier, Thomas Lee; Brady, Thomas J.; Liang, Steven H.; Vasdev, Neil] Harvard Univ, Dept Radiol, Sch Med, Boston, MA 02114 USA.
[Hooker, Jacob M.] Massachusetts Gen Hosp, Athinoula A Martinos Ctr Biomed Imaging, Charlestown, MA 02129 USA.
[Collier, Thomas Lee] Advion Inc, Ithaca, NY 14850 USA.
RP Liang, SH (reprint author), Massachusetts Gen Hosp, Div Nucl Med & Mol Imaging, Boston, MA 02114 USA.
EM liang.steven@mgh.harvard.edu; vasdev.neil@mgh.harvard.edu
OI Hooker, Jacob/0000-0002-9394-7708; Rotstein,
Benjamin/0000-0001-9707-9357
FU Natural Sciences and Engineering Research Council of Canada (NSERC)
FX B.H.R. is a Natural Sciences and Engineering Research Council of Canada
(NSERC) Postdoctoral Fellow.
NR 25
TC 9
Z9 9
U1 0
U2 11
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1948-5875
J9 ACS MED CHEM LETT
JI ACS Med. Chem. Lett.
PD JUN
PY 2014
VL 5
IS 6
BP 668
EP 672
DI 10.1021/ml500065q
PG 5
WC Chemistry, Medicinal
SC Pharmacology & Pharmacy
GA AJ2OM
UT WOS:000337497200013
PM 24944741
ER
PT J
AU Miller, RA
Harrison, DE
Astle, CM
Fernandez, E
Flurkey, K
Han, M
Javors, MA
Li, XN
Nadon, NL
Nelson, JF
Pletcher, S
Salmon, AB
Sharp, ZD
Van Roekel, S
Winkleman, L
Strong, R
AF Miller, Richard A.
Harrison, David E.
Astle, Clinton M.
Fernandez, Elizabeth
Flurkey, Kevin
Han, Melissa
Javors, Martin A.
Li, Xinna
Nadon, Nancy L.
Nelson, James F.
Pletcher, Scott
Salmon, Adam B.
Sharp, Zelton Dave
Van Roekel, Sabrina
Winkleman, Lynn
Strong, Randy
TI Rapamycin-mediated lifespan increase in mice is dose and sex dependent
and metabolically distinct from dietary restriction
SO AGING CELL
LA English
DT Article
DE aging; caloric restriction; glucose; IGF-1; insulin; longevity; mouse;
mTOR; rapamycin; xenobiotic metabolism
ID GENETICALLY HETEROGENEOUS MICE; INTERVENTIONS TESTING PROGRAM; AMES
DWARF MICE; INSULIN SENSITIVITY; EXTENSION; LONGEVITY; TOR; RESISTANCE;
PATHWAY; GENES
AB Rapamycin, an inhibitor of mTOR kinase, increased median lifespan of genetically heterogeneous mice by 23% (males) to 26% (females) when tested at a dose threefold higher than that used in our previous studies; maximal longevity was also increased in both sexes. Rapamycin increased lifespan more in females than in males at each dose evaluated, perhaps reflecting sexual dimorphism in blood levels of this drug. Some of the endocrine and metabolic changes seen in diet-restricted mice are not seen in mice exposed to rapamycin, and the pattern of expression of hepatic genes involved in xenobiotic metabolism is also quite distinct in rapamycin-treated and diet-restricted mice, suggesting that these two interventions for extending mouse lifespan differ in many respects.
C1 [Miller, Richard A.; Han, Melissa; Li, Xinna; Van Roekel, Sabrina; Winkleman, Lynn] Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
[Miller, Richard A.; Han, Melissa; Li, Xinna; Pletcher, Scott; Van Roekel, Sabrina; Winkleman, Lynn] Univ Michigan, Geriatr Ctr, Ann Arbor, MI 48109 USA.
[Harrison, David E.; Astle, Clinton M.; Flurkey, Kevin] Jackson Lab, Bar Harbor, ME 04609 USA.
[Fernandez, Elizabeth; Strong, Randy] South Texas Vet Hlth Care Syst, Geriatr Res Educ & Clin Ctr, San Antonio, TX 78229 USA.
[Fernandez, Elizabeth; Strong, Randy] South Texas Vet Hlth Care Syst, Res Serv, San Antonio, TX 78229 USA.
[Javors, Martin A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA.
[Nadon, Nancy L.] NIA, Div Aging Biol, Bethesda, MD 20892 USA.
[Nelson, James F.] Univ Texas Hlth Sci Ctr San Antonio, Dept Physiol, San Antonio, TX 78229 USA.
[Nelson, James F.; Salmon, Adam B.; Sharp, Zelton Dave; Strong, Randy] Univ Texas Hlth Sci Ctr San Antonio, Barshop Inst Longev & Aging Studies, San Antonio, TX 78229 USA.
[Pletcher, Scott] Univ Michigan, Dept Mol & Integrat Physiol, Ann Arbor, MI 48109 USA.
[Sharp, Zelton Dave] Univ Texas Hlth Sci Ctr San Antonio, Dept Mol Med, San Antonio, TX 78245 USA.
RP Miller, RA (reprint author), Univ Michigan, Dept Pathol, Ann Arbor, MI 48109 USA.
EM millerr@umich.edu
FU NIH [AG022303, AG031736, AG022307, AG013319, AG022308, CA034196];
Department of Veterans Affairs
FX This work was supported by NIH grants AG022303, AG031736 (RAM),
AG022307, AG013319 (RS), and AG022308 (DEH), with important facilities
supported by CA034196 (DEH) and the Department of Veterans Affairs (RS),
We thank Lili Deng and Andrzej Galecki for statistical assistance, Jeff
Halter for comments on an early draft of the paper, and Lisa Burmeister,
Vivian Diaz, Nelson Durgin, Vicki Ingalls, Amanda Keedle, and Pam J
Krason for technical assistance.
NR 46
TC 103
Z9 105
U1 4
U2 20
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1474-9718
EI 1474-9726
J9 AGING CELL
JI Aging Cell
PD JUN
PY 2014
VL 13
IS 3
BP 468
EP 477
DI 10.1111/acel.12194
PG 10
WC Cell Biology; Geriatrics & Gerontology
SC Cell Biology; Geriatrics & Gerontology
GA AJ2VV
UT WOS:000337523400009
PM 24341993
ER
PT J
AU Buck, KJ
Iancu, OD
Walter, NAR
AF Buck, K. J.
Iancu, O. D.
Walter, N. A. R.
TI QUANTITIATIVE TRAIT LOCUS (QTL), GENE EXPRESSION AND COEXPRESSION
NETWORK ANALYSES IDENTIFY A ROLE FOR OXIDATIVE PHOSPHORYLATION IN
ETHANOL WITHDRAWAL
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA) / 17th Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 Portland VA Med Ctr, Dept Behav Neurosci, Portland, OR 97239 USA.
Portland VA Med Ctr, Portland Alcohol Res Ctr, Portland, OR 97239 USA.
Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0011
BP 3A
EP 3A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523700012
ER
PT J
AU Dou, X
Chen, X
Chen, SY
Charness, ME
AF Dou, X.
Chen, X.
Chen, S-Y
Charness, M. E.
TI SRC FAMILY KINASE PHOSPHORYLATION OF Y1176 IN THE L1 CYTOPLASMIC DOMAIN
IS REQUIRED FOR ETHANOL INHIBITION OF L1 ADHESION
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA) / 17th Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 [Dou, X.; Charness, M. E.] Harvard Univ, Sch Med, Dept Neurol, VA Boston Healthcare Syst, West Roxbury, MA 02132 USA.
[Chen, X.; Chen, S-Y] Univ Illinois, Coll Med Peoria, Peoria, IL 61605 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0109
BP 28A
EP 28A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523700110
ER
PT J
AU Bergman, BG
Nelson, L
Slaymaker, V
Kelly, JF
AF Bergman, B. G.
Nelson, L.
Slaymaker, V.
Kelly, J. F.
TI A LONGITUDINAL INVESTIGATION OF CONTINUING CARE FOLLOWING RESIDENTIAL
TREATMENT IN EMERGING ADULTS: ISMUTUAL-HELP "WITHOUT PARALLEL"?
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA) / 17th Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 [Bergman, B. G.; Nelson, L.; Slaymaker, V.; Kelly, J. F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Addict Med, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0208
BP 52A
EP 52A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523700209
ER
PT J
AU Labbe, AK
Slaymaker, V
Kelly, JF
AF Labbe, A. K.
Slaymaker, V.
Kelly, J. F.
TI TOWARD ENHANCING TWELVE-STEP FACILITATION AMONG OUNG PEOPLE: A
SYSTEMATIC QUALITATIVE INVESTIGATION OF YOUNG ADULTS' 12-STEP
EXPERIENCES
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA) / 17th Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 [Labbe, A. K.; Slaymaker, V.; Kelly, J. F.] Massachusetts Gen Hosp, Dept Psychiat, Ctr Addict Med, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0210
BP 53A
EP 53A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523700211
ER
PT J
AU Williams, EC
Lapham, GT
Lee, AK
Richards, JE
Berger, DB
Ludman, E
Bradley, KA
AF Williams, E. C.
Lapham, G. T.
Lee, A. K.
Richards, J. E.
Berger, D. B.
Ludman, E.
Bradley, K. A.
TI READINESS TO CHANGE AND SEVERITY OF UNHEALTHY ALCOHOL USE AMONG PRIMARY
CARE PATIENTS RECRUITED TO A TRIAL OF COLLABORATIVE CARE
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA) / 17th Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 [Williams, E. C.] VA Puget Sound HSR&D COIN, Seattle, WA USA.
[Williams, E. C.] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA.
[Lapham, G. T.; Lee, A. K.; Richards, J. E.; Ludman, E.; Bradley, K. A.] Grp Hlth Res Inst, Seattle, WA USA.
[Berger, D. B.] VA Puget Sound, Seattle, WA USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0226
BP 57A
EP 57A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523700227
ER
PT J
AU Hawkins, EJ
Lapham, GT
Lee, AK
Kivlahan, DR
Berger, BD
Hebert, PL
Saxon, AJ
Bradley, KA
AF Hawkins, E. J.
Lapham, G. T.
Lee, A. K.
Kivlahan, D. R.
Berger, B. D.
Hebert, P. L.
Saxon, A. J.
Bradley, K. A.
TI PREVALENCE AND COMORBIDITY OF PTSD AMONG HEAVY DRINKERS ENROLLED IN A
COLLABORATIVE CARE TRIAL FOR ALCOHOL USE DISORDERS IN VA PRIMARY CARE
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA) / 17th Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 Grp Hlth Res Inst, Seattle, WA 98101 USA.
VA Puget Sound Hlth Care Syst, Seattle, WA 98118 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0252
BP 63A
EP 63A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523700253
ER
PT J
AU Pietrzykowski, AZ
Mead, EA
Wang, Y
Thekkumthala, A
Ren, J
Liu, C
Liu, PK
AF Pietrzykowski, A. Z.
Mead, E. A.
Wang, Y.
Thekkumthala, A.
Ren, J.
Liu, C.
Liu, P. K.
TI ALCOHOL REGULATION OF MIR-9 IN THE LIVE BRAIN
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA) / 17th Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 Rutgers State Univ, New Brunswick, NJ 08901 USA.
Massachusetts Gen Hosp, Charlestown, MA 02129 USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0305
BP 77A
EP 77A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523700306
ER
PT J
AU Sawyer, KS
Ruiz, SMM
Galvez, DA
Makris, N
Harris, GJ
Valera, EM
Oscar-Berman, M
AF Sawyer, K. S.
Ruiz, S. M. M.
Galvez, D. A.
Makris, N.
Harris, G. J.
Valera, E. M.
Oscar-Berman, M.
TI CEREBELLAR MORPHOMETRIC ABNORMALITIES IN ALCOHOLICS
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA) / 17th Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 Boston Univ, Sch Med, Boston, MA 02118 USA.
VA Healthcare Syst, Boston, MA 02130 USA.
Massachusetts Gen Hosp, Martinos Ctr, Boston, MA 02114 USA.
Massachusetts Gen Hosp, Ctr Morphometr Anal, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0475
BP 119A
EP 119A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523700476
ER
PT J
AU Bradley, KA
Lapham, GT
Richards, J
Merrill, JO
Williams, EC
Lee, AK
Holden, E
Chavez, LJ
Kivlahan, DR
AF Bradley, K. A.
Lapham, G. T.
Richards, J.
Merrill, J. O.
Williams, E. C.
Lee, A. K.
Holden, E.
Chavez, L. J.
Kivlahan, D. R.
TI THE PREVALENCE OF DSM-IV VERSUS DSM-5 ALCOHOL USE DISORDERS (AUD) IN
PRIMARY CARE PATIENTS AT HIGH RISK FOR AUD IN THE CHOICE TRIAL
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA) / 17th Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 Univ Washington, VA Puget Sound, HSR&D COIN & Gen Med Serv, Grp Hlth Res Inst,Dept Med, Seattle, WA 98195 USA.
Univ Washington, VA Puget Sound, HSR&D COIN & Gen Med Serv, Grp Hlth Res Inst,Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
Univ Washington, VA Puget Sound, HSR&D COIN & Gen Med Serv, Grp Hlth Res Inst,Dept Hlth Serv, Seattle, WA 98195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0493
BP 124A
EP 124A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523700494
ER
PT J
AU Bergman, BG
Greene, MC
Slaymaker, V
Hoeppner, BB
Kelly, JF
AF Bergman, B. G.
Greene, M. C.
Slaymaker, V.
Hoeppner, B. B.
Kelly, J. F.
TI THE ROLE OF CO-OCCURRING PSYCHIATRIC DISORDERS IN EMERGING ADULTS'
RESIDENTIAL SUD TREATMENT RESPONSE AND OUTCOMES
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA) / 17th Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 [Bergman, B. G.; Greene, M. C.; Slaymaker, V.; Hoeppner, B. B.; Kelly, J. F.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Ctr Addict Med, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0532
BP 133A
EP 133A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523700533
ER
PT J
AU Pennington, DL
Lasher, BA
Herbst, E
Schrodek, E
Hong, E
Waldrop, A
Heinz, A
Williams, C
Abrams, G
Neylan, TC
Seal, K
Carney, C
Besterman, A
Batki, SL
AF Pennington, D. L.
Lasher, B. A.
Herbst, E.
Schrodek, E.
Hong, E.
Waldrop, A.
Heinz, A.
Williams, C.
Abrams, G.
Neylan, T. C.
Seal, K.
Carney, C.
Besterman, A.
Batki, S. L.
TI COGNITION AND SELF-REGULATION IN VETERANS WITH ALCOHOL USE DISORDER,
PTSD AND TBI: BASELINE SUBJECT CHARACTERISTICS IN TOPIRAMATE TREATMENT
TRIALS
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA) / 17th Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 [Pennington, D. L.; Lasher, B. A.; Herbst, E.; Schrodek, E.; Hong, E.; Waldrop, A.; Heinz, A.; Williams, C.; Abrams, G.; Neylan, T. C.; Seal, K.; Carney, C.; Besterman, A.; Batki, S. L.] UCSF Dept Psychiat, Addict Res Program, San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
NR 0
TC 0
Z9 0
U1 2
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0547
BP 137A
EP 137A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523700548
ER
PT J
AU Gubner, NR
Phillips, TJ
AF Gubner, N. R.
Phillips, T. J.
TI EFFECTS OF VARENICLINE ON THE EXPRESSION OF ETHANOL-INDUCED LOCOMOTOR
SENSITIZATION, A MOUSE MODEL OF NEUROADAPTATION
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA) / 17th Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 [Gubner, N. R.; Phillips, T. J.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland Alcohol Res Ctr, Dept Behav Neurosci, Portland, OR 97239 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0622
BP 156A
EP 156A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523700623
ER
PT J
AU Pedrelli, P
Fisher, L
Farabaugh, A
Nyer, M
Borsari, B
Parkin, S
Jaeger, A
MacPherson, L
AF Pedrelli, P.
Fisher, L.
Farabaugh, A.
Nyer, M.
Borsari, B.
Parkin, S.
Jaeger, A.
MacPherson, L.
TI DISTRESS TOLERANCE AND HEAVY EPISODIC DRINKING IN COLLEGE STUDENTS: DOES
IT MAKE A DIFFERENCE HOW IT IS MEASURED?
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA) / 17th Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 [Pedrelli, P.; Fisher, L.; Farabaugh, A.; Nyer, M.; Borsari, B.; Parkin, S.; Jaeger, A.; MacPherson, L.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0733
BP 184A
EP 184A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523700734
ER
PT J
AU Krenek, M
Simpson, TL
AF Krenek, M.
Simpson, T. L.
TI DEGREE OF CORRESPONDENCE BETWEEN DAILY MONITORING AND RETROSPECTIVE
RECALL OF ALCOHOL USE AMONG INDIVIDUALS WITH COMORBID AUD AND PTSD
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA) / 17th Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 [Krenek, M.; Simpson, T. L.] VA Puget Sound Healthcare Syst, Seattle Div, Seattle, WA 98108 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0823
BP 206A
EP 206A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523701023
ER
PT J
AU Collins, SE
Duncan, MH
Smart, BF
Saxon, AJ
Malone, DK
Jackson, TR
Ries, RK
AF Collins, S. E.
Duncan, M. H.
Smart, B. F.
Saxon, A. J.
Malone, D. K.
Jackson, T. R.
Ries, R. K.
TI A PILOT STUDY OF EXTENDED-RELEASE NALTREXONE AND HARM REDUCTION
COUNSELING FOR CHRONICALLY HOMELESS PEOPLE WITH ALCOHOL DEPENDENCE
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA) / 17th Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 [Collins, S. E.; Duncan, M. H.; Smart, B. F.; Ries, R. K.] Univ Washington, Seattle, WA 98195 USA.
[Saxon, A. J.] VA Puget Sound, Seattle, WA 98108 USA.
[Malone, D. K.] DESC, Seattle, WA 98104 USA.
[Jackson, T. R.] Evergreen Treatment Serv, Seattle, WA 98134 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0850
BP 213A
EP 213A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523701050
ER
PT J
AU Batki, SL
Pennington, DL
Lasher, BA
Herbst, E
Schrodek, E
Hong, E
Waldrop, A
Heinz, A
Williams, C
Abrams, G
Neylan, TC
Seal, K
Carney, C
Besterman, A
AF Batki, S. L.
Pennington, D. L.
Lasher, B. A.
Herbst, E.
Schrodek, E.
Hong, E.
Waldrop, A.
Heinz, A.
Williams, C.
Abrams, G.
Neylan, T. C.
Seal, K.
Carney, C.
Besterman, A.
TI ALCOHOL USE DISORDER AND PTSD SEVERITY IN VETERANS WITH AND WITHOUT
COMORBID TBI: BASELINE SUBJECT CHARACTERISTICS IN TOPIRAMATE TREATMENT
TRIALS
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA) / 17th Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 [Batki, S. L.; Pennington, D. L.; Lasher, B. A.; Herbst, E.; Schrodek, E.; Hong, E.; Waldrop, A.; Heinz, A.; Williams, C.; Abrams, G.; Neylan, T. C.; Seal, K.; Carney, C.; Besterman, A.] Univ Calif San Francisco, Dept Psychiat, Addict Res Program, San Francisco VA Med Ctr, San Francisco, CA 94121 USA.
NR 0
TC 0
Z9 0
U1 1
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0855
BP 214A
EP 214A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523701055
ER
PT J
AU Barkley-Levenson, AM
Crabbe, JC
AF Barkley-Levenson, A. M.
Crabbe, J. C.
TI NEUROPEPTIDE Y AND BINGE-LIKE DRINKING IN HIGH DRINKING IN THE DARK
SELECTED MICE
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA) / 17th Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland Alcohol Res Ctr, Portland, OR 97239 USA.
Portland VA Med Ctr, Portland, OR 97239 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0896
BP 224A
EP 224A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523701096
ER
PT J
AU Wilhelm, CJ
Beard, DR
Hashimoto, JG
Roberts, ML
Loftis, JM
Wiren, KM
AF Wilhelm, C. J.
Beard, D. R.
Hashimoto, J. G.
Roberts, M. L.
Loftis, J. M.
Wiren, K. M.
TI DISTINCT GLUCOCORTICOID SIGNALING ASSOCIATED WITH ETHANOL-INDUCED
INFLAMMOTOXICITY
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA) / 17th Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 Portland VA Med Ctr, Res Serv, Portland, OR 97239 USA.
Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 0991
BP 248A
EP 248A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523701191
ER
PT J
AU McGinnis, K
Tate, J
Bryant, K
Fiellin, D
Justice, A
AF McGinnis, K.
Tate, J.
Bryant, K.
Fiellin, D.
Justice, A.
TI SENSITIVITY TO ALCOHOL INTOXICATION EFFECTS BY HIV STATUS AND TREATMENT
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA) / 17th Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
CT VA Healthcare Syst, Vet Aging Cohort Study, West Haven, CT USA.
Yale Univ, New Haven, CT USA.
NIAAA, Bethesda, MD USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 1131
BP 283A
EP 283A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523701330
ER
PT J
AU Gilman, JM
Calderon, V
Curran, MT
Evins, AE
AF Gilman, J. M.
Calderon, V.
Curran, M. T.
Evins, A. E.
TI THE EFFECT OF SOCIAL INFLUENCE ON DECISION-MAKING IN YOUNG ADULTS USING
ALCOHOL AND MARIJUANA: A COMPARISON
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA) / 17th Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 [Gilman, J. M.; Calderon, V.; Curran, M. T.; Evins, A. E.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Addict Med, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 049
BP 305A
EP 305A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523701416
ER
PT J
AU Kelly, JF
Stout, RL
Greene, MC
Slaymaker, V
AF Kelly, J. F.
Stout, R. L.
Greene, M. C.
Slaymaker, V.
TI YOUNG ADULTS, SOCIAL NETWORKS, AND ADDICTION RECOVERY
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA) / 17th Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 [Kelly, J. F.; Greene, M. C.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Cambridge, MA 02138 USA.
[Stout, R. L.] Pacific Inst Res & Evaluat, Calverton, MD USA.
[Slaymaker, V.] Hazelden Fdn, Chicago, IL USA.
NR 0
TC 0
Z9 0
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 123
BP 323A
EP 323A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523701490
ER
PT J
AU Barkley-Levenson, AM
Crabbe, JC
AF Barkley-Levenson, A. M.
Crabbe, J. C.
TI BEHAVIORAL AND MOLECULAR CHARACTERISTICS OF MICE 'AT-RISK' FOR
BINGE-LIKE DRINKING
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA) / 17th Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 Oregon Hlth & Sci Univ, Portland Alcohol Res Ctr, Dept Behav Neurosci, Portland, OR 97239 USA.
Portland VA Med Ctr, Portland, OR 97239 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 247
BP 354A
EP 354A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523701614
ER
PT J
AU Dou, X
Chen, X
Chen, SY
Charness, ME
AF Dou, X.
Chen, X.
Chen, S-Y
Charness, M. E.
TI IDENTIFICATION OF CANDIDATE FASD SUSCEPTIBILITY GENES IN L1 TRANSFECTED
FIBROBLASTS AND MOUSE EMBRYOS
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Meeting Abstract
CT 37th Annual Scientific Meeting of the Research-Society-on-Alcoholism
(RSA) / 17th Congress of the
International-Society-for-Biomedical-Research-on-Alcoholism (ISBRA)
CY JUN 21-25, 2014
CL Bellevue, WA
SP Res Soc Alcoholism, Int Soc Biomed Res Alcoholism
C1 [Dou, X.; Charness, M. E.] Harvard Univ, Sch Med, VA Boston Healthcare Syst, West Roxbury, MA 02132 USA.
[Dou, X.; Charness, M. E.] Harvard Univ, Sch Med, Dept Neurol, West Roxbury, MA 02132 USA.
[Chen, X.; Chen, S-Y] Univ Illinois, Coll Med Peoria, Peoria, IL 61605 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
SU 1
SI SI
MA 259
BP 357A
EP 357A
PG 1
WC Substance Abuse
SC Substance Abuse
GA AJ2VX
UT WOS:000337523701626
ER
PT J
AU Rasmussen, DD
Beckwith, LE
Kincaid, CL
Froehlich, JC
AF Rasmussen, Dennis D.
Beckwith, Lauren E.
Kincaid, Carrie L.
Froehlich, Janice C.
TI Combining the 1-Adrenergic Receptor Antagonist, Prazosin, with the
-Adrenergic Receptor Antagonist, Propranolol, Reduces Alcohol Drinking
More Effectively Than Either Drug Alone
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Propranolol; Prazosin; Alcoholism Treatment; Noradrenergic
ID PREFERRING P RATS; DEPENDENCE; ETHANOL; WITHDRAWAL; PREFERENCE
AB Background Evidence suggests that activation of the noradrenergic system may contribute to alcohol drinking in animals and humans. Our previous studies demonstrated that blocking 1-adrenergic receptors with the antagonist, prazosin, decreased alcohol drinking in rats under various conditions. As noradrenergic activation is also regulated by -adrenergic receptors, we now examine the effects of the -adrenergic receptor antagonist, propranolol, alone or in combination with prazosin, on alcohol drinking in rats selectively bred for high voluntary alcohol intake and alcohol preference (P line). Methods Two studies were conducted with male P rats. In study 1, rats were allowed to become alcohol-dependent during 14weeks of ad libitum access to food, water, and 20% alcohol, and the effect of propranolol (5 to 15mg/kg, intraperitoneally [IP]) and prazosin (1 to 2mg/kg, IP) on alcohol intake during withdrawal was assessed. In study 2, the effect of propranolol (5mg/kg, IP) and prazosin (2mg/kg, IP) on alcohol intake following prolonged imposed abstinence was assessed. Results Alcohol drinking following propranolol treatment was variable, but the combination of propranolol+prazosin consistently suppressed alcohol drinking during both alcohol withdrawal and following prolonged imposed abstinence, and the combination of these 2 drugs was more effective than was treatment with either drug alone. Conclusions Treatment with prazosin+propranolol, or a combination of other centrally active 1- and -adrenergic receptor antagonists, may assist in preventing alcohol relapse in some individuals.
C1 [Rasmussen, Dennis D.] VISN 20 Mental Illness Res Educ & Clin Ctr, Seattle, WA USA.
[Rasmussen, Dennis D.; Beckwith, Lauren E.; Kincaid, Carrie L.] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
[Rasmussen, Dennis D.; Beckwith, Lauren E.; Kincaid, Carrie L.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA.
[Froehlich, Janice C.] Indiana Univ Sch Med, Dept Med, Indianapolis, IN 46202 USA.
RP Rasmussen, DD (reprint author), VA Puget Sound Hlth Care Syst, Med Ctr, MIRECC 116, 1660 S Columbian Way, Seattle, WA 98108 USA.
EM drasmuss@u.washington.edu
FU NIH [R01 AA018604, P20 AA017839, AA018604, P60 AA007611, R24 AA15512]
FX This material is based on work supported in part by resources from the
VA Puget Sound Health Care System, the VA VISN 20 Mental Illness
Research, Education and Clinical Center (MIRECC), and by NIH grants R01
AA018604, P20 AA017839 (DDR) and AA018604, P60 AA007611 (JCF). P rats
were provided by the Alcohol Research Resource Center supported by NIH
grant R24 AA15512.
NR 28
TC 8
Z9 8
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
IS 6
BP 1532
EP 1539
DI 10.1111/acer.12441
PG 8
WC Substance Abuse
SC Substance Abuse
GA AJ2SI
UT WOS:000337511400006
PM 24891220
ER
PT J
AU Medici, V
Schroeder, DI
Woods, R
LaSalle, JM
Geng, YZ
Shibata, NM
Peerson, J
Hodzic, E
Dayal, S
Tsukamoto, H
Kharbanda, KK
Tillman, B
French, SW
Halsted, CH
AF Medici, Valentina
Schroeder, Diane I.
Woods, Rima
LaSalle, Janine M.
Geng, Yongzhi
Shibata, Noreene M.
Peerson, Janet
Hodzic, Emir
Dayal, Sanjana
Tsukamoto, Hidekazu
Kharbanda, Kusum K.
Tillman, Brittany
French, Samuel W.
Halsted, Charles H.
TI Methylation and Gene Expression Responses to Ethanol Feeding and Betaine
Supplementation in the Cystathionine Beta Synthase-Deficient Mouse
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Alcohol; S-Adenosylmethionine; S-Adenosylhomocysteine; Cystathionine
Beta Synthase; DNA Methylation
ID ALCOHOLIC LIVER-DISEASE; ENDOPLASMIC-RETICULUM STRESS; NITRIC-OXIDE
SYNTHASE; GLOBAL DNA METHYLATION; MICROPIGS FED ETHANOL; ALPHA
PPAR-ALPHA; METHIONINE METABOLISM; EPIGENETIC REGULATION; MICE; INJURY
AB Background Alcoholic steatohepatitis (ASH) is caused in part by the effects of ethanol (EtOH) on hepatic methionine metabolism. Methods To investigate the phenotypic and epigenetic consequences of altered methionine metabolism in this disease, we studied the effects of 4-week intragastric EtOH feeding with and without the methyl donor betaine in cystathionine beta synthase (CS) heterozygous C57BL/6J mice. Results The histopathology of early ASH was induced by EtOH feeding and prevented by betaine supplementation, while EtOH feeding reduced and betaine supplementation maintained the hepatic methylation ratio of the universal methyl donor S-adenosylmethionine (SAM) to the methyltransferase inhibitor S-adenosylhomocysteine (SAH). MethylC-seq genomic sequencing of heterozygous liver samples from each diet group found 2 to 4% reduced methylation in gene bodies, but not promoter regions of all autosomes of EtOH-fed mice, each of which were normalized in samples from mice fed the betaine-supplemented diet. The transcript levels of nitric oxide synthase (Nos2) and DNA methyltransferase 1 (Dnmt1) were increased, while those of peroxisome proliferator receptor- (Ppar) were reduced in EtOH-fed mice, and each was normalized in mice fed the betaine-supplemented diet. DNA pyrosequencing of CS heterozygous samples found reduced methylation in a gene body of Nos2 by EtOH feeding that was restored by betaine supplementation and was correlated inversely with its expression and positively with SAM/SAH ratios. Conclusions The present study has demonstrated relationships among EtOH induction of ASH with aberrant methionine metabolism that was associated with gene body DNA hypomethylation in all autosomes and was prevented by betaine supplementation. The data imply that EtOH-induced changes in selected gene transcript levels and hypomethylation in gene bodies during the induction of ASH are a result of altered methionine metabolism that can be reversed through dietary supplementation of methyl donors.
C1 [Medici, Valentina; Geng, Yongzhi; Shibata, Noreene M.; Halsted, Charles H.] Univ Calif Davis, Dept Internal Med, Sacramento, CA 95817 USA.
[Schroeder, Diane I.; Woods, Rima; LaSalle, Janine M.] Univ Calif Davis, Dept Med Microbiol & Immunol, Genome Ctr, Sacramento, CA 95817 USA.
Univ Calif Davis, MIND Inst, Sacramento, CA 95817 USA.
[Peerson, Janet] Univ Calif Davis, Dept Nutr, Sacramento, CA 95817 USA.
[Hodzic, Emir] Univ Calif Davis, Sch Vet Med, Real Time PCR & Res Diagnost Facil, Sacramento, CA 95817 USA.
[Dayal, Sanjana] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA.
[Tsukamoto, Hidekazu] Univ So Calif, Keck Sch Med, Southern Calif Res Ctr ALPD & Cirrhosis, Los Angeles, CA 90033 USA.
[Tsukamoto, Hidekazu] Greater Los Angeles VA Healthcare Syst, Los Angeles, CA USA.
[Kharbanda, Kusum K.] Vet Affairs Nebraska Western Iowa Hlth Care Syst, Res Serv, Omaha, NE USA.
[Tillman, Brittany; French, Samuel W.] Harbor UCLA Med Ctr, Dept Pathol, Torrance, CA 90509 USA.
RP Medici, V (reprint author), Univ Calif Davis, Div Gastroenterol & Hepatol, Dept Internal Med, 4150 5 St,Suite 3500, Sacramento, CA 95817 USA.
EM valentina.medici@ucdmc.ucdavis.edu
RI Schroeder, Diane/I-2200-2015;
OI Schroeder, Diane/0000-0003-2282-9912; LaSalle,
Janine/0000-0002-3480-2031
FU National Institutes of Health [K08DK084111, R03AA020577-01, P50AA11991];
Southern California Research Center for ALPD and Cirrhosis; Morphology
Core [P50AA11991]; Department of Veterans Affairs, Office of Research
and Development [BX001155]; Liver Center [P30 DK026743]; Division of
Gastroenterology and Hepatology at UC Davis; [R01ES021707]
FX This research was supported by National Institutes of Health grant
numbers K08DK084111 (to VM), R03AA020577-01 (to CHH), P50AA11991
Southern California Research Center for ALPD and Cirrhosis (to HT),
P50AA11991 Morphology Core (to SWF), R01ES021707 (to JML and DIS), and
by a Biomedical Laboratory Research and Development National Merit
Review grant BX001155 from the Department of Veterans Affairs, Office of
Research and Development (to KKK). VM is a member of the University of
California San Francisco Liver Center (Liver Center grant number P30
DK026743) and received funds from the Division of Gastroenterology and
Hepatology at UC Davis. The content is the sole responsibility of the
authors and does not necessarily represent the official views of the
National Institutes of Health.
NR 49
TC 7
Z9 7
U1 1
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
IS 6
BP 1540
EP 1549
DI 10.1111/acer.12405
PG 10
WC Substance Abuse
SC Substance Abuse
GA AJ2SI
UT WOS:000337511400007
PM 24730561
ER
PT J
AU Glass, JE
Williams, EC
Bucholz, KK
AF Glass, Joseph E.
Williams, Emily C.
Bucholz, Kathleen K.
TI Psychiatric Comorbidity and Perceived Alcohol Stigma in a Nationally
Representative Sample of Individuals with DSM-5 Alcohol Use Disorder
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Perceived Stigma; Alcoholism Stigma; Alcohol; Psychiatric Disorders;
Latent Class Analysis
ID SUBSTANCE USE DISORDERS; LABELING THEORY APPROACH; LATENT CLASS
ANALYSIS; DRUG-USE DISORDERS; UNITED-STATES; EPIDEMIOLOGIC SURVEY;
MENTAL-DISORDERS; SEXUAL MINORITY; HEALTH; CONSEQUENCES
AB Background Alcohol use disorder (AUD) is among the most stigmatized health conditions and is frequently comorbid with mood, anxiety, and drug use disorders. Theoretical frameworks have conceptualized stigma-related stress as a predictor of psychiatric disorders. We described profiles of psychiatric comorbidity among people with AUD and compared levels of perceived alcohol stigma across profiles. Methods Cross-sectional data were analyzed from a general population sample of U.S. adults with past-year DSM-5 AUD (n=3,368) from the National Epidemiologic Survey on Alcohol and Related Conditions, which was collected from 2001 to 2005. Empirically derived psychiatric comorbidity profiles were established with latent class analysis, and mean levels of perceived alcohol stigma were compared across the latent classes while adjusting for sociodemographic characteristics and AUD severity. Results Four classes of psychiatric comorbidity emerged within this AUD sample, including those with: (i) high comorbidity, reflecting internalizing (i.e., mood and anxiety disorders) and externalizing (i.e., antisocial personality and drug use disorders) disorders; (ii) externalizing comorbidity; (iii) internalizing comorbidity; and (iv) no comorbidity. Perceived alcohol stigma was significantly higher in those with internalizing comorbidity (but not those with high comorbidity) as compared to those with no comorbidity or externalizing comorbidity. Conclusions Perceived stigma, as manifested by anticipations of social rejection and discrimination, may increase risk of internalizing psychiatric comorbidity. Alternatively, internalizing psychiatric comorbidity could sensitize affected individuals to perceive more negative attitudes toward them. Future research is needed to understand causal and bidirectional associations between alcohol stigma and psychiatric comorbidity.
C1 [Glass, Joseph E.] Univ Wisconsin, Sch Social Work, Madison, WI 53706 USA.
[Williams, Emily C.] VA Puget Sound Hlth Care Syst, Denver Seattle Ctr Innovat Vet Ctr & Value Driven, Hlth Serv Res & Dev, Seattle, WA USA.
[Williams, Emily C.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA.
[Bucholz, Kathleen K.] Washington Univ, Sch Med, Dept Psychiat, St Louis, MO 63110 USA.
[Bucholz, Kathleen K.] Washington Univ, Sch Med, Midwest Alcoholism Res Ctr, St Louis, MO USA.
RP Glass, JE (reprint author), Univ Wisconsin, Sch Social Work, 1350 Univ Ave, Madison, WI 53706 USA.
EM jglass2@wisc.edu
FU National Institutes of Health under Ruth L. Kirschstein National
Research Service [5T32 DA015035, 1F31AA021034]; VA Health Services
Research Development [CDA 12-276]; National Institute of Mental Health
[R25 MH080916-01A2]; Department of Veterans Affairs, Health Services
Research & Development Service, Quality Enhancement Research Initiative
(QUERI); National Institute on Alcohol Abuse and Alcoholism; National
Institute on Drug Abuse of the National Institute of Health
[R01AA012460, P60AA011998, U01AA008401, R01AA017915, R01AA01 7444,
R21AA020018, R01DA014363]
FX We are grateful to Sean D. Kristjannson for consultations on the
statistical analysis and the feedback that he provided on this work. Dr.
Glass received support to conduct this project from the National
Institutes of Health under Ruth L. Kirschstein National Research Service
Awards 5T32 DA015035 and 1F31AA021034. Dr. Williams is supported by a
Career Development Award from VA Health Services Research & Development
(CDA 12-276) and is an investigator with the Implementation Research
Institute (IRI) at the George Warren Brown School of Social Work at
Washington University in St. Louis. IRI is supported through an award
from the National Institute of Mental Health (R25 MH080916-01A2) and the
Department of Veterans Affairs, Health Services Research & Development
Service, Quality Enhancement Research Initiative (QUERI). For the
research reported in this publication, KKB was supported by the National
Institute on Alcohol Abuse and Alcoholism and the National Institute on
Drug Abuse of the National Institute of Health under award numbers
R01AA012460, P60AA011998, U01AA008401, R01AA017915, R01AA01 7444,
R21AA020018, and R01DA014363.
NR 50
TC 5
Z9 5
U1 4
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
IS 6
BP 1697
EP 1705
DI 10.1111/acer.12422
PG 9
WC Substance Abuse
SC Substance Abuse
GA AJ2SI
UT WOS:000337511400025
PM 24848495
ER
PT J
AU Schmidt, TP
Pennington, DL
Durazzo, TC
Meyerhoff, DJ
AF Schmidt, Thomas P.
Pennington, David L.
Durazzo, Timothy C.
Meyerhoff, Dieter J.
TI Postural Stability in Cigarette Smokers and During Abstinence from
Alcohol
SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH
LA English
DT Article
DE Ataxia; Balance; Postural Stability; Alcohol Dependence; Cigarette
Smoking; Abstinence
ID CROSS-SECTIONAL ANALYSIS; GRAY-MATTER VOLUMES; SHORT-TERM RECOVERY;
ATAXIA TEST BATTERY; NEUROCOGNITIVE RECOVERY; NICOTINE DEPENDENCE;
MAGNETIC-RESONANCE; GAIT DISTURBANCES; MAJOR DEPRESSION; BRAIN STRUCTURE
AB Background Static postural instability is common in alcohol-dependent individuals (ALC). Chronic alcohol consumption has deleterious effects on the neural and perceptual systems subserving postural stability. However, little is known about the effects of chronic cigarette smoking on postural stability and its changes during abstinence from alcohol. Methods A modified Fregly ataxia battery was administered to a total of 115 smoking (sALC) and nonsmoking ALC (nsALC) and to 71 smoking (sCON) and nonsmoking light/nondrinking controls (nsCON). Subgroups of abstinent ALC were assessed at 3 time points (TPs; approximately 1, 5, 34weeks of abstinence from alcohol); a subset of nsCON was retested at 40weeks. We tested whether cigarette smoking affects postural stability in CON and in ALC during extended abstinence from alcohol, and we used linear mixed effects modeling to measure change across TPs within ALC. Results Chronic smoking was associated with reduced performance on the Sharpened Romberg eyes-closed task in abstinent ALC at all 3 TPs and in CON. The test performance of nsALC increased significantly between 1 and 32weeks of abstinence, whereas the corresponding increases for sALC between 1 and 35weeks were nonsignificant. With long-term abstinence from alcohol, nsALC recovered into the range of nsCON and sALC recovered into the range of sCON. Static postural stability decreased with age and correlated with smoking variables but not with drinking measures. Conclusions Chronic smoking was associated with reduced static postural stability with eyes closed and with lower increases of postural stability during abstinence from alcohol. Smoking cessation in alcohol dependence treatment may facilitate recovery from static postural instability during abstinence.
C1 [Schmidt, Thomas P.; Pennington, David L.; Durazzo, Timothy C.; Meyerhoff, Dieter J.] San Francisco VA Med Ctr, CIND, San Francisco, CA 94121 USA.
[Schmidt, Thomas P.; Pennington, David L.; Durazzo, Timothy C.; Meyerhoff, Dieter J.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA.
RP Schmidt, TP (reprint author), San Francisco VA Med Ctr, Ctr Imaging Neurodegenerat Dis 114M, 4150 Clement St, San Francisco, CA 94121 USA.
EM thomas.schmidt@ucsf.edu
FU National Institutes of Health [AA10788, DA24136]
FX This work was supported by grants from the National Institutes of Health
[AA10788 to DJM.; DA24136 to TCD] administered by the Northern
California Institute for Research and Education, and by the use of
resources and facilities at the San Francisco Veterans Administration
Medical Center. We thank Mary Rebecca Young, Kathleen Altieri, Ricky
Chen, and Drs. Peter Banys, Steven Batki, and Ellen Herbst of the
Veterans Administration Substance Abuse Day Hospital, and Dr. David
Pating, Karen Moise, and their colleagues at the Kaiser Permanente
Chemical Dependency Recovery Program in San Francisco for their valuable
assistance in recruiting participants. We also wish to extend our
gratitude to the study participants, who made this research possible.
NR 54
TC 1
Z9 1
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0145-6008
EI 1530-0277
J9 ALCOHOL CLIN EXP RES
JI Alcoholism (NY)
PD JUN
PY 2014
VL 38
IS 6
BP 1753
EP 1760
DI 10.1111/acer.12409
PG 8
WC Substance Abuse
SC Substance Abuse
GA AJ2SI
UT WOS:000337511400032
PM 24721012
ER
PT J
AU Samuels, J
Shugart, YY
Wang, Y
Grados, MA
Bienvenu, OJ
Pinto, A
Rauch, SL
Greenberg, BD
Knowles, JA
Fyer, AJ
Piacentini, J
Pauls, DL
Cullen, B
Rasmussen, SA
Stewart, SE
Geller, DA
Maher, BS
Goes, FS
Murphy, DL
McCracken, JT
Riddle, MA
Nestadt, G
AF Samuels, Jack
Shugart, Yin Yao
Wang, Ying
Grados, Marco A.
Bienvenu, O. Joseph
Pinto, Anthony
Rauch, Scott L.
Greenberg, Benjamin D.
Knowles, James A.
Fyer, Abby J.
Piacentini, John
Pauls, David L.
Cullen, Bernadette
Rasmussen, Steven A.
Stewart, S. Evelyn
Geller, Dan A.
Maher, Brion S.
Goes, Fernando S.
Murphy, Dennis L.
McCracken, James T.
Riddle, Mark A.
Nestadt, Gerald
TI Clinical Correlates and Genetic Linkage of Social and Communication
Difficulties in Families with Obsessive-Compulsive Disorder: Results
From the OCD Collaborative Genetics Study
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS
LA English
DT Article
DE obsessive-compulsive disorder; OCD; pragmatics; genetic linkage
ID BROAD AUTISM PHENOTYPE; PSYCHIATRIC-DISORDERS; ASPERGER-SYNDROME;
CHILDREN; PARENTS; INDIVIDUALS; PERSONALITY; BEHAVIORS; TRAITS; SCAN
AB Some individuals with obsessive-compulsive disorder (OCD) have autistic-like traits, including deficits in social and communication behaviors (pragmatics). The objective of this study was to determine if pragmatic impairment aggregates in OCD families and discriminates a clinically and genetically distinct subtype of OCD. We conducted clinical examinations on, and collected DNA samples from, 706 individuals with OCD in 221 multiply affected OCD families. Using the Pragmatic Rating Scale (PRS), we compared the prevalence of pragmatic impairment in OCD-affected relatives of probands with and without pragmatic impairment. We also compared clinical features of OCD-affected individuals in families having at least one, versus no, individual with pragmatic impairment, and assessed for linkage to OCD in the two groups of families. The odds of pragmatic impairment were substantially greater in OCD-affected relatives of probands with pragmatic impairment. Individuals in high-PRS families had greater odds of separation anxiety disorder and social phobia, and a greater number of schizotypal personality traits. In high-PRS families, there was suggestive linkage to OCD on chromosome 12 at marker D12S1064 and on chromosome X at marker DXS7132 whereas, in low-PRS families, there was suggestive linkage to chromosome 3 at marker D3S2398. Pragmatic impairment aggregates in OCD families. Separation anxiety disorder, social phobia, and schizotypal personality traits are part of a clinical spectrum associated with pragmatic impairment in these families. Specific regions of chromosomes 12 and X are linked to OCD in high-PRS families. Thus, pragmatic impairment may distinguish a clinically and genetically homogeneous subtype of OCD. (C) 2014 Wiley Periodicals, Inc.
C1 [Samuels, Jack; Wang, Ying; Grados, Marco A.; Bienvenu, O. Joseph; Cullen, Bernadette; Goes, Fernando S.; Riddle, Mark A.; Nestadt, Gerald] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21205 USA.
[Shugart, Yin Yao] NIMH, Genom Res Branch, Div Neurosci & Basic Behav Sci, NIH, Bethesda, MD 20892 USA.
[Pinto, Anthony; Fyer, Abby J.] Columbia Univ, Coll Phys & Surg, Dept Psychiat, New York, NY USA.
[Pinto, Anthony; Fyer, Abby J.] New York State Psychiat Inst & Hosp, New York, NY 10032 USA.
[Rauch, Scott L.; Geller, Dan A.] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Greenberg, Benjamin D.; Rasmussen, Steven A.] Butler Hosp, Brown Med Sch, Dept Psychiat & Human Behav, Providence, RI 02906 USA.
[Knowles, James A.] Univ So Calif, Dept Psychiat, Sch Med, Los Angeles, CA USA.
[Piacentini, John; McCracken, James T.] Univ Calif Los Angeles, Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Pauls, David L.] Massachusetts Gen Hosp, Dept Psychiat, Boston, MA 02114 USA.
[Pauls, David L.] Massachusetts Gen Hosp, Psychiat & Neurodev Genet Unit, Boston, MA 02114 USA.
[Pauls, David L.] Harvard Univ, Sch Med, Boston, MA USA.
[Stewart, S. Evelyn] Univ British Columbia, Fac Med, Dept Psychiat, Vancouver Fac Med, Vancouver, BC, Canada.
[Maher, Brion S.] Johns Hopkins Univ, Dept Mental Hlth, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
[Murphy, Dennis L.] NIMH, Clin Sci Lab, NIH, Bethesda, MD 20892 USA.
RP Samuels, J (reprint author), Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, 550 N Broadway 901, Baltimore, MD 21205 USA.
EM jacks@jhmi.edu
RI Pinto, Anthony/D-2718-2017;
OI Pinto, Anthony/0000-0002-6078-7242; Samuels, Jack/0000-0002-6715-7905;
Stewart, S. Evelyn/0000-0002-0994-6383
FU National Institutes of Health [R01-MH-50214, R01MH071507, K23-MH-64543,
NIH/NCRR/OPD-GCRC RR00052]; James E. Marshall OCD Foundation
FX Grant sponsor: National Institutes of Health; Grant numbers:
R01-MH-50214, R01MH071507, K23-MH-64543, NIH/NCRR/OPD-GCRC RR00052;
Grant sponsor: James E. Marshall OCD Foundation.
NR 57
TC 3
Z9 3
U1 3
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4841
EI 1552-485X
J9 AM J MED GENET B
JI Am. J. Med. Genet. B
PD JUN
PY 2014
VL 165
IS 4
BP 326
EP 336
DI 10.1002/ajmg.b.32235
PG 11
WC Genetics & Heredity; Psychiatry
SC Genetics & Heredity; Psychiatry
GA AJ4UX
UT WOS:000337674600006
PM 24798771
ER
PT J
AU Harvey, PD
Siever, LJ
Huang, GD
Muralidhar, S
Zhao, HY
Miller, P
Aslan, M
Mane, S
McNamara, M
Gleason, T
Brophy, M
Przygodszki, R
O'Leary, TJ
Gaziano, M
Concato, J
AF Harvey, Philip D.
Siever, Larry J.
Huang, Grant D.
Muralidhar, Sumitra
Zhao, Hongyu
Miller, Perry
Aslan, Mihaela
Mane, Shrikant
McNamara, Margaret
Gleason, Theresa
Brophy, Mary
Przygodszki, Ronald
O'Leary, Timothy J.
Gaziano, Michael
Concato, John
TI The Genetics of Functional Disability in Schizophrenia and Bipolar
Illness: Methods and Initial Results for VA Cooperative Study #572
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART B-NEUROPSYCHIATRIC GENETICS
LA English
DT Article
DE schizophrenia; bipolar; genetics; neurocognition; disability
ID CONSENSUS COGNITIVE BATTERY; MENTAL-ILLNESS; UNITED-STATES; I DISORDER;
CONSORTIUM; ENDOPHENOTYPES; IMPAIRMENT; PREDICTION; STABILITY; CANDIDATE
AB Given the prominence of cognitive impairments and disability associated with schizophrenia and bipolar disorder, substantial interest has arisen in identifying determinants of the diseases and their features. Genetic variation has been linked to skills that underlie disability ("functional capacity" or FC), highlighting need for understanding of these relationships. We describe the design and methods of a large, multisite, observational study focusing on the genetics of functional disability in schizophrenia and bipolar disorder, presenting initial data on recruitment, and characterization of the sample. Known as Veterans Affairs (VA) Cooperative Studies Program (CSP)#572, this study is recruiting, diagnosing, and assessing U.S. Veterans with either schizophrenia or bipolar I disorder. Assessments include neuropsychological (NP) testing, FC, suicidality, and co-morbid conditions such as posttraumatic stress disorder (PTSD). A sample of "psychiatrically healthy" Veterans from another project serves as a comparison group. An interim total of 8,140 participants (42.1% schizophrenia) have been recruited and assessed as of September 30, 2013, with 9 months of enrollment remaining and with a target sample size of 9,500. Veterans with schizophrenia were more likely to never have married, whereas lifetime PTSD and suicidality were more common in the bipolar veterans. Performance on the FC measures and NP tests was consistent with previous results, with mean t-scores of 35 (-1.5 SD) for schizophrenia and 41 (-0.9 SD) for the bipolar Veterans. This large population is representative of previous studies in terms of patient performance and co-morbidities. Subsequent genomic analyses will examine the genomic correlates of performance-based measures. Published 2014. This article is a U.S. Government work and is in the public domain in the USA.
C1 [Harvey, Philip D.] Bruce W Carter Miami Vet Affairs VA Med Ctr, Miami, FL USA.
[Harvey, Philip D.] Univ Miami, Sch Med, Miami, FL 33136 USA.
[Siever, Larry J.; McNamara, Margaret] James J Peters Vet Affairs Med Ctr, Bronx, NY USA.
[Siever, Larry J.; McNamara, Margaret] Mt Sinai Sch Med, New York, NY USA.
[Huang, Grant D.; Muralidhar, Sumitra; Gleason, Theresa; Przygodszki, Ronald; O'Leary, Timothy J.] Vet Hlth Adm, Off Res & Dev, Washington, DC USA.
[Zhao, Hongyu; Miller, Perry; Aslan, Mihaela; Concato, John] VA Connecticut Healthcare Syst, CERC, West Haven, CT USA.
[Zhao, Hongyu; Miller, Perry; Aslan, Mihaela; Mane, Shrikant; Concato, John] Yale Univ, Sch Med, New Haven, CT USA.
[Brophy, Mary; Gaziano, Michael] MAVERIC, Jamaica Plain, MA USA.
[Brophy, Mary] Boston Univ, Sch Med, Boston, MA 02118 USA.
[Gaziano, Michael] Harvard Univ, Boston, MA 02115 USA.
RP Harvey, PD (reprint author), Univ Miami, Miller Sch Med, 1120 NW 14th St,Suite 1450, Miami, FL 33136 USA.
EM pharvey@med.miami.edu
OI Przygodzki, Ronald/0000-0002-1238-262X
FU Department of Veterans Affairs Cooperative Studies Program
FX Grant sponsor: Department of Veterans Affairs Cooperative Studies
Program.
NR 36
TC 9
Z9 9
U1 8
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4841
EI 1552-485X
J9 AM J MED GENET B
JI Am. J. Med. Genet. B
PD JUN
PY 2014
VL 165
IS 4
BP 381
EP 389
DI 10.1002/ajmg.b.32242
PG 9
WC Genetics & Heredity; Psychiatry
SC Genetics & Heredity; Psychiatry
GA AJ4UX
UT WOS:000337674600012
PM 24798943
ER
PT J
AU Hirsch, JA
Donovan, WD
Barr, RM
Nicola, GN
Rosman, DA
Schaefer, PW
Manchikanti, L
AF Hirsch, J. A.
Donovan, W. D.
Barr, R. M.
Nicola, G. N.
Rosman, D. A.
Schaefer, P. W.
Manchikanti, L.
TI The Independent Payment Advisory Board
SO AMERICAN JOURNAL OF NEURORADIOLOGY
LA English
DT Editorial Material
ID INTERVENTIONAL PAIN MANAGEMENT; AFFORDABLE CARE ACT; OUTCOMES
RESEARCH-INSTITUTE; PATIENT PROTECTION; NEUROINTERVENTIONALISTS;
PROGNOSIS; EVOLUTION; IMPACT
C1 [Hirsch, J. A.; Rosman, D. A.; Schaefer, P. W.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Donovan, W. D.] Norwich Diagnost Imaging Associates, Norwich, CT USA.
[Barr, R. M.] Mecklenburg Radiol Associates, Charlotte, NC USA.
[Nicola, G. N.] Hackensack Univ, Med Ctr, Hackensack, NJ USA.
[Manchikanti, L.] Pain Management Ctr Paducah, Paducah, KY USA.
[Manchikanti, L.] Univ Louisville, Louisville, KY 40292 USA.
RP Hirsch, JA (reprint author), Massachusetts Gen Hosp, Dept Radiol, 55 Fruit St,Gray Bldg,2nd Floor, Boston, MA 02114 USA.
EM Hirsch@snisonline.org
NR 17
TC 0
Z9 0
U1 1
U2 3
PU AMER SOC NEURORADIOLOGY
PI DENVILLE
PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA
SN 0195-6108
EI 1936-959X
J9 AM J NEURORADIOL
JI Am. J. Neuroradiol.
PD JUN
PY 2014
VL 35
IS 6
BP 1066
EP 1069
DI 10.3174/ajnr.A3736
PG 4
WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical
Imaging
SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging
GA AJ4NK
UT WOS:000337652900006
PM 24136648
ER
PT J
AU Lee, SE
Kang, SY
Cho, J
Lee, B
Chang, DK
Woo, H
Kim, JW
Park, HY
Do, IG
Kim, YE
Kushima, R
Lauwers, GY
Park, CK
Kim, KM
AF Lee, Seung Eun
Kang, So Young
Cho, Junhun
Lee, Boram
Chang, Dong Kyung
Woo, Hyein
Kim, Jong Won
Park, Ha Young
Do, In Gu
Kim, Young Eun
Kushima, Ryoji
Lauwers, Gregory Y.
Park, Cheol Keun
Kim, Kyoung M.
TI Pyloric Gland Adenoma in Lynch Syndrome
SO AMERICAN JOURNAL OF SURGICAL PATHOLOGY
LA English
DT Article
DE gastric; pyloric gland adenoma; carcinoma; precursor; Lynch syndrome
ID NONPOLYPOSIS COLORECTAL-CANCER; MICROSATELLITE INSTABILITY;
GASTRIC-CANCER; POLYPS; IMMUNOHISTOCHEMISTRY; NETHERLANDS; EXPRESSION;
GUIDELINES; MANAGEMENT; MUTATIONS
AB The prevalence of gastric cancer associated with Lynch syndrome (LS) is highly variable, and the underlying histologic pathway or molecular mechanisms remain unclear. From 1995 to 2012, 15 patients had been treated for both gastric and colonic adenocarcinomas and diagnosed as LS. In all cases, pathologic review, immunohistochemical analysis for mismatch-repair proteins, and microsatellite instability (MSI) tests were performed. To confirm LS, germline mutation tests and multiplex ligation-dependent probe amplification were performed. All gastric and colonic carcinomas were MSI-high and lost expressions of MLH1/PMS2 in 11 (73%) cases and MSH2/MSH6 in 4 (27%) cases. Remarkably, in a patient with LS and germline mutation of MLH1 gene, pyloric gland adenoma (PGA) transformed to adenocarcinoma during follow-up. In 2 additional cases, PGA was found adjacent to advanced gastric cancers. All PGAs in LS patients were MSI-high and lost expression of mismatch-repair proteins (MLH1/PMS2 in 2 cases and MSH2/MSH6 in 1 case), whereas none of the 14 sporadic PGAs was MSI-high or had lost expression of mismatch-repair proteins. On the basis of these observations, although very rare, we suggest the possibility that PGA may be a precursor lesion to gastric adenocarcinoma in LS and that the mismatch-repair deficient pathway of carcinogenesis is involved early in the gastric carcinogenesis pathway.
C1 [Lee, Seung Eun; Kang, So Young; Cho, Junhun; Lee, Boram; Park, Ha Young; Do, In Gu; Kim, Young Eun; Park, Cheol Keun; Kim, Kyoung M.] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, Seoul 135710, South Korea.
[Chang, Dong Kyung] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Gastroenterol, Seoul 135710, South Korea.
[Woo, Hyein; Kim, Jong Won] Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Lab Med, Seoul 135710, South Korea.
[Kushima, Ryoji] Natl Canc Ctr, Clin Lab Div, Tokyo, Japan.
[Lauwers, Gregory Y.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Kim, KM (reprint author), Sungkyunkwan Univ, Sch Med, Samsung Med Ctr, Dept Pathol, 50 Irwon Dong, Seoul 135710, South Korea.
EM kkmkys@skku.edu
FU Korea Healthcare Technology R&D project, Ministry of Health & Welfare,
Republic of Korea [A101130]
FX Funded by a grant from the Korea Healthcare Technology R&D project,
Ministry of Health & Welfare, Republic of Korea (A101130). The authors
have disclosed that they have no significant relationships with, or
financial interest in, any commercial companies pertaining to this
article.
NR 32
TC 11
Z9 11
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0147-5185
EI 1532-0979
J9 AM J SURG PATHOL
JI Am. J. Surg. Pathol.
PD JUN
PY 2014
VL 38
IS 6
BP 784
EP 792
DI 10.1097/PAS.0000000000000185
PG 9
WC Pathology; Surgery
SC Pathology; Surgery
GA AJ0CD
UT WOS:000337315800006
PM 24518125
ER
PT J
AU Bruinsma, BG
Yeh, H
Ozer, S
Martins, PN
Farmer, A
Wu, W
Saeidi, N
Op den Dries, S
Berendsen, TA
Smith, RN
Markmann, JF
Porte, RJ
Yarmush, ML
Uygun, K
Izamis, ML
AF Bruinsma, B. G.
Yeh, H.
Oezer, S.
Martins, P. N.
Farmer, A.
Wu, W.
Saeidi, N.
Op den Dries, S.
Berendsen, T. A.
Smith, R. N.
Markmann, J. F.
Porte, R. J.
Yarmush, M. L.
Uygun, K.
Izamis, M. -L.
TI Subnormothermic Machine Perfusion for Ex Vivo Preservation and Recovery
of the Human Liver for Transplantation
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Donation after circulatory death; liver transplantation; organ
preservation; subnormothermic machine perfusion
ID HEART-BEATING DONOR; RAT-LIVER; COLD-STORAGE; NORMOTHERMIC PRESERVATION;
ORGAN VIABILITY; PORCINE LIVERS; HOPE PROTECTS; CARDIAC DEATH;
SINGLE-CENTER; BILE-DUCTS
AB To reduce widespread shortages, attempts are made to use more marginal livers for transplantation. Many of these grafts are discarded for fear of inferior survival rates or biliary complications. Recent advances in organ preservation have shown that ex vivo subnormothermic machine perfusion has the potential to improve preservation and recover marginal livers pretransplantation. To determine the feasibility in human livers, we assessed the effect of 3 h of oxygenated subnormothermic machine perfusion (21 degrees C) on seven livers discarded for transplantation. Biochemical and microscopic assessment revealed minimal injury sustained during perfusion. Improved oxygen uptake (1.30 [1.11-1.94] to 6.74 [4.15-8.16] mL O-2/min kg liver), lactate levels (4.04 [3.70-5.99] to 2.29 [1.20-3.43] mmol/L) and adenosine triphosphate content (45.0 [70.6-87.5] pmol/mg preperfusion to 167.5 [151.5-237.2] pmol/mg after perfusion) were observed. Liver function, reflected by urea, albumin and bile production, was seen during perfusion. Bile production increased and the composition of bile (bile salts/phospholipid ratio, pH and bicarbonate concentration) became more favorable. In conclusion, ex vivo subnormothermic machine perfusion effectively maintains liver function with minimal injury and sustains or improves various hepatobiliary parameters postischemia.
C1 [Bruinsma, B. G.; Oezer, S.; Farmer, A.; Wu, W.; Saeidi, N.; Berendsen, T. A.; Yarmush, M. L.; Uygun, K.; Izamis, M. -L.] Harvard Univ, Sch Med, Dept Surg, Ctr Engn Med,Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Bruinsma, B. G.] Univ Amsterdam, Acad Med Ctr, Dept Surg, Surg Lab, NL-1105 AZ Amsterdam, Netherlands.
[Yeh, H.; Markmann, J. F.] Massachusetts Gen Hosp, Transplant Ctr, Boston, MA 02114 USA.
[Martins, P. N.] UMass Mem Med Ctr, Boston, MA USA.
[Op den Dries, S.; Porte, R. J.] Univ Groningen, Univ Med Ctr Groningen, Sect Hepatobiliary Surg & Liver Transplantat, Dept Surg, Groningen, Netherlands.
[Smith, R. N.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Yarmush, M. L.] Rutgers State Univ, Dept Biomed Engn, Piscataway, NJ USA.
RP Uygun, K (reprint author), Harvard Univ, Sch Med, Dept Surg, Ctr Engn Med,Massachusetts Gen Hosp, Boston, MA 02115 USA.
EM uygun.korkut@mgh.harvard.edu; mizamis@partners.org
FU National Institutes of Health [R00DK080942, R01DK096075, R01EB008678];
Shriners Hospitals for Children
FX We would like to gratefully acknowledge the NEOB and the surgical
procurement teams for supporting this work through the supply of
discarded livers and commendable coordination. We are also grateful to
the perfusionists at MGH for their support. Funding from the National
Institutes of Health (R00DK080942, R01DK096075, R01EB008678) and the
Shriners Hospitals for Children are gratefully acknowledged.
NR 51
TC 34
Z9 40
U1 2
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
IS 6
BP 1400
EP 1409
DI 10.1111/ajt.12727
PG 10
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ2UP
UT WOS:000337519500022
PM 24758155
ER
PT J
AU Chandraker, A
Arscott, R
Murphy, GF
Lian, CG
Bueno, EM
Marty, FM
Rennke, HG
Milford, E
Tullius, SG
Pomahac, B
AF Chandraker, A.
Arscott, R.
Murphy, G. F.
Lian, C. G.
Bueno, E. M.
Marty, F. M.
Rennke, H. G.
Milford, E.
Tullius, S. G.
Pomahac, B.
TI The Management of Antibody-Mediated Rejection in the First Presensitized
Recipient of a Full-Face Allotransplant
SO AMERICAN JOURNAL OF TRANSPLANTATION
LA English
DT Article
DE Antibody-mediated rejection; C4d; cross-match; donor-specific
antibodies; face allotransplantation; vascularized composite tissue
allotransplantation
ID COMPOSITE TISSUE ALLOTRANSPLANTATION; FACIAL TRANSPLANTATION; HAND
ALLOGRAFT; C4D DEPOSITION; BRIGHAM
AB We report on the management of the first full-face transplantation in a sensitized recipient with a positive preoperative crossmatch and subsequent antibodymediated rejection (AMR). The recipient is a 45-year-old female who sustained extensive chemical burns, with residual poor function and high levels of circulating anti-HLA antibodies. With a clear immunosuppression plan and salvage options in place, a full-face allotransplant was performed using a crossmatch positive donor. Despite plasmapheresis alongside a standard induction regimen, clinical signs of rejection were noted on postoperative day 5 (POD5). Donor-specific antibody (DSA) titers rose with evidence of C4d deposits on biopsy. By POD19, biopsies showed Banff Grade III rejection. Combination therapy consisting of plasmapheresis, eculizumab, bortezomib and alemtuzumab decreased DSA levels, improved clinical exam, and by 6 months postop she had no histological signs of rejection. This case is the first to demonstrate evidence and management of AMR in face allotransplantation. Our findings lend support to the call for an update to the Banff classification of rejection in vascularized composite tissue allotransplantation (VCA) to includeAMR, and for further studies to better classify the histology and mechanism of action of AMR in VCA.
C1 [Chandraker, A.] Brigham & Womens Hosp, Div Renal, Schuster Family Transplantat Res Ctr, Boston, MA 02115 USA.
[Chandraker, A.] Harvard Univ, Sch Med, Childrens Hosp Boston, Boston, MA USA.
[Arscott, R.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Surg, Boston, MA 02115 USA.
[Murphy, G. F.; Lian, C. G.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Dermatopathol,Dept Pathol, Boston, MA 02115 USA.
[Bueno, E. M.; Pomahac, B.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Plast Surg,Dept Surg, Boston, MA 02115 USA.
[Marty, F. M.] Dana Farber Canc Inst, Div Infect Dis, Boston, MA 02115 USA.
[Marty, F. M.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Rennke, H. G.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Pathol, Boston, MA 02115 USA.
[Milford, E.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med,Div Nephrol, Boston, MA 02115 USA.
[Tullius, S. G.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Transplant Surg,Dept Surg, Boston, MA 02115 USA.
RP Chandraker, A (reprint author), Brigham & Womens Hosp, Div Renal, Schuster Family Transplantat Res Ctr, Boston, MA 02115 USA.
EM achandraker@partners.org
OI Lian, Christine/0000-0003-4626-1612
NR 15
TC 28
Z9 28
U1 1
U2 4
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1600-6135
EI 1600-6143
J9 AM J TRANSPLANT
JI Am. J. Transplant.
PD JUN
PY 2014
VL 14
IS 6
BP 1446
EP 1452
DI 10.1111/ajt.12715
PG 7
WC Surgery; Transplantation
SC Surgery; Transplantation
GA AJ2UP
UT WOS:000337519500028
PM 24797454
ER
PT J
AU Kamdar, BB
Kamdar, BB
Needham, DM
AF Kamdar, B. B.
Kamdar, B. B.
Needham, D. M.
TI Bundling sleep promotion with delirium prevention: ready for prime time?
SO ANAESTHESIA
LA English
DT Editorial Material
ID INTENSIVE-CARE-UNIT; CRITICALLY-ILL PATIENTS; ICU PATIENTS; EYE MASKS;
QUALITY; PERCEPTION; SEDATION; NOISE; INTERVENTION; DEPRIVATION
C1 [Kamdar, B. B.] Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA.
[Kamdar, B. B.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Anaesthesiol Crit Care & Pain Med, Boston, MA USA.
[Needham, D. M.] Johns Hopkins Univ, Div Pulm & Crit Care Med, Outcomes Crit Illness & Surg OACIS Grp, Baltimore, MD USA.
[Needham, D. M.] Johns Hopkins Univ, Dept Phys Med & Rehabil, Baltimore, MD USA.
RP Kamdar, BB (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm & Crit Care Med, Los Angeles, CA 90095 USA.
EM bkamdar@mednet.ucla.edu
OI Kamdar, Biren/0000-0002-9245-6229
NR 33
TC 2
Z9 2
U1 4
U2 18
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0003-2409
EI 1365-2044
J9 ANAESTHESIA
JI Anaesthesia
PD JUN
PY 2014
VL 69
IS 6
BP 527
EP 531
DI 10.1111/anae.12686
PG 5
WC Anesthesiology
SC Anesthesiology
GA AJ3LV
UT WOS:000337568900003
PM 24813131
ER
PT J
AU Edwards, FH
Shahian, DM
Grau-Sepulveda, MV
Grover, FL
Mayer, JE
O'Brien, SM
DeLong, E
Peterson, ED
McKay, C
Shaw, RE
Garratt, KN
Dangas, GD
Messenger, J
Klein, LW
Popma, JJ
Weintraub, WS
AF Edwards, Fred H.
Shahian, David M.
Grau-Sepulveda, Maria V.
Grover, Frederick L.
Mayer, John E.
O'Brien, Sean M.
DeLong, Elizabeth
Peterson, Eric D.
McKay, Charles
Shaw, Richard E.
Garratt, Kirk N.
Dangas, George D.
Messenger, John
Klein, Lloyd W.
Popma, Jeffrey J.
Weintraub, William S.
TI Composite Outcomes in Coronary Bypass Surgery Versus Percutaneous
Intervention
SO ANNALS OF THORACIC SURGERY
LA English
DT Article; Proceedings Paper
CT 49th Annual Meeting of the Society-of-Thoracic-Surgeons
CY JAN 26-30, 2013
CL Los Angeles, CA
SP Soc Thorac Surg
ID DRUG-ELUTING STENTS; LONG-TERM SURVIVAL; 5-YEAR FOLLOW-UP;
ARTERY-DISEASE; SYNTAX TRIAL; REVASCULARIZATION STRATEGIES; 3-VESSEL
DISEASE; GRAFT-SURGERY; MULTIVESSEL; PROPENSITY
AB Background. Recent observational studies show that patients with multivessel coronary disease have a long-term survival advantage with coronary artery bypass grafting (CABG) compared with percutaneous coronary intervention (PCI). Important nonfatal outcomes may also affect optimal treatment recommendation.
Methods. CABG was compared with percutaneous catheter intervention by using a composite of death, myocardial infarction (MI), or stroke. Medicare patients undergoing revascularization for stable multivessel coronary disease from 2004 through 2008 were identified in national registries. Short-term clinical information from the registries was linked to Medicare data to obtain long-term follow-up out to 4 years from the time of the procedure. Propensity scoring with inverse probability weighting was used to adjust for baseline risk factors.
Results. There were 86,244 CABG and 103,549 PCI patients. The mean age was 74 years, with a median 2.67 years of follow-up. At 4 years, the propensity-adjusted adjusted cumulative incidence of MI was 3.2% in CABG compared with 6.6% in PCI (risk ratio, 0.49; 95% confidence interval, 0.45 to 0.53). At 4 years, the cumulative incidence of stroke was 4.5% in CABG compared with 3.1% in PCI patients (risk ratio, 1.43; 95% confidence interval, 1.31 to 1.54). This difference was primarily due to the higher 30-day stroke rate for CABG (1.55% vs 0.37%). For the composite of death, MI, or stroke, the 4-year adjusted cumulative incidence was 21.6% for CABG and 26.7% for PCI (risk ratio, 0.81; 95% confidence interval, 0.78 to 0.83).
Conclusions. The 4-year composite event rate of death, MI, and stroke favored CABG, whereas the risk of stroke alone favored PCI. (C) 2014 by The Society of Thoracic Surgeons
C1 Soc Thorac Surg, Chicago, IL USA.
Massachusetts Gen Hosp, Boston, MA 02114 USA.
Duke Clin Res Inst, Durham, NC USA.
Univ Colorado, Sch Med, Aurora, CO USA.
Childrens Hosp Boston, Boston, MA USA.
Harbor UCLA Med Ctr, Torrance, CA 90509 USA.
Calif Pacific Med Ctr, San Francisco, CA USA.
Lenox Hill Heart & Vasc Inst New York, New York, NY USA.
Mt Sinai Med Ctr, New York, NY 10029 USA.
Advocate Illinois Masonic Med Ctr, Chicago, IL USA.
Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
Christiana Care Ctr Outcome Res, Newark, DE USA.
RP Edwards, FH (reprint author), STS Res Ctr, 633 N St Clair St, Chicago, IL 60611 USA.
EM fred.edwards@jax.ufl.edu
FU NHLBI NIH HHS [RC2HL101489, RC2 HL101489]
NR 32
TC 5
Z9 5
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD JUN
PY 2014
VL 97
IS 6
BP 1983
EP 1990
DI 10.1016/j.athoracsur.2014.01.087
PG 8
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA AI9KT
UT WOS:000337252200019
PM 24775805
ER
PT J
AU Molnar, AO
Parikh, CR
Coca, SG
Thiessen-Philbrook, H
Koyner, JL
Shlipak, MG
Myers, ML
Garg, AX
AF Molnar, Amber O.
Parikh, Chirag R.
Coca, Steven G.
Thiessen-Philbrook, Heather
Koyner, Jay L.
Shlipak, Michael G.
Myers, Mary Lee
Garg, Amit X.
CA TRIBE-AKI Consortium
TI Association Between Preoperative Statin Use and Acute Kidney Injury
Biomarkers in Cardiac Surgical Procedures
SO ANNALS OF THORACIC SURGERY
LA English
DT Article
ID ACUTE-RENAL-FAILURE; ISCHEMIA-REPERFUSION INJURY; URINARY BIOMARKERS;
SURGERY; THERAPY; RISK; OUTCOMES; BYPASS; PRAVASTATIN; DEFINITION
AB Background. Acute kidney injury (AKI) is a serious complication of cardiac operations for which there remains no specific therapy. Animal data and several observational studies suggest that statins prevent AKI, but the results are not conclusive, and many studies are retrospective in nature.
Methods. We conducted a multicenter prospective cohort study of 625 adult patients undergoing elective cardiac operations. All patients were taking statins and were grouped according to whether statins were continued or held in the 24 hours before operation. The primary outcome was AKI as defined by a doubling of serum creatinine or dialysis. The secondary outcome was the peak level of several kidney injury biomarkers. The results were adjusted for demographic and clinical factors.
Results. Continuing(vs holding) a statin before operation was not associated with a lower risk of AKI, as defined by a doubling of serum creatinine or dialysis (adjusted relative risk [RR] 1.09; 95% confidence interval [CI] 0.44, 2.70). However, continuing a statin was associated with a lower risk of elevation of the following AKI biomarkers: urine interleukin-18, urine neutrophil gelatinase-associated lipocalin, urine kidney injury molecule-1, and plasma neutrophil gelatinase-associated lipocalin (adjusted RR 0.34; 95% CI 0.18, 0.62), (adjusted RR 0.41; 95% CI 0.22, 0.76), (adjusted RR 0.37; 95% CI 0.20, 0.76), (adjusted RR 0.62; 95% CI 0.39, 0.98), respectively.
Conclusions. Statins may prevent kidney injury after cardiac operations, as evidenced by lower levels of kidney injury biomarkers. (c) 2014 by The Society of Thoracic Surgeons
C1 Univ Ottawa, Dept Med, Div Nephrol, Ottawa, ON, Canada.
Yale Univ, Sch Med, Nephrol Sect, Vet Affairs CT Healthcare Syst, New Haven, CT USA.
Yale Univ, Program Appl Translat Res, New Haven, CT USA.
Vet Affairs Med Ctr, Dept Med, West Haven, CT USA.
Univ Western Ontario, Dept Med, Div Nephrol, London, ON, Canada.
Univ Chicago, Pritzker Sch Med, Dept Med, Nephrol Sect, Chicago, IL 60637 USA.
Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Gen Internal Med, San Francisco, CA 94143 USA.
Univ Western Ontario, Div Cardiac Surg, London, ON, Canada.
McMaster Univ, Dept Clin Epidemiol & Biostat, Hamilton, ON, Canada.
Univ Western Ontario, Dept Epidemiol & Biostat, London, ON, Canada.
Inst Clin Evaluat Sci, Toronto, ON, Canada.
RP Parikh, CR (reprint author), Yale Univ, Nephrol Sect, 950 Campbell Ave,Mail Code 151B,Bldg 35 A,Rm 219, West Haven, CT 06516 USA.
EM chirag.parikh@yale.edu
FU NIH [RO1HL085757, K24DK090203]; TRIBE-AKI Consortium; National
Institutes of Health [K23DK080132, R01DK096549, R01HL085757]; Acute
Kidney Injury (ASSESS-AKI) Consortium [U01DK082185]
FX This study was supported by the NIH grant RO1HL085757 (CRP) to fund the
TRIBE-AKI Consortium to study novel biomarkers of acute kidney injury in
cardiac surgery. S.G.C. is supported by National Institutes of Health
Grants K23DK080132, R01DK096549, and R01HL085757. C.R.P. is also
supported by NIH grant K24DK090203. S.G.C., A.X.G., and C.R.P. are also
members of the NIH-sponsored ASsess, Serial Evaluation, and Subsequent
Sequelae in Acute Kidney Injury (ASSESS-AKI) Consortium (U01DK082185).
The urine biomarker assays were donated by Abbott Diagnostics (IL-18 and
NGAL) and Sekisui Diagnostics, LLC (KIM-1 and L-FABP). The granting
agencies, Abbott Diagnostics and Sekisui Diagnostics, Inc, did not
participate in the design and conduct of the study; collection,
management, analysis, and interpretation of the data; and preparation,
review, or approval of the manuscript.
NR 40
TC 17
Z9 17
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0003-4975
EI 1552-6259
J9 ANN THORAC SURG
JI Ann. Thorac. Surg.
PD JUN
PY 2014
VL 97
IS 6
BP 2081
EP 2088
DI 10.1016/j.athoracsur.2014.02.033
PG 9
WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery
SC Cardiovascular System & Cardiology; Respiratory System; Surgery
GA AI9KT
UT WOS:000337252200032
PM 24725831
ER
PT J
AU Domsic, RT
Nihtyanova, SI
Wisniewski, SR
Fine, MJ
Lucas, M
Kwoh, CK
Denton, CP
Medsger, TA
AF Domsic, Robyn T.
Nihtyanova, Svetlana I.
Wisniewski, Stephen R.
Fine, Michael J.
Lucas, Mary
Kwoh, C. Kent
Denton, Christopher P.
Medsger, Thomas A., Jr.
TI Derivation and Validation of a Prediction Rule for Two-Year Mortality in
Early Diffuse Cutaneous Systemic Sclerosis
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Article
ID CLINICAL-PREDICTION; SCLERODERMA; SURVIVAL; FEATURES; DEATH; EMPHASIS;
DISEASE; COHORT; MODEL
AB Objective. Systemic sclerosis (SSc) is associated with a reduction in life expectancy, but there are no validated prognostic models for determining short-term mortality. The objective of this study was to derive and validate a prediction rule for 2-year mortality in patients with early diffuse cutaneous SSc (dcSSc).
Methods. We studied a prospectively enrolled cohort of 387 US Caucasian patients with early dcSSc (<2 years from the appearance of the first symptom), randomly divided into a derivation cohort (n = 260) and a validation cohort (n = 127). Predefined baseline predictor variables were analyzed in a stepwise multi-variable logistic regression model in order to identify factors independently associated with 2-year all-cause mortality using a cutoff of P < 0.05. We rounded the beta values to the nearest integer and summed the points assigned to each variable in order to stratify patients into low-risk, moderate-risk, and high-risk groups. We then applied this rule to an external validation cohort of 110 Caucasian patients with early dcSSc from a single UK center and compared stratum-specific mortality using chi-square statistics.
Results. Four independent predictor variables (with assigned integer values) comprised the model: age at first visit (points allotted: -1, 0, or 1), skin thickness progression rate (points allotted: 0 or 1), gastrointestinal tract severity (points allotted: 0, 1, or 2), and anemia (points allotted: 0 or 2). The prediction model performed well, with no significant differences between the derivation cohort and the US or UK validation cohorts in the low-risk and moderate-risk groups.
Conclusion. We derived a 4-variable prediction rule that can be used to stratify patients with early dcSSc into groups by risk of 2-year mortality, and we validated that prediction rule in US and UK cohorts.
C1 [Domsic, Robyn T.; Wisniewski, Stephen R.; Fine, Michael J.; Lucas, Mary; Kwoh, C. Kent; Medsger, Thomas A., Jr.] Univ Pittsburgh, Pittsburgh, PA 15261 USA.
[Nihtyanova, Svetlana I.; Denton, Christopher P.] UCL, Sch Med, Royal Free Hosp, London W1N 8AA, England.
[Fine, Michael J.; Kwoh, C. Kent] Vet Affairs Pittsburgh Healthcare, Vet Affairs Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
RP Domsic, RT (reprint author), Univ Pittsburgh, S724 Biomed Sci Tower,3500 Terrace St, Pittsburgh, PA 15261 USA.
EM rtd4@pitt.edu
OI Wisniewski, Stephen/0000-0002-3877-9860
FU NIH (from the National Institute of Arthritis and Musculoskeletal and
Skin Diseases) [K23-AR-057845]
FX Dr. Domsic's work was supported by the NIH (grant K23-AR-057845 from the
National Institute of Arthritis and Musculoskeletal and Skin Diseases).
NR 34
TC 9
Z9 9
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2326-5191
EI 2326-5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD JUN
PY 2014
VL 66
IS 6
BP 1616
EP 1624
DI 10.1002/art.38381
PG 9
WC Rheumatology
SC Rheumatology
GA AJ0SL
UT WOS:000337366200024
PM 24470430
ER
PT J
AU Loggia, ML
Edwards, RR
Harris, RE
Napadow, V
AF Loggia, Marco L.
Edwards, Robert R.
Harris, Richard E.
Napadow, Vitaly
TI What is the proper control group for a fibromyalgia study? Comment on
the article by Loggia et al Reply
SO ARTHRITIS & RHEUMATOLOGY
LA English
DT Letter
C1 [Loggia, Marco L.; Napadow, Vitaly] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Loggia, Marco L.; Edwards, Robert R.; Napadow, Vitaly] Harvard Univ, Sch Med, Boston, MA USA.
[Edwards, Robert R.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Harris, Richard E.] Univ Michigan, Ann Arbor, MI 48109 USA.
RP Loggia, ML (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
FU NCCIH NIH HHS [P01 AT006663, P01-AT006663, R01 AT004714, R01 AT005280,
R01-AT004714, R01-AT005280]; NIA NIH HHS [R01 AG034982, R01-AG034982];
NIAMS NIH HHS [R21-AR057920, R21 AR057920]
NR 3
TC 1
Z9 1
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2326-5191
EI 2326-5205
J9 ARTHRITIS RHEUMATOL
JI Arthritis Rheumatol.
PD JUN
PY 2014
VL 66
IS 6
BP 1684
EP 1685
DI 10.1002/art.38396
PG 4
WC Rheumatology
SC Rheumatology
GA AJ0SL
UT WOS:000337366200041
PM 24515749
ER
PT J
AU Sher, L
Braquehais, MD
AF Sher, Leo
Dolores Braquehais, Maria
TI Suicidal behavior in military veterans and health care professionals
SO AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY
LA English
DT Letter
ID MORTALITY
C1 [Sher, Leo] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.
[Sher, Leo] James J Peters Vet Adm, Med Ctr, New York, NY USA.
[Dolores Braquehais, Maria] Galatea Fdn, Coll Metges Barcelona, Galatea Clin, Integral Care Program Sick Doctors, Barcelona, Spain.
[Dolores Braquehais, Maria] Univ Autonoma Barcelona, Vail dHebron Univ Hosp, Dept Psychiat & Legal Med, CIBERSAM, E-08193 Barcelona, Spain.
RP Sher, L (reprint author), Icahn Sch Med Mt Sinai, James J Peters Vet Adm, Med Ctr, 130 West Kingsbridge Rd, Bronx, NY 10468 USA.
EM DrLeoSher@gmail.com
NR 3
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 0004-8674
EI 1440-1614
J9 AUST NZ J PSYCHIAT
JI Aust. N. Z. J. Psych.
PD JUN
PY 2014
VL 48
IS 6
BP 589
EP 589
DI 10.1177/0004867413517761
PG 1
WC Psychiatry
SC Psychiatry
GA AJ4RE
UT WOS:000337662700020
PM 24366856
ER
PT J
AU Courtis, AM
Santos, SA
Guan, YH
Hendricks, JA
Ghosh, B
Szantai-Kis, DM
Reis, SA
Shah, JV
Mazitschek, R
AF Courtis, Alexandra M.
Santos, Sofia A.
Guan, Yinghua
Hendricks, J. Adam
Ghosh, Balaram
Szantai-Kis, D. Miklos
Reis, Surya A.
Shah, Jagesh V.
Mazitschek, Ralph
TI Monoalkoxy BODIPYs-A Fluorophore Class for Bioimaging
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID FLUORESCENT-PROBES; DIFLUORIDE BODIPY; LIVE CELLS; DYES; BIOLOGY;
DERIVATIVES; CYCLOADDITIONS; MICROSCOPY; CHEMISTRY; SYSTEMS
AB Small molecule fluorophores are indispensable tools for modern biomedical imaging techniques. In this report, we present the development of a new class of BODIPY dyes based on an alkoxy-fluoro-boron-dipyrromethene core. These novel fluorescent dyes, which we term MayaFluors, are characterized by good aqueous solubility and favorable in vitro physicochemical properties. MayaFluors are readily accessible in good yields in a one-pot, two-step approach starting from well-established BODIPY dyes, and allow for facile modification with functional groups of relevance to bioconjugate chemistry and bioorthogonal labeling. Biological profiling in living cells demonstrates excellent membrane permeability, low nonspecific binding, and lack of cytotoxicity.
C1 [Courtis, Alexandra M.; Santos, Sofia A.; Hendricks, J. Adam; Ghosh, Balaram; Szantai-Kis, D. Miklos; Mazitschek, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Santos, Sofia A.; Ghosh, Balaram; Reis, Surya A.] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Santos, Sofia A.] Univ Lisbon, Fac Farm, Inst Invest Med iMed ULisboa, P-1640003 Lisbon, Portugal.
[Guan, Yinghua; Shah, Jagesh V.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
[Guan, Yinghua; Shah, Jagesh V.] Brigham & Womens Hosp, Div Renal, Boston, MA 02115 USA.
[Mazitschek, Ralph] Broad Inst Harvard & MIT, Cambridge, MA 02142 USA.
RP Mazitschek, R (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, 185 Cambridge St, Boston, MA 02114 USA.
EM rmazitschek@mgh.harvard.edu
RI iMed.ULisboa, iMed.ULisboa/C-6292-2014; iMed.ULisboa, MedChem
/B-4834-2014;
OI Szantai-Kis, D. Miklos/0000-0001-5958-5478
FU NCI [P50CA086355, T32-CA079443]; Fundacao para a Ciencia e a Tecnologia
[SFRH/BD/80162/2011]
FX Financial support from the NCI (P50CA086355, T32-CA079443) and Fundacao
para a Ciencia e a Tecnologia (SFRH/BD/80162/2011) is gratefully
acknowledged. We thank Drs. R. Weissleder and S. Haggarty for support
and J. Carlson for helpful discussions.
NR 35
TC 16
Z9 16
U1 5
U2 36
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD JUN
PY 2014
VL 25
IS 6
BP 1043
EP 1051
DI 10.1021/bc400575w
PG 9
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA AJ5KB
UT WOS:000337720000004
PM 24797834
ER
PT J
AU Sprachman, MM
Laughney, AM
Kohler, RH
Weissleder, R
AF Sprachman, Melissa M.
Laughney, Ashley M.
Kohler, Rainer H.
Weissleder, Ralph
TI In Vivo Imaging of Multidrug Resistance Using a Third Generation MDR1
Inhibitor
SO BIOCONJUGATE CHEMISTRY
LA English
DT Article
ID P-GLYCOPROTEIN; CLINICAL-RELEVANCE; ANTICANCER DRUGS; CANCER;
MODULATORS; ABCB1; MECHANISMS; TARIQUIDAR; SUBSTRATE; TRANSPORT
AB Cellular up-regulation of multidrug resistance protein 1 (MDR1) is a common cause for resistance to chemotherapy; development of third generation MDR1 inhibitors several of which contain a common 6,7-dimethoxy-2-phenethyl-1,2,3,4-tetrahydroisoquinoline substructure-is underway. Efficacy of these agents has been difficult to ascertain, partly due to a lack of pharmacokinetic reporters for quantifying inhibitor localization and transport dynamics. Some of the recent third generation inhibitors have a pendant heterocycle, for example, a chromone moiety, which we hypothesized could be converted to a fluorophore. Following synthesis and teasing of a small set of analogues, we identified one lead compound that can be used as a cellular imaging agent that exhibits structural similarity and behavior akin to the latest generation of MDR1 inhibitors.
C1 [Sprachman, Melissa M.; Laughney, Ashley M.; Kohler, Rainer H.; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
RP Weissleder, R (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, 185 Cambridge St,CPZN 5206, Boston, MA 02114 USA.
EM rweissleder@mgh.harvard.edu
FU NIH [T32-CA079443]
FX M.M.S. and A.M.L. were supported by a NIH grant T32-CA079443. We are
grateful to Dr. Sarit Agasti for helpful discussions and the kind gift
of 6-chloro-7-hydroxycoumarin-3-carboxylic acid; Dr. Ralph Mazitschek
for computational modeling of the tariquidar and HM30181 structure
overlays; and Dr. Jonathan Carlson, Dr. Labros Meimitis, and Dr. Eunha
Kim for many helpful discussions.
NR 33
TC 5
Z9 5
U1 1
U2 26
PU AMER CHEMICAL SOC
PI WASHINGTON
PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA
SN 1043-1802
J9 BIOCONJUGATE CHEM
JI Bioconjugate Chem.
PD JUN
PY 2014
VL 25
IS 6
BP 1137
EP 1142
DI 10.1021/bc500154c
PG 6
WC Biochemical Research Methods; Biochemistry & Molecular Biology;
Chemistry, Multidisciplinary; Chemistry, Organic
SC Biochemistry & Molecular Biology; Chemistry
GA AJ5KB
UT WOS:000337720000013
PM 24806886
ER
PT J
AU Hurdle, V
Ouellet, JF
Dixon, E
Howard, TJ
Lillemoe, KD
Vollmer, CM
Sutherland, FR
Ball, CG
AF Hurdle, Valerie
Ouellet, Jean-Francois
Dixon, Elijah
Howard, Thomas J.
Lillemoe, Keith D.
Vollmer, Charles M.
Sutherland, Francis R.
Ball, Chad G.
TI Does regional variation impact decision-making in the management and
palliation of pancreatic head adenocarcinoma? Results from an
international survey
SO CANADIAN JOURNAL OF SURGERY
LA English
DT Article
ID OF-LIFE DECISIONS; INTENSIVE-CARE UNITS; SUSTAINING TREATMENTS;
CRITICALLY-ILL; FAMILY-MEMBERS; END; PHYSICIANS; STATES; MORTALITY;
ATTITUDES
AB Background: Management and palliation of pancreatic head adenocarcinoma is challenging. End-of-life decision-making is a variable process involving multiple factors.
Methods: We conducted a qualitative, physician-based, 40-question international survey characterizing the impact of medical, religious, social, training and system factors on care.
Results: A total of 258 international clinicians completed the survey. Respondents were typically fellowship-trained (78%), with a mean of 16 years' experience in a university-affiliated (93%) hepato-pancreato-biliary group (96%) practice. Most (91%) believed resection is potentially curative. Most patients were discussed preoperatively by multi-disciplinary teams (94%) and medical assessment clinics (68%), but rarely critical care (21%). Intraoperative surgical palliation included double bypass or no intervention for locally advanced nonresectable tumours (41% and 49% v. 14% and 85%, respectively, for patients with hepatic metastases). Postoperative admission to the intensive care unit was frequent (58%). Severe postoperative complications were often treated with aggressive cardiopulmonary resuscitation, intubation and critical care (96%), with no defined time points for futility (74%). Admitting surgeons guided most end-of-life decisions (97%). Formal medical futility laws were rarely available (26%). Insurance status did not alter treatment (97%) or palliation (95%) in non-universal care regions. Clinician ex perience, regional culture and training background impacted treatment (all p < 0.05).
Conclusion: Despite remarkable overall agreement, geographic and training differences are evident in the treatment and palliation of pancreatic head adenocarcinoma.
C1 [Hurdle, Valerie; Dixon, Elijah; Sutherland, Francis R.; Ball, Chad G.] Univ Calgary, Dept Surg, Calgary, AB, Canada.
[Ouellet, Jean-Francois] Univ Laval, Dept Surg, Quebec City, PQ, Canada.
[Howard, Thomas J.] Community Hlth Network, Dept Surg, Indianapolis, IN USA.
[Lillemoe, Keith D.] Harvard Univ, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02115 USA.
[Vollmer, Charles M.] Univ Penn, Dept Surg, Philadelphia, PA 19104 USA.
RP Ball, CG (reprint author), Foothills Med Ctr, Dept Surg, 1403-29 St NW, Calgary, AB T2N 2T9, Canada.
EM ball.chad@gmail.com
NR 45
TC 0
Z9 0
U1 3
U2 5
PU CMA-CANADIAN MEDICAL ASSOC
PI OTTAWA
PA 1867 ALTA VISTA DR, OTTAWA, ONTARIO K1G 5W8, CANADA
SN 0008-428X
EI 1488-2310
J9 CAN J SURG
JI Can. J. Surg.
PD JUN
PY 2014
VL 57
IS 3
BP E69
EP E74
DI 10.1503/cjs.011213
PG 6
WC Surgery
SC Surgery
GA AJ5SU
UT WOS:000337748900003
PM 24869619
ER
PT J
AU Pitman, MB
Layfield, LJ
AF Pitman, Martha B.
Layfield, Lester J.
TI Guidelines for Pancreaticobiliary Cytology from the Papanicolaou Society
of Cytopathology: A Review
SO CANCER CYTOPATHOLOGY
LA English
DT Review
DE pancreas; guidelines; Papanicolaou Society of Cytopathology; review
ID FINE-NEEDLE-ASPIRATION; BILE-DUCT STRICTURES; PAPILLARY MUCINOUS
NEOPLASMS; IN-SITU HYBRIDIZATION; PRIMARY SCLEROSING CHOLANGITIS; ACINAR
CELL-CARCINOMA; ENDOSCOPIC ULTRASOUND; OF-CYTOPATHOLOGY;
DIAGNOSTIC-ACCURACY; BILIARY STRICTURES
AB The newest installment on state-of-the-art standards of practice in cytopathology from the Papanicolaou Society of Cytopathology (PSC) focuses on the pancreaticobiliary system. Similar to the National Cancer Institute recommendations for aspiration cytology of the thyroid, the PSC guidelines for pancreaticobiliary cytology addresses indications, techniques, terminology and nomenclature, ancillary studies, and postprocedure management. Each committee was composed of a multidisciplinary group of experts in diagnosing, managing, and treating patients with pancreaticobiliary disease. Draft documents were posted on an interactive Web-based forum hosted by the PSC Web site (www.papsociety.org) and the topics of terminology, ancillary testing, and management were presented at national and international meetings over an 18-month period for discussion and feedback from practicing pathologists around the world. This review provides a synopsis of these guidelines. (C) 2014 American Cancer Society.
C1 [Pitman, Martha B.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 01907 USA.
[Layfield, Lester J.] Univ Missouri, Dept Pathol & Anat Sci, Columbia, MO USA.
RP Pitman, MB (reprint author), Massachusetts Gen Hosp, Dept Pathol, 55 Fruit St, Boston, MA 01907 USA.
EM mpitman@partners.org
NR 105
TC 14
Z9 16
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1934-662X
EI 1934-6638
J9 CANCER CYTOPATHOL
JI Cancer Cytopathol.
PD JUN
PY 2014
VL 122
IS 6
BP 399
EP 411
DI 10.1002/cncy.21427
PG 13
WC Oncology; Pathology
SC Oncology; Pathology
GA AJ4CR
UT WOS:000337618400003
PM 24777782
ER
PT J
AU Wu, RI
Yoon, WJ
Brugge, WR
Mino-Kenudson, M
Pitman, MB
AF Wu, Roseann I.
Yoon, Won Jae
Brugge, William R.
Mino-Kenudson, Mari
Pitman, Martha B.
TI Endoscopic Ultrasound-Guided Fine Needle Aspiration (EUS-FNA)
Contributes to a Triple-Negative Test in Preoperative Screening of
Pancreatic Cysts
SO CANCER CYTOPATHOLOGY
LA English
DT Article
DE endoscopic ultrasound-guided fine-needle aspiration; pancreatic cyst;
pancreatic neoplasms; cytopathology; carcinoembryonic antigen
ID PAPILLARY MUCINOUS NEOPLASMS; INTERNATIONAL CONSENSUS GUIDELINES;
LESS-THAN-OR-EQUAL-TO-3 CM; RISK-ASSESSMENT; FLUID ANALYSIS; ADDS VALUE;
CYTOLOGY; MALIGNANCY; DIAGNOSIS; TUMORS
AB BACKGROUND: Endoscopic ultrasound-guided fine-needle aspiration (EUS-FNA) of pancreatic cysts obtains cyst fluid for cytologic and biochemical analysis, which may determine whether the cyst is mucinous and malignant, contributing to patient management. Despite this added value, EUS-FNA remains controversial in the preoperative assessment of pancreatic cysts. The objective of this study was to assess the utility of EUS-FNA in a cohort of small pancreatic cysts that were benign on imaging studies. METHODS: All pancreatic cysts that underwent initial EUS-FNA in 2006 and 2007 were retrospectively analyzed. Ninety-two patients with pancreatic cysts met the inclusion criteria. Patients who had high-risk or worrisome features on imaging studies were excluded. Cytology, histology, and cyst fluid analysis data were collected. The main outcome measurements were radiologic and clinical follow-up as well as cytopathologic and histologic results. RESULTS: EUS-FNA supported a diagnosis of a mucinous cyst in 38 of 92 patients (41%) by carcinoembryonic antigen (CEA) measurement and/or cytology. Cytology demonstrated an absence of high-grade atypia (HGA) in 89 of 92 patients (97%). The mean follow-up was 4.4 years (range, 0-7.7 years), during which 6 cysts were surgically resected and 16 cysts were resampled by at least 1 subsequent EUS-FNA. The overall negative predictive value of cytologic examination for HGA was 99%. CONCLUSIONS: EUS-FNA is a screening test that contributes to a triple-negative test for pancreatic cysts-no high-risk stigmata, no worrisome features, and no HGA on cytology-providing a negative predictive value of 99% for conservative management. (C) 2013 American Cancer Society.
C1 [Wu, Roseann I.; Mino-Kenudson, Mari; Pitman, Martha B.] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
[Yoon, Won Jae; Brugge, William R.] Massachusetts Gen Hosp, Gastrointestinal Unit, Boston, MA 02114 USA.
[Yoon, Won Jae] Inje Univ, Coll Med, Seoul Paik Hosp, Dept Internal Med, Seoul, South Korea.
RP Pitman, MB (reprint author), Massachusetts Gen Hosp, Dept Pathol, Warren 105,55 Fruit St, Boston, MA 02114 USA.
EM mpitman@partners.org
FU RedPath; Asuragen
FX William R. Brugge is currently receiving research grants from RedPath
and Asuragen.
NR 38
TC 6
Z9 7
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1934-662X
EI 1934-6638
J9 CANCER CYTOPATHOL
JI Cancer Cytopathol.
PD JUN
PY 2014
VL 122
IS 6
BP 412
EP 419
DI 10.1002/cncy.21385
PG 8
WC Oncology; Pathology
SC Oncology; Pathology
GA AJ4CR
UT WOS:000337618400004
PM 24327575
ER
PT J
AU Morales-Oyarvide, V
Yoon, WJ
Ingkakul, T
Forcione, DG
Casey, BW
Brugge, WR
Fernandez-del Castillo, C
Pitman, MB
AF Morales-Oyarvide, Vicente
Yoon, Won Jae
Ingkakul, Thun
Forcione, David G.
Casey, Brenna W.
Brugge, William R.
Fernandez-del Castillo, Carlos
Pitman, Martha B.
TI Cystic Pancreatic Neuroendocrine Tumors
SO CANCER CYTOPATHOLOGY
LA English
DT Article
DE pancreatic cyst; pancreatic endocrine tumor; endoscopic
ultrasound-guided fine-needle aspiration; cytology
ID FINE-NEEDLE-ASPIRATION; PAPILLARY MUCINOUS NEOPLASMS; ENDOSCOPIC
ULTRASOUND; PREOPERATIVE DIAGNOSIS; ENDOCRINE TUMORS; MULTIMODAL
APPROACH; MOLECULAR ANALYSIS; EPITHELIAL ATYPIA; FLUID ANALYSIS;
FEATURES
AB BACKGROUND: Cystic pancreatic neuroendocrine tumors (cPanNETs) account for 13% to 17% of PanNETs. Although the value of endoscopic ultrasound (EUS) imaging and cyst fluid analysis (CFA) in their preoperative diagnosis has been well described, limited information is available about the diagnostic role of cytology samples obtained from fine-needle aspiration (FNA). METHODS: Cytopathology records between 1992 and 2013 were searched for all reports of cysts interpreted as PanNET. Patient demographics, clinical and radiologic information, CFA, histopathology, and cytopathology findings were recorded. Performance characteristics of cytology and EUS for the accurate diagnosis of cPanNET were calculated. RESULTS: In total, 35 FNAs from 33 patients with cPanNETs were identified, and 34 EUS were performed. Cytology made a specific diagnosis of a cPanNET in 71% of the biopsies compared with a specific diagnosis by EUS in 38% of cases. An interpretation of suspicious for cPanNET was given in 77% of cases by cytology and in 47% by EUS. Cytology identified 86% of the lesions as high-risk pancreatic cysts compared with 56% by EUS. Diagnostic morphology was present on both cytology and cell block preparations in 60% of aspirates, on cytology only in 20%, and on cell block only in 20%. CFA was performed on 51% cyst fluids. All cysts but 1 revealed low carcinoembryonic antigen levels (range, 0.2 to >500 ng/mL; mean, 29.5 ng/mL), and amylase levels were <500 U/L in all but 2 cases (range, 16-1493 U/L; mean, 205 U/L). CONCLUSIONS: Cytology is the most accurate test for preoperative diagnosis of cPanNETs. EUS is insufficiently accurate for independent diagnosis, and carcinoembryonic antigen and amylase analyses are noncontributory. (C) 2014 American Cancer Society.
C1 [Morales-Oyarvide, Vicente; Ingkakul, Thun; Fernandez-del Castillo, Carlos] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
[Yoon, Won Jae] Inje Univ, Coll Med, Seoul Paik Hosp, Dept Internal Med, Seoul, South Korea.
[Forcione, David G.; Casey, Brenna W.; Brugge, William R.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Med,Gastroenterol Unit, Boston, MA 02114 USA.
[Pitman, Martha B.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Pitman, MB (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, 55 Fruit St,Warren 105, Boston, MA 02114 USA.
EM mpitman@partners.org
NR 39
TC 13
Z9 13
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1934-662X
EI 1934-6638
J9 CANCER CYTOPATHOL
JI Cancer Cytopathol.
PD JUN
PY 2014
VL 122
IS 6
BP 435
EP 444
DI 10.1002/cncy.21403
PG 10
WC Oncology; Pathology
SC Oncology; Pathology
GA AJ4CR
UT WOS:000337618400007
PM 24591417
ER
PT J
AU Miller, MA
Askevold, B
Yang, KS
Kohler, RH
Weissleder, R
AF Miller, Miles A.
Askevold, Bjorn
Yang, Katherine S.
Kohler, Rainer H.
Weissleder, Ralph
TI Platinum Compounds for High-Resolution In Vivo Cancer Imaging
SO CHEMMEDCHEM
LA English
DT Article
DE DNA damage; fluorescent probes; intravital imaging agents;
pharmacokinetics; pharmacology
ID SINGLE-CELL; FLUORESCENCE MICROSCOPY; ANTICANCER DRUGS; LABELED
PLATINUM; CISPLATIN; COMPLEXES; PHARMACOKINETICS; CHEMOTHERAPY;
CARBOPLATIN; RESISTANCE
AB Platinum(II) compounds, principally cisplatin and carboplatin, are commonly used front-line cancer therapeutics. Despite their widespread use and continued interest in the development of new derivatives, including nanoformulations with improved properties, it has been difficult to visualize platinum compounds in live subjects, in real time, and with subcellular resolution. Here, we present four novel cisplatin- and carboplatin-derived fluorescent imaging compounds for quantitative intravital cancer imaging. We conjugated 4,4-difluoro-5,7-dimethyl-4-bora-3a,4a-daiza-s-indacene (BODIPY) to PtII complexes to generate derivatives with robust in vivo fluorescence and retained DNA-damaging and cytotoxic properties. We successfully applied these compounds to image pharmacokinetics and tumor uptake in a xenograft cancer mouse model. By using a genetic reporter of single-cell DNA damage for in vivo imaging, Pt drug accumulation and resultant DNA damage could be monitored in individual tumor cells, at subcellular resolution, and in real time in a live animal model of cancer. These derivatives represent promising imaging tools that will be useful in understanding further the distribution and interactions of platinum within tumors.
C1 [Miller, Miles A.; Askevold, Bjorn; Yang, Katherine S.; Kohler, Rainer H.; Weissleder, Ralph] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Weissleder, Ralph] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA 02115 USA.
RP Miller, MA (reprint author), Massachusetts Gen Hosp, Ctr Syst Biol, 185 Cambridge St, Boston, MA 02114 USA.
EM rweissleder@mgh.harvard.edu
FU US National Institutes of Health (NIH) [U54-CA151884]; German National
Academy of Sciences Leopoldina
FX Part of this work was supported by the US National Institutes of Health
(NIH) (U54-CA151884) and a fellowship to B.A. from the German National
Academy of Sciences Leopoldina. The authors thank Alex Zaltsman, Matthew
Sebas, and Olivier Kister for technical assistance, and Drs. Lippard,
Farokhzad, and Langer for helpful discussions.
NR 37
TC 15
Z9 15
U1 4
U2 37
PU WILEY-V C H VERLAG GMBH
PI WEINHEIM
PA BOSCHSTRASSE 12, D-69469 WEINHEIM, GERMANY
SN 1860-7179
EI 1860-7187
J9 CHEMMEDCHEM
JI ChemMedChem
PD JUN
PY 2014
VL 9
IS 6
SI SI
BP 1131
EP 1135
DI 10.1002/cmdc.201300502
PG 5
WC Chemistry, Medicinal; Pharmacology & Pharmacy
SC Pharmacology & Pharmacy
GA AJ2WN
UT WOS:000337525300004
PM 24504646
ER
PT J
AU Wiener, RS
Ouellette, DR
Diamond, E
Fan, VS
Maurer, JR
Mularski, RA
Peters, JI
Halpern, SD
AF Wiener, Renda Soylemez
Ouellette, Daniel R.
Diamond, Edward
Fan, Vincent S.
Maurer, Janet R.
Mularski, Richard A.
Peters, Jay I.
Halpern, Scott D.
TI An Official American Thoracic Society/American College of Chest
Physicians Policy Statement
SO CHEST
LA English
DT Article
ID PULMONARY ARTERIAL-HYPERTENSION; CLINICAL-PRACTICE GUIDELINES; SYSTOLIC
HEART-FAILURE; LUNG-CANCER DIAGNOSIS; COMPUTED-TOMOGRAPHY; PATIENT
COMMUNICATION; EMERGENCY-DEPARTMENT; EXERCISE CAPACITY;
DECISION-ANALYSIS; CONTROLLED-TRIAL
AB The American Board of Internal Medicine Foundation's Choosing Wisely campaign aims to curb health-care costs and improve patient care by soliciting lists from medical societies of the top five tests or treatments in their specialty that are used too frequently and inappropriately. The American Thoracic Society (ATS) and American College of Chest Physicians created a joint task force, which produced a top five list for adult pulmonary medicine. Our top five recommendations, which were approved by the executive committees of the ATS and American College of Chest Physicians and published by Choosing Wisely in October 2013, are as follows: (1) Do not perform CT scan surveillance for evaluation of indeterminate pulmonary nodules at more frequent intervals or for a longer period of time than recommended by established guidelines; (2) do not routinely offer pharmacologic treatment with advanced vasoactive agents approved only for the management of pulmonary arterial hypertension to patients with pulmonary hypertension resulting from left heart disease or hypoxemic lung diseases (groups II or III pulmonary hypertension); (3) for patients recently discharged on supplemental home oxygen following hospitalization for an acute illness, do not renew the prescription without assessing the patient for ongoing hypoxemia; (4) do not perform chest CT angiography to evaluate for possible pulmonary embolism in patients with a low clinical probability and negative results of a highly sensitive D-dimer assay; (5) do not perform CT scan screening for lung cancer among patients at low risk for lung cancer. We hope pulmonologists will use these recommendations to stimulate frank discussions with patients about when these tests and treatments are indicated-and when they are not.
C1 [Wiener, Renda Soylemez] Boston Univ, Sch Med, Ctr Pulm, Boston, MA 02118 USA.
[Wiener, Renda Soylemez] Edith Nourse Rogers Mem Vet Hosp, Ctr Healthcare Org & Implementat Res, Bedford, MA USA.
[Wiener, Renda Soylemez] Dartmouth Inst Hlth Policy & Clin Practice, Hanover, NH USA.
[Ouellette, Daniel R.] Henry Ford Hlth Syst, Detroit, MI USA.
[Diamond, Edward] Suburban Lung Associates, Elk Grove Village, IL USA.
[Fan, Vincent S.] VA Puget Sound Hlth Care Syst, Seattle, WA USA.
[Fan, Vincent S.] Univ Washington, Dept Med, Seattle, WA USA.
[Maurer, Janet R.] Univ Arizona, Coll Med, Dept Med, Phoenix, AZ USA.
[Maurer, Janet R.] Magellan Hlth Serv Inc, Natl Imaging Associates, Qual Improvement & Compliance, Phoenix, AZ USA.
[Mularski, Richard A.] Kaiser Permanente Northwest, Ctr Hlth Res, Portland, OR USA.
[Mularski, Richard A.] Northwest Permanente PC, Dept Pulm Crit Care Med, Portland, OR USA.
[Mularski, Richard A.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA.
[Peters, Jay I.] UT Hlth Sci Ctr, San Antonio, TX USA.
[Peters, Jay I.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Halpern, Scott D.] Univ Penn, Dept Med, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
[Halpern, Scott D.] Univ Penn, Dept Biostat & Epidemiol, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
[Halpern, Scott D.] Univ Penn, Dept Med Eth & Hlth Policy, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
[Halpern, Scott D.] Univ Penn, Leonard Davis Inst, Ctr Hlth Incent & Behav Econ, Philadelphia, PA 19104 USA.
RP Wiener, RS (reprint author), Ctr Pulm, 72 E Concord St,R-304, Boston, MA 02118 USA.
EM rwiener@bu.edu
OI Wiener, Renda/0000-0001-7712-2135
FU NCI NIH HHS [K07 CA138772]
NR 79
TC 13
Z9 14
U1 0
U2 6
PU AMER COLL CHEST PHYSICIANS
PI GLENVIEW
PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA
SN 0012-3692
J9 CHEST
JI Chest
PD JUN
PY 2014
VL 145
IS 6
BP 1383
EP 1391
DI 10.1378/chest.14-0670
PG 9
WC Critical Care Medicine; Respiratory System
SC General & Internal Medicine; Respiratory System
GA AJ0OV
UT WOS:000337355600032
PM 24889436
ER
PT J
AU Siev, M
Wilson, D
Kainth, S
Kasprowicz, VO
Feintuch, CM
Jenny-Avital, ER
Achkar, JM
AF Siev, Michael
Wilson, Douglas
Kainth, Supreet
Kasprowicz, Victoria O.
Feintuch, Catherine M.
Jenny-Avital, Elizabeth R.
Achkar, Jacqueline M.
TI Antibodies against Mycobacterial Proteins as Biomarkers for
HIV-Associated Smear-Negative Tuberculosis
SO CLINICAL AND VACCINE IMMUNOLOGY
LA English
DT Article
ID HUMAN-IMMUNODEFICIENCY-VIRUS; PULMONARY TUBERCULOSIS; SUBCLINICAL
TUBERCULOSIS; OPPORTUNISTIC INFECTIONS; IMMUNE-RESPONSES; SOUTH-AFRICA;
BOVIS BCG; DIAGNOSIS; INCIPIENT; ANTIGENS
AB Serology data are limited for patients with sputum smear-negative HIV-associated active tuberculosis (TB). We evaluated the serum antibody responses against the mycobacterial proteins MPT51, MS, and echA1 and the 38-kDa protein via enzyme-linked immunosorbent assay (ELISA) in South African (S.A.) HIV-positive (HIV+) smear-negative TB patients (n = 56), U. S. HIV+ controls with a positive tuberculin skin test (TST+; n = 21), and S. A. HIV-negative (HIV-) (n = 18) and HIV+ (n = 24) controls. TB patients had positive antibody reactivity against MPT51 (73%), echA1 (59%), MS (36%), and the 38-kDa protein (11%). Little reactivity against MPT51 and echA1 was observed in control groups at low risk for TB, i.e., S.A. HIV- (0% and 6%, respectively), and at moderate risk for TB development, i.e., U.S. HIV+ TST+ controls (14% and 10%, respectively). By contrast, more reactivity was detected in the S.A. HIV+ control group at higher risk for TB (25% and 45%, respectively). Our data hold promise that antibody detection against MPT51 and echA1 might have adjunctive value in the detection of HIV+ smear-negative TB and might reflect increasing Mycobacterium tuberculosis infection activity in asymptomatic HIV+ individuals.
C1 [Siev, Michael; Kainth, Supreet; Feintuch, Catherine M.; Jenny-Avital, Elizabeth R.; Achkar, Jacqueline M.] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA.
[Wilson, Douglas] Edendale Hosp, Dept Med, Pietermaritzburg, South Africa.
[Kasprowicz, Victoria O.] Massachusetts Gen Hosp, MIT & Harvard, Ragon Inst, Cambridge, MA USA.
[Kasprowicz, Victoria O.] Univ KwaZulu Natal, Nelson R Mandela Sch Med, KwaZulu Natal Res Inst TB & HIV, Durban, South Africa.
[Kasprowicz, Victoria O.] Univ KwaZulu Natal, Nelson R Mandela Sch Med, HIV Pathogenesis Programme, Durban, South Africa.
RP Achkar, JM (reprint author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Med, Bronx, NY 10467 USA.
EM jacqueline.achkar@einstein.yu.edu
FU National Institutes of Health (NIH)/National Institute of Allergy and
Infectious Diseases (NIAID) [AI067665, AI105684]; Center for AIDS
Research (CFAR) at the Albert Einstein College of Medicine [AI51519];
Howard Hughes Medical Institute (HHMI) [55006535]; KwaZulu-Natal
Research Institute for Tuberculosis and HIV (K-RITH)
FX This work was supported in part by funds from the National Institutes of
Health (NIH)/National Institute of Allergy and Infectious Diseases
(NIAID; grants AI067665 and AI105684 to J.M.A.), the Center for AIDS
Research (CFAR) at the Albert Einstein College of Medicine (grant
AI51519 to J.M.A.), the Howard Hughes Medical Institute (HHMI; seed
grant 55006535 to J.M.A.), and the KwaZulu-Natal Research Institute for
Tuberculosis and HIV (K-RITH) (steering grant to D.W.).
NR 57
TC 4
Z9 4
U1 1
U2 6
PU AMER SOC MICROBIOLOGY
PI WASHINGTON
PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA
SN 1556-6811
EI 1556-679X
J9 CLIN VACCINE IMMUNOL
JI Clin. Vaccine Immunol.
PD JUN
PY 2014
VL 21
IS 6
BP 791
EP 798
DI 10.1128/CVI.00805-13
PG 8
WC Immunology; Infectious Diseases; Microbiology
SC Immunology; Infectious Diseases; Microbiology
GA AJ0NW
UT WOS:000337352500002
PM 24671553
ER
PT J
AU Zenati, MA
Gaziano, JM
Collins, JF
Biswas, K
Gabany, JM
Quin, JA
Bitondo, JM
Bakaeen, FG
Kelly, RF
Shroyer, AL
Bhatt, DL
AF Zenati, Marco A.
Gaziano, J. Michael
Collins, Joseph F.
Biswas, Kousick
Gabany, Jennifer M.
Quin, Jacquelyn A.
Bitondo, Jerene M.
Bakaeen, Faisal G.
Kelly, Rosemary F.
Shroyer, A. Laurie
Bhatt, Deepak L.
TI Choice of Vein-Harvest Technique for Coronary Artery Bypass Grafting:
Rationale and Design of the REGROUP Trial
SO CLINICAL CARDIOLOGY
LA English
DT Article
ID PROSPECTIVE RANDOMIZED-TRIAL; WOUND COMPLICATIONS; SURGERY;
METAANALYSIS; PATENCY; ASSOCIATION; PUMP; REVASCULARIZATION; OUTCOMES;
FAILURE
AB The Randomized Endo-vein Graft Prospective (REGROUP) trial (ClinicalTrials.gov NCT01850082) is a randomized, intent-to-treat, 2-arm, parallel-design, multicenter study funded by the Cooperative Studies Program (CSP No. 588) of the US Department of Veterans Affairs. Cardiac surgeons at 16 Veterans Affairs (VA) medical centers with technical expertise in performing both endoscopic vein harvesting (EVH) and open vein harvesting (OVH) were recruited as the REGROUP surgeon participants. Subjects requiring elective or urgent coronary artery bypass grafting using cardiopulmonary bypass with use of >= 1 saphenous vein graft will be screened for enrollment using pre-established inclusion/exclusion criteria. Enrolled subjects (planned N=1150) will be randomized to 1 of the 2 arms (EVH or OVH) after an experienced vein harvester has been assigned. The primary outcomes measure is the rate of major adverse cardiac events (MACE), including death, myocardial infarction, or revascularization. Subject assessments will be performed at multiple times, including at baseline, intraoperatively, postoperatively, and at discharge (or 30 days after surgery, if still hospitalized). Assessment of leg-wound complications will be completed at 6 weeks after surgery. Telephone follow-ups will occur at 3-month intervals after surgery until the participating sites are decommissioned after the trial's completion (approximately 4.5 years after the full study startup). To assess long-term outcomes, centralized follow-up of MACE for 2 additional years will be centrally performed using VA and non-VA clinical and administrative databases. The primary MACE outcome will be compared between the 2 arms, EVH and OVH, at the end of the trial duration.
C1 [Zenati, Marco A.; Gabany, Jennifer M.; Quin, Jacquelyn A.] Vet Affairs Boston Healthcare Syst, Div Cardiothorac Surg, Boston, MA USA.
[Zenati, Marco A.; Gabany, Jennifer M.; Quin, Jacquelyn A.] Vet Affairs Boston Healthcare Syst, Surg Serv, Boston, MA USA.
[Zenati, Marco A.; Gabany, Jennifer M.; Quin, Jacquelyn A.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA.
[Gaziano, J. Michael] MAVERIC, Boston, MA USA.
[Gaziano, J. Michael] Vet Affairs Boston Healthcare Syst, Boston, MA USA.
[Gaziano, J. Michael] Harvard Univ, Brigham & Womens Hosp, Sch Med, Dept Med, Boston, MA 02115 USA.
[Collins, Joseph F.; Biswas, Kousick] Vet Affairs Cooperat Studies Program Coordinating, Perry Point, MD USA.
[Bitondo, Jerene M.] Massachusetts Gen Hosp, Div Cardiac Surg, Boston, MA 02114 USA.
[Bakaeen, Faisal G.] Michael E DeBakey VA Med Ctr, Div Cardiac Surg, Houston, TX USA.
[Bakaeen, Faisal G.] Baylor Coll Med, Houston, TX 77030 USA.
[Kelly, Rosemary F.] Minneapolis Vet Affairs Med Ctr, Div Cardiac Surg, Minneapolis, MN USA.
[Kelly, Rosemary F.] Univ Minnesota, Minneapolis, MN USA.
[Shroyer, A. Laurie] Northport Vet Affairs Med Ctr, Northport, NY USA.
[Shroyer, A. Laurie] SUNY Stony Brook, Sch Med, Dept Surg, Stony Brook, NY 11794 USA.
[Bhatt, Deepak L.] Vet Affairs Boston Healthcare Syst, Div Cardiol, Boston, MA 02115 USA.
[Bhatt, Deepak L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Heart & Vasc Ctr, Boston, MA 02115 USA.
RP Zenati, MA (reprint author), Vet Affairs Boston Healthcare Syst, Dept Cardiothorac Surg, 1400 VFW Pkwy, West Roxbury, MA 02132 USA.
EM marco_zenati@hms.harvard.edu
RI Shroyer, Annie Laurie/B-8836-2016
OI Shroyer, Annie Laurie/0000-0001-6461-0623
FU Amarin; AstraZeneca; Bristol-Myers Squibb; Eisai; Ethicon; Medtronic;
Sanofi-Aventis; Medicines Company
FX Dr. Deepak L. Bhatt has served on advisory boards for Elsevier
PracticeUpdate Cardiology, Medscape Cardiology, and Regado Biosciences;
has served on the board of directors for the Boston VA Research
Institute and Society of Cardiovascular Patient Care; has chaired the
American Heart Association Get With The Guidelines Steering Committee;
has received honoraria from the American College of Cardiology (editor,
Clinical Trials, CardioSource), Belvoir Publications (editor-in-chief,
Harvard Heart Letter), Duke Clinical Research Institute (clinical trial
steering committees), Population Health Research Institute (clinical
trial steering committee), Slack Publications (chief medical editor,
Cardiology Today's Intervention), and WebMD (CME steering committees);
served as senior associate editor and is now editor-in-chief for the
Journal of Invasive Cardiology; has served on data-monitoring committees
for Duke Clinical Research Institute, Mayo Clinic, and Population Health
Research Institute; has received research grants from Amarin,
AstraZeneca, Bristol-Myers Squibb, Eisai, Ethicon, Medtronic,
Sanofi-Aventis, and The Medicines Company; and has conducted unfunded
research for FlowCo, PLx Pharma, and Takeda.
NR 35
TC 4
Z9 4
U1 2
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0160-9289
EI 1932-8737
J9 CLIN CARDIOL
JI Clin. Cardiol.
PD JUN
PY 2014
VL 37
IS 6
BP 325
EP 330
DI 10.1002/clc.22267
PG 6
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AJ3WF
UT WOS:000337597900001
PM 24633760
ER
PT J
AU Rhee, JW
Wiviott, SD
Scirica, BM
Gibson, CM
Murphy, SA
Bonaca, MP
Morrow, DA
Mega, JL
AF Rhee, June-Wha
Wiviott, Stephen D.
Scirica, Benjamin M.
Gibson, C. Michael
Murphy, Sabina A.
Bonaca, Marc P.
Morrow, David A.
Mega, Jessica L.
TI Clinical Features, Use of Evidence-Based Therapies, and Cardiovascular
Outcomes Among Patients With Chronic Kidney Disease Following
Non-ST-Elevation Acute Coronary Syndrome
SO CLINICAL CARDIOLOGY
LA English
DT Article
ID ACUTE MYOCARDIAL-INFARCTION; CHRONIC RENAL-INSUFFICIENCY; UNITED-STATES;
CREATININE CLEARANCE; ARTERY-DISEASE; TERM OUTCOMES; RISK-FACTORS;
DATA-SYSTEM; DYSFUNCTION; DIALYSIS
AB Background: Chronic kidney disease (CKD) is associated with an increased risk of cardiovascular events following acute coronary syndrome (ACS). The underlying pathobiology and optimal treatments for this population continue to be evaluated.
Hypothesis: Patients with CKD will receive fewer evidence-based therapies and experience high rates of adverse cardiovascular events in both the short-and long term.
Methods: The MERLIN-TIMI 36 (Metabolic Efficiency With Ranolazine for Less Ischemia in Non-ST-Elevation Acute Coronary Syndromes-Thrombolysis in Myocardial Infarction 36) trial randomized non-ST-elevation ACS patients to ranolazine or placebo, with no exclusion for renal dysfunction (except dialysis). We conducted a prespecified analysis among 6543 patients based on the degree of CKD.
Results: Patients with worse renal function were older with more comorbidities (P < 0.0001 for each). They were less likely to receive evidence-based cardiovascular medicines (P < 0.04 for each). Rates of an early invasive management strategy varied based on renal function; however, among patients with the highest TIMI risk scores, the rates of an early invasive management strategy were similar regardless of glomerular filtration rate (GFR) (P-interaction = 0.005). Lower GFR was associated with increased rates of cardiovascular disease or myocardial infarction in the short and long term, even after adjustment (GFR < 30 vs >= 90 mL/min/1.73 m(2); hazard ratio [HR]: 3.24 [95% confidence interval [CI]: 1.26-8.38] through 7 days and HR: 2.12 [95% CI: 1.33-3.39]through 1 year). The effect of ranolazine vs placebo on clinical outcomes was similar among those with and without CKD (P-interaction = not significant).
Conclusions: Following ACS, patients with renal dysfunction had more cardiovascular risk factors but were less likely to receive evidence-based medical therapies. A strong graded, independent relationship between the degree of CKD and poor clinical outcomes was observed over time. Continued efforts to optimize ACS treatment strategies in patients with CKD are warranted.
C1 [Rhee, June-Wha] Stanford Univ, Med Ctr, Dept Med, Stanford, CA 94305 USA.
[Wiviott, Stephen D.; Scirica, Benjamin M.; Gibson, C. Michael; Murphy, Sabina A.; Bonaca, Marc P.; Morrow, David A.] Harvard Univ, Brigham & Womens Hosp, Sch Med, TIMI Study Grp,Cardiovasc Div,Dept Med, Boston, MA 02115 USA.
[Gibson, C. Michael] Harvard Univ, Beth Israel Deaconess Med Ctr, Sch Med, Cardiovasc Div,Dept Med, Boston, MA 02215 USA.
RP Mega, JL (reprint author), Brigham & Womens Hosp, 221 Longwood Ave, Boston, MA 02115 USA.
EM jmega@partners.org
FU Gilead; Abbott; Amgen; AstraZeneca; Athera; Beckman Coulter; BG
Medicine; Bristol-Myers Squibb; Buhlmann Laboratories; Daiichi Sankyo;
Eli Lilly Co.; Eisai; Glaxo Smith Kline; Johnson Johnson; Merck;
Nanosphere; Novartis Pharmaceuticals; Ortho-Clinical Diagnostics;
Pfizer; Randox; Roche Diagnostics; sanofi-aventis; Singulex;
Merck/Schering-Plough; Arena Pharmaceuticals; Bayer Healthcare;
Novartis; GlaxoSmithKline; Lexicon; Arena; St. Jude Medical; Boston
Clinical Research Institute; Decision Resources; University of Calgary;
Elsevier Practice Update Cardiology; Angel Medical Corp.; Atrium Medical
System; Bayer Corp.; Ikaria, Inc.; Janssen Pharmaceuticals; Lantheus
Medical Imaging; Portola Pharmaceuticals; Volcano Corp.; Walk Vascular;
Atrium Medical Systems; Baxter Healthcare; Bristol Myers; Cardiovascular
Research Foundation; Consensus Medical Communications; CSL Behring;
Cytori Therapeutics; Daiichi Sankyo, Inc.; Eli Lily Co.; Exeter Group;
Genentech, Inc.; Medicines Company; Critical Diagnostics; Genentech;
Instrumentation Laboratory; Konica/Minolta; Servier; Bristol-Myers
Squibb/sanofi-aventis; Boehringer Ingelheim
FX The MERLIN-TIMI 36 trial was funded by Gilead. The TIMI Study Group has
received significant research grant support from Abbott, Amgen,
AstraZeneca, Athera, Beckman Coulter, BG Medicine, Bristol-Myers Squibb,
Buhlmann Laboratories, Daiichi Sankyo, Eli Lilly & Co., Eisai, Glaxo
Smith Kline, Johnson & Johnson, Merck, Nanosphere, Novartis
Pharmaceuticals, Ortho-Clinical Diagnostics, Pfizer, Randox, Roche
Diagnostics, sanofi-aventis, and Singulex.; Dr. Rhee reports no
disclosures. Dr. Wiviott reports research grant support from Johnson &
Johnson, Eli Lilly & Co., Daiichi Sankyo, and Merck/Schering-Plough. Dr.
Wiviott has received consulting fees from Arena Pharmaceuticals, Bayer
Healthcare, Bristol-Myers Squibb, and AstraZeneca. Dr. Wiviott has
received continuing medical education speaking fees from Eli Lilly &
Co., Daiichi Sankyo, AstraZeneca, Novartis, and Merck/Schering-Plough.
Dr. Scirica reports research grant support from AstraZeneca,
Bristol-Myers Squibb, Daiichi-Sankyo, GlaxoSmithKline, Johnson &
Johnson, Bayer Healthcare, Gilead, Eisai, and Merck. Dr. Scirica has
received consulting fees from Gilead, Lexicon, Arena, Eisai, St. Jude
Medical, Boston Clinical Research Institute, Decision Resources,
University of Calgary, and Elsevier Practice Update Cardiology. Dr.
Gibson reports research grant support from Angel Medical Corp., Atrium
Medical System, Bayer Corp., Ikaria, Inc., Janssen Pharmaceuticals,
Johnson & Johnson, Lantheus Medical Imaging, Merck, Portola
Pharmaceuticals, Roche Diagnostics, sanofi-aventis, St. Jude Medical,
Volcano Corp., and Walk Vascular. Dr. Gibson has received consulting
fees from AstraZeneca, Atrium Medical Systems, Baxter Healthcare,
Bristol Myers, Cardiovascular Research Foundation, Consensus Medical
Communications, CSL Behring, Cytori Therapeutics, Daiichi Sankyo, Inc.,
Eli Lily & Co., Exeter Group, Genentech, Inc., GlaxoSmithKline, St. Jude
Medical, and The Medicines Company. Ms. Murphy does not report any
additional disclosures apart from the TIMI Study Group. Dr. Bonaca has
received consulting fees from Roche diagnostics. Dr. Morrow has received
consulting fees from BG Medicine, Critical Diagnostics, Eli Lilly & Co.,
Genentech, Gilead, Instrumentation Laboratory, Johnson & Johnson,
Konica/Minolta, Merck, Novartis, Roche Diagnostics, and Servier. Dr.
Mega reports research grant support from Johnson & Johnson, Bayer
Healthcare, Bristol-Myers Squibb/sanofi-aventis, Daiichi Sankyo, Inc.,
AstraZeneca, and Eli Lilly & Co. Dr. Mega has received consulting fees
from Boehringer Ingelheim and Janssen Pharmaceuticals.
NR 30
TC 1
Z9 1
U1 1
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0160-9289
EI 1932-8737
J9 CLIN CARDIOL
JI Clin. Cardiol.
PD JUN
PY 2014
VL 37
IS 6
BP 350
EP 356
DI 10.1002/clc.22253
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AJ3WF
UT WOS:000337597900005
PM 24481910
ER
PT J
AU Fan, VS
Meek, PM
AF Fan, Vincent S.
Meek, Paula M.
TI Anxiety, Depression, and Cognitive Impairment in Patients with Chronic
Respiratory Disease
SO CLINICS IN CHEST MEDICINE
LA English
DT Article
DE Anxiety; Depression; Cognitive impairment; Chronic respiratory disease
ID OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CONTROLLED-TRIAL;
QUALITY-OF-LIFE; STATE WORRY QUESTIONNAIRE; WORKING-MEMORY; COPD
PATIENTS; PRIMARY-CARE; PSYCHOMETRIC PROPERTIES; REHABILITATION PROGRAM;
ARTERIAL-HYPERTENSION
AB In this article, the prevalence of depression, anxiety, and cognitive impairment in persons with chronic obstructive pulmonary disease, and the impact of these psychological and cognitive factors on clinical outcomes in COPD is reviewed. Methods for screening and identification of these conditions in COPD are described. The extent to which depression, anxiety or cognitive impairment limit or modify the effectiveness of pulmonary rehabilitation, and whether pulmonary rehabilitation may ameliorate these psychological and cognitive impairments are discussed.
C1 [Fan, Vincent S.] Univ Washington, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98105 USA.
[Meek, Paula M.] Univ Colorado, Coll Nursing, Boulder, CO 80309 USA.
RP Fan, VS (reprint author), Univ Washington, Dept Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98105 USA.
EM Vincent.fan@va.gov
NR 85
TC 5
Z9 5
U1 2
U2 23
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0272-5231
EI 1557-8216
J9 CLIN CHEST MED
JI Clin. Chest Med.
PD JUN
PY 2014
VL 35
IS 2
BP 399
EP +
DI 10.1016/j.ccm.2014.02.012
PG 12
WC Respiratory System
SC Respiratory System
GA AJ5ZL
UT WOS:000337769400013
PM 24874134
ER
PT J
AU Bangash, HK
Ibrahimi, OA
Green, LJ
Alam, M
Eisen, DB
Armstrong, AW
AF Bangash, Haider K.
Ibrahimi, Omar A.
Green, Lawrence J.
Alam, Murad
Eisen, Daniel B.
Armstrong, April W.
TI Who Do You Prefer? A Study of Public Preferences for Health Care
Provider Type in Performing Cutaneous Surgery and Cosmetic Procedures in
the United States
SO DERMATOLOGIC SURGERY
LA English
DT Article
ID DERMATOLOGICAL SURGERY; LIPOSUCTION; PHOTOTHERMOLYSIS; SPECIALTIES;
PERSPECTIVE; PERCEPTION
AB BACKGROUND The public preference for provider type in performing cutaneous surgery and cosmetic procedures is unknown in the United States.
METHODS An internet-based survey was administered to the lay public. Respondents were asked to select the health care provider (dermatologist, plastic surgeon, primary care physician, general surgeon, and nurse practitioner/physician's assistant) they mostly prefer to perform different cutaneous cosmetic and surgical procedures.
RESULTS Three hundred fifty-four respondents undertook the survey. Dermatologists were identified as the most preferable health care provider to evaluate and biopsy worrisome lesions on the face (69.8%), perform skin cancer surgery on the back (73.4%), perform skin cancer surgery on the face (62.7%), and perform laser procedures (56.3%) by most of the respondents. For filler injections, the responders similarly identified plastic surgeons and dermatologists (47.3% vs 44.6%, respectively) as the most preferred health care provider. For botulinum toxin injections, there was a slight preference for plastic surgeons followed by dermatologists (50.6% vs 38.4%). Plastic surgeons were the preferred health care provider for procedures such as liposuction (74.4%) and face-lift surgery (96.1%) by most of the respondents.
CONCLUSION Dermatologists are recognized as the preferred health care providers over plastic surgeons, primary care physicians, general surgeons, and nurse practitioners/physician's assistants to perform a variety of cutaneous cosmetic and surgical procedures including skin cancer surgery, on the face and body, and laser procedures. The general public expressed similar preferences for dermatologists and plastic surgeons regarding filler injections.
C1 [Bangash, Haider K.] Univ Connecticut, Ctr Hlth, Dept Internal Med, Farmington, CT USA.
[Ibrahimi, Omar A.] Connecticut Skin Inst, Stamford, CT 06032 USA.
[Ibrahimi, Omar A.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
[Green, Lawrence J.] George Washington Univ, Sch Med, Dept Dermatol, Washington, DC USA.
[Alam, Murad] Northwestern Univ, Dept Dermatol, Chicago, IL 60611 USA.
[Eisen, Daniel B.; Armstrong, April W.] Univ Calif Davis, Dept Dermatol, Sacramento, CA 95817 USA.
RP Ibrahimi, OA (reprint author), Connecticut Skin Inst, 999 Summer St,Suite 205, Stamford, CT 06032 USA.
EM omar.ibrahimi@gmail.com
OI Eisen, Daniel/0000-0001-6741-3182
NR 27
TC 10
Z9 10
U1 1
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1076-0512
EI 1524-4725
J9 DERMATOL SURG
JI Dermatol. Surg.
PD JUN
PY 2014
VL 40
IS 6
BP 671
EP 678
DI 10.1111/dsu.0000000000000016
PG 8
WC Dermatology; Surgery
SC Dermatology; Surgery
GA AJ5FP
UT WOS:000337708400010
PM 24852472
ER
PT J
AU Tripathy, D
Clement, SC
Schwenke, DC
Banerji, M
Bray, GA
Buchanan, TA
Gastaldelli, A
Henry, RR
Kitabchi, AE
Mudaliar, S
Ratner, RE
Stentz, FB
Musi, N
Reaven, PD
DeFronzo, RA
AF Tripathy, Devjit
Clement, Stephen C.
Schwenke, Dawn C.
Banerji, MaryAnn
Bray, George A.
Buchanan, Thomas A.
Gastaldelli, Amalia
Henry, Robert R.
Kitabchi, Abbas E.
Mudaliar, Sunder
Ratner, Robert E.
Stentz, Frankie B.
Musi, Nicolas
Reaven, Peter D.
DeFronzo, Ralph A.
TI Baseline Adiponectin Levels Do Not Influence the Response to
Pioglitazone in ACT NOW
SO DIABETES CARE
LA English
DT Article
ID TYPE-2 DIABETES-MELLITUS; ACTIVATED PROTEIN-KINASE; PPAR-GAMMA AGONISTS;
INSULIN SENSITIVITY; GLUCOSE; RESISTANCE; EXPRESSION; PREVENTION;
OXIDATION; INDEX
AB OBJECTIVE
Plasma adiponectin levels are reduced in type 2 diabetes mellitus (T2DM) and other insulin-resistant states. We examined whether plasma adiponectin levels at baseline and after pioglitazone treatment in impaired glucose tolerance (IGT) subjects were associated with improved insulin sensitivity (Si) and glucose tolerance status.
RESEARCH DESIGN AND METHODS
A total of 602 high-risk IGT subjects in ACT NOW were randomized to receive pioglitazone or placebo with a median follow-up of 2.4 years.
RESULTS
Pioglitazone reduced IGT conversion to diabetes by 72% in association with improved n-cell function by 64% (insulin secretion/insulin resistance index) and increased tissue sensitivity by 88% (Matsuda index). In pioglitazone-treated subjects, plasma adiponectin concentration increased threefold from 13 +/- 0.5 to 38 +/- 2.5 mu g/mL (P < 0.001) and was strongly correlated with the improvement in SI (r = 0.436, P < 0.001) and modestly correlated with glucose area under the curve during oral glucose tolerance test (r = 0.238, P < 0.005) and insulin secretion/insulin resistance index (r = 0.306, P < 0.005). The increase in adiponectin was a strong predictor of reversion to normal glucose tolerance and prevention of T2DM. In the placebo group, plasma adiponectin did not change and was not correlated with changes in glucose levels. There was an inverse association between baseline plasma adiponectin concentration and progression to diabetes in the placebo group but not in the pioglitazone group.
CONCLUSIONS
Baseline adiponectin does not predict the response to pioglitazone. The increase in plasma adiponectin concentration after pioglitazone therapy in IGT subjects is strongly related to improved glucose tolerance status and enhanced tissue sensitivity to insulin.
C1 [Tripathy, Devjit; Musi, Nicolas; DeFronzo, Ralph A.] Texas Diabet Inst, San Antonio, TX 78207 USA.
[Tripathy, Devjit; Gastaldelli, Amalia; Musi, Nicolas; DeFronzo, Ralph A.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
[Tripathy, Devjit; Musi, Nicolas; DeFronzo, Ralph A.] South Texas VA Hlth Care Syst, Audie L Murphy Hosp, San Antonio, TX USA.
[Clement, Stephen C.] Georgetown Univ, Div Endocrinol & Metab, Washington, DC USA.
[Schwenke, Dawn C.; Reaven, Peter D.] Phoenix VA Hlth Care Syst, Phoenix, AZ USA.
[Schwenke, Dawn C.] Arizona State Univ, Coll Nursing & Hlth Innovat, Phoenix, AZ USA.
[Banerji, MaryAnn] SUNY Hlth Sci Ctr, Brooklyn, NY USA.
[Bray, George A.] Louisiana State Univ, Pennington Biomed Res Ctr, Baton Rouge, LA 70803 USA.
[Buchanan, Thomas A.] Univ So Calif, Keck Sch Med, Los Angeles, CA 90033 USA.
[Gastaldelli, Amalia] CNR, Inst Clin Physiol, Cardiometab Risk Unit, I-56100 Pisa, Italy.
[Henry, Robert R.; Mudaliar, Sunder] VA San Diego Healthcare Syst, San Diego, CA USA.
[Henry, Robert R.; Mudaliar, Sunder] Univ Calif San Diego, San Diego, CA 92103 USA.
[Kitabchi, Abbas E.; Stentz, Frankie B.] Univ Tennessee, Div Endocrinol Diabet & Metab, Memphis, TN USA.
[Ratner, Robert E.] Medstar Res Inst, Hyattsville, MD USA.
RP DeFronzo, RA (reprint author), Texas Diabet Inst, San Antonio, TX 78207 USA.
EM albarado@uthscsa.edu
RI Gastaldelli, Amalia/H-3319-2014
OI Gastaldelli, Amalia/0000-0003-2594-1651
FU General Clinical Research Center at the University of Tennessee Health
Science Center, Clinical and Translational Science Award [M01-RR-00221,
UL1-TR-000130]; South Texas Veterans Health Care System-Audie Murphy
Division; Veterans Administration Health Care System
FX This study was supported in part by General Clinical Research Center
grant M01-RR-00221 at the University of Tennessee Health Science Center,
Clinical and Translational Science Award grant UL1-TR-000130 to the
University of Southern California, and the South Texas Veterans Health
Care System-Audie Murphy Division. Part (five-eighths) of R.A.D.'s
salary is supported by the Veterans Administration Health Care System.
Takeda Pharmaceuticals North America provided the study drug.
NR 22
TC 2
Z9 2
U1 0
U2 3
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD JUN
PY 2014
VL 37
IS 6
BP 1706
EP 1711
DI 10.2337/dc13-1745
PG 6
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AJ5RX
UT WOS:000337746100048
PM 24705615
ER
PT J
AU Halban, PA
Polonsky, KS
Bowden, DW
Hawkins, MA
Ling, C
Mather, KJ
Powers, AC
Rhodes, CJ
Sussel, L
Weir, GC
AF Halban, Philippe A.
Polonsky, Kenneth S.
Bowden, Donald W.
Hawkins, Meredith A.
Ling, Charlotte
Mather, Kieren J.
Powers, Alvin C.
Rhodes, Christopher J.
Sussel, Lori
Weir, Gordon C.
TI beta-Cell Failure in Type 2 Diabetes: Postulated Mechanisms and
Prospects for Prevention and Treatment
SO DIABETES CARE
LA English
DT Article
ID STIMULATED INSULIN-SECRETION; HUMAN PANCREATIC-ISLETS;
GASTRIC-BYPASS-SURGERY; DNA METHYLATION; EPIGENETIC REGULATION; HISTONE
MODIFICATIONS; ACTIVATING MUTATIONS; SUSCEPTIBILITY LOCI; GLYCEMIC
CONTROL; CONTROLLED-TRIAL
AB OBJECTIVE
This article examines the foundation of beta-cell failure in type 2 diabetes (T2D) and suggests areas for future research on the underlying mechanisms that may lead to improved prevention and treatment.
RESEARCH DESIGN AND METHODS
A group of experts participated in a conference on 14-16 October 2013 cosponsored by the Endocrine Society and the American Diabetes Association. A writing group prepared this summary and recommendations.
RESULTS
The writing group based this article on conference presentations, discussion, and debate. Topics covered include genetic predisposition, foundations of beta-cell failure, natural history of beta-cell failure, and impact of therapeutic interventions.
CONCLUSIONS
beta-Cell failure is central to the development and progression of T2D. It antedates and predicts diabetes onset and progression, is in part genetically determined, and often can be identified with accuracy even though current tests are cumbersome and not well standardized. Multiple pathways underlie decreased beta-cell function and mass, some of which may be shared and may also be a consequence of processes that initially caused dysfunction. Goals for future research include to 1) impact the natural history of beta-cell failure; 2) identify and characterize genetic loci for T2D; 3) target beta-cell signaling, metabolic, and genetic pathways to improve function/mass; 4) develop alternative sources of beta-cells for cell-based therapy; 5) focus on metabolic environment to provide indirect benefit to beta-cells; 6) improve understanding of the physiology of responses to bypass surgery; and 7) identify circulating factors and neuronal circuits underlying the axis of communication between the brain and beta-cells.
C1 [Halban, Philippe A.] Univ Geneva, Dept Genet Med & Dev, Geneva, Switzerland.
[Polonsky, Kenneth S.] Univ Chicago, Dept Med, Endocrinol Sect, Chicago, IL 60637 USA.
[Bowden, Donald W.] Wake Forest Univ, Ctr Genom & Personalized Med Res, Winston Salem, NC 27109 USA.
[Bowden, Donald W.] Wake Forest Univ, Ctr Diabet Res, Winston Salem, NC 27109 USA.
[Hawkins, Meredith A.] Albert Einstein Coll Med, Dept Med Endocrinol, Bronx, NY 10467 USA.
[Hawkins, Meredith A.] Albert Einstein Coll Med, Global Diabet Inst, Bronx, NY 10467 USA.
[Ling, Charlotte] Lund Univ, Dept Clin Sci, Lund, Sweden.
[Mather, Kieren J.] Indiana Univ, Dept Endocrinol, Indianapolis, IN 46204 USA.
[Powers, Alvin C.] Vanderbilt Univ, Sch Med, Div Diabet Endocrinol & Metab, Nashville, TN 37212 USA.
[Rhodes, Christopher J.] Univ Chicago, Dept Med, Kovler Diabet Ctr, Chicago, IL 60637 USA.
[Sussel, Lori] Columbia Univ, Naomi Berrie Diabet Ctr, New York, NY USA.
[Weir, Gordon C.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.
RP Halban, PA (reprint author), Univ Geneva, Dept Genet Med & Dev, Geneva, Switzerland.
EM philippe.halban@unige.ch; polonsky@bsd.uchicago.edu
RI Ling, Charlotte/Q-2432-2015
OI Ling, Charlotte/0000-0003-0587-7154
FU Endocrine Society; American Diabetes Association; Novo Nordisk; Sanofi;
Lilly USA
FX This article is based on a conference jointly sponsored by the Endocrine
Society and the American Diabetes Association and supported by an
educational grant from Novo Nordisk, Sanofi, and Lilly USA.
NR 86
TC 59
Z9 61
U1 3
U2 19
PU AMER DIABETES ASSOC
PI ALEXANDRIA
PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA
SN 0149-5992
EI 1935-5548
J9 DIABETES CARE
JI Diabetes Care
PD JUN
PY 2014
VL 37
IS 6
BP 1751
EP 1758
DI 10.2337/dc14-0396
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AJ5RX
UT WOS:000337746100055
PM 24812433
ER
PT J
AU Lee, S
Kim, SM
Dotimas, J
Li, L
Feener, EP
Baldus, S
Myers, RB
Chutkow, WA
Patwari, P
Yoshioka, J
Lee, RT
AF Lee, Samuel
Kim, Soo Min
Dotimas, James
Li, Letitia
Feener, Edward P.
Baldus, Stephan
Myers, Ronald B.
Chutkow, William A.
Patwari, Parth
Yoshioka, Jun
Lee, Richard T.
TI Thioredoxin-interacting protein regulates protein disulfide isomerases
and endoplasmic reticulum stress
SO EMBO MOLECULAR MEDICINE
LA English
DT Article
DE endoplasmic reticulum stress; protein disulfide isomerases;
thioredoxin-interacting protein; unfolded protein response
ID ER STRESS; GLUCOSE-HOMEOSTASIS; MOUSE MODEL; CELL-DEATH; ARRESTIN;
TXNIP; LINKS; INFLAMMASOME; ADIPOGENESIS; EXPRESSION
AB The endoplasmic reticulum (ER) is responsible for protein folding, modification, and trafficking. Accumulation of unfolded or misfolded proteins represents the condition of ER stress and triggers the unfolded protein response (UPR), a key mechanism linking supply of excess nutrients to insulin resistance and type 2 diabetes in obesity. The ER harbors proteins that participate in protein folding including protein disulfide isomerases (PDIs). Changes in PDI activity are associated with protein misfolding and ER stress. Here, we show that thioredoxin-interacting protein (Txnip), a member of the arrestin protein superfamily and one of the most strongly induced proteins in diabetic patients, regulates PDI activity and UPR signaling. We found that Txnip binds to PDIs and increases their enzymatic activity. Genetic deletion of Txnip in cells and mice led to increased protein ubiquitination and splicing of the UPR regulated transcription factor X-box-binding protein 1 (Xbp1s) at baseline as well as under ER stress. Our results reveal Txnip as a novel direct regulator of PDI activity and a feedback mechanism of UPR signaling to decrease ER stress.
C1 [Lee, Samuel; Kim, Soo Min; Dotimas, James; Li, Letitia; Myers, Ronald B.; Lee, Richard T.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Harvard Dept Stem Cell & Regenerat Biol,Harvard S, Cambridge, MA 02138 USA.
[Lee, Samuel; Kim, Soo Min; Dotimas, James; Li, Letitia; Myers, Ronald B.; Chutkow, William A.; Patwari, Parth; Yoshioka, Jun; Lee, Richard T.] Harvard Univ, Sch Med, Brigham & Womens Hosp, Cardiovasc Div,Dept Med, Cambridge, MA 02138 USA.
[Lee, Samuel; Baldus, Stephan] Univ Hosp Cologne, Dept Internal Med 3, Cologne, Germany.
[Feener, Edward P.] Harvard Univ, Sch Med, Joslin Diabet Ctr, Boston, MA 02115 USA.
RP Lee, RT (reprint author), Harvard Univ, Sch Med, Brigham & Womens Hosp, Harvard Dept Stem Cell & Regenerat Biol,Harvard S, Cambridge, MA 02138 USA.
EM RLee@partners.org
FU Koln Fortune Program, Faculty of Medicine, University of Cologne,
Germany; German Research Foundation [LE 2728/1-1]; American Diabetes
Association [7-12-MN-46]; American Heart Association [13GRNT1687007];
National Institutes of Health [HL048743, HL103582]
FX We thank Roland Strong for generously providing PDI reagents. We thank
the CECAD Imaging Facility, University of Cologne, Germany, for
providing excellent technical assistance. This work was supported by the
Koln Fortune Program, Faculty of Medicine, University of Cologne,
Germany (to SL), the German Research Foundation (LE 2728/1-1 to SL), the
American Diabetes Association (7-12-MN-46 to RTL and SL), the American
Heart Association (13GRNT1687007 to JY), and the National Institutes of
Health (HL048743, HL103582).
NR 49
TC 12
Z9 13
U1 0
U2 14
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1757-4676
EI 1757-4684
J9 EMBO MOL MED
JI EMBO Mol. Med.
PD JUN
PY 2014
VL 6
IS 6
BP 732
EP 743
DI 10.15252/emmm.201302561
PG 12
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AJ3DT
UT WOS:000337546600004
PM 24843047
ER
PT J
AU Mentz, RJ
Cotter, G
Cleland, JGF
Stevens, SR
Chiswell, K
Davison, BA
Teerlink, JR
Metra, M
Voors, AA
Grinfeld, L
Ruda, M
Mareev, V
Lotan, C
Bloomfield, DM
Fiuzat, M
Givertz, MM
Ponikowski, P
Massie, BM
O'Connor, CM
AF Mentz, Robert J.
Cotter, Gad
Cleland, John G. F.
Stevens, Susanna R.
Chiswell, Karen
Davison, Beth A.
Teerlink, John R.
Metra, Marco
Voors, Adriaan A.
Grinfeld, Liliana
Ruda, Mikhail
Mareev, Viacheslav
Lotan, Chaim
Bloomfield, Daniel M.
Fiuzat, Mona
Givertz, Michael M.
Ponikowski, Piotr
Massie, Barry M.
O'Connor, Christopher M.
TI International differences in clinical characteristics, management, and
outcomes in acute heart failure patients: better short-term outcomes in
patients enrolled in Eastern Europe and Russia in the PROTECT trial
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Article
DE Acute heart failure; Length of stay; Trial; Regional differences; Global
variation; Outcomes
ID ACUTE MYOCARDIAL-INFARCTION; QUALITY-OF-CARE; VASOPRESSIN ANTAGONISM;
HOSPITAL READMISSION; EVEREST EFFICACY; SURVEY PROGRAM; RATES; SURVIVAL;
TRENDS; HF
AB AimsThe implications of geographical variation are unknown following adjustment for hospital length of stay (LOS) in heart failure (HF) trials that included patients whether or not they had systolic dysfunction. We investigated regional differences in an international acute HF trial.
Methods and resultsThe PROTECT trial investigated 2033 patients with acute HF and renal dysfunction hospitalized at 173 sites in 17 countries with randomization to rolofylline or placebo. We grouped enrolling countries into six regions. Baseline characteristics, in-hospital management, and outcomes were explored by region. The primary study outcome was 60-day mortality or cardiovascular/renal hospitalization. Secondary outcomes included 180-day mortality. Of 2033 patients, 33% were from Eastern Europe, 19% from Western Europe, 16% from Israel, 15% from North America, 14% from Russia, and 3% from Argentina. Marked differences in baseline characteristics, HF phenotype, in-hospital diuretic and vasodilator strategies, and LOS were observed by region. LOS was shortest in North America and Israel (median 5 days) and longest in Russia (median 15 days). Regional event rates varied significantly. Following multivariable adjustment, region was an independent predictor of the risk of mortality/hospitalization at 60 days, with the lowest risk in Russia (hazard ratio 0.39, 95% confidence interval 0.23-0.64 vs. Western Europe) due to lower rehospitalization; mortality differences were attenuated by 180 days.
ConclusionsIn an international HF trial, there were differences in baseline characteristics, treatments, LOS, and rehospitalization amongst regions, but little difference in longer term mortality. Rehospitalization differences exist independent of LOS. This analysis may help inform future trial design and should be externally validated.
C1 [Mentz, Robert J.; Fiuzat, Mona; O'Connor, Christopher M.] Duke Univ, Durham, NC 27710 USA.
[Cotter, Gad; Davison, Beth A.] Momentum Res Inc, Durham, NC USA.
[Cleland, John G. F.] Univ Hull, Kingston Upon Hull, Yorks, England.
[Stevens, Susanna R.; Chiswell, Karen] Duke Clin Res Inst, Durham, NC USA.
[Teerlink, John R.; Massie, Barry M.] Univ Calif San Francisco, San Francisco, CA 94143 USA.
[Teerlink, John R.; Massie, Barry M.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Metra, Marco] Univ Brescia, Brescia, Italy.
[Voors, Adriaan A.] Univ Groningen, Groningen, Netherlands.
[Grinfeld, Liliana] Univ Buenos Aires, Buenos Aires, DF, Argentina.
[Ruda, Mikhail] Cardiol Res Ctr, Moscow 121552, Russia.
[Mareev, Viacheslav] Russian Acad Med Sci, Cardiol Sci Ctr, Inst Clin Cardiol, Moscow, Russia.
[Lotan, Chaim] Hadassah Med Org Ein Karem, Jerusalem, Israel.
[Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA.
[Givertz, Michael M.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland.
RP Mentz, RJ (reprint author), Duke Univ, Med Ctr, 2301 Erwin Rd, Durham, NC 27710 USA.
EM robert.mentz@duke.edu
RI Ponikowski, Piotr/O-6454-2015;
OI Ponikowski, Piotr/0000-0002-3391-7064; Mareev, Vyacheslav
Yurievich/0000-0002-7285-2048; Metra, Marco/0000-0001-6691-8568;
Davison, Beth/0000-0003-2374-6449; Cleland, John/0000-0002-1471-7016
FU NIGMS NIH HHS [T32 GM086330]
NR 26
TC 26
Z9 26
U1 0
U2 7
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1388-9842
EI 1879-0844
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD JUN
PY 2014
VL 16
IS 6
BP 614
EP 624
DI 10.1002/ejhf.92
PG 11
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AJ2FG
UT WOS:000337470400006
PM 24771609
ER
PT J
AU Jhund, PS
Claggett, B
Packer, M
Zile, MR
Voors, AA
Pieske, B
Lefkowitz, M
Shi, V
Bransford, T
McMurray, JJV
Solomon, SD
AF Jhund, Pardeep S.
Claggett, Brian
Packer, Milton
Zile, Michael R.
Voors, Adriaan A.
Pieske, Burkert
Lefkowitz, Martin
Shi, Victor
Bransford, Toni
McMurray, John J. V.
Solomon, Scott D.
TI Independence of the blood pressure lowering effect and efficacy of the
angiotensin receptor neprilysin inhibitor, LCZ696, in patients with
heart failure with preserved ejection fraction: an analysis of the
PARAMOUNT trial
SO EUROPEAN JOURNAL OF HEART FAILURE
LA English
DT Article
DE Blood pressure; Heart failure; Neprilysin inhibitor; NT-proBNP;
Preserved ejection fraction
ID RANDOMIZED CONTROLLED-TRIAL; ATRIAL-NATRIURETIC-PEPTIDE; DIASTOLIC
FUNCTION; CONVERTING ENZYME; RAT; OMAPATRILAT; MORTALITY; DIAGNOSIS
AB AimsThe first in class angiotensin receptor neprilysin inhibitor, LCZ696 has been shown to reduce levels of N-terminal pro-brain natriuretic peptide (NT-proBNP), reduce left atrial size and improve New York Heart Association (NYHA) class in patients with heart failure with preserved ejection fraction (HFpEF). We examined whether the effects of LCZ696 were independent of systolic blood pressure (SBP) lowering.
Methods and resultsIn the Prospective comparison of ARNi (angiotensin receptor neprilysin inhibitor) with ARB (angiotensin receptor blocker) on Management Of heart failUre with preserved ejectioN fracTion (PARAMOUNT) trial 301 patients were randomly assigned to LCZ696 or valsartan. We examined the relationship between SBP lowering and LCZ696 on NT-proBNP level, left atrial size, NYHA class and estimated glomerular filtration rate (eGFR). By 12weeks blood pressure was reduced by 9mmHg (SD 15)/5mmHg (SD 11) in patients receiving LCZ696 in comparison with 3mmHg (SD 17)/2mmHg (SD 12) in those receiving valsartan. The change in NT-proBNP was poorly correlated with change in SBP (LCZ696, r=0.17, P=0.06; valsartan, r=0.05, P=0.58) After adjustment for change in SBP, the ratio of change in NT-proBNP at 12weeks for LCZ696 vs. valsartan was 0.76 (95% CI 0.63-0.93, P=0.008), and similar to the ratio not adjusting for SBP (0.76, 95% CI 0.63-0.92, P=0.006); P for interaction was 0.38). Similarly, reduction in left atrial volume index at 36weeks, improvement in NYHA class and eGFR were all independent of the change in SBP.
ConclusionIn patients with HFpEF, the effect of the angiotensin receptor neprilysin inhibitor LCZ696 on NT-proBNP, left atrial volume, functional class, and eGFR was independent of reduction in SBP.
C1 [Jhund, Pardeep S.; Claggett, Brian; Solomon, Scott D.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA.
[Jhund, Pardeep S.; McMurray, John J. V.] Univ Glasgow, BHF Glasgow Cardiovasc Res Ctr, Inst Cardiovasc & Med Sci, Glasgow, Lanark, Scotland.
[Packer, Milton] Univ Texas SW Med Ctr Dallas, Dept Clin Sci, Dallas, TX 75390 USA.
[Zile, Michael R.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA.
[Zile, Michael R.] Med Univ S Carolina, Charleston, SC 29425 USA.
[Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands.
[Pieske, Burkert] Med Univ Graz, Dept Cardiol, Graz, Austria.
[Lefkowitz, Martin; Shi, Victor; Bransford, Toni] Novartis Pharmaceut, E Hanover, NJ USA.
RP Solomon, SD (reprint author), Brigham & Womens Hosp, Div Cardiovasc, 75 Francis St, Boston, MA 02115 USA.
EM ssolomon@rics.bwh.harvard.edu
OI mcmurray, john/0000-0002-6317-3975; Jhund, Pardeep/0000-0003-4306-5317
NR 22
TC 27
Z9 30
U1 0
U2 16
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1388-9842
EI 1879-0844
J9 EUR J HEART FAIL
JI Eur. J. Heart Fail.
PD JUN
PY 2014
VL 16
IS 6
BP 671
EP 677
DI 10.1002/ejhf.76
PG 7
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AJ2FG
UT WOS:000337470400013
PM 24692284
ER
PT J
AU Goldman, RH
Batsis, M
Petrozza, JC
Souter, I
AF Goldman, Randi H.
Batsis, Maria
Petrozza, John C.
Souter, Irene
TI Patient-specific predictions of outcome after gonadotropin ovulation
induction/intrauterine insemination
SO FERTILITY AND STERILITY
LA English
DT Article
DE Ovulation induction; intrauterine insemination; clinical pregnancy rate;
multiple pregnancy; predictive models
ID CONTROLLED OVARIAN HYPERSTIMULATION; INTRAUTERINE INSEMINATION;
PREOVULATORY FOLLICLES; MULTIPLE PREGNANCY; CYCLES; STIMULATION; NUMBER;
SUBFERTILITY; SUCCESS; SPERM
AB Objective: To use patient-specific and cycle-specific characteristics to predict clinical pregnancy, multiple pregnancy, and spontaneous abortion rates after gonadotropin ovulation induction (OI)/IUI.
Design: Retrospective chart review.
Setting: Academic fertility center.
Patient(s): A total of 1,438 women who underwent 3,375 gonadotropin OI/IUI cycles.
Intervention(s): Individual and cycle-specific characteristics were evaluated to determine predictors of the rates of clinical pregnancy, multiple pregnancy, and spontaneous abortion. Logistic regression using individual parameters was used to create predictive models.
Main Outcome Measure(s): Clinical pregnancy (CPR), multiple pregnancy (MPR), and spontaneous abortion rates (SABR).
Result(s): Multiple predictors were identified for CPR, MPR, and SABR. The presence of at least two follicles >= 13 mm at ovulation trigger significantly increased CPR (odds ratio [ OR], 95% confidence interval [ CI] = 1.45, 1.18-1.78) and MPR (OR, 95% CI = 5.17, 2.16-12.41). An E-2 level > 400 pg/mL significantly increased MPR (OR, 95% CI = 9.54, 2.31-39.42). Logistic regression models were developed for individualized predictions of outcome.
Conclusion(s): Regression analysis reveals the patient and cycle-specific characteristics that are significant predictors of CPR, MPR, and SABR after OI/IUI. Logistic models using significant or nearly significant predictors for CPR, MPR, and SABR offer improved predictive power relative to simpler models, and allow for the development of a risk calculator for personalized patient counseling. (C) 2014 by American Society for Reproductive Medicine.
C1 [Goldman, Randi H.; Petrozza, John C.; Souter, Irene] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Vincent Dept Obstet & Gynecol,Fertil Ctr, Boston, MA USA.
[Batsis, Maria; Petrozza, John C.; Souter, Irene] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Reprod Endocrinol & Infertil Div,Fertil Ctr, Boston, MA USA.
RP Goldman, RH (reprint author), Massachusetts Gen Hosp, 55 Fruit St,Yawkey 4E, Boston, MA 02114 USA.
EM rhgoldman@partners.org
FU Harvard Clinical and Translational Science Center (National Center for
Research Resources and the National Center for Advancing Translational
Sciences, National Institutes of Health) [8UL1TR000170-05]
FX The authors thank Michele Hacker, Sc. D., M.S.P.H. for statistical
consultation; and the Harvard Catalyst vertical bar The Harvard Clinical
and Translational Science Center (National Center for Research Resources
and the National Center for Advancing Translational Sciences, National
Institutes of Health Award 8UL1TR000170-05 and financial contributions
from Harvard University and its affiliated academic health care centers)
for support.
NR 21
TC 0
Z9 0
U1 1
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0015-0282
EI 1556-5653
J9 FERTIL STERIL
JI Fertil. Steril.
PD JUN
PY 2014
VL 101
IS 6
BP 1649
EP U504
DI 10.1016/j.fertnstert.2014.02.028
PG 9
WC Obstetrics & Gynecology; Reproductive Biology
SC Obstetrics & Gynecology; Reproductive Biology
GA AJ0RU
UT WOS:000337364300034
PM 24690238
ER
PT J
AU Ghassemi, M
Van Stan, JH
Mehta, DD
Zanartu, M
Cheyne, HA
Hillman, RE
Guttag, JV
AF Ghassemi, Marzyeh
Van Stan, Jarrad H.
Mehta, Daryush D.
Zanartu, Matias
Cheyne, Harold A., II
Hillman, Robert E.
Guttag, John V.
TI Learning to Detect Vocal Hyperfunction From Ambulatory Neck-Surface
Acceleration Features: Initial Results for Vocal Fold Nodules
SO IEEE TRANSACTIONS ON BIOMEDICAL ENGINEERING
LA English
DT Article
DE Ambulatory voice monitoring; clinical detection; machine learning; vocal
cord; vocal fold nodules
ID VOICE DISORDERS; V-RQOL; TEACHERS
AB Voice disorders are medical conditions that often result from vocal abuse/misuse which is referred to generically as vocal hyperfunction. Standard voice assessment approaches cannot accurately determine the actual nature, prevalence, and pathological impact of hyperfunctional vocal behaviors because such behaviors can vary greatly across the course of an individual's typical day and may not be clearly demonstrated during a brief clinical encounter. Thus, it would be clinically valuable to develop noninvasive ambulatory measures that can reliably differentiate vocal hyperfunction from normal patterns of vocal behavior. As an initial step toward this goal we used an accelerometer taped to the neck surface to provide a continuous, noninvasive acceleration signal designed to capture some aspects of vocal behavior related to vocal cord nodules, a common manifestation of vocal hyperfunction. We gathered data from 12 female adult patients diagnosed with vocal fold nodules and 12 control speakers matched for age and occupation. We derived features from weeklong neck-surface acceleration recordings by using distributions of sound pressure level and fundamental frequency over 5-min windows of the acceleration signal and normalized these features so that intersubject comparisons were meaningful. We then used supervised machine learning to show that the two groups exhibit distinct vocal behaviors that can be detected using the acceleration signal. We were able to correctly classify 22 of the 24 subjects, suggesting that in the future measures of the acceleration signal could be used to detect patients with the types of aberrant vocal behaviors that are associated with hyperfunctional voice disorders.
C1 [Ghassemi, Marzyeh; Guttag, John V.] MIT, Comp Sci & Artificial Intelligence Lab, Cambridge, MA 02139 USA.
[Van Stan, Jarrad H.; Mehta, Daryush D.; Hillman, Robert E.] Massachusetts Gen Hosp, Ctr Laryngeal Surg & Voice Rehabil, Boston, MA 02114 USA.
[Van Stan, Jarrad H.; Hillman, Robert E.] Massachusetts Gen Hosp, Inst Hlth Profess, Boston, MA 02114 USA.
[Mehta, Daryush D.; Hillman, Robert E.] Harvard Univ, Sch Med, Dept Surg, Boston, MA 02115 USA.
[Zanartu, Matias] Univ Tecn Federico Santa Maria, Dept Elect Engn, Valparaiso 2390123, Chile.
[Cheyne, Harold A., II] Cornell Univ, Bioacoust Res Program, Lab Ornithol, Ithaca, NY 14850 USA.
RP Ghassemi, M (reprint author), MIT, Comp Sci & Artificial Intelligence Lab, 77 Massachusetts Ave, Cambridge, MA 02139 USA.
EM mghassem@mit.edu; JVanStan@mghihp.edu; daryush.mehta@alum.mit.edu;
matias.zanartu@usm.cl; hac68@cornell.edu;
hillman.robert@mgh.harvard.edu; guttag@csail.mit.edu
RI Zanartu, Matias/I-3133-2012; researchers, ac3e/N-2008-2016
OI Zanartu, Matias/0000-0001-5581-4392;
FU National Library of Medicine's university-based Biomedical Informatics
Research Training Program; Intel Science and Technology Center; National
Institutes of Health National Institute on Deafness and Other
Communication Disorders [R33DC011588]; Chilean CONICYT [FONDECYT
11110147]; MIT International Science and Technology Initiatives
MIT-Chile Seed Fund [2745333]
FX This work was supported in part by the National Library of Medicine's
university-based Biomedical Informatics Research Training Program, in
part by the Intel Science and Technology Center, and in part by the
National Institutes of Health National Institute on Deafness and Other
Communication Disorders under Grant R33DC011588, the Chilean CONICYT
under Grant FONDECYT 11110147, and the MIT International Science and
Technology Initiatives MIT-Chile Seed Fund under Grant 2745333. Asterisk
indicates Corresponding author.
NR 26
TC 11
Z9 11
U1 6
U2 10
PU IEEE-INST ELECTRICAL ELECTRONICS ENGINEERS INC
PI PISCATAWAY
PA 445 HOES LANE, PISCATAWAY, NJ 08855-4141 USA
SN 0018-9294
EI 1558-2531
J9 IEEE T BIO-MED ENG
JI IEEE Trans. Biomed. Eng.
PD JUN
PY 2014
VL 61
IS 6
BP 1668
EP 1675
DI 10.1109/TBME.2013.2297372
PG 8
WC Engineering, Biomedical
SC Engineering
GA AJ5PB
UT WOS:000337736000009
PM 24845276
ER
PT J
AU Rodriguez-Diaz, E
Atkinson, C
Jepeal, LI
Berg, A
Huang, CS
Cerda, SR
O'Brien, MJ
Bigio, IJ
Farraye, FA
Singh, SK
AF Rodriguez-Diaz, Eladio
Atkinson, Christopher
Jepeal, Lisa I.
Berg, Adam
Huang, Christopher S.
Cerda, Sandra R.
O'Brien, Michael J.
Bigio, Irving J.
Farraye, Francis A.
Singh, Satish K.
TI Elastic Scattering Spectroscopy as an Optical Marker of Inflammatory
Bowel Disease Activity and Subtypes
SO INFLAMMATORY BOWEL DISEASES
LA English
DT Article
DE spectrum analysis; spectroscopy; endoscopy; inflammatory bowel disease;
Crohn's disease; ulcerative colitis; biomarker
ID SOURCE-DETECTOR SEPARATIONS; LIGHT-SCATTERING; CROHNS-DISEASE;
MICROVASCULAR BLOOD; ULCERATIVE-COLITIS; BARRETTS-ESOPHAGUS; COLONIC
NEOPLASIA; UNITED-STATES; NORMAL MUCOSA; IN-VIVO
AB Background: In 10% to 15% of individuals, inflammatory bowel disease (IBD) is difficult to classify as ulcerative colitis (UC) or Crohn's disease (CD). Previous work has demonstrated that probe-based elastic scattering spectroscopy (ESS) can produce spectra, informed by parameters like tissue ultrastructure and hemoglobin content, capable of differentiating pathologies. This study investigates whether ESS is an in vivo optical biomarker for the presence, activity, and type of IBD in the colon.
Methods: Pilot study, a retrospective data analysis. ESS spectra of endoscopically normal and inflamed colon were obtained from 48 patients with IBD and 46 non-IBD controls. Measurements from patients with IBD were categorized as CD or UC based on clinical diagnosis. Spectra were analyzed using high-dimensional methods. Leave-one-patient-out cross-validation was used to obtain diagnostic performance estimates.
Results: Patients with IBD were distinguishable from non-IBD controls with a sensitivity of 0.93 and specificity of 0.91 based on readings from endoscopically normal mucosa, and 0.94 and 0.93 from inflamed mucosa. In patients with IBD, histologically normal and inflamed colon were distinguishable with per-class accuracies of 0.83 and 0.89, respectively; histologically normal from inactive inflammation with accuracies of 0.73 and 0.89, respectively; and inactive from active colitis with accuracies of 0.87 and 0.84, respectively. The diagnosis of CD versus UC was made with per-class accuracies of 0.92 and 0.87 in normal and 0.87 and 0.85 in inflamed mucosa, respectively.
Conclusions: ESS, a simple, low-cost clinically friendly optical biopsy modality, has the potential to enhance the endoscopic assessment of IBD and its activity in real time and may help to distinguish CD from UC.
C1 [Rodriguez-Diaz, Eladio; Jepeal, Lisa I.; Berg, Adam; Huang, Christopher S.; Bigio, Irving J.; Farraye, Francis A.; Singh, Satish K.] Boston Univ, Sch Med, Dept Med, Gastroenterol Sect, Boston, MA 02118 USA.
[Atkinson, Christopher] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA.
[Cerda, Sandra R.; O'Brien, Michael J.] Boston Univ, Sch Med, Dept Pathol & Lab Med, Boston, MA 02118 USA.
[Bigio, Irving J.; Singh, Satish K.] Boston Univ, Coll Engn, Dept Biomed Engn, Boston, MA 02118 USA.
[Singh, Satish K.] VA Boston Healthcare Syst, Med Serv, Gastroenterol Unit, Boston, MA USA.
RP Singh, SK (reprint author), Boston Univ, Sch Med, Dept Med, Gastroenterol Sect, Suite 504,650 Albany St, Boston, MA 02118 USA.
EM singhsk@bu.edu
FU VA CSRD Merit Award [1I01CX000347]; NIH/NCI [U54 CA10467]; Wallace H.
Coulter Foundation; Center for the Integration of Medicine and
Innovative Technology
FX Supported by VA CSR&D Merit Award (1I01CX000347), NIH/NCI (U54 CA10467),
Wallace H. Coulter Foundation, and Center for the Integration of
Medicine and Innovative Technology.
NR 52
TC 3
Z9 3
U1 0
U2 5
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1078-0998
EI 1536-4844
J9 INFLAMM BOWEL DIS
JI Inflamm. Bowel Dis.
PD JUN
PY 2014
VL 20
IS 6
BP 1029
EP 1036
DI 10.1097/MIB.0000000000000058
PG 8
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AJ5SY
UT WOS:000337749500010
PM 24798637
ER
PT J
AU Bleier, BS
Nocera, AL
Iqbal, H
Hoang, JD
Alvarez, U
Feldman, RE
Han, X
AF Bleier, Benjamin S.
Nocera, Angela L.
Iqbal, Hufsa
Hoang, John D.
Alvarez, Ulises
Feldman, Rachel E.
Han, Xue
TI P-glycoprotein promotes epithelial T helper 2-associated cytokine
secretion in chronic sinusitis with nasal polyps
SO INTERNATIONAL FORUM OF ALLERGY & RHINOLOGY
LA English
DT Article
DE chronic sinusitis with nasal polyps; immunomodulator; nasal epithelium;
P-glycoprotein; Th2 inflammation
ID CELLS IN-VITRO; CHRONIC RHINOSINUSITIS; MULTIDRUG-RESISTANCE;
EXPRESSION; IMMUNOMODULATOR; INFLAMMATION; EOTAXIN-3; REVERSAL; IL-6
AB Background Sinonasal epithelial cells are recognized as drivers of inflammation in chronic sinusitis with nasal polyps (CRSwNP) through secretion of T helper 2 (Th2)-promoting cytokines. P-glycoprotein (P-gp) is overexpressed in nasal polyps and modulates epithelial cytokine secretion in healthy mucosa. The objective of this study is to determine whether P-gp overactivity promotes Th2-associated cytokine secretion in CRSwNP. Methods Polyp explants (n = 4) and primary epithelial cell cultures (n = 5) were cultivated from patients with CRSwNP. Explant P-gp activity was determined using a calcein assay. In culture, P-gp was quantified by enzyme-linked immunosorbent assay (ELISA) and sensitivity to PSC-833 inhibition was determined using a calcein assay. Lipopolysaccharide (LPS)-stimulated cytokine secretion of interleukin 6 (IL-6), IL-8, IL-25, and granulocyte macrophage colony stimulating factor (GM-CSF) were quantified by ELISA and compared to secretion following P-gp inhibition. Differences in P-gp expression and cytokine secretion were compared using a Mann-Whitney U test. Secretion was correlated with P-gp expression using a Pearson correlation coefficient. Results Calcein retention is increased in P-gp inhibited vs uninhibited polyp explants (mean +/- standard deviation [SD]; 5.17 +/- 1.76 vs 2.55 +/- 0.62; p < 0.05) but not in controls, indicating increased nasal polyp P-gp activity. P-gp is sensitive to dose-dependent P-gp inhibition with PSC-833 in vitro. LPS-stimulated secretion of normalized GM-CSF (45.21 +/- 41.39) and IL-6 (63.16 +/- 36.37) were significantly reduced following P-gp inhibition (8.47 +/- 3.28; p < 0.01, and 39.94 +/- 31.07; p < 0.05; respectively) and secretion was highly correlated with P-gp expression(r = 0.824, p < 0.05, and r = 0.833, p < 0.05; respectively). Conclusion P-gp overactivity promotes Th2-associated epithelial cytokine secretion in nasal polyps, suggesting a novel mechanism for maintaining chronic inflammation in CRSwNP.
C1 [Bleier, Benjamin S.; Feldman, Rachel E.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Boston, MA USA.
[Nocera, Angela L.; Iqbal, Hufsa; Hoang, John D.; Alvarez, Ulises; Han, Xue] Boston Univ, Dept Biomed Engn, Boston, MA 02215 USA.
RP Bleier, BS (reprint author), 243 Charles St, Boston, MA 02114 USA.
EM benjamin_bleier@meei.harvard.edu
FU American Rhinologic Society
FX American Rhinologic Society New Investigator Grant.
NR 28
TC 9
Z9 9
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 2042-6976
EI 2042-6984
J9 INT FORUM ALLERGY RH
JI Int. Forum Allergy Rhinol.
PD JUN
PY 2014
VL 4
IS 6
BP 488
EP 494
DI 10.1002/alr.21316
PG 7
WC Otorhinolaryngology
SC Otorhinolaryngology
GA AJ3DA
UT WOS:000337544500010
PM 24599606
ER
PT J
AU Guddati, AK
Kumar, G
Ahmed, S
Ali, M
Kumar, N
Hari, P
Venu, N
AF Guddati, Achuta Kumar
Kumar, Gagan
Ahmed, Shahryar
Ali, Muhammad
Kumar, Nilay
Hari, Parameswaran
Venu, Nanda
TI Incidence and outcomes of Clostridium difficile-associated disease in
hematopoietic cell transplant recipients
SO INTERNATIONAL JOURNAL OF HEMATOLOGY
LA English
DT Article
DE Hematopoietic stem cell transplant; Graft versus host disease;
Clostridium difficile-associated disease; Mortality
ID MARROW-TRANSPLANTATION; DIARRHEA; INFECTION; EPIDEMIOLOGY; PREVALENCE
AB Hematopoietic stem cell transplant (HSCT) recipients are at a high risk of Clostridium difficile-associated disease (CDAD) given frequent hospitalizations, prolonged antibiotic usage and altered integrity of intestinal mucosa. The prevalence and trends of CDAD in HSCT patients have not been extensively studied. In this study, the International Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) codes were used to identify CDAD in HSCT patients using a nationwide inpatient sample in the United States from 2000 to 2009. The prevalence of CDAD and in-hospital mortality in HSCT were investigated and compared to those without any transplants. Multivariate analysis was performed to identify if BMT and graft versus host disease (GVHD) were independently associated with mortality in CDAD patients. Of the 344,507 HSCT discharges, 4.7 % had CDAD. This was about 5 times higher when compared to non-transplant discharges. During engraftment admission, rates of CDAD were higher in allogenic group (8.4 vs. 5.7 %, p < 0.001). In subsequent admissions, those with GVHD had higher rates of CDAD (5.7 vs. 3.2 %, p < 0.001). On adjusted analysis in patients with CDAD, during engraftment admission, allogenic group had significantly higher mortality when compared with non-transplants (OR 3.7). Notably, there was no significant difference in mortality between patients with and without CDAD during the engraftment period for the allogeneic group. In subsequent admissions, there was higher mortality in those with GVHD (OR 4.8). Though the prevalence of CDAD in non-transplant population doubled (from 0.44 % in 2000 to 0.99 % in 2008), it has remained stable in HSCT patients (from 4.8 % in 2000 to 5.6 % in 2008). HSCT and GVHD are independently associated with CDAD though its presence does not affect mortality.
C1 [Guddati, Achuta Kumar] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Internal Med, Boston, MA 02163 USA.
[Kumar, Gagan] Med Coll Wisconsin, Div Pulm & Crit Care, Milwaukee, WI 53226 USA.
[Ahmed, Shahryar; Ali, Muhammad] Med Coll Wisconsin, Dept Internal Med, Milwaukee, WI 53226 USA.
[Kumar, Nilay; Venu, Nanda] Med Coll Wisconsin, Div Gastroenterol & Hepatol, Milwaukee, WI 53226 USA.
[Hari, Parameswaran] Med Coll Wisconsin, Div Hematol & Oncol, Milwaukee, WI 53226 USA.
RP Guddati, AK (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Internal Med, 50 Fruit St, Boston, MA 02163 USA.
EM aguddati@partners.org
OI Hari, Parameswaran/0000-0002-8800-297X
NR 30
TC 7
Z9 8
U1 0
U2 3
PU SPRINGER JAPAN KK
PI TOKYO
PA CHIYODA FIRST BLDG EAST, 3-8-1 NISHI-KANDA, CHIYODA-KU, TOKYO, 101-0065,
JAPAN
SN 0925-5710
EI 1865-3774
J9 INT J HEMATOL
JI Int. J. Hematol.
PD JUN
PY 2014
VL 99
IS 6
BP 758
EP 765
DI 10.1007/s12185-014-1577-z
PG 8
WC Hematology
SC Hematology
GA AJ3YG
UT WOS:000337603400013
PM 24715522
ER
PT J
AU Tawakol, A
Lo, J
Zanni, MV
Marmarelis, E
Ihenachor, EJ
MacNabb, M
Wai, B
Hoffmann, U
Abbara, S
Grinspoon, S
AF Tawakol, Ahmed
Lo, Janet
Zanni, Markella V.
Marmarelis, Eleni
Ihenachor, Ezinne J.
MacNabb, Megan
Wai, Bryan
Hoffmann, Udo
Abbara, Suhny
Grinspoon, Steven
TI Increased Arterial Inflammation Relates to High-Risk Coronary Plaque
Morphology in HIV-Infected Patients
SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES
LA English
DT Article
DE HIV; arterial inflammation; coronary atherosclerotic plaque;
cardiovascular disease
ID ACUTE MYOCARDIAL-INFARCTION; TOMOGRAPHY; LESIONS
AB Background:Mechanisms predisposing HIV-infected patients to increased cardiovascular disease (CVD) risk remain unclear.Objective:To determine the interrelationship between arterial inflammation and high-risk coronary plaque morphology in HIV-infected patients with subclinical coronary atherosclerosis.Methods:Forty-one HIV-infected patients on stable antiretroviral therapy without known CVD but with atherosclerotic plaque on coronary CT angiography were evaluated with F-18-FDG-PET. Patients were stratified into 2 groups based on relative degree of arterial inflammation [aortic target-to-background ratio (TBR)]. High-risk coronary atherosclerotic plaque morphology features were compared between groups.Results:HIV-infected patients with higher and lower TBRs were similar with respect to traditional CVD risk parameters. Among HIV-infected patients with higher TBR, an increased percentage of patients demonstrated at least 1 low-attenuation coronary atherosclerotic plaque (40% vs. 10%, P = 0.02) and at least 1 coronary atherosclerotic plaque with both low attenuation and positive remodeling (35% vs. 10%, P = 0.04). Moreover, in the higher TBR group, both the number of low-attenuation plaques per patient (P = 0.02) and the number of vulnerability features in the most vulnerable plaque (P = 0.02) were increased. TBR grouping remained significantly related to the number of low-attenuation plaques/subject ( = 0.35, P = 0.004), controlling for age, gender, low-density lipoprotein, duration of HIV, and CD4.Conclusions:These data demonstrate a relationship between arterial inflammation on F-18-FDG-PET and high-risk coronary atherosclerotic plaque features among HIV-infected patients with subclinical coronary atherosclerosis. Further studies are needed to determine whether arterial inflammation and related high-risk coronary morphology increase the risk of clinical CVD events in the HIV population.
C1 [Tawakol, Ahmed; MacNabb, Megan] Massachusetts Gen Hosp, Div Cardiol, Boston, MA 02114 USA.
[Tawakol, Ahmed; Lo, Janet; Zanni, Markella V.; Marmarelis, Eleni; Ihenachor, Ezinne J.; MacNabb, Megan; Wai, Bryan; Hoffmann, Udo; Abbara, Suhny; Grinspoon, Steven] Harvard Univ, Sch Med, Boston, MA USA.
[Lo, Janet; Zanni, Markella V.; Marmarelis, Eleni; Ihenachor, Ezinne J.; Grinspoon, Steven] Massachusetts Gen Hosp, Program Nutr Metab, Boston, MA 02114 USA.
[Wai, Bryan; Hoffmann, Udo; Abbara, Suhny] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Grinspoon, S (reprint author), Massachusetts Gen Hosp, Program Nutr Metab, 55 Fruit St,5 Longfellow Plaza,Suite 207, Boston, MA 02114 USA.
EM sgrinspoon@partners.org
FU NIH [R01 HL095123, K23 HL092792]
FX Supported by the grants NIH R01 HL095123 to S. G. and NIH K23 HL092792
to J.L.
NR 14
TC 14
Z9 14
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1525-4135
EI 1077-9450
J9 JAIDS-J ACQ IMM DEF
JI JAIDS
PD JUN 1
PY 2014
VL 66
IS 2
BP 164
EP 171
DI 10.1097/QAI.0000000000000138
PG 8
WC Immunology; Infectious Diseases
SC Immunology; Infectious Diseases
GA AJ4YJ
UT WOS:000337685800018
PM 24828267
ER
PT J
AU Allred, EN
Capone, A
Fraioli, A
Dammann, O
Droste, P
Duker, J
Gise, R
Kuban, K
Leviton, A
O'Shea, TM
Paneth, N
Petersen, R
Trese, M
Stoessel, K
Vanderveen, D
Wallace, DK
Weaver, G
AF Allred, Elizabeth N.
Capone, Antonio, Jr.
Fraioli, Anthony
Dammann, Olaf
Droste, Patrick
Duker, Jay
Gise, Robert
Kuban, Karl
Leviton, Alan
O'Shea, T. Michael
Paneth, Nigel
Petersen, Robert
Trese, Michael
Stoessel, Kathleen
Vanderveen, Deborah
Wallace, David K.
Weaver, Grey
TI Retinopathy of prematurity and brain damage in the very preterm newborn
SO JOURNAL OF AAPOS
LA English
DT Article
ID PREGNANCY DISORDERS; CEREBRAL-PALSY; CHILDREN BORN; WHITE-MATTER;
BIRTH-WEIGHT; INFLAMMATION; RISK; INFANTS; AGE; HYPOTHYROXINEMIA
AB PURPOSE To explain why very preterm newborns who develop retinopathy of prematurity (ROP) appear to be at increased risk of abnormalities of both brain structure and function.
METHODS A total of 1,085 children born at <28 weeks' gestation had clinically indicated retinal ex-. aminations and had a developmental assessment at 2 years corrected age. Relationships between ROP categories and brain abnormalities were explored using logistic regression models with adjustment for potential confounders.
RESULTS The 173 children who had severe ROP, defined as prethreshold ROP (n = 146) or worse (n = 27) were somewhat more likely than their peers without ROP to have brain ultrasound lesions or cerebral palsy. They were approximately twice as likely to have very low Bayley Scales scores. After adjusting for risk factors common to both ROP and brain disorders, infants who developed severe ROP were at increased risk of low Bayley Scales only. Among children with prethreshold ROP, exposure to anesthesia was not associated with low Bayley Scales.
CONCLUSIONS Some but not all of the association of ROP with brain disorders can be explained by common risk factors. Most of the increased risks of very low Bayley Scales associated with ROP are probably not a consequence of exposure to anesthetic agents.
C1 [Allred, Elizabeth N.; Leviton, Alan; Petersen, Robert; Vanderveen, Deborah] Boston Childrens Hosp, Boston, MA 02115 USA.
[Allred, Elizabeth N.; Fraioli, Anthony; Leviton, Alan; Petersen, Robert; Vanderveen, Deborah] Harvard Univ, Sch Med, Boston, MA USA.
[Capone, Antonio, Jr.; Trese, Michael] William Beaumont Hosp, Royal Oak, MI 48072 USA.
[Fraioli, Anthony] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Dammann, Olaf; Duker, Jay] Tufts Univ, Sch Med, Boston, MA 02111 USA.
[Dammann, Olaf; Duker, Jay] Tufts Med Ctr, Floating Hosp Children, Boston, MA USA.
[Dammann, Olaf] Hannover Med Sch, Hannover, Germany.
[Droste, Patrick] Helen DeVos Childrens Hosp, Grand Rapids, MI USA.
[Gise, Robert] UMass Mem Med Ctr, Worcester, MA USA.
[Gise, Robert] Univ Massachusetts, Sch Med, Worcester, MA USA.
[Kuban, Karl] Boston Univ, Sch Med, Boston Med Ctr, Boston, MA 02118 USA.
[O'Shea, T. Michael; Weaver, Grey] Wake Forest Univ, Bowman Gray Sch Med, Winston Salem, NC USA.
[Paneth, Nigel] Michigan State Univ, Coll Human Med, E Lansing, MI 48824 USA.
[Stoessel, Kathleen] Yale Univ, Sch Med, New Haven, CT USA.
[Wallace, David K.] Duke Eye Ctr, Durham, NC USA.
RP Leviton, A (reprint author), Boston Childrens Hosp, Au-414,300 Longwood Ave, Boston, MA 02115 USA.
EM alan.leviton@childrens.harvard.edu
OI Droste, Patrick/0000-0002-6584-9721
FU NEI NIH HHS [R01 EY021820]; NINDS NIH HHS [U01 NS040069]
NR 47
TC 4
Z9 4
U1 0
U2 4
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1091-8531
EI 1528-3933
J9 J AAPOS
JI J. AAPOS
PD JUN
PY 2014
VL 18
IS 3
BP 241
EP 247
DI 10.1016/j.jaapos.2014.01.014
PG 7
WC Ophthalmology; Pediatrics
SC Ophthalmology; Pediatrics
GA AJ5IM
UT WOS:000337715900007
PM 24924276
ER
PT J
AU Kradin, R
AF Kradin, Richard
TI Converting a Freudian analysis into a Jungian one: obsession, addiction,
and an answer from Job
SO JOURNAL OF ANALYTICAL PSYCHOLOGY
LA English
DT Article
DE addiction; Freud; Job; Jungian analysis; obsessive-compulsive; Oedipal
conflict; psychoanalysis; resistance; super-ego; therapeutic alliance;
transference
AB In his analyses of obsessional patients, Sigmund Freud suggested that they suffered from intrusive cognitions and compulsive activities. Early psychoanalysts delineated the phenomenology of obsessionality, but did not differentiate what is currently termed obsessive-compulsive disorder from obsessional personality. However, it was widely recognized that the success of psychoanalysis with obsessional patients was limited due to rigid characterological defences and transference resistances. The present paper examines the case of a middle-aged obsessional academic who had been treated for nearly twenty years in a 'classical' Freudian psychoanalysis prior to entering Jungian analysis. It examines how persistent focus on Oedipal conflicts undesirably reinforced the transference resistance in this obsessional man, and suggests that focusing instead on diminishing the harshness of the super-ego via the therapeutic alliance, and fostering faith in the salutary aspects of unconscious processing has led to salutary results in this case. The biblical book of Job is adopted as ancient instruction in how to address the scrupulosity and addictive mental structuring of obsessionality in analysis.
C1 [Kradin, Richard] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kradin, Richard] CG Jung Inst, Boston, MA USA.
[Kradin, Richard] Mind Body Med Inst, Boston, MA USA.
[Kradin, Richard] Harvard Univ, Med Sch, Cambridge, MA 02138 USA.
RP Kradin, R (reprint author), Massachusetts Gen Hosp, Boston, MA 02114 USA.
EM RKRADIN@mgh.harvard.edu
NR 29
TC 0
Z9 0
U1 4
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0021-8774
EI 1468-5922
J9 J ANAL PSYCHOL
JI J. Anal. Psychol.
PD JUN
PY 2014
VL 59
IS 3
BP 346
EP 365
DI 10.1111/1468-5922.12082
PG 20
WC Psychology, Psychoanalysis
SC Psychology
GA AJ4CB
UT WOS:000337616600005
PM 24919628
ER
PT J
AU Goto, H
Takasugi, N
Kuwahara, T
Verrier, RL
AF Goto, Hiroko
Takasugi, Nobuhiro
Kuwahara, Takashi
Verrier, Richard L.
TI QRST-Wave Alternans in a Child with Type 3 Long-QT Syndrome: An Ominous
ECG Pattern Appearing During Transition from T-Wave Alternans to
Polymorphic VT
SO JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY
LA English
DT Article
C1 [Goto, Hiroko; Kuwahara, Takashi] Gifu Prefectural Gen Med Ctr, Dept Pediat, Gifu, Japan.
[Takasugi, Nobuhiro] Gifu Univ Hosp, Div Cardiovasc Med, Gifu 5011194, Japan.
[Verrier, Richard L.] Harvard Univ, Beth Israel Deaconess Med Ctr, Div Cardiovasc Med, Sch Med, Boston, MA 02215 USA.
RP Takasugi, N (reprint author), Gifu Univ Hosp, Div Cardiovasc Med, 1-1 Yanagido, Gifu 5011194, Japan.
EM konezumi@ccn3.aitai.ne.jp
NR 1
TC 2
Z9 2
U1 0
U2 0
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1045-3873
EI 1540-8167
J9 J CARDIOVASC ELECTR
JI J. Cardiovasc. Electrophysiol.
PD JUN
PY 2014
VL 25
IS 6
BP 657
EP 658
DI 10.1111/jce.12354
PG 2
WC Cardiac & Cardiovascular Systems
SC Cardiovascular System & Cardiology
GA AJ2UB
UT WOS:000337518000014
PM 24383991
ER
PT J
AU Schmittdiel, JA
Dyer, W
Uratsu, C
Magid, DJ
O'Connor, PJ
Beck, A
Butler, M
Ho, MP
Vazquez-Benitez, G
Adams, AS
AF Schmittdiel, Julie A.
Dyer, Wendy
Uratsu, Connie
Magid, David J.
O'Connor, Patrick J.
Beck, Arne
Butler, Melissa
Ho, Michael P.
Vazquez-Benitez, Gabriela
Adams, Alyce S.
TI Initial Persistence With Antihypertensive Therapies Is Associated With
Depression Treatment Persistence, But Not Depression
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Article
ID RANDOMIZED CONTROLLED-TRIAL; MEDICATION ADHERENCE; UNITED-STATES;
HYPERTENSIVE PATIENTS; SYSTEM FACTORS; HEART-DISEASE; BLACK-MEN;
PREVALENCE; SYMPTOMS; TRENDS
AB The purpose of this study was to examine the relationship between the presence of clinical depression and persistence to drug therapy treatment for depression with early nonpersistence to antihypertensive therapies in a large, diverse cohort of newly treated hypertension patients. Using a hypertension registry at Kaiser Permanente Northern California, the authors conducted a retrospective cohort study of 44,167 adults (18years and older) with hypertension who were new users of antihypertensive therapy in 2008. We used multivariate logistic regression analysis to model the relationships between the presence of clinical depression and early nonpersistence (defined as failing to refill the first prescription within 90days after the end of the first fill days' supply) to antihypertensive therapies, controlling for sociodemographic and clinical risk factors. Within the group of 1484 patients who had evidence of clinical depression in the 12months prior to the initiation of antihypertensive therapy, the authors examined the relationship between drug therapy treatment for depression and 6-month persistence with antidepressant therapy with early nonpersistence with antihypertensive therapies. No association was found between the presence of clinical depression and early nonpersistence to antihypertensive therapies after adjustment for individual demographic and clinical characteristics and neighborhood-level socioeconomic status. However, among the subset of 1484 patients with documented evidence of clinical depression in the 12months prior to the initiation of antihypertensive therapy, being prescribed and persistence with antidepressant therapy was strongly associated with lower odds of early nonpersistence to antihypertensive medications (odds ratio, 0.64; confidence interval, 0.42-0.96). In an integrated delivery system, the authors found that treatment for depression was associated with higher levels of antihypertensive persistence. Improving quality of depression care in patients with comorbid hypertension may be an important strategy in decreasing cardiovascular disease risk in these patients.
C1 [Schmittdiel, Julie A.; Dyer, Wendy; Uratsu, Connie; Adams, Alyce S.] Kaiser Permanente, Div Res, Oakland, CA 94612 USA.
[Magid, David J.; Beck, Arne; Ho, Michael P.] Kaiser Permanente, Inst Res, Denver, CO USA.
[Magid, David J.; Ho, Michael P.] Univ Colorado, Denver, CO 80202 USA.
[O'Connor, Patrick J.; Vazquez-Benitez, Gabriela] HealthPartners Res Fdn, Minneapolis, MN USA.
[Butler, Melissa] Kaiser Permanente, Ctr Hlth Res Southeast, Atlanta, GA USA.
[Ho, Michael P.] Denver VA Med Ctr, Denver, CO USA.
RP Schmittdiel, JA (reprint author), Kaiser Permanente, Div Res, 2000 Broadway, Oakland, CA 94612 USA.
EM Julie.A.Schmittdiel@kp.org
FU National Heart, Lung, and Blood Institute [3U19HL091179-04S1]; National
Institute for Mental Health; Health Delivery Systems Center for Diabetes
Translational Research - National Institute for Diabetes, Digestive and
Kidney Diseases [P30DK092924]
FX This study was funded by [3U19HL091179-04S1] the National Heart, Lung,
and Blood Institute and the National Institute for Mental Health as a
supplement to the HMO Research Network Cardiovascular Disease Network.
Additional support for Drs Adams, Schmittdiel, and OConnor was also
provided by the Health Delivery Systems Center for Diabetes
Translational Research [P30DK092924], funded by the National Institute
for Diabetes, Digestive and Kidney Diseases. The funders had no role in
the design or conduct of the study, data collection, management,
analysis or interpretation, or in the preparation, review, or approval
of this manuscript. The authors report no conflicts of interest. Dr
Schmittdiel had full access to all the data in the study and takes
responsibility for the integrity of the data and the accuracy of the
data analysis.
NR 31
TC 2
Z9 2
U1 1
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1524-6175
EI 1751-7176
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD JUN
PY 2014
VL 16
IS 6
BP 412
EP 417
DI 10.1111/jch.12300
PG 6
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AJ3XE
UT WOS:000337600400007
PM 24716533
ER
PT J
AU Shah, RV
Abbasi, SA
Yamal, JM
Davis, BR
Barzilay, J
Einhorn, PT
Goldfine, A
AF Shah, Ravi V.
Abbasi, Siddique A.
Yamal, Jose-Miguel
Davis, Barry R.
Barzilay, Joshua
Einhorn, Paula T.
Goldfine, Allison
CA ALLHAT Collaborative Res Grp
TI Impaired Fasting Glucose and Body Mass Index as Determinants of
Mortality in ALLHAT: Is the Obesity Paradox Real?
SO JOURNAL OF CLINICAL HYPERTENSION
LA English
DT Article
ID CORONARY-HEART-DISEASE; FAT DISTRIBUTION; RISK; ASSOCIATION; ADULTS;
HYPERTENSION; METAANALYSIS; OVERWEIGHT; WEIGHT; STROKE
AB Emerging literature suggests that obesity may be protective against mortality and cardiovascular outcomes, while dysglycemia may worsen outcomes regardless of obesity. The authors measured the association of weight, smoking, and glycemia with mortality in the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Among 5423 ALLHAT participants without established diabetes or cardiovascular disease, 3980 (73%) had normal fasting glucose and 1443 (27%) had impaired fasting glucose (IFG) levels at study entry. After a median of 4.9years follow-up, 554 (10%) had died (37% cardiovascular). IFG was associated with higher all-cause mortality (adjusted hazard ratio [HR], 1.23; 95% confidence interval [CI], 1.02-1.50), while obesity was associated with lower all-cause mortality (adjusted HR, 0.76; 95% CI, 0.60-0.96). However, after excluding underweight individuals (body mass index [BMI] <22kg/m2) and smokers, neither obesity nor IFG was associated with all-cause mortality, but IFG identifies individuals at greater risk in the nonobese population. Although obesity appeared protective against mortality, this association was not significant in never-smokers or after exclusion of BMI <22kg/m2. The obesity paradox may result from confounding by a sicker, underweight referent population and smoking.
C1 [Shah, Ravi V.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA.
[Abbasi, Siddique A.] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Yamal, Jose-Miguel; Davis, Barry R.] Univ Texas Houston, Sch Publ Hlth, Div Biostat, Houston, TX 77030 USA.
[Barzilay, Joshua] Kaiser Permanente Georgia, Gwinnett Comprehens Med Ctr, Duluth, GA USA.
[Einhorn, Paula T.] NHLBI, Div Cardiovasc Sci, Bethesda, MD 20892 USA.
[Goldfine, Allison] Joslin Diabet Ctr, Boston, MA 02215 USA.
RP Yamal, JM (reprint author), Univ Texas Houston, Sch Publ Hlth, Coordinating Ctr Clin Trials, 1200 Pressler St, Houston, TX 77030 USA.
EM jose-miguel.yamal@uth.tmc.edu
OI Abbasi, Siddique/0000-0002-9601-7565
FU National Heart, Lung, and Blood Institute [NO1-HC-35130,
HHSN268201100036C]; American Heart Association Post-Doctoral Research
Award; Pfizer, Inc.
FX This study was supported by contracts NO1-HC-35130 and HHSN268201100036C
with the National Heart, Lung, and Blood Institute and an American Heart
Association Post-Doctoral Research Award to Dr Shah. The ALLHAT
investigators acknowledge study medications contributed by Pfizer, Inc
(amlodipine and doxazosin), AstraZeneca (atenolol and lisinopril), and
Bristol-Myers Squibb (pravastatin) and financial support provided by
Pfizer, Inc.
NR 32
TC 8
Z9 8
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1524-6175
EI 1751-7176
J9 J CLIN HYPERTENS
JI J. Clin. Hypertens.
PD JUN
PY 2014
VL 16
IS 6
BP 451
EP 458
DI 10.1111/jch.12325
PG 8
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AJ3XE
UT WOS:000337600400013
PM 24779706
ER
PT J
AU Friedmann, DP
Avram, MM
Cohen, SR
Duncan, DI
Goldman, MP
Weiss, ET
Young, VL
AF Friedmann, Daniel P.
Avram, Mathew M.
Cohen, Steven R.
Duncan, Diane I.
Goldman, Mitchel P.
Weiss, Elliot T.
Young, V. Leroy
TI An evaluation of the patient population for aesthetic treatments
targeting abdominal subcutaneous adipose tissue
SO JOURNAL OF COSMETIC DERMATOLOGY
LA English
DT Article
DE subcutaneous adipose tissue; central abdominal adiposity; obesity; body
mass index; cryolipolysis; high-intensity focused ultrasound
ID INTENSITY FOCUSED ULTRASOUND; LEVEL LASER THERAPY; NONINVASIVE FAT
REMOVAL; BODY-IMAGE; ADRENERGIC-STIMULATION; ADRENOCEPTOR FUNCTION;
LAYER REDUCTION; CELL LIPOLYSIS; OBESE MEN; LIPOSUCTION
AB A large and growing population of patients currently seeks minimally invasive therapeutic options for the aesthetic treatment of localized, central abdominal subcutaneous adipose tissue (SAT). We sought to evaluate the ideal population for aesthetic treatment of central abdominal SAT, highlight the existing disparities between SAT in obese (body mass index [BMI]30; BMI) and nonobese (BMI<30) patients, and review the available FDA-cleared, minimally invasive treatment options for central abdominal adiposity. The cosmetic issue of localized, central (periumbilical) abdominal adiposity in nonobese individuals is quite distinct from abdominal bulging secondary to obesity. Given the recognized clinical and physiologic differences between obese and nonobese counterparts, the exclusion of obese patients from clinical study by currently available FDA-cleared devices targeting abdominal fat, and the status of obesity as a chronic, systemic disease requiring medical, surgical, and/or lifestyle-altering therapies, minimally invasive therapeutic options for aesthetic reductions in central abdominal SAT must be limited to the nonobese population.
C1 [Friedmann, Daniel P.] Westlake Dermatol & Cosmet Surg, Westlake Dermatol Clin Res Ctr, Austin, TX USA.
[Avram, Mathew M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dermatol Laser & Cosmet Ctr, Boston, MA USA.
[Avram, Mathew M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA USA.
[Cohen, Steven R.] Univ Calif San Diego, Div Plast Surg, San Diego, CA 92103 USA.
[Cohen, Steven R.] FACES Plast Surg Skin & Laser Ctr, San Diego, CA USA.
[Duncan, Diane I.] Plast Surg Associates Ft Collins PC, Ft Collins, CO USA.
[Goldman, Mitchel P.] Univ Calif San Diego, Dept Dermatol, San Diego, CA 92103 USA.
[Friedmann, Daniel P.; Goldman, Mitchel P.] Goldman Butterwick Fitzpatrick Groff & Fabi Cosme, San Diego, CA 92121 USA.
[Weiss, Elliot T.] Weill Cornell Med Coll, Dept Dermatol, New York, NY USA.
[Weiss, Elliot T.] Laser & Skin Surg Ctr New York, New York, NY USA.
[Young, V. Leroy] Body Aesthet Plast Surg & Skincare Ctr, St Louis, MO USA.
RP Friedmann, DP (reprint author), Goldman Butterwick Fitzpatrick Groff & Fabi Cosme, 9339 Genesee Ave,Ste 300, San Diego, CA 92121 USA.
EM danf2300@gmail.com
NR 52
TC 2
Z9 2
U1 0
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1473-2130
EI 1473-2165
J9 J COSMET DERMATOL-US
JI J. Cosmet. Dermatol.
PD JUN
PY 2014
VL 13
IS 2
BP 119
EP 124
DI 10.1111/jocd.12088
PG 6
WC Dermatology
SC Dermatology
GA AJ3SE
UT WOS:000337586800007
PM 24910275
ER
PT J
AU Garshick, MK
Chang, ALS
Kimball, AB
AF Garshick, Marisa Kardos
Chang, Anne Lynn S.
Kimball, Alexandra Boer
TI Only Skin Deep: Optimism and Public Self-Consciousness Did Not Associate
With the Placebo Response in a Dermatology Clinical Trial
SO JOURNAL OF DRUGS IN DERMATOLOGY
LA English
DT Article
ID PHASE-III; DOUBLE-BLIND; PSORIASIS; EXPECTATIONS
AB Objective: Although not well-understood, dermatologic diseases studied in clinical trials often demonstrate substantial response to placebo. The study objective is to determine if optimism, public self-consciousness and other personality traits predict response to placebo or active treatment in a dermatology clinical trial.
Methods: A questionnaire was mailed to subjects previously enrolled in a two-center rosacea study who had been randomized to either a treatment or placebo gel. The questionnaire included the Revised Life Orientation Test (LOT-R), the Public Self-Consciousness Scale, and questions to assess personality traits.
Results: Forty-seven subjects out of 83 (57%) returned the questionnaire, There was no statistically significant difference in the LOT-R score in those who responded to placebo versus those who did not (18.08 vs 1792, P=0.92) nor in those who responded to active treatment versus those who did not (16.27 vs 15.86, P=0.79). There was no statistically significant difference in public-self consciousness among placebo or active treatment responders versus non-responders (11.75 vs 10.67, P=0.66; 13.55 vs 14.45, P=0.68). The placebo responders were more likely to report that they were not unusually sensitive to most drugs/medications (X-2=8.33, P=0.004).
Conclusion: Although this pilot study is small, there was no meaningful difference in levels of optimism or public self-consciousness among those who responded to placebo. Placebo responders were more likely to report that they were not sensitive to most drugs/medications, raising the possibility that they are actually less likely to detect when they are on medications.
C1 [Garshick, Marisa Kardos; Kimball, Alexandra Boer] Harvard Univ, Sch Med, Dept Dermatol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Chang, Anne Lynn S.] Stanford Univ, Dept Dermatol, Sch Med, Stanford, CA 94305 USA.
RP Kimball, AB (reprint author), Harvard Univ, Sch Med, Dept Dermatol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
EM harvardskinstudies@partners.org
NR 15
TC 1
Z9 1
U1 0
U2 6
PU JOURNAL OF DRUGS IN DERMATOLOGY
PI NEW YORK
PA 377 PARK AVE SOUTH, 6TH FLOOR, NEW YORK, NY 10016 USA
SN 1545-9616
J9 J DRUGS DERMATOL
JI J. Drugs Dermatol.
PD JUN
PY 2014
VL 13
IS 6
BP 719
EP 722
PG 4
WC Dermatology
SC Dermatology
GA AJ3FS
UT WOS:000337552500013
PM 24918563
ER
PT J
AU Tang, VL
Halm, EA
Fine, MJ
Johnson, CS
Anzueto, A
Mortensen, EM
AF Tang, Victoria L.
Halm, Ethan A.
Fine, Michael J.
Johnson, Christopher S.
Anzueto, Antonio
Mortensen, Eric M.
TI Predictors of rehospitalization after admission for pneumonia in the
veterans affairs healthcare system
SO JOURNAL OF HOSPITAL MEDICINE
LA English
DT Article
ID COMMUNITY-ACQUIRED PNEUMONIA; HOSPITAL ADMISSION; ELDERLY-PATIENTS;
DISCHARGE; OUTCOMES; RISK; READMISSION; INSTABILITY; MORTALITY
AB INTRODUCTION Although some factors associated with rehospitalization after community-acquired pneumonia have been identified, other factors such as medical care utilization and medication usage have not been previously studied. We investigated novel predictors of rehospitalization in patients admitted with pneumonia. METHODS Using Department of Veteran Affairs (VA) administrative data from October 2001 to September 2007, we examined a cohort of patients 65 years old and older, who were hospitalized with pneumonia, in 150 VA acute care hospitals. The cohort was randomly split into derivation and validation samples, and then logistic regression models were used to identify and validate predictors of all-cause rehospitalization within 30 days. RESULTS Of the 45,134 subjects, 13% were rehospitalized within 30 days. No significant differences were noted between the derivation and validation cohorts. Factors associated with readmission included age, marital status, chronic renal disease, prior malignancy, nursing home residence, congestive heart failure, use of oral corticosteroids, number of emergency department visits a year prior, prior admission, number of outpatient clinic visits in a year prior, and length of hospital stay. The C statistics for the derivation and validation models were 0.615 and 0.613, respectively. CONCLUSIONS Factors associated with readmission were largely unrelated to the underlying pneumonia, but were related to demographics, comorbidities, healthcare utilization, and length of stay on index admission. Journal of Hospital Medicine 2014;9:379-383. 2014 Society of Hospital Medicine
C1 [Tang, Victoria L.; Johnson, Christopher S.; Mortensen, Eric M.] VA North Texas Hlth Care Syst, Div Gen Internal Med, Dallas, TX USA.
[Tang, Victoria L.; Halm, Ethan A.; Johnson, Christopher S.; Mortensen, Eric M.] Univ Texas SW Med Ctr Dallas, Div Gen Internal Med, Dallas, TX 75390 USA.
[Fine, Michael J.] Univ Pittsburgh, VA Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA.
[Fine, Michael J.] Univ Pittsburgh, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[Fine, Michael J.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA.
[Anzueto, Antonio] South Texas Vet Hlth Care Syst, Div Pulm Dis & Crit Care Med, San Antonio, TX USA.
[Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA.
RP Mortensen, EM (reprint author), Dallas VA Med Ctr, 111E,4500 South Lancaster, Dallas, TX 75216 USA.
EM eric.mortensen@UTSouthwestern.edu
OI Mortensen, Eric/0000-0002-3880-5563
FU National Institute of Nursing Research [R01NR010828]
FX The project described was supported by grant number R01NR010828 from the
National Institute of Nursing Research. The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the National Institute of Nursing Research or the
National Institutes of Health. This material is the result of work
supported with resources and the use of facilities at the VA North Texas
Health Care System. Funding agencies had no role in conducting the
study, or role in the preparation, review, or approval of the
manuscript. The views expressed in this article are those of the authors
and do not necessarily represent the views of the Department of Veterans
Affairs.
NR 18
TC 2
Z9 3
U1 0
U2 5
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1553-5592
EI 1553-5606
J9 J HOSP MED
JI J. Hosp. Med.
PD JUN
PY 2014
VL 9
IS 6
BP 379
EP 383
DI 10.1002/jhm.2184
PG 5
WC Medicine, General & Internal
SC General & Internal Medicine
GA AJ2VK
UT WOS:000337522100006
PM 24648401
ER
PT J
AU Amri, R
Stronks, K
Bordeianou, LG
Sylla, P
Berger, DL
AF Amri, Ramzi
Stronks, Karien
Bordeianou, Liliana G.
Sylla, Patricia
Berger, David L.
TI Gender and ethnic disparities in colon cancer presentation and outcomes
in a US universal health care setting
SO JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article
DE colonic neoplasms; healthcare disparities; minority health; health
status disparities; neoplasm staging; disease-free survival; mortality
ID COLORECTAL-CANCER; UNITED-STATES; SOCIOECONOMIC-STATUS; SURVIVAL;
MORTALITY; STAGE; RACE; STATISTICS; GUIDELINES; INSURANCE
AB Objective Access to care is a pillar of U.S. healthcare reform and could potentially challenge existing ethnic and gender disparities in care. We present a snapshot of these disparities in surgical colon cancer patients in the largest public hospital in Massachusetts, a state leading in providing universal healthcare, to indicate potential changes that might result from universal care access. Methods All surgical colon cancer patients at Massachusetts General Hospital (2004-2011) were included. Baseline characteristics, perioperative, and long-term outcomes were compared. Results Among 1,071 patients, the 110 (10.3%) minority patients presented with more comorbid (mean Charlson score 0.84 vs. 0.71; P=0.039), metastatic (21.8% vs. 14%; P=0.026), and node-positive disease (50% vs. 38.8%; P=0.014). Women (n=521; 48.6%) had less screening diagnoses (overall: 17.8% vs. 22.6%; P=0.049, screening age: 26.4% vs. 32.7%; P=0.036) with subsequently higher rates of metastatic disease on pathology (11.3% vs. 7.1%, P=0.02). Multivariate adjustment for baseline staging makes outcome disparities no longer statistically significant. Conclusions Significant gender and ethnic disparities subsist at baseline despite long-standing low-threshold healthcare access, although seemingly mitigated by enrollment into high-level care, empowering equal chances for underprivileged groups. The outcomes are also a reminder that universal healthcare will not be a panacea for the deeply rooted and dynamic causes of presentation inequalities. J. Surg. Oncol 2014; 109:645-651. (c) 2014 Wiley Periodicals, Inc.
C1 [Amri, Ramzi; Bordeianou, Liliana G.; Sylla, Patricia; Berger, David L.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Gen & Gastrointestinal Surg, Boston, MA USA.
[Stronks, Karien] Univ Amsterdam, Acad Med Ctr, Dept Publ Hlth, NL-1105 AZ Amsterdam, Netherlands.
RP Berger, DL (reprint author), Massachusetts Gen Hosp, Div Gen Surg & Gastrointestinal Surg, 15 Parkman St, Boston, MA 02114 USA.
EM dberger@mgh.harvard.edu
OI Amri, Ramzi/0000-0001-7416-6650
FU The Fulbright Foundation; Harvard Catalyst \ The Harvard Clinical and
Translational Science Center; Dutch Cancer Society; Dutch Digestive
Society; Amsterdam University Funds
FX Grant sponsor: The Fulbright Foundation, Harvard Catalyst vertical bar
The Harvard Clinical and Translational Science Center, the Dutch Cancer
Society, the Dutch Digestive Society, and the Amsterdam University
Funds.
NR 36
TC 8
Z9 8
U1 2
U2 6
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-4790
EI 1096-9098
J9 J SURG ONCOL
JI J. Surg. Oncol.
PD JUN
PY 2014
VL 109
IS 7
BP 645
EP 651
DI 10.1002/jso.23567
PG 7
WC Oncology; Surgery
SC Oncology; Surgery
GA AJ2RH
UT WOS:000337507000005
PM 24474677
ER
PT J
AU Murai, T
Yamada, S
Fuchs, BC
Fujii, T
Nakayama, G
Sugimoto, H
Koike, M
Fujiwara, M
Tanabe, KK
Kodera, Y
AF Murai, Toshifumi
Yamada, Suguru
Fuchs, Bryan C.
Fujii, Tsutomu
Nakayama, Goro
Sugimoto, Hiroyuki
Koike, Masahiko
Fujiwara, Michitaka
Tanabe, Kenneth K.
Kodera, Yasuhiro
TI Epithelial-to-mesenchymal transition predicts prognosis in clinical
gastric cancer
SO JOURNAL OF SURGICAL ONCOLOGY
LA English
DT Article
DE gastric cancer; epithelial-to-mesenchymal transition; Zeb-1; prognosis
ID E-CADHERIN EXPRESSION; TUMOR PROGRESSION; UP-REGULATION; LUNG-CANCER;
TWIST; METASTASIS; CELLS; PLASTICITY; CARCINOMA; VIMENTIN
AB Background Epithelial-to-mesenchymal transition (EMT) is considered to play an important role in cancer invasion and metastasis. Methods The mRNA levels of an epithelial marker (E-cadherin), mesenchymal marker (vimentin), and Zeb-1 were measured in 11 gastric cancer cell lines. Functional analysis was performed using Zeb-1 knockdown. EMT status of 116 gastric cancer patients was determined by calculating the vimentin/E-cadherin mRNA expression ratio in cancerous tissue and the correlation between EMT status, clinicopathological factors, prognosis, and Zeb-1 were analyzed. Results Cell lines were classified as epithelial or mesenchymal. Zeb-1 expression was significantly correlated with the mesenchymal phenotype. Treatment with Zeb-1 siRNA also reduced the capacity to proliferate, migrate, and invade. Patients were classified as epithelial or mesenchymal by V/E ratio (vimentin/E-cadherin ratio) and as Zeb-1 low or high expression group. The mesenchymal group was significantly associated with diffuse type cancer and stage IV. On multivariate analysis, the EMT status (mesenchymal group) was an independent prognostic factor (P=0.022). There was a significant correlation between the V/E ratio and Zeb-1 expression (r=0.73). Patients in Zeb-1 high group had significantly poorer survival than those in low group (P=0.0071). Conclusions EMT is a critical prognostic factor for gastric cancer. Zeb-1 might be a promising therapeutic target. J. Surg. Oncol 2014; 109:684-689. (c) 2014 Wiley Periodicals, Inc.
C1 [Murai, Toshifumi; Yamada, Suguru; Fujii, Tsutomu; Nakayama, Goro; Sugimoto, Hiroyuki; Koike, Masahiko; Fujiwara, Michitaka; Kodera, Yasuhiro] Nagoya Univ, Dept Gastroenterol Surg Surg 2, Grad Sch Med, Nagoya, Aichi 4668550, Japan.
[Fuchs, Bryan C.; Tanabe, Kenneth K.] Massachusetts Gen Hosp, Div Surg Oncol, Ctr Canc, Boston, MA 02114 USA.
[Fuchs, Bryan C.; Tanabe, Kenneth K.] Harvard Univ, Sch Med, Cambridge, MA 02138 USA.
RP Yamada, S (reprint author), Nagoya Univ, Dept Gastroenterol Surg Surg 2, Grad Sch Med, Showa Ku, 65 Tsurumai Cho, Nagoya, Aichi 4668550, Japan.
EM suguru@med.nagoya-u.ac.jp
RI Kodera, Yasuhiro/M-4912-2014; Koike, Masahiko/M-4913-2014; Fujii,
Tsutomu/M-4838-2014
FU Charitable Trust Soyu Medical Fundation
FX Grant sponsor: Charitable Trust Soyu Medical Fundation.
NR 32
TC 14
Z9 14
U1 0
U2 9
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0022-4790
EI 1096-9098
J9 J SURG ONCOL
JI J. Surg. Oncol.
PD JUN
PY 2014
VL 109
IS 7
BP 684
EP 689
DI 10.1002/jso.23564
PG 6
WC Oncology; Surgery
SC Oncology; Surgery
GA AJ2RH
UT WOS:000337507000010
PM 24453058
ER
PT J
AU Shaqdan, K
Aran, S
Besheli, LD
Abujudeh, H
AF Shaqdan, Khalid
Aran, Shima
Besheli, Laleh Daftari
Abujudeh, Hani
TI Root-Cause Analysis and Health Failure Mode and Effect Analysis: Two
Leading Techniques in Health Care Quality Assessment
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Article
DE Quality; errors; root-cause analysis; RCA; health failure mode effect
analysis; HFMEA
ID RADIOLOGY
AB In this review article, the authors provide a detailed series of guidelines for effectively performing root-cause analysis (RCA) and health failure mode and effect analysis (HFMEA). RCA is a retrospective approach used to ascertain the "root cause" of a problem that has already occurred, whereas HFMEA is a prospective risk assessment tool whose aim is to recognize risks to patient safety. RCA and HFMEA are used for the prevention of errors or recurring errors to create a safer workplace, maintain high standards in health care quality, and incorporate time-saving and cost-saving modifications to favorably affect the patient care environment. The principles and techniques provided here should allow reviewers to better understand the features of RCA and HFMEA and how to apply these processes appropriately. These principles include how to organize a team, identify root causes, seed out proximate causes, graphically describe the process, conduct a hazard analysis, and develop and implement potential action plans.
C1 [Shaqdan, Khalid; Aran, Shima; Besheli, Laleh Daftari; Abujudeh, Hani] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02114 USA.
RP Abujudeh, H (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, 55 Fruit St,Founders 202, Boston, MA 02114 USA.
EM habujudeh@partners.org
NR 24
TC 6
Z9 7
U1 0
U2 14
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD JUN
PY 2014
VL 11
IS 6
BP 572
EP 579
DI 10.1016/j.jacr.2013.10.024
PG 8
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AJ0HJ
UT WOS:000337331000010
PM 24507549
ER
PT J
AU Lackey, AE
Pandey, T
Moshiri, M
Lalwani, N
Lall, C
Bhargava, P
AF Lackey, Amanda E.
Pandey, Tarun
Moshiri, Mariam
Lalwani, Neeraj
Lall, Chandana
Bhargava, Puneet
TI Productivity, Part 2: Cloud Storage, Remote Meeting Tools,
Screencasting, Speech Recognition Software, Password Managers, and
Online Data Backup
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Article
DE Productivity; cloud applications; collaboration
ID RADIOLOGY EDUCATION 2.0-ON; CUSP
AB It is an opportune time for radiologists to focus on personal productivity. The ever increasing reliance on computers and the Internet has significantly changed the way we work. Myriad software applications are available to help us improve our personal efficiency. In this article, the authors discuss some tools that help improve collaboration and personal productivity, maximize e-learning, and protect valuable digital data.
C1 [Lackey, Amanda E.; Pandey, Tarun] Univ Arkansas Med Sci, Dept Radiol, Little Rock, AR 72205 USA.
[Moshiri, Mariam; Lalwani, Neeraj] Univ Washington, Sch Med, Dept Radiol, Seattle, WA 98195 USA.
[Lall, Chandana] Univ Calif Irvine, Orange, CA 92668 USA.
[Bhargava, Puneet] Univ Washington, Dept Radiol, Seattle, WA 98195 USA.
[Bhargava, Puneet] VA Puget Sound Hlth Care Syst, Seattle, WA 98108 USA.
RP Bhargava, P (reprint author), Univ Washington, Mail Box 358280,S-114 Radiol,1660 S Columbian Way, Seattle, WA 98108 USA.
EM bhargp@uw.edu
RI Lalwani, Neeraj/A-3490-2011;
OI Lalwani, Neeraj/0000-0001-5514-2805; Bhargava,
Puneet/0000-0002-3849-9666
NR 27
TC 1
Z9 1
U1 1
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD JUN
PY 2014
VL 11
IS 6
BP 580
EP 588
DI 10.1016/j.jacr.2013.11.021
PG 9
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AJ0HJ
UT WOS:000337331000011
PM 24674716
ER
PT J
AU Knshnaraj, A
Dutta, S
Reisner, AT
Landman, AB
Choy, G
Biddinger, P
Lin, A
Joshi, N
AF Knshnaraj, Arun
Dutta, Sayon
Reisner, Andrew T.
Landman, Adam B.
Choy, Garry
Biddinger, Paul
Lin, Abraham
Joshi, Neeraj
TI Optimizing Emergency Department Imaging Utilization Through Advanced
Health Record Technology
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Editorial Material
ID INFORMATION-TECHNOLOGY; DECISION-SUPPORT; RADIOLOGY; EFFICIENCY
C1 [Knshnaraj, Arun] Univ Virginia, Charlottesville, VA 22902 USA.
[Dutta, Sayon; Reisner, Andrew T.; Biddinger, Paul] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Choy, Garry; Lin, Abraham; Joshi, Neeraj] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Landman, Adam B.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Knshnaraj, A (reprint author), Univ Virginia, Dept Radiol & Med Imaging, 1215 Lee St,POB 800170, Charlottesville, VA 22902 USA.
EM ak8jj@virginia.edu
OI Landman, Adam/0000-0002-2166-0521
NR 18
TC 0
Z9 0
U1 0
U2 1
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD JUN
PY 2014
VL 11
IS 6
BP 625
EP 628
DI 10.1016/j.jacr.2013.07.011
PG 4
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AJ0HJ
UT WOS:000337331000019
ER
PT J
AU Germino, JC
Rapp, EJ
Hippe, DS
Shah, AC
McFall, ME
Bhargava, P
AF Germino, Jessica C.
Rapp, Elliot J.
Hippe, Daniel S.
Shah, Anura C.
McFall, Miles E.
Bhargava, Puneet
TI Assessing and Optimizing Imaging of Patients with Posttraumatic Stress
Disorder
SO JOURNAL OF THE AMERICAN COLLEGE OF RADIOLOGY
LA English
DT Editorial Material
ID CLAUSTROPHOBIA; ANXIETY; EXPERIENCES
C1 [Germino, Jessica C.; Rapp, Elliot J.; Hippe, Daniel S.] Univ Washington, Dept Radiol, Seattle, WA 98108 USA.
[Shah, Anura C.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Dept Prevent & Management Disrupt Behav, Seattle, WA USA.
[McFall, Miles E.] Vet Affairs Puget Sound Hlth Care Syst, Seattle Div, Seattle, WA USA.
[McFall, Miles E.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98108 USA.
[Bhargava, Puneet] Univ Washington, Dept Radiol, Seattle, WA 98108 USA.
[Bhargava, Puneet] VA Puget Hlth Care Syst, Seattle, WA 98108 USA.
RP Bhargava, P (reprint author), Univ Washington, S-114 RAD,1660 S Columbian Way,Mail Box 358280, Seattle, WA 98108 USA.
EM bhargp@uw.edu
OI Bhargava, Puneet/0000-0002-3849-9666
NR 14
TC 1
Z9 1
U1 0
U2 3
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1546-1440
J9 J AM COLL RADIOL
JI J. Am. Coll. Radiol.
PD JUN
PY 2014
VL 11
IS 6
BP 629
EP 631
DI 10.1016/j.jacr.2013.10.020
PG 3
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AJ0HJ
UT WOS:000337331000020
PM 24613448
ER
PT J
AU Makam, AN
Boscardin, WJ
Mao, YH
Steinman, MA
AF Makam, Anil N.
Boscardin, W. John
Mao, Yinghui
Steinman, Michael A.
TI Risk of Thiazide-Induced Metabolic Adverse Events in Older Adults
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE aged; adverse effects; sodium chloride symporter inhibitors;
hypertension; outcome assessment (health care)
ID INDUCED HYPONATREMIA; BLOOD-PRESSURE; SYSTOLIC HYPERTENSION;
CARDIOVASCULAR EVENTS; ELDERLY PROGRAM; CLINICAL-TRIALS; DRUG-REACTIONS;
DIURETICS; OUTCOMES; METAANALYSIS
AB Objectives To evaluate the risk and predictors of thiazide-induced adverse events (AEs) in multimorbid older adults in real-world clinical settings. Design Observational cohort study. Setting National Veterans Affairs data from 2007 to 2008. Participants Veterans aged 65 and older newly prescribed a thiazide (N=1,060) compared with propensity-matched nonusers of antihypertensive medications (N=1,060). Measurements The primary outcome was a composite of metabolic AEs defined as sodium less than 135mEq/L, potassium less than 3.5mEq/L, or a decrease in the estimated glomerular filtration rate (eGFR) of more than 25% from the baseline rate. Secondary outcomes included sev-ere AEs (sodium <130mEq/L, potassium <3.0mEq/L, or a decrease in eGFR of more than 50%). Results Over 9months of follow-up, 14.3% of new thiazide users developed an AE, compared with 6.0% of nonusers (number needed to harm (NNH) 12, 95% confidence interval (CI)=9-17, P<.001); 1.8% of new users developed a severe AE, compared with 0.6% of nonusers (NNH=82, P=.008), and 3.8% of new users had an emergency department visit or hospitalization with an AE, compared with 2.0% of nonusers (NNH=56, P=.02). Risk of AEs did not vary according to age, but having five or more comorbidities was associated with 3.0 times the odds (95% CI=1.4-6.2) of developing an AE as having one comorbidity (hypertension). Low-normal and unmeasured baseline sodium and potassium values were among the strongest predictors of hyponatremia and hypokalemia, respectively. Only 42% of thiazide users had laboratory monitoring within 90days after initiation. Conclusion Thiazide-induced AEs are common in older adults. Greater attention should be paid to potential complications in prescribing thiazides to older adults, including closer laboratory monitoring before and after initiation of thiazides.
C1 [Makam, Anil N.] Univ Texas SW Med Ctr Dallas, Div Gen Internal Med, Dallas, TX 75390 USA.
[Boscardin, W. John; Mao, Yinghui; Steinman, Michael A.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, Div Geriatr, San Francisco, CA USA.
[Boscardin, W. John] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA.
RP Makam, AN (reprint author), 5323 Harry Hines Blvd,Mail Code 9169, Dallas, TX 75390 USA.
EM anil.makam@utsouthwestern.edu
OI Makam, Anil/0000-0001-7072-9946
FU National Institute on Aging (NIA) [K23-AG030999, RC1-AG036377]; federal
training grant from the National Research Service Award
[T32HP19025-07-00]
FX Conflict of Interest: This study was supported by Grants K23-AG030999
and RC1-AG036377 from the National Institute on Aging (NIA). Dr. Makam's
work on this project was completed while he was a primary care research
fellow at the University of California at San Francisco, funded by a
federal training grant from the National Research Service Award
(T32HP19025-07-00).
NR 36
TC 7
Z9 7
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JUN
PY 2014
VL 62
IS 6
BP 1039
EP 1045
DI 10.1111/jgs.12839
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA AJ4EJ
UT WOS:000337624300005
PM 24823661
ER
PT J
AU Weiner, DK
Morone, NE
Spallek, H
Karp, JF
Schneider, M
Washburn, C
Dziabiak, MP
Hennon, JG
Elnicki, DM
AF Weiner, Debra K.
Morone, Natalia E.
Spallek, Heiko
Karp, Jordan F.
Schneider, Michael
Washburn, Carol
Dziabiak, Michael P.
Hennon, John G.
Elnicki, D. Michael
CA Univ Pittsburgh Ctr Excellence Pai
TI E-Learning Module on Chronic Low Back Pain in Older Adults: Evidence of
Effect on Medical Student Objective Structured Clinical Examination
Performance
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Article
DE medical student education; older adults; low back pain; objective
structured clinical examination
ID EDUCATION; CARE; COMPETENCE; OUTCOMES
AB The Institute of Medicine has highlighted the urgent need to close undergraduate and graduate educational gaps in treating pain. Chronic low back pain (CLBP) is one of the most common pain conditions, and older adults are particularly vulnerable to potential morbidities associated with misinformed treatment. An e-learning case-based interactive module was developed at the University of Pittsburgh Center of Excellence in Pain Education, one of 12 National Institutes of Health-designated centers, to teach students important principles for evaluating and managing CLBP in older adults. A team of six experts in education, information technology, pain management, and geriatrics developed the module. Teaching focused on common errors, interactivity, and expert modeling and feedback. The module mimicked a patient encounter using a standardized patient (the older adult with CLBP) and a pain expert (the patient provider). Twenty-eight medical students were not exposed to the module (Group 1) and 27 were exposed (Group 2). Their clinical skills in evaluating CLBP were assessed using an objective structured clinical examination (OSCE). Mean scores were 62.0 +/- 8.6 for Group 1 and 79.5 +/- 10.4 for Group 2 (P<.001). Using an OSCE pass-fail cutoff score of 60%, 17 of 28 Group 1 students (60.7%) and 26 of 27 Group 2 students (96.3%) passed. The CLBP OSCE was one of 10 OSCE stations in which students were tested at the end of a Combined Ambulatory Medicine and Pediatrics Clerkship. There were no between-group differences in performance on eight of the other nine OSCE stations. This module significantly improved medical student clinical skills in evaluating CLBP. Additional research is needed to ascertain the effect of e-learning modules on more-advanced learners and on improving the care of older adults with CLBP.
C1 [Weiner, Debra K.; Morone, Natalia E.; Hennon, John G.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA.
[Weiner, Debra K.] Univ Pittsburgh, Dept Med, Div Geriatr Med, Pittsburgh, PA USA.
[Weiner, Debra K.; Karp, Jordan F.] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA.
[Weiner, Debra K.; Karp, Jordan F.] Univ Pittsburgh, Dept Anesthesiol, Pittsburgh, PA USA.
[Weiner, Debra K.; Morone, Natalia E.; Karp, Jordan F.] Univ Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA.
[Morone, Natalia E.; Dziabiak, Michael P.; Elnicki, D. Michael] Univ Pittsburgh, Dept Med, Div Gen Internal Med, Pittsburgh, PA USA.
[Spallek, Heiko] Univ Pittsburgh, Sch Dent Med, Dept Dent Publ Hlth, Pittsburgh, PA USA.
[Schneider, Michael] Univ Pittsburgh, Sch Hlth & Rehabil Sci, Pittsburgh, PA USA.
[Washburn, Carol] Univ Pittsburgh, Ctr Instruct Dev & Distance Educ, Pittsburgh, PA USA.
[Hennon, John G.] Univ Pittsburgh, Univ Ctr Social & Urban Res, Pittsburgh, PA USA.
RP Weiner, DK (reprint author), Suite 500,3471 Fifth Ave, Pittsburgh, PA 15213 USA.
EM dweiner@pitt.edu
OI Spallek, Heiko/0000-0001-6865-4818; Schneider,
MIchael/0000-0001-7190-3379
FU Altarum Institute; NIH Pain Consortium [HHSN271201100111U]
FX Conflict of Interest: The editor in chief has reviewed the conflict of
interest checklist provided by the authors and has determined that the
authors have no financial or any-other kind of personal conflicts with
this paper. This work was supported by funding awarded to Centers of
Excellence in Pain Education by the Altarum Institute, which received
funding from the NIH Pain Consortium (HHSN271201100111U). Dr. Karp has
received medication supplies from Pfizer and Reckitt Benckiser for
investigator-initiated trials. The contents of this report do not
necessarily represent the views of the Department of Veterans Affairs OF
the U.S. government.
NR 29
TC 1
Z9 1
U1 1
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JUN
PY 2014
VL 62
IS 6
BP 1161
EP 1167
DI 10.1111/jgs.12871
PG 7
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA AJ4EJ
UT WOS:000337624300023
PM 24833496
ER
PT J
AU Moody, SY
Newsom, EM
Covinsky, KE
AF Moody, Sandra Y.
Newsom, Edwina M.
Covinsky, Kenneth E.
TI Determinants of Perceived Emotional Recovery and Perceived Change in
Health After a Disaster
SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
LA English
DT Letter
ID HURRICANE KATRINA; STORM
C1 [Moody, Sandra Y.; Covinsky, Kenneth E.] Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94117 USA.
[Moody, Sandra Y.; Covinsky, Kenneth E.] San Francisco VA Med Ctr, San Francisco, CA USA.
[Moody, Sandra Y.] Kameda Med Ctr, Kamogawa, Japan.
[Newsom, Edwina M.] Univ Calif San Francisco, Inst Hlth & Aging, San Francisco, CA USA.
RP Moody, SY (reprint author), Univ Calif San Francisco, Dept Med, Div Geriatr, San Francisco, CA 94117 USA.
FU NCATS NIH HHS [UL1 TR000004]; NCRR NIH HHS [UL1 RR024131]; NIA NIH HHS
[5R01AG28621, R01 AG028621]
NR 10
TC 0
Z9 0
U1 0
U2 3
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0002-8614
EI 1532-5415
J9 J AM GERIATR SOC
JI J. Am. Geriatr. Soc.
PD JUN
PY 2014
VL 62
IS 6
BP 1189
EP 1191
DI 10.1111/jgs.12852
PG 3
WC Geriatrics & Gerontology; Gerontology
SC Geriatrics & Gerontology
GA AJ4EJ
UT WOS:000337624300031
PM 24925556
ER
PT J
AU Abtahian, F
Weinberg, I
Hawkins, BM
Cefalo, P
Nasser, NJ
MacKay, C
Jaff, MR
AF Abtahian, F.
Weinberg, I
Hawkins, B. M.
Cefalo, P.
Nasser, N. J.
MacKay, C.
Jaff, M. R.
TI Inferior vena cava filter usage, complications, and retrieval rate in
cancer patients
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Meeting Abstract
C1 [Abtahian, F.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Weinberg, I; MacKay, C.; Jaff, M. R.] Massachusetts Gen Hosp, Inst Heart Vasc & Stroke Care, Boston, MA 02114 USA.
[Hawkins, B. M.] Univ Oklahoma, Coll Med, Oklahoma City, OK 73190 USA.
[Cefalo, P.] Massachusetts Gen Hosp, Dept Med & Phys Med & Rehabil, Boston, MA 02114 USA.
[Nasser, N. J.] Princess Margaret Canc Ctr, Dept Radiat Oncol, Toronto, ON, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
EI 1538-7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD JUN
PY 2014
VL 12
SU 1
SI SI
MA HM07
BP 52
EP 52
PG 1
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA AJ5BR
UT WOS:000337696100138
ER
PT J
AU Savchenko, AS
Martinod, K
Seidman, MA
Wong, SL
Borissoff, JI
Piazza, G
Libby, P
Goldhaber, SZ
Mitchell, RN
Wagner, DD
AF Savchenko, A. S.
Martinod, K.
Seidman, M. A.
Wong, S. L.
Borissoff, J. I.
Piazza, G.
Libby, P.
Goldhaber, S. Z.
Mitchell, R. N.
Wagner, D. D.
TI Neutrophil extracellular traps form predominantly during the organizing
stage of human venous thromboembolism development
SO JOURNAL OF THROMBOSIS AND HAEMOSTASIS
LA English
DT Article
DE blood platelets; clinical pathology; histones; neutrophils; venous
thromboembolism
ID DEEP-VEIN THROMBOSIS; VON-WILLEBRAND-FACTOR; INNATE IMMUNITY; CHROMATIN
DECONDENSATION; MICE; HISTONES; DNA; COAGULATION; ACTIVATION; GENERATION
AB Background A growing health problem, venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT), requires refined diagnostic and therapeutic approaches. Neutrophils contribute to thrombus initiation and development in experimental DVT. Recent animal studies recognized neutrophil extracellular traps (NETs) as an important scaffold supporting thrombus stability. However, the hypothesis that human venous thrombi involve NETs has not undergone rigorous testing. Objective To explore the cellular composition and the presence of NETs within human venous thrombi at different stages of development. Patients and Methods We examined 16 thrombi obtained from 11 patients during surgery or at autopsy using histomorphological, immunohistochemical and immunofluorescence analyses. Results We classified thrombus regions as unorganized, organizing and organized according to their morphological characteristics. We then evaluated them, focusing on neutrophil and platelet deposition as well as micro-vascularization of the thrombus body. We observed evidence of NET accumulation, including the presence of citrullinated histone H3 (H3Cit)-positive cells. NETs, defined as extracellular diffuse H3Cit areas associated with myeloperoxidase and DNA, localized predominantly during the phase of organization in human venous thrombi. Conclusions NETs are present in organizing thrombi in patients with VTE. They are associated with thrombus maturation in humans. Dissolution of NETs might thus facilitate thrombolysis. This finding provides new insights into the clinical development and pathology of thrombosis and provides new perspectives for therapeutic advances.
C1 [Savchenko, A. S.; Martinod, K.; Wong, S. L.; Borissoff, J. I.; Wagner, D. D.] Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
[Savchenko, A. S.; Wong, S. L.; Borissoff, J. I.; Wagner, D. D.] Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
[Martinod, K.] Harvard Univ, Sch Med, Div Med Sci, Grad Program Immunol, Boston, MA USA.
[Seidman, M. A.; Mitchell, R. N.] Harvard Univ, Brigham & Womens Hosp, Med Sch, Dept Pathol & Lab Med, Boston, MA 02115 USA.
[Piazza, G.; Libby, P.; Goldhaber, S. Z.] Harvard Univ, Brigham & Womens Hosp, Med Sch, Cardiovasc Med Div, Boston, MA 02115 USA.
[Wagner, D. D.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02115 USA.
RP Wagner, DD (reprint author), Boston Childrens Hosp, 3 Blackfan Circle,3rd Floor, Boston, MA 02115 USA.
EM Denisa.Wagner@childrens.harvard.edu
OI Martinod, Kimberly/0000-0002-1026-6107; Seidman,
Michael/0000-0002-9594-827X
FU National Heart, Lung, and Blood Institute of the National Institutes of
Health [R01HL102101]; Netherlands Organization for Scientific Research
[825.11.019]
FX The authors thank L. Cowan for help with the preparation of the
manuscript. This research was supported by National Heart, Lung, and
Blood Institute of the National Institutes of Health grant R01HL102101
(DDW). JIB is a recipient of a Rubicon fellowship (825.11.019) from the
Netherlands Organization for Scientific Research.
NR 38
TC 46
Z9 48
U1 3
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1538-7933
EI 1538-7836
J9 J THROMB HAEMOST
JI J. Thromb. Haemost.
PD JUN
PY 2014
VL 12
IS 6
BP 860
EP 870
DI 10.1111/jth.12571
PG 11
WC Hematology; Peripheral Vascular Disease
SC Hematology; Cardiovascular System & Cardiology
GA AJ5AB
UT WOS:000337691200009
PM 24674135
ER
PT J
AU Stankovic, I
Krismer, F
Jesic, A
Antonini, A
Benke, T
Brown, RG
Burn, DJ
Holton, JL
Kaufmann, H
Kostic, VS
Ling, H
Meissner, WG
Poewe, W
Semnic, M
Seppi, K
Takeda, A
Weintraub, D
Wenning, GK
AF Stankovic, Iva
Krismer, Florian
Jesic, Aleksandar
Antonini, Angelo
Benke, Thomas
Brown, Richard G.
Burn, David J.
Holton, Janice L.
Kaufmann, Horacio
Kostic, Vladimir S.
Ling, Helen
Meissner, Wassilios G.
Poewe, Werner
Semnic, Marija
Seppi, Klaus
Takeda, Atsushi
Weintraub, Daniel
Wenning, Gregor K.
CA Movement Disorders Soc MSA MODIMSA
TI Cognitive Impairment in Multiple System Atrophy: A Position Statement by
the Neuropsychology Task Force of the MDS Multiple System Atrophy
(MODIMSA) Study Group
SO MOVEMENT DISORDERS
LA English
DT Article
DE cognition; multiple system atrophy; neuropsychology
ID PROGRESSIVE SUPRANUCLEAR PALSY; VOXEL-BASED MORPHOMETRY; IDIOPATHIC
PARKINSONS-DISEASE; BRAIN GLUCOSE-METABOLISM; CEREBELLAR TYPE;
STRIATONIGRAL DEGENERATION; FRONTAL-LOBE; OLIVOPONTOCEREBELLAR ATROPHY;
DEPRESSIVE SYMPTOMS; CLINICAL-PARAMETERS
AB Consensus diagnostic criteria for multiple system atrophy consider dementia as a nonsupporting feature, despite emerging evidence demonstrating that cognitive impairments are an integral part of the disease. Cognitive disturbances in multiple system atrophy occur across a wide spectrum from mild single domain deficits to impairments in multiple domains and even to frank dementia in some cases. Frontal-executive dysfunction is the most common presentation, while memory and visuospatial functions also may be impaired. Imaging and neuropathological findings support the concept that cognitive impairments in MSA originate from striatofrontal deafferentation, with additional contributions from intrinsic cortical degeneration and cerebellar pathology. Based on a comprehensive evidencebased review, the authors propose future avenues of research that ultimately may lead to diagnostic criteria for cognitive impairment and dementia associated with multiple system atrophy. (C) 2014 International Parkinson and Movement Disorder Society
C1 [Stankovic, Iva; Kostic, Vladimir S.] Univ Belgrade, Sch Med, Clin Ctr Serbia, Neurol Clin, Belgrade, Serbia.
[Krismer, Florian; Benke, Thomas; Poewe, Werner; Seppi, Klaus; Wenning, Gregor K.] Med Univ Innsbruck, Dept Neurol, A-6020 Innsbruck, Austria.
[Jesic, Aleksandar; Semnic, Marija] Univ Novi Sad, Neurol Clin, Clin Ctr Vojvodina, Sch Med Novi Sad, Novi Sad 21000, Serbia.
[Antonini, Angelo] IRCCS, Fdn Osped San Camillo, Dept Parkinsons Dis, Venice, Italy.
[Brown, Richard G.] Kings Coll London, Inst Psychiat, Dept Psychol, London WC2R 2LS, England.
[Burn, David J.] Newcastle Univ, Inst Ageing & Hlth, Newcastle Upon Tyne NE1 7RU, Tyne & Wear, England.
[Holton, Janice L.; Ling, Helen] UCL, Inst Neurol, Queen Sq Brain Bank Neurol Disorders, London, England.
[Kaufmann, Horacio] NYU, Langone Med Ctr, Dysautonomia Ctr, New York, NY USA.
[Meissner, Wassilios G.] Univ Bordeaux, Inst Malad Neurodegenerat, Bordeaux, France.
[Takeda, Atsushi] Sendai Nishitaga Hosp, Natl Hosp Org, Dept Neurol, Sendai, Miyagi, Japan.
[Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Weintraub, Daniel] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA.
RP Wenning, GK (reprint author), Med Univ Innsbruck, Dept Neurol, Anichstr 35, A-6020 Innsbruck, Austria.
EM gregor.wenning@i-med.ac.at
RI Ling, Helen/J-3751-2013; Brown, Richard/A-9599-2010; Meissner,
Wassilios/C-7817-2015;
OI Brown, Richard/0000-0001-9021-0172; Meissner,
Wassilios/0000-0003-2172-7527; Kaufmann, Horacio/0000-0002-1851-9981
FU Austrian Science Fund (FWF) [F04404-B19]; National Institute for Health
Research (NIHR) Mental Health Biomedical Research Centre; Dementia
Biomedical Research Unit at South London, and Maudsley NHS Foundation
Trust and King's College London; Reta Lila Weston Institute for
Neurological Studies; Multiple System Atrophy Trust; National Institute
for Health Research University College London Hospitals Biomedical
Research Centre
FX This study was supported by funds of the Austrian Science Fund (FWF):
F04404-B19. Dr. Brown acknowledges support from the National Institute
for Health Research (NIHR) Mental Health Biomedical Research Centre and
Dementia Biomedical Research Unit at South London, and Maudsley NHS
Foundation Trust and King's College London. The views expressed are
those of the author and not necessarily those of the NHS, the NIHR or
the Department of Health. Dr. Holton is supported by the Reta Lila
Weston Institute for Neurological Studies and the Multiple System
Atrophy Trust. Part of the study was supported by the National Institute
for Health Research University College London Hospitals Biomedical
Research Centre.
NR 80
TC 29
Z9 29
U1 2
U2 13
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD JUN
PY 2014
VL 29
IS 7
BP 857
EP 867
DI 10.1002/mds.25880
PG 11
WC Clinical Neurology
SC Neurosciences & Neurology
GA AJ4TZ
UT WOS:000337670600007
PM 24753321
ER
PT J
AU Achey, M
Aldred, JL
Aljehani, N
Bloem, BR
Biglan, KM
Chan, P
Cubo, E
Dorsey, ER
Goetz, CG
Guttman, M
Hassan, A
Khandhar, SM
Mari, Z
Spindler, M
Tanner, CM
van den Haak, P
Walker, R
Wilkinson, JR
AF Achey, Meredith
Aldred, Jason L.
Aljehani, Noha
Bloem, Bastiaan R.
Biglan, Kevin M.
Chan, Piu
Cubo, Esther
Dorsey, E. Ray
Goetz, Christopher G.
Guttman, Mark
Hassan, Anhar
Khandhar, Suketu M.
Mari, Zoltan
Spindler, Meredith
Tanner, Caroline M.
van den Haak, Pieter
Walker, Richard
Wilkinson, Jayne R.
CA Int Parkinson Movement Disorder
TI The Past, Present, and Future of Telemedicine for Parkinson's Disease
SO MOVEMENT DISORDERS
LA English
DT Article
DE telemedicine; Parkinson's disease
ID NURSING-HOME RESIDENTS; RANDOMIZED CONTROLLED-TRIAL; SEDENTARY PATIENTS;
PHYSICAL-ACTIVITY; CLINICAL-TRIALS; UNITED-STATES; HEALTH-CARE;
PREVALENCE; HISTORY; PEOPLE
AB Travel distance, growing disability, and uneven distribution of doctors limit access to care for most Parkinson's disease (PD) patients worldwide. Telemedicine, the use of telecommunications technology to deliver care at a distance, can help overcome these barriers. In this report, we describe the past, present, and likely future applications of telemedicine to PD. Historically, telemedicine has relied on expensive equipment to connect single patients to a specialist in pilot programs in wealthy nations. As the cost of video conferencing has plummeted, these efforts have expanded in scale and scope, now reaching larger parts of the world and extending the focus from care to training of remote providers. Policy, especially limited reimbursement, currently hinders the growth and adoption of these new care models. As these policies change and technology advances and spreads, the following will likely develop: integrated care networks that connect patients to a wide range of providers; education programs that support patients and health care providers; and new research applications that include remote monitoring and remote visits. Together, these developments will enable more individuals with PD to connect to care, increase access to expertise for patients and providers, and allow more-extensive, less-expensive participation in research. (C) 2014 International Parkinson and Movement Disorder Society
C1 [Achey, Meredith; Dorsey, E. Ray] Univ Rochester, Med Ctr, Ctr Human Expt Therapeut, Rochester, NY 14642 USA.
[Aldred, Jason L.] Northwest Neurol PLLC, Spokane, WA USA.
[Aljehani, Noha; Mari, Zoltan] Johns Hopkins Med, Dept Neurol, Baltimore, MD USA.
[Bloem, Bastiaan R.; van den Haak, Pieter] Radboud Univ Nijmegen, Med Ctr, Donders Inst Brain Cognit & Behav, Dept Neurol, Nijmegen, Netherlands.
[Biglan, Kevin M.; Dorsey, E. Ray] Univ Rochester, Med Ctr, Dept Neurol, Rochester, NY 14642 USA.
[Chan, Piu] Capital Med Univ, Dept Neurol & Neurobiol, Xuanwu Hosp,Beijing Inst Brain Disorders, Beijing Key Lab Parkinsons Dis,Parkinsons Dis Ctr, Beijing, Peoples R China.
[Cubo, Esther] Univ Hosp, Dept Neurol, Burgos, Spain.
[Goetz, Christopher G.] Rush Univ, Med Ctr, Chicago, IL 60612 USA.
[Guttman, Mark] Univ Toronto, Div Neurol, Ctr Movement Disorders, Markham, ON, Canada.
[Hassan, Anhar] Mayo Clin, Dept Neurol, Rochester, MN USA.
[Khandhar, Suketu M.] Kaiser Permanente, Movement Disorders Program, Raleigh, NC USA.
[Spindler, Meredith; Wilkinson, Jayne R.] Univ Penn, Dept Neurol, Philadelphia, PA 19104 USA.
[Tanner, Caroline M.] Univ Calif San Francisco, Parkinsons Dis Res Educ & Clin Ctr, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA.
[Tanner, Caroline M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA.
[Walker, Richard] North Tyneside Gen Hosp, Dept Med, North Shields, Tyne & Wear, England.
[Wilkinson, Jayne R.] Dept Vet Affairs, Dept Neurol, Philadelphia, PA USA.
RP Dorsey, ER (reprint author), Univ Rochester, Med Ctr, Ctr Human Expt Therapeut, 265 Crittenden Blvd,CU 420694, Rochester, NY 14642 USA.
EM ray.dorsey@chet.rochester.edu
RI Bloem, B.R./H-8013-2014
FU Davis Phinney Foundation; Great Lakes NeuroTechnologies; Michael J. Fox
Foundation; Patient-Centered Outcomes Research Institute
FX Dr. Biglan has telemedicine research-related grants with the Davis
Phinney Foundation, Great Lakes NeuroTechnologies, Michael J. Fox
Foundation, and the Patient-Centered Outcomes Research Institute and has
filed a patent related to telemedicine and neurology. Dr. Dorsey has
telemedicine research-related grants with the Davis Phinney Foundation,
Great Lakes NeuroTechnologies, Michael J. Fox Foundation, and the
Patient-Centered Outcomes Research Institute, is a member of the medical
advisory board for, and has stock options in, Grand Rounds (an online
second opinion service), is an unpaid advisor to SBR Health and Vidyo,
and has filed a patent related to telemedicine and neurology. Dr. Goetz
is an officer of the International Parkinson and Movement Disorder
Society (MDS) that supports this program. Dr. Tanner is a coinvestigator
on telemedicine research-related grants with the Davis Phinney
Foundation, the Patient-Centered Outcomes Research Institute, and the
MDS.
NR 89
TC 22
Z9 22
U1 4
U2 24
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0885-3185
EI 1531-8257
J9 MOVEMENT DISORD
JI Mov. Disord.
PD JUN
PY 2014
VL 29
IS 7
BP 871
EP 883
DI 10.1002/mds.25903
PG 13
WC Clinical Neurology
SC Neurosciences & Neurology
GA AJ4TZ
UT WOS:000337670600011
PM 24838316
ER
PT J
AU Gardner, CD
Whitsel, LP
Thorndike, AN
Marrow, MW
Otten, JJ
Foster, GD
Carson, JAS
Johnson, RK
AF Gardner, Christopher D.
Whitsel, Laurie P.
Thorndike, Anne N.
Marrow, Mary W.
Otten, Jennifer J.
Foster, Gary D.
Carson, Jo Ann S.
Johnson, Rachel K.
TI Food-and-beverage environment and procurement policies for healthier
work environments
SO NUTRITION REVIEWS
LA English
DT Review
DE food and beverage environments; nutrition policy; procurement standards;
public health; work environments
ID AMERICAN-HEART-ASSOCIATION; POINT-OF-PURCHASE; NEW-YORK-CITY; FINANCIAL
INCENTIVES; SCIENTIFIC STATEMENT; CALORIE INFORMATION;
PHYSICAL-ACTIVITY; CARDIOVASCULAR-DISEASE; LABELING REGULATION; CONSUMER
AWARENESS
AB The importance of creating healthier work environments by providing healthy foods and beverages in worksite cafeterias, in on-site vending machines, and at meetings and conferences is drawing increasing attention. Large employers, federal and state governments, and hospital systems are significant purchasers and providers of food and beverages. The American Heart Association, federal government, and other organizations have created procurement standards to guide healthy purchasing by these entities. There is a need to review how procurement standards are currently implemented, to identify important minimum criteria for evaluating health and purchasing outcomes, and to recognize significant barriers and challenges to implementation, along with success stories. The purpose of this policy paper is to describe the role of food-and-beverage environment and procurement policy standards in creating healthier worksite environments; to review recently created national model standards; to identify elements across the standards that are important to consider for incorporation into policies; and to delineate issues to address as standards are implemented across the country.
C1 [Gardner, Christopher D.] Stanford Univ, Dept Med, Stanford, CA 94305 USA.
[Whitsel, Laurie P.] Amer Heart Assoc, Washington, DC USA.
[Thorndike, Anne N.] Massachusetts Gen Hosp, Dept Med, Boston, MA 02114 USA.
[Marrow, Mary W.] William Mitchell Coll Law, Publ Hlth Law Ctr, St Paul, MN USA.
[Otten, Jennifer J.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA.
[Foster, Gary D.] Temple Univ, Dept Med, Philadelphia, PA 19122 USA.
[Foster, Gary D.] Temple Univ, Dept Publ Hlth, Philadelphia, PA 19122 USA.
[Foster, Gary D.] Temple Univ, Dept Psychiat, Philadelphia, PA 19122 USA.
[Carson, Jo Ann S.] Univ Texas SW Med Ctr Dallas, Dept Clin Nutr, Dallas, TX 75390 USA.
[Johnson, Rachel K.] Univ Vermont, Dept Nutr & Food Sci, Burlington, VT USA.
RP Gardner, CD (reprint author), 1265 Welch Rd,SPRC 310, Stanford, CA 94305 USA.
EM cgardner@stanford.edu
FU NIH/National Heart Lung and Blood Institute [K23 HL93221]
FX Funding. Dr Thorndike is supported by the NIH/National Heart Lung and
Blood Institute, grant K23 HL93221. None of the other authors have any
funding sources to report.
NR 84
TC 7
Z9 7
U1 5
U2 35
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0029-6643
EI 1753-4887
J9 NUTR REV
JI Nutr. Rev.
PD JUN
PY 2014
VL 72
IS 6
BP 390
EP 410
DI 10.1111/nure.12116
PG 21
WC Nutrition & Dietetics
SC Nutrition & Dietetics
GA AJ3VU
UT WOS:000337596800004
PM 24801009
ER
PT J
AU Huerta, CI
Sarkar, PR
Duong, TQ
Laird, AR
Fox, PT
AF Huerta, Claudia I.
Sarkar, Pooja R.
Duong, Timothy Q.
Laird, Angela R.
Fox, Peter T.
TI Neural Bases of Food Perception: Coordinate-Based Meta-Analyses of
Neuroimaging Studies in Multiple Modalities
SO OBESITY
LA English
DT Article
ID ALE METAANALYSIS; FUNCTIONAL MRI; BRAIN; ACTIVATION; ADDICTION; CALORIE;
OBESITY; INSULA; CUES
AB Objective: The purpose of this study was to compare the results of the three food-cue paradigms most commonly used for functional neuroimaging studies to determine: i) commonalities and differences in the neural response patterns by paradigm and ii) the relative robustness and reliability of responses to each paradigm.
Methods: Functional magnetic resonance imaging studies using standardized stereotactic coordinates to report brain responses to food cues were identified using online databases. Studies were grouped by food-cue modality as: i) tastes (8 studies); ii) odors (8 studies); and, iii) images (11 studies). Activation likelihood estimation was used to identify statistically reliable regional responses within each stimulation paradigm.
Results: Brain response distributions were distinctly different for the three stimulation modalities, corresponding to known differences in location of the respective primary and associative cortices. Visual stimulation induced the most robust and extensive responses. The left anterior insula was the only brain region reliably responding to all three stimulus categories.
Conclusions: These findings suggest visual food-cue paradigm as promising candidate for imaging studies addressing the neural substrate of therapeutic interventions.
C1 [Huerta, Claudia I.; Sarkar, Pooja R.; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA.
[Huerta, Claudia I.; Sarkar, Pooja R.; Duong, Timothy Q.; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
[Duong, Timothy Q.; Laird, Angela R.] Univ Texas Hlth Sci Ctr San Antonio, Dept Ophthalmol, San Antonio, TX 78229 USA.
[Laird, Angela R.] Florida Int Univ, Dept Phys, Miami, FL 33199 USA.
[Fox, Peter T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
RP Huerta, CI (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Radiol, San Antonio, TX 78229 USA.
EM fox@uthscsa.edu
RI Fox, Peter/B-4725-2010
OI Fox, Peter/0000-0002-0465-2028
FU [R01 MH074457]
FX This study was funded by R01 MH074457 (PTF and ARL, PIs).
NR 40
TC 10
Z9 10
U1 0
U2 11
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1930-7381
EI 1930-739X
J9 OBESITY
JI Obesity
PD JUN
PY 2014
VL 22
IS 6
BP 1439
EP 1446
DI 10.1002/oby.20659
PG 8
WC Endocrinology & Metabolism; Nutrition & Dietetics
SC Endocrinology & Metabolism; Nutrition & Dietetics
GA AJ3AM
UT WOS:000337537000009
PM 24174404
ER
PT J
AU Ciaranello, A
Lu, ZG
Ayaya, S
Losina, E
Musick, B
Vreeman, R
Freedberg, KA
Abrams, EJ
Dillabaugh, L
Doherty, K
Ssali, J
Yiannoutsos, CT
Wools-Kaloustian, K
AF Ciaranello, Andrea
Lu, Zhigang
Ayaya, Samuel
Losina, Elena
Musick, Beverly
Vreeman, Rachel
Freedberg, Kenneth A.
Abrams, Elaine J.
Dillabaugh, Lisa
Doherty, Katie
Ssali, John
Yiannoutsos, Constantin T.
Wools-Kaloustian, Kara
TI Incidence of World Health Organization Stage 3 and 4 Events,
Tuberculosis and Mortality in Untreated, HIV-infected Children Enrolling
in Care Before 1 Year of Age An IeDEA (International Epidemiologic
Databases To Evaluate AIDS) East Africa Regional Analysis
SO PEDIATRIC INFECTIOUS DISEASE JOURNAL
LA English
DT Article
DE pediatric HIV; opportunistic infection; morbidity; mortality
ID RESOURCE-LIMITED SETTINGS; ANTIRETROVIRAL THERAPY; HIV-1-INFECTED
CHILDREN; DISEASE PROGRESSION; SOUTH-AFRICA; INFANTS BORN; ZAMBIAN
CHILDREN; UGANDAN CHILDREN; LYMPHOCYTE COUNT; POOLED ANALYSIS
AB Background: Few studies have reported CD4%- and age-stratified rates of World Health Organization Stage 3 (WHO3) events, World Health Organization Stage 4 (WHO4) events, tuberculosis (TB) and mortality in HIV-infected infants before initiation of antiretroviral therapy.
Methods: HIV-infected children enrolled before 1 year of age in the International Epidemiologic Databases to Evaluate AIDS East Africa region (October 1, 2002, to November, 2008) were included. We estimated incidence rates of earliest clinical event (WHO3, WHO4 and TB), before antiretroviral therapy initiation per local guidelines, stratified by current age (< or >= 6 months) and current CD4% (<15%, 15-24%, >= 25%). CD4%-stratified mortality rates were estimated separately for children who did not experience a clinical event ("background" mortality) and for children who experienced an event, including "acute" mortality (<= 30 days post event) and "later" mortality (>30 days post event).
Results: Among 847 children (median enrollment age: 4.8 months; median pre-antiretroviral therapy follow up: 10.8 months; 603 (71%) with >= 1 CD4% recorded), event rates were comparable for those aged <6 and >= 6 months. Current CD4% was associated with risk of WHO4 events for children <6 months of age and with all evaluated events for children >= 6 months old (P < 0.05). "Background" mortality was 3.7-8.4/100 person-years (PY). "Acute" mortality (<= 30 days post event) was 33.8/100 PY (after TB) and 41.1/100 PY (after WHO3 or WHO4). "Later" mortality (>30 days post event) ranged by CD4% from 4.7 to 29.1/100 PY.
Conclusions: In treatment-naive, HIV-infected infants, WHO3, WHO4 and TB events were common before and after 6 months of age and led to substantial increases in mortality. Early infant HIV diagnosis and treatment are critically important, regardless of CD4%.
C1 [Ciaranello, Andrea; Freedberg, Kenneth A.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
[Ciaranello, Andrea; Lu, Zhigang; Losina, Elena; Freedberg, Kenneth A.; Doherty, Katie] Massachusetts Gen Hosp, Med Practice Evaluat Ctr, Boston, MA 02114 USA.
[Lu, Zhigang; Losina, Elena; Freedberg, Kenneth A.; Doherty, Katie] Massachusetts Gen Hosp, Div Gen Med, Boston, MA 02114 USA.
[Ayaya, Samuel] Moi Univ, Sch Med, Dept Child Hlth & Paediat, Eldoret, Kenya.
[Losina, Elena] Brigham & Womens Hosp, Dept Orthoped Surg, Boston, MA 02115 USA.
[Musick, Beverly; Yiannoutsos, Constantin T.] Indiana Univ, Dept Biostat, Indianapolis, IN 46204 USA.
[Vreeman, Rachel] Indiana Univ Sch Med, Dept Pediat, Indianapolis, IN 46202 USA.
[Abrams, Elaine J.] Columbia Univ, Mailman Sch Publ Hlth, ICAP, New York, NY 10027 USA.
[Abrams, Elaine J.] Columbia Univ, Coll Phys & Surg, New York, NY 10027 USA.
[Dillabaugh, Lisa] Family AIDS Care & Educ Serv FACES Program, Kisumu, Kenya.
[Dillabaugh, Lisa] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA.
[Ssali, John] AHF Uganda Cares Masaka, Masaka Reg Referral Hosp, Masaka, Uganda.
[Wools-Kaloustian, Kara] Indiana Univ Sch Med, Div Infect Dis, Indianapolis, IN 46202 USA.
RP Ciaranello, A (reprint author), Massachusetts Gen Hosp, Div Infect Dis, 50 Staniford St,Room 920, Boston, MA 02114 USA.
EM aciaranello@partners.org
FU National Institutes of Health through the International Epidemiologic
Databases to Evaluate AIDS (IeDEA); International Maternal Pediatric
Adolescent AIDS Clinical Trials Group (IMPAACT); National Institute of
Allergy and Infectious Disease (NIAID) [K01 AI078754, R01 AI058736];
President's Emergency Fund for AIDS Relief (PEPfAR); Elizabeth Glaser
Pediatric AIDS Foundation; NIAID; Eunice Kennedy Shriver National
Institute of Child Health and Human Development (NICHD); National Cancer
Institute [U01 AI069911]; NIAID [U01 AI068632]; Eunice Kennedy Shriver
NICHD; National Institute of Mental Health (NIMH) [AI068632];
Statistical and Data Analysis Center at Harvard School of Public Health,
under the NIAID [5 U01 AI41110]; Pediatric AIDS Clinical Trials Group
(PACTG) [1 U01 AI068616]; IMPAACT Group; NICHD International and
Domestic Pediatric and Maternal HIV Clinical Trials Network - NICHD
[N01-DK-9-001/HHSN267200800001C]
FX Funding for this work was provided by the National Institutes of Health
through the International Epidemiologic Databases to Evaluate AIDS
(IeDEA: S. A., B. M., R. V., J.S., C.T.Y., K. W. K.), the International
Maternal Pediatric Adolescent AIDS Clinical Trials Group (IMPAACT; A. L.
C., Z.L., K. A. F., K. D.), and the National Institute of Allergy and
Infectious Disease (NIAID) (K01 AI078754 [ALC], R01 AI058736 [Z.L., E.
L., K. A. F., K. D.]), as well as the President's Emergency Fund for
AIDS Relief (PEPfAR; S. A., B. M., R. V., C.T.Y., K. W. K.), and the
Elizabeth Glaser Pediatric AIDS Foundation (A. L. C., K. A. F.). The
funders had no role in study design, interpretation of results, or
decision to publish. The authors have no other funding or conflicts of
interest to disclose.; Overall support for IeDEA was provided by the
NIAID, the Eunice Kennedy Shriver National Institute of Child Health and
Human Development (NICHD), and the National Cancer Institute, through
U01 AI069911.; Overall support for IMPAACT was provided by the NIAID
(U01 AI068632), the Eunice Kennedy Shriver NICHD, and the National
Institute of Mental Health (NIMH) (AI068632). The content is solely the
responsibility of the authors and does not necessarily represent the
official views of the NIH. This work was supported by the Statistical
and Data Analysis Center at Harvard School of Public Health, under the
NIAID cooperative agreement #5 U01 AI41110 with the Pediatric AIDS
Clinical Trials Group (PACTG) and #1 U01 AI068616 with the IMPAACT
Group. Support of the sites was provided by the NIAID and the NICHD
International and Domestic Pediatric and Maternal HIV Clinical Trials
Network funded by NICHD (contract number
N01-DK-9-001/HHSN267200800001C).
NR 35
TC 5
Z9 5
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0891-3668
EI 1532-0987
J9 PEDIATR INFECT DIS J
JI Pediatr. Infect. Dis. J.
PD JUN
PY 2014
VL 33
IS 6
BP 623
EP 629
DI 10.1097/INF.0000000000000223
PG 7
WC Immunology; Infectious Diseases; Pediatrics
SC Immunology; Infectious Diseases; Pediatrics
GA AJ0OL
UT WOS:000337354400018
PM 24378935
ER
PT J
AU Kaafarani, HMA
Velmahos, GC
AF Kaafarani, H. M. A.
Velmahos, G. C.
TI DAMAGE CONTROL RESUSCITATION IN TRAUMA
SO SCANDINAVIAN JOURNAL OF SURGERY
LA English
DT Review
DE Resuscitation; hemorrhage; consumption coagulopathy; blood component
transfusion; wounds and injury; acidosis
ID FRESH-FROZEN PLASMA; RED-BLOOD-CELL; MASSIVE TRANSFUSION PROTOCOL;
RANDOMIZED CONTROLLED-TRIAL; HYPERTONIC SALINE RESUSCITATION;
LIFE-THREATENING COAGULOPATHY; ADVERSELY AFFECTS OUTCOMES; GLUE GRANT
DATABASE; FLUID RESUSCITATION; HEMORRHAGIC-SHOCK
AB Introduction: Most preventable trauma deaths are due to uncontrolled hemorrhage.
Methods: In this article, we briefly describe the pathophysiology of the classical triad of death in trauma, namely, acidosis, hypothermia, and coagulopathy, and then suggest damage control resuscitation strategies to prevent and/or mitigate the effects of each in the bleeding patient.
Results: Damage control resuscitation strategies include body rewarming, restrictive fluid administration, permissive hypotension, balanced blood product administration, and the implementation of massive transfusion protocols.
Conclusion: Resuscitating and correcting the coagulopathy of the exsanguinating trauma patient is essential to improve chances of survival.
C1 [Kaafarani, H. M. A.] Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, Boston, MA 02114 USA.
[Kaafarani, H. M. A.] Harvard Univ, Sch Med, Boston, MA 02114 USA.
RP Kaafarani, HMA (reprint author), Massachusetts Gen Hosp, Div Trauma Emergency Surg & Surg Crit Care, 165 Cambridge St,Suite 810, Boston, MA 02114 USA.
EM hkaafarani@partners.org
NR 79
TC 13
Z9 14
U1 1
U2 3
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1457-4969
EI 1799-7267
J9 SCAND J SURG
JI Scand. J. Surg.
PD JUN
PY 2014
VL 103
IS 2
BP 81
EP 88
PG 8
WC Surgery
SC Surgery
GA AJ3NL
UT WOS:000337573400002
PM 24777616
ER
PT J
AU Ellis, LE
Beckman, JA
AF Ellis, Lauren E.
Beckman, Joshua A.
TI Baby blue
SO VASCULAR MEDICINE
LA English
DT Editorial Material
ID DERMATOSES
C1 [Ellis, Lauren E.] Massachusetts Gen Hosp, Inst Heart Vasc & Stroke Care, Boston, MA 02114 USA.
[Beckman, Joshua A.] Brigham & Womens Hosp, Div Cardiovasc, Boston, MA 02115 USA.
RP Beckman, JA (reprint author), Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA.
EM jbeckman@partners.org
OI Beckman, Joshua/0000-0001-8332-8439
NR 2
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1358-863X
EI 1477-0377
J9 VASC MED
JI Vasc. Med.
PD JUN
PY 2014
VL 19
IS 3
BP 215
EP 215
DI 10.1177/1358863X14526949
PG 1
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AJ3PS
UT WOS:000337579800008
PM 24608693
ER
PT J
AU Moore, EK
Gu, XK
Olin, JW
Froehlich, JB
Bacharach, JM
Jaff, MR
Katzen, BT
Kline-Rogers, E
Mace, PD
Matsumoto, AH
McBane, RD
White, CJ
Kim, ESH
Gornik, HL
Gray, BH
AF Moore, Erin K.
Gu, Xiaokui
Olin, Jeffrey W.
Froehlich, James B.
Bacharach, J. Michael
Jaff, Michael R.
Katzen, Barry T.
Kline-Rogers, Eva
Mace, Pamela D.
Matsumoto, Alan H.
McBane, Robert D.
White, Christopher J.
Kim, Esther S. H.
Gornik, Heather L.
Gray, Bruce H.
TI Registry findings of fibromuscular dysplasia of the mesenteric arteries
SO VASCULAR MEDICINE
LA English
DT Meeting Abstract
C1 [Moore, Erin K.; Gray, Bruce H.] Greenville Hlth Syst, Greenville, SC USA.
[Gu, Xiaokui; Froehlich, James B.; Kline-Rogers, Eva] Univ Michigan, Ann Arbor, MI 48109 USA.
[Olin, Jeffrey W.] Mt Sinai Med Ctr, New York, NY 10029 USA.
[Bacharach, J. Michael] North Cent Heart, Sioux Falls, SD USA.
[Jaff, Michael R.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Katzen, Barry T.] Miami Baptist Cardiac Vasc Inst, Miami, FL USA.
[Mace, Pamela D.] Fibromuscular Dysplasia Soc Amer, Rocky River, OH USA.
[Matsumoto, Alan H.] Univ Virginia Hlth Syst, Charlottesville, VA USA.
[McBane, Robert D.] Mayo Clin, Rochester, MN USA.
[White, Christopher J.] Ochsner Clin & Alton Ochsner Med Fdn, New Orleans, LA USA.
[Kim, Esther S. H.; Gornik, Heather L.] Cleveland Clin Fdn, Cleveland, OH 44195 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU SAGE PUBLICATIONS LTD
PI LONDON
PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND
SN 1358-863X
EI 1477-0377
J9 VASC MED
JI Vasc. Med.
PD JUN
PY 2014
VL 19
IS 3
MA YIA 4
BP 224
EP 225
PG 2
WC Peripheral Vascular Disease
SC Cardiovascular System & Cardiology
GA AJ3PS
UT WOS:000337579800015
ER
PT J
AU Yen, PJ
Mefford, ME
Hoxie, JA
Williams, KC
Desrosiers, RC
Gabuzda, D
AF Yen, Po-Jen
Mefford, Megan E.
Hoxie, James A.
Williams, Kenneth C.
Desrosiers, Ronald C.
Gabuzda, Dana
TI Identification and characterization of a macrophage-tropic SIV envelope
glycoprotein variant in blood from early infection in SIVmac251-infected
macaques
SO VIROLOGY
LA English
DT Article
DE Human immunodeficiency virus (HIV); Simian immunodeficiency virus (SIV);
Envelope glycoprotein (Env); Macrophage tropism; Brain
ID SIMIAN-IMMUNODEFICIENCY-VIRUS; N-LINKED GLYCOSYLATION;
CENTRAL-NERVOUS-SYSTEM; HIV-1 VACCINE EFFICACY; NEUTRALIZATION
SENSITIVITY; RHESUS MACAQUES; MOLECULAR CLONES; IN-VIVO; BIOLOGICAL
CHARACTERIZATION; PERIVASCULAR MACROPHAGES
AB Macrophages play an important role in HIV/SIV pathogenesis by serving as a reservoir for viral persistence in brain and other tissues. Infected macrophages have been detected in brain early after infection, but macrophage-tropic viruses are rarely isolated until late-stage infection. Little is known about early variants that establish persistent infection in brain. Here, we characterize a unique macrophage-tropic SW envelope glycoprotein (Env) variant from two weeks post-infection in blood of an SIVmac251-infected macaque that is closely related to sequences in brain from animals with neurological disease. SIVmac251 clones expressing this Env are highly fusogenic, and replicate efficiently in T cells and macrophages. N173 and N481 were identified as novel determinants of macrophage tropism and neutralization sensitivity. These results imply that macrophage-tropic SW capable of establishing viral reservoirs in brain can be present in blood during early infection. Furthermore, these SIVmac251 clones will be useful for studies on pathogenesis, eradication, and vaccines. (C) 2014 The Authors. Published by Elsevier Inc.
C1 [Yen, Po-Jen; Mefford, Megan E.; Gabuzda, Dana] Dana Farber Canc Inst, Dept Canc Immunol & AIDS, Boston, MA 02215 USA.
[Yen, Po-Jen; Mefford, Megan E.] Harvard Univ, Sch Med, Div Med Sci, Program Virol, Boston, MA USA.
[Hoxie, James A.] Univ Penn, Dept Med, Hematol Oncol Div, Philadelphia, PA 19104 USA.
[Williams, Kenneth C.] Boston Coll, Dept Biol, Chestnut Hill, MA 02167 USA.
[Desrosiers, Ronald C.] Harvard Univ, Sch Med, New England Primate Res Ctr, Dept Microbiol & Immunobiol, Southborough, MA 01772 USA.
[Gabuzda, Dana] Harvard Univ, Sch Med, Dept Neurol, Boston, MA 02115 USA.
RP Gabuzda, D (reprint author), Dana Farber Canc Inst, CLS-1010,450 Brookline Ave, Boston, MA 02215 USA.
EM Dana_Gabuzda@dfci.harvard.edu
FU NIH [MH83588, MH97659]; NIH fellowship [F31NS060611]
FX This work was supported by NIH grants MH83588 and MH97659 to D.G. M.E.M.
was supported in part by NIH fellowship F31NS060611. Core facilities
were supported by Harvard Medical School Center for AIDS Research (CFAR)
and DFCI/Harvard Cancer Center grants.
NR 89
TC 5
Z9 5
U1 0
U2 4
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0042-6822
J9 VIROLOGY
JI Virology
PD JUN
PY 2014
VL 458
BP 53
EP 68
DI 10.1016/j.virol.2014.03.024
PG 16
WC Virology
SC Virology
GA AJ4RZ
UT WOS:000337664800007
PM 24928039
ER
PT J
AU Geffrey, AL
Shinnick, JE
Staley, BA
Boronat, S
Thiele, EA
AF Geffrey, Alexandra L.
Shinnick, Julianna E.
Staley, Brigid A.
Boronat, Susana
Thiele, Elizabeth A.
TI Lymphedema in tuberous sclerosis complex
SO AMERICAN JOURNAL OF MEDICAL GENETICS PART A
LA English
DT Article
DE edema; lymphatic abnormalities; lymphedema; tuberous sclerosis complex
ID CONGENITAL LYMPHEDEMA; DISEASE; LYMPHANGIOLEIOMYOMATOSIS; PROGNOSIS;
TSC2
AB Congenital lymphedema has been described as a possible rare association of tuberous sclerosis complex (TSC), with only six previous cases reported in the literature. TSC is an autosomal dominant, multisystem disorder connected to aberrant regulation of the mammalian target of rapamycin (mTOR) pathway. The aim of this study is to review cases of lymphedema in a large cohort of TSC patients. The medical records of 268 patients seen at The Herscot Center for Children and Adults with Tuberous Sclerosis Complex at the Massachusetts General Hospital from 2002 to 2012 were retrospectively reviewed for reports of lymphedema or edema of unknown etiology. Genotypic and phenotypic data were collected in accordance with institutional review board (IRB) approval. This cohort presents two new cases of congenital lymphedema in TSC patients and acquired lymphedema was found in eight additional cases. Thus, we report 10 new cases of lymphedema in TSC (4%). The two patients with congenital lymphedema were female, as were the previous six reported cases. The frequency of lymphedema reported here (4%) is higher than the estimated prevalence in the general population (0.133-0.144%), suggesting a higher frequency of lymphedema in TSC. This study shows that patients with TSC and lymphedema are more likely to be females with renal AMLs and suggests that congenital lymphedema is a gender-specific (female) manifestation of TSC. Exploration of the potential role of mTOR antagonists may be important in treatment of lymphedema in TSC patients. (c) 2014 Wiley Periodicals, Inc.
C1 [Geffrey, Alexandra L.; Shinnick, Julianna E.; Staley, Brigid A.; Boronat, Susana; Thiele, Elizabeth A.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Boronat, Susana] Univ Autonoma Barcelona, Vall dHebron Hosp, Dept Pediat Neurol, E-08193 Barcelona, Spain.
RP Thiele, EA (reprint author), Herscot Ctr Tuberous Sclerosis Complex, 175 Cambridge St,Suite 340, Boston, MA 02114 USA.
EM ethiele@partners.org
FU Herscot Center for Tuberous Sclerosis Complex; NIH/NINDS [P01 NS024279]
FX Grant sponsor: Herscot Center for Tuberous Sclerosis Complex; Grant
sponsor: NIH/NINDS; Grant number: P01 NS024279.
NR 28
TC 4
Z9 4
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1552-4825
EI 1552-4833
J9 AM J MED GENET A
JI Am. J. Med. Genet. A
PD JUN
PY 2014
VL 164
IS 6
BP 1438
EP 1442
DI 10.1002/ajmg.a.36469
PG 5
WC Genetics & Heredity
SC Genetics & Heredity
GA AH2BV
UT WOS:000335926600011
PM 24668795
ER
PT J
AU Huddle, TS
Kertesz, SG
Nash, RR
AF Huddle, Thomas S.
Kertesz, Stefan G.
Nash, Ryan R.
TI Health Care Institutions Should Not Exclude Smokers From Employment
SO ACADEMIC MEDICINE
LA English
DT Article
ID SMOKING; WORKPLACE
AB Some health care institutions, including academic health centers, have adopted policies excluding smokers from employment. Claims advanced on behalf of these policies include financial savings from reduced health costs and absenteeism as well as advantages consonant with their message of healthy living. The authors suggest that the institutional savings from these policies are speculative and unproven. Also, in settings where large medical schools operate, it is likely to be the poor, including members of minority groups, who, under an employee smoker ban, will lose the opportunity to work for an employer that offers health insurance and other benefits. In response to the incentives created by such bans, some will quit smoking, but most will not. Thus, at the community level, employee smoker bans are more likely to be harmful than beneficial.
Although private businesses may rightly choose not to hire smokers in the 19 states where such policies are legal, health care institutions, including academic health centers, should consider hiring choices in light of the values they profess. The traditional values of medicine include service to all persons in need, even when illness results from addiction or unsafe behavior. Secular academic communities require a shared dedication to discovery without requiring strict conformity of private behavior or belief. The authors conclude that for health care institutions, policies of hiring smokers and helping them to quit are both prudent and expressive of the norms of medical care, such as inclusion, compassion, and fellowship, that academic health professionals seek to honor.
C1 [Huddle, Thomas S.; Kertesz, Stefan G.] Univ Alabama Birmingham, Sch Med, Birmingham, AL USA.
[Huddle, Thomas S.] Univ Alabama Birmingham, Birmingham VA Med Ctr, Birmingham, AL USA.
[Kertesz, Stefan G.] Birmingham VA Med Ctr, Birmingham, AL USA.
[Nash, Ryan R.] Ohio State Univ, Ctr Bioeth, Columbus, OH 43210 USA.
RP Huddle, TS (reprint author), FOT 720,1530 3rd Ave S, Birmingham, AL 35294 USA.
EM thuddle@uab.edu
OI Kertesz, Stefan/0000-0001-6101-8421
NR 24
TC 3
Z9 3
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 1040-2446
EI 1938-808X
J9 ACAD MED
JI Acad. Med.
PD JUN
PY 2014
VL 89
IS 6
BP 843
EP 847
DI 10.1097/ACM.0000000000000247
PG 5
WC Education, Scientific Disciplines; Health Care Sciences & Services
SC Education & Educational Research; Health Care Sciences & Services
GA AI8NU
UT WOS:000337176300012
PM 24871233
ER
PT J
AU Beresin, EV
Balon, R
Coverdale, J
AF Beresin, Eugene V.
Balon, Richard
Coverdale, John
TI The Psychiatry Milestones: New Developments and Challenges
SO ACADEMIC PSYCHIATRY
LA English
DT Editorial Material
ID MEDICAL-ETHICS
C1 [Beresin, Eugene V.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA.
[Balon, Richard] Wayne State Univ, Detroit, MI USA.
[Coverdale, John] Baylor Coll Med, Houston, TX 77030 USA.
RP Beresin, EV (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Boston, MA 02115 USA.
EM eberesin@partners.org
NR 16
TC 2
Z9 2
U1 0
U2 0
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1042-9670
EI 1545-7230
J9 ACAD PSYCHIATR
JI Acad. Psych.
PD JUN
PY 2014
VL 38
IS 3
BP 249
EP 252
DI 10.1007/s40596-014-0119-6
PG 4
WC Education & Educational Research; Psychiatry
SC Education & Educational Research; Psychiatry
GA AI8FH
UT WOS:000337143800001
PM 24764014
ER
PT J
AU Benjamin, S
Widge, A
Shaw, K
AF Benjamin, Sheldon
Widge, Alik
Shaw, Kailie
TI Neuropsychiatry and Neuroscience Milestones for General Psychiatry
Trainees
SO ACADEMIC PSYCHIATRY
LA English
DT Article
ID CLINICAL NEUROSCIENCE; NEUROLOGY; RESIDENTS; EDUCATION; FUTURE
C1 [Benjamin, Sheldon] Univ Massachusetts, Sch Med, Worcester, MA 01605 USA.
[Widge, Alik] Massachusetts Gen Hosp, Charlestown, MA USA.
[Shaw, Kailie] Univ S Florida, Morsani Coll Med, Tampa, FL USA.
RP Benjamin, S (reprint author), Univ Massachusetts, Sch Med, Worcester, MA 01605 USA.
EM sheldon.benjamin@umassmed.edu
OI Benjamin, Sheldon/0000-0001-6279-1934
NR 41
TC 3
Z9 3
U1 0
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1042-9670
EI 1545-7230
J9 ACAD PSYCHIATR
JI Acad. Psych.
PD JUN
PY 2014
VL 38
IS 3
BP 275
EP 282
DI 10.1007/s40596-014-0112-0
PG 8
WC Education & Educational Research; Psychiatry
SC Education & Educational Research; Psychiatry
GA AI8FH
UT WOS:000337143800006
PM 24715675
ER
PT J
AU Widge, AS
Hunt, J
Servis, M
AF Widge, Alik S.
Hunt, Jeffrey
Servis, Mark
TI Systems-Based Practice and Practice-Based Learning for the General
Psychiatrist: Old Competencies, New Emphasis
SO ACADEMIC PSYCHIATRY
LA English
DT Article
ID HEALTH-CARE; MENTAL-HEALTH; QUALITY IMPROVEMENT; COLLABORATIVE CARE;
OPPORTUNITIES; RESIDENCY; EDUCATION; SETTINGS; RECOVERY; CENTERS
C1 [Hunt, Jeffrey] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA.
[Servis, Mark] Univ Calif Davis, Sacramento, CA 95817 USA.
RP Widge, AS (reprint author), Massachusetts Gen Hosp, Charlestown, MA 02129 USA.
EM awidge@partners.org
NR 41
TC 5
Z9 5
U1 1
U2 2
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1042-9670
EI 1545-7230
J9 ACAD PSYCHIATR
JI Acad. Psych.
PD JUN
PY 2014
VL 38
IS 3
BP 288
EP 293
DI 10.1007/s40596-014-0104-0
PG 6
WC Education & Educational Research; Psychiatry
SC Education & Educational Research; Psychiatry
GA AI8FH
UT WOS:000337143800008
PM 24711094
ER
PT J
AU Widge, AS
Schultz, HE
AF Widge, Alik S.
Schultz, Heather E.
TI Opportunities and Challenges: Residents' Perspectives on the Next
Accreditation System in Psychiatry
SO ACADEMIC PSYCHIATRY
LA English
DT Editorial Material
DE Accreditation; Graduate medical education; Internship and residency
ID ACGME; COUNCIL
C1 [Widge, Alik S.] Massachusetts Gen Hosp, Charlestown, MA 02129 USA.
[Schultz, Heather E.] Univ Michigan Hlth Syst, Ann Arbor, MI USA.
RP Widge, AS (reprint author), Massachusetts Gen Hosp, Charlestown, MA 02129 USA.
EM awidge@partners.org
NR 7
TC 2
Z9 2
U1 1
U2 1
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1042-9670
EI 1545-7230
J9 ACAD PSYCHIATR
JI Acad. Psych.
PD JUN
PY 2014
VL 38
IS 3
BP 303
EP 304
DI 10.1007/s40596-014-0094-y
PG 2
WC Education & Educational Research; Psychiatry
SC Education & Educational Research; Psychiatry
GA AI8FH
UT WOS:000337143800010
PM 24664610
ER
PT J
AU Dickey, C
Dismukes, R
Topor, D
AF Dickey, Chandlee
Dismukes, Rodney
Topor, David
TI Creating Opportunities for Organizational Leadership (COOL): Creating a
Culture and Curriculum that Fosters Psychiatric Leadership Development
and Quality Improvement
SO ACADEMIC PSYCHIATRY
LA English
DT Article
DE Psychiatry residents; Leadership; Curriculum development
ID MANAGEMENT; PROGRAM
AB The authors describe the Harvard South Shore Psychiatry Residency Training Program curriculum "Creating Opportunities for Organizational Leadership," an innovative, multitiered, resident-driven, outcome-focused set of experiences designed to develop residents' leadership skills in personal leadership, organizational leadership, negotiation, strategic thinking, and systems redesign.
C1 [Dickey, Chandlee; Dismukes, Rodney; Topor, David] Harvard Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA 02115 USA.
RP Dickey, C (reprint author), Harvard Univ, Sch Med, VA Boston Healthcare Syst, Boston, MA 02115 USA.
EM Chandlee.Dickey@va.gov
NR 20
TC 1
Z9 1
U1 1
U2 10
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 1042-9670
EI 1545-7230
J9 ACAD PSYCHIATR
JI Acad. Psych.
PD JUN
PY 2014
VL 38
IS 3
BP 383
EP 387
DI 10.1007/s40596-014-0082-2
PG 5
WC Education & Educational Research; Psychiatry
SC Education & Educational Research; Psychiatry
GA AI8FH
UT WOS:000337143800027
PM 24664604
ER
PT J
AU Momplaisir, F
Yehia, BR
Harhay, MO
Fetzer, B
Brady, KA
Long, JA
AF Momplaisir, Florence
Yehia, Baligh R.
Harhay, Michael O.
Fetzer, Bradley
Brady, Kathleen A.
Long, Judith A.
TI HIV Testing Trends: Southeastern Pennsylvania, 2002-2010
SO AIDS PATIENT CARE AND STDS
LA English
DT Article
ID FOR-DISEASE-CONTROL; EMERGENCY-DEPARTMENT; ANTIRETROVIRAL THERAPY;
UNITED-STATES; CLINICAL GUIDELINES; PREVALENCE AREA; SEXUAL HISTORY;
CARE; PREVENTION; PROGRAM
AB There are limited data on HIV testing trends after 2006 when the Centers for Disease Control and Prevention (CDC) introduced opt-out HIV testing with the aims of identifying HIV-infected persons early and linking them to care. We used data from the Southeastern Pennsylvania Household Health Survey between 2002 and 2010 to evaluate HIV testing over time. 50,698 adult (>= 18 years) survey respondents were included. HIV testing increased after the CDC recommendations: 42.1% of survey respondents received testing at least once in 2002 versus 51.4% in 2010, p < 0.001. Testing trends increased among all demographic groups, but existing differences in testing before 2006 persisted after that year as follows: younger patients, racial/ethnic minorities, patients on Medicaid were all more likely to get tested than their counterparts. Blacks and patients seeking care in community health centers had the fastest rise in HIV testing. The probability of HIV testing in Blacks was 0.56 (95% CI 0.54-0.60) in 2002 and increased to 0.73 (0.70-0.76) by 2010. Patients seeking care in community health centers had a probability of HIV testing of 0.57 (0.47-0.66) in 2002, which increased to 0.69 (0.60-0.77) by 2010. In comparison, patients in private clinics had an HIV testing probability of 0.40 (0.360.43) in 2002 compared to 0.47 (0.40-0.54) in 2010. HIV testing is increasing, particularly among ethnic minorities and in community health centers. However, testing remains to be improved in that setting and across all clinic types.
C1 [Momplaisir, Florence] Temple Univ Hosp & Med Sch, Infect Dis Sect, Philadelphia, PA 19140 USA.
[Yehia, Baligh R.] Univ Penn, Div Infect Dis, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Harhay, Michael O.; Fetzer, Bradley; Long, Judith A.] Univ Penn, Div Gen Internal Med, Perelman Sch Med, Philadelphia, PA 19104 USA.
[Brady, Kathleen A.] Philadelphia Dept Publ Hlth, Philadelphia, PA USA.
[Long, Judith A.] Philadelphia VA Ctr Hlth Equ Res & Promot, Philadelphia, PA USA.
RP Momplaisir, F (reprint author), Temple Univ Hosp & Med Sch, Suite 501,3401 North Broad St, Philadelphia, PA 19140 USA.
EM Florence.Momplaisir@tuhs.temple.edu
OI Harhay, Michael/0000-0002-0553-674X
FU NIMH NIH HHS [K23 MH097647]
NR 48
TC 4
Z9 4
U1 1
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1087-2914
EI 1557-7449
J9 AIDS PATIENT CARE ST
JI Aids Patient Care STDS
PD JUN
PY 2014
VL 28
IS 6
BP 303
EP 310
DI 10.1089/apc.2014.0044
PG 8
WC Public, Environmental & Occupational Health; Infectious Diseases
SC Public, Environmental & Occupational Health; Infectious Diseases
GA AI9CG
UT WOS:000337224700005
PM 24742326
ER
PT J
AU Buckheit, RW
Sexauer, SB
Sedaghat, AR
Wilke, CO
Laeyendecker, O
Basseth, CR
Blankson, JN
AF Buckheit, Robert W., III
Sexauer, Stephen B.
Sedaghat, Ahmad R.
Wilke, Claus O.
Laeyendecker, Oliver
Basseth, Christie R.
Blankson, Joel N.
TI Long-Term Control of Viral Replication in a Group O, Human
Immunodeficiency Virus Type 1-Infected Individual
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Letter
ID HIV-1; INFECTION; EVOLUTION; CAMEROON
C1 [Buckheit, Robert W., III; Sexauer, Stephen B.; Laeyendecker, Oliver; Basseth, Christie R.; Blankson, Joel N.] Johns Hopkins Univ, Sch Med, Dept Med, Baltimore, MD 21205 USA.
[Sedaghat, Ahmad R.] Harvard Univ, Sch Med, Dept Otolaryngol, Massachusetts Eye & Ear Infirm, Boston, MA 02115 USA.
[Wilke, Claus O.] Ctr Computat Biol & Bioinformat, Sect Integrat Biol, Austin, TX USA.
[Wilke, Claus O.] Univ Texas Austin, Inst Cell & Mol Biol, Austin, TX 78712 USA.
[Laeyendecker, Oliver] NIAID, Div Intramural Res, NIH, Baltimore, MD USA.
RP Blankson, JN (reprint author), Johns Hopkins Univ, Sch Med, Dept Med, 733 North Broadway,BRB 880, Baltimore, MD 21205 USA.
EM jblanks@jhmi.edu
OI Laeyendecker, Oliver/0000-0002-6429-4760; Wilke,
Claus/0000-0002-7470-9261
FU NIGMS NIH HHS [T32 GM008752]
NR 13
TC 2
Z9 2
U1 0
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD JUN
PY 2014
VL 30
IS 6
BP 511
EP 513
DI 10.1089/aid.2014.0054
PG 3
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA AI9CE
UT WOS:000337224400001
PM 24798496
ER
PT J
AU Pena, J
Jones, NG
Bousheri, S
Bangsberg, DR
Cao, HY
AF Pena, Jose
Jones, Norman G.
Bousheri, Stephanie
Bangsberg, David R.
Cao, Huyen
TI Lymphocyte Activation Gene-3 Expression Defines a Discrete Subset of
HIV-Specific CD8(+) T Cells That Is Associated with Lower Viral Load
SO AIDS RESEARCH AND HUMAN RETROVIRUSES
LA English
DT Article
ID MHC CLASS-II; NEGATIVE REGULATORY FUNCTION; ANTIRETROVIRAL THERAPY;
DISEASE PROGRESSION; PD-1 EXPRESSION; FLOW-CYTOMETRY; UP-REGULATION;
LAG-3; INFECTION; CD223
AB Mechanisms leading to the observed immune dysregulation in chronic HIV infection are not well understood. The MHC-II class ligand, lymphocyte activation gene-3 (LAG-3, CD223), has been implicated in the complex regulation mechanism of immune functions. In this study, we describe a new population of HIV-specific CD8(+) T cells expressing LAG-3. These LAG-3(+)CD8(+) T cells do not display immunophenotypic patterns traditionally attributed to regulatory T cells. The LAG3(+)CD8(+) T cells are CCR7(+), CD127(-), and display heterogeneous surface expressions of CD45RA and CD25. Interestingly, HIV-specific LAG-3(+)CD8(+) T cells do not substantially express CTLA-4 and LAG-3 expression does not correlate with interleukin (IL)-10 or tumor growth factor (TGF)-beta production. In addition, HIV-specific LAG3(+)CD8(+) T cells do not produce interferon (IFN-gamma) or express CD107a. The frequency of HIV-specific LAG3(+)CD8(+) T cells negative correlated with plasma viral load. Our study introduces a new population of HIV-specific CD8(+) T cells and proposes additional mechanisms of immune regulation in chronic HIV infection.
C1 [Pena, Jose; Jones, Norman G.; Bousheri, Stephanie; Cao, Huyen] Calif Dept Publ Hlth, Richmond, CA USA.
[Bangsberg, David R.] Harvard Univ, Ragon Inst MGH MIT & Harvard, Massachusetts Gen Hosp Ctr Global Hlth, Mbarara Univ Sci & Technol,Med Sch, Boston, MA USA.
RP Pena, J (reprint author), Care Of Huyen Cao, Calif Dept Publ Hlth, VRDL, 850 Marina Bay Pkwy, Richmond, CA 94804 USA.
EM huyen.cao@cdph.dhs.ca.gov
FU NIH [AI43885, MH54907, AI71772, K24 MH87227]
FX This work was supported by NIH grants AI43885, MH54907, AI71772, and K24
MH87227.
NR 43
TC 4
Z9 6
U1 1
U2 2
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0889-2229
EI 1931-8405
J9 AIDS RES HUM RETROV
JI Aids Res. Hum. Retrovir.
PD JUN
PY 2014
VL 30
IS 6
BP 535
EP 541
DI 10.1089/aid.2012.0195
PG 7
WC Immunology; Infectious Diseases; Virology
SC Immunology; Infectious Diseases; Virology
GA AI9CE
UT WOS:000337224400005
PM 24180338
ER
PT J
AU Kang, SK
Huang, WC
Pandharipande, PV
Chandarana, H
AF Kang, Stella K.
Huang, William C.
Pandharipande, Pari V.
Chandarana, Hersh
TI Solid Renal Masses: What the Numbers Tell Us
SO AMERICAN JOURNAL OF ROENTGENOLOGY
LA English
DT Review
DE angiomyolipoma; diffusion-weighted imaging; oncocytoma; renal cell
carcinoma; renal mass
ID SEGMENTAL ENHANCEMENT INVERSION; CELL CARCINOMA SUBTYPES;
FINE-NEEDLE-ASPIRATION; DIFFUSION-WEIGHTED MRI; T2 SIGNAL INTENSITY;
CHEMICAL-SHIFT MRI; MINIMAL FAT; HELICAL CT; TUMOR SIZE; PATHOLOGICAL
FEATURES
AB OBJECTIVE. Solid renal masses are most often incidentally detected at imaging as small (<= 4 cm) localized lesions. These lesions comprise a wide spectrum of benign and malignant histologic subtypes, but are largely treated with surgical resection given the limited ability of imaging to differentiate among them with consistency and high accuracy. Numerous studies have thus examined the ability of CT and MRI techniques to separate benign lesions from malignancies and to predict renal cancer histologic grade and subtype. This article synthesizes the evidence regarding renal mass characterization at CT and MRI, provides diagnostic algorithms for evidence-based practice, and highlights areas of further research needed to drive imaging-based management of renal masses.
CONCLUSION. Despite extensive study of morphologic and quantitative criteria at conventional imaging, no CT or MRI techniques can reliably distinguish solid benign tumors, such as oncocytoma and lipid-poor angiomyolipoma, from malignant renal tumors. Larger studies are required to validate recently developed techniques, such as diffusion-weighted imaging. Evidence-based practice includes MRI to assess renal lesions in situations where CT is limited and to help guide management in patients who are considered borderline surgical candidates.
C1 [Kang, Stella K.; Chandarana, Hersh] NYU, Langone Med Ctr, New York, NY 10016 USA.
[Huang, William C.] NYU, Langone Med Ctr, Dept Urol, New York, NY 10016 USA.
[Pandharipande, Pari V.] Massachusetts Gen Hosp, Inst Technol Assessment, Dept Radiol, Boston, MA 02114 USA.
RP Kang, SK (reprint author), NYU, Langone Med Ctr, 550 First Ave, New York, NY 10016 USA.
EM stella.kang@nyumc.org
RI Kang, Stella/O-7003-2015;
OI Chandarana, Hersh/0000-0002-6807-4589; Kang, Stella/0000-0003-2402-3787;
Huang, William/0000-0001-5261-0650
FU Association of University Radiologists GE Radiology Research Academic
Fellowship; National Cancer Institute [K07CA133097]
FX S. K. Kang is funded in part by the Association of University
Radiologists GE Radiology Research Academic Fellowship. P. V.
Pandharipande has received support from the National Cancer Institute
(award number K07CA133097). The research content is solely the
responsibility of the authors and does not necessarily represent the
official views of the National Cancer Institute or the National
Institutes of Health.
NR 97
TC 12
Z9 12
U1 0
U2 5
PU AMER ROENTGEN RAY SOC
PI RESTON
PA 1891 PRESTON WHITE DR, SUBSCRIPTION FULFILLMENT, RESTON, VA 22091 USA
SN 0361-803X
EI 1546-3141
J9 AM J ROENTGENOL
JI Am. J. Roentgenol.
PD JUN
PY 2014
VL 202
IS 6
BP 1196
EP 1206
DI 10.2214/AJR.14.12502
PG 11
WC Radiology, Nuclear Medicine & Medical Imaging
SC Radiology, Nuclear Medicine & Medical Imaging
GA AI6DB
UT WOS:000336959000026
PM 24848816
ER
PT J
AU Lillemoe, KD
AF Lillemoe, Keith D.
TI Surgical Perspectives: An Introduction
SO ANNALS OF SURGERY
LA English
DT Editorial Material
C1 Massachusetts Gen Hosp, Dept Surg, Boston, MA 02114 USA.
RP Lillemoe, KD (reprint author), Massachusetts Gen Hosp, Dept Surg, 55 Fruit St,WHT 506, Boston, MA 02114 USA.
EM klillemoe@partners.org
NR 0
TC 0
Z9 0
U1 0
U2 0
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-4932
EI 1528-1140
J9 ANN SURG
JI Ann. Surg.
PD JUN
PY 2014
VL 259
IS 6
BP 1037
EP 1037
DI 10.1097/SLA.0000000000000720
PG 1
WC Surgery
SC Surgery
GA AI9WW
UT WOS:000337296700009
PM 24814501
ER
PT J
AU Tsai, TC
Orav, EJ
Joynt, KE
AF Tsai, Thomas C.
Orav, E. John
Joynt, Karen E.
TI Disparities in Surgical 30-Day Readmission Rates for Medicare
Beneficiaries by Race and Site of Care
SO ANNALS OF SURGERY
LA English
DT Article
DE disparity; quality improvement; race; readmission; surgery
ID HIGH-VOLUME HOSPITALS; RACIAL DISPARITIES; QUALITY-IMPROVEMENT;
CONTROLLED-TRIAL; BLACK PATIENTS; HEART-FAILURE; COLON-CANCER; SURGERY;
MORTALITY; REVASCULARIZATION
AB Objective: To determine whether black patients have higher odds of readmission than white patients after major surgery, and to ascertain whether these disparities are related to where black patients receive care.
Background: Racial disparities are known to exist for many aspects of surgical care. However, it is unknown if disparities exist in readmissions after a surgical procedure, an area which is becoming a prime focus for clinical leaders and policymakers.
Methods: Using national Medicare data from 2007 to 2010, we examined 30-day readmissions for patients undergoing coronary artery bypass grafting, pulmonary lobectomy, endovascular abdominal aortic aneurysm repair, open abdominal aortic aneurysm repair, colectomy, and hip replacement. The main outcome measure was risk-adjusted odds of all-cause 30-day readmission. We used multivariate logistic regression to determine if black patients had higher readmission rates than white patients, and if so, whether this effect was mediated by the hospitals at which patients received care, or by poverty.
Results: Black patients had higher readmission rates than white patients (14.8% vs 12.8%, odds ratio [OR] 1.19; 95% confidence interval [CI], 1.16-1.22; P < 0.001). Patients undergoing major surgery at minority-serving hospitals also had higher readmission rates (14.3% vs 12.8%, OR 1.14, 95% CI 1.09-1.19; P < 0.001). In multivariate analyses, black patients at minority-serving hospitals had the highest overall odds of readmissions (OR 1.34). White patients at minority-serving hospitals (OR 1.15) and black patients at non-minority-serving hospitals (OR 1.20) also had higher odds of readmission than the reference group of white patients at non-minority-serving hospitals. Racial disparities were mediated in part by poverty.
Conclusions: Among Medicare beneficiaries, black patients were more likely to be readmitted after hospitalization for surgical procedures. Since racial disparities in readmission rates are mediated both by patients' race and the hospital at which care is delivered, efforts at reducing disparities should focus not only on race-based measures but also on improving outcomes of care at minority-serving hospitals.
C1 [Tsai, Thomas C.; Joynt, Karen E.] Harvard Univ, Sch Publ Hlth, Dept Hlth Policy & Management, Boston, MA 02115 USA.
[Orav, E. John] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA.
[Tsai, Thomas C.] Brigham & Womens Hosp, Dept Surg, Boston, MA 02115 USA.
[Joynt, Karen E.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA.
[Orav, E. John] Brigham & Womens Hosp, Boston, MA 02115 USA.
[Joynt, Karen E.] VA Boston Healthcare Syst, Boston, MA USA.
RP Tsai, TC (reprint author), Harvard Univ, Sch Publ Hlth, 677 Huntington Ave, Boston, MA 02115 USA.
EM ttsai@hsph.harvard.edu
FU National Cancer Institute [R25CA92203]; National Heart, Lung, and Blood
Institute [1K23HL109177-01]; Lerner Research Award from Brigham and
Women's Hospital, Cardiovascular Division
FX T.C.T. was supported by grant R25CA92203 from the National Cancer
Institute. K.E.J. was supported by grant 1K23HL109177-01 from the
National Heart, Lung, and Blood Institute and the Lerner Research Award
from Brigham and Women's Hospital, Cardiovascular Division. No conflicts
of interests are declared.
NR 33
TC 38
Z9 38
U1 2
U2 8
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0003-4932
EI 1528-1140
J9 ANN SURG
JI Ann. Surg.
PD JUN
PY 2014
VL 259
IS 6
BP 1086
EP 1090
DI 10.1097/SLA.0000000000000326
PG 5
WC Surgery
SC Surgery
GA AI9WW
UT WOS:000337296700018
PM 24441810
ER
PT J
AU Ndiaye, MA
Nihal, M
Wood, GS
Ahmad, N
AF Ndiaye, Mary A.
Nihal, Minakshi
Wood, Gary S.
Ahmad, Nihal
TI Skin, Reactive Oxygen Species, and Circadian Clocks
SO ANTIOXIDANTS & REDOX SIGNALING
LA English
DT Review
ID SLEEP-WAKE CYCLES; OXIDATIVE STRESS; VITAMIN-A; DNA-DAMAGE;
SIGNAL-TRANSDUCTION; RETINOIC ACID; EPIDERMAL-KERATINOCYTES;
MELATONINERGIC SYSTEMS; EPITHELIAL-CELLS; BARRIER FUNCTION
AB Significance: Skin, a complex organ and the body's first line of defense against environmental insults, plays a critical role in maintaining homeostasis in an organism. This balance is maintained through a complex network of cellular machinery and signaling events, including those regulating oxidative stress and circadian rhythms. These regulatory mechanisms have developed integral systems to protect skin cells and to signal to the rest of the body in the event of internal and environmental stresses. Recent Advances: Interestingly, several signaling pathways and many bioactive molecules have been found to be involved and even important in the regulation of oxidative stress and circadian rhythms, especially in the skin. It is becoming increasingly evident that these two regulatory systems may, in fact, be interconnected in the regulation of homeostasis. Important examples of molecules that connect the two systems include serotonin, melatonin, vitamin D, and vitamin A. Critical Issues: Excessive reactive oxygen species and/or dysregulation of antioxidant system and circadian rhythms can cause critical errors in maintaining proper barrier function and skin health, as well as overall homeostasis. Unfortunately, the modern lifestyle seems to contribute to increasing alterations in redox balance and circadian rhythms, thereby posing a critical problem for normal functioning of the living system. Future Directions: Since the oxidative stress and circadian rhythm systems seem to have areas of overlap, future research needs to be focused on defining the interactions between these two important systems. This may be especially important in the skin where both systems play critical roles in protecting the whole body.
C1 [Ndiaye, Mary A.; Nihal, Minakshi; Wood, Gary S.; Ahmad, Nihal] Univ Wisconsin, Dept Dermatol, Madison, WI 53706 USA.
[Wood, Gary S.; Ahmad, Nihal] William S Middleton Mem Vet Adm Med Ctr, Madison, WI 53705 USA.
RP Ahmad, N (reprint author), Univ Wisconsin, Dept Dermatol, Med Sci Ctr, Room 423 1300 Univ Ave, Madison, WI 53706 USA.
EM nahmad@wisc.edu
FU NIH [R01AR059130, R01CA176748]; VA Merit Review Award [1I01BX001008]
FX This work was partly supported by funding to N.A. from the NIH
(R01AR059130 and R01CA176748) and VA Merit Review Award (1I01BX001008).
NR 123
TC 5
Z9 6
U1 4
U2 22
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1523-0864
EI 1557-7716
J9 ANTIOXID REDOX SIGN
JI Antioxid. Redox Signal.
PD JUN
PY 2014
VL 20
IS 18
BP 2982
EP 2996
DI 10.1089/ars.2013.5645
PG 15
WC Biochemistry & Molecular Biology; Endocrinology & Metabolism
SC Biochemistry & Molecular Biology; Endocrinology & Metabolism
GA AI8LN
UT WOS:000337167100008
PM 24111846
ER
PT J
AU Zhu, YN
Shah, K
AF Zhu, Yanni
Shah, Khalid
TI Multiple lesions in receptor tyrosine kinase pathway determine
glioblastoma response to pan-ERBB inhibitor PF-00299804 and PI3K/mTOR
dual inhibitor PF-05212384
SO CANCER BIOLOGY & THERAPY
LA English
DT Article
DE EGFR; PI3K; mTOR; glioblastoma (GBM); PF-00299804; dacomitinib;
PF-05212384
ID BECLIN 1 PHOSPHORYLATION; LUNG-CANCER; STEM-CELLS; EGFR; RESISTANCE;
AUTOPHAGY; GENES; CONTRIBUTES; CONCOMITANT; GEFITINIB
AB A novel pan ERBB inhibitor PF-00299804 (dacomitinib) is currently in phase II clinical trials in glioblastoma multiforme (GBM) patients; however its pre-clinical efficacy in GBMs has not been tested. In this study, we evaluated the efficacy of dacomitinib alone or in combination with PI3K/mTOR dual inhibitor PF-05212384 in GBM and assessed the mechanisms of resistance and the molecular determinants of response. A panel of established and patient derived primary GBM lines that present different molecular profiles and also the GBM lines engineered to express EGFRvIII mutant or PTEN were treated with either dacomitinib, PF-05212384, or combination and assessed for their viability and changes in EGFR/PI3K/mTOR signaling. We show that dacomitinib significantly reduced phosphorylated EGFR in all the GBM lines but did not show a dose-dependent response on cell viability in a majority of the lines tested. Multiple lesions in the receptor tyrosine kinases (RTKs) pathway including PTEN mutation, co-activation of RTKs, and EGFRvIII mutation resulted in unaltered active status of PI3K/mTOR in the GBM lines even in the presence of EGFR inhibition. Blocking PI3K/mTOR dramatically inhibited cell proliferation in most GBM lines and enhanced dacomitinib induction of apoptosis in a GBM line that has both EGFR amplification and EGFR-independent PI3K activation. These data suggest molecular profiling of EGFR/PI3K/PTEN status to select GBM patients for EGFR or/and PI3K/mTOR targeted therapies.
C1 [Zhu, Yanni; Shah, Khalid] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mol Neurotherapy & Imaging Lab, Boston, MA 02163 USA.
[Zhu, Yanni; Shah, Khalid] Harvard Univ, Sch Med, Dept Radiol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Shah, Khalid] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Shah, Khalid] Harvard Univ, Harvard Stem Cell Inst, Cambridge, MA 02138 USA.
RP Shah, K (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Mol Neurotherapy & Imaging Lab, Boston, MA 02163 USA.
EM kshah@mgh.harvard.edu
FU Pfizer Inc.; [NIH-R01CA138922]
FX This work was supported by Pfizer Inc. (K. S.) and NIH-R01CA138922
(K.S.).
NR 25
TC 8
Z9 8
U1 0
U2 4
PU LANDES BIOSCIENCE
PI AUSTIN
PA 1806 RIO GRANDE ST, AUSTIN, TX 78702 USA
SN 1538-4047
EI 1555-8576
J9 CANCER BIOL THER
JI Cancer Biol. Ther.
PD JUN
PY 2014
VL 15
IS 6
BP 815
EP 822
DI 10.4161/cbt.28585
PG 8
WC Oncology
SC Oncology
GA AI8MC
UT WOS:000337169500019
PM 24658109
ER
PT J
AU Hata, AN
Yeo, A
Faber, AC
Lifshits, E
Chen, Z
Cheng, KA
Walton, Z
Sarosiek, KA
Letai, A
Heist, RS
Mino-Kenudson, M
Wong, KK
Engelman, JA
AF Hata, Aaron N.
Yeo, Alan
Faber, Anthony C.
Lifshits, Eugene
Chen, Zhao
Cheng, Katherine A.
Walton, Zandra
Sarosiek, Kristopher A.
Letai, Anthony
Heist, Rebecca S.
Mino-Kenudson, Mari
Wong, Kwok-Kin
Engelman, Jeffrey A.
TI Failure to Induce Apoptosis via BCL-2 Family Proteins Underlies Lack of
Efficacy of Combined MEK and PI3K Inhibitors for KRAS-Mutant Lung
Cancers
SO CANCER RESEARCH
LA English
DT Article
ID KINASE INHIBITORS; ACTIVATION; RESISTANCE; GEFITINIB; PROMOTES; PATHWAY;
TUMORS; CELLS; EGFR
AB Although several groups have demonstrated that concomitant use of MEK and phosphoinositide 3-kinase (PI3K) inhibitors (MEKi/PI3Ki) can induce dramatic tumor regressions in mouse models of KRAS-mutant non-small cell lung cancer (NSCLC), ongoing clinical trials investigating this strategy have been underwhelming to date. While efficacy may be hampered by a narrow therapeutic index, the contribution of biologic heterogeneity in the response of KRAS-mutant NSCLCs to MEKi/PI3Ki has been largely unexplored. In this study, we find that most human KRAS-mutant NSCLC cell lines fail to undergo marked apoptosis in response to MEKi/PI3Ki, which is key for tumor responsiveness in vivo. This heterogeneity of apoptotic response occurs despite relatively uniform induction of growth arrest. Using a targeted short hairpin RNA screen of BCL-2 family members, we identify BIM, PUMA, and BCL-XL as key regulators of the apoptotic response induced by MEKi/PI3Ki, with decreased expression of BIM and PUMA relative to BCL-XL in cell lines with intrinsic resistance. In addition, by modeling adaptive resistance to MEKi/PI3Ki both in vitro and in vivo, we find that, upon the development of resistance, tumors have a diminished apoptotic response due to downregulation of BIM and PUMA. These results suggest that the inability to induce apoptosis may limit the effectiveness of MEKi/PI3Ki for KRAS-mutant NSCLCs by contributing to intrinsic and adaptive resistance to this therapy.
C1 [Hata, Aaron N.; Yeo, Alan; Faber, Anthony C.; Lifshits, Eugene; Heist, Rebecca S.; Engelman, Jeffrey A.] Massachusetts Gen Hosp, Ctr Canc, Charlestown, MA 02129 USA.
[Hata, Aaron N.; Chen, Zhao; Heist, Rebecca S.; Wong, Kwok-Kin; Engelman, Jeffrey A.] Harvard Univ, Sch Med, Dept Med, Boston, MA USA.
[Chen, Zhao; Cheng, Katherine A.; Walton, Zandra; Sarosiek, Kristopher A.; Letai, Anthony; Wong, Kwok-Kin] Dana Farber Canc Inst, Dept Med Oncol, Boston, MA 02115 USA.
[Mino-Kenudson, Mari] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Engelman, JA (reprint author), Massachusetts Gen Hosp, Ctr Canc, 149 13th St, Charlestown, MA 02129 USA.
EM jengelman@partners.org
FU NIH [R01CA137008-01, R01CA140594, 1U01CA141457-01, R01CA122794,
R01CA137181, 1RC2CA147940]; NCI Lung [SPORE P50CA090578]; V Foundation
Translational Research Grant; American Cancer Society
[RSG-06-102-01-CCE]; Ellison Foundation Scholar Award; American Lung
Cancer Association Lung Cancer Discover Award; Uniting Against Lung
Cancer Foundation; Susan Spooner Research Fund
FX The study was supported by the following grants: NIH R01CA137008-01
(J.A. Engelman), R01CA140594 (J.A. Engelman/K.-K. Wong), 1U01CA141457-01
(J.A. Engelman), R01CA122794 (K.-K. Wong), R01CA137181 (K.-K. Wong),
1RC2CA147940 (K.-K. Wong), NCI Lung SPORE P50CA090578 (J.A.
Engelman/K.-K. Wong), V Foundation Translational Research Grant (J.A.
Engelman), American Cancer Society RSG-06-102-01-CCE (J.A. Engelman),
Ellison Foundation Scholar Award (J.A. Engelman), American Lung Cancer
Association Lung Cancer Discover Award (J.A. Engelman), Uniting Against
Lung Cancer Foundation (K.-K. Wong), and the Susan Spooner Research Fund
(K.-K. Wong).
NR 39
TC 26
Z9 26
U1 0
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 0008-5472
EI 1538-7445
J9 CANCER RES
JI Cancer Res.
PD JUN 1
PY 2014
VL 74
IS 11
BP 3146
EP 3156
DI 10.1158/0008-5472.CAN-13-3728
PG 11
WC Oncology
SC Oncology
GA AI8ML
UT WOS:000337170600024
PM 24675361
ER
PT J
AU Sumer, H
Kim, K
Liu, J
Ng, K
Daley, GQ
Verma, PJ
AF Sumer, Huseyin
Kim, Kitai
Liu, Jun
Ng, Kitwa
Daley, George Q.
Verma, Paul J.
TI Functional Evaluation of ES-Somatic Cell Hybrids In Vitro and In Vivo
SO CELLULAR REPROGRAMMING
LA English
DT Article
ID EMBRYONIC STEM-CELLS; NUCLEAR TRANSFER; MOUSE; FUSION; PLURIPOTENCY;
GENE; EXPRESSION; GENERATION; MICE
AB Embryonic stem cells (ESCs) have previously been reported to reprogram somatic cells following fusion. The resulting ES-somatic cell hybrids have been shown to adopt the transcriptional profile of ESCs, suggesting that the pluripotent program is dominant. ES-somatic cell hybrids have most characteristics of pluripotent cells in vitro; however, it remains unclear whether the somatic genome is an active partner in the hybrid cells or simply retained predominately as silent cargo. Furthermore, the functional properties of ES-somatic cell hybrids in vivo have been limited to studies on their contribution to teratomas and developing embryos/chimeras. The extent of their pluripotency remains largely unclear. Here we determined that the somatic genome is actively transcribed by generating ES-somatic cell hybrids using Rag2-deficient ESCs fused to autologous wild-type somatic cells. Rag2 expression was detected during in vitro differentiation, suggesting that the somatic genome follows the correct temporal cues during differentiation. Furthermore, ES-somatic cell hybrids maintain their tetraploid state following 4 weeks of differentiation in vivo and are immune tolerated when transferred into matched individuals. The ES-somatic cell hybrids can efficiently differentiate into hematopoietic precursors in both myeloid and lymphoid lineages in vitro, suggesting that the somatic genome is actively transcribed following cell fusion based reprogramming. However, the ES-somatic cell hybrids showed an altered hematopoietic potential following in vitro differentiation and were unable to show hematopoietic engraftment in a mouse model.
C1 [Sumer, Huseyin; Liu, Jun; Verma, Paul J.] Monash Univ, Monash Inst Med Res, Clayton, Vic 3168, Australia.
[Sumer, Huseyin] Swinburne Univ Technol, Dept Chem & Biotechnol, Fac Sci Engn & Technol, Hawthorn, Vic 3122, Australia.
[Kim, Kitai; Ng, Kitwa; Daley, George Q.] Childrens Hosp Boston, Stem Cell Transplantat Program, Div Pediat Hematol Oncol, Manton Ctr Orphan Dis Res,Howard Hughes Med Inst, Boston, MA 02115 USA.
[Kim, Kitai; Ng, Kitwa; Daley, George Q.] Dana Farber Canc Inst, Boston, MA USA.
[Kim, Kitai; Ng, Kitwa; Daley, George Q.] Brigham & Womens Hosp, Div Hematol, Boston, MA USA.
[Kim, Kitai; Ng, Kitwa; Daley, George Q.] Harvard Univ, Dept Biol Chem & Mol Pharmacol, Sch Med, Boston, MA USA.
[Kim, Kitai; Ng, Kitwa; Daley, George Q.] Harvard Stem Cell Inst, Boston, MA 02115 USA.
[Kim, Kitai] Sloan Kettering Inst, Canc Biol & Genet Program, Ctr Cell Engn, Ctr Stem Cell Biol, New York, NY USA.
[Kim, Kitai] Cornell Univ, Weill Med Coll, New York, NY USA.
[Verma, Paul J.] Turretfield Res Ctr, South Australian Res Inst SARDI, Rosedale, SA 5350, Australia.
RP Sumer, H (reprint author), Swinburne Univ Technol, Dept Chem & Biotechnol, Fac Sci Engn & Technol, John St, Melbourne, Vic 3122, Australia.
EM hsumer@swin.edu.au
OI Liu, Jun/0000-0003-4561-1190
FU Australian Stem Cell Centre; NH & MRC Biomedical Training Fellowship;
Dairy Australia; Dairy Futures CRC; MIMR; Victorian Government's
Operational Infrastructure Support Program; National Institutes of
Health (NIH) [K99HL093212-01]; Leukemia & Lymphoma Society (LLS)
[3567-07]; Cooley's Anemia Foundation
FX This project was supported by funding from the Australian Stem Cell
Centre. We would like to thank R. Jaenisch for the kind gift of the Rag2
ntES cells and the pSicoR-Hygro-Tk vector. H.S. was supported by an NH &
MRC Biomedical Training Fellowship and an Establishment Gift from the
Clive and Vera Ramaciotti Foundation. H.S. and P.J.V. acknowledge
funding support from Dairy Australia, funding from the Dairy Futures
CRC, and MIMR infrastructure funding supported by the Victorian
Government's Operational Infrastructure Support Program. K. K. was
supported by the National Institutes of Health (NIH; grant no.
K99HL093212-01), Leukemia & Lymphoma Society (LLS; grant no. 3567-07),
and Cooley's Anemia Foundation. The funders had no role in study design,
data collection and analysis, decision to publish, or preparation of the
manuscript.
NR 31
TC 0
Z9 0
U1 2
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 2152-4971
EI 2152-4998
J9 CELL REPROGRAM
JI Cell. Reprogramm.
PD JUN
PY 2014
VL 16
IS 3
BP 167
EP 174
DI 10.1089/cell.2013.0079
PG 8
WC Cell & Tissue Engineering; Biotechnology & Applied Microbiology;
Genetics & Heredity
SC Cell Biology; Biotechnology & Applied Microbiology; Genetics & Heredity
GA AI9JO
UT WOS:000337249100001
PM 24787484
ER
PT J
AU Wakimoto, H
Tanaka, S
Curry, WT
Loebel, F
Zhao, D
Tateishi, K
Chen, JX
Klofas, LK
Lelic, N
Kim, JC
Dias-Santagata, D
Ellisen, LW
Borger, DR
Fendt, SM
Vander Heiden, MG
Batchelor, TT
Iafrate, AJ
Cahill, DP
Chi, AS
AF Wakimoto, Hiroaki
Tanaka, Shota
Curry, William T.
Loebel, Franziska
Zhao, Dan
Tateishi, Kensuke
Chen, Juxiang
Klofas, Lindsay K.
Lelic, Nina
Kim, James C.
Dias-Santagata, Dora
Ellisen, Leif W.
Borger, Darrell R.
Fendt, Sarah-Maria
Vander Heiden, Matthew G.
Batchelor, Tracy T.
Iafrate, A. John
Cahill, Daniel P.
Chi, Andrew S.
TI Targetable Signaling Pathway Mutations Are Associated with Malignant
Phenotype in IDH-Mutant Gliomas
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID REDUCTIVE GLUTAMINE-METABOLISM; HIGH-GRADE ASTROCYTOMAS; CANCER
STEM-CELLS; BRAIN-TUMORS; GLIOBLASTOMA-MULTIFORME; OLIGODENDROGLIOMA;
EVOLUTION; CLASSIFICATION; CHEMOTHERAPY; INHIBITION
AB Purpose: Isocitrate dehydrogenase (IDH) gene mutations occur in low-grade and high-grade gliomas. We sought to identify the genetic basis of malignant phenotype heterogeneity in IDH-mutant gliomas.
Methods: We prospectively implanted tumor specimens from 20 consecutive IDH1-mutant glioma resections into mouse brains and genotyped all resection specimens using a CLIA-certified molecular panel. Gliomas with cancer driver mutations were tested for sensitivity to targeted inhibitors in vitro. Associations between genomic alterations and outcomes were analyzed in patients.
Results: By 10 months, 8 of 20 IDH1-mutant gliomas developed intracerebral xenografts. All xenografts maintained mutant IDH1 and high levels of 2-hydroxyglutarate on serial transplantation. All xenograft-producing gliomas harbored "lineage-defining" mutations in CIC (oligodendroglioma) or TP53 (astrocytoma), and 6 of 8 additionally had activating mutations in PIK3CA or amplification of PDGFRA, MET, or N-MYC. Only IDH1 and CIC/TP53 mutations were detected in non-xenograft-forming gliomas (P = 0.0007). Targeted inhibition of the additional alterations decreased proliferation in vitro. Moreover, we detected alterations in known cancer driver genes in 13.4% of IDH-mutant glioma patients, including PIK3CA, KRAS, AKT, or PTEN mutation or PDGFRA, MET, or N-MYC amplification. IDH/CIC mutant tumors were associated with PIK3CA/KRAS mutations whereas IDH/TP53 tumors correlated with PDGFRA/MET amplification. Presence of driver alterations at progression was associated with shorter subsequent progression-free survival (median 9.0 vs. 36.1 months; P = 0.0011).
Conclusion: A subset of IDH-mutant gliomas with mutations in driver oncogenes has a more malignant phenotype in patients. Identification of these alterations may provide an opportunity for use of targeted therapies in these patients. (C) 2014 AACR.
C1 [Wakimoto, Hiroaki; Curry, William T.; Loebel, Franziska; Tateishi, Kensuke; Lelic, Nina; Cahill, Daniel P.] MIT, Stephen E & Catherine Pappas Ctr Neurooncol, Dept Neurosurg, Cambridge, MA 02139 USA.
[Tanaka, Shota; Zhao, Dan; Klofas, Lindsay K.; Batchelor, Tracy T.; Chi, Andrew S.] MIT, Stephen E & Catherine Pappas Ctr Neurooncol, Dept Neurol, Div Hematol Oncol, Cambridge, MA 02139 USA.
[Chen, Juxiang; Dias-Santagata, Dora; Ellisen, Leif W.; Borger, Darrell R.; Iafrate, A. John] MIT, Translat Res Lab, Cambridge, MA 02139 USA.
[Kim, James C.; Iafrate, A. John] MIT, Dept Pathol, Cambridge, MA 02139 USA.
[Vander Heiden, Matthew G.] MIT, Koch Inst Integrat Canc Res, Cambridge, MA 02139 USA.
[Wakimoto, Hiroaki; Tanaka, Shota; Loebel, Franziska; Zhao, Dan; Tateishi, Kensuke; Chen, Juxiang; Klofas, Lindsay K.; Lelic, Nina; Batchelor, Tracy T.; Cahill, Daniel P.; Chi, Andrew S.] Harvard Univ, Sch Med, Translat Neurooncol Lab, Boston, MA 02114 USA.
[Wakimoto, Hiroaki; Tanaka, Shota; Curry, William T.; Loebel, Franziska; Zhao, Dan; Tateishi, Kensuke; Chen, Juxiang; Klofas, Lindsay K.; Lelic, Nina; Kim, James C.; Dias-Santagata, Dora; Ellisen, Leif W.; Borger, Darrell R.; Batchelor, Tracy T.; Iafrate, A. John; Cahill, Daniel P.; Chi, Andrew S.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Ctr Canc, Boston, MA 02114 USA.
[Fendt, Sarah-Maria] VIB, Vesalius Res Ctr, Leuven, Belgium.
[Fendt, Sarah-Maria] Katholieke Univ Leuven, Dept Oncol, Leuven, Belgium.
RP Chi, AS (reprint author), Massachusetts Gen Hosp, Ctr Canc, 55 Fruit St,Yawkey 9E, Boston, MA 02114 USA.
EM cahill@mgh.harvard.edu; chi.andrew@mgh.harvard.edu
OI Cahill, Daniel/0000-0003-2552-6546; Fendt,
Sarah-Maria/0000-0001-6018-9296
FU American Cancer Society Institutional Research Grant; Richard B. Simches
Scholars Award; Burroughs-Wellcome Career Award; Koch Institute Dana
Farber/Harvard Cancer Center Bridge Project
FX This work was supported by the American Cancer Society Institutional
Research Grant and Richard B. Simches Scholars Award (A.S. Chi),
Burroughs-Wellcome Career Award (D.P. Cahill), and The Koch Institute
Dana Farber/Harvard Cancer Center Bridge Project (H. Wakimoto, A.S. Chi,
D.P. Cahill and M. G. Vander Heiden).
NR 50
TC 31
Z9 31
U1 1
U2 8
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUN 1
PY 2014
VL 20
IS 11
BP 2898
EP 2909
DI 10.1158/1078-0432.CCR-13-3052
PG 12
WC Oncology
SC Oncology
GA AI8IS
UT WOS:000337157000010
PM 24714777
ER
PT J
AU Psyrri, A
Lee, JW
Pectasides, E
Vassilakopoulou, M
Kosmidis, EK
Burtness, BA
Rimm, DL
Wanebo, HJ
Forastiere, AA
AF Psyrri, Amanda
Lee, Ju-Whei
Pectasides, Eirini
Vassilakopoulou, Maria
Kosmidis, Efstratios K.
Burtness, Barbara A.
Rimm, David L.
Wanebo, Harold J.
Forastiere, Arlene A.
TI Prognostic Biomarkers in Phase II Trial of Cetuximab-Containing
Induction and Chemoradiation in Resectable HNSCC: Eastern Cooperative
Oncology Group E2303
SO CLINICAL CANCER RESEARCH
LA English
DT Article
ID GROWTH-FACTOR RECEPTOR; SQUAMOUS-CELL CARCINOMA; NECK-CANCER;
SUBCELLULAR-LOCALIZATION; SIGNAL TRANSDUCER; PLUS CETUXIMAB; KINASE
PATHWAY; ADVANCED HEAD; RESISTANCE; EGFR
AB Purpose: We sought to evaluate the correlation between tissue biomarker expression (using standardized, quantitative immunofluorescence) and clinical outcome in the E2303 trial.
Experimental Design: Sixty-three eligible patients with operable stage III/IV head and neck squamous cell cancer (HNSCC) participated in the Eastern Cooperative Oncology Group (ECOG) 2303 phase II trial of induction chemotherapy with weekly cetuximab, paclitaxel, and carboplatin followed by chemoradiation with the same regimen. A tissue microarray (TMA) was constructed and EGF receptor (EGFR), ERK1/2, Met, Akt, STAT3, beta-catenin, E-cadherin, EGFR Variant III, insulin-like growth factor-1 receptor, NF-kappa B, p53, PI3Kp85, PI3Kp110a, PTEN, NRAS, and pRb protein expression levels were assessed using automated quantitative protein analysis (AQUA). For each dichotomized biomarker, overall survival (OS), progression- free survival (PFS), and event-free survival (EFS) were estimated by the Kaplan-Meier method and compared using log-rank tests. Multivariable Cox proportional hazards models were used to estimate HRs and test for significance.
Results: Forty-two of 63 patients with TMAdata on at least one biomarker were included in the biomarker analysis. Tumor extracellular signal-regulated kinase (ERK) 1/2 levels were significantly associated with PFS [HR (low/high), 3.29; P = 0.026] and OS[HR (low/high), 4.34; P = 0.008]. On multivariable Cox regression analysis, ERK1/2 remained significantly associated with OS (P = 0.024) and PFS (P = 0.022) after controlling for primary site (oropharynx vs. non-oropharynx) and disease stage (III vs. IV), respectively. Clustering analysis revealed that clusters indicative of activated RAS/MAPK/ERK and/or PI3K/Akt pathways were associated with inferior OS and/or PFS and maintained significance in multivariable analysis.
Conclusions: These results implicate PI3K/Akt and RAS/MAPK/ERK pathways in resistance to cetuximab-containing chemoradiation in HNSCC. Large prospective studies are required to validate these results. (C) 2014 AACR.
C1 [Psyrri, Amanda; Pectasides, Eirini; Vassilakopoulou, Maria; Rimm, David L.] Yale Univ, Sch Med, New Haven, CT 06520 USA.
[Lee, Ju-Whei] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Burtness, Barbara A.] Fox Chase Canc Ctr, Philadelphia, PA 19111 USA.
[Wanebo, Harold J.] Landmark Med Ctr, Woonsocket, RI USA.
[Forastiere, Arlene A.] Johns Hopkins Univ, Baltimore, MD USA.
[Kosmidis, Efstratios K.] Aristotle Univ Thessaloniki, GR-54006 Thessaloniki, Greece.
RP Psyrri, A (reprint author), Yale Univ, Sch Med, New Haven, CT 06520 USA.
FU Public Health Service [CA23318, CA66636, CA21115, CA27525, CA16116];
National Cancer Institute; NIH; Department of Health and Human Services
FX This study was coordinated by the Eastern Cooperative Oncology Group
(Robert L. Comis, M. D., Chair) and supported in part by Public Health
Service Grants CA23318, CA66636, CA21115, CA27525, and CA16116 and from
the National Cancer Institute, NIH, and the Department of Health and
Human Services.
NR 36
TC 10
Z9 10
U1 1
U2 6
PU AMER ASSOC CANCER RESEARCH
PI PHILADELPHIA
PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA
SN 1078-0432
EI 1557-3265
J9 CLIN CANCER RES
JI Clin. Cancer Res.
PD JUN 1
PY 2014
VL 20
IS 11
BP 3023
EP 3032
DI 10.1158/1078-0432.CCR-14-0113
PG 10
WC Oncology
SC Oncology
GA AI8IS
UT WOS:000337157000021
PM 24700741
ER
PT J
AU Cilio, MR
Thiele, EA
Devinsky, O
AF Cilio, Maria Roberta
Thiele, Elizabeth A.
Devinsky, Orrin
TI The case for assessing cannabidiol in epilepsy
SO EPILEPSIA
LA English
DT Article
DE Epilepsy; Childhood; Cannabidiol
ID PHARMACORESISTANT EPILEPSY; DELTA(9)-TETRAHYDROCANNABINOL; CANNABINOIDS;
PHARMACOLOGY; PSYCHOSIS; SEIZURES; CHILDREN; DRUG; AGE
AB Intractable epilepsies have an extraordinary impact on cognitive and behavioral function and quality of life, and the treatment of seizures represents a challenge and a unique opportunity. Over the past few years, considerable attention has focused on cannabidiol (CBD), the major nonpsychotropic compound of Cannabis sativa. Basic research studies have provided strong evidence for safety and anticonvulsant properties of CBD. However, the lack of pure, pharmacologically active compounds and legal restrictions have prevented clinical research and confined data on efficacy and safety to anecdotal reports. Pure CBD appears to be an ideal candidate among phytocannabinoids as a therapy for treatment-resistant epilepsy. A first step in this direction is to systematically investigate the safety, pharmacokinetics, and interactions of CBD with other antiepileptic drugs and obtain an initial signal regarding efficacy at different dosages. These data can then be used to plan double-blinded placebo-controlled efficacy trials.
C1 [Cilio, Maria Roberta] Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
[Cilio, Maria Roberta] Univ Calif San Francisco, Dept Pediat, San Francisco, CA USA.
[Thiele, Elizabeth A.] Harvard Univ, Sch Med, Dept Neurol, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Thiele, Elizabeth A.] Harvard Univ, Sch Med, Dept Pediat, Massachusetts Gen Hosp, Boston, MA 02115 USA.
[Devinsky, Orrin] NYU Langone Sch Med, Dept Neurol, New York, NY USA.
RP Cilio, MR (reprint author), Univ Calif San Francisco, Dept Neurol, San Francisco, CA 94143 USA.
EM maria.cilio@ucsf.edu
OI Devinsky, Orrin/0000-0003-0044-4632
FU Epilepsy Therapy Project/Epilepsy Foundation Seal Award
FX The authors received an Epilepsy Therapy Project/Epilepsy Foundation
Seal Award to support a cannabidiol study.
NR 28
TC 23
Z9 23
U1 1
U2 38
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
EI 1528-1167
J9 EPILEPSIA
JI Epilepsia
PD JUN
PY 2014
VL 55
IS 6
BP 787
EP 790
DI 10.1111/epi.12635
PG 4
WC Clinical Neurology
SC Neurosciences & Neurology
GA AJ4DE
UT WOS:000337620200006
PM 24854434
ER
PT J
AU Devinsky, O
Cilio, MR
Cross, H
Fernandez-Ruiz, J
French, J
Hill, C
Katz, R
Di Marzo, V
Jutras-Aswad, D
Notcutt, WG
Martinez-Orgado, J
Robson, PJ
Rohrback, BG
Thiele, E
Whalley, B
Friedman, D
AF Devinsky, Orrin
Cilio, Maria Roberta
Cross, Helen
Fernandez-Ruiz, Javier
French, Jacqueline
Hill, Charlotte
Katz, Russell
Di Marzo, Vincenzo
Jutras-Aswad, Didier
Notcutt, William George
Martinez-Orgado, Jose
Robson, Philip J.
Rohrback, Brian G.
Thiele, Elizabeth
Whalley, Benjamin
Friedman, Daniel
TI Cannabidiol: Pharmacology and potential therapeutic role in epilepsy and
other neuropsychiatric disorders
SO EPILEPSIA
LA English
DT Review
DE Cannabidiol; Cannabis; Tetrahydroacannabinol; Dravet syndrome; GPR55;
Medical marijuana
ID IN-VITRO; ANTICONVULSANT ACTION; HYPOXIA-ISCHEMIA; BRAIN-DAMAGE; NEWBORN
PIGS; RATS; CANNABINOIDS; SEIZURES; SYMPTOMS; MODEL
AB To present a summary of current scientific evidence about the cannabinoid, cannabidiol (CBD) with regard to its relevance to epilepsy and other selected neuropsychiatric disorders. We summarize the presentations from a conference in which invited participants reviewed relevant aspects of the physiology, mechanisms of action, pharmacology, and data from studies with animal models and human subjects. Cannabis has been used to treat disease since ancient times. 9-Tetrahydrocannabinol (9-THC) is the major psychoactive ingredient and CBD is the major nonpsychoactive ingredient in cannabis. Cannabis and 9-THC are anticonvulsant in most animal models but can be proconvulsant in some healthy animals. The psychotropic effects of 9-THC limit tolerability. CBD is anticonvulsant in many acute animal models, but there are limited data in chronic models. The antiepileptic mechanisms of CBD are not known, but may include effects on the equilibrative nucleoside transporter; the orphan G-protein-coupled receptor GPR55; the transient receptor potential of vanilloid type-1 channel; the 5-HT1a receptor; and the 3 and 1 glycine receptors. CBD has neuroprotective and antiinflammatory effects, and it appears to be well tolerated in humans, but small and methodologically limited studies of CBD in human epilepsy have been inconclusive. More recent anecdotal reports of high-ratio CBD:9-THC medical marijuana have claimed efficacy, but studies were not controlled. CBD bears investigation in epilepsy and other neuropsychiatric disorders, including anxiety, schizophrenia, addiction, and neonatal hypoxic-ischemic encephalopathy. However, we lack data from well-powered double-blind randomized, controlled studies on the efficacy of pure CBD for any disorder. Initial dose-tolerability and double-blind randomized, controlled studies focusing on target intractable epilepsy populations such as patients with Dravet and Lennox-Gastaut syndromes are being planned. Trials in other treatment-resistant epilepsies may also be warranted.
C1 [Devinsky, Orrin; Friedman, Daniel] NYU, Sch Med, Comprehens Epilepsy Ctr, Dept Neurol, New York, NY 10016 USA.
[Cilio, Maria Roberta] Univ Calif San Francisco, Dept Neurol, Pediat Epilepsy Ctr, San Francisco, CA USA.
[Cross, Helen] Children NHS Fdn Trust, Great Ormond St Hosp, London, England.
[Fernandez-Ruiz, Javier] Univ Complutense Madrid, Fac Med, Dept Biochem & Mol Biol, Ctr Networked Biomed Res Neurodegenerat Dis, Madrid, Spain.
[Fernandez-Ruiz, Javier] Ramon & Cajal Inst Hlth Res, Madrid, Spain.
[Hill, Charlotte; Whalley, Benjamin] Univ Reading, Reading Sch Pharm, Reading, Berks, England.
[Di Marzo, Vincenzo] Natl Res Council Italy, ERG, Inst Biomol Chem, Naples, Italy.
[Jutras-Aswad, Didier] Univ Montreal, Ctr Hlth, Res Ctr, Montreal, PQ, Canada.
[Jutras-Aswad, Didier] Univ Montreal, Dept Psychiat, Montreal, PQ H3C 3J7, Canada.
[Notcutt, William George] James Paget Univ Hosp, Great Yarmouth, Norfolk, England.
[Notcutt, William George] Univ E Anglia, Norwich NR4 7TJ, Norfolk, England.
[Martinez-Orgado, Jose] Univ Hosp Puerta de Hierro, Dept Pediat, Madrid, Spain.
[Robson, Philip J.] GW Res Ltd, Salisbury, Wilts, England.
[Rohrback, Brian G.] Infometrix Inc, Bothell, WA USA.
[Thiele, Elizabeth] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
RP Devinsky, O (reprint author), NYU, Sch Med, Comprehens Epilepsy Ctr, 223 East 34th St, New York, NY 10016 USA.
EM od4@nyu.edu
OI Devinsky, Orrin/0000-0003-0044-4632; French,
Jacqueline/0000-0003-2242-8027; Di Marzo, Vincenzo/0000-0002-1490-3070
FU GW Pharmaceuticals; Epilepsy Therapy Project for human trials of CBD;
UCB; Eisai; Action Medical Research; Epilepsy Research UK; Great Ormond
Street Hospital Children's Charity; Bristol-Myers Squibb; Mylan; Pfizer;
Reckitt Benckiser Pharmaceuticals; Merck; CHUM Department of Psychiatry;
Universite de Montreal Department of Psychiatry; CHUM Research Center;
National Institutes of Health (National Center for the Advancement of
Translational Science) [UL1 TR000038]
FX The content of this review was adapted from a conference entitled
"Cannabidiols: Potential use in epilepsy and other neurological
disorders" held at the NYU Langone School of Medicine on October 4,
2013. This conference, whose content was reviewed by an independent
advisory board for potential conflicts of interest as per the policies
of the NYU Postgraduate Medical School, was sponsored by an unrestricted
medical education grant from GW Pharmaceuticals. The selection of
speakers and contributors was made by the conference chair (O.D.). GW
Pharmaceuticals has a commercial interest in developing cannabidiols for
the treatment of epilepsy and other conditions, some of which are
detailed in this article. In addition:; O.D. has received an
unrestricted medical education grant from GW Pharmaceuticals and funding
from the Epilepsy Therapy Project for human trials of CBD. Dr Devinsky
is involved in assessing the safety and tolerability, and is involved in
planning randomized controlled trials of CBD supplied by GW
Pharmaceuticals in patients with epilepsy.; M.R.C. has received funding
from Epilepsy Therapy Project for human trials of CBD.; J.H.C. J. Helen
Cross holds an endowed Chair through University College, London. She has
sat on Advisory Panels for Eisai and Viropharma for which remuneration
has been paid to her department. She has received money to the
Department as an educational grant from UCB and Eisai for a Clinical
Training Fellowship in Epilepsy. She currently holds grants for research
as from Action Medical Research, Epilepsy Research UK, and the Great
Ormond Street Hospital Children's Charity. She worked as Clinical
Advisor to the update of the National Institute of Health and Care
Excellence guidelines on the diagnosis and management of epilepsy
(20092012) and is currently Clinical Advisor to the Children's Epilepsy
Surgery Service (England & Wales) for which remuneration is made to her
department. J. F-R. receives funds for research from GW Pharmaceuticals.
J. F. has no relevant disclosures. C. H. has no relevant disclosures. R.
K. has no relevant disclosures. V. D. is a consultant for GW
Pharmaceuticals and receives research funds from GW Pharmaceuticals.
D.J-A. has received research/education grant support from Bristol-Myers
Squibb, Mylan, Pfizer, and Reckitt Benckiser Pharmaceuticals;
presentation honoraria from Janssen-Ortho; consultation fees from Merck;
as well as grant support from the CHUM Department of Psychiatry,
Universite de Montreal Department of Psychiatry, and the CHUM Research
Center. W.G.N. Research supported by grants from GW Pharmaceuticals as
well as fees from consultancies to GW Pharmaceuticals. J.M-O. receives
research support from GW Pharmaceuticals. P. J. R. is a part-time
employee with GW Research Ltd as Medical Director of its Cannabinoid
Research Institute, and holds stock in the company. B. G. R. serves as
the president of Infometrix, a company under contract by GW
Pharmaceuticals to produce a quality assurance system in the manufacture
of Sativex/Nabiximols. E. T. agreement with GW Pharmaceuticals to supply
CBD to patients in an investigator initiated study. B. J. W. received
research support from GW Pharmaceuticals. He is named as an inventor on
patents that have arisen from this research, although he has waived any
rights to financial or other material benefits that may come from these
patents in the future. He has also acted as a consultant for GW
Pharmaceuticals, but has received no financial payment for this activity
and hold no shares in the company. D. F. receives grant funding from the
National Institutes of Health (UL1 TR000038 from the National Center for
the Advancement of Translational Science). We confirm that we have read
the Journal's position on issues involved in ethical publication and
affirm that this report is consistent with those guidelines.
NR 75
TC 110
Z9 111
U1 23
U2 170
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
EI 1528-1167
J9 EPILEPSIA
JI Epilepsia
PD JUN
PY 2014
VL 55
IS 6
BP 791
EP 802
DI 10.1111/epi.12631
PG 12
WC Clinical Neurology
SC Neurosciences & Neurology
GA AJ4DE
UT WOS:000337620200007
PM 24854329
ER
PT J
AU Puskarjov, M
Kahle, KT
Ruusuvuori, E
Kaila, K
AF Puskarjov, Martin
Kahle, Kristopher T.
Ruusuvuori, Eva
Kaila, Kai
TI Pharmacotherapeutic targeting of cation-chloride cotransporters in
neonatal seizures
SO EPILEPSIA
LA English
DT Review
DE KCC2; NKCC1; Cation-chloride cotransporters; Neonate; Bumetanide
ID K-CL COTRANSPORTER; CORTICOTROPIN-RELEASING HORMONE; CRITICALLY ILL
INFANTS; PITUITARY-ADRENAL AXIS; NA+-K+-2CL(-) COTRANSPORTER;
HYPOXIA-ISCHEMIA; PROTEIN-BINDING; NA-K-2CL COTRANSPORTER; GABAERGIC
EXCITATION; GABA(A) RECEPTORS
AB Seizures are a common manifestation of acute neurologic insults in neonates and are often resistant to the standard antiepileptic drugs that are efficacious in children and adults. The paucity of evidence-based treatment guidelines, coupled with a rudimentary understanding of disease pathogenesis, has made the current treatment of neonatal seizures empiric and often ineffective, highlighting the need for novel therapies. Key developmental differences in -aminobutyric acid (GABA)ergic neurotransmission between the immature and mature brain, and trauma-induced alterations in the function of the cation-chloride cotransporters (CCCs) NKCC1 and KCC2, probably contribute to the poor efficacy of standard antiepileptic drugs used in the treatment of neonatal seizures. Although CCCs are attractive drug targets, bumetanide and other existing CCC inhibitors are suboptimal because of pharmacokinetic constraints and lack of target specificity. Newer approaches including isoform-specific NKCC1 inhibitors with increased central nervous system penetration, and direct and indirect strategies to enhance KCC2-mediated neuronal chloride extrusion, might allow therapeutic modulation of the GABAergic system for neonatal seizure treatment.
C1 [Puskarjov, Martin; Ruusuvuori, Eva; Kaila, Kai] Univ Helsinki, Dept Biosci, FIN-00014 Helsinki, Finland.
[Puskarjov, Martin; Ruusuvuori, Eva; Kaila, Kai] Univ Helsinki, Neurosci Ctr, FIN-00014 Helsinki, Finland.
[Kahle, Kristopher T.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Neurosurg, Boston, MA USA.
RP Kaila, K (reprint author), Univ Helsinki, Dept Biosci, POB 65 Viikinkaari 1, FIN-00014 Helsinki, Finland.
EM kai.kaila@helsinki.fi
RI Kaila, Kai/R-8528-2016
OI Kaila, Kai/0000-0003-0668-5955
FU Letten Foundation; Academy of Finland; Sigrid Juselius Foundation; Jane
and Aatos Erkko Foundation; National Institutes of Health; Manton Center
for Orphan Disease Research
FX We thank Prof. Wolfgang Loscher, Drs. Tarek Z. Deeb, Jamie Maguire, and
Patricia Seja for comments on an early version of the manuscript. The
authors' original research work was supported by grants from the Letten
Foundation, the Academy of Finland, the Sigrid Juselius Foundation, the
Jane and Aatos Erkko Foundation (K. Kaila), the National Institutes of
Health, and the Manton Center for Orphan Disease Research (K. Kahle).
NR 114
TC 29
Z9 29
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
EI 1528-1167
J9 EPILEPSIA
JI Epilepsia
PD JUN
PY 2014
VL 55
IS 6
BP 806
EP 818
DI 10.1111/epi.12620
PG 13
WC Clinical Neurology
SC Neurosciences & Neurology
GA AJ4DE
UT WOS:000337620200009
PM 24802699
ER
PT J
AU Barron, DS
Tandon, N
Lancaster, JL
Fox, PT
AF Barron, Daniel S.
Tandon, Nitin
Lancaster, Jack L.
Fox, Peter T.
TI Thalamic structural connectivity in medial temporal lobe epilepsy
SO EPILEPSIA
LA English
DT Article
DE Hippocampal sclerosis; Magnetic resonance imaging; Diffusion-weighted
imaging; Thalamic connectivity
ID DEEP BRAIN-STIMULATION; SEGMENTATION; PULVINAR; SEIZURES; NUCLEUS
AB The thalamus has been implicated in various stages of medial temporal lobe epilepsy (MTLE) seizure evolution. The relative density and functional significance (in epileptogenesis) of thalamic projections to MTL subregions, however, remains to be determined. This study used structural and diffusion magnetic resonance imaging (MRI) to evaluate thalamic connection density with distinct MTL subregions in terms of location and volume. Nineteen MTLE patients with unilateral hippocampal sclerosis (HS; 12 right; 10 female) were compared to 19 age-matched controls. Five regions of interest (ROIs) per hemisphere were created in native space: thalamus, amygdala, entorhinal cortex, hippocampus, and parahippocampus. Separate probabilistic tractography analyses were performed between the thalamus and each ipsilateral MTL subregion (four per hemisphere). Individual connectivity profiles and regional volumes were assessed. The medial pulvinar consistently showed the highest connection density with the hippocampus in healthy controls and in MTLE patients. Decreased thalamic connected volume was observed for thalamohippocampal pathways in patients with MTLE, and indicates pathway-specific deafferentation. Regional hippocampal and thalamic atrophy was also observed, indicating gray and white matter loss in the thalamohippocampal pathway. Consistent localization of dense medial pulvinar (PuM) connectivity with the hippocampus suggests chronic PuM stimulation could modulate the MTLE seizure network. Decreased thalamic connected volume is a promising biomarker for epileptogenesis that merits longitudinal validation.
C1 [Barron, Daniel S.; Lancaster, Jack L.; Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Res Imaging Inst, San Antonio, TX 78229 USA.
[Barron, Daniel S.] Yale Univ, Sch Med, New Haven, CT 06510 USA.
[Tandon, Nitin] Univ Texas Hlth Sci Ctr Houston, Dept Neurosurg, Houston, TX 77030 USA.
[Lancaster, Jack L.; Fox, Peter T.] Univ Texas Hlth Sci Ctr Houston, Dept Radiol, Houston, TX 77030 USA.
[Fox, Peter T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA.
[Fox, Peter T.] Univ Hong Kong, State Key Lab Brain & Cognit Sci, Hong Kong, Peoples R China.
[Fox, Peter T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Neurol, San Antonio, TX 78229 USA.
RP Barron, DS (reprint author), Yale Univ, Sch Med, 367 Cedar St, New Haven, CT 06510 USA.
EM daniel.s.barron@yale.edu
RI Fox, Peter/B-4725-2010
OI Fox, Peter/0000-0002-0465-2028
FU [1F31 NS083160-01]; [RO1 MH074457]
FX The authors thank Jose E. Cavazos (UTHSC-SA, edits), Kristin S. Budde
(UTHSC-SA, edits), Vatche G. Baboyan (UTHSC-H, data transfer), and the
patients who participated in this study. The authors also thank the
anonymous reviewers for their time and helpful directives. This study
was funded by 1F31 NS083160-01 (D.S.B.) and RO1 MH074457 (P.T.F.).
NR 16
TC 14
Z9 15
U1 0
U2 8
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0013-9580
EI 1528-1167
J9 EPILEPSIA
JI Epilepsia
PD JUN
PY 2014
VL 55
IS 6
BP e50
EP e55
DI 10.1111/epi.12637
PG 6
WC Clinical Neurology
SC Neurosciences & Neurology
GA AJ4DE
UT WOS:000337620200001
PM 24802969
ER
PT J
AU Lee, KM
Stott, RT
Zhao, GP
SooHoo, J
Xiong, W
Lian, MM
Fitzgerald, L
Shi, S
Akrawi, E
Lei, J
Deng, SP
Yeh, H
Markmann, JF
Kim, JI
AF Lee, Kang Mi
Stott, Ryan T.
Zhao, Gaoping
SooHoo, Julie
Xiong, Wei
Lian, Moh Moh
Fitzgerald, Lindsey
Shi, Shuai
Akrawi, Elsie
Lei, Ji
Deng, Shaoping
Yeh, Heidi
Markmann, James F.
Kim, James I.
TI TGF-beta-producing regulatory B cells induce regulatory T cells and
promote transplantation tolerance
SO EUROPEAN JOURNAL OF IMMUNOLOGY
LA English
DT Article
DE Breg cells; TGF-beta; Transplant; Treg cells; Tolerance
ID GROWTH-FACTOR-BETA; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; ALLERGIC
AIRWAY DISEASE; IMMUNE-RESPONSES; MURINE MODEL; MICE; IL-10;
LIPOPOLYSACCHARIDE; LYMPHOCYTES; EXPRESSION
AB Regulatory B (Breg) cells have been shown to play a critical role in immune homeostasis and in autoimmunity models. We have recently demonstrated that combined anti-T cell immunoglobulin domain and mucin domain-1 and anti-CD45RB antibody treatment results in tolerance to full MHC-mismatched islet allografts in mice by generating Breg cells that are necessary for tolerance. Breg cells are antigen-specific and are capable of transferring tolerance to untreated, transplanted animals. Here, we demonstrate that adoptively transferred Breg cells require the presence of regulatory T (Treg) cells to establish tolerance, and that adoptive transfer of Breg cells increases the number of Treg cells. Interaction with Breg cells in vivo induces significantly more Foxp3 expression in CD4+CD25- T cells than with naive B cells. We also show that Breg cells express the TGF beta- associated latency-associated peptide and that Breg-cell mediated graft prolongation post-adoptive transfer is abrogated by neutralization of TGF-beta activity. Breg cells, like Treg cells, demonstrate preferential expression of both C-C chemokine receptor 6 and CXCR3. Collectively, these findings suggest that in this model of antibody-induced transplantation tolerance, Breg cells promote graft survival by promoting Treg-cell development, possibly via TGF-beta production.
C1 [Lee, Kang Mi; Stott, Ryan T.; Zhao, Gaoping; SooHoo, Julie; Xiong, Wei; Lian, Moh Moh; Fitzgerald, Lindsey; Shi, Shuai; Akrawi, Elsie; Lei, Ji; Deng, Shaoping; Yeh, Heidi; Markmann, James F.; Kim, James I.] Harvard Univ, Massachusetts Gen Hosp, Dept Surg, Transplantat Unit,Sch Med, Boston, MA 02114 USA.
[Zhao, Gaoping; Xiong, Wei; Deng, Shaoping] Sichuan Prov Peoples Hosp, Dept Surg, Chengdu, Sichuan Provinc, Peoples R China.
[Zhao, Gaoping; Xiong, Wei; Deng, Shaoping] Sichuan Acad Med Sci, Chengdu, Sichuan Provinc, Peoples R China.
RP Markmann, JF (reprint author), Harvard Univ, Massachusetts Gen Hosp, Dept Surg, Transplantat Unit,Sch Med, 55 Fruit St 5 White, Boston, MA 02114 USA.
EM jmarkmann@partners.org
FU NIH [RO1AI057851-05, K08-DK094965, 5T32AI7529]
FX This work was supported in part by NIH grant RO1AI057851-05 (JFM),
K08-DK094965 (HY), and 5T32AI7529 (KML). We thank Alicia Johnson, PhD,
for statistical analysis. We thank the MGH Flow Cytometry Core for cell
sorting.
NR 36
TC 42
Z9 48
U1 0
U2 10
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 0014-2980
EI 1521-4141
J9 EUR J IMMUNOL
JI Eur. J. Immunol.
PD JUN
PY 2014
VL 44
IS 6
BP 1728
EP 1736
DI 10.1002/eji.201344062
PG 9
WC Immunology
SC Immunology
GA AJ2YL
UT WOS:000337531200017
PM 24700192
ER
PT J
AU Wang, T
Peng, YB
Shen, NC
Yu, Y
Yao, M
Zhu, JY
AF Wang, Ti
Peng, Yinbo
Shen, Nianci
Yu, Yan
Yao, Min
Zhu, Jingyin
TI Photochemical activation increases the porcine corneal stiffness and
resistance to collagenase digestion
SO EXPERIMENTAL EYE RESEARCH
LA English
DT Article
DE photochemical activation; corneal cross-linking; Rose Bengal; tensile
strength; collagenase
ID HYPOOSMOLAR RIBOFLAVIN SOLUTION; TREATMENT IN-VITRO; CROSS-LINKING;
ULTRAVIOLET-A; BIOMECHANICAL CHANGES; ROSE-BENGAL; KERATOCONUS; LIGHT;
SKIN; INCISIONS
AB In this study, we explore the effect of photochemical activation induced corneal cross-linking, utilizing Rose Bengal (RB) and 532 nm green light irradiation (RB-PCL), on porcine corneal biomechanical rigidity and the biochemical resistance against collagenase digestion. A protocol with a wavelength of 532 nm and illumination intensity of 0.4W/cm(2) for 250 s to deliver a dose of 100 J/cm(2) was chosen. Using confocal microscopy, we demonstrated that the diffusion depth of RB into porcine cornea was approximately 150 gm and mostly localized in anterior stroma 25 min followed by RB application. After photochemical cross-linking, an increase in tensile strength (by average 200%) and Young's modulus (by average 200%) in porcine corneas was observed. The corneal buttons treated by RB-PCL showed doubling of collagenase digestion time from 10.8 +/- 3.1 days in the blank group to 19.7 +/- 6.2 days in the RB-PCL group, indicating increased resistance to enzymatic digestion. In conclusion, Collagen cross-linking by RB-PCL increased both the biomechanical stiffness and the biochemical resistance against collagenase digestion in porcine corneas, therefore to allow stabilizing and solidifier the cornea. The advantages and disadvantages of RB-PCL versus UVA/riboflavin cross-linking technique (UV-CXL) are fully explored. Due to the nature of minimal penetration of RB into corneal stroma, the RB-PCL method could potentially be used in patients with corneal thickness less than 400 gm where UV-CXL is limited. (C) 2014 Elsevier Ltd. All rights reserved.
C1 [Wang, Ti] 85th Hosp PLA, Dept Ophthalmol, Shanghai 200052, Peoples R China.
[Peng, Yinbo; Yao, Min] Shanghai Jiao Tong Univ, Peoples Hosp 3, Dept Burns & Plast Surg, Shanghai 201900, Peoples R China.
[Peng, Yinbo; Yao, Min] Shanghai Jiao Tong Univ, Sch Med, Inst Traumat Med, Shanghai 201900, Peoples R China.
[Shen, Nianci; Zhu, Jingyin] Fudan Univ, Huadong Hosp, Dept Ophthalmol, Shanghai 200040, Peoples R China.
[Yu, Yan] RA Consulting, Chalfont, PA 18914 USA.
[Yao, Min] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Wellman Ctr Photomed, Boston, MA 02114 USA.
RP Zhu, JY (reprint author), Fudan Univ, Huadong Hosp, Dept Ophthalmol, 221 West Yan An Rd,Bldg 7-410, Shanghai 20040, Peoples R China.
EM jingyinz@gmail.com
FU Shanghai Municipal Health Bureau Foundation [2010253]; Young Scholars
Foundation from Fudan University School of Medicine; Shanghai Key
Laboratory of Clinical Geriatric Medicine [13dz2260700]; Medical
Foundation from Nanjing Region of PLA; Huadong Hospital Foundation
FX This work was supported by Shanghai Municipal Health Bureau Foundation
(#2010253), Young Scholars Foundation from Fudan University School of
Medicine (2010), Shanghai Key Laboratory of Clinical Geriatric Medicine
(13dz2260700), Medical Foundation from Nanjing Region of PLA (2012), and
Huadong Hospital Foundation (2010). We are grateful for the technical
assistance of Prof. Hongjiu Hu, Xiaolong Zhang, MS and Chen Lu, MD.
NR 43
TC 5
Z9 5
U1 1
U2 13
PU ACADEMIC PRESS LTD- ELSEVIER SCIENCE LTD
PI LONDON
PA 24-28 OVAL RD, LONDON NW1 7DX, ENGLAND
SN 0014-4835
EI 1096-0007
J9 EXP EYE RES
JI Exp. Eye Res.
PD JUN
PY 2014
VL 123
SI SI
BP 97
EP 104
DI 10.1016/j.exer.2014.04.008
PG 8
WC Ophthalmology
SC Ophthalmology
GA AJ0HY
UT WOS:000337332800010
PM 24768762
ER
PT J
AU Campos, SM
Brady, WE
Moxley, KM
O'Cearbhaill, RE
Lee, PS
DiSilvestro, PA
Rotmensch, J
Rose, PG
Thaker, PH
O'Malley, DM
Hanjani, P
Zuna, RE
Hensley, ML
AF Campos, Susana M.
Brady, William E.
Moxley, Katherine M.
O'Cearbhaill, Roisin E.
Lee, Paula S.
DiSilvestro, Paul A.
Rotmensch, Jacob
Rose, Peter G.
Thaker, Premal H.
O'Malley, David M.
Hanjani, Parviz
Zuna, Rosemary E.
Hensley, Martee L.
TI A phase II evaluation of pazopanib in the treatment of recurrent or
persistent carcinosarcoma of the uterus: A Gynecologic Oncology Group
study
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article
DE Carcinosarcoma; Uterus; VEGFR inhibitors; Angiogenesis
ID MIXED MULLERIAN TUMORS; ENDOTHELIAL GROWTH-FACTOR; ENDOMETRIAL CANCER;
PROGNOSTIC-SIGNIFICANCE; UTERINE CARCINOSARCOMA; MESODERMAL TUMOR;
OPEN-LABEL; TRIAL; ANGIOGENESIS; PACLITAXEL
AB Objective. Carcinosarcomas of the female genital tract, also called malignant mixed mullerian tumors, are aggressive biphasic tumors. Second-line treatment options in the recurrent/persistent setting have yielded marginal responses. Given the potential role of angiogenesis in the gynecological carcinomas, pazopanib, a VEGFR inhibitor, was investigated in the management of patients with recurrent carcinosarcoma of the uterus.
Methods. Eligible patients had histologically confirmed carcinosarcoma of the uterus, a maximum of two prior lines of therapy, adequate renal, hepatic and hematologic function and a performance status of 0-2. Pazopanib was administered orally at 800 mg. Two dose reductions were allowed. The primary objective was to ascertain the activity of pazopanib as measured by the proportion of patients who survive progression-free for at least six months and the proportion of patients that have objective tumor responses. Secondary objectives included the frequency and severity of adverse events as assessed by CTCAE v4.0.
Results. Of the 22 enrolled patients, 19 were eligible and evaluable for toxicity and survival. No patients had a partial or complete response (90% confidence interval [CI]: 0%, 14.6%). Three patients (15.8%) had PFS >= 6 months (90% CI: 4.4%, 35.9%). The median PFS was 2.0 months (first and third quartiles were 1.6 and 4.0 months, respectively). The median overall survival was 8.7 months (first and third quartiles were 2.6 and 14.0 months, respectively).
Conclusion. Pazopanib demonstrated minimal activity as a second or third line treatment for advanced uterine carcinosarcoma. Potential clinical trial participation should be discussed with the patients. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Campos, Susana M.] Dana Farber Canc Inst, Dana Farber Partners Canc Care, Boston, MA 02115 USA.
[Brady, William E.] Roswell Pk Canc Inst, Gynecol Oncol Grp, Stat & Data Ctr, Buffalo, NY 14263 USA.
[Moxley, Katherine M.; Zuna, Rosemary E.] Univ Oklahoma, Ctr Sci, Oklahoma City, OK 73104 USA.
[O'Cearbhaill, Roisin E.; Hensley, Martee L.] Mem Sloan Kettering Canc Ctr, New York, NY 10065 USA.
[Lee, Paula S.] Duke Univ, Med Ctr, Durham, NC 27710 USA.
[DiSilvestro, Paul A.] Brown Univ, Women & Infants Hosp, Providence, RI 02905 USA.
[Rotmensch, Jacob] Rush Presbyterian St Lukes Med Ctr, Chicago, IL 60612 USA.
[Rose, Peter G.] Cleveland Clin, Cleveland, OH 44195 USA.
[Thaker, Premal H.] Washington Univ, Sch Med, St Louis, MO 63110 USA.
[O'Malley, David M.] Ohio State Univ, Columbus Canc Council, Hilliard, OH 43026 USA.
[Hanjani, Parviz] Abington Mem Hosp, Abington, PA 19001 USA.
RP Campos, SM (reprint author), Dana Farber Canc Inst, Dana Farber Partners Canc Care, 44 Binney St, Boston, MA 02115 USA.
EM Susana_Campos@dfci.harvard.edu
RI OMalley, David/E-3789-2011
FU National Cancer Institute [CA 27469]; Gynecological Oncology Study Group
Statistical Office [CA 37517]
FX This study was supported by the National Cancer Institute grants to the
Gynecologic Oncology Group (GOG) Administrative Office (CA 27469) and
the Gynecological Oncology Study Group Statistical Office (CA 37517).
The following Gynecologic Oncology institutions participated in this
study: Abington Memorial Hospital, Columbus Cancer Council/Ohio State,
Walter Reed Army Medical Center, Memorial Sloan Kettering Cancer Center,
Women and Infants' Hospital, University of Oklahoma, Washington
University Medical Center, The Cleveland Clinic Foundation, Rush
University Medical Center, University of North Carolina School of
Medicine and Duke University Medical Center.
NR 42
TC 8
Z9 9
U1 0
U2 1
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
EI 1095-6859
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD JUN
PY 2014
VL 133
IS 3
BP 537
EP 541
DI 10.1016/j.ygyno.2014.02.036
PG 5
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA AI8ZH
UT WOS:000337215000024
PM 24594074
ER
PT J
AU Konstantinopoulos, PA
Wilson, AJ
Saskowski, J
Wass, E
Khabele, D
AF Konstantinopoulos, Panagiotis A.
Wilson, Andrew J.
Saskowski, Jeanette
Wass, Erica
Khabele, Dineo
TI Suberoylanilide hydroxamic acid (SAHA) enhances olaparib activity by
targeting homologous recombination DNA repair in ovarian cancer
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article
DE Vorinostat (SAHA); Olaparib (Ola); Histone deacetylase inhibitors
(HDACi); Poly(ADP-ribose) polymerase inhibitors (PARPi); Phosphorylated
gamma histone H2AX (pH2AX); Ovarian cancer
ID T-CELL LYMPHOMA; POLY(ADP-RIBOSE) POLYMERASE; HISTONE DEACETYLASES;
IONIZING-RADIATION; REPLICATION FORKS; BREAST-CANCER; STRAND BREAKS;
VORINOSTAT; INHIBITORS; CARCINOMA
AB Objectives. Approximately 50% of serous epithelial ovarian cancers (EOC) contain molecular defects in homologous recombination (HR) DNA repair pathways. Poly(ADP-ribose) polymerase inhibitors (PARPi) have efficacy in HR-deficient, but not in HR-proficient, EOC tumors as a single agent. Our goal was to determine whether the histone deacetylase inhibitor, suberoylanilide hydroxamic acid (SAHA), can sensitize HR-proficient ovarian cancer cells to the PARPi AZD-2281 (olaparib).
Methods. Ovarian cancer cell lines (SKOV-3, OVCAR-8, NCI/ADR-Res, UWB1.289 BRCA1 null and UWB1.289 + BRCA1 wild-type) were treated with saline vehicle, olaparib, SAHA or olaparib/SAHA. Sulforhodamine B (SRB) assessed cytotoxicity and immunofluorescence and Western blot assays assessed markers of apoptosis (cleaved PARP) and DNA damage (pH2AX and RAD51). Drug effects were also tested in SKOV-3 xenografts in Nude mice. Affymetrix microarray experiments were performed in vehicle and SAHA-treated SKOV-3 cells.
Results. In a microarray analysis, SAHA induced coordinated down-regulation of HR pathway genes, including RAD51 and BRCA1. Nuclear co-expression of RAD51 and pH2AX, a marker of efficient HR repair, was reduced approximately 40% by SAHA treatment alone and combined with olaparib. SAHA combined with olaparib induced apoptosis and pH2AX expression to a greater extent than either drug alone. Olaparib reduced cell viability at increasing concentrations and SAHA enhanced these effects in 4 of 5 cell lines, including BRCA1 null and wild-type cells, in vitro and in SKOV-3 xenografts in vivo.
Conclusions. These results provide preclinical rationale for targeting DNA damage response pathways by combining small molecule PARPi with HDACi as a mechanism for reducing HR efficiency in ovarian cancer. (C) 2014 Published by Elsevier Inc.
C1 [Konstantinopoulos, Panagiotis A.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Med Oncol,Med Gynecol Oncol Program, Boston, MA 02115 USA.
[Wilson, Andrew J.; Saskowski, Jeanette; Wass, Erica; Khabele, Dineo] Vanderbilt Univ, Div Gynecol Oncol, Dept Obstet & Gynecol, Med Ctr, Nashville, TN 37232 USA.
[Khabele, Dineo] Vanderbilt Ingram Canc Ctr, Nashville, TN USA.
RP Khabele, D (reprint author), Vanderbilt Univ, Div Gynecol Oncol, Dept Obstet & Gynecol, 21st Ave South,B-1100 Med Ctr North, Nashville, TN 37232 USA.
EM dineo.khabele@vanderbilt.edu
FU Department of Defense Ovarian Cancer Academy Award [DOD
W81XWH-10-1-0585/OC093426]; [1K08CA148887-01]
FX 1K08CA148887-01 (DK) and the Department of Defense Ovarian Cancer
Academy Award DOD W81XWH-10-1-0585/OC093426 (PAK).
NR 39
TC 30
Z9 30
U1 2
U2 6
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
EI 1095-6859
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD JUN
PY 2014
VL 133
IS 3
BP 599
EP 606
DI 10.1016/j.ygyno.2014.03.007
PG 8
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA AI8ZH
UT WOS:000337215000034
PM 24631446
ER
PT J
AU Groeneweg, JW
Hall, TR
Zhang, L
Kim, M
Byron, VF
Tambouret, R
Sathayanrayanan, S
Foster, R
Rueda, BR
Growdon, WB
AF Groeneweg, Jolijn W.
Hall, Tracilyn R.
Zhang, Ling
Kim, Minji
Byron, Virginia F.
Tambouret, Rosemary
Sathayanrayanan, Sriram
Foster, Rosemary
Rueda, Bo R.
Growdon, Whitfield B.
TI Inhibition of gamma-secretase activity impedes uterine serous carcinoma
growth in a human xenograft model
SO GYNECOLOGIC ONCOLOGY
LA English
DT Article
DE Uterine serous carcinoma; Notch; Gamma secretase inhibitor; Patient
derived xenograft model
ID NOTCH SIGNALING MOLECULES; IN-SITU HYBRIDIZATION; CANCER STEM-CELLS;
OVARIAN-CANCER; ENDOMETRIAL CANCER; TARGETING NOTCH; HER-2/NEU
OVEREXPRESSION; PAPILLARY CARCINOMA; GENE AMPLIFICATION; PATHWAY
AB Objective. Uterine serous carcinoma (USC) represents an aggressive subtype of endometrial cancer. We sought to understand Notch pathway activity in USC and determine if pathway inhibition has anti-tumor activity.
Methods. Patient USC tissue blocks were obtained and used to correlate clinical outcomes with Notchl expression. Three established USC cell lines were treated with gamma-secretase inhibitor (GSI) in vitro. Mice harboring cell line derived or patient derived USC xenografts (PDXs) were treated with vehicle, GSI, paclitaxel and carboplatin (P/C), or combination GSI and P/C. Levels of cleaved Notchl protein and Hes1 mRNA were determined in GSI treated samples. Statistical analysis was performed using the Wilcoxon rank sum and Kaplan-Meier methods.
Results. High nuclear Notch1 protein expression was observed in 58% of USC samples with no correlation with overall sUrvival. GSI induced dose-dependent reductions in Cell number and decreased levels of cleaved Notchl protein and Hes1 mRNA in vitro. Treatment of mice with GSI led to decreased Hes1 mRNA expression in USC xenografts. In addition, GSI impeded tumor growth of cell line xenografts as well as UT1 USC PDXs. When GSI and P/C were combined, synergistic anti-tumor activity was observed in UT1 xenografts.
Conclusions. Notch1 is expressed in a large subset of USC. GSI-mediated Notch pathway inhibition led to both reduced cell numbers in vitro and decreased tumor growth of USC some xenograft models. When combined with conventional chemotherapy, GSI augmented anti-tumor activity in one USC PDX line suggesting that targeting of the Notch signaling pathway is a potential therapeutic strategy for future investigation. (C) 2014 Elsevier Inc. All rights reserved.
C1 [Groeneweg, Jolijn W.; Hall, Tracilyn R.; Zhang, Ling; Kim, Minji; Byron, Virginia F.; Foster, Rosemary; Rueda, Bo R.; Growdon, Whitfield B.] Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Dept Obstet & Gynecol, Boston, MA 02114 USA.
[Groeneweg, Jolijn W.; Hall, Tracilyn R.; Tambouret, Rosemary; Foster, Rosemary; Rueda, Bo R.; Growdon, Whitfield B.] Harvard Univ, Sch Med, Boston, MA USA.
[Hall, Tracilyn R.; Foster, Rosemary; Rueda, Bo R.; Growdon, Whitfield B.] Massachusetts Gen Hosp, Dept Obstet & Gynecol, Div Gynecol Oncol, Boston, MA 02114 USA.
[Sathayanrayanan, Sriram] Merck Oncol, Boston, MA USA.
[Tambouret, Rosemary] Massachusetts Gen Hosp, Dept Pathol, Boston, MA 02114 USA.
RP Growdon, WB (reprint author), Massachusetts Gen Hosp, Vincent Ctr Reprod Biol, Vincent Dept Obstet & Gynecol, THR 901,55 Fruit St, Boston, MA 02114 USA.
EM wgrowdon@partners.org
FU Advanced Medical Research Foundation (BRR); Vincent Memorial Research
Funds; Federal Proton Share Program Career Development Grant (WBG);
Merck Oncology
FX This research was funded in part by the Advanced Medical Research
Foundation (BRR), Vincent Memorial Research Funds, Federal Proton Share
Program Career Development Grant (WBG) and Merck Oncology. We
acknowledge Dr. Santin, Yale University, for generously providing the
ARK1 and ARK2 cell lines as well as Dr. Fidler, MD Anderson for
generously providing the SPEC2 cell line.
NR 40
TC 7
Z9 7
U1 0
U2 10
PU ACADEMIC PRESS INC ELSEVIER SCIENCE
PI SAN DIEGO
PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA
SN 0090-8258
EI 1095-6859
J9 GYNECOL ONCOL
JI Gynecol. Oncol.
PD JUN
PY 2014
VL 133
IS 3
BP 607
EP 615
DI 10.1016/j.ygyno.2014.03.560
PG 9
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA AI8ZH
UT WOS:000337215000035
PM 24667249
ER
PT J
AU Eckhard, A
Lowenheim, H
AF Eckhard, A.
Loewenheim, H.
TI Water regulation in the cochlea. Do molecular water channels facilitate
potassium-dependent sound transduction?
SO HNO
LA German
DT Article
DE Aquaporin 4; Perilymph; Endolymph; Cochlea; Hearing loss, sensorineural
ID CENTRAL-NERVOUS-SYSTEM; GUINEA-PIG COCHLEA; INNER-EAR; FUNCTIONAL
EXPRESSION; XENOPUS OOCYTES; ION-TRANSPORT; CELLS; AQUAPORIN-4; HEARING;
MEMBRANE
AB Sound transduction in the cochlea critically depends on the circulation of potassium ions (K+) along so-called "K+ recycling routes" between the endolymph and perilymph. These K+ currents generate high ionic and osmotic gradients, which potentially impair the excitability of sensory hair cells and threaten cell survival in the entire cochlear duct. Molecular water channels-aquaporins (AQP)-are expressed in all cochlear supporting cells along the K+ recycling routes; however, their significance for osmotic equilibration in cochlear duct cells is unknown.
The diffusive and osmotic water permeabilies of Reissner's membrane, the organ of Corti and the entire cochlear duct epithelium were determined. Expression of the potassium channel Kir4.1 and the water channel AQP4 in the cochlear duct was investigated by immunohistochemistry.
The calculated water permeability values indicate the extent of AQP-facilitated water flux across the cochlear duct epithelium. Immunohistochemically, Kir4.1 and AQP4 were found to colocalize in distinct membrane domains of supporting cells along the K+-recycling routes.
These observations suggest the presence of a rapid AQP-mediated water exchange between the endolymph, the cells of the cochlear duct and the perilymph. The subcellular colocalization of Kir4.1 and AQP4 in epithelial supporting cells indicates functional coupling of potassium and water flow in the cochlea. Finally, this offers an explanation for the hearing impairment observed in individuals with mutations in the AQP4 gene.
C1 [Eckhard, A.; Loewenheim, H.] Univ Klinikum Tubingen, Klin Hals Nasen Ohren Heilkunde, D-72076 Tubingen, Germany.
[Eckhard, A.] Harvard Univ, Massachusetts Eye & Ear Infirm, Sch Med, Eaton Peabody Labs, Boston, MA USA.
RP Eckhard, A (reprint author), Univ Klinikum Tubingen, Klin Hals Nasen Ohren Heilkunde, Elfriede Aulhorn Str 5, D-72076 Tubingen, Germany.
EM andreas.eckhard@klinikum.uni-tuebingen.de
NR 38
TC 0
Z9 0
U1 1
U2 7
PU SPRINGER
PI NEW YORK
PA 233 SPRING ST, NEW YORK, NY 10013 USA
SN 0017-6192
EI 1433-0458
J9 HNO
JI HNO
PD JUN
PY 2014
VL 62
IS 6
BP 423
EP 431
DI 10.1007/s00106-014-2872-y
PG 9
WC Otorhinolaryngology
SC Otorhinolaryngology
GA AJ2PG
UT WOS:000337499600004
PM 24916350
ER
PT J
AU Worley, MJ
Joseph, NT
Berkowitz, RS
Goldstein, DP
AF Worley, Michael J., Jr.
Joseph, Naima T.
Berkowitz, Ross S.
Goldstein, Donald P.
TI Women With a Partial Mole During Their First Pregnancy and Diagnosed
Earlier in Gestation Are at Increased Risk of Developing Gestational
Trophoblastic Neoplasia
SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
LA English
DT Article
DE Partial mole; Gestational trophoblastic disease; Gestational
trophoblastic neoplasia
ID PARTIAL HYDATIDIFORM MOLE; CURRENT MANAGEMENT; PRIMARY THERAPY; FOLINIC
ACID; DISEASE; EXPERIENCE; METHOTREXATE; PREDICTORS; TUMORS
AB Objective: The aim of this study is to identify factors associated with gestational trophoblastic neoplasia (GTN) after partial molar pregnancy.
Methods: We retrospectively evaluated clinical data from 111 patients with a partial molar pregnancy between 1995 and 2010.
Results: A total of 111 patients with a partial molar pregnancy were available for analysis. There was no significant difference between patients who did and did not develop GTN with respect to patient age, parity, history of prior molar pregnancy, presenting signs/symptoms, uterine size greater than gestational age, clinical diagnosis, preevacuation sonogram findings, or the preevacuation human chorionic gonadotropin value. Patients who developed GTN had fewer prior pregnancies (median, 2 vs 3; P = 0.02) and were more likely to have had a partial molar pregnancy as their first gestational event (37.1% vs 17.1%; P = 0.03). Among the 35 patients who developed GTN, the median time to diagnosis of GTN was 47 days (range, 25-119 days), and the median human chorionic gonadotropin value at the time of GTN diagnosis was 475 mIU/mL (range, 20-52,630 mIU/mL). All women (100%) who developed GTN had stage I disease, and all patients (100%) had low-risk GTN. All 35 women (100%) were able to achieve remission, and most (85.7%) of these patients received methotrexate as first-line chemotherapy.
Conclusions: Women with a partial molar pregnancy as their first gestational event and diagnosed earlier in gestation are more likely to develop postmolar GTN.
C1 [Worley, Michael J., Jr.; Berkowitz, Ross S.; Goldstein, Donald P.] Brigham & Womens Hosp, Div Gynecol Oncol, Boston, MA 02115 USA.
[Worley, Michael J., Jr.; Berkowitz, Ross S.; Goldstein, Donald P.] New England Trophoblast Dis Ctr, Trophoblast Tumor Registry, Boston, MA USA.
[Worley, Michael J., Jr.; Berkowitz, Ross S.; Goldstein, Donald P.] Harvard Canc Ctr, Dana Farber Canc Inst, Boston, MA USA.
[Worley, Michael J., Jr.; Berkowitz, Ross S.; Goldstein, Donald P.] Harvard Univ, Sch Med, Boston, MA USA.
[Joseph, Naima T.] Massachusetts Gen Hosp, Brigham & Womens Hosp, Integrated Residency Program Obstet & Gynecol, Boston, MA 02114 USA.
RP Berkowitz, RS (reprint author), Brigham & Womens Hosp, Div Gynecol Oncol, 75 Francis St, Boston, MA 02115 USA.
EM rberkowitz@partners.org
NR 22
TC 1
Z9 1
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1048-891X
EI 1525-1438
J9 INT J GYNECOL CANCER
JI Int. J. Gynecol. Cancer
PD JUN
PY 2014
VL 24
IS 5
BP 941
EP 945
DI 10.1097/IGC.0000000000000130
PG 5
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA AI9IS
UT WOS:000337246900020
PM 24819660
ER
PT J
AU Gaffney, DK
Jhingran, A
Portelance, L
Viswanathan, A
Schefter, T
Weidhaas, J
Small, W
AF Gaffney, David K.
Jhingran, Anuja
Portelance, Lorraine
Viswanathan, Akila
Schefter, Tracey
Weidhaas, Joanne
Small, William, Jr.
TI Radiation Therapy Oncology Group Gynecologic Oncology Working Group
Comprehensive Results
SO INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER
LA English
DT Review
DE RTOG; Cervix; Uterus; Radiation
ID ADVANCED CERVICAL-CANCER; MODULATED PELVIC RADIOTHERAPY; EXTENDED-FIELD
IRRADIATION; TWICE-DAILY FRACTIONATION; CLINICAL TARGET VOLUME;
PARAAORTIC LYMPH-NODES; PHASE-II; ENDOMETRIAL CANCER; CONCURRENT
CHEMOTHERAPY; EXTERNAL IRRADIATION
AB The purpose of this report was to comprehensively describe the activities of the Gynecologic Oncology Working Group within the Radiation Therapy Oncology Group (RTOG). Clinical trials will be reviewed as well as translational science and ancillary activities. During the past 40 years, a myriad of clinical trials have been performed within the RTOG with the aim of improving overall survival (OS) and decreasing morbidity in women with cervical or endometrial cancer. Major study questions have included hyperbaric oxygen, neutron radiotherapy, altered fractionation, hypoxic cell sensitization, chemosensitization, and volume-directed radiotherapy.
RTOG 7920 demonstrated improvement in OS in patients with stages IB through IIB cervical carcinoma receiving prophylactic para-aortic irradiation compared to pelvic radiation alone. RTOG 9001 demonstrated that cisplatin and 5-FU chemoradiotherapy to the pelvis for advanced cervix cancer markedly improved OS compared to extended field radiotherapy alone. More recent trials have used radioprotectors, molecular-targeted therapy, and intensity-modulated radiation therapy. Ancillary studies have developed clinical target volume atlases for research protocols and routine clinical use. Worldwide practice patterns have been investigated in cervix, endometrial, and vulvar cancer through the Gynecologic Cancer Intergroup. Translational studies have focused on immunohistochemical markers, changes in gene expression, and miRNA patterns impacting prognosis.
The RTOG gynecologic working group has performed clinical trials that have defined the standard of care, improved survival, and added to our understanding of the biology of cervical and endometrial cancers.
C1 [Gaffney, David K.] Univ Utah, Dept Radiat Oncol, Huntsman Canc Hosp, Salt Lake City, UT 84112 USA.
[Jhingran, Anuja] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, Houston, TX 77030 USA.
[Portelance, Lorraine] Univ Miami, Miller Sch Med, Dept Radiat Oncol, Miami, FL 33136 USA.
[Viswanathan, Akila] Brigham & Womens Hosp, Dept Radiat Oncol, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Schefter, Tracey] Univ Colorado, Dept Radiat Oncol, Denver, CO 80202 USA.
[Weidhaas, Joanne] Yale Univ, Dept Radiat Oncol, New Haven, CT USA.
[Small, William, Jr.] Loyola Univ, Stritch Sch Med, Dept Radiat Oncol, Chicago, IL 60611 USA.
RP Gaffney, DK (reprint author), Univ Utah, Dept Radiat Oncol, Huntsman Canc Hosp, 1950 Circle Hope Rd, Salt Lake City, UT 84112 USA.
EM david.gaffney@hci.utah.edu
OI Weidhaas, Joanne/0000-0002-5096-3281
FU NCI NIH HHS [U10 CA180818]
NR 38
TC 1
Z9 2
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1048-891X
EI 1525-1438
J9 INT J GYNECOL CANCER
JI Int. J. Gynecol. Cancer
PD JUN
PY 2014
VL 24
IS 5
BP 956
EP 962
DI 10.1097/IGC.0000000000000135
PG 7
WC Oncology; Obstetrics & Gynecology
SC Oncology; Obstetrics & Gynecology
GA AI9IS
UT WOS:000337246900023
PM 24819663
ER
PT J
AU Patel, H
Higgins, JM
AF Patel, Harsh
Higgins, John M.
TI MATHEMATICAL MODEL-BASED ESTIMATION OF RED BLOOD CELL CLEARANCE PREDICTS
FUTURE ANEMIA IN PATIENTS WITH NORMAL COMPLETE BLOOD COUNTS
SO INTERNATIONAL JOURNAL OF LABORATORY HEMATOLOGY
LA English
DT Meeting Abstract
C1 [Patel, Harsh; Higgins, John M.] Massachusetts Gen Hosp, Ctr Syst Biol, Boston, MA 02114 USA.
[Higgins, John M.] Harvard Univ, Sch Med, Dept Syst Biol, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 2
PU WILEY-BLACKWELL
PI HOBOKEN
PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA
SN 1751-5521
EI 1751-553X
J9 INT J LAB HEMATOL
JI Int. J. Lab. Hematol.
PD JUN
PY 2014
VL 36
SU 1
SI SI
BP 72
EP 72
PG 1
WC Hematology
SC Hematology
GA AI9HS
UT WOS:000337244300166
ER
PT J
AU Ghamande, S
Lin, CC
Cho, DC
Shapiro, GI
Kwak, EL
Silverman, MH
Tseng, YL
Kuo, MW
Mach, WB
Hsu, SC
Coleman, T
Yang, JCH
Cheng, AL
Ghalib, MH
Chuadhary, I
Goel, S
AF Ghamande, Sharad
Lin, Chia-Chi
Cho, Daniel C.
Shapiro, Geoffrey I.
Kwak, Eunice L.
Silverman, Michael H.
Tseng, Yunlong
Kuo, Min-Wen
Mach, Wendy B.
Hsu, Shu-Chi
Coleman, Teresa
Yang, James Chih-Hsin
Cheng, Ann-Lii
Ghalib, Mohammad H.
Chuadhary, Imran
Goel, Sanjay
TI A phase 1 open-label, sequential dose-escalation study investigating the
safety, tolerability, and pharmacokinetics of intravenous TLC388
administered to patients with advanced solid tumors
SO INVESTIGATIONAL NEW DRUGS
LA English
DT Article
DE Camptothecin; Topotecan; Phase 1 trial; Hypoxia-inducible factor;
Topoisomerase
ID TOPOISOMERASE-I INHIBITOR; TOPOTECAN; CANCER; TRIAL
AB Purpose The first-in-human phase 1 trial examined the dose-limiting toxicities (DLT), maximum tolerated dose (MTD), pharmacokinetic profile, and antitumor activity of TLC388, a novel camptothecin with a unique lactone ring modification, in patients with advanced solid tumors. Experimental design TLC388 was administered intravenously to patients with metastatic chemotherapy refractory solid tumors on days 1, 8, and 15 of a 28-day cycle. Patients underwent tumor assessments every other cycle. Pharmacokinetic samples were drawn on days 1, 8, and 15 of cycles 1 and 2. Results Fifty-four patients were enrolled at doses ranging from 1.5 to 60.0 mg/m(2) over 12 cohorts. Treatment was generally well-tolerated and no cumulative toxicity observed. Two of six patients treated at 60.0 mg/m(2) developed DLTs of grade 3 neutropenia causing dose delay and grade 3 febrile neutropenia. The next lower dose, 50.0 mg/m(2), was declared as MTD. Treatment-related grade 3-4 hematologic toxicities included neutropenia (19 %), leukopenia (15 %), anemia (9 %), and thrombocytopenia (7 %). Grade 3-4 nonhematologic toxicities included diarrhea (2 %) and hyponatremia (4 %). Pharmacokinetics of both diastereomers (S,R and S,S) of TLC388, a mixture of two diastereomers, was dose independent; mean (SD) values for the volume of distribution at steady-state and clearance were 857 (1122) L/m(2) for S,R and 996 (1333) L/m(2) for S,S, and 2174 (2526) L/h-m(2) for S,R and 2670 (2988) L/h-m(2) for S,S, respectively. The half-life values averaged 0.67 (1.15) hours for S,R and 0.64 (1.11) hours for S,S. The best overall response was stable disease in 21 (39 %) patients. Prolonged (a parts per thousand yen 6 months) stable disease was noted in eight patients. Conclusions TLC388 at 50 mg/m(2) on the current treatment schedule is generally safe and well tolerated.
C1 [Ghamande, Sharad; Coleman, Teresa] Georgia Regents Univ, Med Coll Georgia, Augusta, GA USA.
[Lin, Chia-Chi; Yang, James Chih-Hsin; Cheng, Ann-Lii] Natl Taiwan Univ Hosp, Taipei, Taiwan.
[Cho, Daniel C.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
[Shapiro, Geoffrey I.] Dana Farber Canc Inst, Boston, MA 02115 USA.
[Kwak, Eunice L.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Silverman, Michael H.] BioStrateg Consulting Ltd, Marblehead, MA USA.
[Tseng, Yunlong; Kuo, Min-Wen; Mach, Wendy B.; Hsu, Shu-Chi] Taiwan Liposome Co Ltd, Taipei, Taiwan.
[Ghalib, Mohammad H.; Chuadhary, Imran; Goel, Sanjay] Montefiore Med Ctr, Bronx, NY 10461 USA.
[Goel, Sanjay] Montefiore Med Ctr, Albert Einstein Coll Med, Dept Oncol, Bronx, NY 10461 USA.
RP Goel, S (reprint author), Montefiore Med Ctr, Albert Einstein Coll Med, Dept Oncol, 1825 Eastchester Rd,Room 2S-52, Bronx, NY 10461 USA.
EM sgoel@montefiore.org
OI Cheng, Ann-Lii/0000-0002-9152-6512; Yang, James
Chih-Hsin/0000-0002-5586-5138
FU Taiwan Liposome Company, Inc.
FX Yunlong Tseng, Min-Wen Kuo, Wendy B. Mach, and Shu-Chi Hsu are the
employees of the study sponsor (Taiwan Liposome Company, Inc.). The
remaining authors declare that they have no conflict of interest.
NR 9
TC 2
Z9 2
U1 0
U2 2
PU SPRINGER
PI DORDRECHT
PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS
SN 0167-6997
EI 1573-0646
J9 INVEST NEW DRUG
JI Invest. New Drugs
PD JUN
PY 2014
VL 32
IS 3
BP 445
EP 451
DI 10.1007/s10637-013-0044-7
PG 7
WC Oncology; Pharmacology & Pharmacy
SC Oncology; Pharmacology & Pharmacy
GA AI7OU
UT WOS:000337084000006
PM 24271274
ER
PT J
AU Greenspon, AJ
Le, KY
Prutkin, JM
Sohail, MR
Vikram, HR
Baddour, LM
Danik, SB
Peacock, J
Falces, C
Miro, JM
Naber, C
Carrillo, RG
Tseng, CH
Uslan, DZ
AF Greenspon, Arnold J.
Le, Katherine Y.
Prutkin, Jordan M.
Sohail, M. Rizwan
Vikram, Holenarasipur R.
Baddour, Larry M.
Danik, Stephan B.
Peacock, James
Falces, Carlos
Miro, Jose M.
Naber, Christoph
Carrillo, Roger G.
Tseng, Chi-Hong
Uslan, Daniel Z.
TI Influence of Vegetation Size on the Clinical Presentation and Outcome of
Lead-Associated Endocarditis Results From the MEDIC Registry
SO JACC-CARDIOVASCULAR IMAGING
LA English
DT Article
DE endocarditis; implantable cardioverter-defibrillator; permanent
pacemaker
ID ELECTRONIC DEVICE INFECTIONS; IMPLANTABLE CARDIOVERTER-DEFIBRILLATORS;
STAPHYLOCOCCUS-AUREUS BACTEREMIA; CARDIAC DEVICES; PACEMAKERS;
MANAGEMENT; DIAGNOSIS; TRENDS; ECHOCARDIOGRAPHY; EXTRACTION
AB OBJECTIVES The purpose of this study was to determine whether the clinical presentation of lead-associated endocarditis (LAE) is related to the size of lead vegetations and how size is related to bacteriology and clinical outcomes.
BACKGROUND Cardiac implantable electronic device (CIED) infection may present as either local pocket infection or bloodstream infection with or without LAE. LAE is associated with significant morbidity and mortality.
METHODS The clinical presentation and course of LAE were evaluated by the MEDIC (Multicenter Electrophysiologic Device Cohort) registry, an international registry enrolling patients with CIED infection. Consecutive LAE patients enrolled in the MEDIC registry between January 1, 2009 and December 31, 2012 were analyzed. The clinical features and outcomes of 2 groups of patients were compared based on the size of the lead vegetation detected by echocardiography (> or <1 cm in diameter).
RESULTS There were 129 patients with LAE enrolled into the MEDIC registry. Of these, 61 patients had a vegetation <1 cm in diameter (Group I) whereas 68 patients had a vegetation >= 1 cm in diameter (Group II). Patients in Group I more often presented with signs of local pocket infection, whereas Group II patients presented with clinical evidence of systemic infection. Staphylococcus aureus was the organism most often responsible for LAE, whereas infection with coagulase-negative staphylococci was associated with larger vegetations. Outcomes were improved among those who underwent complete device removal. However, major complications were associated with an open surgical approach for device removal.
CONCLUSIONS The clinical presentation of LAE is influenced by the size of the lead vegetation. Prompt recognition and management of LAE depends on obtaining blood cultures and echocardiography, including transesophageal echocardiography, in CIED patients who present with either signs of local pocket or systemic infection. (C) 2014 by the American College of Cardiology Foundation
C1 [Greenspon, Arnold J.] Thomas Jefferson Univ Hosp, Dept Med, Cardiac Electrophysiol Lab, Div Cardiol, Philadelphia, PA 19107 USA.
[Le, Katherine Y.; Sohail, M. Rizwan; Baddour, Larry M.] Mayo Clin, Coll Med, Dept Med, Div Infect Dis, Rochester, MN USA.
[Prutkin, Jordan M.] Univ Washington, Dept Med, Div Cardiol, Seattle, WA USA.
[Vikram, Holenarasipur R.] Mayo Clin, Dept Med, Div Infect Dis, Phoenix, AZ USA.
[Danik, Stephan B.] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA.
[Peacock, James] Wake Forest Univ, Dept Med, Div Infect Dis, Winston Salem, NC 27109 USA.
[Falces, Carlos; Miro, Jose M.] Univ Barcelona, IDIBAPS, Hosp Clin Barcelona, Dept Med,Div Infect Dis, Barcelona, Spain.
[Naber, Christoph] Elisabeth Hosp, Dept Med, Div Cardiol, Essen, Germany.
[Carrillo, Roger G.] Univ Miami, Dept Surg, Div Cardiothorac Surg, Miami, FL USA.
[Tseng, Chi-Hong] Univ Calif Los Angeles, Dept Gen Intemal Med & Hlth Serv, Los Angeles, CA USA.
[Uslan, Daniel Z.] Univ Calif Los Angeles, Dept Med, Div Infect Dis, Los Angeles, CA 90024 USA.
RP Greenspon, AJ (reprint author), Thomas Jefferson Univ Hosp, Jefferson Heart Inst, Cardiac Electrophysiol Lab, 925 Chestnut St, Philadelphia, PA 19107 USA.
EM arnold.greenspon@jefferson.edu
RI Carrillo, Roger/C-2231-2015; Sohail, Muhammad/K-1803-2016;
OI Carrillo, Roger/0000-0002-0443-8689; Sohail,
Muhammad/0000-0001-6355-0526; Falces, Carlos/0000-0002-3483-3786
FU American Heart Association; Medtronic; Boston Scientific; Spectranetics;
Biotronik; St. Jude Medical; Tyco
FX This study was funded, in part, by a grant from the American Heart
Association (to Dr. Uslan). Dr. Greenspon has received honoraria from
Medtronic, Boston Scientific, and St. Jude Medical; and research grants
from Medtronic and Boston Scientific. Dr. Sohail has received consulting
fees from Spectranetics. Dr. Carrillo has received consulting fees from
Spectranetics, Medtronic, Biotronik, St. Jude Medical, and Tyco; and a
research grant from St. Jude Medical. Dr. Uslan has received a research
grant from Medtronic. All other authors have reported that they have no
relationships relevant to the contents of this paper to disclose.
NR 31
TC 8
Z9 8
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-878X
EI 1876-7591
J9 JACC-CARDIOVASC IMAG
JI JACC-Cardiovasc. Imag.
PD JUN
PY 2014
VL 7
IS 6
BP 541
EP 549
DI 10.1016/j.jcmg.2014.01.015
PG 9
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA AJ0HP
UT WOS:000337331800001
PM 24813965
ER
PT J
AU Shaw, LJ
Berman, DS
Picard, MH
Friedrich, MG
Kwong, RY
Stone, GW
Senior, R
Min, JK
Hachamovitch, R
Scherrer-Crosbie, M
Mieres, JH
Marwick, TH
Phillips, LM
Chaudhry, FA
Pellikka, PA
Slomka, P
Arai, AE
Iskandrian, AE
Bateman, TM
Heller, GV
Miller, TD
Nagel, E
Goyal, A
Borges-Neto, S
Boden, WE
Reynolds, HR
Hochman, JS
Maron, DJ
Douglas, PS
AF Shaw, Leslee J.
Berman, Daniel S.
Picard, Michael H.
Friedrich, Matthias G.
Kwong, Raymond Y.
Stone, Gregg W.
Senior, Roxy
Min, James K.
Hachamovitch, Rory
Scherrer-Crosbie, Marielle
Mieres, Jennifer H.
Marwick, Thomas H.
Phillips, Lawrence M.
Chaudhry, Farooq A.
Pellikka, Patricia A.
Slomka, Piotr
Arai, Andrew E.
Iskandrian, Ami E.
Bateman, Timothy M.
Heller, Gary V.
Miller, Todd D.
Nagel, Eike
Goyal, Abhinav
Borges-Neto, Salvador
Boden, William E.
Reynolds, Harmony R.
Hochman, Judith S.
Maron, David J.
Douglas, Pamela S.
CA ISCHEMIA Trial Investigators
TI Comparative Definitions for Moderate-Severe Ischemia in Stress Nuclear,
Echocardiography, and Magnetic Resonance Imaging
SO JACC-CARDIOVASCULAR IMAGING
LA English
DT Article
DE cardiac imaging; ischemia; prognosis
ID CORONARY-ARTERY-DISEASE; EMISSION COMPUTED-TOMOGRAPHY; VENTRICULAR
EJECTION FRACTION; INCREMENTAL PROGNOSTIC VALUE; OPTIMAL MEDICAL
THERAPY; MYOCARDIAL-PERFUSION SCINTIGRAPHY; AMERICAN-HEART-ASSOCIATION;
EXERCISE ECHOCARDIOGRAPHY; RISK STRATIFICATION; REVASCULARIZATION
PROCEDURES
AB The lack of standardized reporting of the magnitude of ischemia on noninvasive imaging contributes to variability in translating the severity of ischemia across stress imaging modalities. We identified the risk of coronary artery disease (CAD) death or myocardial infarction (MI) associated with >= 10% ischemic myocardium on stress nuclear imaging as the risk threshold for stress echocardiography and cardiac magnetic resonance. A narrative review revealed that >= 10% ischemic myocardium on stress nuclear imaging was associated with a median rate of CAD death or MI of 4.9%/year (interquartile range: 3.75% to 5.3%). For stress echocardiography, >= 3 newly dysfunctional segments portend a median rate of CAD death or MI of 4.5%/year (interquartile range: 3.8% to 5.9%). Although imprecisely delineated, moderate-severe ischemia on cardiac magnetic resonance may be indicated by >= 4 of 32 stress perfusion defects or >= 3 dobutamine-induced dysfunctional segments. Risk-based thresholds can define equivalent amounts of ischemia across the stress imaging modalities, which will help to translate a common understanding of patient risk on which to guide subsequent management decisions. (C) 2014 by the American College of Cardiology Foundation
C1 [Shaw, Leslee J.; Goyal, Abhinav] Emory Univ, Dept Med, Div Cardiol, Atlanta, GA 30324 USA.
[Berman, Daniel S.] Cedars Sinai Med Ctr, Dept Med, Div Cardiac Imaging Nucl Cardiol, Los Angeles, CA 90048 USA.
[Picard, Michael H.; Scherrer-Crosbie, Marielle] Massachusetts Gen Hosp, Dept Med, Div Cardiol, Boston, MA 02114 USA.
[Friedrich, Matthias G.] Montreal Heart Inst, Dept Med, Div Cardiol, Montreal, PQ H1T 1C8, Canada.
[Kwong, Raymond Y.] Brigham & Womens Hosp, Dept Med, Div Cardiovasc, Boston, MA 02115 USA.
[Stone, Gregg W.] Columbia Univ, New York Presbyterian Hosp, Med Ctr, Dept Med,Div Cardiol, New York, NY USA.
[Senior, Roxy] Univ London Imperial Coll Sci Technol & Med, Dept Cardiovasc Med, Div Cardiol, London, England.
[Min, James K.] Weill Cornell Med Coll, Dept Cardiovasc Med, Div Radiol, New York, NY USA.
[Hachamovitch, Rory] Cleveland Clin Fdn, Dept Cardiovasc Med, Div Cardiol, Cleveland, OH 44195 USA.
[Mieres, Jennifer H.] North Shore Long Isl Jewish Hosp, Dept Med, Div Cardiol, Manhasset, NY USA.
[Marwick, Thomas H.] Menzies Res Inst Tasmania, Dept Med, Div Cardiol, Hobart, Tas, Australia.
[Phillips, Lawrence M.; Reynolds, Harmony R.; Hochman, Judith S.] NYU, Med Ctr, Dept Med, Div Cardiol, New York, NY 10016 USA.
[Chaudhry, Farooq A.] Icahn Sch Med Mt Sinai, Dept Med, Div Cardiol, New York, NY USA.
[Pellikka, Patricia A.; Miller, Todd D.] Mayo Clin, Dept Med, Div Cardiovasc Med, Rochester, MN USA.
[Slomka, Piotr] Cedars Sinai Med Ctr, Dept Med, Div Imaging, Los Angeles, CA 90048 USA.
[Arai, Andrew E.] NHLBI, Dept Med, Div Cardiovasc Med, NIH, Bethesda, MD 20892 USA.
[Iskandrian, Ami E.] Univ Alabama Birmingham, Dept Radiol, Div Cardiovasc Dis, Birmingham, AL USA.
[Bateman, Timothy M.] St Lukes Mid Amer Heart Inst, Dept Med, Div Cardiol, Kansas City, MO USA.
[Heller, Gary V.] Hartford Hosp, Hartford, CT 06115 USA.
[Nagel, Eike] Kings Coll London, Dept Med, Div Cardiovasc Med, London, England.
[Borges-Neto, Salvador] Duke Clin Res Inst, Dept Nucl Med, Div Radiol, Durham, NC USA.
[Boden, William E.] Samuel S Stratton VA Med Ctr, Dept Med, Div Cardiol, Albany, NY USA.
[Maron, David J.] Stanford Univ, Dept Med, Sch Med, Stanford, CA 94305 USA.
[Douglas, Pamela S.] Duke Clin Res Inst, Dept Med, Div Cardiol, Durham, NC USA.
RP Shaw, LJ (reprint author), Emory Univ, Sch Med, Emory Clin Cardiovasc Res Inst, 1462 Clifton Rd NE,Room 529, Atlanta, GA 30324 USA.
EM lshaw3@emory.edu
RI Nagel, Eike/C-6903-2008;
OI Nagel, Eike/0000-0002-6044-950X; Reynolds, Harmony/0000-0003-0284-0655;
Picard, Michael/0000-0002-9264-3243; Hochman, Judith/0000-0002-5889-5981
FU Astellas; Bracco Diagnostics Inc.; GE Healthcare; Philips Healthcare;
Siemens; Lantheus Medical Imaging; Spectrum Dynamics; Bayer HealthCare;
GlaxoSmithKline
FX Dr. Shaw has received research support from Astellas and Bracco
Diagnostics Inc. Dr. Friedrich is a board member, advisor, and
shareholder for Circle Cardiovascular Imaging. Dr. Senior is a member of
the speaker's bureau for and has received honoraria from Bracco
Diagnostics Inc. and Philips Healthcare. Dr. Min is a member of the
medical advisory board and speaker's bureau for and has received
research support from GE Healthcare; is a member of the medical advisory
board for Arineta Ltd.; has received research support from Philips
Healthcare; and holds equity interest in TC3 and MDDX. Dr. Arai has
received research support from Siemens. Dr. Iskandrian is a member of
the advisory committee for Rapidscan Pharma. Dr. Bateman is a member of
the advisory committee for and receives research support from Astellas,
Lantheus Medical Imaging, GE Healthcare, and Spectrum Dynamics. Dr.
Miller is a consultant for Astellas. Dr. Nagel has received research
support from Philips Healthcare and Bayer HealthCare. Dr. Borges-Neto is
a member of the speaker's bureau and advisory board for and has received
grant support from Astellas and is a member of the advisory board for
and has received grant support from GE Healthcare. Dr. Hochman has
received a consulting fee and modest honoraria from GlaxoSmithKline. All
other authors have reported that they have no relationships relevant to
the contents of this paper to disclose.
NR 65
TC 34
Z9 34
U1 0
U2 4
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1936-878X
EI 1876-7591
J9 JACC-CARDIOVASC IMAG
JI JACC-Cardiovasc. Imag.
PD JUN
PY 2014
VL 7
IS 6
BP 593
EP 604
DI 10.1016/j.jcmg.2013.10.021
PG 12
WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical
Imaging
SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine &
Medical Imaging
GA AJ0HP
UT WOS:000337331800008
PM 24925328
ER
PT J
AU Cone, EB
Eisner, BH
Ursiny, M
Pareek, G
AF Cone, Eugene B.
Eisner, Brian H.
Ursiny, Michal
Pareek, Gyan
TI Cost-Effectiveness Comparison of Renal Calculi Treated with
Ureteroscopic Laser Lithotripsy Versus Shockwave Lithotripsy
SO JOURNAL OF ENDOUROLOGY
LA English
DT Article
ID WAVE LITHOTRIPSY; URETERAL CALCULI; STONES
AB Purpose: To evaluate the cost-effectiveness of shockwave lithotripsy (SWL) vs ureteroscopic lithotripsy (URS) for patients with renal stones < 1.5 cm in diameter.
Methods: Patient age, stone diameter, stone location, and stone-free status were recorded for patients treated with SWL or URS for renal stones < 1.5 cm in maximal diameter over a 1-year period. Institutional charges were obtained from in-house billing. A decision analysis model was constructed to compare the cost-effectiveness of SWL and URS and using our results and success rates for modeling. Three separate models were created to reflect practice patterns for SWL.
Results: One hundred fifty-eight patients were included in the study-78 underwent SWL and 80 underwent URS as primary treatment. Single procedure stone-free rates (SFR) for SWL and URS were 55% and 95%, respectively (P < 0.0001). Decision analysis modeling demonstrated cost-effectiveness of SWL when SWL single procedure SFR were 65% to 67% or when URS single procedure SFR was 72% to 84%.
Conclusions: This retrospective study revealed superior SFR results for renal stones < 1.5 cm for URS compared with SWL. Our decision analysis model demonstrates that for SWL SFR less than 65% to 67% or for URS SFR greater than 72% to 84%, SWL is not a cost-effective treatment option. Based on these findings, careful stratification and selection of stone patients may enable surgeons to increase the cost-effectiveness of SWL.
C1 [Cone, Eugene B.] Duke Univ, Sch Med, Div Urol, Med Ctr, Durham, NC 27708 USA.
[Eisner, Brian H.; Ursiny, Michal] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Urol, Boston, MA USA.
[Pareek, Gyan] Brown Univ, Div Urol, Warren Alpert Med Sch, Providence, RI 02912 USA.
RP Cone, EB (reprint author), Duke Univ, Sch Med, Div Urol, Med Ctr, 200 Trent Dr, Durham, NC 27708 USA.
EM eugene.cone@duke.edu
OI Cone, Eugene/0000-0002-0292-7534
NR 12
TC 9
Z9 10
U1 0
U2 3
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 0892-7790
EI 1557-900X
J9 J ENDOUROL
JI J. Endourol.
PD JUN
PY 2014
VL 28
IS 6
BP 639
EP 643
DI 10.1089/end.2013.0669
PG 5
WC Urology & Nephrology
SC Urology & Nephrology
GA AI9BN
UT WOS:000337221600004
PM 24444144
ER
PT J
AU Porto, I
Ducci, KJ
Angioli, P
Grotti, S
Falsini, G
Vergallo, R
Liistro, F
Bolognese, L
AF Porto, Italo
Ducci, Kenneth J.
Angioli, Paolo
Grotti, Simone
Falsini, Giovanni
Vergallo, Rocco
Liistro, Francesco
Bolognese, Leonardo
TI Optical Frequency-Domain Imaging to Guide Implantation of a
Paclitaxel-Eluting Stent in the Femoral Artery
SO JOURNAL OF ENDOVASCULAR THERAPY
LA English
DT Editorial Material
ID COHERENCE TOMOGRAPHY
C1 [Porto, Italo; Ducci, Kenneth J.; Angioli, Paolo; Grotti, Simone; Falsini, Giovanni; Liistro, Francesco; Bolognese, Leonardo] San Donato Hosp, Intervent Cardiol Unit, Arezzo, Italy.
[Vergallo, Rocco] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Div Cardiol, Boston, MA USA.
RP Porto, I (reprint author), San Donato Hosp, Intervent Cardiol Unit, Arezzo, Italy.
EM italo.porto@gmail.com
OI Grotti, Simone/0000-0002-7165-7355
NR 5
TC 0
Z9 0
U1 0
U2 0
PU ALLIANCE COMMUNICATIONS GROUP DIVISION ALLEN PRESS
PI LAWRENCE
PA 810 EAST 10TH STREET, LAWRENCE, KS 66044 USA
SN 1526-6028
EI 1545-1550
J9 J ENDOVASC THER
JI J. Endovascular Ther.
PD JUN
PY 2014
VL 21
IS 3
BP 456
EP 459
DI 10.1583/13-4634.1
PG 4
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA AJ0IK
UT WOS:000337334000016
PM 24915597
ER
PT J
AU Thomas, MP
Whangbo, J
McCrossan, G
Deutsch, AJ
Martinod, K
Walch, M
Lieberman, J
AF Thomas, Marshall P.
Whangbo, Jennifer
McCrossan, Geoffrey
Deutsch, Aaron J.
Martinod, Kimberly
Walch, Michael
Lieberman, Judy
TI Leukocyte Protease Binding to Nucleic Acids Promotes Nuclear
Localization and Cleavage of Nucleic Acid Binding Proteins
SO JOURNAL OF IMMUNOLOGY
LA English
DT Article
ID NEUTROPHIL EXTRACELLULAR TRAPS; PROGRAMMED CELL-DEATH; HUMAN GRANZYME;
PANCREATIC ELASTASE; CRYSTAL-STRUCTURE; SPECIFICITY; RNA; DNA;
SERGLYCIN; AFFINITY
AB Killer lymphocyte granzyme (Gzm) serine proteases induce apoptosis of pathogen-infected cells and tumor cells. Many known Gzm substrates are nucleic acid binding proteins, and the Gzms accumulate in the target cell nucleus by an unknown mechanism. In this study, we show that human Gzms bind to DNA and RNA with nanomolar affinity. Gzms cleave their substrates most efficiently when both are bound to nucleic acids. RNase treatment of cell lysates reduces Gzm cleavage of RNA binding protein targets, whereas adding RNA to recombinant RNA binding protein substrates increases in vitro cleavage. Binding to nucleic acids also influences Gzm trafficking within target cells. Preincubation with competitor DNA and DNase treatment both reduce Gzm nuclear localization. The Gzms are closely related to neutrophil proteases, including neutrophil elastase (NE) and cathepsin G. During neutrophil activation, NE translocates to the nucleus to initiate DNA extrusion into neutrophil extracellular traps, which bind NE and cathepsin G. These myeloid cell proteases, but not digestive serine proteases, also bind DNA strongly and localize to nuclei and neutrophil extracellular traps in a DNA-dependent manner. Thus, high-affinity nucleic acid binding is a conserved and functionally important property specific to leukocyte serine proteases. Furthermore, nucleic acid binding provides an elegant and simple mechanism to confer specificity of these proteases for cleavage of nucleic acid binding protein substrates that play essential roles in cellular gene expression and cell proliferation.
C1 Boston Childrens Hosp, Program Cellular & Mol Med, Boston, MA 02115 USA.
Boston Childrens Hosp, Div Hematol Oncol, Boston, MA 02215 USA.
Harvard Univ, Sch Med, Dept Pediat, Boston, MA 02115 USA.
RP Lieberman, J (reprint author), Harvard Univ, Sch Med, WAB 255,200 Longwood Ave, Boston, MA 02115 USA.
EM jennifer.whangbo@childrens.harvard.edu; lieberman@childrens.harvard.edu
RI Lieberman, Judy/A-2717-2015;
OI Deutsch, Aaron/0000-0001-6750-5335; Martinod,
Kimberly/0000-0002-1026-6107
FU National Science Foundation graduate research fellowship; National
Institutes of Health K08 [HL094460]; Boston Children's Hospital Career
Development Fellowship; National Institutes of Health [AI45587]
FX This work was supported by a National Science Foundation graduate
research fellowship (to M.P.T.), National Institutes of Health K08 Grant
HL094460 (to J.W.), a Boston Children's Hospital Career Development
Fellowship (to J.W.), and National Institutes of Health Grant AI45587
(to J.L.).
NR 39
TC 7
Z9 7
U1 1
U2 4
PU AMER ASSOC IMMUNOLOGISTS
PI BETHESDA
PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA
SN 0022-1767
EI 1550-6606
J9 J IMMUNOL
JI J. Immunol.
PD JUN 1
PY 2014
VL 192
IS 11
BP 5390
EP 5397
DI 10.4049/jimmunol.1303296
PG 8
WC Immunology
SC Immunology
GA AI8MT
UT WOS:000337171800050
PM 24771851
ER
PT J
AU Gupta, M
Leskov, I
Kruger, JM
Cestari, DM
AF Gupta, Meenakashi
Leskov, Ilya
Kruger, Joshua M.
Cestari, Dean M.
TI Intermittent Horner Syndrome in a Pediatric Patient
SO JOURNAL OF NEURO-OPHTHALMOLOGY
LA English
DT Editorial Material
ID HEADACHE SINE HEADACHE; CERVICAL SPINAL-CORD; CLUSTER HEADACHE
AB Intermittent Horner syndrome is uncommon in both the adult and pediatric population. We describe a case of a pediatric patient with an intermittent Horner syndrome. Infrared photography and videography were used to help establish the diagnosis. (C) 2013 by North American Neuro-Ophthalmology Society
C1 [Gupta, Meenakashi; Leskov, Ilya; Cestari, Dean M.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Boston, MA 02114 USA.
[Cestari, Dean M.] Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Neuroophthalmol Serv, Boston, MA 02114 USA.
[Gupta, Meenakashi; Leskov, Ilya; Cestari, Dean M.] Harvard Univ, Sch Med, Dept Ophthalmol, Boston, MA USA.
RP Cestari, DM (reprint author), Massachusetts Eye & Ear Infirm, Dept Ophthalmol, Neuroophthalmol Serv, 243 Charles St, Boston, MA 02114 USA.
FU NIGMS NIH HHS [T32GM007753]
NR 12
TC 0
Z9 0
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 1070-8022
EI 1536-5166
J9 J NEURO-OPHTHALMOL
JI J. Neuro-Ophthal.
PD JUN
PY 2014
VL 34
IS 2
BP 149
EP 150
DI 10.1097/WNO.0000000000000062
PG 2
WC Clinical Neurology; Ophthalmology
SC Neurosciences & Neurology; Ophthalmology
GA AI9IL
UT WOS:000337246200008
PM 24135969
ER
PT J
AU Deyo, RA
Dworkin, SF
Amtmann, D
Andersson, G
Borenstein, D
Carragee, E
Carrino, J
Chou, R
Cook, K
DeLitto, A
Goertz, C
Khalsa, P
Loeser, J
Mackey, S
Panagis, J
Rainville, J
Tosteson, T
Turk, D
Von Korff, M
Weinertt, DK
AF Deyo, Richard A.
Dworkin, Samuel F.
Amtmann, Dagmar
Andersson, Gunnar
Borenstein, David
Carragee, Eugene
Carrino, John
Chou, Roger
Cook, Karon
DeLitto, Anthony
Goertz, Christine
Khalsa, Partap
Loeser, John
Mackey, Sean
Panagis, James
Rainville, James
Tosteson, Tor
Turk, Dennis
Von Korff, Michael
Weinertt, Debra K.
TI Report of the NIH Task Force on Research Standards for Chronic Low Back
Pain
SO JOURNAL OF PAIN
LA English
DT Article
DE Low back pain; chronic low back pain; research standards; minimum
dataset; NIH Task Force
ID CLINICAL-PRACTICE GUIDELINE; DEFINING CHRONIC PAIN; INFORMATION-SYSTEM
PROMIS; FUNCTION ITEM BANK; QUALITY-OF-LIFE; PRIMARY-CARE; PROGNOSTIC
APPROACH; SCREENING TOOL; START BACK; OUTCOME MEASURES
AB Despite rapidly increasing intervention, functional disability due to chronic low back pain (cLBP) has increased in recent decades. We often cannot identify mechanisms to explain the major negative impact cLBP has on patients' lives. Such cLBP is often termed non-specific and may be due to multiple biologic and behavioral etiologies. Researchers use varied inclusion criteria, definitions, baseline assessments, and outcome measures, which impede comparisons and consensus. Therefore, NIH Pain Consortium charged a Research Task Force (RTF) to draft standards for research on cLBP. The resulting multidisciplinary panel recommended using 2 questions to define cLBP; cLBP by its impact (defined by pain intensity, pain interference, and physical function); use of a minimum dataset to describe research participants (drawing heavily on the PROMIS methodology); reporting "responder analyses" in addition to mean outcome scores; and suggestions for future research and dissemination. The Pain Consortium has approved the recommendations, which investigators should incorporate into NIH grant proposals. The RTF believes that these recommendations will advance the field, help to resolve controversies, and facilitate future research addressing the genomic, neurologic, and other mechanistic substrates of chronic low back pain. We expect that the RTF recommendations will become a dynamic document and undergo continual improvement.
Perspective: A task force was convened by the NIH Pain Consortium with the goal of developing research standards for chronic low back pain. The results included recommendations for definitions, a minimum dataset, reporting outcomes, and future research. Greater consistency in reporting should facilitate comparisons among studies and the development of phenotypes. (C) 2014 by the American Pain Society. Published by Elsevier Inc. All rights reserved
C1 [Deyo, Richard A.; Chou, Roger] Oregon Hlth & Sci Univ, Portland, OR 97239 USA.
[Dworkin, Samuel F.; Amtmann, Dagmar; Loeser, John; Turk, Dennis] Univ Washington, Seattle, WA 98195 USA.
[Andersson, Gunnar] Rush Univ, Med Ctr, Chicago, IL 60612 USA.
[Borenstein, David] George Washington Univ, Washington, DC USA.
[Carragee, Eugene; Mackey, Sean] Stanford Univ, Stanford, CA 94305 USA.
[Carrino, John] Johns Hopkins Univ, Baltimore, MD USA.
[Cook, Karon] Northwestern Univ, Evanston, IL USA.
[DeLitto, Anthony; Weinertt, Debra K.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA.
[DeLitto, Anthony; Weinertt, Debra K.] Univ Pittsburgh, Pittsburgh, PA USA.
[Goertz, Christine] Palmer Coll Chiropract, Davenport, IA USA.
[Khalsa, Partap] Natl Ctr Complementary & Alternat Med, Bethesda, MD USA.
[Panagis, James] NIAMSD, Bethesda, MD 20892 USA.
[Rainville, James] New England Baptist Hosp, Roxbury Crossing, MA USA.
[Tosteson, Tor] Dartmouth Coll, Hanover, NH USA.
[Von Korff, Michael] Grp Hlth Res Inst, Seattle, WA USA.
RP Deyo, RA (reprint author), Oregon Hlth & Sci Univ, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA.
EM deyor@ohsu.edu
FU National Center for Complementary and Alternative Medicine; National
Institute for Arthritis, Musculoskeletal, and Skin Diseases
FX This study was supported by the National Center for Complementary and
Alternative Medicine and the National Institute for Arthritis,
Musculoskeletal, and Skin Diseases.
NR 127
TC 29
Z9 29
U1 9
U2 19
PU CHURCHILL LIVINGSTONE
PI EDINBURGH
PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE,
LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND
SN 1526-5900
J9 J PAIN
JI J. Pain
PD JUN
PY 2014
VL 15
IS 6
BP 569
EP 585
DI 10.1016/j.jpain.2014.03.005
PG 17
WC Clinical Neurology; Neurosciences
SC Neurosciences & Neurology
GA AJ0HM
UT WOS:000337331400001
PM 24787228
ER
PT J
AU Kwolek, CJ
Rordorf, G
Patel, VI
Rosenfield, K
Hirsch, J
Jaff, M
AF Kwolek, Christopher J.
Rordorf, Guy
Patel, Virendra I.
Rosenfield, Kenneth
Hirsch, Joshua
Jaff, Michael
TI Prospective Independent Neurologic Evaluation of Patients Undergoing
Carotid Revascularization: Can We Match the CREST results
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery
CY JUN 05-07, 2014
CL Boston, MA
SP Soc Vasc Surg
C1 [Kwolek, Christopher J.; Rordorf, Guy; Patel, Virendra I.; Rosenfield, Kenneth; Hirsch, Joshua; Jaff, Michael] Massachusetts Gen Hosp, Div Vasc & Endovasc Surg, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2014
VL 59
IS 6
SU S
BP 6S
EP 7S
PG 2
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA AI9ND
UT WOS:000337258400009
ER
PT J
AU Robinson, WP
Huang, W
Rosen, A
Schanzer, A
Fang, H
Anderson, F
Messina, L
AF Robinson, William P.
Huang, Wei
Rosen, Amy
Schanzer, Andres
Fang, Hua
Anderson, Frederick
Messina, Louis
TI Agency for Healthcare Research and Quality (AHRQ) Inpatient Quality
Indicator #11 Fails to Provide Accurate Assessment of Mortality After
Abdominal Aortic Aneurysm Repair
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery
CY JUN 05-07, 2014
CL Boston, MA
SP Soc Vasc Surg
C1 [Robinson, William P.; Schanzer, Andres; Messina, Louis] Univ Massachusetts, Sch Med, Div Vasc & Endovasc Surg, Worcester, MA USA.
[Huang, Wei; Anderson, Frederick] Univ Massachusetts, Sch Med, Ctr Outcomes Res, Worcester, MA USA.
[Fang, Hua] Univ Massachusetts, Sch Med, Dept Quantitat Hlth Sci, Worcester, MA USA.
[Rosen, Amy] VA Boston Healthcare Syst, Boston, MA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2014
VL 59
IS 6
SU S
BP 12S
EP 12S
PG 1
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA AI9ND
UT WOS:000337258400023
ER
PT J
AU Sobel, JD
Vartanian, SM
Gasper, WJ
Grenon, M
Rapp, JH
Hiramoto, JS
Chuter, TA
Reilly, LM
AF Sobel, Julia D.
Vartanian, Shant M.
Gasper, Warren J.
Grenon, Marlene
Rapp, Joseph H.
Hiramoto, Jade S.
Chuter, Timothy A.
Reilly, Linda M.
TI Factors Associated With Spinal Cord Ischemia After Multibranched
Endovascular Thoracoabdominal Aneurysm Repair
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery
CY JUN 05-07, 2014
CL Boston, MA
SP Soc Vasc Surg
C1 [Sobel, Julia D.; Vartanian, Shant M.; Gasper, Warren J.; Hiramoto, Jade S.; Chuter, Timothy A.; Reilly, Linda M.] Univ Calif San Francisco, Div Vasc & Endovasc Surg, San Francisco, CA 94143 USA.
[Grenon, Marlene; Rapp, Joseph H.] San Francisco VA Med Ctr, San Francisco, CA USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2014
VL 59
IS 6
SU S
BP 22S
EP 23S
PG 2
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA AI9ND
UT WOS:000337258400046
ER
PT J
AU Durham, CA
Wang, L
Ergul, EA
Aranson, NJ
Patel, VI
Cambria, R
Conrad, MF
AF Durham, Christopher A.
Wang, Linda
Ergul, Emel A.
Aranson, Nathan J.
Patel, Virendra I.
Cambria, Richard
Conrad, Mark F.
TI Natural History of Medically-Managed Acute Type B Aortic Dissections
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery
CY JUN 05-07, 2014
CL Boston, MA
SP Soc Vasc Surg
C1 [Durham, Christopher A.; Wang, Linda; Ergul, Emel A.; Aranson, Nathan J.; Patel, Virendra I.; Cambria, Richard; Conrad, Mark F.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2014
VL 59
IS 6
SU S
BP 24S
EP 24S
PG 1
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA AI9ND
UT WOS:000337258400049
ER
PT J
AU Ozaki, CK
Hamdan, AD
Barshes, NR
Wyers, MC
Hevelone, ND
Belkin, M
Nguyen, LL
AF Ozaki, C. K.
Hamdan, Allen D.
Barshes, Neal R.
Wyers, Mark C.
Hevelone, Nathanael D.
Belkin, Michael
Nguyen, Louis L.
TI Prospective, Randomized, Multi-Institutional Clinical Trial of a Silver
Alginate Dressing to Reduce Lower Extremity Vascular Surgery Wound
Complications
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery
CY JUN 05-07, 2014
CL Boston, MA
SP Soc Vasc Surg
C1 [Ozaki, C. K.; Hevelone, Nathanael D.; Belkin, Michael; Nguyen, Louis L.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Boston, MA 02115 USA.
[Hamdan, Allen D.; Wyers, Mark C.] Harvard Univ, Beth Israel Deaconess Med Ctr, Medidcal Sch, Boston, MA 02215 USA.
[Barshes, Neal R.] Baylor Coll Med, Michael E Debakey Vet Affairs Med Ctr, Houston, TX 77030 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2014
VL 59
IS 6
SU S
BP 31S
EP 31S
PG 1
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA AI9ND
UT WOS:000337258400063
ER
PT J
AU Azarbal, AF
Harris, S
Mitchell, E
Liem, TK
Landry, GJ
Edwards, J
McLafferty, R
Moneta, GL
AF Azarbal, Amir F.
Harris, Sheena
Mitchell, Erica
Liem, Timothy K.
Landry, Gregory J.
Edwards, James
McLafferty, Robert
Moneta, Gregory L.
TI Nasal Methacillin-Resistant Staphylococcus aureus Colonization Is
Associated With a Higher Postoperative Infection Rate After Major Lower
Extremity Amputation
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery
CY JUN 05-07, 2014
CL Boston, MA
SP Soc Vasc Surg
C1 [Azarbal, Amir F.; Edwards, James; McLafferty, Robert] Portland VA Med Ctr, Portland, OR USA.
[Harris, Sheena; Mitchell, Erica; Liem, Timothy K.; Landry, Gregory J.; Moneta, Gregory L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2014
VL 59
IS 6
SU S
BP 72S
EP 72S
PG 1
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA AI9ND
UT WOS:000337258400150
ER
PT J
AU Saraidaridis, J
Patel, VI
Lancaster, RT
Mukhopadhyay, S
Cambria, R
Conrad, MF
AF Saraidaridis, Julia
Patel, Virendra I.
Lancaster, Robert T.
Mukhopadhyay, Shankha
Cambria, Richard
Conrad, Mark F.
TI Applicability of the Society for Vascular Surgery's Objective
Performance Goals for Critical Limb Ischemia to Current Practice of
Lower Extremity Bypass
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery
CY JUN 05-07, 2014
CL Boston, MA
SP Soc Vasc Surg
C1 [Saraidaridis, Julia; Patel, Virendra I.; Lancaster, Robert T.; Mukhopadhyay, Shankha; Cambria, Richard; Conrad, Mark F.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
NR 0
TC 0
Z9 0
U1 0
U2 1
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2014
VL 59
IS 6
SU S
BP 72S
EP 72S
PG 1
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA AI9ND
UT WOS:000337258400151
ER
PT J
AU Fallon, JM
Goodney, PP
Stone, DH
Patel, VI
Nolan, BW
Kalish, JA
Zhao, YY
Hamdan, AD
AF Fallon, John M.
Goodney, Philip P.
Stone, David H.
Patel, Virendra I.
Nolan, Brian W.
Kalish, Jeffrey A.
Zhao, Yuanyuan
Hamdan, Allen D.
TI Dissecting the Results of Lower Extremity Revascularization in
Dialysis-Dependent Patients
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery
CY JUN 05-07, 2014
CL Boston, MA
SP Soc Vasc Surg
C1 [Fallon, John M.; Goodney, Philip P.; Stone, David H.; Nolan, Brian W.; Zhao, Yuanyuan] Dartmouth Hitchcock Med Ctr, Lebanon, NH 03766 USA.
[Patel, Virendra I.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Kalish, Jeffrey A.] Boston Med Ctr, Boston, MA USA.
[Hamdan, Allen D.] Beth Israel Deaconess Med Ctr, Boston, MA 02215 USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2014
VL 59
IS 6
SU S
BP 74S
EP 74S
PG 1
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA AI9ND
UT WOS:000337258400013
ER
PT J
AU Kwolek, CJ
Moore, R
AF Kwolek, Christopher J.
Moore, Randy
CA Terumo Anaconda Investigators
TI One-Year Results of the Terumo Anaconda One-Lok Trial for Endovascular
Aneurysm Repair
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery
CY JUN 05-07, 2014
CL Boston, MA
SP Soc Vasc Surg
C1 [Kwolek, Christopher J.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Moore, Randy] Peter Lougheed Ctr, Calgary, AB, Canada.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2014
VL 59
IS 6
SU S
BP 98S
EP 98S
PG 1
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA AI9ND
UT WOS:000337258400205
ER
PT J
AU Landry, GJ
Yarmosh, A
Shukla, B
Azarbal, AF
Liem, TK
Mitchell, E
McLafferty, R
Moneta, GL
AF Landry, Gregory J.
Yarmosh, Alla
Shukla, Bhavesh
Azarbal, Amir F.
Liem, Timothy K.
Mitchell, Erica
McLafferty, Robert
Moneta, Gregory L.
TI Current Status of Symptomatic Nonatherosclerotic Mesenteric Vascular
Disease
SO JOURNAL OF VASCULAR SURGERY
LA English
DT Meeting Abstract
CT Vascular Annual Meeting of the Society-for-Vascular-Surgery
CY JUN 05-07, 2014
CL Boston, MA
SP Soc Vasc Surg
C1 [Landry, Gregory J.; Yarmosh, Alla; Shukla, Bhavesh; Liem, Timothy K.; Mitchell, Erica; Moneta, Gregory L.] Oregon Hlth & Sci Univ, Portland, OR 97201 USA.
[Azarbal, Amir F.; McLafferty, Robert] Portland VA Med Ctr, Portland, OR USA.
NR 0
TC 0
Z9 0
U1 0
U2 0
PU MOSBY-ELSEVIER
PI NEW YORK
PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0741-5214
J9 J VASC SURG
JI J. Vasc. Surg.
PD JUN
PY 2014
VL 59
IS 6
SU S
BP 105S
EP 105S
PG 1
WC Surgery; Peripheral Vascular Disease
SC Surgery; Cardiovascular System & Cardiology
GA AI9ND
UT WOS:000337258400219
ER
PT J
AU Kaatz, A
Carnes, M
AF Kaatz, Anna
Carnes, Molly
TI Stuck in the Out-Group: Jennifer Can't Grow Up, Jane's Invisible, and
Janet's Over the Hill
SO JOURNAL OF WOMENS HEALTH
LA English
DT Editorial Material
ID WOMEN; STEREOTYPES; SPECIALTY; MEDICINE; CULTURE; FEMALE; SCHOOL; SEX
AB Fifty years after Title IX, women remain sparsely represented in high ranks and leadership in academic medicine. Although men and women enter the career pipeline at similar rates, academic medicine does not equivalently advance them. Currently, women account for 32% of associate professors, 20% of full professors, 14% of department chairs, and 11% of deans at U. S. medical schools-far from the near sex parity seen in medical students since the 1990s. Over 30 years of research confirms that gender stereotypes can operate to disadvantage women in review processes and consequently bar their advancement in domains like science and medicine. The authors present three vignettes to illustrate how gender stereotypes can also operate to disadvantage women in social interactions by positioning them in the "out-group" for many career-advancing opportunities. The authors argue that policies alone will not achieve gender equity in the academic medicine workforce. Addressing stereotype-based gender bias is critical for the future of academic medicine. Interventions that treat gender bias as a remediable habit show promise in promoting gender equity and transforming institutional culture to achieve the full participation of women at all career stages. A critical step is to recognize when gender stereotyped assumptions are influencing judgments and decision making in ourselves and others, challenge them as unjust, and deliberately practice replacing them with accurate and objective data.
C1 [Kaatz, Anna; Carnes, Molly] Univ Wisconsin, Ctr Womens Hlth Res, Madison, WI 53715 USA.
[Carnes, Molly] Univ Wisconsin, Dept Med, Madison, WI 53715 USA.
[Carnes, Molly] Univ Wisconsin, Dept Psychiat, Madison, WI 53715 USA.
[Carnes, Molly] Univ Wisconsin, Dept Ind & Syst Engn, Madison, WI 53715 USA.
[Carnes, Molly] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA.
RP Carnes, M (reprint author), Univ Wisconsin, Ctr Womens Hlth Res, 700 Regent St,Suite 301, Madison, WI 53715 USA.
EM mlcarnes@wisc.edu
FU NIGMS NIH HHS [R25 GM083252, R01 GM111002]
NR 27
TC 11
Z9 11
U1 3
U2 15
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
EI 1931-843X
J9 J WOMENS HEALTH
JI J. Womens Health
PD JUN
PY 2014
VL 23
IS 6
BP 481
EP 484
DI 10.1089/jwh.2014.4766
PG 4
WC Public, Environmental & Occupational Health; Medicine, General &
Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
Medicine; Obstetrics & Gynecology; Women's Studies
GA AI9BT
UT WOS:000337222700001
PM 24844292
ER
PT J
AU Vogt, D
AF Vogt, Dawne
TI Research on Gender Differences in Deployment Stress and Postdeployment
Mental Health: Addressing Conceptual and Methodological Challenges and
Expanding Our Research Agenda
SO JOURNAL OF WOMENS HEALTH
LA English
DT Editorial Material
ID COMBAT
C1 [Vogt, Dawne] VA Boston Healthcare Syst, Natl Ctr PTSD, Womens Hlth Sci Div, Boston, MA 02130 USA.
[Vogt, Dawne] Boston Univ, Sch Med, Boston, MA 02118 USA.
RP Vogt, D (reprint author), VA Boston Healthcare Syst, Natl Ctr PTSD 116B3, Womens Hlth Sci Div, 150 South Huntington Ave, Boston, MA 02130 USA.
EM Dawne.Vogt@va.gov
NR 6
TC 1
Z9 1
U1 2
U2 7
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
EI 1931-843X
J9 J WOMENS HEALTH
JI J. Womens Health
PD JUN
PY 2014
VL 23
IS 6
BP 485
EP 487
DI 10.1089/jwh.2014.4880
PG 3
WC Public, Environmental & Occupational Health; Medicine, General &
Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
Medicine; Obstetrics & Gynecology; Women's Studies
GA AI9BT
UT WOS:000337222700002
PM 24905670
ER
PT J
AU Clark, CR
Soukup, J
Riden, H
Tovar, D
Orton, P
Burdick, E
Capistran, ME
Morisset, J
Browne, EE
Fitzmaurice, G
Johnson, PA
AF Clark, Cheryl R.
Soukup, Jane
Riden, Heather
Tovar, Dora
Orton, Piper
Burdick, Elisabeth
Capistran, Mary Ellen
Morisset, Jennifer
Browne, Elizabeth E.
Fitzmaurice, Garrett
Johnson, Paula A.
TI Preventive Care for Low-Income Women in Massachusetts Post-Health Reform
SO JOURNAL OF WOMENS HEALTH
LA English
DT Article
ID MAMMOGRAPHY; INSURANCE; SERVICES
AB Background: Before enacting health insurance reform in 2006, Massachusetts provided free breast, cervical cancer, and cardiovascular risk screening for low-income uninsured women through a federally subsidized program called the Women's Health Network (WHN). This article examines whether, as women transitioned to insurance to pay for screening tests after health reform legislation was passed, cancer and cardiovascular disease screening changed among WHN participants between 2004 and 2010.
Methods: We examined claims data from the Massachusetts health insurance exchange and chart review data to measure utilization of mammography, Pap smear, and blood pressure screening among WHN participants in five community health centers in greater Boston. We conducted a longitudinal analysis, by insurance type, using generalized estimating equations to examine the likelihood of screening at recommended intervals in the postreform period compared to the prereform period.
Results: Pre- and postreform, we found a high prevalence of recommended mammography (86% vs. 88%), Pap smear (88% vs. 89%), and blood pressure screening (87% vs. 91%) that was similar or improved for most women postreform. Screening use differed by insurance type. Recommended mammography screening was statistically significantly increased among women with state-subsidized private insurance (odds ratio [OR] 1.58, p < 0.05). Women with unsubsidized private insurance or Medicare had decreased Pap smear use postreform. Although screening prevalence was high, 31% of women required state safety-net funds to pay for screening tests.
Conclusion: Our results suggest a continued need for safety-net programs to support preventive screening among low-income women after implementation of healthcare reform.
C1 [Clark, Cheryl R.; Soukup, Jane; Burdick, Elisabeth; Fitzmaurice, Garrett] Harvard Univ, Sch Med, Div Gen Med & Primary Care, Boston, MA USA.
[Clark, Cheryl R.] Ctr Community Hlth & Hlth Equ, Boston, MA USA.
[Clark, Cheryl R.] Brigham & Womens Faulkner Hospitalist Program, Boston, MA USA.
[Clark, Cheryl R.; Riden, Heather; Tovar, Dora; Johnson, Paula A.] Brigham & Womens Hosp, Div Womens Hlth, Boston, MA 02120 USA.
[Riden, Heather; Tovar, Dora; Orton, Piper; Johnson, Paula A.] Brigham & Womens Hosp, Connors Ctr Womens Hlth & Gender Biol, Boston, MA 02120 USA.
[Capistran, Mary Ellen] Massachusetts Gen Hosp, Chelsea HealthCare Ctr, Chelsea, MA USA.
[Morisset, Jennifer] Mattapan Community Hlth Ctr, Boston, MA USA.
[Browne, Elizabeth E.] Joseph M Smith Community Hlth Ctr, Allston, MA USA.
RP Clark, CR (reprint author), Brigham & Womens Hosp, Div Gen Med & Primary Care, 1620 Tremont St,OBC 2, Boston, MA 02120 USA.
EM crclark@partners.org
FU CDC [U58DP000821]; Advancing System Improvements to Support Targets for
Healthy People (ASIST) grant from the Office on Women's Health in the US
Department of Health and Human Services [ASTWH070011]
FX This article was supported by CDC Cooperative Agreement Number
U58DP000821. Its contents are solely the responsibility of the authors
and do not necessarily represent the official views of CDC. All authors'
work related to this article was supported by Advancing System
Improvements to Support Targets for Healthy People (ASIST) 2010 grant
(No. ASTWH070011) from the Office on Women's Health in the US Department
of Health and Human Services. We acknowledge the ongoing assistance from
the Connors Center for Women's Health and Gender Biology at Brigham and
Women's Hospital for making this work possible.
NR 16
TC 6
Z9 6
U1 1
U2 5
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-9996
EI 1931-843X
J9 J WOMENS HEALTH
JI J. Womens Health
PD JUN
PY 2014
VL 23
IS 6
BP 493
EP 498
DI 10.1089/jwh.2013.4612
PG 6
WC Public, Environmental & Occupational Health; Medicine, General &
Internal; Obstetrics & Gynecology; Women's Studies
SC Public, Environmental & Occupational Health; General & Internal
Medicine; Obstetrics & Gynecology; Women's Studies
GA AI9BT
UT WOS:000337222700004
PM 24798240
ER
PT J
AU Greenberg, SM
Salman, RAS
Biessels, GJ
van Buchem, M
Cordonnier, C
Lee, JM
Montaner, J
Schneider, JA
Smith, EE
Vernooij, M
Werring, DJ
AF Greenberg, Steven M.
Salman, Rustam Al-Shahi
Biessels, Geert Jan
van Buchem, Mark
Cordonnier, Charlotte
Lee, Jin-Moo
Montaner, Joan
Schneider, Julie A.
Smith, Eric E.
Vernooij, Meike
Werring, David J.
TI Developing biomarkers for cerebral amyloid angiopathy trials: do
potential disease phenotypes hold promise? Reply
SO LANCET NEUROLOGY
LA English
DT Letter
ID CLINICAL SPECTRUM
C1 [Greenberg, Steven M.] Massachusetts Gen Hosp, MGH Stroke Res Ctr, Boston, MA 02114 USA.
[Salman, Rustam Al-Shahi] Univ Edinburgh, Ctr Clin Brain Sci, Div Clin Neurosci, Edinburgh, Midlothian, Scotland.
[Biessels, Geert Jan] Univ Med Ctr Utrecht, Brain Ctr Rudolf Magnus, Utrecht, Netherlands.
[van Buchem, Mark] Leiden Univ, Dept Radiol, Med Ctr, Leiden, Netherlands.
[Cordonnier, Charlotte] Univ Lille Nord France, Lille Univ Hosp, Dept Neurol, Lille, France.
[Lee, Jin-Moo] Washington Univ, Sch Med, Dept Neurol, Dept Radiol, St Louis, MO 63110 USA.
[Lee, Jin-Moo] Washington Univ, Sch Med, Dept Biomed Engn, St Louis, MO USA.
[Montaner, Joan] Vail dHebron Univ Hosp & Res Inst, Dept Neurol, Barcelona, Spain.
[Montaner, Joan] Autonomous Univ Barcelona, Res Inst, Barcelona, Spain.
[Schneider, Julie A.] Rush Univ, Dept Pathol, Med Ctr, Chicago, IL 60612 USA.
[Schneider, Julie A.] Rush Univ, Med Ctr, Dept Neurol Sci, Chicago, IL 60612 USA.
[Smith, Eric E.] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada.
[Vernooij, Meike] Erasmus Univ, Dept Radiol & Epidemiol, Med Ctr, Rotterdam, Netherlands.
[Werring, David J.] UCL Inst Neurol, London, England.
RP Greenberg, SM (reprint author), Massachusetts Gen Hosp, MGH Stroke Res Ctr, Boston, MA 02114 USA.
EM sgreenberg@mgh.harvard.edu
RI Smith, Eric/C-5443-2012; Montaner, Joan/D-3063-2015; IBIS,
NEUROVASCULAR/O-1855-2015
OI Smith, Eric/0000-0003-3956-1668;
FU Medical Research Council [G1002605]
NR 6
TC 0
Z9 0
U1 0
U2 6
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 1474-4422
EI 1474-4465
J9 LANCET NEUROL
JI Lancet Neurol.
PD JUN
PY 2014
VL 13
IS 6
BP 540
EP 540
PG 1
WC Clinical Neurology
SC Neurosciences & Neurology
GA AI8YK
UT WOS:000337212700013
PM 24849857
ER
PT J
AU Whitman, SP
Kohlschmidt, J
Maharry, K
Volinia, S
Mrozek, K
Nicolet, D
Schwind, S
Becker, H
Metzeler, KH
Mendler, JH
Eisfeld, AK
Carroll, AJ
Powell, BL
Carter, TH
Baer, MR
Kolitz, JE
Park, IK
Stone, RM
Caligiuri, MA
Marcucci, G
Bloomfield, CD
AF Whitman, S. P.
Kohlschmidt, J.
Maharry, K.
Volinia, S.
Mrozek, K.
Nicolet, D.
Schwind, S.
Becker, H.
Metzeler, K. H.
Mendler, J. H.
Eisfeld, A-K
Carroll, A. J.
Powell, B. L.
Carter, T. H.
Baer, M. R.
Kolitz, J. E.
Park, I-K
Stone, R. M.
Caligiuri, M. A.
Marcucci, G.
Bloomfield, C. D.
TI GAS6 expression identifies high-risk adult AML patients: potential
implications for therapy
SO LEUKEMIA
LA English
DT Article
DE GAS6; acute myeloid leukemia; prognosis
ID ACUTE MYELOID-LEUKEMIA; INTERNAL TANDEM DUPLICATIONS; RECEPTOR TYROSINE
KINASES; AGE 60 YEARS; GROUP-B; OLDER PATIENTS; GROWTH ARREST; DISTINCT
GENE; PROGNOSTIC-SIGNIFICANCE; PREDICTS ADVERSE
AB Emerging data demonstrate important roles for the TYRO3/AXL/MERTK receptor tyrosine kinase (TAM RTK) family in diverse cancers. We investigated the prognostic relevance of GAS6 expression, encoding the common TAM RTK ligand, in 270 adults (n=71 aged <60 years; n=199 aged >= 60 years) with de novo cytogenetically normal acute myeloid leukemia (CN-AML). Patients expressing GAS6 (GAS6+), especially those aged >= 60 years, more often failed to achieve a complete remission (CR). In all patients, GAS6+ patients had shorter disease-free (DFS) and overall (OS) survival than patients without GAS6 expression (GAS6-). After adjusting for other prognostic markers, GAS6+ predicted CR failure (P=0.02), shorter DFS (P=0.004) and OS (P=0.04). To gain further biological insights, we derived a GAS6-associated gene-expression signature (P<0.001) that in GAS6+ patients included overexpressed BAALC and MN1, known to confer adverse prognosis in CN-AML, and overexpressed CXCL12, encoding stromal cell-derived factor, and its receptor genes, chemokine (C-X-C motif) receptor 4 (CXCR4) and CXCR7. This study reports for the first time that GAS6 expression is an adverse prognostic marker in CN-AML. Although GAS6 decoy receptors are not yet available in the clinic for GAS6+ CN-AML therapy, potential alternative therapies targeting GAS6+-associated pathways, for example, CXCR4 antagonists, may be considered for GAS6+ patients to sensitize them to chemotherapy.
C1 [Whitman, S. P.; Kohlschmidt, J.; Maharry, K.; Mrozek, K.; Nicolet, D.; Schwind, S.; Becker, H.; Metzeler, K. H.; Mendler, J. H.; Eisfeld, A-K; Park, I-K; Caligiuri, M. A.; Marcucci, G.; Bloomfield, C. D.] Ohio State Univ, Ctr Comprehens Canc, Columbus, OH 43210 USA.
[Kohlschmidt, J.; Maharry, K.; Nicolet, D.] Mayo Clin, Alliance Clin Trials Oncol Stat, Rochester, MN USA.
[Kohlschmidt, J.; Maharry, K.; Nicolet, D.] Mayo Clin, Ctr Data, Rochester, MN USA.
[Volinia, S.] Ohio State Univ, Dept Mol Virol Immunol & Med Genet, Columbus, OH 43210 USA.
[Carroll, A. J.] Univ Alabama Birmingham, Dept Genet, Birmingham, AL USA.
[Powell, B. L.] Wake Forest Univ, Ctr Comprehens Canc, Winston Salem, NC 27109 USA.
[Carter, T. H.] Univ Iowa, Dept Internal Med, Iowa City, IA 52242 USA.
[Baer, M. R.] Univ Maryland, Greenebaum Canc Ctr, Baltimore, MD 21201 USA.
[Kolitz, J. E.] N Shore Univ Hosp, Manhasset, NY USA.
[Stone, R. M.] Dana Farber Canc Inst, Boston, MA 02115 USA.
RP Caligiuri, MA (reprint author), Ohio State Univ, Ctr Comprehens Canc, James Canc Hosp, Suite 519,300W,10th Ave, Columbus, OH 43210 USA.
EM michael.caligiuri@osumc.edu; guido.marcucci@osumc.edu;
clara.bloomfield@osumc.edu
RI Mrozek, Krzysztof/A-3142-2008; Metzeler, Klaus/C-2118-2009;
OI Metzeler, Klaus/0000-0003-3920-7490; Carter, Thomas/0000-0001-7796-2986;
Mendler, Jason/0000-0001-5605-5324; Volinia, Stefano/0000-0003-0910-3893
FU National Cancer Institute [CA101140, CA114725, CA140158, CA31946,
CA33601, CA16058, CA77658, CA129657]; Coleman Leukemia Research
Foundation; Deutsche Krebshilfe-Dr Mildred Scheel Cancer Foundation;
Pelotonia Fellowship Program; Conquer Cancer Foundation
FX We thank Donna Bucci and the Alliance Leukemia Tissue Bank for sample
processing and storage services, Lisa J Sterling and Christine Finks for
data management and the OSU NCI-designated Comprehensive Cancer Center
Microarray and Nucleic Acid shared resources for sample analyses. We
also thank Dan Sargent for critical review of the manuscript. We also
thank the physicians, nurses, clinical support staff and, most of all,
patients for their invaluable contributions to these studies. This work
was supported in part by the National Cancer Institute (Grants CA101140,
CA114725, CA140158, CA31946, CA33601, CA16058, CA77658 and CA129657),
the Coleman Leukemia Research Foundation, the Deutsche Krebshilfe-Dr
Mildred Scheel Cancer Foundation (to HB), the Pelotonia Fellowship
Program (to A-KE), and the Conquer Cancer Foundation (to JHM).
NR 62
TC 17
Z9 17
U1 0
U2 3
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
EI 1476-5551
J9 LEUKEMIA
JI Leukemia
PD JUN
PY 2014
VL 28
IS 6
BP 1252
EP 1258
DI 10.1038/leu.2013.371
PG 7
WC Oncology; Hematology
SC Oncology; Hematology
GA AI9DV
UT WOS:000337230300009
PM 24326683
ER
PT J
AU Maroz, A
Stachorski, L
Emmrich, S
Reinhardt, K
Xu, J
Shao, Z
Kabler, S
Dertmann, T
Hitzler, J
Roberts, I
Vyas, P
Juban, G
Hennig, C
Hansen, G
Li, Z
Orkin, S
Reinhardt, D
Klusmann, JH
AF Maroz, A.
Stachorski, L.
Emmrich, S.
Reinhardt, K.
Xu, J.
Shao, Z.
Kaebler, S.
Dertmann, T.
Hitzler, J.
Roberts, I.
Vyas, P.
Juban, G.
Hennig, C.
Hansen, G.
Li, Z.
Orkin, S.
Reinhardt, D.
Klusmann, J-H
TI GATA1s induces hyperproliferation of eosinophil precursors in Down
syndrome transient leukemia
SO LEUKEMIA
LA English
DT Article
DE Down syndrome; eosinophilia; GATA1s; MYC; E2F
ID ACUTE MEGAKARYOBLASTIC LEUKEMIA; CELL-CYCLE PROGRESSION; IN-VIVO
BIOTINYLATION; EMBRYONIC STEM-CELLS; MAJOR BASIC-PROTEIN;
MYELOID-LEUKEMIA; TRANSCRIPTION FACTORS; CHROMATIN OCCUPANCY; BLAST
CELLS; MAST-CELLS
AB Transient leukemia (TL) is evident in 5-10% of all neonates with Down syndrome (DS) and associated with N-terminal truncating GATA1 mutations (GATA1s). Here we report that TL-cell clones generate abundant eosinophils in a substantial fraction of patients. Sorted eosinophils from patients with TL and eosinophilia carried the same GATA1s mutations as sorted TL blasts, consistent with their clonal origin. TL blasts exhibited a genetic program characteristic of eosinophils and differentiated along the eosinophil lineage in vitro. Similarly, ectopic expression of Gata1s, but not Gata1, in wild-type CD34(+)-hematopoietic stem and progenitor cells induced hyperproliferation of eosinophil promyelocytes in vitro. Although GATA1s retained the function of GATA1 to induce eosinophil genes by occupying their promoter regions, GATA1s was impaired in its ability to repress oncogenic MYC and the pro-proliferative E2F transcription network. Chromatin Immunoprecipitation Sequencing (ChIP-seq) indicated reduced GATA1s occupancy at the MYC promoter. Knockdown of MYC, or the obligate E2F-cooperation partner DP1, rescued the GATA1s-induced hyperproliferative phenotype. In agreement, terminal eosinophil maturation was blocked in Gata1(Delta e2) knockin mice, exclusively expressing Gata1s, leading to accumulation of eosinophil precursors in blood and bone marrow. These data suggest a direct relationship between the N-terminal truncating mutations of GATA1 and clonal eosinophilia in DS patients.
C1 [Maroz, A.; Stachorski, L.; Emmrich, S.; Reinhardt, K.; Kaebler, S.; Dertmann, T.; Reinhardt, D.; Klusmann, J-H] Hannover Med Sch, Dept Pediat Hematol & Oncol, D-30625 Hannover, Germany.
[Xu, J.; Shao, Z.; Orkin, S.] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA.
[Xu, J.; Shao, Z.; Orkin, S.] Harvard Univ, Sch Med, Howard Hughes Med Inst, Boston, MA 02115 USA.
[Xu, J.; Shao, Z.; Orkin, S.] Harvard Univ, Sch Med, Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02115 USA.
[Hitzler, J.] Hosp Sick Children, Dept Pediat, Div Hematol Oncol, Toronto, ON M5G 1X8, Canada.
[Roberts, I.] Univ Oxford, Dept Paediat, Childrens Hosp, Oxford, England.
[Roberts, I.] John Radcliffe Hosp, Weatherall Inst Mol Med, Mol Haematol Unit, Oxford, England.
[Vyas, P.; Juban, G.] Univ Oxford, Weatherall Inst Mol Med, MRC Mol Haematol Unit, Oxford, England.
[Vyas, P.; Juban, G.] NHS Trust, Oxford Univ Hosp, Dept Haematol, Oxford, England.
[Hennig, C.; Hansen, G.] Hannover Med Sch, Dept Pediat Pneumol, Hannover, Germany.
[Li, Z.] Harvard Univ, Brigham & Womens Hosp, Sch Med, Div Genet, Boston, MA 02115 USA.
RP Klusmann, JH (reprint author), Hannover Med Sch, Dept Pediat Hematol & Oncol, Carl Neuberg Str 1, D-30625 Hannover, Germany.
EM Klusmann.jan-henning@mh-hannover.de
RI Klusmann, Jan-Henning/M-9655-2015;
OI Klusmann, Jan-Henning/0000-0002-1070-0727; Vyas,
Paresh/0000-0003-3931-0914
FU Hannover Biomedical Research School; German Research Foundation
[KL-2374/2-1, KL-2374/1-1]
FX The authors thank J Strouboulis and E Karkoulia for providing
BioGata1/Gata1s ESCs. J Schoening for general lab support;
Drs K Weber and B Fehse for providing plasmids; Dr A Mirenska for chip
cytometry data analysis; Dr R Geffers for microarray analysis. AM, LS,
SE and TD were supported by the Hannover Biomedical Research School. JHK
is a fellow of the Emmy Noether-Programme from the German Research
Foundation (KL-2374/2-1). This work was supported by a grant to JHK from
the German Research Foundation (KL-2374/1-1).
NR 58
TC 6
Z9 6
U1 0
U2 6
PU NATURE PUBLISHING GROUP
PI LONDON
PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND
SN 0887-6924
EI 1476-5551
J9 LEUKEMIA
JI Leukemia
PD JUN
PY 2014
VL 28
IS 6
BP 1259
EP 1270
DI 10.1038/leu.2013.373
PG 12
WC Oncology; Hematology
SC Oncology; Hematology
GA AI9DV
UT WOS:000337230300010
PM 24336126
ER
PT J
AU Guo, FJ
Moellering, DR
Garvey, WT
AF Guo, Fangjian
Moellering, Douglas R.
Garvey, W. Timothy
TI Use of HbA1c for Diagnoses of Diabetes and Prediabetes: Comparison with
Diagnoses Based on Fasting and 2-Hr Glucose Values and Effects of
Gender, Race, and Age
SO METABOLIC SYNDROME AND RELATED DISORDERS
LA English
DT Article
ID LIFE-STYLE; PREVENTION PROGRAM; HEMOGLOBIN A(1C); TOLERANCE; ADULTS;
A1C; PREVALENCE; TRIAL; CLASSIFICATION; MANAGEMENT
AB Background: Glycated hemoglobin (HbA1c) has been advocated for the diagnosis of diabetes and prediabetes. Its performance has been commonly assessed in corroboration with elevated fasting plasma glucose (FPG), but not the combination of FPG and 2-hr glucose values. This study assesses receiver operating characteristics (ROC) curves of HbA1c pertaining to the diagnoses of prediabetes and diabetes by FPG and/or 2-hr glucose, and the effects of age, gender, and race.
Methods: We assessed the utility of HbA1c for diagnosing diabetes and prediabetes among 5395 adults without known diabetes from the National Health and Nutrition Examination Survey (NHANES) 2005-2010.
Results: Current cutoffs of HbA1c for diabetes (6.5%) or prediabetes (5.7%) exhibited low sensitivity (0.249 and 0.354, respectively) and high specificity in identifying patients diagnosed using both FPG and 2-hr glucose, resulting in large false-negative rates (75.1% and 64.9%). Misdiagnosis rates increased with age and in non-Hispanic whites and Mexican Americans. When HbA1c was combined with FPG for diagnoses, the false-negative rate remained high for diabetes (45.7%), but was reduced for prediabetes (9.2%).
Conclusions: When assessed against diagnoses using both FPG and 2-hr glucose, HbA1c had low sensitivity and high specificity for identifying diabetes and prediabetes, which varied as a function of age and race. Regarding recently released American Diabetes Association (ADA) and joint European guidelines, it is important to consider that HbA1c values below 6.5% and 5.7% do not reliably exclude the presence of diabetes and prediabetes, respectively. Overall, the data argue for greater use of oral glucose tolerance tests (OGTTs) and both FPG and 2-hr glucose values for diagnosis of diabetes and prediabetes.
C1 [Guo, Fangjian; Moellering, Douglas R.; Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35233 USA.
[Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA.
RP Guo, FJ (reprint author), Univ Alabama Birmingham, Dept Nutr Sci, Webb 241,1675 Univ Blvd, Birmingham, AL 35233 USA.
EM ilovedd@uab.edu; garveyt@uab.edu
RI Guo, Fangjian/B-7705-2015
OI Guo, Fangjian/0000-0003-3729-2724
FU Merit Review program of the Department of Veterans Affairs, National
Institutes of Health [DK-038765, DK-083562]; UAB Diabetes Research
Center [P30-DK079626]
FX We gratefully acknowledge our funding resources, including the Merit
Review program of the Department of Veterans Affairs, National
Institutes of Health (DK-038765 and DK-083562), and the UAB Diabetes
Research Center (P30-DK079626). All data used in this study were
collected by the National Center for Health Statistics Centers for
Disease Control and Prevention.
NR 35
TC 16
Z9 18
U1 4
U2 18
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1540-4196
EI 1557-8518
J9 METAB SYNDR RELAT D
JI Metab. Syndr. Relat. Disord.
PD JUN
PY 2014
VL 12
IS 5
BP 258
EP 268
DI 10.1089/met.2013.0128
PG 11
WC Medicine, Research & Experimental
SC Research & Experimental Medicine
GA AI9JV
UT WOS:000337249800003
PM 24512556
ER
PT J
AU Tsai, SQ
Wyvekens, N
Khayter, C
Foden, JA
Thapar, V
Reyon, D
Goodwin, MJ
Aryee, MJ
Joung, JK
AF Tsai, Shengdar Q.
Wyvekens, Nicolas
Khayter, Cyd
Foden, Jennifer A.
Thapar, Vishal
Reyon, Deepak
Goodwin, Mathew J.
Aryee, Martin J.
Joung, J. Keith
TI Dimeric CRISPR RNA-guided Fokl nucleases for highly specific genome
editing
SO NATURE BIOTECHNOLOGY
LA English
DT Article
ID ZINC-FINGER NUCLEASES; TARGET DNA; CAS9; ENDONUCLEASE; ACTIVATION;
NICKASES; TALENS; SYSTEM; GENES
AB Monomeric CRISPR-Cas9 nucleases are widely used for targeted genome editing but can induce unwanted off-target mutations with high frequencies. Here we describe dimeric RNA-guided FokI nucleases (RFNs) that can recognize extended sequences and edit endogenous genes with high efficiencies in human cells. RFN cleavage activity depends strictly on the binding of two guide RNAs (gRNAs) to DNA with a defined spacing and orientation substantially reducing the likelihood that a suitable target site will occur more than once in the genome and therefore improving specificities relative to wild-type Cas9 monomers. RFNs guided by a single gRNA generally induce lower levels of unwanted mutations than matched monomeric Cas9 nickases. In addition, we describe a simple method for expressing multiple gRNAs bearing any 5' end nucleotide, which gives dimeric RFNs a broad targeting range. RFNs combine the ease of RNA-based targeting with the specificity enhancement inherent to dimerization and are likely to be useful in applications that require highly precise genome editing.
C1 [Tsai, Shengdar Q.; Wyvekens, Nicolas; Khayter, Cyd; Foden, Jennifer A.; Thapar, Vishal; Reyon, Deepak; Goodwin, Mathew J.; Aryee, Martin J.; Joung, J. Keith] Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA 02129 USA.
[Tsai, Shengdar Q.; Wyvekens, Nicolas; Khayter, Cyd; Foden, Jennifer A.; Thapar, Vishal; Reyon, Deepak; Goodwin, Mathew J.; Aryee, Martin J.; Joung, J. Keith] Massachusetts Gen Hosp, Ctr Canc Res, Charlestown, MA USA.
[Tsai, Shengdar Q.; Wyvekens, Nicolas; Khayter, Cyd; Foden, Jennifer A.; Reyon, Deepak; Goodwin, Mathew J.; Joung, J. Keith] Massachusetts Gen Hosp, Ctr Computat & Integrat Biol, Charlestown, MA USA.
[Tsai, Shengdar Q.; Reyon, Deepak; Aryee, Martin J.; Joung, J. Keith] Harvard Univ, Sch Med, Dept Pathol, Boston, MA 02115 USA.
RP Joung, JK (reprint author), Massachusetts Gen Hosp, Mol Pathol Unit, Charlestown, MA 02129 USA.
EM jjoung@mgh.harvard.edu
FU National Institutes of Health (NIH) Director's Pioneer Award [DP1
GM105378, NIH R01 GM088040, NIH P50 HG005550, NIH R01 AR063070]; Jim and
Ann Orr Massachusetts General Hospital (MGH) Research Scholar Award; NIH
[F32 GM105189]; US Army Research Laboratory and the US Army Research
Office [W911NF-11-2-0056]
FX We thank Y. Fu and M. Maeder for helpful discussions and Y. Fu, J.
Angstman and B. Kleinstiver for comments on the manuscript. This work
was funded by a National Institutes of Health (NIH) Director's Pioneer
Award (DP1 GM105378), NIH R01 GM088040, NIH P50 HG005550, NIH R01
AR063070, and the Jim and Ann Orr Massachusetts General Hospital (MGH)
Research Scholar Award. S.Q.T. was supported by NIH F32 GM105189. This
material is based upon work supported by, or in part by, the US Army
Research Laboratory and the US Army Research Office under grant number
W911NF-11-2-0056. Plasmids described in this work will be deposited with
and made available through the nonprofit plasmid distribution service
Addgene (http://www. addgene. org/crispr-cas).
NR 31
TC 278
Z9 306
U1 22
U2 114
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1087-0156
EI 1546-1696
J9 NAT BIOTECHNOL
JI Nat. Biotechnol.
PD JUN
PY 2014
VL 32
IS 6
BP 569
EP +
DI 10.1038/nbt.2908
PG 9
WC Biotechnology & Applied Microbiology
SC Biotechnology & Applied Microbiology
GA AI9EV
UT WOS:000337233800020
PM 24770325
ER
PT J
AU Chen, JY
Feeney, ER
Chung, RT
AF Chen, Jennifer Y.
Feeney, Eoin R.
Chung, Raymond T.
TI HCV and HIV co-infection: mechanisms and management
SO NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Review
ID HEPATITIS-C-VIRUS; HUMAN-IMMUNODEFICIENCY-VIRUS; INTERFERON PLUS
RIBAVIRIN; SUSTAINED VIROLOGICAL RESPONSE; ACTIVE ANTIRETROVIRAL
THERAPY; LIVER-RELATED COMPLICATIONS; TO-CHILD TRANSMISSION;
INJECTION-DRUG USERS; ALL-CAUSE MORTALITY; INFECTED PATIENTS
AB HCV and HIV co-infection is associated with accelerated hepatic fibrosis progression and higher rates of liver decompensation and death compared to HCV monoinfection, and liver disease is a leading cause of non-AIDS-related mortality among HIV-infected patients. New insights have revealed multiple mechanisms by which HCV and HIV lead to accelerated disease progression, specifically that HIV infection increases HCV replication, augments HCV-induced hepatic inflammation, increases hepatocyte apoptosis, increases microbial translocation from the gut and leads to an impairment of HCV-specific immune responses. Treatment of HIV with antiretroviral therapy and treatment of HCV have independently been shown to delay the progression of fibrosis and reduce complications from end-stage liver disease among co-infected patients. However, rates of sustained virologic response with PEG-IFN and ribavirin have been significantly inferior among co-infected patients compared with HCV-monoinfected patients, and treatment uptake has remained low given the limited efficacy and tolerability of current HCV regimens. With multiple direct-acting antiviral agents in development to treat HCV, a unique opportunity exists to redefine the treatment paradigm for co-infected patients, which incorporates data on fibrosis stage as well as potential drug interactions with antiretroviral therapy.
C1 [Chen, Jennifer Y.; Chung, Raymond T.] Massachusetts Gen Hosp, Ctr Liver, Boston, MA 02114 USA.
[Chen, Jennifer Y.; Chung, Raymond T.] Massachusetts Gen Hosp, Div Gastroenterol, Boston, MA 02114 USA.
[Feeney, Eoin R.] Massachusetts Gen Hosp, Div Infect Dis, Boston, MA 02114 USA.
RP Chung, RT (reprint author), Massachusetts Gen Hosp, Ctr Liver, 55 Fruit St, Boston, MA 02114 USA.
EM rtchung@partners.org
OI Feeney, Eoin/0000-0003-4118-4945
FU HHS/NIH [T32DK007191, DK098079, DA033541]; Harvard University Center for
AIDS Research (HU CFAR NIH/NIAID fund) [5P30AI060354-09]
FX The work of the authors is supported by HHS/NIH grants T32DK007191
(J.Y.C.), DK098079 and DA033541 (R.T.C.) and by the Harvard University
Center for AIDS Research (HU CFAR NIH/NIAID fund 5P30AI060354-09 to
E.R.F.).
NR 133
TC 48
Z9 50
U1 2
U2 12
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-5045
EI 1759-5053
J9 NAT REV GASTRO HEPAT
JI Nat. Rev. Gastroenterol. Hepatol.
PD JUN
PY 2014
VL 11
IS 6
DI 10.1038/nrgastro.2014.17
PG 10
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AI9DX
UT WOS:000337230500007
PM 24535328
ER
PT J
AU Genta, RM
Sonnenberg, A
AF Genta, Robert M.
Sonnenberg, Amnon
TI Big data in gastroenterology research
SO NATURE REVIEWS GASTROENTEROLOGY & HEPATOLOGY
LA English
DT Article
ID INFLAMMATORY-BOWEL-DISEASE; PEPTIC-ULCER DISEASE; HELICOBACTER-PYLORI;
HOSPITAL ADMISSION; BARRETTS-ESOPHAGUS; SURVEILLANCE; RISK; PREVALENCE;
ENDOSCOPY; MORTALITY
AB In epidemiological research, large datasets are essential to reliably capture small variations among comparative groups or detect new unsuspected associations. Although large databases of web-search information, social media, airline traffic and telephone records are already widely used to capture social trends, large databases in medical research are just emerging. With the universal use of electronic medical records underway, vast amounts of health-related information will become available for biomedical research. Accepting such new research tools-based on the analysis of large pre-existing datasets rather than hypothesis-driven, in-depth prospective study-will require a new mindset in clinical research, as data might be `messy' and only associations, but not causality, can be detected. In spite of such limitations, the utilization of these new resources for medical research harbours great potential for advancing knowledge about digestive diseases.
C1 [Genta, Robert M.] Univ Texas SW Med Ctr Dallas, Med Ctr, Dallas, TX 75390 USA.
[Genta, Robert M.] Mirace Life Sci, Miraca Life Sci Res Inst, Irving, TX 75039 USA.
[Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Portland, OR 97239 USA.
RP Genta, RM (reprint author), Univ Texas SW Med Ctr Dallas, Med Ctr, 5323 Harry Hines Blvd, Dallas, TX 75390 USA.
EM robert.genta@utsouthwestern.edu
NR 39
TC 8
Z9 8
U1 1
U2 24
PU NATURE PUBLISHING GROUP
PI NEW YORK
PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA
SN 1759-5045
EI 1759-5053
J9 NAT REV GASTRO HEPAT
JI Nat. Rev. Gastroenterol. Hepatol.
PD JUN
PY 2014
VL 11
IS 6
DI 10.1038/nrgastro.2014.18
PG 5
WC Gastroenterology & Hepatology
SC Gastroenterology & Hepatology
GA AI9DX
UT WOS:000337230500009
PM 24594912
ER
PT J
AU Musolino, PL
Lund, TC
Pan, J
Escolar, ML
Paker, AM
Duncan, CN
Eichler, FS
AF Musolino, Patricia L.
Lund, Troy C.
Pan, Jessica
Escolar, Maria L.
Paker, Asif M.
Duncan, Christine N.
Eichler, Florian S.
TI Hematopoietic Stem Cell Transplantation in the Leukodystrophies: A
Systematic Review of the Literature
SO NEUROPEDIATRICS
LA English
DT Review
DE leukodystrophy; bone marrow transplantation; white matter diseases
ID X-LINKED ADRENOLEUKODYSTROPHY; UMBILICAL-CORD BLOOD;
BONE-MARROW-TRANSPLANTATION; NEUROCOGNITIVE FUNCTION;
PEDIATRIC-PATIENTS; KRABBE-DISEASE; OUTCOMES; PROGRESSION
AB Objective The objective of this study is to systematically review the literature on worldwide numbers of leukodystrophy patients undergoing hematopoietic stem cell transplantation (HSCT) as well as the safety and efficacy of the procedure in this patient population.
Materials and Methods A PubMed and EMBASE search up to June 2012 was conducted with a manual search of references from relevant articles. Selected studies were evaluated using internationally accepted criteria. The effect estimates of HSCT upon survival in early-stage disease versus late-stage disease were compared.
Results One hundred and fifty-two studies qualified for inclusion and reported on a total of 689 patients. Study quality ranged from poor to good; no study was rated excellent. Small sample sizes limited most studies. Meta-analysis in a subset of larger studies indicates that transplantation in earlier stages of disease fairs better than in the late stages. Beyond survival, little longitudinal data on functional outcome is reported and neurological outcome is sparse.
Conclusion Further studies are needed to determine the neurological outcome following HSCT in the leukodystrophies. HSCT in the early stages of cerebral disease is still recommended for select leukodystrophies.
C1 [Musolino, Patricia L.; Pan, Jessica; Paker, Asif M.; Eichler, Florian S.] Massachusetts Gen Hosp, Dept Neurol, Boston, MA 02114 USA.
[Lund, Troy C.] Univ Minnesota, Div Pediat Blood & Marrow Transplantat, Minneapolis, MN USA.
[Escolar, Maria L.] Univ Pittsburgh, Dept Pediat, Pittsburgh, PA 15260 USA.
[Duncan, Christine N.] Boston Childrens Hosp, Dana Farber Canc Inst, Boston, MA USA.
RP Eichler, FS (reprint author), Massachusetts Gen Hosp, Dept Neurol, 55 Fruit St,ACC 708, Boston, MA 02114 USA.
EM feichler@partners.org
RI Escolar, Maria/J-3721-2016
FU Bluebird Bio
FX Florian Eichler and Asif Paker have served as consultants to Bluebird
Bio (Cambridge, Massachusetts, United States). Florian Eichler and
Christine Duncan are both coinvestigators of a clinical trial of gene
therapy for X-linked ALD sponsored by Bluebird Bio.
NR 16
TC 9
Z9 9
U1 0
U2 7
PU GEORG THIEME VERLAG KG
PI STUTTGART
PA RUDIGERSTR 14, D-70469 STUTTGART, GERMANY
SN 0174-304X
EI 1439-1899
J9 NEUROPEDIATRICS
JI Neuropediatrics
PD JUN
PY 2014
VL 45
IS 3
BP 169
EP 174
DI 10.1055/s-0033-1364179
PG 6
WC Clinical Neurology; Pediatrics
SC Neurosciences & Neurology; Pediatrics
GA AI8NG
UT WOS:000337173900004
PM 24459069
ER
PT J
AU Connery, HS
Albright, BB
Rodolico, JM
AF Connery, Hilary Smith
Albright, Brittany B.
Rodolico, John M.
TI Adolescent Substance Use and Unplanned Pregnancy Strategies for Risk
Reduction
SO OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Adolescents; Substance use; Unintended pregnancy; Contraception;
Motivational interviewing
ID ACTING REVERSIBLE CONTRACEPTION; ALCOHOL-EXPOSED PREGNANCIES; UNINTENDED
PREGNANCY; UNITED-STATES; MENTAL-HEALTH; MOTIVATIONAL INTERVENTION;
SEXUAL RISK; YOUNG-WOMEN; DRUG-USE; ABUSE
AB Substance use among adolescents increases the risk of unplanned pregnancies, which then increases the risk of fetal exposure to addictive, teratogenic substances. Specific interventions are necessary to target pregnancy planning and contraception among reproductive-age substance users. Screening for substance use using the CRAFFT is recommended in all health care settings treating adolescent patients. Screening for tobacco and nicotine use is also recommended along with the provision of smoking cessation interventions. Using motivational interviewing style and strategies is recommended to engage adolescents in discussions related to reducing substance use, risky sexual behavior, and probability of unplanned pregnancy or late-detection pregnancy.
C1 [Connery, Hilary Smith] McLean Hosp, Div Alcohol & Drug Abuse, Belmont, MA 02478 USA.
[Connery, Hilary Smith] Harvard Univ, Sch Med, Dept Psychiat, Boston, MA 02115 USA.
[Albright, Brittany B.] Massachusetts Gen Hosp, McLean Hosp, Adult Psychiat Residency Program, Boston, MA 02114 USA.
[Rodolico, John M.] McLean Hosp, Div Child & Adolescent Psychiat, Belmont, MA 02478 USA.
[Rodolico, John M.] Harvard Univ, Sch Med, Boston, MA USA.
RP Connery, HS (reprint author), McLean Hosp, Div Alcohol & Drug Abuse, 115 Mill St,Mailstop 222, Belmont, MA 02478 USA.
EM hconnery@mclean.harvard.edu
FU NIH [U10DA15831]; NIHMS [567747]
FX Funding: NIH, U10DA15831; NIHMS-ID, 567747.
NR 61
TC 4
Z9 4
U1 3
U2 14
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8545
EI 1558-0474
J9 OBSTET GYN CLIN N AM
JI Obstet. Gynecol. Clin. N. Am.
PD JUN
PY 2014
VL 41
IS 2
BP 191
EP +
DI 10.1016/j.ogc.2014.02.011
PG 14
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA AJ0HD
UT WOS:000337330200004
PM 24845484
ER
PT J
AU Chang, G
AF Chang, Grace
TI Screening for Alcohol and Drug Use During Pregnancy
SO OBSTETRICS AND GYNECOLOGY CLINICS OF NORTH AMERICA
LA English
DT Article
DE Biomarkers; Questionnaires; Sensitivity; Specificity
ID NEONATAL ABSTINENCE; UNITED-STATES; WOMEN; ABUSE
AB The use of alcohol and other substances is not infrequent during pregnancy and may be associated with adverse effects on pregnancy outcome. Many pregnant women may continue these practices throughout pregnancy and even after delivery, unless they are recognized and assessed. Screening may be one way to achieve consistent and early identification. Prenatal health care providers may wish to screen all pregnant patients for their use of alcohol and other drugs using an approach that works best in their setting. A positive screen is an opportunity for the clinician and patient to discuss health practices and behaviors.
C1 [Chang, Grace] Harvard Univ, Sch Med, Boston, MA 02115 USA.
[Chang, Grace] VA Boston Healthcare Syst, Dept Psychiat, Brockton, MA 02301 USA.
RP Chang, G (reprint author), VA Boston Healthcare Syst, Dept Psychiat, 940 Belmont St, Brockton, MA 02301 USA.
EM Grace.Chang2@va.gov
NR 23
TC 2
Z9 2
U1 2
U2 5
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0889-8545
EI 1558-0474
J9 OBSTET GYN CLIN N AM
JI Obstet. Gynecol. Clin. N. Am.
PD JUN
PY 2014
VL 41
IS 2
BP 205
EP +
DI 10.1016/j.ogc.2014.02.002
PG 9
WC Obstetrics & Gynecology
SC Obstetrics & Gynecology
GA AJ0HD
UT WOS:000337330200005
PM 24845485
ER
PT J
AU Neophytou, AM
Picciotto, S
Hart, JE
Garshick, E
Eisen, EA
Laden, F
AF Neophytou, Andreas M.
Picciotto, Sally
Hart, Jaime E.
Garshick, Eric
Eisen, Ellen A.
Laden, Francine
TI A structural approach to address the healthy-worker survivor effect in
occupational cohorts: an application in the trucking industry cohort
SO OCCUPATIONAL AND ENVIRONMENTAL MEDICINE
LA English
DT Article
ID FAILURE-TIME MODELS; ARSENIC EXPOSURE; AIR-POLLUTION; HEART-DISEASE;
LUNG-CANCER; US CITIES; MALE BUS; MORTALITY; DRIVERS; RISK
AB Background Occupational cohort studies are often challenged by the Healthy Worker Survivor Effect, which may bias standard methods of analysis. G-estimation of structural failure time models is an approach for reducing this type of bias. Accelerated failure time models have recently been applied in an occupational cohort but cumulative failure time models have not.
Methods We used g-estimation of a cumulative failure time model to assess the effect of working as a long-haul driver on ischaemic heart disease mortality in a cohort of 30 448 men employed in the unionised US trucking industry in 1985. Exposure was defined by job title and based on work records. We also applied g-estimation of an accelerated failure time model as a sensitivity analysis and approximated HRs from both models to compare them.
Results The risk ratio (RR) obtained from the cumulative failure time model, comparing the observed risk under no intervention to the risk had nobody ever been exposed as a long-haul driver, was 1.09 (95% CI 1.02 to 1.16). The RR comparing the risk had everyone been exposed as long-haul driver for 8 years to the risk had nobody ever been exposed was 1.20 (95% CI 1.04 to 1.46). After HR approximations, accelerated failure time model results were similar.
Conclusions The cumulative failure time model can effectively control time-varying confounding by Healthy Worker Survivor Effect, and provides an easily interpretable effect estimate. RRs estimated from the cumulative failure time model indicate an elevated ischaemic heart disease mortality risk for long-haul drivers in the US trucking industry.
C1 [Neophytou, Andreas M.; Hart, Jaime E.; Garshick, Eric; Laden, Francine] Harvard Univ, Sch Publ Hlth, Dept Environm Hlth, Boston, MA 02115 USA.
[Neophytou, Andreas M.; Picciotto, Sally; Eisen, Ellen A.] Univ Calif Berkeley, Sch Publ Hlth, Div Environm Hlth Sci, Berkeley, CA 94720 USA.
[Hart, Jaime E.; Laden, Francine] Brigham & Womens Hosp, Channing Div Network Med, Boston, MA 02115 USA.
[Hart, Jaime E.; Laden, Francine] Harvard Univ, Sch Med, Boston, MA USA.
[Garshick, Eric] VA Boston Healthcare Syst, Primary & Crit Care Med Sect, Boston, MA USA.
RP Neophytou, AM (reprint author), UC Berkeley Sch Publ Hlth, Div Environm Hlth Sci, 772 Univ Hall, Berkeley, CA 94720 USA.
EM aneophytou@berkeley.edu
FU National Institute of Health, National Cancer Institute [R01 CA90792];
National Institute of Environmental Health Sciences [R01 ES016284]; AG
Leventis foundation
FX The study was supported by grants from the National Institute of Health,
National Cancer Institute (R01 CA90792), National Institute of
Environmental Health Sciences (R01 ES016284) and the AG Leventis
foundation.
NR 40
TC 7
Z9 8
U1 0
U2 2
PU BMJ PUBLISHING GROUP
PI LONDON
PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND
SN 1351-0711
EI 1470-7926
J9 OCCUP ENVIRON MED
JI Occup. Environ. Med.
PD JUN
PY 2014
VL 71
IS 6
BP 442
EP 447
DI 10.1136/oemed-2013-102017
PG 6
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AI9MV
UT WOS:000337257600010
PM 24727736
ER
PT J
AU Mays, D
Gilman, SE
Rende, R
Luta, G
Tercyak, KP
Niaura, RS
AF Mays, Darren
Gilman, Stephen E.
Rende, Richard
Luta, George
Tercyak, Kenneth P.
Niaura, Raymond S.
TI Parental Smoking Exposure and Adolescent Smoking Trajectories
SO PEDIATRICS
LA English
DT Article
DE cigarette smoking; nicotine dependence; parental smoking;
intergenerational smoking
ID MIDWESTERN COMMUNITY SAMPLE; NICOTINE DEPENDENCE; CIGARETTE-SMOKING;
INTERGENERATIONAL TRANSMISSION; DEVELOPMENTAL TRAJECTORIES; MULTIPLE
TRAJECTORIES; TOBACCO CONTROL; EARLY ADULTHOOD; RISK-FACTORS; CESSATION
AB OBJECTIVE: In a multigenerational study of smoking risk, the objective was to investigate the intergenerational transmission of smoking by examining if exposure to parental smoking and nicotine dependence predicts prospective smoking trajectories among adolescent offspring.
METHODS: Adolescents (n = 406) ages 12 to 17 and a parent completed baseline interviews (2001-2004), and adolescents completed up to 2 follow-up interviews 1 and 5 years later. Baseline interviews gathered detailed information on parental smoking history, including timing and duration, current smoking, and nicotine dependence. Adolescent smoking and nicotine dependence were assessed at each time point. Latent Class Growth Analysis identified prospective smoking trajectory classes from adolescence into young adulthood. Logistic regression was used to examine relationships between parental smoking and adolescent smoking trajectories.
RESULTS: Four adolescent smoking trajectory classes were identified: early regular smokers (6%), early experimenters (23%), late experimenters (41%), and nonsmokers (30%). Adolescents with parents who were nicotine-dependent smokers at baseline were more likely to be early regular smokers (odds ratio 1.18, 95% confidence interval 1.05-1.33) and early experimenters (odds ratio 1.04, 95% confidence interval 1.04-1.25) with each additional year of previous exposure to parental smoking. Parents' current non-nicotine-dependent and former smoking were not associated with adolescent smoking trajectories.
CONCLUSIONS: Exposure to parental nicotine dependence is a critical factor influencing intergenerational transmission of smoking. Adolescents with nicotine-dependent parents are susceptible to more intense smoking patterns and this risk increases with longer duration of exposure. Research is needed to optimize interventions to help nicotine-dependent parents quit smoking early in their children's lifetime to reduce these risks.
C1 [Mays, Darren; Luta, George; Tercyak, Kenneth P.; Niaura, Raymond S.] Georgetown Univ, Med Ctr, Lombardi Comprehens Canc Ctr, Washington, DC 20007 USA.
[Gilman, Stephen E.] Harvard Univ, Sch Publ Hlth, Boston, MA 02115 USA.
[Gilman, Stephen E.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
[Rende, Richard] Brown Univ, Sch Med, Providence, RI 02912 USA.
[Niaura, Raymond S.] Amer Legacy Fdn, Schroeder Inst Tobacco Res & Policy Studies, Washington, DC USA.
[Niaura, Raymond S.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Baltimore, MD USA.
RP Mays, D (reprint author), Georgetown Univ, Med Ctr, Canc Prevent & Control Program, Lombardi Comprehens Canc Ctr, 3300 Whitehaven St NW,Suite 4100, Washington, DC 20007 USA.
EM dmm239@georgetown.edu
RI Gilman, Stephen/E-7632-2010;
OI Gilman, Stephen/0000-0002-8331-6419; Luta, George/0000-0001-9013-2207;
Luta, George/0000-0002-4035-7632
FU National Institutes of Health Transdisciplinary Tobacco Research Center
award [CA084719]; Biostatistics and Bioinformatics Shared Resource of
Georgetown Lombardi Comprehensive Cancer Center through Comprehensive
Cancer Center support grant [P30CA051008]; National Institutes of Health
(NIH)
FX Supported by National Institutes of Health Transdisciplinary Tobacco
Research Center award CA084719 and by the Biostatistics and
Bioinformatics Shared Resource of Georgetown Lombardi Comprehensive
Cancer Center through Comprehensive Cancer Center support grant
P30CA051008. The content is solely the responsibility of the authors and
does not necessarily represent the official views of the National Cancer
Institute or the National Institutes of Health. Funded by the National
Institutes of Health (NIH).
NR 49
TC 18
Z9 18
U1 4
U2 22
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD JUN
PY 2014
VL 133
IS 6
BP 983
EP 991
DI 10.1542/peds.2013-3003
PG 9
WC Pediatrics
SC Pediatrics
GA AI8MY
UT WOS:000337172600047
PM 24819567
ER
PT J
AU Taveras, EM
Gillman, MW
Pena, MM
Redline, S
Rifas-Shiman, SL
AF Taveras, Elsie M.
Gillman, Matthew W.
Pena, Michelle-Marie
Redline, Susan
Rifas-Shiman, Sheryl L.
TI Chronic Sleep Curtailment and Adiposity
SO PEDIATRICS
LA English
DT Article
DE sleep curtailment; adiposity; fat mass index; BMI; obesity; early
childhood
ID BODY-MASS INDEX; CIRCADIAN CLOCK GENE; RISK-FACTORS; CHILDHOOD
OVERWEIGHT; BLOOD-PRESSURE; LIFE-STYLE; CHILDREN; OBESITY; ADOLESCENTS;
DURATION
AB OBJECTIVES: To examine the extent to which chronic sleep curtailment from infancy to mid-childhood is associated with total and central adiposity.
METHODS: We studied 1046 children participating in a prospective cohort study. At age 6 months and yearly from age 1 to 7 years, mothers reported their children's sleep duration in a usual 24-hour period. The main exposure was a sleep curtailment score from age 6 months to 7 years. The range of the total score was 0 to 13, where 0 indicated the maximal sleep curtailment and 13 indicated never having curtailed sleep. Outcomes in mid-childhood were BMI z score, dual X-ray absorptiometry total and trunk fat mass index (kg/m(2)), and waist and hip circumferences (cm).
RESULTS: The mean (SD) sleep score was 10.2 (2.7); 4.4% scored a 0 to 4, indicating multiple exposures to sleep curtailment between age 6 months to 7 years, 12.3% scored 5 to 7, 14.1% scored 8 to 9, 28.8% scored 10 to 11, and 40.3% scored 12 to 13. In multivariable models, children who had a sleep score of 0 to 4 had a BMI z score that was 0.48 U (95% confidence interval, 0.13 to 0.83) higher than those who had a sleep score of 12 to 13. We observed similar associations of higher total and trunk fat mass index and waist and hip circumferences, and higher odds of obesity (odds ratio, 2.62; 95% confidence interval, 0.99 to 6.97) among children who had a score of 0 to 4 vs 12 to 13.
CONCLUSIONS: Chronic sleep curtailment from infancy to school age was associated with higher overall and central adiposity in midchildhood.
C1 [Taveras, Elsie M.; Pena, Michelle-Marie] Massachusetts Gen Hosp Children, Dept Pediat, Div Gen Acad Pediat, Boston, MA USA.
[Gillman, Matthew W.; Rifas-Shiman, Sheryl L.] Harvard Univ, Sch Med, Dept Populat Med, Obes Prevent Program, Boston, MA USA.
[Gillman, Matthew W.; Rifas-Shiman, Sheryl L.] Harvard Pilgrim Hlth Care Inst, Boston, MA USA.
[Taveras, Elsie M.; Gillman, Matthew W.] Harvard Univ, Sch Publ Hlth, Dept Nutr, Boston, MA 02115 USA.
[Redline, Susan] Brigham & Womens Hosp, Div Sleep Med, Boston, MA 02115 USA.
RP Taveras, EM (reprint author), Massachusetts Gen Hosp, Dept Pediat, Div Gen Acad Pediat, 100 Cambridge St,15th Floor, Boston, MA 02114 USA.
EM etaveras@partners.org
FU National Cancer Institute's Centers for Transdisciplinary Research on
Energetics and Cancer (TREC) [U54CA116847]; Eunice Kennedy Shriver
National Institute of Child Health and Human Development [R37HD034568];
National Institutes of Health (NIH)
FX This work was supported by the National Cancer Institute's Centers for
Transdisciplinary Research on Energetics and Cancer (TREC) (U54CA116847)
and the Eunice Kennedy Shriver National Institute of Child Health and
Human Development (R37HD034568). The opinions or assertions contained
herein are the private ones of the authors and are not considered as
official or reflecting the views of the National Institutes of Health.
Funded by the National Institutes of Health (NIH).
NR 58
TC 25
Z9 25
U1 3
U2 16
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD JUN
PY 2014
VL 133
IS 6
BP 1013
EP 1022
DI 10.1542/peds.2013-3065
PG 10
WC Pediatrics
SC Pediatrics
GA AI8MY
UT WOS:000337172600051
PM 24843068
ER
PT J
AU Boudreau, AA
Goodman, E
Kurowski, D
Perrin, JM
Cooley, WC
Kuhlthau, K
AF Boudreau, Alexy Arauz
Goodman, Elizabeth
Kurowski, Daniel
Perrin, James M.
Cooley, W. Carl
Kuhlthau, Karen
TI Care Coordination and Unmet Specialty Care Among Children With Special
Health Care Needs
SO PEDIATRICS
LA English
DT Article
DE medical home; health care delivery/access; quality of care; children
ID MEDICAL HOME; NATIONAL-SURVEY; SERVICES; ACCESS; YOUTH; DISPARITIES;
SYSTEMS; IMPACT
AB OBJECTIVES: Care coordination and the medical home may ensure access to specialty care. Children with special health care needs (CSHCN) have higher rates of specialty care use and unmet need compared with the general pediatric population. We hypothesized that care coordination, regardless of whether it was provided in a medical home, would decrease unmet specialty care needs among CSHCN and that the effect of care coordination would be greater among low-income families.
METHODS: Secondary data analysis of participants in the 2009-2010 National Survey of CSHCN who reported unmet specialty care needs and for whom care coordination and medical home status could be determined (n = 18 905). Logistic regression models explored the association of unmet need with care coordination and medical home status adjusting for household income.
RESULTS: Approximately 9% of CSHCN reported having unmet specialty care needs. Care coordination was associated with reduced odds of unmet specialty care need (without a medical home, odds ratio: 0.63, 95% confidence interval: 0.47-0.86; within a medical home, odds ratio: 0.22, 95% confidence interval: 0.16-0.29) with a greater reduction among those receiving care coordination within a medical home versus those receiving care coordination without a medical home. We did not find differences in the impact of care coordination by percentage of the federal poverty level.
CONCLUSIONS: Care coordination is associated with family report of decreased unmet specialty care needs among CSHCN independent of household income. The effect of care coordination is greater when care is received in a medical home.
C1 [Boudreau, Alexy Arauz; Goodman, Elizabeth; Perrin, James M.; Kuhlthau, Karen] MassGen Hosp Children, Ctr Child & Adolescent Hlth Res & Policy, Div Gen Acad Pediat, Boston, MA 02114 USA.
[Boudreau, Alexy Arauz; Goodman, Elizabeth; Perrin, James M.; Kuhlthau, Karen] Harvard Univ, Sch Med, Boston, MA USA.
[Kurowski, Daniel] New York Ctr Homecare Policy & Res, Visiting Nurse Serv, New York, NY USA.
[Cooley, W. Carl] Crotched Mt Fdn & Rehabil Ctr, Greenfield, NH USA.
[Cooley, W. Carl] Geisel Sch Med Dartmouth, Dept Pediat, Hanover, NH USA.
RP Boudreau, AA (reprint author), MassGen Hosp Children, Ctr Child & Adolescent Hlth Res & Policy, 15th Floor C100,100 Cambridge St, Boston, MA 02114 USA.
EM aarauz@partners.org
FU Massachusetts General Hospital Multicultural Affairs Career Development
Award
FX Supported by the Massachusetts General Hospital Multicultural Affairs
Career Development Award.
NR 45
TC 15
Z9 16
U1 0
U2 9
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD JUN
PY 2014
VL 133
IS 6
BP 1046
EP 1053
DI 10.1542/peds.2013-2174
PG 8
WC Pediatrics
SC Pediatrics
GA AI8MY
UT WOS:000337172600055
PM 24864172
ER
PT J
AU Green, AL
Srivatsa, A
Rodriguez-Galindo, C
AF Green, Adam L.
Srivatsa, Abhinash
Rodriguez-Galindo, Carlos
TI Delayed Diagnosis and False Relapse Due to Paternal Testosterone Use in
Adrenocortical Carcinoma
SO PEDIATRICS
LA English
DT Article
DE adrenocortical carcinoma; children; delay; diagnosis; exogenous;
paternal; recurrence; testosterone; topical; virilization
ID CHILDREN; TUMORS; VIRILIZATION
AB The prognosis of pediatric adrenocortical carcinoma often depends on prompt diagnosis to begin treatment before metastatic progression. We discuss a girl who presented at 8 months of age with virilization, which was thought to be due to exposure to a topical testosterone preparation being used by her father. Her testosterone level did not decrease promptly after her father discontinued the medication, however, and when she followed up with signs of Cushing syndrome 5 months later, metastatic adrenocortical carcinoma was diagnosed. The patient was successfully treated with surgery and multiagent chemotherapy. Nine months after the end of treatment, her testosterone level was again found to be elevated. Testosterone precursors were now absent, however, and there were no imaging signs of recurrence. Further history showed that her father had restarted topical testosterone, and this time, exogenous exposure was correctly diagnosed. As use of topical testosterone becomes more prevalent, exogenous exposure must be considered in the differential diagnosis of childhood virilization. Any persistent testosterone elevation after exposure ceases or signs of hypercortisolism, however, are inconsistent with this diagnosis. We believe that the risk-benefit ratio favors abdominal ultra-sound to rule out malignancy in all children presenting with virilization.
C1 [Green, Adam L.; Rodriguez-Galindo, Carlos] Dana Farber Canc Inst, Dept Pediat Oncol, Boston, MA 02215 USA.
[Green, Adam L.; Rodriguez-Galindo, Carlos] Boston Childrens Hosp, Div Hematol Oncol, Boston, MA USA.
[Srivatsa, Abhinash] Boston Childrens Hosp, Div Endocrinol, Boston, MA USA.
RP Green, AL (reprint author), Dana Farber Canc Inst, Dana 3,450 Brookline Ave, Boston, MA 02215 USA.
EM adam.green@childrens.harvard.edu
NR 11
TC 1
Z9 1
U1 1
U2 2
PU AMER ACAD PEDIATRICS
PI ELK GROVE VILLAGE
PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA
SN 0031-4005
EI 1098-4275
J9 PEDIATRICS
JI Pediatrics
PD JUN
PY 2014
VL 133
IS 6
BP E1772
EP E1776
DI 10.1542/peds.2013-1454
PG 5
WC Pediatrics
SC Pediatrics
GA AI8MY
UT WOS:000337172600037
PM 24799542
ER
PT J
AU Powers, BW
Chaguturu, SK
AF Powers, Brian W.
Chaguturu, Sreekanth K.
TI Employer Health Incentives: Balancing Consumerism and Coordination
SO POPULATION HEALTH MANAGEMENT
LA English
DT Editorial Material
C1 [Powers, Brian W.; Chaguturu, Sreekanth K.] Harvard Univ, Sch Med, Boston, MA USA.
[Powers, Brian W.; Chaguturu, Sreekanth K.] Partners HealthCare, Boston, MA 02199 USA.
[Chaguturu, Sreekanth K.] Massachusetts Gen Hosp, Boston, MA 02114 USA.
RP Chaguturu, SK (reprint author), Partners HealthCare, 800 Boylston St, Boston, MA 02199 USA.
EM schaguturu@partners.org
NR 5
TC 1
Z9 1
U1 0
U2 1
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1942-7891
EI 1942-7905
J9 POPUL HEALTH MANAG
JI Popul. Health Manag.
PD JUN
PY 2014
VL 17
IS 3
BP 137
EP 138
DI 10.1089/pop.2014.0009
PG 2
WC Health Care Sciences & Services
SC Health Care Sciences & Services
GA AI9BZ
UT WOS:000337223600001
PM 24865283
ER
PT J
AU Tomko, RL
Solhan, MB
Carpenter, RW
Brown, WC
Jahng, S
Wood, PK
Trull, TJ
AF Tomko, Rachel L.
Solhan, Marika B.
Carpenter, Ryan W.
Brown, Whitney C.
Jahng, Seungmin
Wood, Phillip K.
Trull, Timothy J.
TI Measuring Impulsivity in Daily Life: The Momentary Impulsivity Scale
SO PSYCHOLOGICAL ASSESSMENT
LA English
DT Article
DE ambulatory assessment; ecological momentary assessment; impulsivity;
borderline personality disorder; scale development
ID BORDERLINE PERSONALITY-DISORDER; DUAL SYSTEMS-MODEL; AFFECTIVE
INSTABILITY; SELF-REPORT; BEHAVIORAL MEASURES; SENSATION SEEKING;
COMMUNITY SAMPLE; ALCOHOL-USE; DEPRESSION; EXPERIENCE
AB Impulsivity is a core feature of many psychiatric disorders. Traditionally, impulsivity has been assessed using retrospective questionnaires or laboratory tasks. Both approaches neglect intraindividual variability in impulsivity and do not capture impulsivity as it occurs in real-world settings. The goal of the current study was to provide a method for assessing impulsivity in daily life that provides both between-individual and within-individual information. Participants with borderline personality disorder (BPD; n = 67) or a depressive disorder (DD; n = 38) carried an electronic diary for 28 days and responded to 9 impulsivity items up to 6 times per day. Item distributions and iterative exploratory factor analysis (EFA) results were examined to select the items that best captured momentary impulsivity. A brief 4-item scale was created that can be used for the assessment of momentary impulsivity. Model fit was good for both within-and between-individual EFA. As expected, the BPD group showed significantly higher scores on our Momentary Impulsivity Scale than the DD group, and the resulting scale was moderately correlated with common trait impulsivity scales.
C1 [Tomko, Rachel L.; Carpenter, Ryan W.; Brown, Whitney C.; Wood, Phillip K.; Trull, Timothy J.] Univ Missouri, Dept Psychol Sci, Columbia, MO 65211 USA.
[Tomko, Rachel L.; Carpenter, Ryan W.; Brown, Whitney C.; Wood, Phillip K.; Trull, Timothy J.] Midwest Alcoholism Res Ctr, St Louis, MO USA.
[Solhan, Marika B.; Jahng, Seungmin] Univ Missouri Columbia, Dept Psychol Sci, Midwest Alcoholism Res Ctr, St Louis, MO USA.
[Solhan, Marika B.] VA Boston Healthcare Syst, Boston, MA USA.
[Jahng, Seungmin] Hallym Univ, Dept Psychol, Chunchon, South Korea.
RP Trull, TJ (reprint author), Univ Missouri, Dept Psychol Sci, 210 McAlester Hall, Columbia, MO 65211 USA.
EM TrullT@missouri.edu
FU NIAAA NIH HHS [F31 AA022031, K05 AA017242, T32 AA013526]; NIMH NIH HHS
[R21 MH069472]
NR 62
TC 17
Z9 17
U1 3
U2 25
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1040-3590
EI 1939-134X
J9 PSYCHOL ASSESSMENT
JI Psychol. Assess.
PD JUN
PY 2014
VL 26
IS 2
BP 339
EP 349
DI 10.1037/a0035083
PG 11
WC Psychology, Clinical
SC Psychology
GA AJ5EU
UT WOS:000337706000001
PM 24274047
ER
PT J
AU Lewin, AB
Piacentini, J
De Nadai, AS
Jones, AM
Peris, TS
Geffken, GR
Geller, DA
Nadeau, JM
Murphy, TK
Storch, EA
AF Lewin, Adam B.
Piacentini, John
De Nadai, Alessandro S.
Jones, Anna M.
Peris, Tara S.
Geffken, Gary R.
Geller, Daniel A.
Nadeau, Joshua M.
Murphy, Tanya K.
Storch, Eric A.
TI Defining Clinical Severity in Pediatric Obsessive-Compulsive Disorder
SO PSYCHOLOGICAL ASSESSMENT
LA English
DT Article
DE OCD; CYBOCS; normative; child; Children's Yale Brown Obsessive
Compulsive Scale
ID CHILDREN; ADOLESCENTS; RELIABILITY; VALIDITY; FEATURES; THERAPY; SCALE;
OCD
AB Despite extensive use of the Children's Yale Brown Obsessive Compulsive Scale (CYBOCS; Scahill et al., 1997), the lack of normative data impedes interpretation of individual CYBOCS scores. Consequently, psychometrics on CYBOCS severity scores from 815 treatment-seeking youth with obsessive-compulsive disorder (OCD) are presented, across age and sex, so that normative comparisons of obsessive, compulsive, and combined obsessive-compulsive severity could be calculated. Our findings suggest no evidence for marked age or sex differences. Further, obsessive-compulsive symptom severity scores (measured via the CYBOCS) appear consistent with global OCD syndrome severity (measured via the Clinician Global Impression-Severity scale [CGI-S; Guy, 1976]; r = .58). This study contributes the 1st empirically based guidelines for interpreting obsessive-compulsive symptom severity scores. After a diagnosis of OCD is determined, the CYBOCS can be used to determine severity of illness (however, categories of severity proposed by this article should not be used in the screening of OCD symptoms). Findings can facilitate clinicians' and investigators' ability to draw comparisons across obsessive-compulsive severity scores.
C1 [Lewin, Adam B.; Jones, Anna M.; Nadeau, Joshua M.; Murphy, Tanya K.; Storch, Eric A.] Univ S Florida, Dept Pediat, St Petersburg, FL 33701 USA.
[Lewin, Adam B.; De Nadai, Alessandro S.; Storch, Eric A.] Univ S Florida, Dept Psychol, St Petersburg, FL 33701 USA.
[Lewin, Adam B.; Murphy, Tanya K.; Storch, Eric A.] Univ S Florida, Dept Psychiat, St Petersburg, FL 33701 USA.
[Piacentini, John; Peris, Tara S.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA.
[Geffken, Gary R.] Univ Florida, Dept Psychiat, Gainesville, FL 32611 USA.
[Geffken, Gary R.] Univ Florida, Dept Clin & Hlth Psychol, Gainesville, FL 32611 USA.
[Geller, Daniel A.] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Dept Psychiat, Cambridge, MA 02138 USA.
RP Lewin, AB (reprint author), Univ S Florida, Coll Med, Rothman Ctr Neuropsychiat, 880 6th St South,Suite 460 Box 7523, St Petersburg, FL 33701 USA.
EM alewin@health.usf.edu
RI Nadeau, Joshua/F-1462-2015; Murphy, Tanya/J-7079-2013
OI Nadeau, Joshua/0000-0002-9886-4709;
NR 19
TC 10
Z9 10
U1 1
U2 5
PU AMER PSYCHOLOGICAL ASSOC
PI WASHINGTON
PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA
SN 1040-3590
EI 1939-134X
J9 PSYCHOL ASSESSMENT
JI Psychol. Assess.
PD JUN
PY 2014
VL 26
IS 2
BP 679
EP 684
DI 10.1037/a0035174
PG 6
WC Psychology, Clinical
SC Psychology
GA AJ5EU
UT WOS:000337706000030
PM 24320764
ER
PT J
AU Viswanathan, A
AF Viswanathan, Anand
TI Shades of White Separating Degrees of Injury in the Aging Brain
SO STROKE
LA English
DT Editorial Material
DE aging; cognition; leukoencephalopathies
ID MATTER HYPERINTENSITIES; ELDERLY-PEOPLE; MRI; DISEASE; LESIONS;
PREVALENCE; SEVERITY; AGE
C1 [Viswanathan, Anand] Massachusetts Gen Hosp, Kistler Stroke Res Ctr, Dept Neurol, Boston, MA 02114 USA.
RP Viswanathan, A (reprint author), Massachusetts Gen Hosp, Kistler Stroke Res Ctr, 175 Cambridge St,Suite 300, Boston, MA 02114 USA.
EM aviswanathan1@partners.org
FU NIA NIH HHS [P50-AG00513430]; PHS HHS [K23-]
NR 21
TC 1
Z9 1
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD JUN
PY 2014
VL 45
IS 6
BP 1606
EP 1607
DI 10.1161/STROKEAHA.114.005165
PG 2
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA AI7QR
UT WOS:000337090700011
PM 24781085
ER
PT J
AU Wong, KSL
Hu, DY
Oomman, A
Tan, RS
Patel, MR
Singer, DE
Breithardt, G
Mahaffey, KW
Becker, RC
Califf, R
Fox, KAA
Berkowitz, SD
Hacke, W
Hankey, GJ
AF Wong, Ka Sing Lawrence
Hu, Dai Yi
Oomman, Abraham
Tan, Ru-San
Patel, Manesh R.
Singer, Daniel E.
Breithardt, Guenter
Mahaffey, Kenneth W.
Becker, Richard C.
Califf, Robert
Fox, Keith A. A.
Berkowitz, Scott D.
Hacke, Werner
Hankey, Graeme J.
CA Executive Steering Comm
ROCKET AF Study Investigators
TI Rivaroxaban for Stroke Prevention in East Asian Patients From the ROCKET
AF Trial
SO STROKE
LA English
DT Article
DE atrial fibrillation; Far East; rivaroxaban; stroke
ID ATRIAL-FIBRILLATION; JAPANESE PATIENTS; WARFARIN; ANTICOAGULATION;
THERAPY; CHINA; PHARMACODYNAMICS; PHARMACOKINETICS; INTENSITY; SUBTYPES
AB Background and Purpose-In Rivaroxaban Once Daily Oral Direct Factor Xa Inhibitor Compared With Vitamin K Antagonism for Prevention of Stroke and Embolism Trial in Atrial Fibrillation (ROCKET AF) trial, rivaroxaban was noninferior to dose-adjusted warfarin in preventing stroke or systemic embolism among patients with nonvalvular atrial fibrillation at moderate to high stroke risk. Because of differences in patient demographics, epidemiology, and stroke risk management in East Asia, outcomes and relative effects of rivaroxaban versus warfarin were assessed to determine consistency among East Asians versus other ROCKET AF participants.
Methods-Baseline demographics and interaction of treatment effects of rivaroxaban and warfarin among patients within East Asia and outside were assessed.
Results-A total of 932 (6.5%) ROCKET AF participants resided in East Asia. At baseline, East Asians had lower weight, creatinine clearance, and prior vitamin K antagonist use; higher prevalence of prior stroke; and less congestive heart failure and prior myocardial infarction than other participants. Despite higher absolute event rates for efficacy and safety outcomes in East Asians, the relative efficacy of rivaroxaban (20 mg once daily; 15 mg once daily for creatinine clearance of 30-49 mL/min) versus warfarin with respect to the primary efficacy end point (stroke/systemic embolism) was consistent among East Asians and non-East Asians (interaction P=0.666). Relative event rates for the major or nonmajor clinically relevant bleeding in patients treated with rivaroxaban and warfarin were consistent among East Asians and non-East Asians (interaction P=0.867).
Conclusions-Observed relative efficacy and safety of rivaroxaban versus warfarin were similar among patients within and outside East Asia. Rivaroxaban, 20 mg once daily, is an alternative to warfarin for stroke prevention in East Asians with nonvalvular atrial fibrillation.
C1 [Wong, Ka Sing Lawrence] Chinese Univ Hong Kong, Dept Med & Therapeut, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China.
[Hu, Dai Yi] Peking Univ, Peoples Hosp, Ctr Heart, Beijing 100871, Peoples R China.
[Oomman, Abraham] Apollo Hosp, Dept Cardiol, Madras, Tamil Nadu, India.
[Tan, Ru-San] Natl Heart Ctr, Singapore, Singapore.
[Patel, Manesh R.; Mahaffey, Kenneth W.; Becker, Richard C.] Duke Univ, Med Ctr, Dept Med, Div Cardiol,Duke Clin Res Inst, Durham, NC 27710 USA.
[Califf, Robert] Duke Univ, Med Ctr, Dept Med, Div Cardiol,Duke Translat Med Inst, Durham, NC 27710 USA.
[Singer, Daniel E.] Massachusetts Gen Hosp, Dept Epidemiol, Boston, MA 02114 USA.
[Singer, Daniel E.] Harvard Univ, Sch Med, Boston, MA USA.
[Breithardt, Guenter] Univ Hosp Munster, Dept Cardiovasc Med, Munster, Germany.
[Fox, Keith A. A.] Univ Edinburgh, Ctr Cardiovasc Sci, Edinburgh, Midlothian, Scotland.
[Fox, Keith A. A.] Royal Infirm Edinburgh NHS Trust, Edinburgh, Midlothian, Scotland.
[Berkowitz, Scott D.] Bayer HealthCare Pharmaceut, Montville, NJ USA.
[Hacke, Werner] Heidelberg Univ, Dept Neurol, Heidelberg, Germany.
[Hankey, Graeme J.] Univ Western Australia, Royal Perth Hosp, Dept Neurol, Stroke Unit, Perth, WA 6009, Australia.
RP Wong, KSL (reprint author), Chinese Univ Hong Kong, Dept Med & Therapeut, Prince Wales Hosp, Hong Kong, Hong Kong, Peoples R China.
EM ks-wong@cuhk.edu.hk
RI Hankey, Graeme /H-4968-2014; Wong, Ka Sing Lawrence/N-3434-2015
OI Hankey, Graeme /0000-0002-6044-7328; Wong, Ka Sing
Lawrence/0000-0002-2031-9866
FU Janssen Research and Development, LLC; Bayer HealthCare Pharmaceuticals
FX The ROCKET study was funded by Janssen Research and Development, LLC,
and Bayer HealthCare Pharmaceuticals.
NR 29
TC 37
Z9 37
U1 0
U2 4
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD JUN
PY 2014
VL 45
IS 6
BP 1739
EP +
DI 10.1161/STROKEAHA.113.002968
PG 20
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA AI7QR
UT WOS:000337090700034
PM 24763930
ER
PT J
AU Radmanesh, F
Falcone, GJ
Anderson, CD
Battey, TWK
Ayres, AM
Vashkevich, A
McNamara, KA
Schwab, K
Romero, JM
Viswanathan, A
Greenberg, SM
Goldstein, JN
Rosand, J
Brouwers, HB
AF Radmanesh, Farid
Falcone, Guido J.
Anderson, Christopher D.
Battey, Thomas W. K.
Ayres, Alison M.
Vashkevich, Anastasia
McNamara, Kristen A.
Schwab, Kristin
Romero, Javier M.
Viswanathan, Anand
Greenberg, Steven M.
Goldstein, Joshua N.
Rosand, Jonathan
Brouwers, H. Bart
TI Risk Factors for Computed Tomography Angiography Spot Sign in Deep and
Lobar Intracerebral Hemorrhage Are Shared
SO STROKE
LA English
DT Article
DE cerebral amyloid angiopathy; cerebral small vessel disease; computed
tomography angiography; hypertension; intracerebral hemorrhage; spot
sign
ID HEMATOMA EXPANSION
AB Background and Purpose-Patients with intracerebral hemorrhage (ICH) who present with a spot sign on computed tomography angiography are at increased risk of hematoma expansion and poor outcome. Because primary ICH is the acute manifestation of chronic cerebral small vessel disease, we investigated whether different clinical or imaging characteristics predict spot sign presence, using ICH location as a surrogate for arteriolosclerosis-and cerebral amyloid angiopathy-related ICH.
Methods-Patients with primary ICH and available computed tomography angiography at presentation were included. Predictors of spot sign were assessed using uni-and multivariable regression, stratified by ICH location.
Results-Seven hundred forty-one patients were eligible, 335 (45%) deep and 406 (55%) lobar ICH. At least one spot sign was present in 76 (23%) deep and 102 (25%) lobar ICH patients. In multivariable regression, warfarin (odds ratio [OR], 2.42; 95% confidence interval [CI], 1.01-5.71; P=0.04), baseline ICH volume (OR, 1.20; 95% CI, 1.09-1.33, per 10 mL increase; P<0.001), and time from symptom onset to computed tomography angiography (OR, 0.89; 95% CI, 0.80-0.96, per hour; P=0.009) were associated with the spot sign in deep ICH. Predictors of spot sign in lobar ICH were warfarin (OR, 3.95; 95% CI, 1.87-8.51; P<0.001) and baseline ICH volume (OR, 1.20; 95% CI, 1.10-1.31, per 10 mL increase; P<0.001).
Conclusions-The most potent associations with spot sign are shared between deep and lobar ICH, suggesting that the acute bleeding process that arises in the setting of different chronic small vessel diseases shares commonalities.
C1 [Radmanesh, Farid; Falcone, Guido J.; Anderson, Christopher D.; Battey, Thomas W. K.; Rosand, Jonathan; Brouwers, H. Bart] Massachusetts Gen Hosp, Ctr Human Genet Res, Boston, MA 02114 USA.
[Radmanesh, Farid; Falcone, Guido J.; Anderson, Christopher D.; Battey, Thomas W. K.; Rosand, Jonathan; Brouwers, H. Bart] Massachusetts Gen Hosp, Dept Neurol, Div Neurocrit Care & Emergency Neurol, Boston, MA 02114 USA.
[Radmanesh, Farid; Falcone, Guido J.; Anderson, Christopher D.; Battey, Thomas W. K.; Ayres, Alison M.; Vashkevich, Anastasia; McNamara, Kristen A.; Schwab, Kristin; Viswanathan, Anand; Greenberg, Steven M.; Rosand, Jonathan; Brouwers, H. Bart] Massachusetts Gen Hosp, J Philip Kistler Stroke Res Ctr, Boston, MA 02114 USA.
[Romero, Javier M.] Massachusetts Gen Hosp, Dept Radiol, Boston, MA 02114 USA.
[Goldstein, Joshua N.] Massachusetts Gen Hosp, Dept Emergency Med, Boston, MA 02114 USA.
[Brouwers, H. Bart] Univ Utrecht, Dept Neurosurg, Univ Med Ctr Utrecht, Utrecht, Netherlands.
RP Brouwers, HB (reprint author), Univ Med Ctr Utrecht, Dept Neurosurg, Heidelberglaan 100, NL-3584 CX Utrecht, Netherlands.
EM brouwers@chgr.mgh.harvard.edu
RI Goldstein, Joshua/H-8953-2016; Falcone, Guido/L-2287-2016;
OI Falcone, Guido/0000-0002-6407-0302; Anderson,
Christopher/0000-0002-0053-2002
FU National Institutes of Health (NIH)-National Institute of Neurological
Disorders and Stroke (NINDS) [R01NS073344, R01NS059727, 5K23NS059774];
American Heart Association [0755984T]
FX This study was supported by grants R01NS073344, R01NS059727, and
5K23NS059774 from the National Institutes of Health (NIH)-National
Institute of Neurological Disorders and Stroke (NINDS) and 0755984T from
American Heart Association.
NR 9
TC 9
Z9 9
U1 0
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0039-2499
EI 1524-4628
J9 STROKE
JI Stroke
PD JUN
PY 2014
VL 45
IS 6
BP 1833
EP +
DI 10.1161/STROKEAHA.114.005276
PG 11
WC Clinical Neurology; Peripheral Vascular Disease
SC Neurosciences & Neurology; Cardiovascular System & Cardiology
GA AI7QR
UT WOS:000337090700047
PM 24876264
ER
PT J
AU Parangi, S
Suh, H
AF Parangi, Sareh
Suh, Hyunsuk
TI The Role of Genetic Markers in the Evaluation and Management of Thyroid
Nodules
SO SURGICAL CLINICS OF NORTH AMERICA
LA English
DT Article
DE Thyroid nodules; Indeterminate cytology; Molecular markers; Genetic
testing
ID NEEDLE-ASPIRATION BIOPSIES; TERT PROMOTER MUTATIONS; BRAF MUTATION;
EXPRESSION CLASSIFIER; BETHESDA SYSTEM; INDETERMINATE; CANCER;
CARCINOMA; CYTOLOGY; IMPACT
AB Thyroid nodules are common, with increasing incidence, but only 5% to 15% of nodules are malignant. Genetic markers should only be used as an ancillary diagnostic tool for indeterminate thyroid nodules. Veracyte Afirma may improve the diagnostic accuracy for a subset of indeterminate cytologic diagnosis. Overall clinical, imaging, and cytopathologic evaluation in addition to patient preference should guide the management of indeterminate nodules. Further multicentered and independent validation studies are needed in order to prove the efficacy of commercially available genetic markers.
C1 [Parangi, Sareh] Harvard Univ, Sch Med, Massachusetts Gen Hosp, Unit Endocrine Surg, Boston, MA 02115 USA.
[Suh, Hyunsuk] Massachusetts Gen Hosp, Dept Gen Surg, Boston, MA 02115 USA.
RP Parangi, S (reprint author), Harvard Univ, Sch Med, Massachusetts Gen Hosp, Unit Endocrine Surg, Wang ACC 460,15 Parkman St, Boston, MA 02115 USA.
EM sparangi@partners.org
NR 36
TC 4
Z9 4
U1 1
U2 19
PU W B SAUNDERS CO-ELSEVIER INC
PI PHILADELPHIA
PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA
SN 0039-6109
EI 1558-3171
J9 SURG CLIN N AM
JI Surg. Clin.-North Am.
PD JUN
PY 2014
VL 94
IS 3
BP 515
EP +
DI 10.1016/j.suc.2014.03.001
PG 15
WC Surgery
SC Surgery
GA AJ0HB
UT WOS:000337330000005
PM 24857574
ER
PT J
AU Lubitz, CC
Economopoulos, KP
Pawlak, AC
Lynch, K
Dias-Santagata, D
Faquin, WC
Sadow, PM
AF Lubitz, Carrie C.
Economopoulos, Konstantinos P.
Pawlak, Amanda C.
Lynch, Kerry
Dias-Santagata, Dora
Faquin, William C.
Sadow, Peter M.
TI Hobnail Variant of Papillary Thyroid Carcinoma: An Institutional Case
Series and Molecular Profile
SO THYROID
LA English
DT Article
ID BRAF V600E MUTATION; PROGNOSTIC-SIGNIFICANCE; MICROPAPILLARY PATTERN;
HISTOLOGICAL VARIANT; FOLLICULAR VARIANT; COMMON TYPE; RISK GROUP;
FOLLOW-UP; CANCER; FEATURES
AB Background: Papillary thyroid carcinoma (PTC) is increasing in incidence while mortality is unchanged. Identifying patients with higher risk of recurrence and death is essential. Case series identify the hobnail variant of PTC (HVPTC), which is characterized by micropapillary architecture, apocrine features, and loss of cellular polarity. Herein, we describe the clinical course, pathologic features, and mutational profile of patients at our institution with HVPTC.
Methods: A query into the surgical pathologic database (2009-2012) was performed, and clinicopathologic data were collected on all patients carrying the diagnosis of HVPTC. BRAF(V600E) testing was performed on paraffin-embedded blocks using SNaPshot mutational analysis.
Results: Twelve patients with HVPTC were identified, with an average age of 54.1 +/- 18.8 years. Seven patients (63.6%) were AJCC Stage III or IV at presentation. Tumors were large (3.7 +/- 2.0 cm), some were multifocal (33.3%), and frequently with extrathyroidal extension (58.3%), lymphovascular invasion (41.7%), and lymph node metastasis (75%). Forty percent of the patients had concomitant tall cell features (TCF), and two had small foci of undifferentiated (anaplastic) thyroid carcinoma (ATC). Eighty percent of tumors undergoing mutational analysis had the BRAF(V600E) mutation, and the remaining 20% harbored a RET/PTC1 gene rearrangement. No other known thyroid cancer mutations were identified on SNaPshot analysis. At median follow-up of 26 months, four patients had recurrent or persistent disease, one of whom died from the disease one year after surgery.
Conclusions: The hobnail variant of PTC has an aggressive behavior, with a high incidence of infiltrative tumors and metastatic disease. Strikingly, all tumors in our series harbored a PTC-associated genetic abnormality, either a BRAF(V600E) mutation (80%) or a RET/PTC1 rearrangement (20%). This histologic variant warrants further study, and patients with this diagnosis should be observed closely for recurrence.
C1 [Lubitz, Carrie C.; Economopoulos, Konstantinos P.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Endocrine Surg Unit,Dept Surg, Boston, MA 02114 USA.
[Pawlak, Amanda C.; Lynch, Kerry; Dias-Santagata, Dora; Faquin, William C.; Sadow, Peter M.] Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Pathol, Boston, MA 02114 USA.
RP Lubitz, CC (reprint author), Harvard Univ, Massachusetts Gen Hosp, Sch Med, Dept Surg,Div Surg Oncol, 55 Fruit St,Yawkey 7B, Boston, MA 02114 USA.
EM clubitz@partners.org
OI Economopoulos, Konstantinos/0000-0003-4856-0405
FU Program in Cancer Outcomes Research Training Grant [NCI R25CA092203];
Massachusetts General Hospital Department of Surgery; Massachusetts
General Hospital American Cancer Society Institutional Research Grant
FX Funded, in part, by the Program in Cancer Outcomes Research Training
Grant (NCI R25CA092203), Massachusetts General Hospital Department of
Surgery, and Massachusetts General Hospital American Cancer Society
Institutional Research Grant.
NR 37
TC 10
Z9 11
U1 0
U2 0
PU MARY ANN LIEBERT, INC
PI NEW ROCHELLE
PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA
SN 1050-7256
EI 1557-9077
J9 THYROID
JI Thyroid
PD JUN
PY 2014
VL 24
IS 6
BP 958
EP 965
DI 10.1089/thy.2013.0573
PG 8
WC Endocrinology & Metabolism
SC Endocrinology & Metabolism
GA AI9CB
UT WOS:000337224000005
PM 24417340
ER
PT J
AU Bigdeli, TB
Neale, BM
Neale, MC
AF Bigdeli, T. Bernard
Neale, Benjamin M.
Neale, Michael C.
TI Statistical Properties of Single-Marker Tests for Rare Variants
SO TWIN RESEARCH AND HUMAN GENETICS
LA English
DT Article
DE genome-wide association; next-generation sequencing; significance
testing; rare variation
ID GENOME-WIDE ASSOCIATION; COMMON DISEASES; SAMPLE-SIZE; RISK;
SUSCEPTIBILITY; PROPORTIONS; HYPOTHESES; GENOTYPES; GENES
AB With the dramatic technological developments of genome-wide association single-nucleotide polymorphism (SNP) chips and next generation sequencing, human geneticists now have the ability to assay genetic variation at ever-rarer allele frequencies. To fully understand the impact of these rare variants on common, complex diseases, we must be able to accurately assess their statistical significance. However, it is well established that classical association tests are not appropriate for the analysis of low-frequency variation, giving spurious findings when observed counts are too few. To further our understanding of the asymptotic properties of traditional association tests, we conducted a range of simulations of a typical rare variant (similar to 1%) under the null hypothesis and tested the allelic chi(2), Cochran-Armitage trend, Wald, and Fisher's exact tests. We demonstrate that rare variation shows marked deviation from the expected distributional behavior for each test, with fewer minor alleles corresponding to a greater degree of test statistics deflation. The effect becomes more pronounced at progressively smaller a levels. We also show that the Wald test is particularly deflated at a levels consistent with genome-wide association significance, much more so than the other association tests considered. In general, these classical association tests are inappropriate for the analysis of variants for which the minor allele is observed fewer than 80 times, largely irrespective of sample size.
C1 [Bigdeli, T. Bernard; Neale, Michael C.] Virginia Commonwealth Univ, Virginia Inst Psychiat & Behav Genet, Richmond, VA USA.
[Bigdeli, T. Bernard; Neale, Michael C.] Virginia Commonwealth Univ, Dept Human & Mol Genet, Richmond, VA USA.
[Neale, Benjamin M.] Massachusetts Gen Hosp, Dept Med, Analyt & Translat Genet Unit, Boston, MA 02114 USA.
[Neale, Benjamin M.] Harvard Univ, Sch Med, Boston, MA USA.
[Neale, Benjamin M.] Broad Inst Harvard & MIT, Program Med & Populat Genet, Cambridge, MA 02142 USA.
[Neale, Michael C.] Virginia Commonwealth Univ, Dept Psychiat, Richmond, VA USA.
[Neale, Michael C.] Broad Inst Harvard & MIT, Stanley Ctr Psychiat Res, Cambridge, MA 02142 USA.
RP Neale, BM (reprint author), Broad Inst Harvard & MIT, 7 Cambridge Ctr, Cambridge, MA 02142 USA.
EM bneale@broadinstitute.org
FU Netherlands Scientific Organization [NWO 480-05-003]; suppler-nett from
the Dutch Brain Foundation; VU University Amsterdam
FX We thank Mark Daly for useful feedback and comments on the manuscript.
Statistical analyses were carried out on the Genetic Cluster Computer
(http://www.geneticcluster.org), which is financially supported by the
Netherlands Scientific Organization (NWO 480-05-003), along with a
suppler-nett from the Dutch Brain Foundation and the VU University
Amsterdam.
NR 25
TC 2
Z9 2
U1 0
U2 3
PU CAMBRIDGE UNIV PRESS
PI NEW YORK
PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA
SN 1832-4274
EI 1839-2628
J9 TWIN RES HUM GENET
JI Twin Res. Hum. Genet.
PD JUN
PY 2014
VL 17
IS 3
BP 143
EP 150
DI 10.1017/thg.2014.17
PG 8
WC Genetics & Heredity; Obstetrics & Gynecology
SC Genetics & Heredity; Obstetrics & Gynecology
GA AI9NL
UT WOS:000337259200001
PM 24739319
ER
PT J
AU Sher, DJ
Parikh, RB
Mays-Jackson, S
Punglia, RS
AF Sher, David J.
Parikh, Ravi B.
Mays-Jackson, Shawnda
Punglia, Rinaa S.
TI Cost-effectiveness Analysis of SBRT Versus IMRT for Low-risk Prostate
Cancer
SO AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
LA English
DT Article
DE cost-effectiveness analysis; prostate cancer; radiotherapy; IMRT;
stereotactic body radiotherapy
ID STEREOTACTIC BODY RADIOTHERAPY; RADIATION-THERAPY; PRIMARY MANAGEMENT;
STATES
AB Objectives: Intensity-modulated radiation therapy (IMRT) has been established as the standard external-beam modality in treating low-risk prostate cancer. Stereotactic body radiotherapy (SBRT) is a novel approach involving high-dose radiotherapy in 5 fractions. This analysis compared their cost-effectiveness.
Methods: A Markov model was constructed to delineate the health states after treatment with IMRT and SBRT. Disease, treatment, and toxicity data were extracted from the literature. Costs included both robotic (R-SBRT) and nonrobotic (NR-SBRT) reimbursement. Deterministic and probabilistic sensitivity analyses (PSA) were performed over a wide range of potential parameters.
Results: The quality-adjusted life expectancy after IMRT was slightly higher than after SBRT, because we assumed worse toxicity after SBRT. However, the incremental cost-effectiveness ratios (ICER) for IMRT over R-SBRT and NR-SBRT were $285,000 and $591,100/quality-adjusted life year (QALY), respectively. On sensitivity analysis, SBRT was almost always the cost-effective therapy, in which the ICER for IMRT was generally over $100,000/QALY. Reimbursement for R-SBRT versus NR-SBRT significantly influenced its ICER. Treatment efficacy, rectal toxicity and impotence, and the potential for unforeseen SBRT late effects were the most critical parameters in the model; when including these uncertain parameters in a PSA, SBRT was still most likely to be cost-effective at a willingness to pay of $ 100,000/QALY.
Conclusions: SBRT clearly contained more value than IMRT for external-beam treatment. Given the increasing prevalence of the disease and its superb convenience, intensive research should be performed on this novel modality, including the marginal benefit and cost of robotic treatment.
C1 [Sher, David J.; Mays-Jackson, Shawnda] Rush Univ, Med Ctr, Dept Radiat Oncol, Chicago, IL 60612 USA.
[Parikh, Ravi B.; Punglia, Rinaa S.] Dana Farber Canc Inst, Dept Radiat Oncol, Boston, MA 02115 USA.
[Parikh, Ravi B.; Punglia, Rinaa S.] Brigham & Womens Hosp, Boston, MA 02115 USA.
RP Sher, DJ (reprint author), Rush Univ, Med Ctr, Dept Radiat Oncol, Chicago, IL 60612 USA.
EM david_j_sher@rush.edu
NR 20
TC 11
Z9 11
U1 0
U2 2
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0277-3732
EI 1537-453X
J9 AM J CLIN ONCOL-CANC
JI Am. J. Clin. Oncol.-Cancer Clin. Trials
PD JUN
PY 2014
VL 37
IS 3
BP 215
EP 221
DI 10.1097/COC.0b013e31827a7d2a
PG 7
WC Oncology
SC Oncology
GA AI6CU
UT WOS:000336958200001
PM 23275277
ER
PT J
AU Nguyen, PL
Aizer, A
Assimos, DG
D'Amico, AV
Frank, SJ
Gottschalk, AR
Gustafson, GS
Hsu, ICJ
McLaughlin, PW
Merrick, G
Rosenthal, SA
Showalter, TN
Taira, AV
Vapiwala, N
Yamada, Y
Davis, BJ
AF Nguyen, Paul L.
Aizer, Ayal
Assimos, Dean G.
D'Amico, Anthony V.
Frank, Steven J.
Gottschalk, Alexander R.
Gustafson, Gary S.
Hsu, I-Chow Joe
McLaughlin, Patrick W.
Merrick, Gregory
Rosenthal, Seth A.
Showalter, Timothy N.
Taira, Al V.
Vapiwala, Neha
Yamada, Yoshiya
Davis, Brian J.
CA Expert Panel Radiation Oncology-Pr
TI ACR Appropriateness Criteria (R) Definitive External-Beam Irradiation in
Stage T1 and T2 Prostate Cancer
SO AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS
LA English
DT Review
DE appropriateness criteria; prostate cancer; external-beam radiation;
radiation therapy
ID CONFORMAL RADIATION-THERAPY; PHASE-III TRIAL; INTENSITY-MODULATED
RADIOTHERAPY; DOSE-ESCALATION TRIAL; STEREOTACTIC BODY RADIOTHERAPY;
ANDROGEN DEPRIVATION THERAPY; RANDOMIZED CONTROLLED-TRIAL; TREATMENT
RELATED MORBIDITY; RELAPSE-FREE SURVIVAL; QUALITY-OF-LIFE
AB Purpose: To present the most updated American College of Radiology consensus guidelines formed from an expert panel on the appropriate use of external-beam radiation to manage stage T1 and T2 prostate cancer.
Methods: The American College of Radiology Appropriateness Criteria are evidence-based guidelines for specific clinical conditions that are reviewed every 2 years by a multidisciplinary expert panel. The guideline development and review include an extensive analysis of current medical literature from peer-reviewed journals and the application of a well-established consensus methodology (modified Delphi) to rate the appropriateness of imaging and treatment procedures by the panel. In those instances where evidence is lacking or not definitive, expert opinion may be used to recommend imaging or treatment.
Results: The panel summarized the most recent and relevant literature on the topic and voted on 3 clinical variants illustrating the appropriate dose, techniques, and use of adjuvant hormone therapy with external-beam radiation for low-risk, intermediate-risk, and high-risk prostate cancer. Numerical rating and commentary reflecting the panel consensus was given for each treatment approach in each variant.
Conclusions: External-beam radiation is a key component of the curative management of T1 and T2 prostate cancer. By combining the most recent medical literature and expert opinion, this guideline can aid clinicians in the appropriate use of external-beam radiation for prostate cancer.
C1 [Nguyen, Paul L.] Brigham & Womens Hosp, Dana Farber Canc Inst, Boston, MA 02115 USA.
[Aizer, Ayal] Harvard Radiat Oncol Program, Boston, MA USA.
[Assimos, Dean G.] Univ Alabama Birmingham, Sch Med, Dept Urol, Birmingham, AL USA.
[Assimos, Dean G.] Amer Urol Assoc, Linthicum, MD USA.
[D'Amico, Anthony V.] Joint Ctr Radiat Therapy, Boston, MA 02115 USA.
[D'Amico, Anthony V.] Amer Soc Clin Oncol, Alexandria, VA USA.
[Frank, Steven J.] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA.
[Gottschalk, Alexander R.; Hsu, I-Chow Joe] Univ Calif San Francisco, Dept Radiat Oncol, San Francisco, CA USA.
[Rosenthal, Seth A.] Radiol Associates Sacramento, Sacramento, CA USA.
[Rosenthal, Seth A.] Sutter Canc Ctr, Sacramento, CA USA.
[Taira, Al V.] Mt View Oncol, Western Radiat Oncol, Mountain View, CA USA.
[Gustafson, Gary S.] William Beaumont Hosp, Troy, NY USA.
[McLaughlin, Patrick W.] Univ Michigan, Dept Radiat Oncol, Novi, MI USA.
[Merrick, Gregory] Schiffler Canc Ctr, Wheeling, WV USA.
[Merrick, Gregory] Wheeling Jesuit Univ, Wheeling, WV USA.
[Showalter, Timothy N.] Univ Virginia, Dept Radiat Oncol, Charlottesville, VA USA.
[Vapiwala, Neha] Univ Penn, Dept Radiat Oncol, Philadelphia, PA USA.
[Yamada, Yoshiya] Mem Sloan Kettering Canc Ctr, New York, NY 10021 USA.
[Davis, Brian J.] Mayo Clin, Rochester, MN USA.
RP Nguyen, PL (reprint author), Amer Coll Radiol, 1891 Preston White Dr, Reston, VA 20191 USA.
EM pnguyen@lroc.harvard.edu
FU NCI NIH HHS [P30 CA016672]
NR 105
TC 5
Z9 5
U1 0
U2 3
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA
SN 0277-3732
EI 1537-453X
J9 AM J CLIN ONCOL-CANC
JI Am. J. Clin. Oncol.-Cancer Clin. Trials
PD JUN
PY 2014
VL 37
IS 3
BP 278
EP 288
DI 10.1097/COC.0000000000000049
PG 11
WC Oncology
SC Oncology
GA AI6CU
UT WOS:000336958200011
PM 25180754
ER
PT J
AU Welles, CC
Whooley, MA
Karumanchi, SA
Hod, T
Thadhani, R
Berg, AH
Ix, JH
Mukamal, KJ
AF Welles, Christine C.
Whooley, Mary A.
Karumanchi, S. Ananth
Hod, Tammy
Thadhani, Ravi
Berg, Anders H.
Ix, Joachim H.
Mukamal, Kenneth J.
TI Vitamin D Deficiency and Cardiovascular Events in Patients With Coronary
Heart Disease: Data From the Heart and Soul Study
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Article
DE cardiovascular events; coronary heart disease; nutrition; vitamin D;
vitamin D deficiency
ID PERIPHERAL ARTERIAL-DISEASE; 25-HYDROXYVITAMIN D LEVELS; CHRONIC
KIDNEY-DISEASE; PARATHYROID-HORMONE; SERUM 25-HYDROXYVITAMIN-D;
MYOCARDIAL-INFARCTION; BLOOD-PRESSURE; INCIDENT HYPERTENSION; DEPRESSIVE
SYMPTOMS; D SUPPLEMENTATION
AB A growing body of evidence supports an association between vitamin D and cardiovascular disease. However, the mechanisms underlying this association are unknown. From 2000 to 2002, we identified 946 participants with stable cardiovascular disease in San Francisco, California, and followed them prospectively for cardiovascular events (heart failure, myocardial infarction, stroke, or cardiovascular death). We then examined the extent to which the association was attenuated by adjustment for poor health behaviors, comorbid health conditions, and potential biological mediators. During a median follow-up period of 8.0 years (through August 24, 2012), 323 subjects (34.1%) experienced a cardiovascular event. Following adjustment for sociodemographic factors, season of blood measurement, health behaviors, and comorbid conditions, 25-hydroxyvitamin D levels under 20 ng/mL remained independently associated with cardiovascular events (hazard ratio = 1.30, 95% confidence interval: 1.01, 1.67). However, after further adjustment for potential biological mediators, the independent association was no longer present (hazard ratio = 1.11, 95% confidence interval: 0.85, 1.44). Parathyroid hormone, a potentially modifiable biological factor downstream from 25-hydroxyvitamin D, was responsible for the majority of this attenuation. These findings highlight the need for randomized controlled trials to determine whether vitamin D supplementation in persons with deficiency could be beneficial for the primary or secondary prevention of cardiovascular events.
C1 [Welles, Christine C.; Whooley, Mary A.] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, Sch Med, San Francisco, CA USA.
[Ix, Joachim H.] Univ Calif San Diego, Sch Med, Dept Family & Prevent Med, San Diego, CA 92103 USA.
[Ix, Joachim H.] Univ Calif San Diego, Sch Med, Dept Med, Div Nephrol Hypertens, San Diego, CA 92103 USA.
[Mukamal, Kenneth J.] Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, Boston, MA 02215 USA.
[Karumanchi, S. Ananth; Hod, Tammy] Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, Boston, MA 02215 USA.
[Berg, Anders H.] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA.
[Thadhani, Ravi] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA.
RP Welles, CC (reprint author), San Francisco VA Med Ctr, Dept Med, Gen Internal Med Sect, 4150 Clement St,111A1, San Francisco, CA 94121 USA.
EM christywelles@gmail.com
FU Veterans Affairs National Quality Scholars Program; Department of
Veterans Affairs; National Heart, Lung, and Blood Institute; American
Federation for Aging Research; Robert Wood Johnson Foundation; Ischemia
Research and Education Foundation; National Institutes of Health
[DK094486, DK094872]
FX Dr. Christine C. Welles was supported by the Veterans Affairs National
Quality Scholars Program. The Heart and Soul Study was supported by the
Department of Veterans Affairs, the National Heart, Lung, and Blood
Institute, the American Federation for Aging Research, the Robert Wood
Johnson Foundation, and the Ischemia Research and Education Foundation.
Dr. S. Ananth Karumanchi is an investigator of the Howard Hughes Medical
Institute. Dr. Ravi Thadhani was supported by National Institutes of
Health grants DK094486 and DK094872.
NR 46
TC 22
Z9 22
U1 0
U2 6
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD JUN 1
PY 2014
VL 179
IS 11
BP 1279
EP 1287
DI 10.1093/aje/kwu059
PG 9
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AI6ZI
UT WOS:000337027400001
PM 24699783
ER
PT J
AU Welles, CC
Whooley, MA
Karumanchi, SA
Hod, T
Thadhani, R
Berg, AH
Ix, JH
Mukamal, KJ
AF Welles, Christine C.
Whooley, Mary A.
Karumanchi, S. Ananth
Hod, Tammy
Thadhani, Ravi
Berg, Anders H.
Ix, Joachim H.
Mukamal, Kenneth J.
TI Welles et al. Respond to "Low Vitamin D and Cardiovascular Disease"
SO AMERICAN JOURNAL OF EPIDEMIOLOGY
LA English
DT Editorial Material
C1 [Welles, Christine C.; Whooley, Mary A.] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, Sch Med, San Francisco, CA USA.
[Ix, Joachim H.] Univ Calif San Diego, Sch Med, Dept Family & Prevent Med, San Diego, CA 92103 USA.
[Ix, Joachim H.] Univ Calif San Diego, Dept Med, Sch Med, Div Nephrol Hypertens, San Diego, CA 92103 USA.
[Mukamal, Kenneth J.] Beth Israel Deaconess Med Ctr, Dept Med, Div Gen Med & Primary Care, Boston, MA 02215 USA.
[Karumanchi, S. Ananth; Hod, Tammy] Beth Israel Deaconess Med Ctr, Dept Med, Div Nephrol, Boston, MA 02215 USA.
[Berg, Anders H.] Beth Israel Deaconess Med Ctr, Dept Pathol, Boston, MA 02215 USA.
[Thadhani, Ravi] Massachusetts Gen Hosp, Dept Med, Div Nephrol, Boston, MA 02114 USA.
RP Welles, CC (reprint author), San Francisco VA Med Ctr, Gen Internal Med Sect, Dept Med, 4150 Clement St,111A1, San Francisco, CA 94121 USA.
EM christywelles@gmail.com
FU NIDDK NIH HHS [K24 DK094872, R01 DK094486]
NR 4
TC 0
Z9 0
U1 0
U2 1
PU OXFORD UNIV PRESS INC
PI CARY
PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA
SN 0002-9262
EI 1476-6256
J9 AM J EPIDEMIOL
JI Am. J. Epidemiol.
PD JUN 1
PY 2014
VL 179
IS 11
BP 1291
EP 1292
DI 10.1093/aje/kwu058
PG 2
WC Public, Environmental & Occupational Health
SC Public, Environmental & Occupational Health
GA AI6ZI
UT WOS:000337027400003
PM 24699785
ER
PT J
AU He, LZ
Marioutina, M
Dunaief, JL
Marneros, AG
AF He, Lizhi
Marioutina, Mariya
Dunaief, Joshua L.
Marneros, Alexander G.
TI Age- and Gene-Dosage-Dependent Cre-Induced Abnormalities in the Retinal
Pigment Epithelium
SO AMERICAN JOURNAL OF PATHOLOGY
LA English
DT Article
ID MAMMALIAN-CELLS; RECOMBINASE; TOXICITY; EXPRESSION; SITES; MOUSE
AB To conditionally inactivate genes in the retinal pigment epithelium (RPE) transgenic mouse strains have been developed, in which Cre recombinase (Cre) expression is driven by an RPE-specific gene promoter. The RPE is a quiescent epithelium, and continuous expression of Cre could affect its function. Here, we tested the hypothesis that continuous postnatal Cre expression in the RPE may lead to cellular abnormalities, which may depend on both age and Cre gene dosage. We therefore examined the eyes of homozygous and heterozygous VMD2-Cre mice at various ages. In VMD2-Cre heterozygous mice variable progressive age-dependent RPE abnormalities were noticed, including attenuation of phalloidin and cytoplasmic active beta-catenin staining, reduced cell size, and loss of the typical honeycomb pattern of RPE morphology in those RPE cells that stained for Cre. These morphological RPE abnormalities were not noticed in Cre-negative RPE cells in VMD2-Cre or age-matched control mice. In addition, an abnormal number and morphology of cell nuclei were noticed in a subset of Cre-expressing RPE cells in aged heterozygous VMD2-Cre mice, whereas more severe nuclear abnormalities were observed already in young homozygous VMD2-Cre mice. Thus, continuous postnatal expression of Cre causes abnormalities in the RPE in an age- and Cre gene dosage-dependent manner, which needs to be considered in the interpretation of gene targeting studies in the RPE.
C1 [He, Lizhi; Marioutina, Mariya; Marneros, Alexander G.] Massachusetts Gen Hosp, Cutaneous Biol Res Ctr, Charlestown, MA USA.
[He, Lizhi; Marioutina, Mariya; Marneros, Alexander G.] Harvard Univ, Sch Med, Dept Dermatol, Charlestown, MA USA.
[Dunaief, Joshua L.] Univ Penn, Dept Ophthalmol, FM Kirby Ctr Mol Ophthalmol, Philadelphia, PA 19104 USA.
RP Marneros, AG (reprint author), MGH E, CBRC, CNY 149,Rm 3-216,13th St, Charlestown, MA 02129 USA.
EM amarneros@mgh.harvard.edu
FU NIH National Eye Institute [R01-EY019297]
FX This work was supported by NIH National Eye Institute grant R01-EY019297
(A.G.M.).
NR 19
TC 5
Z9 5
U1 0
U2 2
PU ELSEVIER SCIENCE INC
PI NEW YORK
PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN 0002-9440
EI 1525-2191
J9 AM J PATHOL
JI Am. J. Pathol.
PD JUN
PY 2014
VL 184
IS 6
BP 1660
EP 1667
DI 10.1016/j.ajpath.2014.02.007
PG 8
WC Pathology
SC Pathology
GA AI5ZE
UT WOS:000336948700004
PM 24854863
ER
PT J
AU Axon, RN
Penney, FT
Kyle, TR
Zapka, J
Marsden, J
Zhao, YM
Mauldin, PD
Moran, WP
AF Axon, Robert N.
Penney, Fletcher T.
Kyle, Thomas R.
Zapka, Jane
Marsden, Justin
Zhao, Yumin
Mauldin, Patrick D.
Moran, William P.
TI A Hospital Discharge Summary Quality Improvement Program Featuring
Individual and Team-based Feedback and Academic Detailing
SO AMERICAN JOURNAL OF THE MEDICAL SCIENCES
LA English
DT Article
DE Care transitions; Hospital discharge; Discharge summary; Quality
improvement
ID PRIMARY-CARE PHYSICIANS; INTERNAL-MEDICINE; VULNERABLE ELDERS;
AFTER-DISCHARGE; RE-AIM; COMMUNICATION; PERFORMANCE
AB Background: Discharge summaries are an important component of hospital care transitions typically completed by interns in teaching hospitals. However, these documents are often not completed in a timely fashion or do not include pertinent details of hospitalization. This report outlines the development and impact of a curriculum intervention to improve the quality of discharge summaries by interns and residents in Internal Medicine. A previous study demonstrated that a discharge summary curriculum featuring individualized feedback was associated with improved summary quality, but few subsequent studies have described implementation of similar curricula. No information exists on the utility of other strategies such as team-based feedback or academic detailing. Methods: Study participants were 96 Internal Medicine intern and resident physicians at an academic medical center-based training program. A comprehensive evidence-based discharge summary quality improvement program was developed and implemented that featured a discharge summary template to facilitate summary preparation, individual feedback, team-based feedback, academic detailing and an objective discharge summary evaluation instrument. Results: The discharge summary evaluation instrument had moderate interrater reliability (kappa = 0.72). Discharge summary scores improved from mean score of 70% to 82% (P = 0.05). Interns and residents participating in this program also reported increased confidence in producing and critiquing summaries. Conclusions: A comprehensive discharge summary curriculum can be feasibly implemented within the context of a residency program. Team-based feedback and academic detailing may serve to reinforce individual feedback and extend program reach.
C1 [Axon, Robert N.] Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Div Populat, Charleston, SC 29425 USA.
[Axon, Robert N.; Penney, Fletcher T.; Kyle, Thomas R.; Marsden, Justin; Zhao, Yumin; Mauldin, Patrick D.; Moran, William P.] Med Univ S Carolina, Div Gen Internal Med & Geriatr, Charleston, SC 29425 USA.
[Zapka, Jane] Med Univ S Carolina, Div Biostat & Epidemiol, Charleston, SC 29425 USA.
[Mauldin, Patrick D.] South Carolina Coll Pharm, Charleston, SC USA.
RP Axon, RN (reprint author), Ralph H Johnson Vet Affairs Med Ctr, Ctr Dis Prevent & Hlth Intervent Div Populat, 135 Rutledge Ave,MSC 591, Charleston, SC 29425 USA.
EM axon@musc.edu
FU Donald W. Reynolds Foundation; Medical University of South Carolina
(MUSC)
FX This study was supported by a grant from the Donald W. Reynolds
Foundation entitled "Aging Q3: Quality Education, Quality
Care, and Quality of Life" and matching funds provided by the Medical
University of South Carolina (MUSC).
NR 22
TC 7
Z9 7
U1 1
U2 1
PU LIPPINCOTT WILLIAMS & WILKINS
PI PHILADELPHIA
PA 530 WALNUT ST, PHILADELPHIA, PA 19106-3621 USA
SN 0002-9629
EI 1538-2990
J9 AM J MED SCI
JI Am. J. Med. Sci.
PD JUN
PY 2014
VL 347
IS 6
BP 472
EP 477
PG 6
WC Medicine, General & Internal
SC General & Internal Medicine
GA AI5IG
UT WOS:000336898500009
PM 24845304
ER
EF